Scientific Papers found: Click to Expand⟱

3573-

,

Chronic diseases, inflammation, and spices: how are they linked?

-

Review,

Var,

NA

NF-kB↓, XIAP↓, PI3K↓, Akt↓, STAT3↓, JAK2↓, cSrc↓, PCNA↓, MMP2↓, ERK↓, Ki-67↓, Bcl-2↓, VEGF↓, p65↓, COX2↓, MMP9↓,

3562-

,

ACETYLCHOLINESTERASE AND GROWTH INHIBITORY EFFECTS–VARIOUS GRADES OF N. SATIVA OILS

-

Review,

AD,

NA

-

Review,

Var,

NA

*AChE↓, *other↓,

3467-

,

Pulsed Magnetic Field Induces Angiogenesis and Improves Cardiac Function of Surgically Induced Infarcted Myocardium in Sprague-Dawley Rats

3466-

,

The effect of magnetic fields on tumor occurrence and progression: Recent advances

3465-

,

Magnetic fields and angiogenesis

3464-

,

Progressive Study on the Non-thermal Effects of Magnetic Field Therapy in Oncology

3423-

,

Epigenetic role of thymoquinone: impact on cellular mechanism and cancer therapeutics

-

Review,

Var,

NA

AntiCan↑, Inflam↓, hepatoP↑, RenoP↑, BAX↑, Bak↑, Bcl-2↓, Bcl-xL↓, ROS↑, P53↑, PTEN↑, P21↑, p27↑, BRCA1↑, PI3K↓, Akt↓, MAPK↓, ERK↓, p‑ERK↓, MMPs↓, FAK↓, Twist↓, Zeb1↓, EMT↓, TumMeta↓, angioG↓, VEGF↓, HDAC↓, Maspin↑, SIRT1↑, DNMT1↓, DNMT3A↓, HDAC1↓, HDAC4↓,

2327-

2DG,

2-Deoxy-d-Glucose and Its Analogs: From Diagnostic to Therapeutic Agents

-

Review,

Var,

NA

Glycolysis↓, HK2↓, mt-ROS↑, AMPK↑, PPP↓, NADPH↓, GSH↓, Bax:Bcl2↑, Apoptosis↑, RadioS↑, eff↓, Half-Life↓, other↝, eff↓,

2326-

2DG,

Caloric Restriction Mimetic 2-Deoxyglucose Alleviated Inflammatory Lung Injury via Suppressing Nuclear Pyruvate Kinase M2–Signal Transducer and Activator of Transcription 3 Pathway

-

in-vivo,

Nor,

NA

Male BALB/c mice

PKM2↓, Inflam↓, TNF-α↓, IL6↓, OS↑,

2325-

2DG,

Research Progress of Warburg Effect in Hepatocellular Carcinoma

-

Review,

Var,

NA

HK2↓, Glycolysis↓, PKM2↓, LDHA↓, TumCD↑, ChemoSen↑, eff↑,

2424-

2DG,

SRF,

The combination of the glycolysis inhibitor 2-DG and sorafenib can be effective against sorafenib-tolerant persister cancer cells

-

in-vitro,

HCC,

Hep3B

-

in-vitro,

HCC,

HUH7

ChemoSen↓, Glycolysis↓, HK1↓, HK2↓, ATP↓,

2423-

2DG,

SRF,

2-Deoxyglucose and sorafenib synergistically suppress the proliferation and motility of hepatocellular carcinoma cells

-

in-vitro,

HCC,

NA

ChemoSen↑, TumCP↓, cycD1↓, MMP9↓,

2435-

2DG,

Targeting hexokinase 2 for oral cancer therapy: structure-based design and validation of lead compounds

-

in-vitro,

SCC,

CAL27

MMP↓, HK2↓,

2434-

2DG,

Inhibition of Key Glycolytic Enzyme Hexokinase 2 Ameliorates Psoriasiform Inflammation in vitro and in vivo

-

in-vitro,

PSA,

NA

-

in-vivo,

PSA,

NA

HK2↓, NF-kB↓, NLRP3↓,

2433-

2DG,

Hexokinase inhibitor 2-deoxyglucose coordinates citrullination of vimentin and apoptosis of fibroblast-like synoviocytes by inhibiting HK2 /mTORC1-induced autophagy

-

in-vitro,

Arthritis,

NA

-

in-vivo,

NA,

NA

arthritis (AA) rat

Vim↓, HK2↓,

2432-

2DG,

Inhibition of glycolytic enzyme hexokinase II (HK2) suppresses lung tumor growth

-

in-vitro,

Lung,

H23

-

in-vitro,

Lung,

KP2

-

in-vivo,

NA,

NA

HK2↓, Apoptosis↑, TumAuto↑, TumCG↓,

1339-

2DG,

Cisplatin,

2-Deoxy-d-Glucose Combined with Cisplatin Enhances Cytotoxicity via Metabolic Oxidative Stress in Human Head and Neck Cancer Cells

-

in-vitro,

HNSCC,

FaDu

ChemoSen↑, ROS↑, GSH↓, other↓,

1337-

2DG,

Rad,

2-deoxy-D-glucose causes cytotoxicity, oxidative stress, and radiosensitization in pancreatic cancer

-

in-vivo,

NA,

NA

mice

ChemoSen↑, GlucoseCon↓, ROS↑,

1336-

2DG,

2-deoxy-D-glucose induces oxidative stress and cell killing in human neuroblastoma cells

-

in-vitro,

GBM,

SK-N-SH

ROS↑, GlucoseCon↓, other↓,

1341-

3BP,

The HK2 Dependent “Warburg Effect” and Mitochondrial Oxidative Phosphorylation in Cancer: Targets for Effective Therapy with 3-Bromopyruvate

-

Review,

NA,

NA

Glycolysis↓, OXPHOS↓, *toxicity↓, ROS↑, GSH↓, eff↑,

1340-

3BP,

Safety and outcome of treatment of metastatic melanoma using 3-bromopyruvate: a concise literature review and case study

-

Review,

NA,

NA

Glycolysis↓, HK2↓, LDH↓, OXPHOS↓, angioG↓, H2O2↑, eff↑,

3452-

5-ALA,

5-ALA Is a Potent Lactate Dehydrogenase Inhibitor but Not a Substrate: Implications for Cell Glycolysis and New Avenues in 5-ALA-Mediated Anticancer Action

-

in-vitro,

GBM,

T98G

-

in-vitro,

GBM,

LN-18

-

in-vitro,

GBM,

U87MG

Glycolysis↓, LDH↓, eff↝, ECAR↓,

3453-

5-ALA,

The heme precursor 5-aminolevulinic acid disrupts the Warburg effect in tumor cells and induces caspase-dependent apoptosis

-

in-vitro,

Lung,

A549

OXPHOS↑, OCR↑, Warburg↓, ROS↑, SOD2↑, Catalase↑, HO-1↑, Casp3↑, Apoptosis↑,

3538-

5-HTP,

Oral Administration of 5-Hydroxytryptophan Restores Gut Microbiota Dysbiosis in a Mouse Model of Depression

-

in-vivo,

Nor,

NA

mice

*GutMicro↑, *BBB↑, *5HT↑, *Weight↓,

3537-

5-HTP,

5-Hydroxytryptophan: a clinically-effective serotonin precursor

-

Review,

NA,

NA

*5HT↑, *BioAv↑, *BBB↑,

1161-

ACNs,

immuno,

Bilberry anthocyanin extracts enhance anti-PD-L1 efficiency by modulating gut microbiota

-

in-vivo,

Colon,

MC38

mouse

GutMicro↑,

1094-

ACNs,

Anthocyanidins inhibit epithelial-mesenchymal transition through a TGF-β/Smad2 signaling pathway in glioblastoma cells: Anthocyanidins inhibit TGF-β-mediated EMT.

-

in-vitro,

GBM,

U87MG

EMT↓,

1-

Aco,

Acoschimperoside P, 2'-acetate: a Hedgehog signaling inhibitory constituent from Vallaris glabra

-

in-vitro,

PC,

PANC1

0.75–6uM

-

in-vitro,

Pca,

DU145

HH↓, PTCH1↓, Bcl-2↓, Gli1↓,

147-

AG,

EGCG,

CUR,

Increased chemopreventive effect by combining arctigenin, green tea polyphenol and curcumin in prostate and breast cancer cells

-

in-vitro,

Pca,

LNCaP

5–10μM Cur, 1μM Arc and 40μM EGCG

-

in-vitro,

Pca,

MCF-7

5–10μM Cur, 1μM Arc and 40μM EGCG

Bax:Bcl2↑, NF-kB↓, PI3K/Akt↓, STAT3↓,

252-

Ajoene,

Ajoene, a Compound of Garlic, Induces Apoptosis in Human Promyeloleukemic Cells, Accompanied by Generation of Reactive Oxygen Species and Activation of Nuclear Factor κB

-

in-vitro,

AML,

HL-60

10uM

H2O2↑, NF-kB↑, ROS↑,

4-

Akk,

The Emerging Biotherapeutic Agent: Akkermansia

GutMicro↑,

540-

Akk,

Akkermansia muciniphila: a potential booster to improve the effectiveness of cancer immunotherapy

-

Analysis,

NA,

NA

GutMicro↑, carcinogenesis↓, ChemoSideEff↓,

543-

Akk,

Dynamic Changes of the Gut Microbiota and Its Functional Metagenomic Potential during the Development of Non-Small Cell Lung Cancer

other↓,

541-

Akk,

Akkermansia muciniphila as a Next-Generation Probiotic in Modulating Human Metabolic Homeostasis and Disease Progression: A Role Mediated by Gut-Liver-Brain Axes?

-

Review,

NA,

NA

GutMicro↑, PD-1↝, CD8+↑, IL8↑,

542-

Akk,

immuno,

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors

CD4+↑, CXCc↑, PD-1↝,

545-

AL,

Association and mechanism of garlic consumption with gastrointestinal cancer risk: A systematic review and meta‑analysis

Risk↓,

551-

AL,

The Influence of Heating on the Anticancer Properties of Garlic

-

Analysis,

NA,

NA

other↓,

550-

AL,

A Review on Anticancer Activities of Garlic (Allium sativum L.)

-

Review,

NA,

NA

ChemoSideEff↓, other↝,

549-

AL,

Allicin, a naturally occurring antibiotic from garlic, specifically inhibits acetyl-CoA synthetase

ACSS2↓,

548-

AL,

Aged Garlic and Cancer: A Systematic Review

-

Review,

NA,

NA

Risk↓,

547-

AL,

Garlic and Cancer: A Critical Review of the Epidemiologic Literature

-

Review,

NA,

NA

Risk↓,

546-

AL,

Effects of garlic intake on cancer: a systematic review of randomized clinical trials and cohort studies

-

Review,

NA,

NA

Risk↓, TumVol↓,

544-

AL,

Garlic constituents for cancer prevention and therapy: From phytochemistry to novel formulations

Risk↓, ChemoSideEff↓, TumCG↓, NF-kB⇅,

233-

AL,

5-FU,

Allicin sensitizes hepatocellular cancer cells to anti-tumor activity of 5-fluorouracil through ROS-mediated mitochondrial pathway

-

in-vivo,

Liver,

NA

5 mg/kg/d; every two days for 3 weeks

nude mide

ROS↑, MMP↓, Casp3↑, PARP↑, Bcl-2↓,

253-

AL,

Allicin inhibits invasion and migration of breast cancer cells through the suppression of VCAM-1: Regulation of association between p65 and ER-α

-

in-vitro,

BC,

MDA-MB-231

TumCMig↓, ERK↓, VCAM-1↓, NF-kB↓,

234-

AL,

Allicin Induces Anti-human Liver Cancer Cells through the p53 Gene Modulating Apoptosis and Autophagy

-

in-vitro,

HCC,

Hep3B

0, 15, 20, 25, 35, 40 and 50 μM of allicin for 24 h

35 uM @24h

ROS↑, *toxicity∅, MMP↓, BAX↑, Bcl-2↓, AIF↑, Casp3↑, Casp8↑, Casp9↑, eff↓, γH2AX↑, selectivity↑, DNA-PK↑,

235-

AL,

Allicin inhibits cell growth and induces apoptosis in U87MG human glioblastoma cells through an ERK-dependent pathway

-

in-vitro,

GBM,

U87MG

90 μM

Apoptosis↑, Bcl-2↓, BAX↑, MAPK↑, p‑ERK↑, ROS↑, eff↓,

236-

AL,

Allicin: Chemistry and Biological Properties

-

Analysis,

NA,

NA

GSH↓, Bacteria↓, LDL↓, ROS↑, NRF2↑, cognitive↑, memory↑, BP↓, RNS↓,

239-

AL,

Allicin induces apoptosis in gastric cancer cells through activation of both extrinsic and intrinsic pathways

-

in-vitro,

GC,

SGC-7901

30ug/ml

Apoptosis↑, Cyt‑c↑, Casp3↑, Casp8↑, Casp9↑, BAX↑, Fas↑, tumCV↓, DNAdam↑, ROS↑, Telomerase↓,

241-

AL,

Role of p38 MAPK activation and mitochondrial cytochrome-c release in allicin-induced apoptosis in SK-N-SH cells

-

in-vitro,

neuroblastoma,

SK-N-SH

5 μmol/l

(0, 0.5, 1, 5, 10, and 20 μmol/l) of allicin for 12, 24, and 48 h

Casp3↑, Casp9↑, p38↑, MAPK↑, Cyt‑c↑, Apoptosis↑,

245-

AL,

Allicin: a promising modulator of apoptosis and survival signaling in cancer

-

Review,

Var,

NA

Fas↑, Bcl-2↓, BAX↑, PI3k/Akt/mTOR↝, Casp3↑, Casp8↑, Casp9↑, Apoptosis↓, *toxicity↓, Cyt‑c↑,

246-

AL,

Allicin induces apoptosis of the MGC-803 human gastric carcinoma cell line through the p38 mitogen-activated protein kinase/caspase-3 signaling pathway

-

in-vitro,

GC,

MGC803

0-10ug/ml

Apoptosis↑, cl‑Casp3↑, p38↑, tumCV↓, BAX↑, Bcl-2↑,

247-

AL,

Allicin inhibits the invasion of lung adenocarcinoma cells by altering tissue inhibitor of metalloproteinase/matrix metalloproteinase balance via reducing the activity of phosphoinositide 3-kinase/AKT signaling

-

in-vitro,

Lung,

A549

-

in-vitro,

Lung,

H1299

MMP2↓, MMP9↓, TIMP1↑, TIMP2↑, p‑Akt↓, PI3K/Akt↓,

248-

AL,

Allicin inhibits cell growth and induces apoptosis in U87MG human glioblastoma cells through an ERK-dependent pathway

-

in-vitro,

GBM,

U87MG

Bcl-2↓, BAX↑, MAPK↑, ERK↑, ROS↑, p38↑, JNK↑,

249-

AL,

Allicin induces apoptosis of the MGC-803 human gastric carcinoma cell line through the p38 mitogen-activated protein kinase/caspase-3 signaling pathway

-

in-vitro,

GC,

MGC803

0.1, 1 and 10 μg/ml

Casp3↑, p38↑, BAX↑, Bcl-2↓, p38↑, MAPK↑,

250-

AL,

Allicin Induces p53-Mediated Autophagy in Hep G2 Human Liver Cancer Cells

-

in-vitro,

Liver,

HepG2

35uM

P53↓, PI3K↓, mTOR↓, Bcl-2↓, AMPK↑, TSC2↑, Beclin-1↑, TumAuto↑, tumCV↓, ATG7↑, MMP↓,

251-

AL,

Inhibition of allicin in Eca109 and EC9706 cells via G2/M phase arrest and mitochondrial apoptosis pathway

-

in-vitro,

ESCC,

Eca109

0-100ug/ml

-

in-vitro,

ESCC,

EC9706

-

in-vivo,

NA,

NA

5mg/kg/bw

mice

Apoptosis↑, P53↑, P21↑, CHK1↑, CycB↓, BAX↑, Casp3↑, Casp9↑, Cyt‑c↑,

257-

AL,

Cisplatin,

Allicin Overcomes Hypoxia Mediated Cisplatin Resistance in Lung Cancer Cells through ROS Mediated Cell Death Pathway and by Suppressing Hypoxia Inducible Factors

-

in-vitro,

NSCLC,

A549

10μg/ml (LD) and 40μg/ml (HD) allicin for 24hr

~30µg/ml

ROS↑, HIF-1↓, E-cadherin↑, N-cadherin↓, antiOx↓, Dose↝,

256-

AL,

doxoR,

Allicin Overcomes Doxorubicin Resistance of Breast Cancer Cells by Targeting the Nrf2 Pathway

-

in-vitro,

BC,

MCF-7

-

in-vitro,

BC,

MDA-MB-231

NRF2↓, HO-1↓, p‑Akt↓,

255-

AL,

Allicin induces cell cycle arrest and apoptosis of breast cancer cells in vitro via modulating the p53 pathway

-

in-vitro,

BC,

MCF-7

-

in-vitro,

BC,

MDA-MB-231

Apoptosis↑, P53↑, Casp3↑, P53↑, TPM4↓,

254-

AL,

Allicin and Cancer Hallmarks

-

Review,

Var,

NA

NRF2⇅, BAX↑, Bcl-2↓, Fas↑, MMP↓, Bax:Bcl2↑, Cyt‑c↑, Casp3↑, Casp12↑, GSH↓, TumCCA↑, ROS↑, antiOx↓,

231-

AL,

Molecular Docking Studies with Garlic Phytochemical Constituents to Inhibit the Human EGFR Protein for Lung Cancer Therapy

-

Analysis,

Lung,

NA

EGFR↓, ROS↑,

232-

AL,

A Single Meal Containing Raw, Crushed Garlic Influences Expression of Immunity- and Cancer-Related Genes in Whole Blood of Humans

-

Human,

Nor,

NA

17 volunteers consumed a garlic-containing meal (100 g white bread, 15 g butter, and 5 g raw, crushed garlic)

*AhR↑, *ARNT↑, *Hif1a↑, *Jun↑, *NFAT↑, *NFAM1↑, *REL↑, *OSM↑, *NFAT↑, *CXCc↑, *IL2↑, *IL6↑, *LIF↑,

1069-

AL,

Allicin promotes autophagy and ferroptosis in esophageal squamous cell carcinoma by activating AMPK/mTOR signaling

-

vitro+vivo,

ESCC,

TE1

10 mg/kg

12.03 μg/mL

mice

-

vitro+vivo,

ESCC,

KYSE-510

16.76 μg/mL

-

in-vitro,

Nor,

Het-1A

>160 μg/mL

TumCP↓, LC3‑Ⅱ/LC3‑Ⅰ↑, p62↓, p‑AMPK↑, mTOR↓, TumAuto↑, NCOA4↑, MDA↑, Iron↑, TumW↓, TumVol↓, ATG5↑, ATG7↑, TfR1/CD71↓, FTH1↓, ROS↑, Iron↑, Ferroptosis↑, *toxicity↓,

1023-

AL,

Allicin May Promote Reversal of T-Cell Dysfunction in Periodontitis via the PD-1 Pathway

-

in-vitro,

NA,

NA

5, 10, 25, and 50 μM

100 and 250 μM were toxic to T cells

-

Analysis,

NA,

NA

PD-L1↓,

2463-

AL,

Garlic as an antithrombotic and antiplatelet aggregation agent

-

Review,

Nor,

NA

AntiAg↑, other↑,

2462-

AL,

Comparison of antiplatelet activity of garlic tablets with cardio-protective dose of aspirin in healthy volunteers: a randomized clinical trial

-

Trial,

Nor,

NA

1, 2 or 3 garlic tablets (1250 mg) a day for 1 month

AntiAg∅,

2770-

AL,

Allicin protects against renal ischemia–reperfusion injury by attenuating oxidative stress and apoptosis

-

in-vivo,

Nor,

NA

50 mg /kg

Male Sprague Dawley (SD) rats

-

in-vitro,

Nor,

NRK52E

*antiOx↑, *RenoP↑, *MDA↓, *SOD↑,

2655-

AL,

Allicin and Digestive System Cancers: From Chemical Structure to Its Therapeutic Opportunities

-

Review,

GC,

NA

TGF-β↓, cycD1↓, cycE↓, CDK1↓, DNAdam↑, ROS↑, BAX↑, JNK↑, MMP↓, p38↑, MAPK↑, Fas↑, Cyt‑c↑, Casp8↑, PARP↑, Casp3↑, Casp9↑, Ca+2↑, ER Stress↑, P21↑, CDK2↓, CDK6↑, TumCCA↑, CDK4↓,

2557-

AL,

Allicin, a naturally occurring antibiotic from garlic, specifically inhibits acetyl-CoA synthetase

-

in-vitro,

NA,

NA

ACSS2↓,

2558-

AL,

Allicin, an Antioxidant and Neuroprotective Agent, Ameliorates Cognitive Impairment

-

Review,

AD,

NA

*AntiCan↑, *antiOx↑, *cardioP↑, *neuroP↑, cognitive↑, *ROS↓, *NOX↓, *TLR4↓, *NF-kB↓, *JNK↓, *AntiAg↑, *H2S↑, *BP↓, Telomerase↓, *Insulin↑, BioAv↝, *GSH↑, *Catalase↑,

2559-

AL,

Effect of the Garlic Pill in comparison with Plavix on Platelet Aggregation and Bleeding Time

-

Human,

Nor,

NA

36 healthy adult male volunteers without having known digestive, coagulation and cardiovascular disorders

AntiAg↑, COX2↓, cardioP↑,

2560-

AL,

Effect of garlic on platelet aggregation in humans: a study in healthy subjects and patients with coronary artery disease

-

ex-vivo,

Nor,

NA

*AntiAg↑, BioAv↝, Dose↝,

2645-

AL,

Allicin improves endoplasmic reticulum stress-related cognitive deficits via PERK/Nrf2 antioxidative signaling pathway

-

NA,

AD,

NA

*neuroP↑,

2646-

AL,

Anti-Cancer Potential of Homemade Fresh Garlic Extract Is Related to Increased Endoplasmic Reticulum Stress

-

in-vitro,

Pca,

DU145

-

in-vitro,

Melanoma,

RPMI-8226

AntiCan↑, eff↓, ChemoSen↑, ER Stress↑, tumCV↓, DNAdam↑, GSH∅, HSP70/HSPA5↓, UPR↑, β-catenin/ZEB1↓, ROS↑, HO-2↑, SIRT1↑, GlucoseCon∅, lactateProd∅, chemoP↑,

2647-

AL,

The Mechanism in Gastric Cancer Chemoprevention by Allicin

-

Review,

GC,

NA

ChemoSen↓, TumCG↓, TumCCA↑, ER Stress↑, Apoptosis↑, Casp↑, DR5↑,

2648-

AL,

Allicin Inhibits Osteosarcoma Growth by Promoting Oxidative Stress and Autophagy via the Inactivation of the lncRNA MALAT1-miR-376a-Wnt/β-Catenin Signaling Pathway

-

in-vitro,

OS,

SaOS2

-

in-vivo,

OS,

NA

ROS↑, TumCG↓, TumAuto↑, Wnt↓, β-catenin/ZEB1↓, MALAT1↓,

2656-

AL,

Allicin Protects PC12 Cells Against 6-OHDA-Induced Oxidative Stress and Mitochondrial Dysfunction via Regulating Mitochondrial Dynamics

-

in-vitro,

Park,

PC12

*antiOx↑, *Apoptosis↓, *LDH↓, ROS↓, *lipid-P↓, *mtDam↓, *MMP↓, *Cyt‑c↓, *ATP∅, *Ca+2↝, *neuroP↑,

2657-

AL,

Allicin pharmacology: Common molecular mechanisms against neuroinflammation and cardiovascular diseases

-

Review,

CardioV,

NA

-

Review,

AD,

NA

*Inflam↓, *antiOx↑, *neuroP↑, *cardioP↑, *AntiTum↑, *mtDam↑, *HSP70/HSPA5↑, *NRF2↑, *RAAS↓, *cognitive↑, *SOD↑, *ROS↓, *NRF2↑, *ER Stress↓, *neuroP↑, *memory↑, *TBARS↓, *MPO↓, *SOD↑, *GSH↑, *iNOS↓, *p‑eNOS↑, *HO-1↑,

2658-

AL,

The Toxic Effect Ways of Allicin on Different Cell Lines

-

Review,

Var,

NA

*antiOx↑, *AntiAg↑, *cardioP↑, Ca+2↑, ROS↑, Casp↑, p38↑, MAPK↑, hepatoP↑, chemoP↑,

2660-

AL,

Allicin: A review of its important pharmacological activities

-

Review,

AD,

NA

-

Review,

Var,

NA

-

Review,

Park,

NA

-

Review,

Stroke,

NA

*Inflam↓, AntiCan↑, *antiOx↑, *cardioP↑, *hepatoP↑, *BBB↑, *Half-Life↝, *H2S↑, *BP↓, *neuroP↑, *cognitive↑, *neuroP↑, *ROS↓, *GutMicro↑, *LDH↓, *ROS↓, *lipid-P↓, *antiOx↑, *other↑, *PI3K↓, *Akt↓, *NF-kB↓, *NO↓, *iNOS↓, *PGE2↓, *COX2↓, *IL6↓, *TNF-α↓, *MPO↓, *eff↑, *NRF2↑, *Keap1↓, *TBARS↓, *creat↓, *LDH↓, *AST↓, *ALAT↓, *MDA↓, *SOD↑, *GSH↑, *GSTs↑, *memory↑, chemoP↑, IL8↓, Cyt‑c↑, Casp3↑, Casp8↑, Casp9↑, Casp12↑, p38↑, Fas↑, P53↑, P21↑, CHK1↓, CycB↓, GSH↓, ROS↑, TumCCA↑, Hif1a↓, Bcl-2↓, VEGF↓, TumCMig↓, STAT3↓, VEGFR2↓, p‑FAK↓,

2669-

AL,

Rad,

Inhibition of ICAM-1 expression by garlic component, allicin, in gamma-irradiated human vascular endothelial cells via downregulation of the JNK signaling pathway

-

in-vitro,

Nor,

HUVECs

*ICAM-1↓, *AP-1↓, *p‑cJun↓, *radioP↑, JNK↓,

2668-

AL,

Allicin enhances the radiosensitivity of colorectal cancer cells via inhibition of NF-κB signaling pathway

-

in-vitro,

CRC,

HCT116

RadioS↑, NF-kB↓,

2667-

AL,

Allicin in Digestive System Cancer: From Biological Effects to Clinical Treatment

-

Review,

GC,

NA

AntiCan↑, ChemoSen↑, angioG↓, chemoP↑, *GutMicro↑, *antiOx↑, other↝, GSH↓, Thiols↓, *ROS↓, *hepatoP↑, *Inflam↓, *NF-kB↓,

2666-

AL,

Targeting the Interplay of Autophagy and ROS for Cancer Therapy: An Updated Overview on Phytochemicals

-

Review,

Var,

NA

Inflam↓, AntiCan↑, ROS↑, MAPK↑, JNK↑, TumAuto↑, other↑, Dose↝, MALAT1↓, Wnt↓, β-catenin/ZEB1↓,

2665-

AL,

Anticancerous and Antimicrobial Properties of Garlic

-

Review,

Var,

NA

DNMTs↓, DNMT1↓,

2663-

AL,

Therapeutic Effect of Allicin on Glioblastoma

-

in-vitro,

GBM,

U251

-

in-vitro,

GBM,

U87MG

BioAv↝, TumCCA↑, P53↑, HDAC↓, CSCs↓, ROS↑, ChemoSen↑, MGMT↓,

2662-

AL,

Allicin inhibits tubular epithelial-myofibroblast transdifferentiation under high glucose conditions in vitro

-

in-vitro,

Nor,

HK-2

(HK-2) cultured under high glucose concentrations.

*α-SMA↓, *Vim↓, *COL1↓, *E-cadherin↑, *TGF-β1↓, *p‑ERK↓, *EMT↓,

2661-

AL,

Allicin alleviates traumatic brain injury-induced neuroinflammation by enhancing PKC-δ-mediated mitophagy

-

in-vivo,

Nor,

NA

mice

*TNF-α↓, *IL1β↓, *IL6↓, *ROS↓, *NLRP3↓, *TLR4↓, *PKCδ↑, neuroP↑,

2659-

AL,

Allicin inhibits spontaneous and TNF-α induced secretion of proinflammatory cytokines and chemokines from intestinal epithelial cells

-

in-vitro,

HCC,

HT29

-

in-vitro,

HCC,

Caco-2

IL1β↓, IL8↓, Inflam↓,

1290-

AL,

Effect of allicin on the expression of Bcl-2 and Bax protein in LM-8 cells

-

in-vitro,

OS,

LM8

5.0, 10.0 and 15.0 mg/L) for 24, 48 and 72

Bcl-2↓, BAX↑, Apoptosis↑, TumCG↓,

1916-

AL,

Allicin Bioavailability and Bioequivalence from Garlic Supplements and Garlic Foods

-

Review,

Nor,

NA

*BioAv↝, *eff↓, *BioAv↝, *BioAv↝, *eff↑, *Half-Life∅, *eff↑, *eff↑, *Dose∅, *eff↑,

2000-

AL,

Exploring the ROS-mediated anti-cancer potential in human triple-negative breast cancer by garlic bulb extract: A source of therapeutically active compounds

-

in-vitro,

BC,

MDA-MB-231

5–20 mg/mL

13.69 mg/mL

-

in-vitro,

BC,

MCF-7

5–20 mg/mL5–20 mg/mL

15.35 mg/mL

-

in-vitro,

Nor,

NA

selectivity↑, TumCG?, *toxicity∅, ROS↑, MMP↓, TumCCA↑, P53↑, Bcl-2↓, p‑Akt↓, p‑p38↓, *ROS∅,

1235-

ALA,

Cisplatin,

α-Lipoic acid prevents against cisplatin cytotoxicity via activation of the NRF2/HO-1 antioxidant pathway

-

in-vitro,

Nor,

HEI-OC1

20μM cisplatin, 0-2mM(ALA)

-

ex-vivo,

NA,

NA

ROS↑, HO-1↓, *toxicity↓, chemoP↑, *ROS↓, *HO-1↑, *SOD1↑, *NRF2↑,

298-

ALA,

Rad,

Synergistic Tumoricidal Effects of Alpha-Lipoic Acid and Radiotherapy on Human Breast Cancer Cells via HMGB1

-

in-vitro,

BC,

MDA-MB-231

Apoptosis↑, P53↑, p38↑, NF-kB↑, TumCCA↑,

299-

ALA,

Cisplatin,

PacT,

Anti-cancer effects of alpha lipoic acid, cisplatin and paclitaxel combination in the OVCAR-3 ovarian adenocarcinoma cell line

-

in-vitro,

Ovarian,

OVCAR-3

MMP9↓, MMP11↓, MAPK↓,

297-

ALA,

Insights on the Use of α-Lipoic Acid for Therapeutic Purposes

-

Review,

BC,

SkBr3

-

Review,

neuroblastoma,

SK-N-SH

-

Review,

AD,

NA

PDH↑, TumCG↓, ROS↑, AMPK↑, EGR4↓, Half-Life↓, BioAv↝, *GSH↑, *IronCh↑, *ROS↓, *antiOx↑, *neuroP↑, *Ach↑, *lipid-P↓, *IL1β↓, *IL6↓, TumCP↓, FDG↓, Apoptosis↑, AMPK↑, mTOR↓, EGFR↓, TumCI↓, TumCMig↓, *memory↑, *BioAv↑, *BioAv↝, *other↓, *other↝, *Half-Life↓, *BioAv↑, *ChAT↑, *GlucoseCon↑,

301-

ALA,

PacT,

doxoR,

Role of alpha-lipoic acid in counteracting paclitaxel- and doxorubicin-induced toxicities: a randomized controlled trial in breast cancer patients

-

Human,

BC,

NA

BNP↓, TNF-α↓, MDA↓, NeuroT↓,

302-

ALA,

The Antioxidant Alpha-Lipoic Acid Inhibits Proliferation and Invasion of Human Gastric Cancer Cells via Suppression of STAT3-Mediated MUC4 Gene Expression

-

in-vitro,

GC,

AGS

-

in-vitro,

GC,

BGC-823

-

in-vitro,

GC,

MKN-28

MUC4↓, STAT3↓,

303-

ALA,

LDN,

The long-term survival of a patient with pancreatic cancer with metastases to the liver after treatment with the intravenous alpha-lipoic acid/low-dose naltrexone protocol

304-

ALA,

alpha-Lipoic acid induces apoptosis in human colon cancer cells by increasing mitochondrial respiration with a concomitant O2-*-generation

-

in-vitro,

Colon,

HT-29

1 mM DHLA or 1 mM ALA.

mt-ROS↑, Apoptosis↑, Casp3↑, DNAdam↑, Bcl-xL↓, Dose↝,

282-

ALA,

Alpha-lipoic acid induced apoptosis of PC3 prostate cancer cells through an alteration on mitochondrial membrane depolarization and MMP-9 mRNA expression

-

in-vitro,

Pca,

PC3

1.71 mM

MMP↓, Casp↑, MMP9↓,

279-

ALA,

Lipoic acid-induced oxidative stress abrogates IGF-1R maturation by inhibiting the CREB/furin axis in breast cancer cell lines

-

in-vitro,

BC,

MCF-7

1 or 2 mM

-

in-vitro,

BC,

MDA-MB-231

Furin↓, IGF-1R↓, ROS↑, CREB↓, Furin↓, IGF-1R↓,

281-

ALA,

Reactive oxygen species mediate caspase activation and apoptosis induced by lipoic acid in human lung epithelial cancer cells through Bcl-2 down-regulation

-

in-vitro,

Lung,

H460

0-100uM

mt-ROS↑, Apoptosis↑, Casp9↑, Bcl-2↓, eff↓, eff↑, H2O2↑, Dose↑,

280-

ALA,

Alpha‐lipoic acid inhibits lung cancer growth via mTOR‐mediated autophagy inhibition

-

in-vivo,

Lung,

A549

orally administrated with LA (50 mg·kg−1·day−1) in drinking water

mice

p‑mTOR↑, TumCG↓, NA↑, TumAuto↓, p‑P70S6K↑,

278-

ALA,

The Multifaceted Role of Alpha-Lipoic Acid in Cancer Prevention, Occurrence, and Treatment

-

Review,

NA,

NA

ROS↑, NRF2↑, Inflam↓, frataxin↑, *BioAv↓, ChemoSen↑, Hif1a↓, eff↑, FAK↓, ITGB1↓, MMP2↓, MMP9↓, EMT↓, Snail↓, Vim↓, Zeb1↓, P53↑, MGMT↓, Mcl-1↓, Bcl-xL↓, Bcl-2↓, survivin↓, Casp3↑, Casp9↑, BAX↑, p‑Akt↓, GSK‐3β↓, *antiOx↑, *ROS↓, selectivity↑, angioG↓, MMPs↓, NF-kB↓, ITGB3↓, NADPH↓,

277-

ALA,

α-lipoic acid modulates prostate cancer cell growth and bone cell differentiation

-

in-vitro,

Pca,

22Rv1

500 μM

-

in-vitro,

Pca,

C4-2B

ROS↑, Hif1a↑, JNK↑, Casp3↑, P21↑, BAX↑, Bcl-xL↓, cFos↓,

276-

ALA,

Alpha lipoic acid diminishes migration and invasion in hepatocellular carcinoma cells through an AMPK-p53 axis

-

in-vitro,

HCC,

HepG2

significant inhibition of cell migration/invasion only in HepG2/C3A cells

-

in-vitro,

HCC,

Hep3B

P53↑, EMT↓, AMPK↑, cycD1↓, TumCMig↓,

274-

ALA,

LDN,

Revisiting the ALA/N (alpha-lipoic acid/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer: a report of 3 new cases

-

Human,

PC,

NA

OS↑,

272-

ALA,

Evidence that α-lipoic acid inhibits NF-κB activation independent of its antioxidant function

-

in-vitro,

NA,

HUVECs

NF-kB↓,

271-

ALA,

VitC,

LDN,

The Long-Term Survival of a Patient With Stage IV Renal Cell Carcinoma Following an Integrative Treatment Approach Including the Intravenous α-Lipoic Acid/Low-Dose Naltrexone Protocol

OS↑, Weight↑, TumVol↓,

267-

ALA,

α-Lipoic Acid Targeting PDK1/NRF2 Axis Contributes to the Apoptosis Effect of Lung Cancer Cells

-

vitro+vivo,

Lung,

A549

1.5 mM LA for 24 h

-

vitro+vivo,

Lung,

PC9

Apoptosis↑, ROS↑, PDK1↓, NRF2↓, PDK1↓, Bcl-2↓, Casp9↑, Dose∅,

266-

ALA,

Lipoic acid decreases Mcl-1, Bcl-xL and up regulates Bim on ovarian carcinoma cells leading to cell death

-

in-vitro,

Ovarian,

IGROV1

Mcl-1↓, Bcl-xL↓, BIM↑, ROS↑,

265-

ALA,

Alpha-Lipoic Acid Reduces Cell Growth, Inhibits Autophagy, and Counteracts Prostate Cancer Cell Migration and Invasion: Evidence from In Vitro Studies

-

in-vitro,

Pca,

LNCaP

ALA (25–1000 μM) for 48 h

-

in-vitro,

Pca,

DU145

ROS↓, SOD↓, GSTP1/GSTπ↓, NRF2↓, p62↓, p62↑, SOD↑, p‑mTOR↑, Beclin-1↓, ROS↑, SOD1↑,

264-

ALA,

α-Lipoic acid induces Endoplasmic Reticulum stress-mediated apoptosis in hepatoma cells

-

in-vitro,

HCC,

FaO

500uM

ROS↑, P53↑, ER Stress↑, UPR↑, CHOP↑, PDI↑, GRP78/BiP↑, GRP58↓,

263-

ALA,

Alpha-lipoic acid induces p27Kip-dependent cell cycle arrest in non-transformed cell lines and apoptosis in tumor cell lines

-

in-vitro,

SCC,

Jurkat

-

in-vitro,

SCC,

FaDu

p27↑,

262-

ALA,

Lipoic acid decreases breast cancer cell proliferation by inhibiting IGF-1R via furin downregulation

-

in-vitro,

BC,

MCF-7

1 or 2 mM

-

in-vitro,

BC,

MDA-MB-231

TumCP↓, Akt↓, ERK↓, IGF-1R↓, Furin↓, Ki-67↓, AMPK↑, mTOR↓,

261-

ALA,

The natural antioxidant alpha-lipoic acid induces p27(Kip1)-dependent cell cycle arrest and apoptosis in MCF-7 human breast cancer cells

-

in-vitro,

BC,

MCF-7

0-2.5mM

ROS↓, Akt↓, p27↑, Bax:Bcl2↑,

260-

ALA,

The effects of alpha-lipoic acid on breast of female albino rats exposed to malathion: Histopathological and immunohistochemical study

-

in-vivo,

BC,

NA

rats exposed to malathion

PCNA↓, P53↓, Apoptosis↑, BAX↑,

259-

ALA,

Increased ROS generation and p53 activation in alpha-lipoic acid-induced apoptosis of hepatoma cells

-

in-vitro,

Liver,

HepG2

500 µM for 24, 48 and 72 h

-

in-vitro,

Liver,

FaO

Cyc↓, P21↑, ROS↑, p‑P53↑, BAX↑, Cyt‑c↑, Casp↑, survivin↓, JNK↑, Akt↓,

258-

ALA,

Effects of α-lipoic acid on cell proliferation and apoptosis in MDA-MB-231 human breast cells

-

in-vitro,

BC,

MDA-MB-231

250, 500, and 1000 µmol/L

TumCG↓, p‑Akt↓, Akt↓, HER2/EBBR2↓, Bcl-2↓, BAX↑, Casp3↑,

296-

ALA,

Lipoic acid inhibits cell proliferation of tumor cells in vitro and in vivo

-

vitro+vivo,

neuroblastoma,

SK-N-SH

2.5 mM, 5 mM and 7.5 mM

-

vitro+vivo,

BC,

SkBr3

TumCG↓, Casp3↑,

284-

ALA,

Lipoic acid a multi-level molecular inhibitor of tumorigenesis

-

Review,

Var,

NA

EMT↓, TumMeta↓,

285-

ALA,

HCA,

Tolerance of oral lipoid acid and hydroxycitrate combination in cancer patients: first approach of the cancer metabolism research group

-

Human,

Var,

NA

PI3K↝, AMPK↝, TumCG↓, *toxicity↓, Weight∅,

283-

ALA,

alpha-Lipoic acid reduces matrix metalloproteinase activity in MDA-MB-231 human breast cancer cells

-

in-vitro,

BC,

MDA-MB-231

250, 500, or 1000 mumol/L

MMP2↓, MMP9↓, TumMeta↓,

287-

ALA,

HCA,

Lyco,

Metabolic treatment of cancer: intermediate results of a prospective case series

PSA↓, OS↑,

288-

ALA,

HCA,

CAP,

Octr,

Tumor regression with a combination of drugs interfering with the tumor metabolism: efficacy of hydroxycitrate, lipoic acid and capsaicin

TumCG↓,

289-

ALA,

HCA,

EA,

Cancer Metabolism: Fasting Reset, the Keto-Paradox and Drugs for Undoing

-

Analysis,

NA,

NA

ACLY↓,

290-

ALA,

HCA,

A combination of alpha lipoic acid and calcium hydroxycitrate is efficient against mouse cancer models: preliminary results

-

vitro+vivo,

Melanoma,

B16-F10

ALA(0.1-10uM), HCA(10-500uM)

mouse

TumCG↓, OS↑,

291-

ALA,

HCA,

MET,

Dicl,

Metabolic therapies inhibit tumor growth in vivo and in silico

-

in-vivo,

Melanoma,

B16-F10

-

in-vivo,

Lung,

LL/2 (LLC1)

-

in-vivo,

Bladder,

MBT-2

TumCG↓,

295-

ALA,

α-Lipoic acid suppresses migration and invasion via downregulation of cell surface β1-integrin expression in bladder cancer cells

-

in-vitro,

Bladder,

T24

ITGB1↓, TumCMig↓, ERK↓, Akt↓,

1124-

ALA,

Alpha lipoic acid inhibits proliferation and epithelial mesenchymal transition of thyroid cancer cells

-

in-vitro,

Thyroid,

BCPAP

-

in-vitro,

Thyroid,

HTH-83

-

in-vitro,

Thyroid,

CAL-62

-

in-vitro,

Thyroid,

FTC-133

-

in-vivo,

NA,

NA

mouse

TumCP↓, AMPK↑, mTOR↓, TumCMig↓, TumCI↓, EMT↓, E-cadherin↑, β-catenin/ZEB1↓, Vim↓, Snail↓, Twist↓, TGF-β↓, p‑SMAD2↓, TumCG↓,

3446-

ALA,

CUR,

The Potential Protective Effect of Curcumin and α-Lipoic Acid on N-(4-Hydroxyphenyl) Acetamide-induced Hepatotoxicity Through Downregulation of α-SMA and Collagen III Expression

-

in-vivo,

Nor,

NA

Curc (200 mg/kg p. o.) and/or Lip acid (100 mg/kg i. p.)

rats

*hepatoP↑, *α-SMA↓, *COL3A1↓, *ROS↓, *GSH↑, *ALAT↓, *AST↓, *ALP↓, *MDA↓,

3451-

ALA,

Alpha-lipoic acid ameliorates H2O2-induced human vein endothelial cells injury via suppression of inflammation and oxidative stress

-

in-vitro,

Nor,

HUVECs

(HUVECs) injury induced by hydrogen peroxide (H2O2)

*LDH↓, *NOX4↓, *NF-kB↓, *iNOS↓, *VCAM-1↓, *ICAM-1↓, *ROS↓, *cardioP↑,

3445-

ALA,

Rad,

The radioprotective effects of alpha-lipoic acid on radiotherapy-induced toxicities: A systematic review

-

Review,

Var,

NA

*radioP↑, *antiOx↑, *Inflam↓,

3444-

ALA,

Alpha-Lipoic Acid Nootropic Review: Benefits, Use, Dosage & Side Effects

-

Review,

NA,

NA

*BBB↑, *cognitive↑, *neuroP↑, *antiOx↑,

3443-

ALA,

Molecular and Therapeutic Insights of Alpha-Lipoic Acid as a Potential Molecule for Disease Prevention

-

Review,

Var,

NA

-

Review,

AD,

NA

*antiOx↑, *ROS↓, *IronCh↑, *cognitive↑, *cardioP↓, AntiCan↑, *neuroP↑, *Inflam↓, *BioAv↓, *AntiAge↑, *Half-Life↓, *BioAv↝, other↝, EGFR↓, Akt↓, ROS↓, TumCCA↑, p27↑, PDH↑, Glycolysis↓, ROS↑, *eff↑, *memory↑, *motorD↑, *GutMicro↑,

3442-

ALA,

α‑lipoic acid modulates prostate cancer cell growth and bone cell differentiation

-

in-vitro,

Pca,

22Rv1

-

in-vitro,

Pca,

C4-2B

-

in-vitro,

Nor,

3T3

tumCV↓, TumCMig↓, TumCI↓, ROS↑, Hif1a↑, JNK↑, Casp↑, TumCCA↑, Apoptosis↑, selectivity↑,

3441-

ALA,

α-Lipoic Acid Maintains Brain Glucose Metabolism via BDNF/TrkB/HIF-1α Signaling Pathway in P301S Mice

-

in-vivo,

AD,

NA

mice

*tau↓, *GlucoseCon↑, *GLUT3↑, *GLUT4↑, *VEGF↑, *HO-1↑, *Glycolysis↑, *HK1↑, *PGC-1α↑, *Hif1a↑, *neuroP↑,

3440-

ALA,

Protective effects of alpha lipoic acid (ALA) are mediated by hormetic mechanisms

-

Review,

AD,

NA

*ROS↓, *neuroP↑, *Aβ↓, *cardioP?,

3439-

ALA,

The effect of alpha lipoic acid on the developmental competence of mouse isolated preantral follicles

-

in-vitro,

NA,

NA

100uM

Pre-antral follicles were isolated from immature mouse ovaries and were cultured in α- minimal essential medium supplemented

*ROS↓, *TAC↑, *eff↑, *SOD↑, *GPx↑, *Catalase↑, *GlucoseCon↑, *antiOx↑,

3438-

ALA,

The Potent Antioxidant Alpha Lipoic Acid

-

Review,

NA,

NA

-

Review,

AD,

NA

*antiOx↑, *cardioP↑, *cognitive↑, *AntiAge↑, *Inflam↓, *AntiCan↑, *neuroP↑, *IronCh↑, *ROS↑, *Weight↓, *Ach↑, *ROS↓, *GSH↑, *lipid-P↓, *memory↑, *NRF2↑, *ChAT↑, *GlucoseCon↑, *Acetyl-CoA↑,

3437-

ALA,

Revisiting the molecular mechanisms of Alpha Lipoic Acid (ALA) actions on metabolism

-

Review,

Var,

NA

*IronCh↑, *antiOx↑, *ROS↓, *GSH↑, *NF-kB↓, *AMPK⇅, *FAO↑, *GlucoseCon↑, *PI3K↑, *Akt?,

3436-

ALA,

Alpha lipoic acid modulates metabolic reprogramming in breast cancer stem cells enriched 3D spheroids by targeting phosphoinositide 3-kinase: In silico and in vitro insights Author links open overlay panel

-

in-vitro,

BC,

MCF-7

ChemoSen↑, PI3K↓, Akt↓, ATP↓, GlucoseCon↓, ROS↑, PKM2↓, Glycolysis↓, CSCs↓, IGF-1R↓, Furin↓, RadioS↑,

3434-

ALA,

Alpha lipoic acid modulates metabolic reprogramming in breast cancer stem cells enriched 3D spheroids by targeting phosphoinositide 3-kinase: In silico and in vitro insights

-

in-vitro,

BC,

MCF-7

-

in-vitro,

BC,

MDA-MB-231

tumCV↓, PI3K↓, p‑Akt↓, p‑P70S6K↓, mTOR↓, ATP↓, GlucoseCon↓, ROS↑, PKM2↓, LDHA↓, Glycolysis↓, ChemoSen↑,

3433-

ALA,

Alpha lipoic acid promotes development of hematopoietic progenitors derived from human embryonic stem cells by antagonizing ROS signals

*ROS↓, *Apoptosis↓, *Hif1a↑, *FOXO1↑, *FOXO3↑, *ATM↑, *SIRT1↑, *SIRT3↑, *CD34↑,

3447-

ALA,

Redox Active α-Lipoic Acid Differentially Improves Mitochondrial Dysfunction in a Cellular Model of Alzheimer and Its Control Cells

-

in-vitro,

AD,

SH-SY5Y

*ATP↑, *MMP↑, *ROS↓, *GlucoseCon↑, *GSH↑, *neuroP↑, *cognitive↑, *Ach↑, *Inflam↓, *Aβ↓, OXPHOS↓,

3448-

ALA,

Alpha lipoic acid attenuates hypoxia-induced apoptosis, inflammation and mitochondrial oxidative stress via inhibition of TRPA1 channel in human glioblastoma cell line

*Inflam↓, *ROS↓, *GSH↑, *GPx↑, *Casp3↓, *Casp9↓, *MMP↑,

3449-

ALA,

Alpha-Lipoic Acid Downregulates IL-1β and IL-6 by DNA Hypermethylation in SK-N-BE Neuroblastoma Cells

-

in-vitro,

AD,

SK-N-BE

*antiOx↑, *NRF2↑, *NF-kB↓, *IL1β↓, *IL6↓, neuroP↑,

3450-

ALA,

α-Lipoic Acid Inhibits Expression of IL-8 by Suppressing Activation of MAPK, Jak/Stat, and NF-κB in H. pylori-Infected Gastric Epithelial AGS Cells

-

in-vitro,

NA,

AGS

*IL8↓, *MAPK↓, *JAK↓, *STAT↓, *NF-kB↓,

3454-

ALA,

Lipoic acid blocks autophagic flux and impairs cellular bioenergetics in breast cancer and reduces stemness

-

in-vitro,

BC,

MCF-7

(0.5 mM, 1 mM, 2.5 mM, and 5 mM)

-

in-vitro,

BC,

MDA-MB-231

TumCG↑, Glycolysis↓, ROS↑, CSCs↓, selectivity↑, LC3B-II↑, MMP↓, mitResp↓, ATP↓, OCR↓, NAD↓, p‑AMPK↑, GlucoseCon↓, lactateProd↓, HK2↓, PFK↓, LDHA↓, eff↓, mTOR↓, ECAR↓, ALDH↓, CD44↓, CD24↓,

3455-

ALA,

Alpha-lipoic acid inhibits proliferation and migration of human vascular endothelial cells through downregulating HSPA12B/VEGF signaling axis

-

in-vitro,

Nor,

HUVECs

*cMyc↓, *VEGF↓, *eNOS↓, angioG↓,

3456-

ALA,

Renal-Protective Roles of Lipoic Acid in Kidney Disease

-

Review,

NA,

NA

*RenoP↑, *ROS↓, *antiOx↑, *Inflam↓, *Sepsis↓, *IronCh↑, *BUN↓, *creat↓, *TNF-α↓, *IL6↓, *IL1β↓, *MDA↓, *NRF2↑, *HO-1↑, *NQO1↑, *chemoP↑, *eff↑, *NF-kB↓,

3539-

ALA,

Alpha-lipoic acid as a dietary supplement: Molecular mechanisms and therapeutic potential

-

Review,

AD,

NA

*ROS↓, *IronCh↑, *GSH↑, *antiOx↑, *NRF2↑, *MMP9↓, *VCAM-1↓, *NF-kB↓, *cognitive↑, *Inflam↓, *BioAv↝, *BioAv↝, *BBB↑, *H2O2∅, *neuroP↑, *PKCδ↑, *ERK↑, *MAPK↑, *PI3K↑, *Akt↑, *PTEN↓, *AMPK↑, *GLUT4↑, *GlucoseCon↑, *BP↝, *eff↑, *ICAM-1↓, *VCAM-1↓, *Dose↝,

3540-

ALA,

Thioctic (lipoic) acid: a therapeutic metal-chelating antioxidant?

-

in-vitro,

NA,

NA

*lipid-P↓, *H2O2↓, *IronCh↑,

3541-

ALA,

Insights on alpha lipoic and dihydrolipoic acids as promising scavengers of oxidative stress and possible chelators in mercury toxicology

-

Review,

Var,

NA

*antiOx↑, *IronCh↑, *GSH↑, *BBB?, Apoptosis↑, MMP↓, ROS↑, lipid-P↑, PARP1↑, Casp3↑, Casp9↑, *NRF2↑, *GSH↑, *ROS↓, RenoP↑, ChemoSen↑, *BG↓,

3542-

ALA,

Chelation: Harnessing and Enhancing Heavy Metal Detoxification—A Review

-

Review,

Var,

NA

*antiOx↑, *VitE↑, *VitC↑, *GSH↑, *IronCh↑, *BioAv↑, *BBB↑,

3543-

ALA,

The Effect of Lipoic Acid Therapy on Cognitive Functioning in Patients with Alzheimer's Disease

-

Study,

AD,

NA

600 mg/day

126 patients (75 women and 51 men) with AD

*cognitive↑, *antiOx↑, *Inflam↓, *neuroP↑, *Ach↑, *ROS↓, *GlucoseCon↑, *lipid-P↓, *GSH↑, *Acetyl-CoA↑,

3544-

ALA,

Alpha lipoic acid for dementia

-

Review,

AD,

NA

*antiOx↑, *BBB↑, *VitC↑, *VitE↑, *GSH↑, *IronCh↑, *neuroP↑, *NO↓, *cognitive↑, *AntiAge↑, *memory↑, *ROS↓,

3545-

ALA,

Potential therapeutic effects of alpha lipoic acid in memory disorders

-

Review,

AD,

NA

*neuroP↑, *Inflam↓, *VCAM-1↓, *5HT↑, *memory↑, *BioAv↝, *Half-Life↓, *NF-kB↓, *antiOx↑, *IronCh↑, *ROS↓, *ATP↑, *ChAT↑, *Ach↑, *cognitive↑, *lipid-P↓, *VitC↑, *VitE↑, *GSH↑, *SOD↑, *Catalase↑, *GPx↑, *Aβ↓,

3284-

ALA,

Alpha-Lipoic Acid Mediates Clearance of Iron Accumulation by Regulating Iron Metabolism in a Parkinson's Disease Model Induced by 6-OHDA

-

vitro+vivo,

Park,

NA

*antiOx↑, *IronCh↑, *neuroP↑, *ROS↓, *Iron↓, *BBB↑, *motorD↑, *GSH↑,

3283-

ALA,

Alpha-lipoic acid inhibits TNF-alpha-induced NF-kappaB activation and adhesion molecule expression in human aortic endothelial cells

-

in-vitro,

Nor,

NA

*TNF-α↓, *NF-kB↓, *antiOx↑, *IronCh↑, *GSSG↓, *VCAM-1↓, *E-sel↓, *ICAM-1↓, *MCP1↓, *NF-kB↓, IKKα↓,

3272-

ALA,

Alpha-lipoic acid as a dietary supplement: Molecular mechanisms and therapeutic potential

-

Review,

AD,

NA

*antiOx↑, *glucose↑, *eNOS↑, *NRF2↑, *MMP9↓, *VCAM-1↓, *NF-kB↓, *cardioP↑, *cognitive↑, *eff↓, *BBB↑, *IronCh↑, *GSH↑, *PKCδ↑, *ERK↑, *p38↑, *MAPK↑, *PI3K↑, *Akt↑, *PTEN↓, *AMPK↑, *GLUT4↑, *GLUT1↑, *Inflam↓,

3271-

ALA,

Decrypting the potential role of α-lipoic acid in Alzheimer's disease

-

Review,

AD,

NA

*antiOx↑, *memory↑, *neuroP↑, *Inflam↓, *IronCh↑, *NRF2↑, *BBB↑, *GlucoseCon↑, *Ach↑, *ROS↓, *p‑tau↓, *Aβ↓, *cognitive↑, *Hif1a↑, *Ca+2↓, *GLUT3↑, *GLUT4↑, *HO-1↑, *VEGF↑, *PDKs↓, *PDH↑, *VCAM-1↓, *GSH↑, *NRF2↑, *hepatoP↑, *ChAT↑,

3270-

ALA,

Alpha-lipoic acid as a new treatment option for Alzheimer's disease--a 48 months follow-up analysis

-

Trial,

AD,

NA

600mg alpha-lipoic acid was given daily to nine patients

43 AD patients treated with a-lipoic acid for periods up to 4 years were analyzed.

*cognitive↑, *other↝, *neuroP↑, *IronCh↑, *ROS↓, *GSH↑,

3269-

ALA,

Sulfur-containing therapeutics in the treatment of Alzheimer’s disease

-

NA,

AD,

NA

*AChE↓, *GlucoseCon↑, *ACC↑, *GSH↑, *Aβ↓, *Catalase↑, *GSR↑, *GSTs↑, *NADPH↑, *NQO1↑, *iNOS↓, *NF-kB↓, *lipid-P↓, *BBB↑, *memory↑, *cognitive↑, *antiOx↑, *Inflam↓,

3547-

ALA,

Potential Therapeutic Effects of Lipoic Acid on Memory Deficits Related to Aging and Neurodegeneration

-

Review,

AD,

NA

-

Review,

Park,

NA

*memory↑, *neuroP↑, *motorD↑, *VitC↑, *VitE↑, *GSH↑, *SOD↑, *Catalase↑, *GPx↑, *5HT↑, *lipid-P↓, *IronCh↑, *AChE↓, *Inflam↓, *GlucoseCon↑, *GLUT3↑, *GLUT4↑, NF-kB↓, *IGF-1↑, *IL1β↑, *TNF-α↑, *cognitive↑, *ChAT↑, *HO-1↑, *NQO1↑,

3548-

ALA,

How Alpha Linolenic Acid May Sustain Blood–Brain Barrier Integrity and Boost Brain Resilience against Alzheimer’s Disease

-

Review,

AD,

NA

*BBB↑, *other↑, *other↑,

3549-

ALA,

Important roles of linoleic acid and α-linolenic acid in regulating cognitive impairment and neuropsychiatric issues in metabolic-related dementia

-

Review,

AD,

NA

*Inflam↓, *other↝, *other↝, *neuroP↑, *BioAv↝, *adiP↑, *BBB↑, *Casp6↓, *Casp9↓, *TNF-α↓, *IL6↓, *IL1β↓, *ROS↓, *NO↓, *iNOS↓, *COX2↓, *JNK↓, *p‑NF-kB↓, *Aβ↓, *BP↓, *memory↑, *cAMP↑, *ERK↑, *Akt↑, cognitive?,

3550-

ALA,

Mitochondrial Dysfunction and Alpha-Lipoic Acid: Beneficial or Harmful in Alzheimer's Disease?

-

Review,

AD,

NA

*antiOx↑, *Inflam↓, *PGE2↓, *COX2↓, *iNOS↓, *TNF-α↓, *IL1β↓, *IL6↓, *BioAv↓, *Ach↑, *ROS↓, *cognitive↑, *neuroP↑, *BBB↑, *Half-Life↓, *BioAv↑, *Casp3↓, *Casp9↓, *ChAT↑, *cognitive↑, *eff↑, *cAMP↑, *IL2↓, *INF-γ↓, *TNF-α↓, *SIRT1↑, *SOD↑, *GPx↑, *MDA↓, *NRF2↑,

3551-

ALA,

Alpha lipoic acid treatment in late middle age improves cognitive function: Proteomic analysis of the protective mechanisms in the hippocampus

-

in-vivo,

AD,

NA

mice

*cognitive↑, *Apoptosis↓, *Inflam↓, *antiOx↑, *BioAv↝, *neuroP↑,

3552-

ALA,

The dietary fatty acids α-linolenic acid (ALA) and linoleic acid (LA) selectively inhibit microglial nitric oxide production

-

in-vitro,

AD,

BV2

*NO↓, *cognitive↑,

3546-

ALA,

Cognitive and Mood Effect of Alpha-Lipoic Acid Supplementation in a Nonclinical Elder Sample: An Open-Label Pilot Study

-

Study,

AD,

NA

fifteen elder patients (mean age: 84.5 ± 5.77) received ALA at a daily dose of 600 mg/day for 12 weeks.

*antiOx↑, *ROS↓, *cognitive∅, *lipid-P↓, *memory↑, *ChAT↑, *Acetyl-CoA↑, *Aβ↓, *BioAv↑, *BBB↑, *toxicity∅,

3435-

aLinA,

Alpha-linolenic acid-mediated epigenetic reprogramming of cervical cancer cell lines

-

in-vitro,

Cerv,

HeLa

-

in-vitro,

Cerv,

SiHa

-

in-vitro,

Cerv,

C33A

DNMTs↓, HDAC↓, HATs↑, hTERT↓, CDH1↑, RARβ↑, DNMT1↓, DNMT3A↓, TET2↑, HDAC1↓, HDAC8↓, SIRT1↓, HMTs↑, EZH2↓,

1252-

aLinA,

α-Linolenic acid induces apoptosis, inhibits the invasion and metastasis, and arrests cell cycle in human breast cancer cells by inhibiting fatty acid synthase

-

in-vitro,

BC,

NA

FASN↓, Apoptosis↑, TumCI↓, TumMeta↓, TumCCA↑,

1253-

aLinA,

The Antitumor Effects of α-Linolenic Acid

-

Review,

NA,

NA

PPARγ↑, COX2↓, E6↓, E7↓, P53↑, p‑ERK↓, p38↓, lipid-P↑, ROS⇅, MPT↑, MMP↓, Cyt‑c↑, Casp↑, iNOS↓, NO↓, Casp3↑, Bcl-2↓, Hif1a↓, FASN↓, CRP↓, IL6↓, IL1β↓, IFN-γ↓, TNF-α↓, Twist↓, VEGF↓, MMP2↓, MMP9↓,

1123-

aLinA,

Linoleic acid induces an EMT-like process in mammary epithelial cells MCF10A

-

in-vitro,

BC,

NA

LA is cancer promoting

-

in-vitro,

NA,

MCF10

TumCP↑, E-cadherin↓, Snail↑, Twist↑, ZEB2↑, FAK↑, NF-kB↑, MMP2↓, MMP9↓, *EMT↑, TumCI↑,

1440-

AMQ,

Lysosomotropism depends on glucose: a chloroquine resistance mechanism

-

in-vitro,

BC,

4T1

eff↑, Apoptosis↓, Necroptosis↑, eff↓, ChemoSen↑, eff↓,

552-

Anamu,

A critical review of the therapeutic potential of dibenzyl trisulphide isolated from Petiveria alliacea L (guinea hen weed, anamu)

-

Review,

NA,

NA

p‑MAPK↑, Th1 response↓, Th2↑,

553-

Anamu,

The anti-inflammatory and analgesic effects of a crude extract of Petiveria alliacea L. (Phytolaccaceae)

-

in-vivo,

NA,

NA

43.9 mg/kg

rats

TumCMig↓,

554-

Anamu,

Petiveria alliacea extracts uses multiple mechanisms to inhibit growth of human and mouse tumoral cells

-

in-vitro,

NA,

769-P

TumCCA↑, HSP70/HSPA5↓, HSP90↓,

1007-

And,

In vitro and in silico evaluation of Andrographis paniculata ethanolic crude extracts on fatty acid synthase expression on breast cancer cells

-

in-vitro,

BC,

MCF-7

mice

-

in-vitro,

BC,

EMT6

tumCV↓, i-FASN↓,

1009-

And,

5-FU,

Andrographis-mediated chemosensitization through activation of ferroptosis and suppression of β-catenin/Wnt-signaling pathways in colorectal cancer

-

in-vivo,

CRC,

HCT116

-

in-vitro,

CRC,

SW480

ChemoSen↑, Casp9↑, Ferroptosis↑, Wnt/(β-catenin)↓, FTL↑, TP53↑, ACSL5↑, GCLC↑, GCLM↑, SAT1↑, STEAP3↑, ACSL5↑,

1078-

And,

Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway

-

in-vitro,

BC,

MDA-MB-231

5, 10, 25 and 50 μM

20uM

-

in-vitro,

Nor,

HUVECs

50uM

-

in-vivo,

BC,

MCF-7

35uM

xenografts nude mice

-

in-vitro,

BC,

T47D

32uM

-

in-vitro,

BC,

BT549

23uM

-

in-vitro,

BC,

MDA-MB-361

31uM

TumCP↓, COX2↓, *angioG↓, Cyt‑c↑, CREB2↓, cFos↓, NF-kB↓, HATs↓, cl‑Casp3↑, cl‑Casp9↑, Bax:Bcl2↑, Apoptosis↑, *toxicity↓,

931-

And,

Effect of Andrographis Paniculata Aqueous Extract on Hyperammonemia Induced Alteration of Oxidative and Nitrosative Stress Factors in the Liver, Spleen and Kidney of Rats

-

in-vivo,

NA,

NA

rats

*SOD↝, *Catalase↝, *ROS↓, *MDA↓, *NO↓,

1159-

And,

Andrographolide, an Anti-Inflammatory Multitarget Drug: All Roads Lead to Cellular Metabolism

-

Review,

NA,

NA

NRF2↑, COX2↓, IL6↓, IL8↓, IL1↓, iNOS↓, MPO↓, TNF-α↓, VEGF↓, Hif1a↓, p‑AMPK↑,

1158-

And,

GEM,

Andrographolide causes apoptosis via inactivation of STAT3 and Akt and potentiates antitumor activity of gemcitabine in pancreatic cancer

TumCP↓, TumCCA↑, Apoptosis↑, STAT3↓, Akt↓, P21↑, BAX↑, cycD1↓, cycE↓, survivin↓, XIAP↓, Bcl-2↓, eff↑,

1157-

And,

Andrographolide suppresses the migratory ability of human glioblastoma multiforme cells by targeting ERK1/2-mediated matrix metalloproteinase-2 expression

-

in-vitro,

GBM,

GBM8401

-

in-vitro,

GBM,

U251

TumCI↓, TumCMig↓, MMP2↓, ERK↝,

1093-

And,

Andrographolide attenuates epithelial‐mesenchymal transition induced by TGF‐β1 in alveolar epithelial cells

-

in-vitro,

Lung,

A549

TGF-β↓, TumCMig↓, MMP2↓, MMP9↓, ECM/TCF↓, p‑SMAD2↓, p‑SMAD3↓, SMAD4↓, p‑ERK↓, ROS↓, NOX4↓, SOD2↑, SIRT1↑, FOXO3↑,

1156-

And,

Exploring the potential of Andrographis paniculata for developing novel HDAC inhibitors: an in silico approach

-

Analysis,

NA,

NA

HDAC↓,

1351-

And,

MEL,

Impact of Andrographolide and Melatonin Combinatorial Drug Therapy on Metastatic Colon Cancer Cells and Organoids

-

in-vitro,

CRC,

T84

-

in-vitro,

CRC,

COLO205

-

in-vitro,

CRC,

HT-29

-

in-vitro,

CRC,

DLD1

eff↑, Ki-67↓, Casp3↑, ER Stress↑, ROS↑, BAX↑, XBP-1↑, CHOP↑, eff↑,

1294-

And,

5-FU,

Andrographolide reversed 5-FU resistance in human colorectal cancer by elevating BAX expression

-

in-vitro,

CRC,

HCT116

Apoptosis↑, BAX↑,

1352-

And,

Andrographolide downregulates the v-Src and Bcr-Abl oncoproteins and induces Hsp90 cleavage in the ROS-dependent suppression of cancer malignancy

-

in-vitro,

AML,

K562

Apoptosis↑, ROS↑, HSP90↓,

1350-

And,

Cisplatin,

Synergistic antitumor effect of Andrographolide and cisplatin through ROS-mediated ER stress and STAT3 inhibition in colon cancer

-

in-vitro,

Colon,

NA

ChemoSen↑, ER Stress↑, STAT3↓, ROS↑,

1279-

And,

Andrographolide Exhibits Anticancer Activity against Breast Cancer Cells (MCF-7 and MDA-MB-231 Cells) through Suppressing Cell Proliferation and Inducing Cell Apoptosis via Inactivation of ER-α Receptor and PI3K/AKT/mTOR Signaling

-

in-vitro,

BC,

MDA-MB-231

-

in-vitro,

BC,

MCF-7

Apoptosis↑, Bcl-2↓, BAX↑, ERα↓, PI3K↓, mTOR↓,

1353-

And,

Andrographolide Induces Apoptosis and Cell Cycle Arrest through Inhibition of Aberrant Hedgehog Signaling Pathway in Colon Cancer Cells

-

in-vitro,

Colon,

HCT116

ChemoSen↑, TumCCA↑, CDK1↓, CycB↓, HH↓, Smo↓, Gli1↓,

1347-

And,

Suppression of rat neutrophil reactive oxygen species production and adhesion by the diterpenoid lactone andrographolide

-

in-vitro,

Nor,

NA

0.1 to 10 microM

*ROS↓,

1348-

And,

Andrographolide Inhibits ER-Positive Breast Cancer Growth and Enhances Fulvestrant Efficacy via ROS-FOXM1-ER-α Axis

-

in-vitro,

BC,

MCF-7

-

in-vitro,

BC,

T47D

-

in-vivo,

NA,

NA

AD (150 mg/kg per day), fulvestrant (5 mg/mouse administered subcutaneously, once per week)

mice

ERα↓, TumCG↓, ROS↑, Foxm1↓, eff↑,

1349-

And,

Andrographolide promoted ferroptosis to repress the development of non-small cell lung cancer through activation of the mitochondrial dysfunction

-

in-vitro,

Lung,

H460

33.16 μM

-

in-vitro,

Lung,

H1650

32.45 μM

TumCG↓, TumMeta↓, Ferroptosis↑, ROS↑, MDA↑, Iron↑, GSH↓, GPx4↓, xCT↓, MMP↓, ATP↓,

1354-

And,

Andrographolide induces protective autophagy and targeting DJ-1 triggers reactive oxygen species-induced cell death in pancreatic cancer

-

in-vitro,

PC,

NA

0, 10, 20, 40 µM

-

in-vivo,

PC,

NA

Apoptosis↑, DJ-1↓, ROS↑, TumAuto↑, TumCCA↑, TumCP↓, TumW↓, eff↓,

1146-

AP,

Potential use of nanoformulated ascorbyl palmitate as a promising anticancer agent: First comparative assessment between nano and free forms

-

in-vivo,

Nor,

NA

Ehrlich ascites carcinoma (EAC)-bearing mice

TumCCA↑, Apoptosis↑, IL6↓, STAT3↓, angioG↓, TumMeta↓, VEGF↓, MMP9↓, SOD↑, Catalase↑, GSH↓, MDA↓, NO↓, *BioAv↑,

1095-

Api,

Apigenin inhibits epithelial-mesenchymal transition of human colon cancer cells through NF-κB/Snail signaling pathway

-

Analysis,

Colon,

NA

Snail↓, EMT↓, NF-kB↓,

1152-

Api,

Does Oral Apigenin Have Real Potential for a Therapeutic Effect in the Context of Human Gastrointestinal and Other Cancers?

-

Analysis,

Nor,

NA

1–5μmol/L as the target

*BioAv↓, Half-Life∅, *BioAv↓, Dose∅, eff↑, CYP1A2↓, CYP2C9↓, CYP3A4↓,

1151-

Api,

Plant flavone apigenin inhibits HDAC and remodels chromatin to induce growth arrest and apoptosis in human prostate cancer cells: In vitro and in vivo study

-

in-vitro,

Pca,

PC3

20–40μM

-

in-vitro,

Pca,

22Rv1

-

in-vivo,

NA,

NA

oral intake of apigenin at doses of 20 and 50μg/mouse/day

mouse

TumCCA↑, Apoptosis↑, HDAC↓, P21↑, BAX↑, TumCG↓, Bcl-2↓, Bax:Bcl2↑, HDAC1↓, HDAC3↓,

1150-

Api,

Apigenin inhibits the TNFα-induced expression of eNOS and MMP-9 via modulating Akt signalling through oestrogen receptor engagement

-

in-vitro,

Lung,

EAhy926

50 μM

eNOS↓, MMP9↓, Akt↓, p38↓, JNK↓,

1149-

Api,

Apigenin inhibits colonic inflammation and tumorigenesis by suppressing STAT3-NF-κB signaling

-

vitro+vivo,

IBD,

NA

COX2↓, MPO↓, NF-kB↓, STAT3↓, Inflam↓,

1024-

Api,

CUR,

Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects

-

vitro+vivo,

Melanoma,

A375

(30 μM) for 24 h

-

in-vitro,

Melanoma,

A2058

-

in-vitro,

Melanoma,

RPMI-7951

TumCG↓, Apoptosis↑, PD-L1↓, STAT1↓, tumCV↓, T-Cell↑,

1008-

Api,

Apigenin-induced lysosomal degradation of β-catenin in Wnt/β-catenin signaling

-

in-vitro,

CRC,

HCT116

0-50uM

38.15 ± 1.32 μM

-

in-vitro,

CRC,

SW480

Wnt/(β-catenin)↓, β-catenin/ZEB1↓, TumAuto↑, Akt↓, mTOR↓, tumCV↓, TumCCA↑, TumAuto↑, p‑Akt↓, p‑p70S6↓, p‑4E-BP1↓,

1077-

Api,

Apigenin inhibits COX-2, PGE2, and EP1 and also initiates terminal differentiation in the epidermis of tumor bearing mice

-

in-vivo,

NMSC,

NA

mice

*COX2↓, COX2∅,

983-

Api,

Apigenin acts as a partial agonist action at estrogen receptors in vivo

-

in-vivo,

NA,

NA

ERα↑, ERβ↑,

958-

Api,

Apigenin suppresses tumor angiogenesis and growth via inhibiting HIF-1α expression in non-small cell lung carcinoma

-

in-vitro,

Lung,

NCIH1299

Hif1a↓, VEGF↓, VEGFR2↓, PDGF↓, angioG↓,

577-

Api,

PacT,

Inhibition of IL-6/STAT3 axis and targeting Axl and Tyro3 receptor tyrosine kinases by apigenin circumvent taxol resistance in ovarian cancer cells

-

in-vitro,

Ovarian,

SKOV3

40uM

p‑Akt↓, Bcl-xL↓, Bcl-2↓, AXL↓, Tyro3↓,

578-

Api,

Cisplatin,

Apigenin enhances the cisplatin cytotoxic effect through p53-modulated apoptosis

-

in-vitro,

Lung,

A549

30 uM

Multiple tumor cell types

-

in-vitro,

BC,

MCF-7

apigenin at 30 µM with cisplatin at 2.5, 5.0, and 10.0 µM

-

in-vitro,

CRC,

HCT116

-

in-vitro,

Pca,

HeLa

-

in-vitro,

Lung,

H1299

p‑P53↑,

581-

Api,

Cisplatin,

The natural flavonoid apigenin sensitizes human CD44+ prostate cancer stem cells to cisplatin therapy

-

in-vitro,

Pca,

CD44+

15uM / 7.5uM for 48

CD44+PCa

Bcl-2↓, survivin↓, Casp8↑, P53↑, Sharpin↓, APAF1↑, p‑Akt↓, NF-kB↓, P21↑, Cyc↓, CDK2↓, CDK4/6↓, Snail↓, ChemoSen↑,

583-

Api,

Cisplatin,

Apigenin suppresses GLUT-1 and p-AKT expression to enhance the chemosensitivity to cisplatin of laryngeal carcinoma Hep-2 cells: an in vitro study

-

in-vitro,

Laryn,

HEp2

40uM - 160 uM

PI3K/Akt↓, GLUT1↓, Akt↓,

584-

Api,

Cisplatin,

Apigenin potentiates the antitumor activity of 5-FU on solid Ehrlich carcinoma: Crosstalk between apoptotic and JNK-mediated autophagic cell death platforms

-

in-vivo,

Var,

NA

Eighty Swiss albino male mice

Beclin-1↑, Casp3↑, Casp9↑, JNK↑, Mcl-1↓, Ki-67↓,

586-

Api,

5-FU,

5-Fluorouracil combined with apigenin enhances anticancer activity through mitochondrial membrane potential (ΔΨm)-mediated apoptosis in hepatocellular carcinoma

-

in-vivo,

HCC,

NA

4 umol/L

20mg/kg/5x/wk/3wks

ROS↑, MMP↓, Bcl-2↓, Casp3↑, PARP↑,

589-

Api,

5-FU,

Interactions between dietary flavonoids apigenin or luteolin and chemotherapeutic drugs to potentiate anti-proliferative effect on human pancreatic cancer cells, in vitro

-

in-vitro,

PC,

Bxpc-3

0-50 uM

(0, 6, 24 and 42 h) of flavonoids

GSK‐3β↓, NF-kB↓,

591-

Api,

doxoR,

Polyphenols act synergistically with doxorubicin and etoposide in leukaemia cell lines

-

in-vitro,

AML,

Jurkat

-

in-vitro,

AML,

THP1

ATP↓, Casp3↑, γH2AX↑,

938-

Api,

doxoR,

Apigenin and hesperidin augment the toxic effect of doxorubicin against HepG2 cells

-

vitro+vivo,

HCC,

HepG2

LDHA↓, HK2↓,

171-

Api,

Apigenin in cancer therapy: anti-cancer effects and mechanisms of action

-

Review,

Var,

NA

PI3K/Akt↓, NF-kB↓, CK2↓, FOXO↓, MAPK↝, ERK↓, p‑JAK↓, Wnt/(β-catenin)↓, ROS↑, CDC25↓, p‑STAT↓, DNAdam↑,

208-

Api,

Apigenin induces apoptosis by targeting inhibitor of apoptosis proteins and Ku70–Bax interaction in prostate cancer

-

in-vivo,

Pca,

PC3

5-40 uM

20, 50 uM/mouse/day

-

in-vivo,

Pca,

DU145

5-40 uM

XIAP↓, survivin↓, Bcl-xL↓, Bcl-2↓, BAX↑,

240-

Api,

The flavonoid apigenin reduces prostate cancer CD44(+) stem cell survival and migration through PI3K/Akt/NF-κB signaling

-

in-vitro,

Pca,

PC3

25 uM

-

in-vitro,

Pca,

CD44+

P21↑, p27↑, Casp3↑, Casp8↑, Slug↓, Snail↓, NF-kB↓, PI3K↓, Akt↓,

166-

Api,

Common botanical compounds inhibit the hedgehog signaling pathway in prostate cancer

HH↓,

238-

Api,

Apigenin inhibits TGF-β-induced VEGF expression in human prostate carcinoma cells via a Smad2/3- and Src-dependent mechanism

-

in-vitro,

Pca,

PC3

25 uM

-

in-vitro,

Pca,

LNCaP

-

in-vitro,

Pca,

C4-2B

VEGF↓, TGF-β↓, Src↓, FAK↓, Akt↓, SMAD2↓, SMAD3↓,

237-

Api,

Apigenin blocks IKKα activation and suppresses prostate cancer progression

-

in-vivo,

Pca,

PC3

2.5 to 20 uM

-

in-vivo,

Pca,

22Rv1

-

in-vivo,

Pca,

LNCaP

-

in-vivo,

Pca,

DU145

IKKα↓, NF-kB↓,

210-

Api,

Apigenin inhibits migration and invasion via modulation of epithelial mesenchymal transition in prostate cancer

-

in-vitro,

Pca,

DU145

10-80 uM

1 uM/ml (10-80 uM) (24-48 hrs)

EMT↓, E-cadherin↑, Snail↓, Vim↓,

180-

Api,

Induction of caspase-dependent apoptosis by apigenin by inhibiting STAT3 signaling in HER2-overexpressing MDA-MB-453 breast cancer cells

-

in-vitro,

BC,

MDA-MB-231

0-100 uM 72hrs

cl‑Casp8↑, cl‑Casp3↑, cl‑PARP↑, BAX∅, Bcl-2∅, Bcl-xL∅, p‑STAT3↓, P53↑, P21↑, p‑JAK2↓, VEGF↓,

206-

Api,

Inhibition of glutamine utilization sensitizes lung cancer cells to apigenin-induced apoptosis resulting from metabolic and oxidative stress

-

in-vitro,

Lung,

H1299

20 uM

-

in-vitro,

Lung,

H460

-

in-vitro,

Lung,

A549

40 uM

-

in-vitro,

CRC,

HCT116

-

in-vitro,

Melanoma,

A375

-

in-vitro,

Lung,

H2030

-

in-vitro,

CRC,

SW480

Glycolysis↓, NA?, PGK1↓, ALDOA↓, GLUT1↓, ENO1↓, ATP↓, Casp9↑, Casp3↑, cl‑PARP↑, PI3K/Akt↓, HK1↓, HK2↓,

207-

Api,

Involvement of nuclear factor-kappa B, Bax and Bcl-2 in induction of cell cycle arrest and apoptosis by apigenin in human prostate carcinoma cells

-

in-vitro,

Pca,

LNCaP

PSA↓, cycD1↓, cycE↓, CDK2↓, CDK4/6↓, P21↑, AR↓,

211-

Api,

Suppression of NF-κB and NF-κB-Regulated Gene Expression by Apigenin through IκBα and IKK Pathway in TRAMP Mice

-

in-vivo,

Pca,

NA

20, 50 ug/mouse/day, 6days/week for 20 weeks

IKKα↓, NF-kB↓, cycD1↓, COX2↓, Bcl-2↓, Bcl-xL↓, VEGF↓, PCNA↓, BAX↑,

242-

Api,

Apigenin inhibits proliferation and invasion, and induces apoptosis and cell cycle arrest in human melanoma cells

-

in-vitro,

Melanoma,

A375

(40, 80, 120, 160, 200, 240 and 280 µM) for (24, 48, 72 and 96 h).

-

in-vitro,

Melanoma,

C8161

ERK↓, PI3k/Akt/mTOR↓, Casp3↑, PARP↑, p‑mTOR↓, p‑Akt↓,

243-

Api,

Apigenin Attenuates Melanoma Cell Migration by Inducing Anoikis through Integrin and Focal Adhesion Kinase Inhibition

-

in-vitro,

Melanoma,

A375

50 uM

-

in-vitro,

Melanoma,

A2058

p‑FAK↓, ERK↓, Casp3↑, PARP↑, ITGA5↓, NA↓,

244-

Api,

Inhibition of the STAT3 signaling pathway contributes to apigenin-mediated anti-metastatic effect in melanoma

-

in-vivo,

Melanoma,

B16-F10

10 and 20 uM

mice

-

in-vivo,

Melanoma,

A375

-

in-vivo,

Melanoma,

G361

STAT3↓, MMP2↓, MMP9↓, VEGF↓, Twist↓, E-cadherin↑, N-cadherin↓, EMT↓,

179-

Api,

Apigenin induces caspase-dependent apoptosis by inhibiting signal transducer and activator of transcription 3 signaling in HER2-overexpressing SKBR3 breast cancer cells

-

in-vitro,

BC,

NA

cl‑Casp8↑, cl‑Casp3↑, STAT3↓, VEGF↓,

178-

Api,

Autophagy inhibition enhances apigenin-induced apoptosis in human breast cancer cells

-

in-vivo,

BC,

MDA-MB-231

-

in-vitro,

BC,

T47D

Casp3↑, cl‑PARP↑, Bcl-2↓, Bcl-xL↓, BAX↑,

177-

Api,

Inhibition of MDA-MB-231 breast cancer cell proliferation and tumor growth by apigenin through induction of G2/M arrest and histone H3 acetylation-mediated p21WAF1/CIP1 expression

-

in-vitro,

BC,

MDA-MB-231

Cyc↓, CycB↓, CDK1↓, P21↑, PCNA↝, HDAC↓,

172-

Api,

Apigenin suppresses colorectal cancer cell proliferation, migration and invasion via inhibition of the Wnt/β-catenin signaling pathway

-

in-vitro,

CRC,

SW480

5, 10, 20, 40 and 80 µM

18 uM

-

in-vitro,

CRC,

HTC15

23 uM

Wnt/(β-catenin)↓, TCF↓, LEF1↓,

173-

Api,

Apigenin-induced apoptosis is enhanced by inhibition of autophagy formation in HCT116 human colon cancer cells

-

in-vitro,

Colon,

HCT116

25, 50 uM

CycB↓, cDC2↓, CDC25↓, P53↑, P21↑, cl‑PARP↑, proCasp8↓, proCasp9↓, proCasp3↓,

176-

Api,

Induction of caspase-dependent extrinsic apoptosis by apigenin through inhibition of signal transducer and activator of transcription 3 (STAT3) signalling in HER2-overexpressing BT-474 breast cancer cells

-

in-vitro,

BC,

BT474

0-100 uM 72hrs

cl‑Casp8↑, cl‑Casp3↑, p‑JAK1↓, p‑JAK2↓, p‑STAT3↓, P53↑, VEGF↓, Hif1a↓, MMP9↓,

175-

Api,

Apigenin up-regulates transgelin and inhibits invasion and migration of colorectal cancer through decreased phosphorylation of AKT

-

vitro+vivo,

CRC,

SW480

40 uM for 48 hrs

-

vitro+vivo,

CRC,

DLD1

-

vitro+vivo,

CRC,

LS174T

MMP↓, p‑Akt↓,

174-

Api,

Downregulation of NEDD9 by apigenin suppresses migration, invasion, and metastasis of colorectal cancer cells

-

in-vitro,

CRC,

SW480

40 uM

-

in-vitro,

CRC,

DLD1

40 uM

NEDD9↓, NA↓, NA↓,

269-

Api,

Cytotoxicity of apigenin on leukemia cell lines: implications for prevention and therapy

-

in-vitro,

AML,

HL-60

30 uM

200 uM for 24 h

-

in-vitro,

AML,

K562

100 uM

-

in-vitro,

AML,

TF1

100 uM

JAK↓, PI3K↓, cDC2↓, STAT↓,

270-

Api,

Apigenin induces apoptosis in human leukemia cells and exhibits anti-leukemic activity in vivo via inactivation of Akt and activation of JNK

-

in-vivo,

AML,

U937

20-40 uM (12/24h)

Akt↓, JNK↑, Mcl-1↓, cl‑Bcl-2↓, Casp3↑, Casp7↑, Casp9↑, cl‑PARP↑, mTOR↓, GSK‐3β↓,

273-

Api,

Apigenin inhibited migration and invasion of human ovarian cancer A2780 cells through focal adhesion kinase

-

in-vivo,

Ovarian,

A2780S

20, 40 uM

A2780, mice

FAK↓,

275-

Api,

Apigenin inhibits the self-renewal capacity of human ovarian cancer SKOV3‑derived sphere-forming cells

-

in-vitro,

Ovarian,

SKOV3

HH↓, CK2↓, Gli1↓,

5-

Api,

Common Botanical Compounds Inhibit the Hedgehog Signaling Pathway in Prostate Cancer

-

in-vitro,

Pca,

NA

HH↓, Gli1↓,

268-

Api,

Induction of apoptosis by apigenin and related flavonoids through cytochrome c release and activation of caspase-9 and caspase-3 in leukaemia HL-60 cells

-

in-vitro,

AML,

HL-60

60 uM

Casp3↑, PARP↑,

314-

Api,

Apigenin impairs oral squamous cell carcinoma growth in vitro inducing cell cycle arrest and apoptosis

-

in-vitro,

SCC,

HaCaT

100 uM

-

in-vitro,

SCC,

SCC25

TumCCA↑, cycD1↓, cycE↓, CDK1/2/5/9∅,

421-

Api,

Apigenin inhibits HeLa sphere-forming cells through inactivation of casein kinase 2α

-

vitro+vivo,

Cerv,

HeLa

40 uM

(10, 20 and 40 μmol/l)

CK2↓,

419-

Api,

Apigenin inhibited hypoxia induced stem cell marker expression in a head and neck squamous cell carcinoma cell line

-

in-vitro,

SCC,

HN30

40 μM

Head and Neck

-

in-vitro,

SCC,

HN8

Head and Neck

CD44↓, Nanog↓, Endoglin↓, VEGF↓,

418-

Api,

Apigenin inhibits the proliferation and invasion of osteosarcoma cells by suppressing the Wnt/β-catenin signaling pathway

-

vitro+vivo,

OS,

U2OS

50 ug/ml

-

vitro+vivo,

OS,

MG63

β-catenin/ZEB1↓,

416-

Api,

In Vitro and In Vivo Anti-tumoral Effects of the Flavonoid Apigenin in Malignant Mesothelioma

-

vitro+vivo,

NA,

NA

20 mg/kg (C57BL/6 mice, oral gavage)

Malignant mesothelioma (MM)

Bax:Bcl2↑, P53↑, ROS↑, Casp9↑, Casp8↑, cl‑PARP1↑, p‑ERK⇅, p‑JNK↓, p‑p38↑, p‑Akt↓, cJun↓, NF-kB↓, EGFR↓, TumCCA↑,

315-

Api,

Apigenin: Selective CK2 inhibitor increases Ikaros expression and improves T cell homeostasis and function in murine pancreatic cancer

-

vitro+vivo,

PC,

Panc02

20 uM

CK2↓, CD4+↑, CD8+↑, Ikaros↑,

313-

Api,

Apigenin induces autophagic cell death in human papillary thyroid carcinoma BCPAP cells

-

in-vitro,

Thyroid,

BCPAP

25 uM

LC3s↝, p62↓, ROS↑, TumCCA↑, CDC25↓, TumAuto↑, Beclin-1↑, AVOs↑, DNAdam↑,

310-

Api,

Apigenin inhibits renal cell carcinoma cell proliferation

-

vitro+vivo,

RCC,

ACHN

5-80 uM

39.4 μM for 24 h; 15.4 μM for 48 h

5, 10 and 20 uM

-

in-vitro,

RCC,

786-O

39.1 μM for 24 h; 19.0 μM for 48 h

-

in-vitro,

RCC,

Caki-1

50.9 μM for 24 h; 21.4 μM for 48 h

-

in-vitro,

RCC,

HK-2

122.1 μM for 24 h; 70.2 μM for 48 h

TumCCA↑, p‑ATM↑, p‑CHK1↑, p‑CDC25↑, p‑cDC2↑, P53↑, BAX↑, Casp9↑, Casp3↑,

307-

Api,

Flavonoids inhibit angiogenic cytokine production by human glioma cells

-

in-vitro,

GBM,

GL-15

50 uM

TGF-β↓,

308-

Api,

Apigenin Inhibits Cancer Stem Cell-Like Phenotypes in Human Glioblastoma Cells via Suppression of c-Met Signaling

-

in-vitro,

GBM,

U87MG

-

in-vitro,

GBM,

U373MG

cMET↓, Akt↓, Nanog↓, SOX2↓,

311-

Api,

Apigenin inhibits the proliferation of adenoid cystic carcinoma via suppression of glucose transporter-1

-

in-vitro,

ACC,

NA

10-60 uM

GLUT1↓, CC(CDKs/cyclins)↓, TumCCA↑,

2583-

Api,

Rad,

The influence of apigenin on cellular responses to radiation: From protection to sensitization

-

Review,

Var,

NA

radioP↑, RadioS↑, *COX2↓, *ROS↓, VEGF↓, MMP2↓, STAT3↓, AMPK↑, Apoptosis↑, MMP9↓, glucose↓,

2584-

Api,

Chemo,

The versatility of apigenin: Especially as a chemopreventive agent for cancer

-

Review,

Var,

NA

ChemoSen↑, RadioS↑, eff↝, DR5↑, selectivity↑, angioG↓, selectivity↑, chemoP↑, MAPK↓, PI3K↓, Akt↓, mTOR↓, Wnt↓, β-catenin/ZEB1↓, GLUT1↓, radioP↑, BioAv↓,

2585-

Api,

Apigenin inhibits the proliferation of adenoid cystic carcinoma via suppression of glucose transporter-1

-

in-vitro,

ACC,

NA

GLUT1↓, TumCG↓,

2586-

Api,

doxoR,

Apigenin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL-7402/ADM cells to doxorubicin via inhibiting PI3K/Akt/Nrf2 pathway

-

in-vitro,

HCC,

Bel-7402

NRF2↓, ChemoSen↑,

2593-

Api,

Apigenin promotes apoptosis of 4T1 cells through PI3K/AKT/Nrf2 pathway and improves tumor immune microenvironment in vivo

-

in-vivo,

BC,

4T1

4T1 xenograft tumor mouse model

TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, MMP↑, ROS↑, p‑PI3K↓, PI3K↓, Akt↓, NRF2↓, AntiTum↑, OS↑,

2594-

Api,

docx,

Targeted hyaluronic acid-based lipid nanoparticle for apigenin delivery to induce Nrf2-dependent apoptosis in lung cancer cells

-

in-vitro,

Lung,

A549

NRF2↓, ChemoSen↑,

2596-

Api,

LT,

Natural Nrf2 Inhibitors: A Review of Their Potential for Cancer Treatment

-

Review,

Var,

NA

NRF2↓, chemoP↑,

2637-

Api,

Apigenin Alleviates Endoplasmic Reticulum Stress-Mediated Apoptosis in INS-1 β-Cells

-

in-vitro,

Diabetic,

NA

*other↝, *Insulin↑, ER Stress↓, *CHOP↓, *cl‑Casp3↓, *ROS↓, *Inflam↓, *TXNIP↓,

2632-

Api,

Apigenin inhibits migration and induces apoptosis of human endometrial carcinoma Ishikawa cells via PI3K-AKT-GSK-3β pathway and endoplasmic reticulum stress

-

in-vitro,

EC,

NA

20–60 μM

45.55 μM

TumCP↓, TumCCA↑, Apoptosis↑, Bcl-2↓, BAX↑, Bak↑, Casp↑, ER Stress↑, Ca+2↑, ATF4↑, CHOP↑, ROS↑, MMP↓, TumCMig↓, TumCI↓, eff↑, P53↑, P21↑, Cyt‑c↑, Casp9↑, Casp3↑, Bcl-xL↓,

2664-

Api,

Progress in discovery and development of natural inhibitors of histone deacetylases (HDACs) as anti-cancer agents

-

Review,

Var,

NA

HDAC↓,

2641-

Api,

Apigenin inhibits HGF-promoted invasive growth and metastasis involving blocking PI3K/Akt pathway and beta 4 integrin function in MDA-MB-231 breast cancer cells

-

in-vitro,

BC,

MDA-MB-231

TumCMig↓, TumCI↓, ITGB4↓,

2640-

Api,

Apigenin: A Promising Molecule for Cancer Prevention

-

Review,

Var,

NA

chemoP↑, ITGB4↓, TumCI↓, TumMeta↓, Akt↓, ERK↓, p‑JNK↓, *Inflam↓, *PKCδ↓, *MAPK↓, EGFR↓, CK2↓, TumCCA↑, CDK1↓, P53↓, P21↑, Bax:Bcl2↑, Cyt‑c↑, APAF1↑, Casp↑, cl‑PARP↑, VEGF↓, Hif1a↓, IGF-1↓, IGFBP3↑, E-cadherin↑, β-catenin/ZEB1↓, HSPs↓, Telomerase↓, FASN↓, MMPs↓, HER2/EBBR2↓, CK2↓, eff↑, AntiAg↑, eff↑, FAK↓, ROS↑, Bcl-2↓, Cyt‑c↑, cl‑Casp3↑, cl‑Casp7↑, cl‑Casp8↑, cl‑Casp9↑, cl‑IAP2↑, AR↓, PSA↓, p‑pRB↓, p‑GSK‐3β↓, CDK4↓, ChemoSen↑, Ca+2↑, cal2↑,

2639-

Api,

Plant flavone apigenin: An emerging anticancer agent

-

Review,

Var,

NA

*antiOx↑, *Inflam↓, AntiCan↑, ChemoSen↑, BioEnh↑, chemoP↑, IL6↓, STAT3↓, NF-kB↓, IL8↓, eff↝, Akt↓, PI3K↓, HER2/EBBR2↓, cycD1↓, CycD3↓, p27↑, FOXO3↑, STAT3↓, MMP2↓, MMP9↓, VEGF↓, Twist↓, MMP↓, ROS↑, NADPH↑, NRF2↓, SOD↓, COX2↓, p38↑, Telomerase↓, HDAC↓, HDAC1↓, HDAC3↓, Hif1a↓, angioG↓, uPA↓, Ca+2↑, Bax:Bcl2↑, Cyt‑c↑, Casp9↑, Casp12↑, Casp3↑, cl‑PARP↑, E-cadherin↑, β-catenin/ZEB1↓, cMyc↓, CDK4↓, CDK2↓, CDK6↓, IGF-1↓, CK2↓, CSCs↓, FAK↓, Gli↓, GLUT1↓,

2638-

Api,

Apigenin, by activating p53 and inhibiting STAT3, modulates the balance between pro-apoptotic and pro-survival pathways to induce PEL cell death

-

in-vitro,

lymphoma,

PEL

TumCD↑, TumAuto↑, ROS↓, P53↑, Catalase↑, STAT3↓,

2636-

Api,

Apigenin unveiled: an encyclopedic review of its preclinical and clinical insights

-

Review,

NA,

NA

*AntiCan↑, *cardioP↑, *neuroP↑, *Inflam↓, *antiOx↑, *hepatoP↑, ChemoSen↑,

2635-

Api,

CUR,

Synergistic Effect of Apigenin and Curcumin on Apoptosis, Paraptosis and Autophagy-related Cell Death in HeLa Cells

-

in-vitro,

Cerv,

HeLa

TumCD↑, eff↑, TumAuto↑, ER Stress↑, Paraptosis↑, GRP78/BiP↓, Dose↝,

2634-

Api,

Apigenin induces both intrinsic and extrinsic pathways of apoptosis in human colon carcinoma HCT-116 cells

-

in-vitro,

CRC,

HCT116

TumCG↓, TumCCA↑, MMP↓, ROS↑, Ca+2↑, ER Stress↑, mtDam↑, CHOP↑, DR5↑, cl‑BID↑, BAX↑, Cyt‑c↑, cl‑Casp3↑, cl‑Casp8↑, cl‑Casp9↑, Apoptosis↑,

2633-

Api,

Apigenin induces ROS-dependent apoptosis and ER stress in human endometriosis cells

-

in-vitro,

EC,

NA

TumCP↓, TumCCA↑, MMP↓, Ca+2↑, BAX↑, Cyt‑c↑, ROS↑, lipid-P↑, ER Stress↑, UPR↑, p‑ERK↓, ERK↓, JNK↑,

2631-

Api,

Apigenin Induces Autophagy and Cell Death by Targeting EZH2 under Hypoxia Conditions in Gastric Cancer Cells

-

in-vivo,

GC,

NA

mice

-

in-vitro,

GC,

AGS

ER Stress↑, Hif1a↓, EZH2↓, HDAC↓, TumAuto↑, p‑mTOR↓, AMPKα↑, GRP78/BiP↑, ROS↑, MMP↓, Ca+2↑, ATF4↑, CHOP↑,

2317-

Api,

Apigenin intervenes in liver fibrosis by regulating PKM2-HIF-1α mediated oxidative stress

-

in-vivo,

Nor,

NA

on liver fibrosis induced by CCl4 in mice.

*hepatoP↑, *PKM2↓, *Hif1a↓, *MDA↓, *Catalase↓, *GSH↑, *SOD↑, *GPx↑, *TAC↑, *α-SMA↓, *Vim↓, *ROS↓,

2299-

Api,

Flavonoids Targeting HIF-1: Implications on Cancer Metabolism

-

Review,

Var,

NA

TumCP↓, angioG↓, Hif1a↓, VEGF↓, GLUT1↓, PKM2↓, Glycolysis↓,

2314-

Api,

Apigenin Restrains Colon Cancer Cell Proliferation via Targeted Blocking of Pyruvate Kinase M2-Dependent Glycolysis

-

in-vitro,

Colon,

HCT116

27.9uM

-

in-vitro,

Colon,

HT29

48.2uM

-

in-vitro,

Colon,

DLD1

89.5uM

Glycolysis↓, PKM2:PKM1↓, β-catenin/ZEB1↓, cMyc↓,

2316-

Api,

The interaction between apigenin and PKM2 restrains progression of colorectal cancer

-

in-vitro,

CRC,

LS174T

-

in-vitro,

CRC,

HCT8

-

in-vivo,

CRC,

NA

TumCP↓, PKM2↓, Glycolysis↓, TumCG↑, selectivity↑,

2318-

Api,

Apigenin as a multifaceted antifibrotic agent: Therapeutic potential across organ systems

-

Review,

Nor,

NA

*ROS↓, *PKM2↓, *Hif1a↓, *TGF-β↓, *AMPK↑, *Inflam↓, *PI3K↓, *Akt↑, *NRF2↑, *NF-kB↓,

2319-

Api,

Apigenin sensitizes radiotherapy of mouse subcutaneous glioma through attenuations of cell stemness and DNA damage repair by inhibiting NF-κB/HIF-1α-mediated glycolysis

-

in-vitro,

GBM,

NA

apigenin 20 mg/kg for 12 days

Glycolysis↓, NF-kB↓, p65↓, Hif1a↓, GLUT1↓, GLUT3↓, PKM2↓, RadioS↑, TumVol↓, TumW↓,

1301-

Api,

Bcl-2 inhibitor and apigenin worked synergistically in human malignant neuroblastoma cell lines and increased apoptosis with activation of extrinsic and intrinsic pathways

-

in-vitro,

neuroblastoma,

NA

BAX↑, Bcl-2↓, Cyt‑c↑, cal2↑, Casp3↑,

1999-

Api,

doxoR,

Apigenin ameliorates doxorubicin-induced renal injury via inhibition of oxidative stress and inflammation

-

in-vitro,

Nor,

NRK52E

-

in-vitro,

Nor,

MPC5

-

in-vitro,

BC,

4T1

-

in-vivo,

NA,

NA

APG (125, 250, and 500 mg/kg) for two weeks,

mice

neuroP↑, ChemoSen∅, RenoP↑, selectivity↑, chemoP↑, ROS↑, *ROS∅, *antiOx↑, *toxicity↓,

1550-

Api,

Formulation and characterization of an apigenin-phospholipid phytosome (APLC) for improved solubility, in vivo bioavailability, and antioxidant potential

-

Analysis,

NA,

NA

*BioAv↑, *antiOx↑,

1537-

Api,

Apigenin as Tumor Suppressor in Cancers: Biotherapeutic Activity, Nanodelivery, and Mechanisms With Emphasis on Pancreatic Cancer

-

Review,

PC,

NA

20-80uM

5-50mg/kg

TumCP↓, TumCCA↑, Apoptosis↑, MMPs↓, Akt↓, *BioAv↑, *BioAv↓, Half-Life∅, Hif1a↓, GLUT1↓, VEGF↓, ChemoSen↑, ROS↑, Bcl-2↓, Bcl-xL↓, BAX↑, BIM↑,

1536-

Api,

Apigenin causes necroptosis by inducing ROS accumulation, mitochondrial dysfunction, and ATP depletion in malignant mesothelioma cells

-

in-vitro,

MM,

MSTO-211H

0, 10, 30, and 50 µM) of apigenin for 48 h and 72 h

-

in-vitro,

MM,

H2452

tumCV↓, ROS↑, MMP↓, ATP↓, Apoptosis↑, Necroptosis↑, DNAdam↑, TumCCA↑, Casp3↑, cl‑PARP↑, MLKL↑, p‑RIP3↑, Bax:Bcl2↑, eff↓, eff↓,

1538-

Api,

Enhancing oral bioavailability using preparations of apigenin-loaded W/O/W emulsions: In vitro and in vivo evaluations

-

in-vivo,

Nor,

NA

rats

*BioAv↑,

1564-

Api,

Apigenin-induced prostate cancer cell death is initiated by reactive oxygen species and p53 activation

-

in-vitro,

Pca,

22Rv1

10–80 μM

-

in-vivo,

NA,

NA

MDM2↓, NF-kB↓, p65↓, P21↑, ROS↑, GSH↓, MMP↓, Cyt‑c↑, Apoptosis↑, P53↑, eff↓, Bcl-xL↓, Bcl-2↓, BAX↑, Casp↑, TumCG↓, TumVol↓, TumW↓,

1539-

Api,

LT,

Dietary flavones counteract phorbol 12-myristate 13-acetate-induced SREBP-2 processing in hepatic cells

-

in-vitro,

Liver,

HepG2

1,10,25uM

SREBP2↓, eff↑, p‑MEK↓, p‑ERK↓,

1540-

Api,

Determination of Total Apigenin in Herbs by Micellar Electrokinetic Chromatography with UV Detection

-

Analysis,

NA,

NA

*BioAv↑,

1541-

Api,

EGCG,

Prospective cohort comparison of flavonoid treatment in patients with resected colorectal cancer to prevent recurrence

-

Human,

NA,

NA

20 mg api + 20 mg EGCG

Eighty-seven patients, 36 patients with resected colon cancer and 51 patients after polypectomy,

OS↑, Remission↓, Dose∅,

1542-

Api,

Bioavailability of Apigenin from Apiin-Rich Parsley in Humans

-

Human,

NA,

NA

Eleven healthy subjects (5 women, 6 men) in the age range of 23-41 years

*BioAv?, *Half-Life?,

1543-

Api,

Therapeutical properties of apigenin: a review on the experimental evidence and basic mechanisms

-

Review,

NA,

NA

TNF-α↓, IL1β↓, IL6↓, IL10↓, COX2↓, iNOS↓, Inflam↓, Dose∅, Dose∅,

1544-

Api,

The flavone apigenin blocks nuclear translocation of sterol regulatory element-binding protein-2 in the hepatic cells WRL-68

-

in-vitro,

Nor,

WRL68

*SREBF2↓, *HMGCR↓, *Dose∅, *BioAv?,

1545-

Api,

The Potential Role of Apigenin in Cancer Prevention and Treatment

-

Review,

NA,

NA

TNF-α↓, IL6↓, IL1α↓, P53↑, Bcl-xL↓, Bcl-2↓, BAX↑, Hif1a↓, VEGF↓, TumCCA↑, DNAdam↑, Apoptosis↑, CycB↓, cycA1↓, CDK1↓, PI3K↓, Akt↓, mTOR↓, IKKα↓, ERK↓, p‑Akt↓, p‑P70S6K↓, p‑S6↓, p‑ERK↓, p‑P90RSK↑, STAT3↓, MMP2↓, MMP9↓, TumCP↓, TumCMig↓, TumCI↓, Wnt/(β-catenin)↓,

1546-

Api,

Apigenin in Cancer Prevention and Therapy: A Systematic Review and Meta-Analysis of Animal Models

-

Review,

NA,

NA

TumVol↓, TumW↓, AntiCan↑, Apoptosis↑, TumCCA↑,

1547-

Api,

Apigenin: Molecular Mechanisms and Therapeutic Potential against Cancer Spreading

-

Review,

NA,

NA

angioG↓, EMT↓, CSCs↓, TumCCA↑, Dose∅, ROS↑, MMP↓, Catalase↓, GSH↓, PI3K↓, Akt↓, NF-kB↓, OCT4↓, Nanog↓, SIRT3↓, SIRT6↓, eff↑, eff↑, Cyt‑c↑, Bax:Bcl2↑, p‑GSK‐3β↓, FOXO3↑, p‑STAT3↓, MMP2↓, MMP9↓, COX2↓, MMPs↓, NRF2↓, HDAC↓, Telomerase↓, eff↑, eff↑, eff↑, eff↑, eff↑, XIAP↓, survivin↓, CK2↓, HSP90↓, Hif1a↓, FAK↓, EMT↓,

1548-

Api,

A comprehensive view on the apigenin impact on colorectal cancer: Focusing on cellular and molecular mechanisms

-

Review,

Colon,

NA

*BioAv↓, *Half-Life∅, selectivity↑, *toxicity↓, Wnt/(β-catenin)↓, P53↑, P21↑, PI3K↓, Akt↓, mTOR↓, TumCCA↑, TumCI↓, TumCMig↓, STAT3↓, PKM2↓, EMT↓, cl‑PARP↑, Casp3↑, Bax:Bcl2↑, VEGF↓, Hif1a↓, Dose∅, GLUT1↓, GlucoseCon↓,

1549-

Api,

Chemo,

Chemoprotective and chemosensitizing effects of apigenin on cancer therapy

-

Review,

NA,

NA

ChemoSideEff↓, *toxicity∅, ChemoSen↑, eff↑, eff↑, eff↑,

1551-

Api,

Chemotherapeutic effects of Apigenin in breast cancer: Preclinical evidence and molecular mechanisms; enhanced bioavailability by nanoparticles

-

Review,

NA,

NA

*BioAv↑,

1552-

Api,

Apigenin inhibits the growth of colorectal cancer through down-regulation of E2F1/3 by miRNA-215-5p

-

in-vitro,

CRC,

HCT116

Apoptosis↑, TumCP↓, miR-215-5p↑, TumCCA↑, E2Fs↓,

1553-

Api,

Role of Apigenin in Cancer Prevention via the Induction of Apoptosis and Autophagy

-

Review,

NA,

NA

Dose∅, TumVol↓, Dose∅, COX2↓, Hif1a↓, TumCCA↑, P53↑, P21↑, Casp3↑, DNAdam↑, TumAuto↝,

1554-

Api,

A Review on Flavonoid Apigenin: Dietary Intake, ADME, Antimicrobial Effects, and Interactions with Human Gut Microbiota

-

Review,

NA,

NA

*BioAv↑, *BioAv↑, *BioAv↑, *BioAv↓, *eff↑,

1555-

Api,

USDA Database for the Flavonoid Content of Selected Foods

-

Analysis,

NA,

NA

Dose?,

1565-

Api,

Apigenin-7-glucoside induces apoptosis and ROS accumulation in lung cancer cells, and inhibits PI3K/Akt/mTOR pathway

-

in-vitro,

Lung,

A549

25, 50, 100, and 200 μM AGL

-

in-vitro,

Nor,

BEAS-2B

-

in-vitro,

Lung,

H1975

TumCP↓, Apoptosis↑, TumCMig↓, TumCI↓, Cyt‑c↑, MDA↑, GSH↓, ROS↑, PI3K↓, Akt↓, mTOR↓,

1556-

Api,

Dissolution and antioxidant potential of apigenin self nanoemulsifying drug delivery system (SNEDDS) for oral delivery

-

Analysis,

NA,

NA

*BioAv↑, *Dose∅,

1557-

Api,

Preparation of apigenin nanocrystals using supercritical antisolvent process for dissolution and bioavailability enhancement

-

in-vitro,

Nor,

NA

*BioAv↑,

1558-

Api,

Preparation, characterization and antitumor activity evaluation of apigenin nanoparticles by the liquid antisolvent precipitation technique

-

in-vitro,

Liver,

HepG2

BioAv↑, *toxicity∅, eff↑,

1559-

Api,

Dually Active Apigenin-Loaded Nanostructured Lipid Carriers for Cancer Treatment

-

in-vitro,

Lung,

A549

-

in-vitro,

BC,

MCF-7

-

in-vitro,

BC,

MDA-MB-231

Dose↓, selectivity↑,

1560-

Api,

Apigenin as an anticancer agent

-

Review,

NA,

NA

Apoptosis↑, Casp3∅, Casp8∅, TNF-α∅, Cyt‑c↑, MMP2↓, MMP9↓, Snail↓, Slug↓, NF-kB↓, p50↓, PI3K↓, Akt↓, p‑Akt↓,

1561-

Api,

Apigenin Reactivates Nrf2 Anti-oxidative Stress Signaling in Mouse Skin Epidermal JB6 P + Cells Through Epigenetics Modifications

-

in-vivo,

Nor,

JB6

*NRF2↑, *DNMT1↓, *DNMT3A↓, *HDAC↓, *AntiCan↑,

1562-

Api,

Apigenin protects human melanocytes against oxidative damage by activation of the Nrf2 pathway

-

in-vitro,

Vit,

NA

*SOD↑, *Catalase↑, *GPx↑, *MDA↓, *NRF2↑, *toxicity∅,

1563-

Api,

MET,

Metformin-induced ROS upregulation as amplified by apigenin causes profound anticancer activity while sparing normal cells

-

in-vitro,

Nor,

HDFa

metformin (5 mM), apigenin (1 or 20 µM),

-

in-vitro,

PC,

AsPC-1

-

in-vitro,

PC,

MIA PaCa-2

-

in-vitro,

Pca,

DU145

-

in-vitro,

Pca,

LNCaP

-

in-vivo,

NA,

NA

mice

selectivity↑, selectivity↑, selectivity↓, ROS↑, eff↑, tumCV↓, MMP↓, Dose∅, eff↓, DNAdam↑, Apoptosis↑, TumAuto↑, Necroptosis↑, p‑P53↑, BIM↑, BAX↑, p‑PARP↑, Casp3↑, Casp8↑, Casp9↑, Cyt‑c↑, Bcl-2↓, AIF↑, p62↑, LC3B↑, MLKL↑, p‑MLKL↓, RIP3↑, p‑RIP3↑, TumCG↑, TumW↓,

957-

ART/DHA,

Artemisinin inhibits the development of esophageal cancer by targeting HIF-1α to reduce glycolysis levels

-

in-vitro,

ESCC,

KYSE150

10 µmol/L

-

in-vitro,

ESCC,

KYSE170

TumCP↓, TumMeta↓, Glycolysis↓, N-cadherin↓, PKM2↓, Hif1a↓,

1074-

ART/DHA,

Artemisinin attenuates lipopolysaccharide-stimulated proinflammatory responses by inhibiting NF-κB pathway in microglia cells

-

in-vitro,

Nor,

BV2

BV-2 microglia

*TNF-α↓, *IL6↓, *MCP1↓, *NO↓, *iNOS↓, *IκB↑,

1075-

ART/DHA,

Artemisinin derivatives inactivate cancer-associated fibroblasts through suppressing TGF-β signaling in breast cancer

-

in-vitro,

Nor,

L929

*TGF-β↓,

1076-

ART/DHA,

The Potential Mechanisms by which Artemisinin and Its Derivatives Induce Ferroptosis in the Treatment of Cancer

-

Review,

NA,

NA

Ferroptosis↑, ROS↑, ER Stress↑, i-Iron↓, TumAuto↑, AMPK↑, mTOR↑, P70S6K↑, Fenton↑, lipid-P↑, ROS↑, ChemoSen↑, NRF2↑,

985-

ART/DHA,

Artemisinin suppresses aerobic glycolysis in thyroid cancer cells by downregulating HIF-1a, which is increased by the XIST/miR-93/HIF-1a pathway

-

in-vitro,

Thyroid,

TPC-1

XIST levels in serum may be used as a tumor marker for TC promoted by HIF-1a, which could be treated using artemisinin.

-

Human,

NA,

NA

HIF-1a is highly expressed in TC tissues and is positively correlated with the level of XIST in the serum of patients with TC.

XIST↓, Hif1a↓, Glycolysis↓, TumCCA↑, TumMeta↓,

1079-

ART/DHA,

Artesunate inhibits the growth and induces apoptosis of human gastric cancer cells by downregulating COX-2

-

in-vitro,

GC,

BGC-823

20 mg/L

20 mg/L @ 60hr

-

in-vitro,

GC,

HGC27

-

in-vitro,

GC,

MGC803

TumCP↓, Apoptosis↑, COX2↓, BAX↑, Bcl-2↓, Casp3↑, Casp9↑, MMP↓,

976-

ART/DHA,

Artemisinin selectively decreases functional levels of estrogen receptor-alpha and ablates estrogen-induced proliferation in human breast cancer cells

-

in-vitro,

BC,

MCF-7

ERα↓,

1026-

ART/DHA,

Artemisinin improves the efficiency of anti-PD-L1 therapy in T-cell lymphoma

Ferroptosis↑, ROS↑, ERK↓, PD-L1↓,

1148-

ART/DHA,

Artemisinin inhibits extracellular matrix metalloproteinase inducer (EMMPRIN) and matrix metalloproteinase-9 expression via a protein kinase Cδ/p38/extracellular signal-regulated kinase pathway in phorbol myristate acetate-induced THP-1 macrophages

-

in-vitro,

AML,

THP1

20-80 μg/mL

MMP9↓, EMMPRIN↓, p‑PKCδ↓, p‑JNK↓, p‑p38↓, p‑ERK↓,

1147-

ART/DHA,

Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1

-

vitro+vivo,

Ovarian,

HO-8910

0.5-50uM/L

-

vitro+vivo,

Nor,

HUVECs

angioG↓, TumCG↓, VEGF↓, KDR/FLK-1↓, *toxicity↓,

1099-

ART/DHA,

Dihydroartemisinin inhibits IL-6-induced epithelial–mesenchymal transition in laryngeal squamous cell carcinoma via the miR-130b-3p/STAT3/β-catenin signaling pathway

-

in-vitro,

NA,

NA

EMT↓, TumCI↓, STAT3↓, β-catenin/ZEB1↓,

563-

ART/DHA,

Artesunate down-regulates immunosuppression from colorectal cancer Colon26 and RKO cells in vitro by decreasing transforming growth factor β1 and interleukin-10

-

in-vitro,

Colon,

colon26

-

in-vitro,

CRC,

RKO

TGF-β↓, IL10↓,

555-

ART/DHA,

Artemisinin as an anticancer drug: Recent advances in target profiling and mechanisms of action

-

Review,

NA,

NA

STAT3↓,

556-

ART/DHA,

Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing

-

Review,

NA,

NA

IL6↓, IL1↓, TNF-α↓, TGF-β↓, NF-kB↓, MIP2↓, PGE2↓, NO↓, Hif1a↓, KDR/FLK-1↓, VEGF↓, MMP2↓, TIMP2↑, ITGB1↑, NCAM↑, p‑ATM↑, p‑ATR↑, p‑CHK1↑, p‑Chk2↑, Wnt/(β-catenin)↓, PI3K↓, Akt↓, ERK↓, cMyc↓, mTOR↓, survivin↓, cMET↓, EGFR↓, cycD1↓, cycE1↓, CDK4/6↓, p16↑, p27↑, Apoptosis↑, TumAuto↑, Ferroptosis↑, oncosis↑, TumCCA↑, ROS↑, DNAdam↑, RAD51↓, HR↓,

557-

ART/DHA,

Artemisinin and Its Derivatives in Cancer Care

-

Review,

Var,

NA

100-250mg/d

400 mg 3x/day dosed it every other week

*BioAv↓, *BioAv↑, Apoptosis↑, EGFR↓, CD31↓, Ki-67↓, P53↓, TfR1/CD71↑, P-gp↓, PD-1↝,

558-

ART/DHA,

Artemisinin and Its Synthetic Derivatives as a Possible Therapy for Cancer

-

Review,

NA,

NA

ROS↑, oncosis↑, Apoptosis↑, LysoPr↑, TumAuto↑, Wnt/(β-catenin)↑, AMP↓, NF-kB↓, Myc↓, CREBBP↓, mTOR↓, E-cadherin↑,

560-

ART/DHA,

Dihydroartemisinin shift the immune response towards Th1, inhibit the tumor growth in vitro and in vivo

-

in-vivo,

NA,

NA

30 μM

mice

IL4↓, CD4+↓, CD25+↓, FoxP3+↓, Treg lymp↓,

576-

ART/DHA,

Profiling of Multiple Targets of Artemisinin Activated by Hemin in Cancer Cell Proteome

-

Analysis,

NA,

NA

GSTP1/GSTπ↓, TfR1/CD71↓,

575-

ART/DHA,

Dihydroartemisinin initiates ferroptosis in glioblastoma through GPX4 inhibition

-

in-vitro,

GBM,

U87MG

GPx4↓, xCT∅, ROS↑, Ferroptosis↑, ACSL4∅,

574-

ART/DHA,

Dihydroartemisinin suppresses glioma proliferation and invasion via inhibition of the ADAM17 pathway

TumCP↓, TumCMig↓, TumCI↓, MMP17↓, p‑EGFR↓, p‑Akt↓,

573-

ART/DHA,

Artesunate suppresses tumor growth and induces apoptosis through the modulation of multiple oncogenic cascades in a chronic myeloid leukemia xenograft mouse model

-

vitro+vivo,

NA,

NA

p‑p38↓, p‑ERK↓, p‑CREB↓, p‑Chk2↓, p‑STAT5↓, p‑RSK↓, SOCS1↑, Apoptosis↑, Casp3↑,

572-

ART/DHA,

High-throughput screening identifies artesunate as selective inhibitor of cancer stemness: Involvement of mitochondrial metabolism

CSCs↓, mtDam↑,

571-

ART/DHA,

TMZ,

Artesunate enhances the therapeutic response of glioma cells to temozolomide by inhibition of homologous recombination and senescence

-

vitro+vivo,

GBM,

A172

30 μg/ml

mouse

-

vitro+vivo,

GBM,

U87MG

HR↓, RAD51↓, Apoptosis↑, necrosis↑, ROS↑, ChemoSen↑,

570-

ART/DHA,

Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through Wnt/β-catenin signaling

-

vitro+vivo,

NSCLC,

A549

76.95 μM

mice

-

vitro+vivo,

NSCLC,

H1299

TumCCA↑, CSCs↓, TumCI↓, TumCMig↓, TumCG↓, Wnt/(β-catenin)↓, Nanog↓, SOX2↓, OCT4↓, N-cadherin↓, Vim↓, E-cadherin↑,

569-

ART/DHA,

Dihydroartemisinin exhibits anti-glioma stem cell activity through inhibiting p-AKT and activating caspase-3

-

in-vitro,

GBM,

NA

20, 40, and 80 μM DHA, 24hr

Glioma stem cells (GSCs)

TumCP↓, Apoptosis↑, TumCCA↑, Casp3↑, p‑Akt↓,

568-

ART/DHA,

Mechanism-Guided Design and Synthesis of a Mitochondria-Targeting Artemisinin Analogue with Enhanced Anticancer Activity

-

in-vitro,

NA,

MDA-MB-231

2.84 μM

cytotoxicity of ART-TPP is 26-fold and 94-fold more potent than ART in MDA- MB-231 and HeLa cells, respectively.

-

in-vitro,

NA,

HeLa

0.82 μM

ART-TPP, ART-triphenylphosphoniumbromide

-

in-vitro,

NA,

SkBr3

6.13 μM

-

in-vitro,

NA,

HCT116

1.73 μM

Iron↝,

567-

ART/DHA,

An Untargeted Proteomics and Systems-based Mechanistic Investigation of Artesunate in Human Bronchial Epithelial Cells

-

in-vitro,

Lung,

BEAS-2B

NRF2↑, AP-1↑, NFAT↑,

566-

ART/DHA,

2DG,

Dihydroartemisinin inhibits glucose uptake and cooperates with glycolysis inhibitor to induce apoptosis in non-small cell lung carcinoma cells

-

in-vitro,

Lung,

A549

-

in-vitro,

Lung,

PC9

GlucoseCon↓, ATP↓, lactateProd↓, p‑S6↓, mTOR↓, GLUT1↓, Casp9↑, Casp8↑, Casp3↑, Cyt‑c↑, AIF↑, ROS↑,

565-

ART/DHA,

Artesunate as an Anti-Cancer Agent Targets Stat-3 and Favorably Suppresses Hepatocellular Carcinoma

STAT↓, IL6↓, pro‑Casp3↝, Bcl-xL↝, survivin↝,

564-

ART/DHA,

Cisplatin,

Dihydroartemisinin as a Putative STAT3 Inhibitor, Suppresses the Growth of Head and Neck Squamous Cell Carcinoma by Targeting Jak2/STAT3 Signaling

-

in-vitro,

NA,

HN30

JAK2↓, STAT3↓, MMP2↓, MMP9↓, Mcl-1↓, Bcl-xL↓, cycD1↓, VEGF↓, TumCCA↑, ChemoSen↑,

562-

ART/DHA,

Artesunate exerts an anti-immunosuppressive effect on cervical cancer by inhibiting PGE2 production and Foxp3 expression

-

in-vivo,

NA,

HeLa

mice

CD4+↓, CD25+↓, FoxP3+↓, Treg lymp↓, PGE2↓, FOXP3↓, COX2↓,

561-

ART/DHA,

Antitumor and immunomodulatory properties of artemether and its ability to reduce CD4+ CD25+ FoxP3+ T reg cells in vivo

-

in-vivo,

NA,

NA

10-20 mg/kg/day

mice

TumCG↓, CD4+↓, CD25+↓, FoxP3+↓, IL4↑,

559-

ART/DHA,

Artemisinin and its derivatives: a promising cancer therapy

-

Review,

NA,

NA

2.69uM Artesunate

artemisinin (IC 50 > 50 μM) , DHA is one of the most potent derivatives of artemisinin

ROS↑,

2320-

ART/DHA,

Dihydroartemisinin Inhibits the Proliferation of Leukemia Cells K562 by Suppressing PKM2 and GLUT1 Mediated Aerobic Glycolysis

-

in-vitro,

AML,

K562

1.1–2.6 μM

-

in-vitro,

Liver,

HepG2

Glycolysis↓, GlucoseCon↓, lactateProd↓, GLUT1↓, PKM2↓, ECAR↓, LDHA↓, cMyc↓, other↝,

2321-

ART/DHA,

Dihydroartemisinin mediating PKM2-caspase-8/3-GSDME axis for pyroptosis in esophageal squamous cell carcinoma

-

in-vitro,

ESCC,

Eca109

-

in-vitro,

ESCC,

EC9706

Pyro↑, PKM2↓, Casp8↑, Casp3↑, Warburg↓, TumCCA↑, Apoptosis↑,

2322-

ART/DHA,

Dihydroartemisinin Regulates Self-Renewal of Human Melanoma-Initiating Cells by Targeting PKM2/LDHARelated Glycolysis

-

in-vitro,

Melanoma,

NA

TumCP↓, PKM2↓, LDHA↓, Glycolysis↓,

2323-

ART/DHA,

Dihydroartemisinin represses esophageal cancer glycolysis by down-regulating pyruvate kinase M2

-

in-vitro,

ESCC,

Eca109

10, 40, 80, 120 umol/L)

-

in-vitro,

ESCC,

EC9706

PKM2↓, lactateProd↓, GlucoseCon↓, cycD1↓, Bcl-2↓, MMP2↓, VEGF↓, Casp3↑, cl‑PARP↑, BAX↑, DNAdam↑, ROS↑,

2324-

ART/DHA,

Research Progress of Warburg Effect in Hepatocellular Carcinoma

-

Review,

Var,

NA

PKM2↓, GLUT1↓, Glycolysis↓, Akt↓, mTOR↓, Hif1a↓, HK2↓, LDH↓, NF-kB↓,

2570-

ART/DHA,

Discovery, mechanisms of action and combination therapy of artemisinin

-

Review,

Nor,

NA

*BioAv↓, *Half-Life↓, *toxicity↓, *ROS↑, GSH↓, selectivity↑,

2582-

ART/DHA,

5-ALA,

Mechanistic Investigation of the Specific Anticancer Property of Artemisinin and Its Combination with Aminolevulinic Acid for Enhanced Anticolorectal Cancer Activity

-

in-vivo,

CRC,

HCT116

mouse xenograft CRC model

-

in-vitro,

CRC,

HCT116

eff↑, ROS↑, selectivity↑, TumCG↓, toxicity↓,

2581-

ART/DHA,

PB,

Synergistic cytotoxicity of artemisinin and sodium butyrate on human cancer cells

-

in-vitro,

AML,

NA

Molt-4 cells

eff↑, selectivity↑,

2580-

ART/DHA,

VitC,

Effects of Antioxidants and Pro-oxidants on Cytotoxicity of Dihydroartemisinin to Molt-4 Human Leukemia Cells

-

in-vitro,

AML,

NA

Molt-4 cell culture

eff↓, other↝, ROS↑, eff↓, eff↓,

2578-

ART/DHA,

RES,

Synergic effects of artemisinin and resveratrol in cancer cells

-

in-vitro,

Liver,

HepG2

-

in-vitro,

Cerv,

HeLa

Dose↝, TumCMig↓, Apoptosis↑, necrosis↑, ROS↑, eff↑,

2577-

ART/DHA,

Artemisinin and its derivatives in cancer therapy: status of progress, mechanism of action, and future perspectives

-

Review,

Var,

NA

eff↑, TumCCA↑, BioAv↑, eff↑, ChemoSen↑,

2576-

ART/DHA,

AL,

The Synergistic Anticancer Effect of Artesunate Combined with Allicin in Osteosarcoma Cell Line in Vitro and in Vivo

-

in-vitro,

OS,

MG63

-

in-vivo,

NA,

NA

0 mg/kg per day, i.p.), allicin (5 mg/kg per day, i.p.)

mice

eff↑, tumCV↓, Casp3↑, Casp9↑, Apoptosis↑, TumCG↓,

2575-

ART/DHA,

docx,

Artemisia santolinifolia-Mediated Chemosensitization via Activation of Distinct Cell Death Modes and Suppression of STAT3/Survivin-Signaling Pathways in NSCLC

-

in-vitro,

Lung,

H23

AS at concentrations of 100 and 200 μg/mL in combination with DTX at concentrations of 0.5, 1 and 2.5 nM for 48 h.

ChemoSen↑, GPx4↓, ROS↑, Ferroptosis↑, eff↑,

2573-

ART/DHA,

Cell death mechanisms induced by synergistic effects of halofuginone and artemisinin in colorectal cancer cells

-

in-vitro,

CRC,

HCT116

eff↑,

2572-

ART/DHA,

SRF,

Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax

-

in-vitro,

AML,

NA

CHOP↑, Mcl-1↓, ChemoSen↑, selectivity↑,

2571-

ART/DHA,

Cancer combination therapies with artemisinin-type drugs

-

Review,

Var,

NA

AntiTum↑, ChemoSen↑, hepatoP↝,

2574-

ART/DHA,

Artemisinin: A Promising Adjunct for Cancer Therapy

-

Review,

Var,

NA

selectivity↑, eff↑,

2569-

ART/DHA,

A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction

-

Human,

Nor,

NA

Twenty-four healthy males

*Half-Life↝, BioAv↝, *Half-Life↓, BioAv↑, *Dose↝,

3345-

ART/DHA,

Dihydroartemisinin-induced unfolded protein response feedback attenuates ferroptosis via PERK/ATF4/HSPA5 pathway in glioma cells

-

in-vitro,

GBM,

NA

ROS↑, Ferroptosis↑, lipid-P↑, HSP70/HSPA5↑, ER Stress↑, ATF4↑, GRP78/BiP↑, MDA↑, GSH↓, eff↑, GPx4↑,

3382-

ART/DHA,

Repurposing Artemisinin and its Derivatives as Anticancer Drugs: A Chance or Challenge?

-

Review,

Var,

NA

1.20–15.2 μM

AntiCan↑, toxicity↑, Ferroptosis↑, ROS↑, TumCCA↑, BioAv↝, eff↝, Half-Life↓, Ferritin↓, GPx4↓, NADPH↓, GSH↓, BAX↑, Cyt‑c↑, cl‑Casp3↑, VEGF↓, IL8↓, COX2↓, MMP9↓, E-cadherin↑, MMP2↓, NF-kB↓, p16↑, CDK4↓, cycD1↓, p62↓, LC3II↑, EMT↓, CSCs↓, Wnt↓, β-catenin/ZEB1↓, uPA↓, TumAuto↑, angioG↓, ChemoSen↑,

3383-

ART/DHA,

Dihydroartemisinin: A Potential Natural Anticancer Drug

-

Review,

Var,

NA

TumCP↓, Apoptosis↑, TumMeta↓, angioG↓, TumAuto↑, ER Stress↑, ROS↑, Ca+2↑, p38↑, HSP70/HSPA5↓, PPARγ↑, GLUT1↓, Glycolysis↓, PI3K↓, Akt↓, Hif1a↓, PKM2↓, lactateProd↓, GlucoseCon↓, EMT↓, Slug↓, Zeb1↓, ZEB2↓, Twist↓, Snail?, CAFs/TAFs↓, TGF-β↓, p‑STAT3↓, M2 MC↓, uPA↓, HH↓, AXL↓, VEGFR2↓, JNK↑, Beclin-1↑, GRP78/BiP↑, eff↑, eff↑, eff↑, eff↑, eff↑, eff↑, IL4↓, DR5↑, Cyt‑c↑, Fas↑, FADD↑, cl‑PARP↑, cycE↓, CDK2↓, CDK4↓, Mcl-1↓, Ki-67↓, Bcl-2↓, CDK6↓, VEGF↓, COX2↓, MMP9↓,

3384-

ART/DHA,

Dihydroartemisinin triggers ferroptosis in primary liver cancer cells by promoting and unfolded protein response‑induced upregulation of CHAC1 expression

-

in-vitro,

Liver,

Hep3B

29.4±1.7 µM

-

in-vitro,

Liver,

HUH7

32.1±4.5 µM

-

in-vitro,

Liver,

HepG2

40.2±2.1 µM

Ferroptosis↑, ROS↑, GSH↓, UPR↑, GPx4↓, PERK↑, eIF2α↑, ATF4↑,

3392-

ART/DHA,

Artemisinin inhibits inflammatory response via regulating NF-κB and MAPK signaling pathways

-

in-vitro,

Nor,

Hep3B

-

in-vivo,

NA,

NA

TPA-induced skin inflammation in mice.

*Inflam↓, *NF-kB↓, *ROS↓, *p‑p38↓, *p‑ERK↓,

3391-

ART/DHA,

Antitumor Activity of Artemisinin and Its Derivatives: From a Well-Known Antimalarial Agent to a Potential Anticancer Drug

-

Review,

Var,

NA

TumCP↓, TumMeta↓, angioG↓, TumVol↓, BioAv↓, Half-Life↓, BioAv↑, eff↑, eff↓, ROS↑, selectivity↑, TumCCA↑, survivin↓, BAX↑, Casp3↓, Casp8↑, Casp9↑, CDC25↓, CycB↓, NF-kB↓, cycD1↓, cycE↓, E2Fs↓, P21↑, p27↑, ADP:ATP↑, MDM2↓, VEGF↓, IL8↓, COX2↓, MMP9↓, ER Stress↓, cMyc↓, GRP78/BiP↑, DNAdam↑, AP-1↓, MMP2↓, PKCδ↓, Raf↓, ERK↓, JNK↓, PCNA↓, CDK2↓, CDK4↓, TOP2↓, uPA↓, MMP7↓, TIMP2↑, Cdc42↑, E-cadherin↑,

3390-

ART/DHA,

Ferroptosis: The Silver Lining of Cancer Therapy

Ferroptosis↑, Iron↑, NCOA4↝, ROS↑, Fenton↑, Tf↓,

3389-

ART/DHA,

Emerging mechanisms and applications of ferroptosis in the treatment of resistant cancers

-

Review,

Var,

NA

GSH↓, ROS↑, NRF2↑, eff↑,

3385-

ART/DHA,

Interaction of artemisinin protects the activity of antioxidant enzyme catalase: A biophysical study

-

Study,

NA,

NA

*NF-kB↑, *Catalase↑,

3386-

ART/DHA,

Effects of Caffeine-Artemisinin Combination on Liver Function and Oxidative Stress in Selected Organs in 7,12-Dimethylbenzanthracene-Treated Rats

-

in-vivo,

Nor,

NA

Thirty healthy Wistar rats, 4-6 weeks old

*MDA↑, *SOD↓, *GSH∅, *Catalase↓,

3387-

ART/DHA,

Ferroptosis: A New Research Direction of Artemisinin and Its Derivatives in Anti-Cancer Treatment

-

Review,

Var,

NA

BioAv↓, lipid-P↑, Ferroptosis↑, Iron↑, GPx4↓, GSH↓, P53↑, ER Stress↑, PERK↑, ATF4↑, GRP78/BiP↑, CHOP↑, ROS↑, NRF2↑,

3388-

ART/DHA,

Keap1 Cystenine 151 as a Potential Target for Artemisitene-Induced Nrf2 Activation

-

in-vitro,

Lung,

A549

-

in-vitro,

Nor,

GP-293

-

in-vitro,

BC,

MDA-MB-231

NRF2↑, ROS∅,

3394-

ART/DHA,

Anticancer activities and mechanisms of heat-clearing and detoxicating traditional Chinese herbal medicine

IGF-1R↓,

3393-

ART/DHA,

Artemisinin-derived artemisitene blocks ROS-mediated NLRP3 inflammasome and alleviates ulcerative colitis

-

in-vivo,

Col,

NA

*ROS↓, *NLRP3↓, *Inflam↓,

3395-

ART/DHA,

Artesunate Induces Ferroptosis in Hepatic Stellate Cells and Alleviates Liver Fibrosis via the ROCK1/ATF3 Axis

-

in-vitro,

NA,

HSC-T6

Liver Fibrosis LX2

*Ferroptosis↑, *GSH↓, *ROCK1↓,

3396-

ART/DHA,

Progress on the study of the anticancer effects of artesunate

-

Review,

Var,

NA

TumCP↓, TumCI↓, TumCMig↓, Apoptosis↑, Diff↑, TumAuto↑, angioG↓, TumCCA↑, ROS↑, AMPK↑, mTOR↑, ChemoSen↑, Tf↑, Ferroptosis↑, Ferritin↓, lipid-P↑, CDK1↑, CDK2↑, CDK4↑, CDK6↑, SIRT1↑, COX2↓, IL1β↓, survivin↓, DNAdam↑, RadioS↑,

1335-

AS,

Extract from Astragalus membranaceus inhibit breast cancer cells proliferation via PI3K/AKT/mTOR signaling pathway

-

in-vitro,

BC,

MCF-7

25 μg/ml and 50 μg/ml AM extract

-

in-vitro,

BC,

MDA-MB-231

-

in-vitro,

BC,

SkBr3

p‑PI3K↓, p‑GS3Kβ↓, p‑Akt↓, p‑mTOR↓,

1295-

AS,

Cisplatin,

Chemosensitizing Effect of Astragalus Polysaccharides on Nasopharyngeal Carcinoma Cells by Inducing Apoptosis and Modulating Expression of Bax/Bcl-2 Ratio and Caspases

-

in-vivo,

Laryn,

NA

mice

AntiTum↑, Apoptosis↑, Bcl-2↓, BAX↑, Casp3↑, Casp9↑, Bax:Bcl2↑,

1338-

AS,

The Modulatory Properties of Astragalus membranaceus Treatment on Triple-Negative Breast Cancer: An Integrated Pharmacological Method

-

in-vitro,

BC,

NA

TumCI↓, Apoptosis↑, Symptoms↓, PIK3CA↓, Akt↓, Bcl-2↓,

1333-

AS,

Astragalus polysaccharide inhibits breast cancer cell migration and invasion by regulating epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway

-

in-vitro,

BC,

NA

TumCMig↓, TumCI↓, Ki-67↓, TumCP↓, Snail↓, Vim↓, E-cadherin↑, Wnt↓, β-catenin/ZEB1↓,

1334-

AS,

Astragalus membranaceus: A Review of Its Antitumor Effects on Non-Small Cell Lung Cancer

-

Review,

NA,

NA

TumCP↓, Apoptosis↑, NF-kB↓, p50↓, cycD1↓, Bcl-xL↓, ChemoSen↑, angioG↓, ChemoSen↑,

1027-

AS,

Astragalus polysaccharide (APS) attenuated PD-L1-mediated immunosuppression via the miR-133a-3p/MSN axis in HCC

-

vitro+vivo,

HCC,

SMMC-7721 cell

ntraperitoneally injected with 100, 200 and 400 mg/kg APS for 12 days

4.2 mg/mL

mice

PD-L1↓, miR-133a-3p↝,

1000-

AS,

5-FU,

Characterization and anti-tumor bioactivity of astragalus polysaccharides by immunomodulation

-

vitro+vivo,

BC,

4T1

TumCG↓, TumCCA↑, Apoptosis↑, *IL2↑, *TNF-α↑, *IFN-γ↑,

1097-

AS,

Astragalus Inhibits Epithelial-to-Mesenchymal Transition of Peritoneal Mesothelial Cells by Down-Regulating β-Catenin

-

in-vitro,

Nor,

HMrSV5

-

in-vivo,

NA,

NA

rat

*EMT↓, *E-cadherin↑, *α-SMA↓, *Vim↓, *β-catenin/ZEB1↓, *Smad7↑,

944-

AS,

Astragalus saponins inhibit cell growth, aerobic glycolysis and attenuate the inflammatory response in a DSS-induced colitis model

-

vitro+vivo,

CRC,

NA

Glycolysis↓, lactateProd↓, TumCG↓,

1096-

ASA,

Aspirin inhibit platelet-induced epithelial-to-mesenchymal transition of circulating tumor cells (Review)

-

Review,

NA,

NA

TumMeta↓, COX1↓, CTC↓,

1028-

ASA,

Aspirin Suppressed PD-L1 Expression through Suppressing KAT5 and Subsequently Inhibited PD-1 and PD-L1 Signaling to Attenuate OC Development

-

vitro+vivo,

Ovarian,

NA

TumCP↓, TumW↓, PD-L1↓, Ki-67↓, H3K27ac∅, eff↑,

2461-

ASA,

Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis

-

Review,

NA,

NA

AntiAg↑, COX1↓, eff↑,

1304-

ASA,

Aspirin Inhibits Colorectal Cancer via the TIGIT-BCL2-BAX pathway in T Cells

-

in-vitro,

CRC,

NA

-

in-vivo,

NA,

NA

mice

TumCP↓, Apoptosis↑, Bcl-2↓, BAX↑, IL10↓, TNF-β↓,

1370-

Ash,

Withaferin A induces mitochondrial-dependent apoptosis in non-small cell lung cancer cells via generation of reactive oxygen species

-

in-vitro,

Lung,

A549

ROS↑, eff↓,

1367-

Ash,

An anti-cancerous protein fraction from Withania somnifera induces ROS-dependent mitochondria-mediated apoptosis in human MDA-MB-231 breast cancer cells

-

in-vitro,

BC,

MDA-MB-231

92 μg/mL

Apoptosis↑, ROS↑, Bax:Bcl2↑, MMP↓, Casp3↑, TumCCA↑,

1366-

Ash,

Selective Killing of Cancer Cells by Ashwagandha Leaf Extract and Its Component Withanone Involves ROS Signaling

-

in-vitro,

BC,

MCF-7

ROS↑, P53↑,

1365-

Ash,

Withaferin A Induces Oxidative Stress-Mediated Apoptosis and DNA Damage in Oral Cancer Cells

-

in-vitro,

Oral,

Ca9-22

0.5, 1, 2, and 3 μM

-

in-vitro,

Oral,

CAL27

ROS↑, *toxicity↓, Apoptosis↑, TumCCA↑, MMP↓, p‑γH2AX↑, DNAdam↑, eff↓,

1364-

Ash,

Withaferin a Triggers Apoptosis and DNA Damage in Bladder Cancer J82 Cells through Oxidative Stress

-

in-vitro,

Bladder,

J82

cl‑Casp3↑, cl‑Casp8↑, cl‑Casp9↑, cl‑PARP↑, ROS↑, MMP↓, DNAdam↑, eff↓,

1363-

Ash,

doxoR,

Withaferin A Synergizes the Therapeutic Effect of Doxorubicin through ROS-Mediated Autophagy in Ovarian Cancer

-

in-vitro,

Ovarian,

A2780S

-

in-vitro,

Ovarian,

CaOV3

-

in-vivo,

NA,

NA

in vivo xenograft model of ovarian cancer.

ChemoSen↑, ROS↑, DNAdam↑, TumCCA↑, LC3B↑, TumCG↓, cl‑Casp3↑,

1362-

Ash,

GEM,

Synergistic Inhibition of Pancreatic Cancer Cell Growth and Migration by Gemcitabine and Withaferin A

-

in-vitro,

PC,

PANC1

28nM(GC), 18uM(WFA)

-

in-vitro,

PC,

Hs766t

63nM(GC), 13uM(WFA)

ChemoSen↑, ROS↑, Apoptosis↑, TumCMig↓, F-actin↓, YMcells↓, NF-kB↓,

1361-

Ash,

SRF,

Withaferin A, a natural thioredoxin reductase 1 (TrxR1) inhibitor, synergistically enhances the antitumor efficacy of sorafenib through ROS-mediated ER stress and DNA damage in hepatocellular carcinoma cells

-

in-vitro,

Liver,

HUH7

-

in-vivo,

Liver,

HUH7

TrxR↓, ROS↑, DNA-PK↑, ER Stress↑, Apoptosis↑, eff↓,

1360-

Ash,

immuno,

Withaferin A Increases the Effectiveness of Immune Checkpoint Blocker for the Treatment of Non-Small Cell Lung Cancer

-

in-vitro,

Lung,

H1650

-

in-vitro,

Lung,

A549

-

in-vitro,

CRC,

HCT116

-

in-vitro,

BC,

MDA-MB-231

-

in-vivo,

NA,

NA

mice

PD-L1↑, eff↓, ROS↑, ER Stress↑, Apoptosis↑, BAX↑, Bak↑, BAD↑, Bcl-2↓, XIAP↓, survivin↓, cl‑PARP↑, CHOP↑, p‑eIF2α↑, ICD↑, eff↑,

1359-

Ash,

Withaferin A Induces ROS-Mediated Paraptosis in Human Breast Cancer Cell-Lines MCF-7 and MDA-MB-231

-

in-vitro,

BC,

MCF-7

0.5-2uM

-

in-vitro,

BC,

MDA-MB-231

MMP↓, Alix/AIP‑1↓, ROS↑, Paraptosis↑, ER Stress↝,

1358-

Ash,

Withaferin A: A Dietary Supplement with Promising Potential as an Anti-Tumor Therapeutic for Cancer Treatment - Pharmacology and Mechanisms

-

Review,

Var,

NA

TumCCA↑, Apoptosis↑, TumAuto↑, Ferroptosis↑, TumCP↓, CSCs↓, TumMeta↓, EMT↓, angioG↓, Vim↓, HSP90↓, annexin II↓, m-FAM72A↓, BCR-ABL↓, Mortalin↓, NRF2↓, cMYB↓, ROS↑, ChemoSen↑, eff↑, ChemoSen↑, ChemoSen↑, eff↑, *BioAv↓, ROCK1↓, TumCI↓, Sp1/3/4↓, VEGF↓, Hif1a↓, EGFR↓,

1368-

Ash,

Cisplatin,

Withania somnifera Root Extract Enhances Chemotherapy through ‘Priming’

-

in-vitro,

Colon,

HT-29

1 μg/mL, 5 μg/mL and 10 μg/mL W. somnifera for 48 h

-

in-vitro,

BC,

MDA-MB-231

tumCV↓, *toxicity↓, ROS↑, mitResp↓, ChemoSen↑,

1369-

Ash,

Withaferin A inhibits cell proliferation of U266B1 and IM-9 human myeloma cells by inducing intrinsic apoptosis

-

in-vitro,

Melanoma,

U266

9 μM

tumCV↓, Apoptosis↑, BAX↑, Cyt‑c↑, Bcl-2↓, cl‑PARP↑, cl‑Casp3↑, cl‑Casp9↑, ROS↑, eff↓,

1357-

Ash,

Cytotoxicity of withaferin A in glioblastomas involves induction of an oxidative stress-mediated heat shock response while altering Akt/mTOR and MAPK signaling pathways

-

in-vitro,

GBM,

U87MG

1.07±0.071µM

-

in-vitro,

GBM,

U251

0.69±0.041µM

-

in-vitro,

GBM,

GL26

0.23±0.015µM

mouse line

TumCP↓, TumCCA↑, Akt↓, mTOR↓, p70S6↓, p85S6K↓, AMPKα↑, TSC2↑, HSP70/HSPA5↑, HO-1↑, HSF1↓, Apoptosis↑, ROS↑, eff↓,

1356-

Ash,

Withaferin A induces apoptosis by ROS-dependent mitochondrial dysfunction in human colorectal cancer cells

-

in-vitro,

CRC,

HCT116

ROS↑, TumCCA↑, MMP↓, TumCG↓, Apoptosis↑, JNK↝,

1355-

Ash,

Withaferin A-Induced Apoptosis in Human Breast Cancer Cells Is Mediated by Reactive Oxygen Species

-

in-vitro,

BC,

MDA-MB-231

2.5 or 5 µM WA

WA treatment caused ROS production in MDA-MB-231 and MCF-7 cells, but not in a normal human mammary epithelial cell line (HMEC). The HMEC was also resistant to WA-induced apoptosis.

-

in-vitro,

BC,

MCF-7

-

in-vitro,

Nor,

HMEC

eff↑, mt-ROS↑, mitResp↓, OXPHOS↓, compIII↑, BAX↑, Bak↑, other↓, ATP∅, *ROS∅,

1372-

Ash,

Withaferin-A Induces Apoptosis in Osteosarcoma U2OS Cell Line via Generation of ROS and Disruption of Mitochondrial Membrane Potential

-

in-vitro,

OS,

U2OS

0.32 to 7.6 μM

Apoptosis↑, ROS↑, MMP↓, Casp3↑,

1373-

Ash,

Endoplasmic reticulum stress mediates withaferin A-induced apoptosis in human renal carcinoma cells

-

in-vitro,

Kidney,

Caki-1

ER Stress↑, p‑eIF2α↑, XBP-1↑, GRP78/BiP↑, CHOP↑, eff↓,

1433-

Ash,

SFN,

A Novel Combination of Withaferin A and Sulforaphane Inhibits Epigenetic Machinery, Cellular Viability and Induces Apoptosis of Breast Cancer Cells

-

in-vitro,

BC,

MCF-7

1.0 µM WA and 5.0 µM SFN

-

in-vitro,

BC,

MDA-MB-231

eff↑, Bcl-2↓, BAX↑, tumCV↓, DNMT1↓, DNMT3A↓, HDAC↓,

1371-

Ash,

Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic cell death of human myeloid leukemia HL-60 cells by a dietary compound withaferin A with concomitant protection by N-acetyl cysteine

-

in-vitro,

AML,

HL-60

ROS↑, MMP↓, cl‑Casp3↑, cl‑Casp9↑, cl‑PARP↑, eff↓,

2003-

Ash,

Withaferin A Induces Cell Death Selectively in Androgen-Independent Prostate Cancer Cells but Not in Normal Fibroblast Cells

-

in-vitro,

Pca,

PC3

2 μM WA

-

in-vitro,

Pca,

DU145

-

in-vitro,

Nor,

TIG-1

-

in-vitro,

PC,

LNCaP

TumCD↑, selectivity↑, cFos↑, ROS↑, *ROS∅, HSP70/HSPA5↑, Apoptosis↑, ER Stress↑, TumCCA↑,

2002-

Ash,

Ancient medicine, modern use: Withania somnifera and its potential role in integrative oncology

-

Review,

Var,

NA

antiOx↑, Inflam↓, TumCP↓, OS↑, RadioS↑, radioP↑, chemoP↑,

2001-

Ash,

Withania somnifera: from prevention to treatment of cancer

-

Review,

Var,

NA

toxicity↓, TumW↓, Dose?, eff↝, Ki-67↓, survivin↓, XIAP↓, PERK↑, p‑RSK↑, CHOP↑, DR5↑, Dose↝, BG↓, DNMTs↓,

1181-

Ash,

Withaferin A inhibits Epithelial to Mesenchymal Transition in Non-Small Cell Lung Cancer Cells

-

in-vitro,

Lung,

A549

0.5-4uM

-

in-vitro,

Lung,

H1299

TumCMig↓, TumCI↓, EMT↓, p‑SMAD2↓, p‑SMAD3↓, p‑NF-kB↓,

1180-

Ash,

Withaferin A Inhibits Liver Cancer Tumorigenesis by Suppressing Aerobic Glycolysis through the p53/IDH1/HIF-1α Signaling Axis

-

in-vitro,

Liver,

HepG2

IDH1↑, Glycolysis↓, P53↑, Hif1a↓,

1179-

Ash,

Withaferin-A Inhibits Colon Cancer Cell Growth by Blocking STAT3 Transcriptional Activity

-

in-vitro,

CRC,

HCT116

-

in-vivo,

NA,

NA

mouse

TumCP↓, TumCMig↓, STAT3↓, TumVol↓, TumW↓,

1178-

Ash,

Withaferin A suppresses the expression of vascular endothelial growth factor in Ehrlich ascites tumor cells via Sp1 transcription factor

-

in-vitro,

Nor,

HUVECs

-

in-vivo,

NA,

NA

mice

*VEGF↓, *angioG↓, *ascitic↓, *Sp1/3/4↓,

1177-

Ash,

Withaferin A downregulates COX-2/NF-κB signaling and modulates MMP-2/9 in experimental endometriosis

-

in-vivo,

EC,

NA

150 mg withaferin A treated EM-induced rats

rats

TumVol↓, MMP2↓, MMP9↓, NF-kB↓, COX2↓, NO↓, IL1β↓, IL6↓,

1176-

Ash,

Metabolic Alterations in Mammary Cancer Prevention by Withaferin A in a Clinically Relevant Mouse Model

-

in-vivo,

NA,

NA

mice

TumVol↓, Apoptosis↑, Glycolysis↓, PKM2↓, PGK1↓, ALDOAiso2↓,

1174-

Ash,

Withaferin A Suppresses Estrogen Receptor-α Expression in Human Breast Cancer Cells

-

in-vitro,

BC,

MCF-7

-

in-vivo,

BC,

MDA-MB-231

-

in-vitro,

BC,

T47D

p‑P53↑, Apoptosis↑, ERα↓,

1173-

Ash,

Withaferin A inhibits proliferation of human endometrial cancer cells via transforming growth factor-β (TGF-β) signalling

-

in-vitro,

EC,

K1

10 μM

-

in-vitro,

Nor,

THESCs

TumCP↓, *toxicity↓, Apoptosis↑, TumCCA↑, TumCMig↓, TumCI↓, p‑SMAD2↓, TGF-β↓, *toxicity↓,

1172-

Ash,

Withaferin A Inhibits Fatty Acid Synthesis in Rat Mammary Tumors

-

in-vitro,

BC,

MCF-7

-

in-vitro,

BC,

MDA-MB-231

-

in-vivo,

NA,

NA

rats

FASN↓, ACLY↓, ACC1↓, CPT1A↓, SREBP1↓,

1142-

Ash,

Ashwagandha-Induced Programmed Cell Death in the Treatment of Breast Cancer

-

Review,

BC,

MCF-7

typ 2-5uM

Ashwagandha was well tolerated at a dose of 300 mg per day in an eight-week study [147]. For insomnia, a dose of 600 milligrams per day has been found to be safe and effective

-

NA,

BC,

MDA-MB-231

-

NA,

Nor,

HMEC

Apoptosis↑, ROS↑, DNAdam↑, OXPHOS↓, *ROS∅, Bcl-2↓, XIAP↓, survivin↓, DR5↑, IKKα↓, NF-kB↓, selectivity↑, *ROS∅, eff↓, Paraptosis↑,

2388-

Ash,

Withaferin A decreases glycolytic reprogramming in breast cancer

-

in-vitro,

BC,

MDA-MB-231

5 μM WA

-

in-vitro,

BC,

MDA-MB-468

-

in-vitro,

BC,

MCF-7

-

in-vitro,

BC,

MDA-MB-453

GlucoseCon↓, lactateProd↓, ATP↓, Glycolysis↓, GLUT1↓, HK2↓, PKM2↓, cMyc↓, Warburg↓, cMyc↓,

3178-

Ash,

Withaferin A Inhibits Neutrophil Adhesion, Migration, and Respiratory Burst and Promotes Timely Neutrophil Apoptosis

-

Review,

Nor,

NA

ITGB1↓,

3179-

Ash,

Withaferin A inhibits JAK/STAT3 signaling and induces apoptosis of human renal carcinoma Caki cells

-

in-vitro,

RCC,

Caki-1

JAK↓, STAT3↓, Apoptosis↑,

3154-

Ash,

Pharmacokinetics and bioequivalence of Withania somnifera (Ashwagandha) extracts – A double blind, crossover study in healthy adults

BioAv↑, BioAv↓,

3155-

Ash,

Overview of the anticancer activity of withaferin A, an active constituent of the Indian ginseng Withania somnifera

-

Review,

Var,

NA

Half-Life↝, Inflam↓, antiOx↓, angioG↓, ROS↑, BAX↑, Bak↑, E6↓, E7↓, P53↑, Casp3↑, cl‑PARP↑, STAT3↓, eff↑, HSP90↓, TGF-β↓, TNF-α↓, EMT↑, mTOR↓, NOTCH1↓, p‑Akt↓, NF-kB↓, Dose↝,

3156-

Ash,

Withaferin A: From ayurvedic folk medicine to preclinical anti-cancer drug

-

Review,

Var,

NA

MAPK↑, p38↑, BAX↑, BIM↑, CHOP↑, ROS↑, DR5↑, Apoptosis↑, Ferroptosis↑, GPx4↓, BioAv↝, HSP90↓, RET↓, E6↓, E7↓, Akt↓, cMET↓, Glycolysis↓, TCA↓, NOTCH1↓, STAT3↓, AP-1↓, PI3K↓, eIF2α↓, HO-1↑, TumCCA↑, CDK1↓, *hepatoP↑, *GSH↑, *NRF2↑, Wnt↓, EMT↓, uPA↓, CSCs↓, Nanog↓, SOX2↓, CD44↓, lactateProd↓, Iron↑, NF-kB↓,

3157-

Ash,

Withaferin A and Ovarian Cancer Antagonistically Regulate Skeletal Muscle Mass

-

in-vivo,

Ovarian,

A2780S

mouse

*cachexia↑, *UPR↑, Strength↑,

3158-

Ash,

Natural products triptolide, celastrol, and withaferin A inhibit the chaperone activity of peroxiredoxin I

-

Study,

NA,

NA

Prx↓,

3159-

Ash,

Neuroprotective effects of Withania somnifera in the SH-SY5Y Parkinson cell model

-

in-vitro,

Park,

SH-SY5Y

*neuroP↑, *Inflam↓, *ROS↓, *cognitive↑, *memory↑, *GPx↑, *Prx↓, *ATP↑, *Vim↓, *mtDam↓,

3160-

Ash,

Withaferin A: A Pleiotropic Anticancer Agent from the Indian Medicinal Plant Withania somnifera (L.) Dunal

-

Review,

Var,

NA

TumCCA↑, H3↑, P21↑, cycA1↓, CycB↓, cycE↓, CDC2↓, CHK1↓, Chk2↓, p38↑, MAPK↑, E6↓, E7↓, P53↑, Akt↓, FOXO3↑, ROS↑, γH2AX↑, MMP↓, mitResp↓, eff↑, TumCD↑, Mcl-1↓, ER Stress↑, ATF4↑, ATF3↑, CHOP↑, NOTCH↓, NF-kB↓, Bcl-2↓, STAT3↓, CDK1↓, β-catenin/ZEB1↓, N-cadherin↓, EMT↓, Cyt‑c↑, eff↑, CDK4↓, p‑RB1↓, PARP↑, cl‑Casp3↑, cl‑Casp9↑, NRF2↑, ER-α36↓, LDHA↓, lipid-P↑, AP-1↓, COX2↓, RenoP↑, PDGFR-BB↓, SIRT3↑, MMP2↓, MMP9↓, NADPH↑, NQO1↑, GSR↑, HO-1↑, *SOD2↑, *Prx↑, *Casp3?, eff↑, Snail↓, Slug↓, Vim↓, CSCs↓, HEY1↓, MMPs↓, VEGF↓, uPA↓, *toxicity↓, CDK2↓, CDK4↓, HSP90↓,

3161-

Ash,

Withaferin A inhibits ferroptosis and protects against intracerebral hemorrhage

-

in-vivo,

Stroke,

NA

mice

*neuroP↑, *MDA↓, *ROS↓, *SOD↑, *GPx↑, *NRF2↑, *HO-1↑,

3162-

Ash,

Molecular insights into cancer therapeutic effects of the dietary medicinal phytochemical withaferin A

-

Review,

Var,

NA

lipid-P↓, SOD↑, GPx↑, P53↑, Bcl-2↑, E6↓, E7↓, pRB↑, CycB↑, CDC2↑, P21↑, PCNA↓, ALDH1A1↓, Vim↓, Glycolysis↓, cMyc↓, BAX↑, NF-kB↓, Casp3↑, CHOP↑, DR5↑, ERK↓, Wnt↓, β-catenin/ZEB1↓, Akt↓, HSP90↓,

3163-

Ash,

Rad,

Withaferin A, a steroidal lactone, selectively protects normal lymphocytes against ionizing radiation induced apoptosis and genotoxicity via activation of ERK/Nrf-2/HO-1 axis

*radioP↑, selectivity↑, *Casp3↓, *DNAdam↓, *ROS↓, *GSH↓, *NRF2↑, *HO-1↑, *Catalase↑, *SOD↑, *Prx↑, *ERK↑,

3164-

Ash,

Withaferin A alleviates fulminant hepatitis by targeting macrophage and NLRP3

*hepatoP↑, *IKKα↓, *NLRP3↓, *NRF2↑, *AMPK↑, *Inflam↓, *Apoptosis↓, *cl‑Casp3↓, *cl‑PARP1↓, *NLRP3↓, *ROS↓, *ALAT↓, *AST↓, *GSH↑,

3165-

Ash,

Inhibitory effect of withaferin A on Helicobacter pylori‑induced IL‑8 production and NF‑κB activation in gastric epithelial cells

-

in-vitro,

Nor,

NA

gastric epithelial cells

*IL8↓, *Inflam↓,

3167-

Ash,

Withaferin A Inhibits the Proteasome Activity in Mesothelioma In Vitro and In Vivo

-

in-vitro,

MM,

H226

0-5uM

TumCP↓, cMyc↓, cFos↓, cJun↓, TIMP2↑, Vim↓, ROS↑, BAX↑, IKKα↑, Casp3↑, cl‑PARP↑,

3177-

Ash,

Emerging Role of Hypoxia-Inducible Factors (HIFs) in Modulating Autophagy: Perspectives on Cancer Therapy

-

Review,

Var,

NA

Hif1a↓, ROS↑, ER Stress↑,

3176-

Ash,

Apoptosis is induced in leishmanial cells by a novel protein kinase inhibitor withaferin A and is facilitated by apoptotic topoisomerase I-DNA complex

-

in-vitro,

NA,

NA

Leishmanial cell- parasites

PKCδ↓, TOP1∅, ROS↑, GSH↓, DNAdam↑, MMP↓, Cyt‑c↑,

3175-

Ash,

SFN,

Withaferin A and sulforaphane regulate breast cancer cell cycle progression through epigenetic mechanisms

-

in-vitro,

BC,

MDA-MB-231

-

in-vitro,

BC,

MCF-7

DNMTs↓, HDAC↓, eff↑,

3174-

Ash,

Withaferin A Acts as a Novel Regulator of Liver X Receptor-α in HCC

-

in-vitro,

HCC,

HepG2

-

in-vitro,

HCC,

Hep3B

-

in-vitro,

HCC,

HUH7

NF-kB↓, angioG↓, Inflam↓, TumCP↓, TumCMig↓, TumCI↓, Sp1/3/4↓, VEGF↓, angioG↓, uPA↓, PDGF↓, MCP1↓, ICAM-1↓, *NRF2↑, *hepatoP↑,

3173-

Ash,

Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastoma

-

in-vitro,

neuroblastoma,

NA

GPx4↓, HO-1↑, lipid-P↑, Keap1↓, NRF2↑, Ferroptosis↑,

3171-

Ash,

Unlocking the epigenetic code: new insights into triple-negative breast cancer

-

Review,

BC,

NA

DNMTs↓,

3170-

Ash,

Withaferin A protects against hyperuricemia induced kidney injury and its possible mechanisms

-

in-vitro,

Nor,

NRK52E

-

in-vivo,

NA,

NA

mice

*RenoP↑, *hepatoP↑, *creat↓, *BUN↓, *uricA↓, *Apoptosis↓, *α-SMA↓,

3169-

Ash,

Withaferin A blocks formation of IFN-γ-induced metastatic cancer stem cells through inhibition of the CXCR4/CXCL12 pathway in the UP-LN1 carcinoma cell model

-

in-vitro,

GC,

NA

CXCR4↓, CXCL12↓,

3168-

Ash,

Withaferin A targeting both cancer stem cells and metastatic cancer stem cells in the UP-LN1 carcinoma cell model

-

in-vitro,

Var,

NA

CXCR4↓, STAT3↓, CSCs↓,

3166-

Ash,

Exploring the Multifaceted Therapeutic Potential of Withaferin A and Its Derivatives

-

Review,

Var,

NA

*p‑PPARγ↓, *cardioP↑, *AMPK↑, *BioAv↝, *Half-Life↝, *Half-Life↝, *Dose↑, *chemoP↑, IL6↓, STAT3↓, ROS↓, OXPHOS↓, PCNA↓, LDH↓, AMPK↑, TumCCA↑, NOTCH3↓, Akt↓, Bcl-2↓, Casp3↑, Apoptosis↑, eff↑, NF-kB↓, CSCs↓, HSP90↓, PI3K↓, FOXO3↑, β-catenin/ZEB1↓, N-cadherin↓, EMT↓, FASN↓, ACLY↓, ROS↑, NRF2↑, HO-1↑, NQO1↑, JNK↑, mTOR↓, neuroP↑, *TNF-α↓, *IL1β↓, *IL6↓, *IL8↓, *IL18↓, RadioS↑, eff↑,

3172-

Ash,

Implications of Withaferin A for the metastatic potential and drug resistance in hepatocellular carcinoma cells via Nrf2-mediated EMT and ferroptosis

-

in-vitro,

HCC,

HepG2

-

in-vitro,

Nor,

HL7702

Keap1↑, NRF2↓, EMT↓, TumCP↓, TumCI↓, selectivity↑, *toxicity↓, ROS↑, MDA↑, GSH↓, Ferroptosis↑,

1900-

Aur,

Potential Anticancer Activity of Auranofin

-

Review,

Var,

NA

TrxR↓, ROS↑, Apoptosis↓, TumCP↓, eff↑,

1302-

AV,

Quantitative measurement of Bax and Bcl2 genes and protein expression in MCF7 cell-line when treated by Aloe Vera extract

-

in-vitro,

BC,

MCF-7

BAX↑, Bcl-2↓,

875-

B-Gluc,

Chemistry, physico-chemistry and applications linked to biological activities of β-glucans

-

Review,

NA,

NA

AntiCan↑,

876-

B-Gluc,

Clinical and Physiological Perspectives of β-Glucans: The Past, Present, and Future

-

Review,

NA,

NA

AntiTum↑,

874-

B-Gluc,

Potential promising anticancer applications of β-glucans: a review

-

Review,

NA,

NA

AntiCan↑, TumCG↓, BAX↑, Bcl-2↓, IFN-γ↑, PI3K/Akt↑, MAPK↑, NFAT↑, NF-kB↑, ROS↑, NK cell↑, TumCCA↑, ERK↓, Telomerase↓,

1224-

BA,

Intratumor microbiome-derived butyrate promotes lung cancer metastasis

-

in-vivo,

Lung,

NA

TumCG↑, H19↑, HDAC2↓,

1098-

BA,

Baicalein inhibits fibronectin-induced epithelial–mesenchymal transition by decreasing activation and upregulation of calpain-2

-

in-vitro,

Nor,

MCF10

-

in-vivo,

NA,

NA

mouse

*TumCMig↓, *F-actin↓, *E-cadherin↑, *ZO-1↑, *N-cadherin↓, *Vim↓, *Snail↓, *cal2↓, *Ca+2↝,

6-

Ba,

Common Botanical Compounds Inhibit the Hedgehog Signaling Pathway in Prostate Cancer

-

in-vitro,

Pca,

NA

HH↓, Gli1↓,

1029-

Ba,

BA,

Baicalein and baicalin promote antitumor immunity by suppressing PD-L1 expression in hepatocellular carcinoma cells

-

vitro+vivo,

HCC,

NA

PD-L1↓, T-Cell↑, STAT3↓,

1053-

Ba,

docx,

Baicalin, a Potent Inhibitor of NF-κB Signaling Pathway, Enhances Chemosensitivity of Breast Cancer Cells to Docetaxel and Inhibits Tumor Growth and Metastasis Both In Vitro and In Vivo

-

in-vivo,

BC,

4T1

mouse

TumCP↓, Apoptosis↑, ROS↑, Bax:Bcl2↑, NF-kB↓, ChemoSen↑, survivin↓,

999-

Ba,

Baicalin Inhibits EMT through PDK1/AKT Signaling in Human Nonsmall Cell Lung Cancer

-

in-vitro,

Lung,

H460

TumCP↓, p‑PDK1↓, p‑Akt↓, EMT↓, E-cadherin↑, Vim↓,

1032-

BA,

Gut microbiome-derived butyrate inhibits the immunosuppressive factors PD-L1 and IL-10 in tumor-associated macrophages in gastric cancer

-

in-vivo,

GC,

AGS

human and mice

GutMicro↑, PD-L1↓, IL10↓, TumCG↓,

996-

Ba,

Tam,

Baicalein resensitizes tamoxifen‐resistant breast cancer cells by reducing aerobic glycolysis and reversing mitochondrial dysfunction via inhibition of hypoxia‐inducible factor‐1α

Hif1a↓, Glycolysis↓, GlucoseCon↓, lactateProd↓, lact/pyru↓, ROS↑, Apoptosis↑,

1080-

BA,

Butyrate suppresses Cox-2 activation in colon cancer cells through HDAC inhibition

-

in-vitro,

CRC,

HT-29

HDAC↓, TNF-α↓, COX2↓,

2295-

Ba,

5-FU,

Baicalein reverses hypoxia-induced 5-FU resistance in gastric cancer AGS cells through suppression of glycolysis and the PTEN/Akt/HIF-1α signaling pathway

-

in-vitro,

GC,

AGS

ChemoSen↑, HK2↓, LDHA↓, PDK1↓, Akt↓, PTEN↑, Hif1a↓, Glycolysis↓, ROS↑, CHOP↑,

2289-

Ba,

Rad,

Baicalein Inhibits the Progression and Promotes Radiosensitivity of Esophageal Squamous Cell Carcinoma by Targeting HIF-1A

-

in-vitro,

ESCC,

KYSE150

20uM

TumCP↓, TumCMig↓, Glycolysis↓, cycD1↓, CDK4↓, ECAR↓, TumCCA↑, HK1↓, ALDH↓, ALDOA↓, PKM2↓, Hif1a↓,

2290-

Ba,

Research Progress of Scutellaria baicalensis in the Treatment of Gastrointestinal Cancer

-

Review,

GI,

NA

p‑mTOR↓, p‑Akt↓, p‑IKKα↓, NF-kB↓, PI3K↓, Akt↓, ROCK1↓, GSK‐3β↓, CycB↓, cycD1↓, cycA1↑, CDK4↓, P53↑, P21↑, TumCCA↑, MMP2↓, MMP9↓, EMT↓, Hif1a↓, Shh↓, PD-L1↓, STAT3↓, IL1β↓, IL2↓, IL6↓, PKM2↓, HDAC10↓, P-gp↓, Bcl-xL↓, eff↓, BioAv↓, BioAv↑,

2291-

Ba,

BA,

Baicalein and Baicalin Promote Melanoma Apoptosis and Senescence via Metabolic Inhibition

-

in-vitro,

Melanoma,

SK-MEL-28

0-40uM

-

in-vitro,

Melanoma,

A375

LDHA↓, ENO1↓, PKM2↓, GLUT1↓, GLUT3↓, HK2↓, PFK1↓, GPI↓, TPI↓, GlucoseCon↓, TumCG↓, TumCP↓, mTORC1↓, Hif1a↓, Ki-67↓,

2292-

Ba,

BA,

Baicalin and baicalein in modulating tumor microenvironment for cancer treatment: A comprehensive review with future perspectives

-

Review,

Var,

NA

AntiCan↑, *toxicity↓, BioAv↝, BioAv↓, *ROS↓, *TLR2↓, *NF-kB↓, *NRF2↑, *antiOx↑, *Inflam↓, HDAC1↓, HDAC8↓, Wnt↓, β-catenin/ZEB1↓, PD-L1↓, Sepsis↓, NF-kB↓, LOX1↓, COX2↓, VEGF↑, PI3K↓, Akt↓, mTOR↓, MMP2↓, MMP9↓, SIRT1↑, AMPK↑,

2293-

Ba,

Baicalein suppresses inflammation and attenuates acute lung injury by inhibiting glycolysis via HIF‑1α signaling

-

in-vitro,

Nor,

MH-S

40, 20 and 10 µM

present study aimed to investigate the effects of baicalein on lung injury and inflammation

-

in-vivo,

NA,

NA

30 male C57BL/6 mice

*Hif1a↓, *Glycolysis↓, *Inflam↓, *HK2↓, *PFK1↓, *PKM2↓,

2294-

Ba,

Baicalein attenuates cardiac hypertrophy in mice via suppressing oxidative stress and activating autophagy in cardiomyocytes

-

in-vivo,

Nor,

NA

20–30 μM

mice. Cardiac hypertrophy was induced in mice by injection of isoproterenol (ISO, 30 mg·kg−1·d−1) for 15 days

*Catalase↑, *ROS↓, *cardioP↑, *FOXO3?,

2296-

Ba,

The most recent progress of baicalein in its anti-neoplastic effects and mechanisms

-

Review,

Var,

NA

CDK1↓, Cyc↓, p27↑, P21↑, P53↑, TumCCA↑, TumCI↓, MMP2↓, MMP9↓, E-cadherin↑, N-cadherin↓, Vim↓, LC3A↑, p62↓, p‑mTOR↓, PD-L1↓, CAFs/TAFs↓, VEGF↓, ROCK1↓, Bcl-2↓, Bcl-xL↓, BAX↑, ROS↑, cl‑PARP↑, Casp3↑, Casp9↑, PTEN↑, MMP↓, Cyt‑c↑, Ca+2↑, PERK↑, IRE1↑, CHOP↑, Copper↑, Snail↓, Vim↓, Twist↓, GSH↓, NRF2↓, HO-1↓, GPx4↓, XIAP↓, survivin↓, DR5↑,

2298-

Ba,

Flavonoids Targeting HIF-1: Implications on Cancer Metabolism

-

Review,

Var,

NA

TumCG↓, TumCP↓, Hif1a↓, VEGF↓, ChemoSen↑, Glycolysis↓, HK2↓, PDK1↓, LDHA↓, p‑Akt↓, PTEN↑,

2297-

Ba,

Significance of flavonoids targeting PI3K/Akt/HIF-1α signaling pathway in therapy-resistant cancer cells – A potential contribution to the predictive, preventive, and personalized medicine

-

Review,

Var,

NA

Glycolysis↓, Hif1a↓, PKM2↓, RadioS↑,

2597-

Ba,

Baicalein – An Intriguing Therapeutic Phytochemical in Pancreatic Cancer

-

Review,

PC,

NA

chemoP↑, ChemoSen↑, 12LOX?, Bcl-2↓, BAX↑, Mcl-1↓, ERK↓, Prx6↑, Dose↝, BioAv↓, eff↑,

2613-

Ba,

Hepatoprotective Effect of Baicalein Against Acetaminophen-Induced Acute Liver Injury in Mice

-

in-vivo,

Nor,

NA

mice

*hepatoP↑, *MDA↓, *SOD↑, *Catalase↑, *GSH↑, *MAPK↓, *p‑JAK2↓, *p‑STAT3↓, *ALAT↓, *AST↓, *ROS↓, *antiOx↑,

2598-

Ba,

Baicalein inhibits melanogenesis through activation of the ERK signaling pathway

-

in-vitro,

Melanoma,

B16-F10

other↓, other?, ERK↑,

2599-

Ba,

Baicalein induces apoptosis and autophagy of breast cancer cells via inhibiting PI3K/AKT pathway in vivo and vitro

-

in-vitro,

BC,

MCF-7

0, 10, 20, and 40 µM

14uM

IC50 values of baicalein at 24, 48, and 72 hours were 51.06, 22.16, and 13.98 µM

-

in-vitro,

BC,

MDA-MB-231

60.12, 27.98, and 19.01 µM

-

in-vivo,

NA,

NA

Female BALB/c nude mice

TumCP↓, Apoptosis↑, p‑Akt↓, p‑mTOR↓, NF-kB↓, p‑IKKα↓, IKKα↑, PI3K↓, MMP↓, TumAuto↑, TumVol↓, TumW↓,

2600-

Ba,

Baicalein Induces Apoptosis and Autophagy via Endoplasmic Reticulum Stress in Hepatocellular Carcinoma Cells

-

in-vitro,

HCC,

SMMC-7721 cell

19.89uM 48h

-

in-vitro,

HCC,

Bel-7402

ER Stress↑, Bcl-2↓, Ca+2↑, JNK↑, CHOP↑, Casp9↑, Casp3↑, PARP↑, Apoptosis↑, UPR↑,

2601-

Ba,

Cardioprotective effects of baicalein on heart failure via modulation of Ca2 + handling proteins in vivo and in vitro

-

in-vitro,

Nor,

NA

-

in-vivo,

Nor,

NA

rat

*cardioP↑, *p‑Ca+2↓,

2602-

Ba,

Downregulation of ZFX is associated with inhibition of prostate cancer progression by baicalein

-

in-vitro,

Pca,

NA

-

in-vivo,

Pca,

NA

ZFX↓, TumCP↓,

2603-

Ba,

Baicalein inhibits prostate cancer cell growth and metastasis via the caveolin-1/AKT/mTOR pathway

-

in-vitro,

Pca,

DU145

-

in-vitro,

Pca,

PC3

TumCG↓, Apoptosis↑, Cav1↓, p‑Akt↓, p‑mTOR↓, Bax:Bcl2↑, survivin↓, cl‑PARP↑, BioAv↓,

2604-

Ba,

BA,

Comparison of metabolic pharmacokinetics of baicalin and baicalein in rats

-

in-vivo,

Nor,

NA

Rats

*BioAv↝, *BioAv↝,

2605-

Ba,

BA,

Potential therapeutic effects of baicalin and baicalein

-

Review,

Var,

NA

-

Review,

Stroke,

NA

-

Review,

IBD,

NA

-

Review,

Arthritis,

NA

-

Review,

AD,

NA

-

Review,

Park,

NA

cardioP↑, Inflam↓, cognitive↑, *hepatoP↑, *ROS?, *SOD↑, *GSH↑, *MMP↑, *GutMicro↑, ChemoSen↑, *TNF-α↓, *IL10↑, *IL6↓, *eff↑, *ROS↓, *COX2↓, *NF-kB↓, *STAT3↓, *PGE2↓, *MPO↓, *IL1β↓, *MMP2↓, *MMP9↓, *β-Amyloid↓, *neuroP↑, *Dose↝, *BioAv↝, *BioAv↝, *BBB↑,

2606-

Ba,

Baicalein: A review of its anti-cancer effects and mechanisms in Hepatocellular Carcinoma

-

Review,

HCC,

NA

ChemoSen↑, TumCP↓, TumCCA↑, TumCMig↓, TumCI↓, MMPs↓, MAPK↓, TGF-β↓, ZFX↓, p‑MEK↓, ERK↓, MMP2↓, MMP9↓, uPA↓, TIMP1↓, TIMP2↓, NF-kB↓, p65↓, p‑IKKα↓, Fas↑, Casp2↑, Casp3↑, Casp8↑, Casp9↑, Bcl-xL↓, BAX↑, ER Stress↑, Ca+2↑, JNK↑, P53↑, ROS↑, H2O2↑, cMyc↓, CD24↓, 12LOX↓,

2607-

Ba,

SIL,

Baicalein Enhances the Oral Bioavailability and Hepatoprotective Effects of Silybin Through the Inhibition of Efflux Transporters BCRP and MRP2

-

in-vivo,

Nor,

NA

sandwich-cultured rat hepatocyte (SCH) mode

*BioEnh↑, *hepatoP↑, *antiOx↑, *Inflam↓,

2608-

Ba,

Baicalein sensitizes hepatocellular carcinoma cells to 5-FU and Epirubicin by activating apoptosis and ameliorating P-glycoprotein activity

-

in-vitro,

HCC,

Bel-7402

Apoptosis↑, TumAuto↑, P-gp↓, Bcl-xL↓, ChemoSen↑,

2609-

Ba,

Baicalein: unveiling the multifaceted marvel of hepatoprotection and beyond

-

Review,

NA,

NA

*hepatoP↑, *neuroP↑, *Inflam↓,

2610-

Ba,

Hepatoprotective effects of baicalein against CCl4-induced acute liver injury in mice

-

in-vivo,

Nor,

NA

mice

*TNF-α↑, *IL6↑, *hepatoP↑,

2611-

Ba,

Baicalein as a potent neuroprotective agent: A review

-

Review,

Nor,

NA

-

Review,

AD,

NA

-

Review,

Park,

NA

*neuroP↑, *ROS↓, *β-Amyloid↓,

2612-

Ba,

MF,

The effect of a static magnetic field and baicalin or baicalein interactions on amelanotic melanoma cell cultures (C32)

-

in-vitro,

Melanoma,

NA

SOD1↑, SOD2↑, GPx1↑, Dose?, eff↝, SOD1↓, SOD2↓, GPx1↓,

2619-

Ba,

Tumor cell membrane-coated continuous electrochemical sensor for GLUT1 inhibitor screening

-

in-vitro,

HCC,

HepG2

200 μM

-

in-vitro,

GBM,

U87MG

-

in-vitro,

BC,

MGC803

-

in-vitro,

Lung,

A549

GLUT1↓, TumCP↓,

2622-

Ba,

Cisplatin,

Rad,

Natural Baicalein-Rich Fraction as Radiosensitizer in Combination with Bismuth Oxide Nanoparticles and Cisplatin for Clinical Radiotherapy

-

in-vitro,

BC,

MDA-MB-231

-

in-vitro,

BC,

MCF-7

RadioS↑,

2623-

Ba,

Activation of the Nrf2/HO-1 signaling pathway contributes to the protective effects of baicalein against oxidative stress-induced DNA damage and apoptosis in HEI193 Schwann cells

-

in-vitro,

Nor,

HEI193

50 and 100 μM

*DNAdam↓, *ROS↓, *Bax:Bcl2↓, *p‑NRF2↑, *HO-1↑, *neuroP↑, *MMP↑,

2624-

Ba,

Baicalein inhibition of hydrogen peroxide-induced apoptosis via ROS-dependent heme oxygenase 1 gene expression

-

in-vitro,

Nor,

RAW264.7

*HO-1↑, *ERK↑, *ROS↓, *eff↑, *MMP↑, *Cyt‑c∅,

2625-

Ba,

LT,

Baicalein and luteolin inhibit ischemia/reperfusion-induced ferroptosis in rat cardiomyocyte

-

in-vivo,

Stroke,

NA

rat

*lipid-P↓, *ACSL4∅, *NRF2∅, *GPx4∅, *Ferroptosis↓, *ROS↓, *MDA↓, *eff↑, *HO-1∅,

2626-

Ba,

Molecular targets and therapeutic potential of baicalein: a review

-

Review,

Var,

NA

-

Review,

AD,

NA

-

Review,

Stroke,

NA

AntiCan↓, *neuroP↑, *cardioP↑, *hepatoP↑, *RenoP↑, TumCCA↑, CDK4↓, cycD1↓, cycE↑, BAX↑, Bcl-2↓, VEGF↓, Hif1a↓, cMyc↓, NF-kB↓, ROS↑, BNIP3↑, *neuroP↑, *cognitive↑, *NO↓, *iNOS↓, *COX2↓, *PGE2↓, *NRF2↑, *p‑AMPK↑, *Ferroptosis↓, *lipid-P↓, *ALAT↓, *AST↓, *Fas↓, *BAX↓, *Apoptosis↓,

2627-

Ba,

Cisplatin,

Baicalein, a Bioflavonoid, Prevents Cisplatin-Induced Acute Kidney Injury by Up-Regulating Antioxidant Defenses and Down-Regulating the MAPKs and NF-κB Pathways

RenoP↑, *iNOS↑, *TNF-α↓, *IL6↓, *NF-kB↓, *MAPK↓, *ERK↓, *JNK↓, *antiOx↑, *NRF2↓, *HO-1↑, *Cyt‑c∅, *Casp3∅, *Casp9∅, *PARP∅,

2620-

Ba,

Natural compounds targeting glycolysis as promising therapeutics for gastric cancer: A review

-

Review,

GC,

NA

Hif1a↓, HK2↓, LDHA↓, PDK1↓, p‑Akt↓, PTEN↑, GlucoseCon↓, lactateProd↓, Glycolysis↓,

2630-

Ba,

Baicalein decreases uric acid and prevents hyperuricemic nephropathy in mice

-

in-vivo,

Nor,

NA

50 mg/kg/d

mice

*RenoP↑, *uricA↓, *ROS↓, EMT↓,

2618-

Ba,

Baicalein induces apoptosis by inhibiting the glutamine-mTOR metabolic pathway in lung cancer

-

in-vitro,

Lung,

H1299

12.5, 25, and 50 μM

-

in-vivo,

Lung,

A549

10, 20, and 40 μM

TumCG↓, TumCP↓, Apoptosis↑, GLUT1↓, GLS↓, mTOR↓, *toxicity∅, cl‑Casp9↓, cl‑Casp3↓, GSH↓, GlutMet↓,

2617-

Ba,

Potential of baicalein in the prevention and treatment of cancer: A scientometric analyses based review

-

Review,

Var,

NA

Ca+2↑, MMP2↓, MMP9↓, Vim↓, Snail↓, E-cadherin↑, Wnt↓, β-catenin/ZEB1↓, p‑Akt↓, p‑mTOR↓, NF-kB↓, i-ROS↑, Bcl-2↓, BAX↑, Cyt‑c↑, Casp3↑, Casp9↑, STAT3↓, IL6↓, MMP2↓, MMP9↓, NOTCH↓, PPARγ↓, p‑NRF2↓, HK2↓, LDHA↓, PDK1↓, Glycolysis↓, PTEN↑, Akt↓, Hif1a↓, MMP↓, VEGF↓, VEGFR2↓, TOP2↓, uPA↓, TIMP1↓, TIMP2↓, cMyc↓, TrxR↓, ASK1↑, Vim↓, ZO-1↑, E-cadherin↑, SOX2↓, OCT4↓, Shh↓, Smo↓, Gli1↓, N-cadherin↓, XIAP↓,

2616-

Ba,

The Role of HK2 in Tumorigenesis and Development: Potential for Targeted Therapy with Natural Products

-

Review,

Var,

NA

Glycolysis↓, HK2↓, LDHA↓, PDK1↓, PTEN↑,

2615-

Ba,

The Multifaceted Role of Baicalein in Cancer Management through Modulation of Cell Signalling Pathways

-

Review,

Var,

NA

*AntiCan↓, *Inflam↓, TumCP↓, NF-kB↓, PPARγ↑, TumCCA↑, JAK2↓, STAT3↓, TumCMig↓, Glycolysis↓, MMP2↓, MMP9↓, selectivity↑, VEGF↓, Hif1a↓, cMyc↓, ChemoSen↑, ROS↑, p‑mTOR↓, PTEN↑,

2628-

Ba,

Cisplatin,

Baicalein alleviates cisplatin-induced acute kidney injury by inhibiting ALOX12-dependent ferroptosis

-

in-vitro,

Nor,

HK-2

*RenoP↑, *12LOX↓, *Ferroptosis↓,

2629-

Ba,

Baicalein, a Component of Scutellaria baicalensis, Attenuates Kidney Injury Induced by Myocardial Ischemia and Reperfusion

-

in-vivo,

Nor,

NA

Rats, Myocardial ischemia and reperfusion, induced by a 40-minute occlusion and a 3-hour reperfusion of the left anterior descending coronary artery

*RenoP↑, *Apoptosis↓, *TNF-α↓, *IL1↓, *Bcl-2↑, *BAX↓, *Akt↑,

2614-

Ba,

Therapeutic potentials of baicalin and its aglycone, baicalein against inflammatory disorders

-

Review,

NA,

NA

*toxicity↓, *antiOx↑, *Inflam↓, *ROS↓, *NF-kB↓, *MCP1↓, *hepatoP↑, *neuroP↑,

2389-

BA,

Baicalin alleviates lipid accumulation in adipocytes via inducing metabolic reprogramming and targeting Adenosine A1 receptor

-

in-vitro,

Obesity,

3T3

*ECAR↑, *OCR↓, *p‑AMPK↑, *p‑ACC↑, *Glycolysis↑, *lipidDe↓, *SREBP1↓, *FAO↑, *HK2↑, *PKM2↑, *LDHA↑, *PDKs↓, *ACC↓,

2391-

Ba,

Scutellaria baicalensis and its flavonoids in the treatment of digestive system tumors

-

Review,

GC,

NA

Hif1a↓, PKM2↓, RadioS↑, Glycolysis↓, PAK↓,

2473-

BA,

Baicalin Inhibits EMT through PDK1/AKT Signaling in Human Nonsmall Cell Lung Cancer

-

in-vitro,

Lung,

A549

30uM

85.12 uM

-

in-vitro,

Nor,

BEAS-2B

140.7 μM

normal cells

-

in-vitro,

Lung,

H460

53.93 uM

EMT↓, PDK1↓, Akt↓, TumCMig↓, E-cadherin↑, Vim↓,

2474-

Ba,

Anticancer properties of baicalein: a review

-

Review,

Var,

NA

-

in-vitro,

Nor,

BV2

ROS⇅, ROS↑, ER Stress↑, Ca+2↑, Apoptosis↑, eff↑, DR5↑, 12LOX↓, Cyt‑c↑, Casp7↑, Casp9↑, Casp3↑, cl‑PARP↑, TumCCA↑, cycE↑, CDK4↓, cycD1↓, VEGF↓, cMyc↓, Hif1a↓, NF-kB↓, BioEnh↑, BioEnh↑, P450↓, *Hif1a↓, *iNOS↓, *COX2↓, *VEGF↓, *ROS↓, *PI3K↓, *Akt↓,

2475-

Ba,

Baicalein triggers ferroptosis in colorectal cancer cells via blocking the JAK2/STAT3/GPX4 axis

-

in-vitro,

CRC,

HCT116

-

in-vitro,

CRC,

DLD1

-

in-vivo,

NA,

NA

(10, 20 mg/kg, i.g., every two days for two weeks)

CRC xenograft mouse model,

tumCV↓, GPx4↓, STAT3↓, Ferroptosis↑,

2477-

Ba,

Baicalein induces apoptosis via a mitochondrial-dependent caspase activation pathway in T24 bladder cancer cells

-

in-vitro,

CRC,

T24

TumCG↓, TumCCA↑, MMP↓, Cyt‑c↑, Casp9↑, Casp3↑, p‑Akt↓, Bcl-2↓, BAX↑, Bax:Bcl2↑, 12LOX↓,

2483-

Ba,

Baicalein and 12/15-Lipoxygenase in the Ischemic Brain

-

in-vivo,

Stroke,

NA

rat brains

*12LOX↓, *antiOx↓, *neuroP↑,

2482-

Ba,

Modulation of Neuroinflammation in Poststroke Rehabilitation: The Role of 12/15-Lipoxygenase Inhibition and Baicalein

-

Review,

Stroke,

NA

*12LOX↓, *neuroP↑, *eff↑,

2481-

Ba,

Rad,

Radiotherapy Increases 12-LOX and CCL5 Levels in Esophageal Cancer Cells and Promotes Cancer Metastasis via THP-1-Derived Macrophages

-

in-vitro,

ESCC,

Eca109

0, 20, 40, or 80 µmol/L

-

in-vitro,

ESCC,

KYSE150

12LOX↓, RadioS↑, Dose↝, RANTES↓, MCP1↓,

2480-

Ba,

Inhibition of 12/15 lipoxygenase by baicalein reduces myocardial ischemia/reperfusion injury via modulation of multiple signaling pathways

-

in-vivo,

Stroke,

NA

rat

*12LOX↓, *ROS↓, *ERK↑, *Akt↑, *p38↓, *JNK↓, *NF-kB↓, *cardioP↑,

2479-

Ba,

Baicalein Overcomes Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Resistance via Two Different Cell-Specific Pathways in Cancer Cells but not in Normal Cells

-

in-vitro,

HCC,

SW480

40 μmol/L

-

in-vitro,

Pca,

PC3

12LOX↓, DR5↑, CHOP↑, ROS↑, *ROS∅, selectivity↑,

2478-

Ba,

The role of Ca2+ in baicalein-induced apoptosis in human breast MDA-MB-231 cancer cells through mitochondria- and caspase-3-dependent pathway

-

in-vitro,

BC,

MDA-MB-231

Bcl-2↓, BAX↓, Cyt‑c↑, Casp3↑, Ca+2↓,

2476-

Ba,

Baicalein Induces Caspase-dependent Apoptosis Associated with the Generation of ROS and the Activation of AMPK in Human Lung Carcinoma A549 Cells

-

in-vitro,

Lung,

A549

0-125uM

TumCG↓, Apoptosis↑, DR5↑, FasL↑, FADD↑, Casp8↑, cFLIP↓, Casp9↑, Casp3↑, cl‑PARP↑, MMP↓, BID↑, BAX↑, Cyt‑c↑, ROS↑, eff↓, AMPK↑,

2769-

Ba,

Rad,

Baicalein ameliorates ionizing radiation-induced injuries by rebalancing gut microbiota and inhibiting apoptosis

-

in-vivo,

Nor,

NA

MICE

*radioP↑, GutMicro↑, *P53↓, *Apoptosis↑, *DR4↓,

1288-

Ba,

The Traditional Chinese Medicine Baicalein Potently Inhibits Gastric Cancer Cells

-

in-vitro,

GC,

SGC-7901

0-60uM/L

TumCG↓, TumCCA↑, Apoptosis↑, MMP↓, Bcl-2↓, BAX↑,

1535-

Ba,

Baicalein May Act as a Caloric Restriction Mimetic Candidate to Improve the Antioxidant Profile in a Natural Rodent Model of Aging

-

in-vivo,

Nor,

NA

Rats

*antiOx↑, *ROS∅, *CRM↑,

1533-

Ba,

Baicalein, as a Prooxidant, Triggers Mitochondrial Apoptosis in MCF-7 Human Breast Cancer Cells Through Mobilization of Intracellular Copper and Reactive Oxygen Species Generation

-

in-vitro,

BrCC,

MCF-7

85μM for 24 h

-

in-vitro,

Nor,

MCF10

557uM

tumCV↓, i-ROS↑, MMP↓, Bcl-2↓, BAX↑, Cyt‑c↑, Casp9↑, Casp3↑, eff↓, selectivity↑, *toxicity∅, Apoptosis↑, Fenton↑,

1519-

Ba,

Baicalein inhibits KB oral cancer cells by inducing apoptosis via modulation of ROS

-

in-vitro,

Oral,

KB

10, 20 and 40 μM

Apoptosis↑, Dose∅, ROS↑,

1520-

Ba,

Baicalein Induces G2/M Cell Cycle Arrest Associated with ROS Generation and CHK2 Activation in Highly Invasive Human Ovarian Cancer Cells

-

in-vitro,

Ovarian,

SKOV3

50–200 µM baicalein for 48 and 72 h

54uM

-

in-vitro,

Ovarian,

TOV-21G

91uM

TumCG↓, TumCCA↑, ROS↑, DNAdam↑, Chk2↑, Dose∅, p‑γH2AX↑, CDC25↓, CHK1↓, cycD1↓, eff↓, 12LOX↓,

1521-

Ba,

Baicalein induces apoptosis via ROS-dependent activation of caspases in human bladder cancer 5637 cells

-

in-vitro,

Bladder,

5637

0,50,150,250 uM

TumCG↓, Apoptosis↑, IAP1↓, IAP2↓, Casp3↑, Casp9↑, BAX↑, Bcl-2↓, MMP↓, Casp8↑, BID↑, ROS?, eff↓, DR4↑, DR5↑, FasL↑, TRAIL↑,

1522-

Ba,

Baicalein reduces lipopolysaccharide-induced inflammation via suppressing JAK/STATs activation and ROS production

-

in-vitro,

Nor,

RAW264.7

0,20,40,80 uM

*p‑STAT1↓, *p‑STAT3↓, *p‑JAK1↓, *p‑JAK2↓, *iNOS↓, *NO↓, *IL1β↓, *IL6↓, *TNF-α↓, *ROS↓,

1523-

Ba,

Baicalein induces human osteosarcoma cell line MG-63 apoptosis via ROS-induced BNIP3 expression

-

in-vitro,

OS,

MG63

(12.5, 25, and 50 μM)

-

in-vitro,

Nor,

hFOB1.19

TumCD↑, Apoptosis↑, ROS↑, eff↓, Casp3↑, Bcl-2↓, selectivity↑, Cyt‑c↑, LDH?, BNIP3?, BAX↑,

1524-

Ba,

Baicalein Induces Caspase‐dependent Apoptosis Associated with the Generation of ROS and the Activation of AMPK in Human Lung Carcinoma A549 Cells

-

in-vitro,

Lung,

A549

25–125 uM, 24hr

100uM

DR5↑, FADD↑, FasL↑, Casp8↑, cFLIP↓, Casp3↑, Casp9↑, cl‑PARP↑, MMP↓, BID↑, Cyt‑c↑, ROS↑, eff↓, AMPK↑, Apoptosis↑, TumCCA↑, DR5↑, FasL↑, DR4∅, cFLIP↓, FADD↑, MMPs↓,

1525-

Ba,

almon,

Synergistic antitumor activity of baicalein combined with almonertinib in almonertinib-resistant non-small cell lung cancer cells through the reactive oxygen species-mediated PI3K/Akt pathway

-

in-vitro,

Lung,

H1975

-

in-vivo,

Lung,

NA

mice

eff↑, TumCP↓, Apoptosis↑, cl‑Casp3↑, cl‑PARP↑, cl‑Casp9↑, p‑PI3K↓, p‑Akt↓, ROS↑, eff↓,

1527-

Ba,

Baicalein Alleviates Arsenic-induced Oxidative Stress through Activation of the Keap1/Nrf2 Signalling Pathway in Normal Human Liver Cells

-

in-vitro,

Nor,

MIHA

25, 50 or 100 μM) for 24 h

Normal human liver cells (MIHA cells)

*p‑NRF2↑, *ROS↓, *MDA↓, *antiOx↑,

1528-

Ba,

Inhibiting reactive oxygen species-dependent autophagy enhanced baicalein-induced apoptosis in oral squamous cell carcinoma

-

in-vitro,

OS,

CAL27

1-100uM

Apoptosis↑, ROS↑, eff↓, TumAuto↑, cl‑PARP↑, Bax:Bcl2↑, Beclin-1↑, p62↓,

1529-

Ba,

Studies on the Inhibitory Mechanisms of Baicalein in B16F10 Melanoma Cell Proliferation

-

in-vitro,

Melanoma,

B16-F10

ROS↑, eff↓, tumCV↓, Casp3↑, necrosis↑,

1530-

Ba,

Baicalein Decreases Hydrogen Peroxide‐Induced Damage to NG108‐15 Cells via Upregulation of Nrf2

-

in-vitro,

Nor,

NG108-15

15 u­M(H2O2) + 8uM(BA)

*12LOX↓, *ROS↓, *NRF2↑, *eff↑,

1531-

Ba,

Proteomic analysis of the effects of baicalein on colorectal cancer cells

-

in-vitro,

CRC,

DLD1

(0-100uM) for 24 h

-

in-vitro,

CRC,

SW48

TumCP↓, ROS↓, Prx6↑, eff↓, TumCCA↑, ROS↝, *ROS∅,

1532-

Ba,

Baicalein as Promising Anticancer Agent: A Comprehensive Analysis on Molecular Mechanisms and Therapeutic Perspectives

-

Review,

NA,

NA

ROS↑, ER Stress↑, Ca+2↑, MMPs↓, Cyt‑c↑, Casp3↑, ROS↑, DR5↑, ROS↑, BAX↑, Bcl-2↓, MMP↓, Casp3↑, Casp9↑, P53↑, p16↑, P21↑, p27↑, HDAC10↑, MDM2↓, Apoptosis↑, PI3K↓, Akt↓, p‑Akt↓, p‑mTOR↓, NF-kB↓, p‑IκB↓, IκB↑, BAX↑, Bcl-2↓, ROS⇅, BNIP3↑, p38↑, 12LOX↓, Mcl-1↓, Wnt?, GLI2↓, AR↓, eff↑,

1526-

Ba,

Baicalein induces apoptosis through ROS-mediated mitochondrial dysfunction pathway in HL-60 cells

-

in-vitro,

AML,

HL-60

25uM

Apoptosis↑, cl‑PARP↑, DNAdam↑, cl‑BID↑, Cyt‑c↑, Casp3↑, Casp8↑, Casp9?, H2O2↑, ROS↑,

2047-

BA,

Sodium butyrate inhibits migration and induces AMPK-mTOR pathway-dependent autophagy and ROS-mediated apoptosis via the miR-139-5p/Bmi-1 axis in human bladder cancer cells

-

in-vitro,

CRC,

T24

0-10mM

-

in-vitro,

Nor,

SV-HUC-1

-

in-vitro,

Bladder,

5637

-

in-vivo,

NA,

NA

200 mg/kg/day, i.g., n = 5

mice

HDAC↓, AntiTum↑, TumCMig↓, AMPK↑, mTOR↑, TumAuto↑, ROS↑, miR-139-5p↑, BMI1↓, TumCI?, E-cadherin↑, N-cadherin↓, Vim↓, Snail↓, cl‑PARP↑, cl‑Casp3↑, BAX↑, Bcl-2↓, Bcl-xL↓, MMP↓, PINK1↑, PARK2↑, TumMeta↓, TumCG↓, LC3II↑, p62↓, eff↓,

2050-

BA,

The Role of Sodium Phenylbutyrate in Modifying the Methylome of Breast Cancer Cells

-

in-vitro,

BC,

MCF-7

3μM and 5μM

eff↑, HDAC↓, TumCG↓,

1242-

BBM,

Berbamine Exerts Anti-Inflammatory Effects via Inhibition of NF-κB and MAPK Signaling Pathways

-

in-vivo,

Nor,

NA

mouse

*Macrophages↓, *Neut↓, *p‑NF-kB↓, *p‑MAPK↓, *p‑JNK↓, *p‑ERK↓,

1299-

BBR,

Effects of Berberine and Its Derivatives on Cancer: A Systems Pharmacology Review

-

Review,

NA,

NA

TumCCA↑, TP53↑, COX2↓, Bax:Bcl2↑, ROS↑, VEGFR2↓, Akt↓, ERK↓, MMP2↓, MMP9↓, IL8↑, P21↑, p27↑, E-cadherin↓, Fibronectin↓, cMyc↓,

2023-

BBR,

Berberine Induces Caspase-Independent Cell Death in Colon Tumor Cells through Activation of Apoptosis-Inducing Factor

-

in-vitro,

Colon,

NA

0-100uM

-

in-vitro,

Nor,

YAMC

TumCD↑, *toxicity↓, selectivity↑, ROS↑, *ROS∅, MMP↓, *MMP∅, PARP↑, BioAv↝,

2022-

BBR,

GoldNP,

Rad,

Berberine-loaded Janus gold mesoporous silica nanocarriers for chemo/radio/photothermal therapy of liver cancer and radiation-induced injury inhibition

-

in-vitro,

Liver,

SMMC-7721 cell

-

in-vitro,

Nor,

HL7702

*toxicity↓, radioP↑, BioAv↑, AntiTum↑, selectivity↑, eff↑, chemoP↑,

2021-

BBR,

Berberine: An Important Emphasis on Its Anticancer Effects through Modulation of Various Cell Signaling Pathways

-

Review,

NA,

NA

*antiOx?, *Inflam↓, Apoptosis↑, TumCCA↑, BAX↑, eff↑, VEGF↓, PI3K↓, Akt↓, mTOR↓, Telomerase↓, β-catenin/ZEB1↓, Wnt↓, EGFR↓, AP-1↓, NF-kB↓, COX2↑, NRF2↓, RadioS↑, STAT3↓, ERK↓, AR↓, ROS↑, eff↑, selectivity↑, selectivity↑, BioAv↓, DNMT1↓, cMyc↓,

1390-

BBR,

Rad,

Berberine Inhibited Radioresistant Effects and Enhanced Anti-Tumor Effects in the Irradiated-Human Prostate Cancer Cells

-

in-vitro,

Pca,

PC3

RadioS↑, Apoptosis↑, ROS↑, eff↑, BAX↑, Casp3↑, P53↑, p38↑, JNK↑, Bcl-2↓, ERK↓, HO-1↓,

1398-

BBR,

Berberine inhibits the progression of renal cell carcinoma cells by regulating reactive oxygen species generation and inducing DNA damage

-

in-vitro,

Kidney,

NA

TumCP↓, TumCMig↓, ROS↑, Apoptosis↑, BAX↑, BAD↑, Bak↑, Cyt‑c↑, cl‑Casp3↑, cl‑Casp9↑, E-cadherin↑, TIMP1↑, γH2AX↑, Bcl-2↓, N-cadherin↓, Vim↓, Snail↓, RAD51↓, PCNA↓,

1392-

BBR,

Based on network pharmacology and experimental validation, berberine can inhibit the progression of gastric cancer by modulating oxidative stress

-

in-vitro,

GC,

AGS

2.5, 5, 10, 20, 40 µM

-

in-vitro,

GC,

MKN45

TumCG↓, TumCMig↓, ROS↑, MDA↑, SOD↓, NRF2↓, HO-1↓, Hif1a↓, EMT↓, Snail↓, Vim↓,

1393-

BBR,

EPI,

Berberine promotes antiproliferative effects of epirubicin in T24 bladder cancer cells by enhancing apoptosis and cell cycle arrest

-

in-vitro,

Bladder,

T24

ChemoSen↑, TumCCA↑, Apoptosis↑, cl‑Casp3↑, cl‑Casp9↑, BAX↑, P53↑, P21↑, Bcl-2↓, ROS↑,

1394-

BBR,

DL,

Synergistic Inhibitory Effect of Berberine and d-Limonene on Human Gastric Carcinoma Cell Line MGC803

-

in-vitro,

GC,

MGC803

eff↑, ROS↑, MMP↓, Casp3↑, Bcl-2↓, TumCCA↑,

1395-

BBR,

Analysis of the mechanism of berberine against stomach carcinoma based on network pharmacology and experimental validation

-

in-vitro,

GC,

NA

20, 50, and 80 µM

Apoptosis↑, ROS↑, MMP↓, ATP↓, AMPK↑, TP53↑, p‑MAPK↓, p‑ERK↓,

1396-

BBR,

Berberine induced down-regulation of matrix metalloproteinase-1, -2 and -9 in human gastric cancer cells (SNU-5) in vitro

-

in-vitro,

GC,

SNU1041

-

in-vitro,

GC,

SNU5

tumCV↓, ROS↑, MMP1↓, MMP2↓, MMP9↓, MMP7∅,

1397-

BBR,

Chemo,

Effects of Coptis extract combined with chemotherapeutic agents on ROS production, multidrug resistance, and cell growth in A549 human lung cancer cells

-

in-vitro,

Lung,

A549

TumCG↓, ROS↑, MDR1↓,

1399-

BBR,

Rad,

Radiotherapy Enhancing and Radioprotective Properties of Berberine: A Systematic Review

-

Review,

NA,

NA

*ROS↓, *MDA↓, *TNF-α↓, *TGF-β↓, *IL10↑, ROS↑, DNAdam↑, mtDam↑, MMP↓, Apoptosis↑, TumCCA↑, Hif1a↓, VEGF↓, RadioS↑,

1400-

BBR,

Set9, NF-κB, and microRNA-21 mediate berberine-induced apoptosis of human multiple myeloma cells

-

in-vitro,

Melanoma,

U266

40−160 μmol/L

ROS↑, TumCCA↑, Apoptosis↑, miR-21↓, Bcl-2↓, NF-kB↓, Set9↑,

1401-

BBR,

Berberine induces apoptosis in glioblastoma multiforme U87MG cells via oxidative stress and independent of AMPK activity

-

in-vitro,

GBM,

U87MG

BBR (10, 25, 100 and 250 µM) for 24, 48 and 72 h

TumCP↓, Apoptosis↑, ROS↑,

1402-

BBR,

Berberine-induced apoptosis in human glioblastoma T98G cells is mediated by endoplasmic reticulum stress accompanying reactive oxygen species and mitochondrial dysfunction

-

in-vitro,

GBM,

T98G

tumCV↓, ROS↑, Ca+2↑, ER Stress↑, eff↓, Bax:Bcl2↑, MMP↓, Casp9↑, Casp3↑, cl‑PARP↑,

1404-

BBR,

Berberine-induced apoptosis in human prostate cancer cells is initiated by reactive oxygen species generation

-

in-vitro,

Pca,

PC3

Apoptosis↑, *Apoptosis∅, MMP↓, cl‑Casp3↑, cl‑Casp9↑, cl‑PARP↑, ROS↑, eff↓, Cyt‑c↑,

1405-

BBR,

Chit,

Chitosan/alginate nanogel potentiate berberine uptake and enhance oxidative stress mediated apoptotic cell death in HepG2 cells

-

in-vitro,

Liver,

HepG2

*BioAv↑, ROS↑, MMP↓, TumCP↓,

1374-

BBR,

PDT,

Berberine associated photodynamic therapy promotes autophagy and apoptosis via ROS generation in renal carcinoma cells

-

in-vitro,

RCC,

786-O

5, 10, 20, 40, 80, 160 and 320 μM

40 μM of BBR presented viability <80 % in 48 h

-

in-vitro,

RCC,

HK-2

ROS↑, TumAuto↑, Apoptosis↑, Casp3↑, eff↑,

1387-

BBR,

Antitumor Activity of Berberine by Activating Autophagy and Apoptosis in CAL-62 and BHT-101 Anaplastic Thyroid Carcinoma Cell Lines

-

in-vitro,

Thyroid,

CAL-62

TumCG↓, Apoptosis↑, LC3B↑, ROS↑, PI3K↓, Akt↓, mTOR↓,

1386-

BBR,

Berberine-induced apoptosis in human breast cancer cells is mediated by reactive oxygen species generation and mitochondrial-related apoptotic pathway

-

in-vitro,

BC,

MCF-7

-

in-vitro,

BC,

MDA-MB-231

tumCV↓, ROS↑, JNK↑, MMP↓, Bcl-2↓, BAX↑, Cyt‑c↑, AIF↝,

1385-

BBR,

5-FU,

Low-Dose Berberine Attenuates the Anti-Breast Cancer Activity of Chemotherapeutic Agents via Induction of Autophagy and Antioxidation

-

in-vitro,

BC,

MCF-7

BBR (0-10 μM) with 5-FU (0-250 μM)

-

in-vitro,

BC,

MDA-MB-231

eff↓, ROS↑, TumCP↑, NRF2↑, ChemoSen↓,

1384-

BBR,

Berberine induces apoptosis via ROS generation in PANC-1 and MIA-PaCa2 pancreatic cell lines

-

in-vitro,

PC,

PANC1

TumCCA↑, ROS↑, Apoptosis↑,

1382-

BBR,

Berberine increases the expression of cytokines and proteins linked to apoptosis in human melanoma cells

-

in-vitro,

Melanoma,

SK-MEL-28

50 μM BBR treatment for 24 h

Apoptosis↑, necrosis↑, DNAdam↑, TumCCA↑, ROS↑, Casp3↑, p‑P53↑, ERK↑,

1381-

BBR,

Rad,

Berberine enhances the sensitivity of radiotherapy in ovarian cancer cell line (SKOV-3)

-

in-vitro,

Ovarian,

SKOV3

5 µM

RadioS↑, ROS↑, GSH↓, Apoptosis↑,

1389-

BBR,

Lap,

Berberine reverses lapatinib resistance of HER2-positive breast cancer cells by increasing the level of ROS

-

in-vitro,

BC,

BT474

-

in-vitro,

BC,

AU-565

ChemoSen↑, Apoptosis↑, ROS↑, NRF2↓,

1380-

BBR,

doxoR,

treatment with ROS scavenger N-acetylcysteine (NAC) and JNK inhibitor SP600125 could partially attenuate apoptosis and DNA damage triggered by DCZ0358.

-

in-vivo,

Nor,

NA

Rats

*ROS↓, *MDA↓, *SOD↑, *NRF2↑, *HO-1↑,

1379-

BBR,

Berberine derivative DCZ0358 induce oxidative damage by ROS-mediated JNK signaling in DLBCL cells

-

in-vitro,

lymphoma,

NA

TumCP↓, CDK4↓, CDK6↓, cycD1↓, TumCCA↑, MMP↓, Ca+2↑, ATP↓, mtDam↑, Apoptosis↑, ROS↑, JNK↑, eff↓,

1378-

BBR,

Berberine induces non-small cell lung cancer apoptosis via the activation of the ROS/ASK1/JNK pathway

-

in-vitro,

Lung,

NA

Apoptosis↑, Casp3↑, Cyt‑c↑, MMP↓, p‑JNK↑, eff↓,

1377-

BBR,

Berberine inhibits autophagy and promotes apoptosis of fibroblast-like synovial cells from rheumatoid arthritis patients through the ROS/mTOR signaling pathway

-

in-vitro,

Arthritis,

NA

10, 20, 30, 40, 50, 60, 70, and 80 μmol/L berberine

Apoptosis↑, MMP↓, Bax:Bcl2↑, LC3‑Ⅱ/LC3‑Ⅰ↓, p62↑, *ROS↓,

1375-

BBR,

13-[CH2CO-Cys-(Bzl)-OBzl]-Berberine: Exploring The Correlation Of Anti-Tumor Efficacy With ROS And Apoptosis Protein

-

in-vitro,

CRC,

HCT8

~15–40 μM

-

in-vivo,

NA,

NA

mouse

ROS↑, TumCP↓, XIAP↓, TumCG↓, *toxicity↓,

1376-

BBR,

immuno,

Berberine sensitizes immune checkpoint blockade therapy in melanoma by NQO1 inhibition and ROS activation

-

in-vivo,

Melanoma,

NA

mice

OS↑, ROS↑, NQO1↓, ICD↑,

1030-

BBR,

Berberine diminishes cancer cell PD-L1 expression and facilitates antitumor immunity via inhibiting the deubiquitination activity of CSN5

-

in-vitro,

Lung,

H460

0–20 μmol/L 24hr

lewis tumor xenograft mice

PD-L1↓, TumCG↓, Ki-67↓, cl‑Casp3↑,

1010-

BBR,

Berberine binds RXRα to suppress β-catenin signaling in colon cancer cells

-

vitro+vivo,

CRC,

NA

mice

β-catenin/ZEB1↓, TumCG↓,

956-

BBR,

Berberine inhibits HIF-1alpha expression via enhanced proteolysis

-

in-vitro,

Nor,

HUVECs

7.5uM/16hr

mice

-

in-vitro,

GC,

SCM1

Hif1a↓, angioG↓,

7-

BBR,

Berberine, a natural compound, suppresses Hedgehog signaling pathway activity and cancer growth

-

vitro+vivo,

MB,

NA

HH↓, Gli1↓, PTCH1↓, Smo↓,

940-

BBR,

Functional inhibition of lactate dehydrogenase suppresses pancreatic adenocarcinoma progression

-

vitro+vivo,

PC,

PANC1

33uM-62uM

253 patients who were treatment‐naive and pathologically diagnosed with pancreatic adenocarcinoma

-

in-vivo,

PC,

MIA PaCa-2

mouse

LDHA↓, lactateProd↓, AMPKα↓, TumVol↓, Ki-67↓,

932-

BBR,

The short-term effects of berberine in the liver: Narrow margins between benefits and toxicity

-

in-vivo,

Nor,

NA

Rat liver

*glucoNG↓, *Glycolysis↑, *NH3↑, *NADPH/NADP+↑, *ATP↓, *toxicity↑,

1102-

BBR,

Berberine suppressed epithelial mesenchymal transition through cross-talk regulation of PI3K/AKT and RARα/RARβ in melanoma cells

-

in-vitro,

Melanoma,

B16-BL6

TumCMig↓, TumCI↓, EMT↓, p‑PI3K↓, p‑Akt↓, RARα↓, RARβ↑, RARγ↑, E-cadherin↑, N-cadherin↓,

1092-

BBR,

Berberine as a Potential Anticancer Agent: A Comprehensive Review

-

Review,

NA,

NA

0.2-0.5uM

U87 and U251 human glioblastoma cell lines in BALB/c nude mice (IC50 of 42 and 32 μmol/L, respectively).

Apoptosis↑, TumCCA↑, TumAuto↑, TumCI↓, IL1↓, IL6↓, TNF-α↓, LDH↓, P2X7↓, proCasp1↓, Casp1↓, ASC↓,

2706-

BBR,

Berberine Inhibits Growth of Liver Cancer Cells by Suppressing Glutamine Uptake

-

in-vitro,

HCC,

Hep3B

50, 75, 100 and 125 μM

-

in-vitro,

HCC,

Bel-7402

-

in-vivo,

NA,

NA

TumCP↓, glut↓, SLC12A5↓, cMyc↓, GLS↓,

2696-

BBR,

Berberine regulates proliferation, collagen synthesis and cytokine secretion of cardiac fibroblasts via AMPK-mTOR-p70S6K signaling pathway

-

in-vivo,

Nor,

NA

1-3 day-old SD rats

*α-SMA↓, *TGF-β1↓, *IL10↑, *p‑AMPK↑, *p‑mTOR↓, *P70S6K↓, *cardioP↑,

2697-

BBR,

Structural exploration of common pharmacophore based berberine derivatives as novel histone deacetylase inhibitor targeting HDACs enzymes

-

Analysis,

Var,

NA

HDAC↓,

2698-

BBR,

A gene expression signature-based approach reveals the mechanisms of action of the Chinese herbal medicine berberine

-

Analysis,

BC,

MDA-MB-231

HDAC↓, Akt↓, mTOR↓, ER Stress↑, TumAuto↑, AMPK↑, mTOR∅, HDAC∅, ac‑α-tubulin↑,

2699-

BBR,

Plant Isoquinoline Alkaloid Berberine Exhibits Chromatin Remodeling by Modulation of Histone Deacetylase To Induce Growth Arrest and Apoptosis in the A549 Cell Line

-

in-vitro,

Lung,

A549

HDAC↓, TumCCA↑, TNF-α↓, COX2↓, MMP2↓, MMP9↓, P21↑, P53↑, Casp↑, ac‑H3↑, ac‑H4↑, ROS↑, MMP↓,

2700-

BBR,

Cell-specific pattern of berberine pleiotropic effects on different human cell lines

-

in-vitro,

GBM,

U343

-

in-vitro,

GBM,

MIA PaCa-2

-

in-vitro,

Nor,

HDFa

selectivity↑, TumCCA↑, Casp3↑, TumCI↓, TumCMig↓, N-cadherin?, DNMT1↑,

2701-

BBR,

Berberine Inhibits KLF4 Promoter Methylation and Ferroptosis to Ameliorate Diabetic Nephropathy in Mice

-

in-vivo,

Diabetic,

NA

MICE

*Inflam↓, *antiOx↑, *Ferroptosis↓, *RenoP↑, *DNMT1↓, *DNMTs↓, *KLF4↑,

2702-

BBR,

The enhancement of combination of berberine and metformin in inhibition of DNMT1 gene expression through interplay of SP1 and PDPK1

-

in-vitro,

Lung,

A549

-

in-vitro,

Lung,

H1975

TumCG↓, MAPK↓, FOXO3↑, TumCCA↑, TumCMig↓, TumCI↓, Sp1/3/4↓, PDK1↓, DNMT1↓, eff↑,

2703-

BBR,

CUR,

SFN,

UA,

GamB

Naturally occurring anti-cancer agents targeting EZH2

-

Review,

Var,

NA

EZH2↓,

2704-

BBR,

Inhibitory Effect of Berberine on Zeste Homolog 2 (Ezh2) Enhancement in Human Esophageal Cell Lines

-

in-vitro,

ESCC,

KYSE450

EZH2↓, AXL↓,

2705-

BBR,

Mechanism underlying berberine's effects on HSP70/TNFα under heat stress: Correlation with the TATA boxes

-

in-vivo,

Nor,

NA

male ICR mice (8-10 weeks old, weighing 21-23 g)

-

in-vitro,

Nor,

PC12

HSP70/HSPA5↓, TNF-α↓,

2672-

BBR,

The anti-aging mechanism of Berberine associated with metabolic control

-

Review,

Var,

NA

*BioAv↝, *BioAv↝, *BioAv↝, *Half-Life↓,

2707-

BBR,

Berberine exerts its antineoplastic effects by reversing the Warburg effect via downregulation of the Akt/mTOR/GLUT1 signaling pathway

-

in-vitro,

Liver,

HepG2

concentrations >25 µM after 48 h

-

in-vitro,

BC,

MCF-7

GLUT1↓, Akt↓, mTOR↓, ATP↓, GlucoseCon↓, TumCP↓, Warburg↓, selectivity↑, TumCCA↑, Glycolysis↓,

2708-

BBR,

Berberine decelerates glucose metabolism via suppression of mTOR‑dependent HIF‑1α protein synthesis in colon cancer cells

-

in-vitro,

CRC,

HCT116

0, 6.25, 12.5, 25, 50 and 100 µM of berberine for 24 or 15 h

TumCG↓, GlucoseCon↓, GLUT1↓, LDHA↓, HK2↓, Hif1a↓, mTOR↓, Glycolysis↓,

2709-

BBR,

Berberine inhibits the glycolysis and proliferation of hepatocellular carcinoma cells by down-regulating HIF-1α

-

in-vitro,

HCC,

HepG2

0, 50, 100, or 200 μmol/

TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, Glycolysis↓, Hif1a↓, GLUT1↓, HK2↓, PKM2↓, LDHA↓,

2710-

BBR,

Berberine inhibits the Warburg effect through TET3/miR-145/HK2 pathways in ovarian cancer cells

-

in-vitro,

Ovarian,

SKOV3

Warburg↓, miR-145↑, HK2↓, TET3↑, Glycolysis↓, PKM2↓, GLUT1↓, LDH↓, PFK2↓, PDK1↓,

2711-

BBR,

Berberine inhibits the progression of breast cancer by regulating METTL3-mediated m6A modification of FGF7 mRNA

-

in-vitro,

BC,

MCF-7

0, 20, 40, and 60 μM) of BBR for 48 h

-

in-vitro,

BC,

MDA-MB-231

-

in-vivo,

NA,

NA

TumCP↓, TumCI↓, TumCMig↓, Apoptosis↑, FGF↓, IGFBP3↑,

2712-

BBR,

Suppression of colon cancer growth by berberine mediated by the intestinal microbiota and the suppression of DNA methyltransferases (DNMTs)

-

in-vitro,

Colon,

HT29

-

in-vivo,

NA,

NA

TumCG↓, GutMicro↑, other↝, IL10↓, cMyc↓, DNMT1↓, DNMTs↓,

2713-

BBR,

Berberine improved the microbiota in lung tissue of colon cancer and reversed the bronchial epithelial cell changes caused by cancer cells

-

in-vitro,

Nor,

BEAS-2B

Thirty-six BALB/c nude mice

*GutMicro↑, *IL6↑, *IL10↑, *IL17↑, *IFN-γ↑, PDGF↓, *RAD51↓,

2714-

BBR,

Integrins and Cell Metabolism: An Intimate Relationship Impacting Cancer

AMPK↑, ITGB1↓,

2715-

BBR,

Rad,

Berberine Can Amplify Cytotoxic Effect of Radiotherapy by Targeting Cancer Stem Cells

-

in-vitro,

BC,

MCF-7

tumCV↓, OCT4↓, SOX2↓, RadioS↑, CSCs↓,

2671-

BBR,

Berberine and Its More Biologically Available Derivative, Dihydroberberine, Inhibit Mitochondrial Respiratory Complex I: A Mechanism for the Action of Berberine to Activate AMP-Activated Protein Kinase and Improve Insulin Action

-

in-vivo,

Diabetic,

NA

*BioAv↓, *Half-Life↝, *OCR↓, *AMPK↑,

2694-

BBR,

Berberine down-regulates IL-8 expression through inhibition of the EGFR/MEK/ERK pathway in triple-negative breast cancer cells

-

in-vitro,

BC,

NA

IL8↓, TumCI↓, EGFR↓, MEK↓, ERK↓, TGF-β1↓, VEGF↓,

2673-

BBR,

Therapeutic potential and recent delivery systems of berberine: A wonder molecule

-

Review,

Var,

NA

*BioAv↓, *Half-Life↓, *neuroP↑, BBB↑, toxicity↓,

2674-

BBR,

Berberine: A novel therapeutic strategy for cancer

-

Review,

Var,

NA

-

Review,

IBD,

NA

Inflam↓, AntiCan↑, Apoptosis↑, TumAuto↑, TumCCA↑, TumMeta↓, TumCI↓, eff↑, eff↑, CD4+↓, TNF-α↓, IL1↓, BioAv↓, BioAv↓, other↓, AMPK↑, MAPK↓, NF-kB↓, IL6↓, MCP1↓, PGE2↓, COX2↓, *ROS↓, *antiOx↑, *GPx↑, *Catalase↑, AntiTum↑, TumCP↓, angioG↓, Fas↑, FasL↑, ROS↑, ATM↑, P53↑, RB1↑, Casp9↑, Casp8↑, Casp3↓, BAX↑, Bcl-2↓, Bcl-xL↓, IAP1↓, XIAP↓, survivin↓, MMP2↓, MMP9↓, CycB↓, CDC25↓, CDC25↓, Cyt‑c↑, MMP↓, RenoP↑, mTOR↓, MDM2↓, LC3II↑, ERK↓, COX2↓, MMP3↓, TGF-β↓, EMT↑, ROCK1↓, FAK↓, RAS↓, Rho↓, NF-kB↓, uPA↓, MMP1↓, MMP13↓, ChemoSen↑,

2675-

BBR,

The therapeutic effects of berberine against different diseases: A review on the involvement of the endoplasmic reticulum stress

-

Review,

Var,

NA

*Inflam↓, *antiOx↑, *ER Stress↓, *cardioP↑, *RenoP↑, *hepatoP↑,

2676-

BBR,

Berberine protects rat heart from ischemia/reperfusion injury via activating JAK2/STAT3 signaling and attenuating endoplasmic reticulum stress

-

in-vivo,

Nor,

NA

Male rats were treated with BBR (200 mg·kg−1·d−1, ig) for 2 weeks, and then subjected to MI/R surgery.

-

in-vivo,

CardioV,

NA

*cardioP↑, *ROS↓, *ER Stress↓, *p‑PERK↓, *p‑eIF2α↓, *ATF4↓, CHOP↓, *JAK2↑, *STAT3↑, *UPR↓,

2677-

BBR,

Liposome-Encapsulated Berberine Alleviates Liver Injury in Type 2 Diabetes via Promoting AMPK/mTOR-Mediated Autophagy and Reducing ER Stress: Morphometric and Immunohistochemical Scoring

-

in-vivo,

Diabetic,

NA

Rats

*hepatoP↑, *LC3II↑, *Beclin-1↑, *AMPK↑, *mTOR↑, *ER Stress↓, *CHOP↓, *JNK↓, *ROS↓, *Inflam↓, *BG↓, *SOD↑, *GPx↑, *Catalase↑, *IL10↑, *IL6↓, *TNF-α↓, *ALAT↓, *AST↓, *ALP↓,

2678-

BBR,

Berberine as a Potential Agent for the Treatment of Colorectal Cancer

-

Review,

CRC,

NA

*Inflam↓, *antiOx↑, *cardioP↑, *neuroP↑, TumCCA↑, cycD1↓, cycE↓, CDC2↓, AMPK↝, mTOR↝, Casp8↑, Casp9↑, Cyt‑c↑, TumCMig↓, TumCI↓, EMT↓, MMPs↓, E-cadherin↓, Telomerase↓, *toxicity↓, GRP78/BiP↓, EGFR↓, CDK4↓, COX2↓, PGE2↓, p‑JAK2↓, p‑STAT3↓, MMP2↓, MMP9↓, GutMicro↑, eff↝, *BioAv↓, BioAv↑,

2679-

BBR,

Berberine Improves Behavioral and Cognitive Deficits in a Mouse Model of Alzheimer’s Disease via Regulation of β-Amyloid Production and Endoplasmic Reticulum Stress

-

in-vivo,

AD,

NA

*cognitive↑, PERK↓, *eIF2α↓, *neuroP↑, *ER Stress↓, *ROS↓,

2680-

BBR,

PDT,

Photodynamic therapy-triggered nuclear translocation of berberine from mitochondria leads to liver cancer cell death

-

in-vitro,

Liver,

HUH7

TumCD↑, ROS↑, TumCCA↑, ER Stress↑,

2681-

BBR,

PDT,

Berberine-photodynamic induced apoptosis by activating endoplasmic reticulum stress-autophagy pathway involving CHOP in human malignant melanoma cells

-

in-vitro,

Melanoma,

NA

Apoptosis↑, cl‑Casp3↑, LC3s↑, ER Stress↑, ROS↑, CHOP↑,

2682-

BBR,

Berberine Inhibited Growth and Migration of Human Colon Cancer Cell Lines by Increasing Phosphatase and Tensin and Inhibiting Aquaporins 1, 3 and 5 Expressions

-

in-vitro,

CRC,

HT29

-

in-vitro,

CRC,

SW480

-

in-vitro,

CRC,

HCT116

TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, necrosis↑, AQPs↓, PTEN↑, PI3K↓, Akt↓, p‑Akt↓, mTOR↓, p‑mTOR↓,

2684-

BBR,

Berberine is a Novel Mitochondrial Calcium Uniporter Inhibitor that Disrupts MCU‐EMRE Assembly

-

in-vivo,

Nor,

NA

mice

*MCU↓, *mt-Ca+2↓, *cardioP↑,

2685-

BBR,

Berberine induces neuronal differentiation through inhibition of cancer stemness and epithelial-mesenchymal transition in neuroblastoma cells

-

in-vitro,

neuroblastoma,

NA

CSCs↓, CD133↓, β-catenin/ZEB1↓, n-MYC↓, SOX2↓, NOTCH2↓, Nestin↓, TumCCA↑, TumCP↓, CDK1↓, Cyc↓, Apoptosis↑, Bax:Bcl2↑, NCAM↓, MMP2↓, MMP9↓, *Smad1↑, *HSP70/HSPA5↑, *LAMs↑,

2686-

BBR,

Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs

-

Review,

Nor,

NA

Inflam↓, IL6↓, MCP1↓, COX2↓, PGE2↓, MMP2↓, MMP9↓, DNAdam↑, eff↝, Telomerase↓, Bcl-2↓, AMPK↑, ROS↑, MMP↓, ATP↓, p‑mTORC1↓, p‑S6K↓, ERK↓, PI3K↓, PTEN↑, Akt↓, Raf↓, MEK↓, Dose↓, Dose↑, selectivity↑, TumCCA↑, eff↑, EGFR↓, Glycolysis↓, Dose?, p27↑, CDK2↓, CDK4↓, cycD1↓, cycE↓, Bax:Bcl2↑, Casp3↑, Casp9↑, VEGFR2↓, ChemoSen↑, eff↑, eff↑, PGE2↓, JAK2↓, STAT3↓, CXCR4↓, CCR7↓, uPA↓, CSCs↓, EMT↓, Diff↓, CD133↓, Nestin↓, n-MYC↓, NOTCH↓, SOX2↓, Hif1a↓, VEGF↓, RadioS↑,

2695-

BBR,

The effects of Berberis vulgaris consumption on plasma levels of IGF-1, IGFBPs, PPAR-γ and the expression of angiogenic genes in women with benign breast disease: a randomized controlled clinical trial

-

Trial,

BC,

NA

85 eligible patients diagnosed with benign breast disease.

IGF-1↓, PPARγ↓, VEGF↓, Hif1a↓, angioG↓,

2689-

BBR,

Berberine protects against glutamate-induced oxidative stress and apoptosis in PC12 and N2a cells

-

in-vitro,

Nor,

PC12

-

in-vitro,

AD,

NA

-

in-vitro,

Stroke,

NA

*ROS↓, *lipid-P↓, *DNAdam↓, *GSH↑, *SOD↑, *eff↑, *cl‑Casp3↓, *BAX↓, *neuroP↑, *Dose↝, *Ca+2↓,

2690-

BBR,

Berberine Differentially Modulates the Activities of ERK, p38 MAPK, and JNK to Suppress Th17 and Th1 T Cell Differentiation in Type 1 Diabetic Mice

-

in-vivo,

Diabetic,

NA

berberine (Sigma, 200 mg/kg body weight), by gavage, daily for 2 weeks

11-week-old female NOD mice

*Inflam↓, *Th17↓, *Th1 response↓, *ERK↑, *p38↓, *JNK↓, *STAT1↓, *STAT4↓, *MAPK↓,

2691-

BBR,

Berberine induces FasL-related apoptosis through p38 activation in KB human oral cancer cells

-

in-vitro,

Oral,

KB

tumCV↓, DNAdam↑, Casp3↑, Casp7↑, FasL↑, Casp8↑, Casp9↑, PARP↑, BAX↑, BAD↑, APAF1↑, MMP2↓, MMP9↓, p‑p38↑, ERK↑, MAPK↑,

2692-

BBR,

Berberine affects osteosarcoma via downregulating the caspase-1/IL-1β signaling axis

-

in-vitro,

OS,

MG63

-

in-vitro,

OS,

SaOS2

-

in-vivo,

NA,

NA

mice

Casp1↓, IL1β↓, TumCG↓, Dose↝, Apoptosis↑, Inflam↓,

2693-

BBR,

Antitumor Effects of Berberine on Gliomas via Inactivation of Caspase-1-Mediated IL-1β and IL-18 Release

-

in-vitro,

GBM,

U251

-

in-vitro,

GBM,

U87MG

Casp1↓, ERK↓, IL1β↓, IL18↓, EMT↑,

2683-

BBR,

Berberine reduces endoplasmic reticulum stress and improves insulin signal transduction in Hep G2 cells

-

in-vitro,

Liver,

HepG2

JNK↓, p‑PERK↓, p‑eIF2α↓, *ER Stress↓,

2335-

BBR,

Chemoproteomics reveals berberine directly binds to PKM2 to inhibit the progression of colorectal cancer

-

in-vitro,

CRC,

HT29

EC50 of 4.62 μM

-

in-vitro,

CRC,

HCT116

and 9.39 μM

-

in-vivo,

NA,

NA

mice

PKM2↓, Glycolysis↓, p‑STAT3↓, Bcl-2↓, cycD1↓, TumCG↓, Ki-67↓, lactateProd↓, glucose↓,

2337-

BBR,

Berberine Inhibited the Proliferation of Cancer Cells by Suppressing the Activity of Tumor Pyruvate Kinase M2

-

in-vitro,

CRC,

HCT116

63.6 ± 3.0uM

-

in-vitro,

Cerv,

HeLa

157.4 ± 3.8uM

TumCP↓, PKM2↓,

2336-

BBR,

Berberine Targets PKM2 to Activate the t-PA-Induced Fibrinolytic System and Improves Thrombosis

-

in-vivo,

Nor,

NA

SD rats - FeCl3-Injury-Induced Carotid Thrombosis

*PKM2↓,

2670-

BBR,

Berberine: A Review of its Pharmacokinetics Properties and Therapeutic Potentials in Diverse Vascular Diseases

-

Review,

Var,

NA

*Inflam↓, *antiOx↑, *Ca+2↓, *BioAv↓, *BioAv↑, *BioAv↑, *angioG↑, *MAPK↓, *AMPK↓, *NF-kB↓, VEGF↓, PI3K↓, Akt↓, MMP2↓, Bcl-2↓, ERK↓,

1473-

BCA,

SFN,

An Insight on Synergistic Anti-cancer Efficacy of Biochanin A and Sulforaphane Combination Against Breast Cancer

-

in-vitro,

BC,

MCF-7

eff↑, ROS↑, other↑, ERK↓, Apoptosis↑,

1031-

BCA,

Biochanin A Suppresses Tumor Progression and PD-L1 Expression via Inhibiting ZEB1 Expression in Colorectal Cancer

-

vitro+vivo,

CRC,

HCT116

20-100uM

-

vitro+vivo,

CRC,

SW-620

PD-L1↓, TumCG↓, Zeb1↓, E-cadherin↑, N-cadherin↓, EMT↓,

943-

BetA,

Betulinic acid suppresses breast cancer aerobic glycolysis via caveolin-1/NF-κB/c-Myc pathway

-

in-vitro,

BC,

MCF-7

-

in-vitro,

BC,

MDA-MB-231

-

in-vivo,

NA,

NA

mouse model

Glycolysis↓, lactateProd↓, GlucoseCon↓, ECAR↓, cMyc↓, LDHA↓, p‑PDK1↓, PDK1↓, Cav1↑, *Glycolysis↑, selectivity↑, OCR↓, OXPHOS↓,

2754-

BetA,

Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors

-

in-vitro,

Pca,

LNCaP

VEGF↓, survivin↓, Sp1/3/4↓, Casp↑, PARP↑, survivin↓, angioG↓,

2753-

BetA,

Betulinic acid induces apoptosis by regulating PI3K/Akt signaling and mitochondrial pathways in human cervical cancer cells

-

in-vitro,

Cerv,

HeLa

30 µmol/l BA

PI3K↓, p‑Akt↓, ROS↑, TumCCA↑, p27↑, P21↑, mt-Apoptosis↑, BAD↑, Casp9↑, MMP↓, eff↓,

2752-

BetA,

Betulinic acid: a natural product with anticancer activity

-

Review,

Var,

NA

selectivity↑, ChemoSen↑, RadioS↑, MMP↓, cl‑Casp3↑, Cyt‑c↑, ROS↑, NF-kB↑, TOP1↓,

2751-

BetA,

Betulinic acid inhibits proliferation and triggers apoptosis in human breast cancer cells by modulating ER (α/β) and p53

-

in-vitro,

BC,

MDA-MB-231

-

in-vitro,

BC,

MCF-7

tumCV↓, ER-α36↓,

2750-

BetA,

GEM,

Betulinic acid, a major therapeutic triterpene of Celastrus orbiculatus Thunb., acts as a chemosensitizer of gemcitabine by promoting Chk1 degradation

-

in-vitro,

PC,

Bxpc-3

-

in-vitro,

Lung,

H1299

CHK1↓, ChemoSen↑, tumCV↓, Apoptosis↑, DNAdam↑,

2749-

BetA,

Anti-Inflammatory Activities of Betulinic Acid: A Review

-

Review,

Nor,

NA

Inflam↓, *NO↓, *IL10↑, *ICAM-1↓, *VCAM-1↓, *E-sel↓, *NF-kB↓, *IKKα↓, *COX2↓, *PGE2↓, *IL1β↓, *IL6↓, *IL8↓, *IL12↓, *TNF-α↑, *HO-1↑, *IL10↑, *IL2↓, *IL17↓, *IFN-γ↓, *SOD↑, *GPx↑, *GSR↑, *MDA↓, *MAPK↓,

2748-

BetA,

Betulinic Acid: Recent Advances in Chemical Modifications, Effective Delivery, and Molecular Mechanisms of a Promising Anticancer Therapy

-

Review,

Var,

NA

Bcl-2↓, MMP↓, Cyt‑c↑, Casp↑, Diablo↑, AIF↑, angioG↓, BioAv↓, NF-kB↓,

2747-

BetA,

Betulinic acid, a natural compound with potent anticancer effects

-

Review,

Var,

NA

selectivity↑, Cyt‑c↑, *toxicity↓, TOP1↓, NF-kB↓, ROS↑, RadioS↑, ChemoSen↑,

2746-

BetA,

Betulinic acid induces apoptosis and inhibits metastasis of human colorectal cancer cells in vitro and in vivo

-

in-vitro,

CRC,

HCT116

-

in-vivo,

CRC,

NA

20 mg/kg/day of BA

TumCG↓, BAX↑, Bcl-2↓, ROS↑, MMP↓, TIMP2↑, TumVol↓,

2745-

BetA,

Betulinic acid inhibits colon cancer cell and tumor growth and induces proteasome-dependent and -independent downregulation of specificity proteins (Sp) transcription factors

-

in-vitro,

CRC,

RKO

-

in-vitro,

CRC,

SW480

-

in-vivo,

NA,

NA

nude mice

Apoptosis↑, TumCG↓, Sp1/3/4↓, survivin↓, VEGF↓, p65↓, EGFR↓, cycD1↓, ROS↑, MMP↓,

2744-

BetA,

Betulin and betulinic acid: triterpenoids derivatives with a powerful biological potential

-

Review,

Var,

NA

Apoptosis↓, TumCCA↑, Casp9↑, Casp3↑, Casp7↑, cl‑PARP↑, MMP↓, ROS↑, TOP1↓, NF-kB↓,

2743-

BetA,

Betulinic acid and the pharmacological effects of tumor suppression

-

Review,

Var,

NA

ROS↓, MMP↓, Cyt‑c↑, Apoptosis↑, TumCCA↑, Sp1/3/4↓, STAT3↓, NF-kB↓, EMT↓, TOP1↓, MAPK↑, p38↑, JNK↑, Casp↑, Bcl-2↓, BAX↑, VEGF↓, LAMs↓,

2742-

BetA,

Betulinic acid impairs metastasis and reduces immunosuppressive cells in breast cancer models

-

in-vitro,

BC,

MDA-MB-231

-

in-vivo,

BC,

4T1

intraperitoneal administration of 10 mg/kg/day BA

-

in-vitro,

BC,

MCF-7

tumCV↓, TumCMig↓, TumCI↓, STAT3↑, FAK↓, MMPs↓, MMP2↓, MMP9↓, TIMP2↑,

2755-

BetA,

Cytotoxic Potential of Betulinic Acid Fatty Esters and Their Liposomal Formulations: Targeting Breast, Colon, and Lung Cancer Cell Lines

-

in-vitro,

Colon,

HT29

-

in-vitro,

BC,

MCF-7

-

in-vitro,

Lung,

H460

eff↑, Casp3↑, Casp7↑, NF-kB↓,

2756-

BetA,

Betulinic acid inhibits growth of hepatoma cells through activating the NCOA4-mediated ferritinophagy pathway

-

in-vitro,

HCC,

HUH7

10 μM was selected as a low dose (BETL group), 20 μM as a medium dose (BETM group) and 40 μM as a high dose (BETH group)

-

in-vitro,

HCC,

H1299

TumCP↓, ROS↓, antiOx↓, TumCG↓, TumCMig↓, NRF2↓, GPx4↓, HO-1↓, NCOA4↑, FTH1↓, Ferritin↑, Ferroptosis↑, GSH↓, MDA↓,

2757-

BetA,

Betulinic Acid Inhibits Glioma Progression by Inducing Ferroptosis Through the PI3K/Akt and NRF2/HO-1 Pathways

-

in-vitro,

GBM,

U251

tumCV↓, TumCMig↓, TumCI↓, Apoptosis↑, p‑PI3K↓, p‑Akt↓, Ferroptosis↑, HO-1↑, NRF2↑,

2758-

BetA,

Betulinic Acid Attenuates Oxidative Stress in the Thymus Induced by Acute Exposure to T-2 Toxin via Regulation of the MAPK/Nrf2 Signaling Pathway

-

in-vivo,

Nor,

NA

mice

*ROS↓, *MDA↓, *SOD↑, *GSH↑, *p‑p38↓, *p‑JNK↓, *p‑ERK↓, *NRF2↑, *HO-1↑, *MAPK↓, *heparanase↑, *antiOx↑,

2759-

BetA,

Chemopreventive and Chemotherapeutic Potential of Betulin and Betulinic Acid: Mechanistic Insights From In Vitro, In Vivo and Clinical Studies

-

Review,

Var,

NA

chemoP↑, ChemoSen↑, *Inflam↓, *NRF2↑, *NF-kB↓, *COX2↓, ROS↑, MMP↓, Sp1/3/4↓, VEGF↓,

2760-

BetA,

A Review on Preparation of Betulinic Acid and Its Biological Activities

-

Review,

Var,

NA

-

Review,

Stroke,

NA

AntiTum↑, Cyt‑c↑, Smad1↑, Sepsis↓, NF-kB↓, ICAM-1↓, MCP1↓, MMP9↓, COX2↓, PGE2↓, ERK↓, p‑Akt↓, *ROS↓, *LDH↓, *hepatoP↑, *SOD↑, *Catalase↑, *GSH↑, *AST↓, *ALAT↓, *RenoP↑, *ROS↓, *α-SMA↓,

2761-

BetA,

Betulinic acid increases lifespan and stress resistance via insulin/IGF-1 signaling pathway in Caenorhabditis elegans

-

in-vivo,

Nor,

NA

Insulin↓, IGF-1↓, *SOD↑, *Catalase↑, *GSH↑, *MDA↓, *antiOx?,

2762-

BetA,

Targeting Effect of Betulinic Acid Liposome Modified by Hyaluronic Acid on Hepatoma Cells In Vitro

-

in-vitro,

Liver,

HepG2

ROCK1↓, RAS↓, *BioAv↓, BioAv↑,

2763-

BetA,

Betulinic Acid Inhibits the Stemness of Gastric Cancer Cells by Regulating the GRP78-TGF-β1 Signaling Pathway and Macrophage Polarization

-

in-vitro,

GC,

NA

GRP78/BiP↓, TGF-β↓, ChemoSen↑, CSCs↓, SMAD2↓, SMAD3↓, OCT4↓,

2764-

BetA,

In silico profiling of histone deacetylase inhibitory activity of compounds isolated from Cajanus cajan

-

Analysis,

Var,

NA

HDAC↓,

2765-

BetA,

Unveiling Betulinic Acid as a Potent CDK4 Inhibitor for Cancer Therapeutics

-

in-vitro,

Lung,

A549

CDK4↓,

2766-

BetA,

Role of natural secondary metabolites as HIF-1 inhibitors in cancer therapy

-

Review,

Var,

NA

Hif1a↓, VEGF↓, GLUT1↓,

2771-

BetA,

Cardioprotective Effect of Betulinic Acid on Myocardial Ischemia Reperfusion Injury in Rats

-

in-vivo,

Nor,

NA

Rats

-

in-vivo,

Stroke,

NA

*cardioP↑, *LDH↓, eff↑,

2740-

BetA,

Effects and mechanisms of fatty acid metabolism-mediated glycolysis regulated by betulinic acid-loaded nanoliposomes in colorectal cancer

-

in-vitro,

CRC,

HCT116

TumCP↓, Glycolysis↓, HK2↓, PFK1↓, PKM2↓, ACSL1↓, CPT1A↓, FASN↓, FAO↓, GlucoseCon↓, lactateProd↓,

2716-

BetA,

Cellular and molecular mechanisms underlying the potential of betulinic acid in cancer prevention and treatment

-

Review,

Var,

NA

AntiCan↑, TumCD↑, TumCCA↑, ROS↑, NF-kB↓, Bcl-2↓, Half-Life↝, GLUT1↓, VEGF↓, PDK1↓,

2741-

BetA,

Betulinic acid triggers apoptosis and inhibits migration and invasion of gastric cancer cells by impairing EMT progress

-

in-vitro,

GC,

SNU16

-

in-vitro,

GC,

NCI-N87

-

in-vivo,

NA,

NA

(40 mg/kg)

mice

TumCG↓, TumCMig↓, TumCI↓, N-cadherin↓, E-cadherin↑, EMT↓, Ki-67↓, MMP2↓,

2717-

BetA,

Betulinic Acid Induces ROS-Dependent Apoptosis and S-Phase Arrest by Inhibiting the NF-κB Pathway in Human Multiple Myeloma

-

in-vitro,

Melanoma,

U266

10-40uM

-

in-vivo,

Melanoma,

NA

Nude Mouse Xenograft Model

-

in-vitro,

Melanoma,

RPMI-8226

Apoptosis↑, TumCCA↑, MMP↓, ROS↑, eff↓, NF-kB↓, Cyt‑c↑, Casp3↑, Casp8↑, Casp9↑, cl‑PARP1↑, MDA↑, SOD↓, SOD2↓, GCLM↓, GSTA1↓, FTH1↓, GSTs↓, TumVol↓,

2718-

BetA,

The anti-cancer effect of betulinic acid in u937 human leukemia cells is mediated through ROS-dependent cell cycle arrest and apoptosis

-

in-vitro,

AML,

U937

TumCCA↑, Apoptosis↑, i-ROS↑, cycA1↓, CycB↓, P21↑, Cyt‑c↑, MMP↓, Bax:Bcl2↑, Casp9↑, Casp3↑, PARP↓, eff↓, *antiOx↑, *Inflam↓, *hepatoP↑, selectivity↑, NF-kB↓, *ROS↓,

2719-

BetA,

Betulinic Acid Restricts Human Bladder Cancer Cell Proliferation In Vitro by Inducing Caspase-Dependent Cell Death and Cell Cycle Arrest, and Decreasing Metastatic Potential

-

in-vitro,

CRC,

T24

30 μg/mL BA for 48 h

-

in-vitro,

Bladder,

UMUC3

33.2 μg/mL

-

in-vitro,

Bladder,

5637

28.5 μg/mL

TumCD↑, Apoptosis↑, TumCCA↑, CycB↓, cycA1↓, CDK2↓, CDC25↓, mtDam↑, BAX↑, cl‑PARP↑, Casp3↑, Casp8↑, Casp9↑, Snail↓, Slug↓, MMP9↓, selectivity↑, MMP↓, ROS∅, TumCMig↓, TumCI↓,

2720-

BetA,

Betulinic acid induces apoptosis of HeLa cells via ROS-dependent ER stress and autophagy in vitro and in vivo

-

in-vitro,

Cerv,

HeLa

Keap1↝, ROS↑, Ca+2↑, Beclin-1↓, GRP78/BiP↑, LC3II↑, p62↑, ERS↑, TumAuto↑,

2721-

BetA,

Proteomic Investigation into Betulinic Acid-Induced Apoptosis of Human Cervical Cancer HeLa Cells

-

in-vitro,

Cerv,

HeLa

15 µmol/L, 30 µmol/L, 50 µmol/L) of BA for 24 h, 48 h, and 72 h.

30.42±2.39 µM

ROS↑, Dose↝, Bcl-2↓, BAX↑, ER Stress↑,

2722-

BetA,

Betulinic Acid for Cancer Treatment and Prevention

-

Review,

Var,

NA

MMP↓, Cyt‑c↑, cl‑Casp3↑, cl‑Casp8↑, ROS↑, NF-kB↑, TOP1↓,

2723-

BetA,

Betulinic acid and oleanolic acid modulate CD81 expression and induce apoptosis in triple-negative breast cancer cells through ROS generation

-

in-vitro,

BC,

MDA-MB-231

Apoptosis↑, tumCV↓, ROS↑,

2724-

BetA,

Down-regulation of NOX4 by betulinic acid protects against cerebral ischemia-reperfusion in mice

-

in-vivo,

Nor,

NA

mice

-

in-vivo,

Stroke,

NA

AntiTum↑, *Inflam↓, *ROS↓, *NOX4↓, *Apoptosis↓, neuroP↑,

2725-

BetA,

Betulinic acid protects against renal damage by attenuation of oxidative stress and inflammation via Nrf2 signaling pathway in T-2 toxin-induced mice

-

in-vivo,

Nor,

NA

*RenoP↑, *SOD?, *Catalase↑, *GSH↑, *ROS↓, *MDA↓, *IL1β↓, *TNF-α↓, *IL10↓, *IL6↑, *NRF2↑,

2726-

BetA,

Betulinic acid induces DNA damage and apoptosis in SiHa cells

-

in-vitro,

Cerv,

SiHa

39.83 μg/ml

tumCV↓, DNAdam↑, MMP↓, ROS↑, TumCCA↑, TOP1↓,

2727-

BetA,

Betulinic acid in the treatment of breast cancer: Application and mechanism progress

-

Review,

BC,

NA

mt-ROS↑, Sp1/3/4↓, TumMeta↓, GlucoseCon↓, NF-kB↓, ChemoSen↑, chemoP↑, m-Apoptosis↑, TOP1↓,

2729-

BetA,

Betulinic acid in the treatment of tumour diseases: Application and research progress

-

Review,

Var,

NA

ChemoSen↑, mt-ROS↑, STAT3↓, NF-kB↓, selectivity↑, *toxicity↓, eff↑, GRP78/BiP↑, MMP2↓, P90RSK↓, TumCI↓, EMT↓, MALAT1↓, Glycolysis↓, AMPK↑, Sp1/3/4↓, Hif1a↓, angioG↓, NF-kB↑, NF-kB↓, MMP↓, Cyt‑c↑, Casp9↑, Casp3↑, RadioS↑, PERK↑, CHOP↑, *toxicity↓,

2739-

BetA,

Glycolytic Switch in Response to Betulinic Acid in Non-Cancer Cells

-

in-vitro,

Nor,

HUVECs

10 µM

-

in-vitro,

Nor,

MEF

*Glycolysis↑, *GlucoseCon↑, *Apoptosis↓, *UCP1↓, *AMPK↑, GLUT1↑, mt-ROS↑,

2738-

BetA,

Betulinic Acid Suppresses Breast Cancer Metastasis by Targeting GRP78-Mediated Glycolysis and ER Stress Apoptotic Pathway

-

in-vitro,

BC,

MDA-MB-231

-

in-vitro,

BC,

BT549

-

in-vivo,

NA,

NA

mice

TumCI↓, TumCMig↓, Glycolysis↓, lactateProd↓, GRP78/BiP↑, ER Stress↑, PERK↑, p‑eIF2α↑, β-catenin/ZEB1↓, cMyc↓, ROS↑, angioG↓, Sp1/3/4↓, DNAdam↑, TOP1↓, TumMeta↓, MMP2↓, MMP9↓, N-cadherin↓, Vim↓, E-cadherin↑, EMT↓, LDHA↓, p‑PDK1↓, PDK1↓, ECAR↓, OCR↓, Hif1a↓, STAT3↓,

2737-

BetA,

Multiple molecular targets in breast cancer therapy by betulinic acid

-

Review,

Var,

NA

TumCP↓, Cyc↓, TOP1↓, TumCCA↑, angioG↓, NF-kB↓, Sp1/3/4↓, VEGF↓, MMPs↓, ChemoSen↑, eff↑, MMP↓, ROS↑, Bcl-2↓, Bcl-xL↓, Mcl-1↓, lipid-P↑, RadioS↑, eff↑,

2736-

BetA,

Chemo,

Multifunctional Roles of Betulinic Acid in Cancer Chemoprevention: Spotlight on JAK/STAT, VEGF, EGF/EGFR, TRAIL/TRAIL-R, AKT/mTOR and Non-Coding RNAs in the Inhibition of Carcinogenesis and Metastasis

-

Review,

Var,

NA

chemoP↑, p‑STAT3↓, JAK1↓, JAK2↓, VEGF↓, EGFR↓, Cyt‑c↑, Diablo↑, AMPK↑, mTOR↓, Sp1/3/4↓, DNAdam↑, Gli1↓, GLI2↓, PTCH1↓, MMP2↓, MMP9↓, miR-21↓, SOD2↓, ROS↑, Apoptosis↑,

2735-

BetA,

Betulinic acid as apoptosis activator: Molecular mechanisms, mathematical modeling and chemical modifications

-

Review,

Var,

NA

mt-Apoptosis↑, Casp↑, p38↑, MAPK↓, JNK↓, VEGF↓, AIF↑, Cyt‑c↑, ROS↑, Ca+2↑, ATP↓, NF-kB↓, ATF3↓, TOP1↓, VEGF↓, survivin↓, Sp1/3/4↓, MMP↓, ChemoSen↑, selectivity↑, BioAv↓, BioAv↑, BioAv↑, BioAv↑, BioAv↑,

2734-

BetA,

Betulinic Acid Modulates the Expression of HSPA and Activates Apoptosis in Two Cell Lines of Human Colorectal Cancer

-

in-vitro,

CRC,

HCT116

6.441 µg/mL (14.15 µM)

-

in-vitro,

CRC,

SW480

1.67 µg/mL (3.670 µM)

tumCV↓, HSP70/HSPA5⇅, ROS↑, cl‑Casp3↑, mt-Apoptosis↑, Dose↝,

2733-

BetA,

Betulinic Acid Inhibits Cell Proliferation in Human Oral Squamous Cell Carcinoma via Modulating ROS-Regulated p53 Signaling

-

in-vitro,

Oral,

KB

12.5–100 μM BA for 24–72 h

-

in-vivo,

NA,

NA

BA against OSCC in implanted mice in vivo

TumCP↓, TumVol↓, mt-Apoptosis↑, Casp3↑, Casp9↑, BAX↑, Bcl-2↑, OCR↓, TumCCA↑, ROS↑, eff↓, P53↑, STAT3↓, cycD1↑,

2732-

BetA,

Chemo,

Betulinic acid chemosensitizes breast cancer by triggering ER stress-mediated apoptosis by directly targeting GRP78

-

in-vitro,

BC,

MCF-7

18.411

-

in-vitro,

BC,

MDA-MB-231

20.465 μM

-

in-vitro,

Nor,

MCF10

ChemoSen↑, selectivity↑, GRP78/BiP↑, ER Stress↑, PERK↑, Ca+2↑, Cyt‑c↑, BAX↑, Bcl-2↓,

2731-

BetA,

Betulinic Acid for Glioblastoma Treatment: Reality, Challenges and Perspectives

-

Review,

GBM,

NA

-

Review,

Park,

NA

-

Review,

AD,

NA

BBB↑, *GSH↑, *Catalase↑, *motorD↑, *neuroP↑, *cognitive↑, *ROS↓, *antiOx↑, *Inflam↓, MMP↓, STAT3↓, NF-kB↓, Sp1/3/4↓, TOP1↓, EMT↓, Hif1a↓, VEGF↓, ChemoSen↑, RadioS↑, BioAv↓,

2730-

BetA,

Betulinic acid induces autophagy-dependent apoptosis via Bmi-1/ROS/AMPK-mTOR-ULK1 axis in human bladder cancer cells

-

in-vitro,

Bladder,

T24

tumCV↓, TumCP↓, TumCMig↓, Casp↑, TumAuto↑, LC3B-II↑, p‑AMPK↑, mTOR↓, BMI1↓, ROS↑, eff↓,

2728-

BetA,

Betulinic acid as new activator of NF-kappaB: molecular mechanisms and implications for cancer therapy

-

in-vitro,

Var,

NA

NF-kB↑, IKKα↑, eff↓,

1285-

BetA,

Betulinic acid decreases expression of bcl-2 and cyclin D1, inhibits proliferation, migration and induces apoptosis in cancer cells

-

in-vitro,

Var,

NA

Apoptosis↑, Bcl-2↓, cycD1↓, BAX↑,

1305-

BetA,

Betulinic acid decreases expression of bcl-2 and cyclin D1, inhibits proliferation, migration and induces apoptosis in cancer cells

-

in-vitro,

UEC,

NA

Apoptosis↑, Bcl-2↓, BAX↑,

1566-

betaCar,

Lyco,

Antioxidant and pro-oxidant effects of lycopene in comparison with beta-carotene on oxidant-induced damage in Hs68 cells

-

in-vitro,

Nor,

HS68

*ROS↑, *ROS⇅, *Dose?,

2502-

Bical,

Complete Response of Metastatic Androgen Receptor–Positive Breast Cancer to Bicalutamide: Case Report and Review of the Literature

-

Case Report,

BC,

NA

Dose↝, Remission↑,

1250-

Bif,

Oral administration of Bifidobacterium breve promotes antitumor efficacy via dendritic cells-derived interleukin 12

-

in-vitro,

SCC,

NA

TumCG↓, Apoptosis↑, CCL20↑, IL12↑,

726-

Bor,

Redox Mechanisms Underlying the Cytostatic Effects of Boric Acid on Cancer Cells—An Issue Still Open

-

Review,

NA,

NA

NAD↝, SAM-e↝, PSA↓, IGF-1↓, Cyc↓, P21↓, p‑MEK↓, p‑ERK↓, ROS↑, SOD↓, Catalase↓, MDA↑, GSH↓, IL1↓, IL6↓, TNF-α↓, BRAF↝, MAPK↝, PTEN↝, PI3K/Akt↝, eIF2α↑, ATF4↑, ATF6↑, NRF2↑, BAX↑, BID↑, Casp3↑, Casp9↑, Bcl-2↓, Bcl-xL↓,

718-

Bor,

Boric Acid Exhibits Anticancer Properties in Human Endometrial Cancer Ishikawa Cells

-

in-vitro,

NA,

NA

40 mM

Ishikawa cells

OSI↑, TNF-α↓, IL1↓, Casp3↑, Apoptosis↑, TOS↑,

719-

Bor,

Boric Acid Affects Cell Proliferation, Apoptosis, and Oxidative Stress in ALL Cells

-

in-vitro,

ALL,

NA

802.7 μg/mL

Jurkat cell

Apoptosis↑, miR-21↓, TOS↓,

720-

Bor,

High Concentrations of Boric Acid Trigger Concentration-Dependent Oxidative Stress, Apoptotic Pathways and Morphological Alterations in DU-145 Human Prostate Cancer Cell Line

-

in-vitro,

Pca,

DU145

ROS↑, TumCG↓, Apoptosis↑,

721-

Bor,

Polymers Based on Phenyl Boric Acid in Tumor-Targeted Therapy

-

Analysis,

NA,

NA

SA↓,

722-

Bor,

Boric acid as a promising agent in the treatment of ovarian cancer: Molecular mechanisms

-

in-vitro,

Ovarian,

MDAH-2774

TumCP↓, TumCI↓, TumCMig↓, Apoptosis↑, ROS↑, miR-21↓, miR-130a↓, Casp8∅, Casp10∅, cycD1∅, CDK6∅, CDK4∅, FADD∅, DR4∅, DR5∅,

723-

Bor,

Boric acid suppresses cell proliferation by TNF signaling pathway mediated apoptosis in SW-480 human colon cancer line

-

in-vitro,

Colon,

SW480

Apoptosis↑, TNF-α↝,

724-

Bor,

Does Boric Acid Inhibit Cell Proliferation on MCF-7 and MDA-MB-231 Cells in Monolayer and Spheroid Cultures by Using Apoptosis Pathways?

-

in-vitro,

BC,

MDA-MB-231

-

in-vitro,

BC,

MCF-7

Apoptosis↑, Casp3↝, Casp8↝, Casp9↝,

725-

Bor,

Boric acid exert anti-cancer effect in poorly differentiated hepatocellular carcinoma cells via inhibition of AKT signaling pathway

-

in-vitro,

HCC,

NA

tumCV↓, Apoptosis↑, TumAuto↑, p‑Akt↓,

717-

Bor,

PacT,

Boric acid as a protector against paclitaxel genotoxicity

-

in-vitro,

NA,

NA

in human blood cultures

ChemoSideEff↓,

727-

Bor,

RSL3,

erastin,

Enhancement of ferroptosis by boric acid and its potential use as chemosensitizer in anticancer chemotherapy

-

in-vitro,

Liver,

HepG2

ROS↑, GSH↓, TBARS↑, Ferroptosis↑, ChemoSen↑,

728-

Bor,

Boric Acid and Borax Protect Human Lymphocytes from Oxidative Stress and Genotoxicity Induced by 3-Monochloropropane-1,2-diol

other↓,

729-

Bor,

Promising potential of boron compounds against Glioblastoma: In Vitro antioxidant, anti-inflammatory and anticancer studies

-

in-vitro,

GBM,

U87MG

-

in-vivo,

Nor,

HaCaT

We verified the selectivity of the compounds using a normal cell line, HaCaT and found an exact opposite condition after treating HaCaT cells with BA

TOS↑, TumCG↓, MDA↑, SOD↑, Catalase↑, TAC↓, GSH↓, BRAF↑, MAPK↓, PTEN↓, Raf↓, *toxicity↓,

730-

Bor,

Cisplatin,

The Effect of Boric Acid and Borax on Oxidative Stress, Inflammation, ER Stress and Apoptosis in Cisplatin Toxication and Nephrotoxicity Developing as a Result of Toxication

-

in-vivo,

NA,

NA

rats

*ROS↓, *Inflam↓, RenoP↑,

731-

Bor,

Protective Effect of Boric Acid Against Ochratoxin A-Induced Toxic Effects in Human Embryonal Kidney Cells (HEK293): A Study on Cytotoxic, Genotoxic, Oxidative, and Apoptotic Effects

-

in-vitro,

Nor,

HEK293

*ROS↓,

732-

Bor,

Boron's neurophysiological effects and tumoricidal activity on glioblastoma cells with implications for clinical treatment

eff↑, IGF-1↝, Glycolysis↝,

733-

Bor,

The analysis of boric acid effect on epithelial-mesenchymal transition of CD133 + CD117 + lung cancer stem cells

-

in-vitro,

Lung,

NA

1-100mM

Targeting lung cancer stem cells (LC-SCs) for metastasis

Snail↑, ITGB1↑, ITGA5↑, COL1A1↓, LAMA5↑, MMP3↓, Vim↓, E-cadherin↑, EMT↓, Zeb1↑,

734-

Bor,

Boric Acid Affects the Expression of DNA Double-Strand Break Repair Factors in A549 Cells and A549 Cancer Stem Cells: An In Vitro Study

-

in-vitro,

Lung,

A549

1 to 100 mM)

effects start at 10mM

ATM↓, Casp3↑, E-cadherin↑,

709-

Bor,

Cellular changes in boric acid-treated DU-145 prostate cancer cells

-

in-vitro,

Pca,

DU145

Cyc↓, MAPK↓, TumCMig↓, LAMP2↓, p‑ERK⇅, TumCM/A↑,

701-

Bor,

Dietary boron intake and prostate cancer risk

-

Analysis,

NA,

NA

Risk↓,

702-

Bor,

GEN,

SeMet,

Rad,

Evaluation of ecological and in vitro effects of boron on prostate cancer risk (United States)

-

Analysis,

NA,

NA

Risk↓, TumCMig↓, Bcl-2↓,

703-

Bor,

Boron intake and prostate cancer risk

-

Analysis,

NA,

NA

Risk∅,

704-

Bor,

Inhibition of the enzymatic activity of prostate-specific antigen by boric acid and 3-nitrophenyl boronic acid

-

in-vitro,

Pca,

NA

PSA↓,

705-

Bor,

Boric acid inhibits human prostate cancer cell proliferation

-

in-vitro,

Pca,

DU145

-

in-vitro,

Pca,

LNCaP

TumCP↓,

706-

Bor,

Boron supplementation inhibits the growth and local expression of IGF-1 in human prostate adenocarcinoma (LNCaP) tumors in nude mice

-

in-vivo,

Pca,

LNCaP

1.7, mgB/kg/day

mice

TumVol↓, IGF-1↓, PSA↓,

707-

Bor,

Cytotoxic and apoptotic effects of boron compounds on leukemia cell line

-

in-vitro,

AML,

HL-60

500-1000uM

Apoptosis↑,

708-

Bor,

Boron containing compounds as protease inhibitors

PSA↓,

735-

Bor,

Boric Acid Alters the Expression of DNA Double Break Repair Genes in MCF-7-Derived Breast Cancer Stem Cells

-

in-vitro,

BC,

NA

BRCA1↑, BRCA2↑, ATM↓,

710-

Bor,

Boric acid inhibits stored Ca2+ release in DU-145 prostate cancer cells

-

in-vitro,

Pca,

DU145

NAD↓, TumCP↓, CD38↑, Ca+2↓,

711-

Bor,

Receptor Activated Ca2+ Release Is Inhibited by Boric Acid in Prostate Cancer Cells

-

in-vitro,

Pca,

DU145

Ca+2↓,

712-

Bor,

Boron concentrations in selected foods from borate-producing regions in Turkey

-

Analysis,

NA,

NA

Risk↓,

713-

Bor,

Effects of dietary boron on cervical cytopathology and on micronucleus frequency in exfoliated buccal cells

-

Analysis,

NA,

NA

Risk↓,

714-

Bor,

Dietary Boron and Hormone Replacement Therapy as Risk Factors for Lung Cancer in Women

-

Analysis,

NA,

NA

Risk↓,

715-

Bor,

Boron-containing phenoxyacetanilide derivatives as hypoxia-inducible factor (HIF)-1alpha inhibitors

-

in-vitro,

Pca,

HeLa

Hif1a↓,

716-

Bor,

Sugar-borate esters--potential chemical agents in prostate cancer chemoprevention

TumCG↓, Apoptosis↑,

761-

Bor,

Prevalence of Prostate Cancer in High Boron-Exposed Population: A Community-Based Study

other↓,

753-

Bor,

Boron Intake and decreased risk of mortality in kidney transplant recipients

OS↑,

754-

Bor,

HRT,

Dietary Boron and Hormone Replacement Therapy as Risk Factors for Lung Cancer in Women

-

Analysis,

NA,

NA

Risk↓,

755-

Bor,

https://aacrjournals.org/cancerres/article/67/9_Supplement/4220/535557/Boric-acid-induces-apoptosis-in-both-prostate-and

-

in-vitro,

Pca,

DU145

-

in-vitro,

PC,

PC3

TumCG↓, Apoptosis↑,

756-

Bor,

Evaluation of Boric Acid Treatment on microRNA‐127‐5p and Metastasis Genes Orchestration of Breast Cancer Stem Cells

-

in-vitro,

BC,

MCF-7

45.69 mM

However, it cannot be said that it improves the metastasis properties of breast cancer stem cells.

COL1A1↓, Vim↓, miR-127-5p↑, Zeb1↑, CDH1↑, ITGB1↑, ITGA5↑, LAMA5↑, Snail↑,

757-

Bor,

Phenylboronic acid is a more potent inhibitor than boric acid of key signaling networks involved in cancer cell migration

-

in-vitro,

Pca,

DU145

-

in-vitro,

Nor,

RWPE-1

Rho↓, Rac1↓, Cdc42↓, *eff↑,

758-

Bor,

Comparative effects of daily and weekly boron supplementation on plasma steroid hormones and proinflammatory cytokines

-

Human,

NA,

NA

11.5mg

*hs-CRP↓, *TNF-α↓, *SHBG↓, *DHT↑, *cortisol↑, *VitD↑, *BioAv↑, *Inflam↓,

759-

Bor,

The nutritional and metabolic effects of boron in humans and animals

-

in-vivo,

NA,

NA

rata

DHT↑, VitD↑, HDL↓,

760-

Bor,

Therapeutic Efficacy of Boric Acid Treatment on Brain Tissue and Cognitive Functions in Rats with Experimental Alzheimer’s Disease

-

in-vivo,

AD,

NA

rats

*memory↑, *ROS↓, *GSH↑, *Aβ↓, *Inflam↓, *MMP↑, *lipid-P↓, *Ca+2↓, *cognitive↑, *TOS↓,

752-

Bor,

The Potential Role of Boron in the Modulation of Gut Microbiota Composition: An In Vivo Pilot Study

GutMicro↑,

762-

Bor,

Mechanism of boric acid cytotoxicity in breast cancer cell lines

-

in-vitro,

BC,

MCF-7

1mM PBA

70% inhibition of growth on day 5 in MCF-7

-

in-vitro,

BC,

ZR-75-1

1mM PBA

68% inhibition of growth beginning on day 3 in ZR-75-1 cells

TumCG↓,

763-

Bor,

Investigation of The Apoptotic and Antiproliferative Effects of Boron on CCL-233 Human Colon Cancer Cells

-

in-vitro,

Colon,

CCl233

50mM

effect starts at 10mM

TumCP↓, PARP↓, VEGF↓,

764-

Bor,

Effect of Tumor Microenvironment on Selective Uptake of Boric Acid in HepG2 Human Hepatoma Cells

-

in-vitro,

Liver,

HepG2

BioAv↑,

765-

Bor,

High concentrations of boric acid induce autophagy in cancer cell lines

p62↓, LC3II↑, TumAuto↑,

766-

Bor,

In vitro effects of boric acid on human liver hepatoma cell line (HepG2) at the half-maximal inhibitory concentration

-

in-vitro,

Liver,

HepG2

24mM

TumCCA↑, DNAdam↑, Apoptosis↑,

767-

Bor,

Boric acid induces cytoplasmic stress granule formation, eIF2α phosphorylation, and ATF4 in prostate DU-145 cells

-

in-vitro,

Pca,

DU145

ER Stress↑, eIF2α↑, GRP78/BiP↑, ATF4↑,

768-

Bor,

In vitro and in vivo antitumour effects of phenylboronic acid against mouse mammary adenocarcinoma 4T1 and squamous carcinoma SCCVII cells

-

in-vitro,

BC,

4T1

1mM

TumCP↓,

744-

Bor,

Borax affects cellular viability by inducing ER stress in hepatocellular carcinoma cells by targeting SLC12A5

-

in-vitro,

HCC,

HepG2

22.6 mM

-

in-vitro,

Nor,

HL7702

40.8 mM

TumCCA↑, SLC12A5↓, ATF6↑, CHOP↑, GRP78/BiP↑, Casp3↑, ER Stress↝, *toxicity↓, *eff↓,

736-

Bor,

Evaluation of Boric Acid Treatment on microRNA-127-5p and Metastasis Genes Orchestration of Breast Cancer Stem Cells

-

in-vitro,

BC,

MCF-7

45.69 mM

miR-126↑, COL1A1↓, Vim↓, Zeb1↑, CDH1↑, ITGB1↑, ITGA5↑, LAMA5↑, Snail↑, miR-127-5p↑,

737-

Bor,

Boric Acid Activation of eIF2α and Nrf2 Is PERK Dependent: a Mechanism that Explains How Boron Prevents DNA Damage and Enhances Antioxidant Statu

-

in-vitro,

Pca,

DU145

10uM

Risk↓, p‑eIF2α↑, ATF4↑, GADD34↑,

738-

Bor,

Borax induces ferroptosis of glioblastoma by targeting HSPA5/NRF2/GPx4/GSH pathways

-

in-vitro,

GBM,

U251

-

in-vitro,

GBM,

A172

-

in-vitro,

Nor,

SVGp12

TumCP↓, GPx4↓, GSH↓, HSP70/HSPA5↓, NRF2↓, MDA↑, Casp3↑, Casp7↑, Ferroptosis↑, selectivity↑,

739-

Bor,

Borax regulates iron chaperone- and autophagy-mediated ferroptosis pathway in glioblastoma cells

-

in-vitro,

GBM,

U87MG

-

in-vitro,

Nor,

HMC3

this report calls HMC3 "normal cells"

TumCG↓, TumCP↓, TumCCA↑, PCBP1↓, GSH↓, GPx4↓, Beclin-1↑, MDA↑, ACSL4↑, Casp3↑, Casp7↑, Ferroptosis↑, *toxicity↓,

740-

Bor,

Anti-cancer effect of boron derivatives on small-cell lung cancer

-

in-vitro,

Lung,

DMS114

-

in-vitro,

Nor,

MRC-5

without damaging normal MRC-5 cells

Apoptosis↑, TumCCA↑, P53↑, Casp3↑, *toxicity↓,

741-

Bor,

Boron Derivatives Inhibit the Proliferation of Breast Cancer Cells and Affect Tumor-Specific T Cell Activity In Vitro by Distinct Mechanisms

-

in-vitro,

BC,

MCF-7

-

in-vitro,

BC,

MDA-MB-231

MOB1↓, PD-L1↑, p‑YAP/TEAD↝, IFN-γ↓, sFasL↑, Perforin↓, GranA↓, GranB↓, GNLY↓, PD-1↑,

742-

Bor,

In Vitro Effects of Boric Acid on Cell Cycle, Apoptosis, and miRNAs in Medullary Thyroid Cancer Cells

-

in-vitro,

Thyroid,

NA

35 μM

NOXA↑, APAF1↑, BAX↑, Casp3↑, Casp9↑, Bcl-2↓, Bcl-xL↓, miR-21↓,

743-

Bor,

Boric Acid (Boron) Attenuates AOM-Induced Colorectal Cancer in Rats by Augmentation of Apoptotic and Antioxidant Mechanisms

-

in-vitro,

CRC,

NA

rats

BAX↑, Bcl-2↓, GPx↑, SOD↑, Catalase↑, MDA↓, TNF-α↓, IL6↓, IL10↑,

700-

Bor,

Diadenosine phosphates and S-adenosylmethionine: novel boron binding biomolecules detected by capillary electrophoresis

-

Analysis,

NA,

NA

SAM-e↝,

745-

Bor,

Investigation of cytotoxic antiproliferative and antiapoptotic effects of nanosized boron phosphate filled sodium alginate composite on glioblastoma cancer cells

-

in-vitro,

GBM,

U87MG

-

in-vitro,

Nor,

L929

-

in-vitro,

GBM,

T98G

TumCD↑, *toxicity↓,

746-

Bor,

Organoboronic acids/esters as effective drug and prodrug candidates in cancer treatments: challenge and hope

-

Review,

NA,

NA

50 mM CCL-233 colon

eff↑, *toxicity↓, ROS↑, LAT↓, AntiCan↑, AR↓, PSMB5↓, IGF-1↓, PSA↓, TumVol↓, eff↑, Rho↓, Cdc42↓, Ca+2↓, eff↑,

747-

Bor,

Growing Evidence for Human Health Benefits of Boron

-

Review,

NA,

NA

acceptable safe range of population mean intakes of boron for adults could be 1 to 13 mg/d.

29 mg/L boron and to boron mining and production, no adverse effects on health or fertility were found over 3 generations

TumCG↓, Risk↓,

748-

Bor,

A Study on the Anticarcinogenic Effects of Calcium Fructoborate

-

in-vitro,

BC,

MDA-MB-231

50uM

p‑ATM↑, p‑P53↑, Casp9↑, PARP↓, VEGF↓, Casp3↑,

749-

Bor,

Comparative effects of boric acid and calcium fructoborate on breast cancer cells

P53↓, Bcl-2↓, Casp3↑, Apoptosis↑,

750-

Bor,

Calcium fructoborate regulate colon cancer (Caco-2) cytotoxicity through modulation of apoptosis

-

in-vitro,

CRC,

Caco-2

CaFB 10mM

Bcl-2↓, BAX↑, Akt↓, p70S6↓, PTEN↑, TSC2↑,

751-

Bor,

5-FU,

Cytotoxic and Apoptotic Effects of the Combination of Borax (Sodium Tetraborate) and 5-Fluorouracil on DLD-1 Human Colorectal Adenocarcinoma Cell Line

-

in-vitro,

CRC,

DLD1

Apoptosis↑,

699-

Bor,

Boric Acid Alleviates Gastric Ulcer by Regulating Oxidative Stress and Inflammation-Related Multiple Signaling Pathways

-

in-vivo,

NA,

NA

*ROS↓, *MDA↓, *TNF-α↓, *IL6↓, *JAK2↓, *STAT3↓, *AMPK↑, *Sema3A/PlexinA1↑,

698-

Bor,

Boron deprivation decreases liver S-adenosylmethionine and spermidine and increases plasma homocysteine and cysteine in rats

-

in-vitro,

NA,

NA

rats

SAM-e↑,

697-

Bor,

Boron-containing compounds as preventive and chemotherapeutic agents for cancer

-

Review,

NA,

NA

serineP↓, NADHdeh↓, Apoptosis↑,

696-

Bor,

Nothing Boring About Boron

-

Review,

Var,

NA

>3mg

upper intake level (UL) of 20 mg/d

*hs-CRP↓, *TNF-α↓, *SOD↑, *Catalase↑, *GPx↑, *cognitive↑, *memory↑, *Risk↓, *SAM-e↑, *NAD↝, *ATP↝, *Ca+2↝, HDAC↓, TumVol↓, IGF-1↓, PSA↓, Cyc↓, TumCMig↓, *serineP↓, HIF-1↓, *ChemoSideEff↓, *VitD↑, *Mag↑, *eff↑, Risk↓, *Inflam↓, *neuroP↑, *Calcium↑, *BMD↑, *chemoP↑, AntiCan↑, *Dose↑, *Dose↝, *BMPs↑, *testos↑, angioG↓, Apoptosis↑, *selectivity↑,

3519-

Bor,

Boron-Based Inhibitors of the NLRP3 Inflammasome

-

Review,

NA,

NA

NLRP3↓,

3512-

Bor,

Activation of the EIF2α/ATF4 and ATF6 Pathways in DU-145 Cells by Boric Acid at the Concentration Reported in Men at the US Mean Boron Intake

-

in-vitro,

Pca,

DU145

TumCP↓, eIF2α↑, ATF4↑, ATF6↑, GADD34↑, CHOP↓, GRP78/BiP↑, GRP94↑, Risk↓, *BMD↑, Ca+2↓, *Half-Life↝, IRE1∅, chemoP↑,

3518-

Bor,

Boron Report

-

Review,

Var,

NA

-

Review,

AD,

NA

Risk↓, serineP↓, PSA↓, TumVol↓, IGF-1↓, *Mag↑, *Calcium↑, *VitD↑, *COX2↓, *5LO↓, *PGE2↓, *NF-kB↓, *cognitive↑,

3517-

Bor,

Se,

The protective effects of selenium and boron on cyclophosphamide-induced hepatic oxidative stress, inflammation, and apoptosis in rats

-

in-vivo,

Nor,

NA

rats + Cyclophosphamide (CP) is an alkylating anticancer drug

*hepatoP↑, *ALAT↓, *AST↓, *ALP↓, *NF-kB↓, *TNF-α↓, *IL1β↓, *IL6↓, *IL10↑, *SOD↑, *Catalase↑, *MDA↓, *GSH↑, *GPx↑, *antiOx↑, *NRF2↑, *Keap1↓,

3516-

Bor,

Boron in wound healing: a comprehensive investigation of its diverse mechanisms

-

Review,

Wounds,

NA

*Inflam↓, *antiOx↑, *ROS↓, *angioG↑, *COL1↑, *α-SMA↑, *TGF-β↑, *BMD↑, *hepatoP↑, *TNF-α↑, *HSP70/HSPA5↑, *SOD↑, *Catalase↑, *GSH↑, *MDA↓, *TOS↓, *IL6↓, *JAK2↓, *STAT3↓, *AMPK↑, *lipid-P↓, *VEGF↑, *Half-Life↝,

3515-

Bor,

EVIDENCE THAT BORON DOWN-REGULATES INFLAMMATION THROUGH THE NF-(KAPPA)B PATHWAY

-

in-vitro,

Nor,

NA

774-A1, was grown in the presence and absence of supplemental boron for a minimum of 5 days

*TNF-α↓, *IL1β↓, *MIP‑1α↓, *iNOS↓, *NF-kB↓,

3514-

Bor,

CUR,

Effects of Curcumin and Boric Acid Against Neurodegenerative Damage Induced by Amyloid Beta

-

in-vivo,

AD,

NA

rat

*DNAdam↓, *MDA↓, *AChE↓, *neuroP↑, *ROS↓, *NO↓,

3513-

Bor,

Boric Acid Activation of eIF2α and Nrf2 Is PERK Dependent: a Mechanism that Explains How Boron Prevents DNA Damage and Enhances Antioxidant Status

-

in-vitro,

Pca,

DU145

-

in-vitro,

Nor,

MEF

NRF2↑, selectivity↑, NQO1↑, GCLC↑, HO-1↑, TumCP↓,

3511-

Bor,

Boron

-

Review,

NA,

NA

*memory↑, *motorD↑, *neuroP↑, Ca+2↓, ATF4↑, NRF2↑, *Inflam↓, *ROS↓,

3510-

Bor,

Boron Affects the Development of the Kidney Through Modulation of Apoptosis, Antioxidant Capacity, and Nrf2 Pathway in the African Ostrich Chicks

-

in-vivo,

Nor,

NA

ostrich chicks

*RenoP↑, *ROS↓, *antiOx↑, *Apoptosis↓, *NRF2↑, *HO-1↑, *MDA↓, *lipid-P↓, *GPx↓, *Catalase↑, *SOD↑, *ALAT↓, *AST↓, *ALP↓,

3509-

Bor,

Boron and Prostate Cancer a Model for Understanding Boron Biology

-

NA,

Pca,

NA

Ca+2↓,

3508-

Bor,

The Effect of Boron on the UPR in Prostate Cancer Cells is Biphasic

-

in-vitro,

Pca,

LNCaP

-

in-vitro,

Pca,

DU145

ER Stress↑, GRP78/BiP↑, p‑eIF2α↑, UPR↑, eff↓,

3507-

Bor,

Boron inhibits apoptosis in hyperapoptosis condition: Acts by stabilizing the mitochondrial membrane and inhibiting matrix remodeling

*MMP↑, *Cyt‑c↓, *Apoptosis↓, *Casp3↓, *NO↓, *iNOS↓,

3506-

Bor,

Boron Chemistry for Medical Applications

-

Review,

NA,

NA

radioP↑, selectivity↑,

3505-

Bor,

Mineral requirements for mitochondrial function: A connection to redox balance and cellular differentiation

-

Review,

NA,

NA

*glucose↓, *creat↓, *SOD↑, *MMP↑, *ROS↓,

3504-

Bor,

Boron Contents of German Mineral and Medicinal Waters and Their Bioavailability in Drosophila melanogaster and Humans

-

Review,

NA,

NA

other↑, BioAv↑,

3503-

Bor,

Chemical disposition of boron in animals and humans

-

Review,

NA,

NA

*Half-Life↑, *other↑,

3502-

Bor,

Plasma boron concentrations in the general population: a cross-sectional analysis of cardio-metabolic and dietary correlates

-

Review,

NA,

NA

*Half-Life↑, *VitD↑, *cardioP↑, *RenoP↓,

3521-

Bor,

A new hope for obesity management: Boron inhibits adipogenesis in progenitor cells through the Wnt/β-catenin pathway

-

in-vitro,

Obesity,

3T3

*CEBPA↓, *PPARγ↓, *FASN↓, *SREBP1↓, *FABP4↓, *GLUT4↓, *β-catenin/ZEB1↑, *MMP2↓, *FGF↑, *Ca+2?,

3522-

Bor,

The Boron Advantage: The Evolution and Diversification of Boron’s Applications in Medicinal Chemistry

-

Review,

Var,

NA

Hif1a↓, HDAC↓, *CXCR2↑, ROS↑,

3523-

Bor,

Design, Synthesis, and Biological Activity of Boronic Acid-Based Histone Deacetylase Inhibitors

-

in-vitro,

Var,

NA

HDAC↓,

3520-

Bor,

Effect of boron element on photoaging in rats

-

in-vivo,

NA,

NA

rats

*hepatoP↑, *BMD↑, *COX2↓, *IL8↓, *NF-kB↓, *IL6↓, *TNF-α↓,

3524-

Bor,

Boric Acid Alleviates Lipopolysaccharide-Induced Acute Lung Injury in Mice

*Inflam↓, *SOD↑, *MDA↓, *GRP78/BiP↓, *CHOP↓, *NRF2↑, *HO-1↑,

3525-

Bor,

Synthesis of DNA-Boron Cluster Composites and Assembly into Functional Nanoparticles with Dual, Anti-EGFR, and Anti-c-MYC Oncogene Silencing Activity

-

in-vitro,

PC,

PANC1

EGFR↓, cMyc↓,

3527-

Bor,

The potential role of borophene as a radiosensitizer in boron neutron capture therapy (BNCT) and particle therapy (PT)

-

NA,

Var,

NA

RadioS↑,

2779-

Bos,

Identification of a natural inhibitor of methionine adenosyltransferase 2A regulating one-carbon metabolism in keratinocytes

-

in-vitro,

Nor,

HaCaT

-

in-vitro,

PSA,

NA

*MATs↓, *SAM-e↓,

2767-

Bos,

The potential role of boswellic acids in cancer prevention and treatment

-

Review,

Var,

NA

*Inflam↓, AntiCan↑, *MAPK↑, *Ca+2↝, p‑ERK↓, TumCI↓, cycD1↓, cycE↓, CDK2↓, CDK4↓, p‑RB1↓, *NF-kB↓, *TNF-α↓, NF-kB↓, IKKα↓, MCP1↓, IL1α↓, MIP2↓, VEGF↓, Tf↓, COX2↓, MMP9↓, CXCR4↓, VEGF↓, eff↑, PPARα↓, lipid-P?, STAT3↓, TOP1↓, TOP2↑, 5HT↓, p‑PDGFR-BB↓, PDGF↓, AR↓, DR5↑, angioG↓, DR4↑, Casp3↑, Casp8↑, cl‑PARP↑, eff↑, chemoP↑, Wnt↓, β-catenin/ZEB1↓, ascitic↓, Let-7↑, miR-200b↑, eff↑, MMP1↓, MMP2↓, eff↑, BioAv↓, BioAv↑, Half-Life↓, toxicity↓, Dose↑, BioAv↑, ChemoSen↑,

2778-

Bos,

Development, Analytical Characterization, and Bioactivity Evaluation of Boswellia serrata Extract-Layered Double Hydroxide Hybrid Composites

-

in-vitro,

Nor,

NA

*ATP↓, *ROS↓,

2777-

Bos,

Boswellia serrata Preserves Intestinal Epithelial Barrier from Oxidative and Inflammatory Damage

-

in-vitro,

IBD,

NA

*p‑NF-kB↓, *ROS↓, Inflam↓,

2776-

Bos,

Anti-inflammatory and anti-cancer activities of frankincense: Targets, treatments and toxicities

-

Review,

Var,

NA

*5LO↓, *TNF-α↓, *MMP3↓, *COX1↓, *COX2↓, *PGE2↓, *Th2↑, *Catalase↑, *SOD↑, *NO↑, *PGE2↑, *IL1β↓, *IL6↓, *Th1 response↓, *Th2↑, *iNOS↓, *NO↓, *p‑JNK↓, *p38↓, GutMicro↑, p‑Akt↓, GSK‐3β↓, cycD1↓, Akt↓, STAT3↓, CSCs↓, AR↓, P21↑, DR5↑, CHOP↑, Casp3↑, Casp8↑, cl‑PARP↑, DNAdam↑, p‑RB1↓, Foxm1↓, TOP2↓, CDC25↓, p‑CDK1↓, p‑ERK↓, MMP9↓, VEGF↓, angioG↓, ROS↑, Cyt‑c↑, AIF↑, Diablo↑, survivin↓, ICAD↓, ChemoSen↑, SOX9↓, ER Stress↑, GRP78/BiP↑, cal2↓, AMPK↓, mTOR↓, ROS↓,

2775-

Bos,

The journey of boswellic acids from synthesis to pharmacological activities

-

Review,

Var,

NA

-

Review,

AD,

NA

-

Review,

PSA,

NA

ROS↑, ER Stress↑, TumCG↓, Apoptosis↑, Inflam↓, ChemoSen↑, Casp↑, ERK↓, cl‑PARP↑, AR↓, cycD1↓, VEGFR2↓, CXCR4↓, radioP↑, NF-kB↓, VEGF↓, P21↑, Wnt↓, β-catenin/ZEB1↓, Cyt‑c↑, MMP2↓, MMP1↓, MMP9↓, PI3K↓, MAPK↓, JNK↑, *5LO↓, *NRF2↑, *HO-1↑, *MDA↓, *SOD↑, *hepatoP↑, *ALAT↓, *AST↓, *LDH↑, *CRP↓, *COX2↓, *GSH↑, *ROS↓, *Imm↑, *Dose↝, *eff↑, *neuroP↑, *cognitive↑, *IL6↓, *TNF-α↓,

2773-

Bos,

Targeted inhibition of tumor proliferation, survival, and metastasis by pentacyclic triterpenoids: Potential role in prevention and therapy of cancer

-

Review,

Var,

NA

Inflam↓, TumCCA↑, Casp3↑, Casp8↑, Casp9↑, STAT3↑, SHP1↓, NF-kB↓, cycD1↓, COX2↓, Ki-67↓, CD31↓, IAP1↓, MMPs↓, Bcl-2↓, Bcl-xL↓,

2772-

Bos,

Mechanistic role of boswellic acids in Alzheimer’s disease: Emphasis on anti-inflammatory properties

-

Review,

AD,

NA

*neuroP↑, *Inflam↓, *AChE↓, *Choline↑, *NRF2↑, *NF-kB↑, *BBB↑, *BioAv↑, *Half-Life↓, *Dose↝, *PGE2↓, *ROS↓, *cognitive↑, *antiOx↑, 5LO↓, *TNF-α↓, *IL6↓, *HO-1↑,

2774-

Bos,

Boswellia ovalifoliolata abrogates ROS mediated NF-κB activation, causes apoptosis and chemosensitization in Triple Negative Breast Cancer cells

-

in-vitro,

BC,

MDA-MB-231

67.48 μg/ml

-

in-vitro,

BC,

MDA-MB-453

70.03 ± 4.76 μg/ml

ChemoSen↑, Casp3↑, ROS↓, NF-kB↓,

2768-

Bos,

Boswellic acids as promising agents for the management of brain diseases

-

Review,

Var,

NA

-

Review,

AD,

NA

-

Review,

Park,

NA

*neuroP↑, *ROS↓, *cognitive↓, TumCP↓, TumCMig↓, TumMeta↓, angioG↓, Apoptosis↑, *Inflam↓, IL1↓, IL2↓, IL4↓, IL6↓, TNF-α↓, P53↑, Akt↓, NF-kB↓, DNAdam↑, Casp↑, COX2↓, MMP9↓, CXCR4↓, VEGF↓, *SOD↑, *Catalase↑, *GPx↑, *NRF2↑,

1248-

Bos,

The anti-proliferative effects of a frankincense extract in a window of opportunity phase ia clinical trial for patients with breast cancer

-

Trial,

BC,

NA

2400 mg/day PO

20 patients

TumCP↓,

1425-

Bos,

Protective Effect of Boswellic Acids against Doxorubicin-Induced Hepatotoxicity: Impact on Nrf2/HO-1 Defense Pathway

-

in-vivo,

Nor,

NA

*ChemoSen↑, *NRF2↑, *HO-1↑, *ROS↓, *lipid-P↓, *DNAdam↓,

1419-

Bos,

Enhanced Bioavailability of Boswellic Acid by Piper longum: A Computational and Pharmacokinetic Study

-

in-vivo,

Nor,

NA

rabbits

*BioAv↑,

1417-

Bos,

Potential complementary and/or synergistic effects of curcumin and boswellic acids for management of osteoarthritis

-

Review,

Arthritis,

NA

5LO↓, COX2↓, PGE2↓,

1450-

Bos,

Cisplatin,

3-Acetyl-11-keto-β-boswellic acid (AKBA) induced antiproliferative effect by suppressing Notch signaling pathway and synergistic interaction with cisplatin against prostate cancer cells

-

in-vitro,

Pca,

DU145

16.50 µM at 48 h

ROS↑, MMP↓, Casp↑, Apoptosis↑, Bax:Bcl2↑, TumCCA?, cycD1↓, CDK4↓, P21↑, p27↑, NOTCH↓, ChemoSen↑,

1416-

Bos,

Anti-cancer properties of boswellic acids: mechanism of action as anti-cancerous agent

-

Review,

NA,

NA

5LO↓, TumCCA↑, LC3B↓, PI3K↓, Akt↓, Glycolysis↓, AMPK↑, mTOR↓, Let-7↑, COX2↓, VEGF↓, CXCR4↓, MMP2↓, MMP9↓, HIF-1↓, angioG↓, TumCP↓, TumCMig↓, NF-kB↓,

1420-

Bos,

Acetyl-11-keto-β-boswellic acid inhibits proliferation and induces apoptosis of gastric cancer cells through the phosphatase and tensin homolog /Akt/ cyclooxygenase-2 signaling pathway

-

vitro+vivo,

GC,

BGC-823

(0–50 µM for 24, 48, and 72 h). AKBA

TumCP↓, TumCG↓, PTEN↑, BAX↑, Bcl-2↓, p‑Akt↓, COX2↓,

1421-

Bos,

Coupling of boswellic acid-induced Ca2+ mobilisation and MAPK activation to lipid metabolism and peroxide formation in human leucocytes

-

in-vitro,

AML,

HL-60

10–30 μM

-

in-vitro,

Nor,

NA

venous blood was taken from healthy adult donors

ROS↑, NADPH↝, 5LO↓, Ca+2↑, p38↑, p42↑,

1422-

Bos,

Boswellic acid exerts antitumor effects in colorectal cancer cells by modulating expression of the let-7 and miR-200 microRNA family

-

in-vitro,

CRC,

NA

20-40uM

-

in-vivo,

NA,

NA

(0, 50, 100 and 200mg/kg/day for 28 days

mice

5LO↓, TumCG↓, Let-7↑, miR-200b↑, NF-kB↓, cMyc↓, cycD1↓, MMP9↓, CXCR4↓, VEGF↓, Bcl-xL↓, survivin↓, IAP1↓, XIAP↓, TumCG↓, CDK6↓, Vim↓, E-cadherin↑,

1423-

Bos,

Acetyl-11-keto-β-Boswellic Acid Suppresses Invasion of Pancreatic Cancer Cells Through The Downregulation of CXCR4 Chemokine Receptor Expression

-

in-vitro,

Melanoma,

U266

-

in-vitro,

BC,

MDA-MB-231

-

in-vitro,

BC,

SkBr3

-

in-vitro,

PC,

PANC1

CXCR4↓, TumCI↓, HER2/EBBR2↓, NF-kB↓,

1424-

Bos,

Boswellia sacra essential oil induces tumor cell-specific apoptosis and suppresses tumor aggressiveness in cultured human breast cancer cells

-

in-vitro,

BC,

T47D

-

in-vitro,

BC,

MCF-7

-

in-vitro,

BC,

MDA-MB-231

tumCV↓, Apoptosis↑, cl‑Casp8↑, cl‑Casp9↑, cl‑PARP↑,

1426-

Bos,

CUR,

Chemo,

Novel evidence for curcumin and boswellic acid induced chemoprevention through regulation of miR-34a and miR-27a in colorectal cancer

-

in-vivo,

CRC,

NA

10um(cur), 30uM(AKBA)

mouse

-

in-vitro,

CRC,

HCT116

-

in-vitro,

CRC,

RKO

-

in-vitro,

CRC,

SW480

-

in-vitro,

RCC,

SW-620

-

in-vitro,

RCC,

HT-29

-

in-vitro,

CRC,

Caco-2

miR-34a↑, miR-27a-3p↓, TumCG↓, BAX↑, Bcl-2↓, PARP1↓, TumCCA↑, Apoptosis↑, cMyc↓, CDK4↓, CDK6↓, cycD1↓, ChemoSen↑, miR-34a↑, miR-27a-3p↓,

1427-

Bos,

Acetyl-keto-β-boswellic acid inhibits cellular proliferation through a p21-dependent pathway in colon cancer cells

-

in-vitro,

CRC,

HT-29

20 μM AKBA

25 μM AKBA after 48 h of treatment

-

in-vitro,

CRC,

HCT116

-

in-vitro,

CRC,

LS174T

TumCG↓, TumCCA↑, cycD1↓, cycE↓, CDK2↓, CDK4↓, p‑RB1↓, P21↑,

1451-

Bos,

Phytochemical Analysis and Anti-cancer Investigation of Boswellia serrata Bioactive Constituents In Vitro

-

in-vitro,

CRC,

HepG2

1.58 and 5.82 μg/mL at 48 h

HepG2 cell line, extracts 1 and 2

-

in-vitro,

CRC,

HCT116

eff↑,

1449-

Bos,

Chemo,

Anti-proliferative, Pro-apoptotic, and Chemosensitizing Potential of 3-Acetyl-11-keto-β-boswellic Acid (AKBA) Against Prostate Cancer Cells

-

in-vitro,

Pca,

PC3

AKBA (10-50 µM)

TumCP↓, ChemoSen↑, MMP↝, ROS↝, Apoptosis↑,

1448-

Bos,

A triterpenediol from Boswellia serrata induces apoptosis through both the intrinsic and extrinsic apoptotic pathways in human leukemia HL-60 cells

-

in-vitro,

AML,

HL-60

12ug/ml

TumCP↓, Apoptosis↑, ROS↑, NO↑, cl‑Bcl-2↑, BAX↑, MMP↓, Cyt‑c↑, AIF↑, Diablo↑, survivin↓, ICAD↓, Casp↑, cl‑PARP↑, DR4↑, TNFR 1↑,

1447-

Bos,

Boswellia carterii n-hexane extract suppresses breast cancer growth via induction of ferroptosis by downregulated GPX4 and upregulated transferrin

-

in-vitro,

BC,

MDA-MB-231

1-100uM BCHE

-

in-vitro,

BC,

MCF-7

-

in-vivo,

BC,

4T1

400-800 mg/kg

mouse BC 4T1

-

in-vitro,

Nor,

MCF10

tumCV↓, AntiCan↑, *toxicity↓, Ferroptosis↑, i-Iron↑, GPx4↓, ROS↑, lipid-P↑, Tf↑, TumCG↓,

2024-

Bos,

Antiproliferative and cell cycle arrest potentials of 3-O-acetyl-11-keto-β-boswellic acid against MCF-7 cells in vitro

-

in-vitro,

BC,

MCF-7

101.1

-

in-vitro,

Nor,

MCF10

275.2

MMP↓, Cyt‑c↑, ROS↑, Casp8↑, Casp9↑, AntiTum↑, selectivity↑, TumCCA↑,

1185-

Bos,

The journey of boswellic acids from synthesis to pharmacological activities

-

Review,

NA,

NA

BAX↑, NF-kB↓, cl‑PARP↑, Casp3↑, Casp8↑,

1169-

Bos,

Boswellic Acid Inhibits Growth and Metastasis of Human Colorectal Cancer in Orthotopic Mouse Model By Downregulating Inflammatory, Proliferative, Invasive, and Angiogenic Biomarkers

-

in-vivo,

CRC,

NA

50-200 mg/kg

mice

TumCG↓, TumVol↓, Weight∅, ascitic↓, TumMeta↓, Ki-67↓, CD31↓, NF-kB↓, COX2↓, Bcl-2↓, Bcl-xL↓, IAP1↓, survivin↓, cycD1↓, ICAM-1↓, MMP9↓, CXCR4↓, VEGF↓,

1101-

CA,

Tras,

Cooperative antitumor activities of carnosic acid and Trastuzumab in ERBB2+ breast cancer cells

-

in-vitro,

BC,

NA

in ERBB2+ BC cells

ChemoSen↑, HER2/EBBR2↓, PI3K↓, Akt↓, mTOR↓, p62↑,

1207-

CA,

PacT,

Caffeine inhibits the anticancer activity of paclitaxel via down-regulation of α-tubulin acetylation

-

in-vitro,

Lung,

A549

patients receiving treatment with taxanes, such as paclitaxel, should avoid consuming caffeinated beverages or foods.

-

in-vitro,

Cerv,

HeLa

TumCG↑, TumCMig↓, Apoptosis↓, ac‑α-tubulin↑,

1011-

CA,

Dihydrocaffeic acid improves IL-1β-induced inflammation and cartilage degradation via inhibiting NF-κB and MAPK signalling pathways

-

in-vivo,

NA,

NA

mice

iNOS↓, IL6↓, SOX9↑, NF-kB↓, MAPK↓,

145-

CA,

CUR,

The anti-cancer effects of carotenoids and other phytonutrients resides in their combined activity

-

in-vitro,

NA,

NA

AR↓, ARE/EpRE↑,

2399-

CA,

EA,

Polyphenol-rich diet mediates interplay between macrophage-neutrophil and gut microbiota to alleviate intestinal inflammation

-

Review,

Col,

NA

eff↝, eff↑, Weight↑,

3032-

CA,

Carnosic Acid Induces Apoptosis Through Reactive Oxygen Species-mediated Endoplasmic Reticulum Stress Induction in Human Renal Carcinoma Caki Cells

-

in-vitro,

Kidney,

Caki-1

cl‑PARP↑, ROS↑, ER Stress↑, ATF4↑, CHOP↑, selectivity↑,

1230-

CA,

Caff,

Caffeine and Caffeic Acid Inhibit Growth and Modify Estrogen Receptor and Insulin-like Growth Factor I Receptor Levels in Human Breast Cancer

-

in-vitro,

BC,

MCF-7

-

in-vitro,

BC,

MDA-MB-231

-

Human,

NA,

NA

cohort of 1,090 patients with invasive primary breast cancer in Sweden

TumVol↓, TumCG↓, ER(estro)↓, cycD1↓, IGF-1R↓, p‑Akt↓,

1297-

CA,

Caffeic Acid Phenethyl Ester (CAPE) Induced Apoptosis in Serous Ovarian Cancer OV7 Cells by Deregulation of BCL2/BAX Genes

-

in-vitro,

Ovarian,

OV7

lysosome↓, Apoptosis↑, Bax:Bcl2↑,

1646-

CA,

Caffeic acid: a brief overview of its presence, metabolism, and bioactivity

-

Review,

Nor,

NA

*BioAv↓, ROS⇅, selectivity↑, other∅, VEGF↓, MMP2↓, MMP9↓,

1650-

CA,

Adjuvant Properties of Caffeic Acid in Cancer Treatment

-

Review,

Var,

NA

ROS↑, antiOx↑, Inflam↓, AntiCan↑, NF-kB↓, STAT3↓, ERK↓, ChemoSen↑, RadioS↑, AMPK↑, eff↑, selectivity↑, COX2↓, Dose∅, PHDs↓, MMP9↓, MMP2↓, Dose∅, Dose∅, Ca+2↑, Dose?, MMP↓, RadioS↑,

1651-

CA,

PBG,

Caffeic acid and its derivatives as potential modulators of oncogenic molecular pathways: New hope in the fight against cancer

-

Review,

Var,

NA

Apoptosis↑, TumCCA↓, TumCMig↓, TumMeta↓, ChemoSen↑, eff↑, eff↑, eff↓, eff↝, Dose∅, AMPK↑, p62↓, LC3II↑, Ca+2↑, Bax:Bcl2↑, CDK4↑, CDK6↑, RB1↑, EMT↓, E-cadherin↑, Vim↓, β-catenin/ZEB1↓, NF-kB↓, angioG↑, VEGF↓, TSP-1↑, MMP9↓, MMP2↓, ChemoSen↑, eff↑, ROS↑, CSCs↓, Fas↑, P53↑, BAX↑, Casp↑, β-catenin/ZEB1↓, NDRG1↑, STAT3↓, MAPK↑, ERK↑, eff↑, eff↑, eff↑,

1652-

CA,

Caffeic Acid and Diseases—Mechanisms of Action

-

Review,

Var,

NA

Dose∅, ROS⇅, NF-kB↓, STAT3↓, VEGF↓, MMP9↓, HSP70/HSPA5↑, AST↝, ALAT↝, ALP↝, Hif1a↓, IL6↓, IGF-1R↓, P21↑, iNOS↓, ERK↓, Snail↓, BID↑, BAX↑, Casp3↑, Casp7↑, Casp9↑, cycD1↓, Vim↓, β-catenin/ZEB1↓, COX2↓, ROS↑,

1640-

CA,

MET,

Caffeic Acid Targets AMPK Signaling and Regulates Tricarboxylic Acid Cycle Anaplerosis while Metformin Downregulates HIF-1α-Induced Glycolytic Enzymes in Human Cervical Squamous Cell Carcinoma Lines

-

in-vitro,

Cerv,

SiHa

GLS↓, NADPH↓, ROS↑, TumCD↑, AMPK↑, Hif1a↓, GLUT1↓, GLUT3↓, HK2↓, PFK↓, PKM2↓, LDH↓, cMyc↓, BAX↓, cycD1↓, PDH↓, ROS↑, Apoptosis↑, eff↑, ACLY↓, FASN↓, Bcl-2↓, Glycolysis↓,

1653-

Caff,

Higher Caffeinated Coffee Intake Is Associated with Reduced Malignant Melanoma Risk: A Meta-Analysis Study

-

Review,

Melanoma,

NA

AntiCan↑, eff↓,

1205-

Caff,

immuno,

Caffeine-enhanced anti-tumor activity of anti-PD1 monoclonal antibody

-

in-vivo,

Melanoma,

B16-F10

OS↑, CD4+↑, CD8+↑, AntiTum↑, TNF-α↑, IFN-γ↑,

1206-

Caff,

Caffeine inhibits TGFβ activation in epithelial cells, interrupts fibroblast responses to TGFβ, and reduces established fibrosis in ex vivo precision-cut lung slices

-

in-vitro,

NA,

NA

-

ex-vivo,

NA,

NA

Fibrosis↓, TGF-β↓, α-SMA↓,

1265-

CAP,

Capsaicin shapes gut microbiota and pre-metastatic niche to facilitate cancer metastasis to liver

-

in-vivo,

CRC,

NA

300 mg/kg

mice

GutMicro↓, Risk↑,

1264-

CAP,

Capsaicin modulates proliferation, migration, and activation of hepatic stellate cells

-

in-vitro,

HCC,

NA

100 lM

TumCP↓, TumCMig↓, TumCCA↑, MMP∅, MMP2↓, MMP9↓, α-SMA↓, COL1A1↓, COL3A1↓, TIMP1↓,

1263-

CAP,

Capsaicin inhibits the migration and invasion via the AMPK/NF-κB signaling pathway in esophagus sequamous cell carcinoma by decreasing matrix metalloproteinase-9 expression

-

in-vitro,

ESCC,

Eca109

TumCMig↓, TumCI↓, MMP9↓, p‑AMPK↑, SIRT1↑, NF-kB↓, p‑IκB↑,

1262-

CAP,

Capsaicin Inhibits Proliferation and Induces Apoptosis in Breast Cancer by Down-Regulating FBI-1-Mediated NF-κB Pathway

-

vitro+vivo,

BC,

NA

FBI-1↓, Ki-67↓, Bcl-2↓, survivin↓, BAX↑, Casp3↑, TumCP↓, Apoptosis↑,

1261-

CAP,

Capsaicin inhibits glycolysis in esophageal squamous cell carcinoma by regulating hexokinase‑2 expression

-

in-vitro,

ESCC,

KYSE150

GlucoseCon↓, lactateProd↓, HK2↓, Glycolysis↓, PTEN↑, AKT1↓,

1260-

CAP,

Capsaicin inhibits in vitro and in vivo angiogenesis

-

vitro+vivo,

NA,

NA

VEGF↓, angioG↓, TumCCA↑, cycD1↓, Akt↓,

1259-

CAP,

Capsaicin inhibits HIF-1α accumulation through suppression of mitochondrial respiration in lung cancer cells

-

in-vitro,

Lung,

H1299

-

in-vitro,

Lung,

A549

-

in-vitro,

Lung,

H23

-

in-vitro,

Lung,

H2009

Hif1a↓, PDK1↓, GLUT1↓, ROS↑, mitResp↓, ATP↓,

2013-

CAP,

Capsaicin, a component of red peppers, inhibits the growth of androgen-independent, p53 mutant prostate cancer cells

-

in-vitro,

Pca,

PC3

0-5 x 10-4 mol/L

-

in-vitro,

Pca,

LNCaP

-

in-vitro,

Pca,

DU145

-

in-vivo,

NA,

NA

5 mg/kg/d;

mice

TumCP↓, P53↑, P21↑, BAX↑, PSA↓, AR↓, NF-kB↓, Proteasome↓, TumVol↓, eff∅,

2014-

CAP,

Role of Mitochondrial Electron Transport Chain Complexes in Capsaicin Mediated Oxidative Stress Leading to Apoptosis in Pancreatic Cancer Cells

-

in-vitro,

PC,

Bxpc-3

150uM

-

in-vitro,

Nor,

HPDE-6

150uM

normal pancreatic epithelial cells were resistant to the effects of capsaicin.

-

in-vivo,

PC,

AsPC-1

mice orally fed with 2.5 mg/kg capsaicin

mice, 2.5 mg/kg capsaicin was given to mice by oral gavage, which is 0.202 mg/kg when converted to human equivalent dose (HED) and equates to 13.2 mg dose of capsaicin for a 60 kg person

ROS↑, *ROS∅, selectivity↑, compI↓, compIII↓, eff↑, selectivity↑, ATP↓, Cyt‑c↑, Casp9↑, Casp3↑, MMP↓, SOD↓, GSH/GSSG↓, Apoptosis↑, *toxicity∅, GSH↓, Catalase↓, GPx↓, Dose↝,

2015-

CAP,

CUR,

urea,

Anti-cancer Activity of Sustained Release Capsaicin Formulations

-

Review,

Var,

NA

AntiCan↑, TumCG↓, angioG↓, TumMeta↓, BioAv↓, BioAv↓, BioAv↑, selectivity↑, EPR↑, eff↓, ChemoSen↑, Dose∅, Half-Life∅, eff↑,

2016-

CAP,

Capsaicin binds the N-terminus of Hsp90, induces lysosomal degradation of Hsp70, and enhances the anti-tumor effects of 17-AAG (Tanespimycin)

HSP90↓, ATPase↓, eff↑, HSP70/HSPA5↓, other↝, NF-kB↓, EGFR↓, CDK4↓, Src↓, VEGF↓, PI3K↓, Akt↓,

2017-

CAP,

Spice Up Your Kidney: A Review on the Effects of Capsaicin in Renal Physiology and Disease

-

Review,

Var,

NA

RenoP↑, AntiTum↑, AMPK↑, mTOR↑, PD-1↓, PD-L1↓,

2018-

CAP,

MF,

Capsaicin: Effects on the Pathogenesis of Hepatocellular Carcinoma

-

Review,

HCC,

NA

TRPV1↑, eff↑, Akt↓, mTOR↓, p‑STAT3↑, MMP2↑, ER Stress↑, Ca+2↑, ROS↑, selectivity↑, MMP↓, eff↑,

2019-

CAP,

Capsaicin: A Two-Decade Systematic Review of Global Research Output and Recent Advances Against Human Cancer

-

Review,

Var,

NA

chemoP↑, Ca+2↑, antiOx↑, *ROS↓, *MMP∅, *Cyt‑c∅, *Casp3∅, *eff↑, *Inflam↓, *NF-kB↓, *COX2↓, iNOS↓, TRPV1↑, i-Ca+2?, MMP↓, Cyt‑c↑, Bax:Bcl2↑, P53↑, JNK↑, PI3K↓, Akt↓, mTOR↓, LC3II↑, ATG5↑, p62↑, Fap1↓, Casp3↑, Apoptosis↑, ROS↑, MMP9↓, eff↑, eff↓, eff↑, selectivity↑, eff↑, ChemoSen↑,

2012-

CAP,

Capsaicin induces cytotoxicity in human osteosarcoma MG63 cells through TRPV1-dependent and -independent pathways

-

NA,

OS,

MG63

0-40 μM

20 μM

AntiTum↑, Apoptosis↑, TRPV1↑, ROS↑, SOD↓, AMPK↑, P53↑, JNK↑, Bcl-2↓, Cyt‑c↑, cl‑Casp3↑, cl‑PARP↑, Ca+2↑, MMP↓,

2020-

CAP,

Capsaicinoids and Their Effects on Cancer: The “Double-Edged Sword” Postulate from the Molecular Scale

-

Review,

Var,

NA

AntiTum↑, selectivity↑, TRPV1↑, MMP↓, Ca+2↑, ER Stress↑, angioG↓, Casp3?, cl‑PARP↑, selectivity↑, ROS↑, *ROS∅, selectivity↑,

1517-

CAP,

Capsaicin Inhibits Multiple Bladder Cancer Cell Phenotypes by Inhibiting Tumor-Associated NADH Oxidase (tNOX) and Sirtuin1 (SIRT1)

-

in-vitro,

Bladder,

TSGH8301

-

in-vitro,

CRC,

T24

ENOX2↓, TumCCA↑, ERK↓, p‑FAK↓, p‑pax↓, TumCMig↓, EMT↓, SIRT1↓, Dose∅, ROS↑, MMP↓, Bcl-2↓, Bak↑, cl‑PARP↑, Casp3↑, SIRT1↓, ac‑P53↑, BIM↑, p‑RB1↓, cycD1↓, Dose∅, β-catenin/ZEB1↓, N-cadherin↓, E-cadherin↑,

1518-

CAP,

Capsaicin-mediated tNOX (ENOX2) up-regulation enhances cell proliferation and migration in vitro and in vivo

-

in-vitro,

CRC,

HCT116

ENOX2↑, TumCP↑, TumCMig↑, Dose?, eff↑,

2652-

CAP,

Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence

-

Review,

Var,

NA

chemoP↑, AntiCan↑, ROS↑, TumCG↓, ROS↑, MMP↑, Apoptosis↑, TumCCA↑, JNK↑, SOD↓, Catalase↓, GPx↓, other↓, SIRT1↓, NADPH↑, FOXO3↑,

2394-

CAP,

Capsaicin acts as a novel NRF2 agonist to suppress ethanol induced gastric mucosa oxidative damage by directly disrupting the KEAP1-NRF2 interaction

-

in-vitro,

Nor,

GES-1

(0, 2, and 8 μM)

*mtDam↓, *NRF2↑, *HO-1↑, *Trx↑, *GSS↑, *NQO1↑, *Keap1↓, *ROS↓, *PKM2↓, *LDHA↓, *Inflam↓,

2347-

CAP,

Capsaicin ameliorates inflammation in a TRPV1-independent mechanism by inhibiting PKM2-LDHA-mediated Warburg effect in sepsis

-

in-vivo,

Nor,

NA

-

in-vitro,

Nor,

RAW264.7

*PKM2↓, *LDHA↓, *Warburg↓, *COX2↓, *Sepsis↓, *Inflam↓, *ECAR↓, *OCR↑,

2348-

CAP,

Recent advances in analysis of capsaicin and its effects on metabolic pathways by mass spectrometry

-

Analysis,

Nor,

NA

Warburg↓, *PKM2↓, *COX2↓, *Inflam↓, *Sepsis↓, *AMPK↑, *PKA↑, *mitResp↑, *FAO↑, *FASN↓, *PGM1?, *ATP↑, *ROS↓,

2349-

CAP,

The TRPV1-PKM2-SREBP1 axis maintains microglial lipid homeostasis in Alzheimer’s disease

-

in-vivo,

AD,

NA

mouse brain

*TRPV1↑, *PKM2↓, *SREBP2↑, *memory↑,

1104-

CAR,

Carvacrol Ameliorates Transforming Growth Factor-β1-Induced Extracellular Matrix Deposition and Reduces Epithelial-Mesenchymal Transition by Regulating The Phosphatidylinositol 3-Kinase/Protein Kinase B Pathway In Hk-2 Cells

-

in-vitro,

Kidney,

HK-2

tumCV↓, COL4↓, COL1↓, Fibronectin↓, E-cadherin↑, Snail↑, Vim↑, α-SMA↑, PI3K↓, Akt↓,

1082-

CAR,

Carvacrol, a component of thyme oil, activates PPARα and γ and suppresses COX-2 expression

-

in-vitro,

lymphoma,

U937

200-400uM carvacrol

COX2↓, PPARα↑, PPARγ↑,

1287-

CAR,

Carvacrol induces apoptosis in human breast cancer cells via Bcl-2/CytC signaling pathway

-

in-vitro,

BC,

HCC1937

320mM

TumCP↓, TumCCA↑, Apoptosis↑, BAX↑, Cyt‑c↑, Casp3↑, Bcl-2↓,

939-

Catechins,

5-FU,

Targeting Lactate Dehydrogenase A with Catechin Resensitizes SNU620/5FU Gastric Cancer Cells to 5-Fluorouracil

-

vitro+vivo,

GC,

SNU620

lactateProd↓, ROS↑, tumCV↓, LDHA↓, mt-ROS↑, proApCas↑,

603-

Catechins,

Catechins induce oxidative damage to cellular and isolated DNA through the generation of reactive oxygen species

-

in-vitro,

NA,

HL-60

ROS↑, DNAdam↑, H2O2↑,

18-

CBC/D,

Cynanbungeigenin C and D, a pair of novel epimers from Cynanchum bungei, suppress hedgehog pathway-dependent medulloblastoma by blocking signaling at the level of Gli

-

vitro+vivo,

MB,

NA

HH↓, Gli1↓,

17-

CBC/D,

CBC-1 as a Cynanbungeigenin C derivative inhibits the growth of colorectal cancer through targeting Hedgehog pathway component GLI 1

-

in-vivo,

CRC,

NA

HH↓, Gli1↓,

1199-

CBD,

Cannabidiol improves muscular lipid profile by affecting the expression of fatty acid transporters and inhibiting de novo lipogenesis

-

in-vivo,

Obesity,

NA

10 mg/kg of body mass for 14 days)

rat

lipoGen↓,

1103-

CBD,

Cannabidiol inhibits invasion and metastasis in colorectal cancer cells by reversing epithelial-mesenchymal transition through the Wnt/β-catenin signaling pathway

-

vitro+vivo,

NA,

NA

Apoptosis↑, TumCP↓, TumCMig↓, TumMeta↓, EMT↓, E-cadherin↑, N-cadherin↓, Snail↓, Vim↓, Hif1a↓, Wnt/(β-catenin)↓, AXIN1↑, TumVol↓, TumW↓,

1081-

CBDA,

Down-regulation of cyclooxygenase-2 (COX-2) by cannabidiolic acid in human breast cancer cells

-

in-vitro,

BC,

MDA-MB-231

25uM 48hr

COX2↓, Id1↓, SHARP↑,

1054-

CEL,

Celecoxib inhibited activation of NF-κB and expression of NF-κB P65 protein in HepG2 cells

-

in-vitro,

Liver,

HepG2

25 and 50 μmol/L

NF-kB↓, p65↓,

955-

CEL,

Celecoxib Down-Regulates the Hypoxia-Induced Expression of HIF-1α and VEGF Through the PI3K/AKT Pathway in Retinal Pigment Epithelial Cells

-

in-vitro,

RPE,

D407

TumCP↓, VEGF↓, Hif1a↓,

1105-

CEL,

Celecoxib inhibits the epithelial-to-mesenchymal transition in bladder cancer via the miRNA-145/TGFBR2/Smad3 axis

-

in-vitro,

BC,

NA

COX2↓, TumCP↓, TumCMig↓, TumCI↓, EMT↓, miR-145↑, TGF-β↓, SMAD3↓,

2392-

Cela,

The role of natural products targeting macrophage polarization in sepsis-induced lung injury

-

Review,

Sepsis,

NA

TNF-α↓, IL1β↓, IL6↓, Warburg↓, PKM2↓, NRF2↑, HO-1↑, NF-kB↓, iNOS↓, M1↓,

2393-

Cela,

Celastrol mitigates inflammation in sepsis by inhibiting the PKM2-dependent Warburg effect

-

in-vivo,

Sepsis,

NA

mice

-

in-vitro,

Nor,

RAW264.7

OS↑, PKM2↓, Glycolysis↓, Warburg↓, Inflam↓, HMGB1↓, ALAT↓, AST↓, TNF-α↓, IL1β↓, IL6↓,

2653-

Cela,

Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence

-

Review,

Var,

NA

chemoP↑, Catalase↑, ROS↑, HSP90↓, Sp1/3/4↓, AMPK↑, P53↑, JNK↑, ER Stress↑, MMP↓, TumCCA↑, TumAuto↑, Hif1a↑, Akt↑, other↓, Prx↓,

2398-

CGA,

Polyphenol-rich diet mediates interplay between macrophage-neutrophil and gut microbiota to alleviate intestinal inflammation

-

in-vivo,

Col,

NA

Mice with or without depletion of macrophages were administered with four individual phenolic acids including chlorogenic, ferulic, caffeic, and ellagic acids,

PKM2↓, Glycolysis↓, NLRP3↓, Inflam↓, HK2↓, PDK1↓, LDHA↓, GLUT1↓, ECAR↓,

1106-

CGA,

Chlorogenic Acid Inhibits Epithelial-Mesenchymal Transition and Invasion of Breast Cancer by Down-Regulating LRP6

-

vitro+vivo,

BC,

MCF-7

E-cadherin↑, ZO-1↑, Zeb1↓, N-cadherin↓, Vim↓, Snail↓, Slug↓, MMP2↓, MMP9↓, TumCMig↓, TumCI↓, LRP6↓, p‑LRP6↓, β-catenin/ZEB1↓, TumVol↓, TumW↓,

954-

CGA,

Chlorogenic acid inhibits hypoxia-induced angiogenesis via down-regulation of the HIF-1α/AKT pathway

-

in-vitro,

Lung,

A549

-

in-vitro,

Nor,

HUVECs

under hypoxic conditions

Hif1a↓, VEGF↓, angioG↓, Akt↓,

1083-

CGA,

In Silico Insight the Prediction of Chlorogenic Acid in Coffee through Cyclooxygenase-2 (COX2) Interaction

-

Analysis,

NA,

NA

COX2↓,

1298-

CGA,

Chlorogenic acid regulates apoptosis and stem cell marker-related gene expression in A549 human lung cancer cells

-

in-vitro,

Lung,

A549

Bcl-2↓, BAX↑, Casp3↑, p38↑, JNK↑, Nanog↓, SOX2↓, OCT4↓,

1244-

CGA,

immuno,

Cancer Differentiation Inducer Chlorogenic Acid Suppresses PD-L1 Expression and Boosts Antitumor Immunity of PD-1 Antibody

-

in-vivo,

NA,

NA

murine tumor xenografts

PD-L1↓, T-Cell↑, eff↑,

2175-

Chemo,

VitB12,

FA,

Systemic Chemotherapy Interferes in Homocysteine Metabolism in Breast Cancer Patients

-

Study,

BC,

NA

other↓, other↝, homoC↓, eff↝, other↝,

428-

Chit,

docx,

CUR,

Chitosan-based nanoparticle co-delivery of docetaxel and curcumin ameliorates anti-tumor chemoimmunotherapy in lung cancer

-

vitro+vivo,

Lung,

H460

4, 8, 12, 16, 20, 24 and 28 μg/mL, 24 h; 5 mg/kg, 24 h

-

vitro+vivo,

Lung,

H1299

-

vitro+vivo,

Lung,

A549

-

vitro+vivo,

Lung,

PC9

MDSCs↓, TregCell↓, IL10↓, NK cell↑,

953-

CHr,

Inhibition of Hypoxia-Inducible Factor-1α and Vascular Endothelial Growth Factor by Chrysin in a Rat Model of Choroidal Neovascularization

-

in-vivo,

NA,

NA

single intravitreal injection of chrysin solution (5 µL, 60 mM in 0.5% DMSO and balanced salt solution)

Brown Norway rats

Hif1a↓, VEGF↓,

1033-

CHr,

Chrysin inhibits hepatocellular carcinoma progression through suppressing programmed death ligand 1 expression

-

vitro+vivo,

HCC,

NA

H22 xenograft mouse model

TumCG↓, CD4+↑, CD8+↑, PD-L1↓,

1107-

CHr,

Chrysin inhibits metastatic potential of human triple-negative breast cancer cells by modulating matrix metalloproteinase-10, epithelial to mesenchymal transition, and PI3K/Akt signaling pathway

-

in-vitro,

BC,

NA

(5, 10 and 20 μM

TumCP↓, Apoptosis↑, MMP-10↓, E-cadherin↑, Vim↓, Snail↓, Slug↓, EMT↓,

1145-

CHr,

Chrysin inhibits propagation of HeLa cells by attenuating cell survival and inducing apoptotic pathways

-

in-vitro,

Cerv,

HeLa

tumCV↓, BAX↑, BID↑, BOK↑, APAF1↑, TNF-α↑, FasL↑, Fas↑, FADD↑, Casp3↑, Casp7↑, Casp8↑, Casp9↑, Mcl-1↓, NAIP↓, Bcl-2↓, CDK4↓, CycB↓, cycD1↓, cycE1↓, TRAIL↑, p‑Akt↓, Akt↓, mTOR↓, PDK1↓, BAD↓, GSK‐3β↑, AMPK↑, p27↑, P53↑,

1144-

CHr,

8-bromo-7-methoxychrysin-induced apoptosis of hepatocellular carcinoma cells involves ROS and JNK

-

in-vitro,

HCC,

HepG2

10 μmol/L

-

in-vitro,

HCC,

Bel-7402

-

in-vitro,

Nor,

HL7702

BrMC had little effect on human embryo liver L-02 cells ****

Casp3↑, *ROS∅, ROS↑, JNK↑, *toxicity↓,

1143-

CHr,

Chrysin inhibited tumor glycolysis and induced apoptosis in hepatocellular carcinoma by targeting hexokinase-2

-

in-vitro,

HCC,

HepG2

0-60uM

-

in-vivo,

NA,

NA

mouse

-

in-vitro,

HCC,

HepG3

-

in-vitro,

HCC,

HUH7

HK2↓, GlucoseCon↓, lactateProd↓, Glycolysis↓, Apoptosis↑,

2794-

CHr,

An updated review on the versatile role of chrysin in neurological diseases: Chemistry, pharmacology, and drug delivery approaches

-

Review,

Park,

NA

-

Review,

Stroke,

NA

*neuroP↑, *ROS↓, *Inflam↓, *Apoptosis↓, *IL1β↓, *TNF-α↓, *COX2↓, *iNOS↓, *NF-kB↓, *JNK↓, *HDAC↓, *GSK‐3β↓, *IFN-γ↓, *IL17↓, *GSH↑, *NRF2↑, *HO-1↑, *SOD↑, *MDA↓, *NO↓, *GPx↑, *TBARS↓, *AChE↓, *GR↑, *Catalase↑, *VitC↑, *memory↑, *lipid-P↓, *ROS↓,

2795-

CHr,

Combination of chrysin and cisplatin promotes the apoptosis of Hep G2 cells by up-regulating p53

-

in-vitro,

Liver,

HepG2

ChemoSen↑, P53↑, ERK↑, BAX↑, DR5↑, Bcl-2↓, Casp8↑, Cyt‑c↑, Casp9↑,

2796-

CHr,

Chemopreventive effect of chrysin, a dietary flavone against benzo(a)pyrene induced lung carcinogenesis in Swiss albino mice

-

in-vivo,

Lung,

NA

(250mg/kg

Swiss albino mice

PCNA↓, COX2↓, NF-kB↓, chemoP↑, *SOD↑, *Catalase↓, *GR↓, *GPx↓, *lipid-P↓, *COX2↓, *NF-kB↓, *ROS↓,

2797-

CHr,

A flavonoid chrysin suppresses hypoxic survival and metastatic growth of mouse breast cancer cells

-

in-vivo,

BC,

NA

40-100 uM

metastasis mouse model of breast cancer

-

in-vitro,

BC,

4T1

100 and 250 mg/kg daily

tumCV↓, p‑STAT3↓, VEGF↓, Weight∅, angioG↓,

2798-

CHr,

Chrysin: a histone deacetylase 8 inhibitor with anticancer activity and a suitable candidate for the standardization of Chinese propolis

-

in-vitro,

BC,

MDA-MB-231

-

in-vivo,

NA,

NA

90 mg/kg/day

xenograft animal model

HDAC↓, HDAC8↓, TumCG↓, Diff↑,

2799-

CHr,

Chrysin suppresses renal carcinogenesis via amelioration of hyperproliferation, oxidative stress and inflammation: plausible role of NF-κB

-

in-vivo,

RCC,

NA

20 and 40 mg/kg body weight

Rat

*chemoP↑, *ROS↓, *Inflam↓,

2800-

CHr,

Chrysin Activates Notch1 Signaling and Suppresses Tumor Growth of Anaplastic Thyroid Carcinoma In vitro and In vivo

-

in-vitro,

Thyroid,

NA

TumCG↓, NOTCH↑, cl‑PARP↑, Apoptosis↑,

2801-

CHr,

AMP-activated protein kinase (AMPK) activation is involved in chrysin-induced growth inhibition and apoptosis in cultured A549 lung cancer cells

-

in-vitro,

Lung,

A549

AMPK↑, Akt↓, ChemoSen↑, ROS↑,

2802-

CHr,

Chrysin inhibits expression of hypoxia-inducible factor-1alpha through reducing hypoxia-inducible factor-1alpha stability and inhibiting its protein synthesis

-

in-vitro,

Pca,

DU145

-

in-vivo,

Pca,

NA

nude mice

Hif1a↓, VEGF↓, angioG↓,

2803-

CHr,

5-FU,

Potentiating activities of chrysin in the therapeutic efficacy of 5-fluorouracil in gastric cancer cells

-

in-vitro,

GC,

AGS

chrysin doses of 40, 50, 60 and 80 µM, and 5-FU doses of 20, 25, 30 and 40 µM,

ChemoSen↑, TumCCA↑, eff↑, MDR1↓,

2804-

CHr,

Rad,

Gamma-Irradiated Chrysin Improves Anticancer Activity in HT-29 Colon Cancer Cells Through Mitochondria-Related Pathway

-

in-vitro,

CRC,

HT29

RadioS↑, ROS↑, MMP↓, Casp3↑, Casp9↑, cl‑PARP↑,

2781-

CHr,

PBG,

Chrysin a promising anticancer agent: recent perspectives

-

Review,

Var,

NA

PI3K↓, Akt↓, mTOR↓, MMP9↑, uPA↓, VEGF↓, AR↓, Casp↑, TumMeta↓, TumCCA↑, angioG↓, BioAv↓, *hepatoP↑, *neuroP↑, *SOD↑, *GPx↑, *ROS↓, *Inflam↓, *Catalase↑, *MDA↓, ROS↓, BBB↑, Half-Life↓, BioAv↑, ROS↑, eff↑, ROS↑, ROS↑, lipid-P↑, ER Stress↑, NOTCH1↑, NRF2↓, p‑FAK↓, Rho↓, PCNA↓, COX2↓, NF-kB↓, PDK1↓, PDK3↑, GLUT1↓, Glycolysis↓, mt-ATP↓, Ki-67↓, cMyc↓, ROCK1↓, TOP1↓, TNF-α↓, IL1β↓, CycB↓, CDK2↓, EMT↓, STAT3↓, PD-L1↓, IL2↑,

2805-

CHr,

Chrysin serves as a novel inhibitor of DGKα/FAK interaction to suppress the malignancy of esophageal squamous cell carcinoma (ESCC)

-

in-vitro,

ESCC,

KYSE150

-

in-vivo,

ESCC,

NA

FAK↓, GlucoseCon↓, Casp3↑, Casp7↑, p‑Akt↓, TumCG↓, Weight∅,

2807-

CHr,

Evidence-based mechanistic role of chrysin towards protection of cardiac hypertrophy and fibrosis in rats

-

in-vivo,

Nor,

NA

Wistar rats

*antiOx↑, Inflam↓, *cardioP↑, *GSH↑, *SOD↑, *Catalase↑, *GAPDH↑, *BAX↓, *Bcl-2↑, *PARP↓, *Cyt‑c↓, *Casp3↓, *NOX4↓, *NRF2↑, *HO-1↑, *HSP70/HSPA5↑,

2806-

CHr,

Se,

Selenium-containing chrysin and quercetin derivatives: attractive scaffolds for cancer therapy

-

in-vitro,

Var,

NA

eff↑, selectivity↑, Dose↝, TrxR↓, GSH↓, MMP↓, ROS↑, H2O2↑,

2792-

CHr,

Chrysin induces death of prostate cancer cells by inducing ROS and ER stress

-

in-vitro,

Pca,

DU145

0, 5, 10, 20, 50 and 100 μM

-

in-vitro,

Pca,

PC3

DNAdam↑, TumCCA↑, MMP↓, ROS↑, lipid-P↑, ER Stress↑, UPR↑, PERK↑, eIF2α↑, GRP78/BiP↑, PI3K↓, Akt↓, p70S6↓, MAPK↑,

2793-

CHr,

Chrysin Inhibits TAMs-Mediated Autophagy Activation via CDK1/ULK1 Pathway and Reverses TAMs-Mediated Growth-Promoting Effects in Non-Small Cell Lung Cancer

-

in-vitro,

Lung,

A549

17.59 μM, 7.29 μM, and 4.11 μM at 24 h, 48 h, and 72 h,

-

in-vitro,

Lung,

H157

20.65 μM, 7.83 μM, and 3.70 μM

-

in-vivo,

NA,

NA

mice

TumCG↓, M2 MC↑, CDK1↓,

2780-

CHr,

Anti-cancer Activity of Chrysin in Cancer Therapy: a Systematic Review

-

Review,

Var,

NA

*antiOx↑, Inflam↓, *hepatoP↑, AntiCan↑, Cyt‑c↑, Casp3↑, XIAP↓, p‑Akt↓, PI3K↑, Apoptosis↑, COX2↓, FAK↓, AMPK↑, STAT3↑, MMP↓, DNAdam↑, BAX↑, Bak↑, Casp9↑, p38↑, MAPK↑, TumCCA↑, ChemoSen↑, HDAC8↓, Wnt↓, NF-kB↓, angioG↓, BioAv↓,

2782-

CHr,

Broad-Spectrum Preclinical Antitumor Activity of Chrysin: Current Trends and Future Perspectives

-

Review,

Var,

NA

-

Review,

Stroke,

NA

-

Review,

Park,

NA

*antiOx↑, *Inflam↓, *hepatoP↑, *neuroP↑, *BioAv↓, *cardioP↑, *lipidLev↓, *RenoP↑, *TNF-α↓, *IL2↓, *PI3K↓, *Akt↓, *ROS↓, *cognitive↑, eff↑, cycD1↓, hTERT↓, VEGF↓, p‑STAT3↓, TumMeta↓, TumCP↓, eff↑, eff↑, IL1β↓, IL6↓, NF-kB↓, ROS↑, MMP↓, Cyt‑c↑, Apoptosis↑, ER Stress↑, Ca+2↑, TET1↑, Let-7↑, Twist↓, EMT↓, TumCCA↑, Casp3↑, Casp9↑, BAX↑, HK2↓, GlucoseCon↓, lactateProd↓, Glycolysis↓, SHP1↑, N-cadherin↓, E-cadherin↑, UPR↑, PERK↑, ATF4↑, eIF2α↑, RadioS↑, NOTCH1↑, NRF2↓, BioAv↑, eff↑,

2783-

CHr,

Apoptotic Effects of Chrysin in Human Cancer Cell Lines

-

Review,

Var,

NA

TumCP↓, Apoptosis↑, Casp↑, PCNA↓, p38↑, NF-kB↑, DNAdam↑, XIAP↓, Cyt‑c↑, Casp3↑, Akt↓, SCF↓, hTERT↓, COX2↓, *Inflam↓, *antiOx↑, *chemoP↑, AR-V7?, CYP19?,

2784-

CHr,

Chrysin targets aberrant molecular signatures and pathways in carcinogenesis (Review)

-

Review,

Var,

NA

Apoptosis↑, TumCMig↓, *toxicity↝, ChemoSen↑, *BioAv↓, Dose↝, neuroP↑, *P450↓, *ROS↓, *HDL↑, *GSTs↑, *SOD↑, *Catalase↑, *MAPK↓, *NF-kB↓, *PTEN↑, *VEGF↑, ROS↑, MMP↓, Ca+2↑, selectivity↑, PCNA↓, Twist↓, EMT↓, CDKN1C↑, p‑STAT3↑, MMP2↓, MMP9↓, eff↑, cycD1↓, hTERT↓, CLDN1↓, TumVol↓, OS↑, COX2↓, eff↑, CDK2↓, CDK4↓, selectivity↑, TumCCA↑, E-cadherin↑, HK2↓, HDAC↓,

2785-

CHr,

Emerging cellular and molecular mechanisms underlying anticancer indications of chrysin

-

Review,

Var,

NA

*NF-kB↓, *COX2↓, *iNOS↓, angioG↓, TOP1↓, HDAC↓, TNF-α↓, IL1β↓, cardioP↑, RenoP↑, neuroP↑, LDL↓, BioAv↑, eff↑, cycD1↓, hTERT↓, MMP-10↓, Akt↓, STAT3↓, VEGF↓, EGFR↓, Snail↓, Slug↓, Vim↓, E-cadherin↑, eff↑, TET1↑, ROS↑, mTOR↓, PPARα↓, ER Stress↑, Ca+2↑, ERK↓, MMP↑, Cyt‑c↑, Casp3↑, HK2↓, NRF2↓, HO-1↓, MMP2↓, MMP9↓, Fibronectin↓, GRP78/BiP↑, XBP-1↓, p‑eIF2α↑, *AST↓, ALAT↓, ALP↓, LDH↓, COX2↑, Bcl-xL↓, IL6↓, PGE2↓, iNOS↓, DNAdam↑, UPR↑, Hif1a↓, EMT↓, Twist↓, lipid-P↑, CLDN1↓, PDK1↓, IL10↓, TLR4↓, NOTCH1↑, PARP↑, Mcl-1↓, XIAP↓,

2786-

CHr,

Chemopreventive and therapeutic potential of chrysin in cancer: mechanistic perspectives

-

Review,

Var,

NA

Apoptosis↑, TumCCA↑, angioG↓, TumCI↓, TumMeta↑, *toxicity↓, selectivity↑, chemoP↑, *GSTs↑, *NADPH↑, *GSH↑, HDAC8↓, Hif1a↓, *ROS↓, *NF-kB↓, SCF↓, cl‑PARP↑, survivin↓, XIAP↓, Casp3↑, Casp9↑, GSH↓, ChemoSen↑, Fenton↑, P21↑, P53↑, cycD1↓, CDK2↓, STAT3↓, VEGF↓, Akt↓, NRF2↓,

2787-

CHr,

Network pharmacology unveils the intricate molecular landscape of Chrysin in breast cancer therapeutics

-

Analysis,

Var,

MCF-7

22.55 µM

TumCP↓, angioG↓, TumCI↓, TumMeta↓, TP53↑, Akt↓, Casp3↑, tumCV↓, TNF-α↓, BioAv↑, BioAv↑, AKT1↓,

2788-

CHr,

Chrysin: Sources, beneficial pharmacological activities, and molecular mechanism of action

-

Review,

Var,

NA

*neuroP↑, *Inflam↓, *ROS↓, NF-kB↓, *PCNA↓, *COX2↓, ChemoSen↑, Hif1a↓, angioG↓, *chemoP↑, PDGF↓, *memory↑, *RenoP↑, *PPARα↑, *lipidLev↓, *hepatoP↑, *cardioP⇅, *BioAv↓,

2789-

CHr,

Anticancer Activity of Ether Derivatives of Chrysin

-

Review,

Var,

NA

eff↑, COX2↓, PGE2↓, eff↑,

2790-

CHr,

Chrysin: Pharmacological and therapeutic properties

-

Review,

Var,

NA

*hepatoP↑, *neuroP↓, *ROS↓, *cardioP↑, *Inflam↓, eff↑, hTERT↓, cycD1↓, MMP9↓, MMP2↓, TIMP1↑, TIMP2↑, BioAv↑, HK2↓, ROS↑, MMP↓, Casp3↑, ADP:ATP↑, Apoptosis↑, ER Stress↑, UPR↑, GRP78/BiP↝, eff↑, Ca+2↑,

2791-

CHr,

Chrysin attenuates progression of ovarian cancer cells by regulating signaling cascades and mitochondrial dysfunction

-

in-vitro,

Ovarian,

OV90

TumCP↓, TumCD↑, ROS↑, Ca+2↑, MMP↓, MAPK↑, PI3K↑, p‑Akt↑, PCNA↓, p‑p70S6↑, p‑ERK↑, p38↑, JNK↑, DNAdam↑, TumCCA↑, chemoP↑,

3258-

CHr,

PBG,

Chrysin Induced Cell Apoptosis and Inhibited Invasion Through Regulation of TET1 Expression in Gastric Cancer Cells

-

in-vitro,

GC,

MKN45

40 μM

TET1↑, Apoptosis↑, TumCI↓, TumCMig↓,

2591-

CHr,

doxoR,

Chrysin enhances sensitivity of BEL-7402/ADM cells to doxorubicin by suppressing PI3K/Akt/Nrf2 and ERK/Nrf2 pathway

-

in-vitro,

HCC,

Bel-7402

NRF2↓, ChemoSen↑, HO-1↓,

2590-

CHr,

Chrysin suppresses proliferation, migration, and invasion in glioblastoma cell lines via mediating the ERK/Nrf2 signaling pathway

-

in-vitro,

GBM,

T98G

-

in-vitro,

GBM,

U251

-

in-vitro,

GBM,

U87MG

TumCP↓, TumCMig↓, TumCI↓, NRF2↓, HO-1↓, NADPH↓, ERK↓,

1249-

CHr,

Chrysin as an Anti-Cancer Agent Exerts Selective Toxicity by Directly Inhibiting Mitochondrial Complex II and V in CLL B-lymphocytes

-

in-vitro,

CLL,

NA

ROS↑, MMP↓, ADP:ATP↑, Casp3↑, Apoptosis↑,

1274-

Cin,

Cinnamon bark extract suppresses metastatic dissemination of cancer cells through inhibition of glycolytic metabolism

-

vitro+vivo,

BC,

MDA-MB-231

TumCI↓, G6PD↓, HK2↓, Glycolysis↓,

1567-

Cin,

Cinnamon: Mystic powers of a minute ingredient

-

Review,

Var,

NA

other∅, cognitive↑, antiOx↑, lipid-P↓, Apoptosis↑, NF-kB↓,

1568-

Cin,

Can Cinnamon be the Silver Bullet for Cancer?

-

Review,

NA,

NA

VEGF↓, Hif1a↓,

952-

Cin,

Cinnamon Extract Reduces VEGF Expression Via Suppressing HIF-1α Gene Expression and Inhibits Tumor Growth in Mice

-

in-vitro,

BC,

MDA-MB-231

0-30um/ml

mice

-

in-vitro,

GBM,

U251

-

in-vivo,

Ovarian,

SKOV3

inoculated in mice

VEGF↓, Hif1a↓, p‑STAT3↓, p‑Akt↓, angioG↓, TumCG↓, TumW↓, ascitic↓,

1055-

Cin,

Cinnamon extract induces tumor cell death through inhibition of NFκB and AP1

-

vitro+vivo,

Melanoma,

NA

mouse

-

vitro+vivo,

CRC,

NA

-

vitro+vivo,

lymphoma,

NA

TumCP↓, NF-kB↓, AP-1↓, Bcl-2↓, Bcl-xL↓, survivin↓,

1588-

Citrate,

ATP citrate lyase (ACLY) inhibitors: An anti-cancer strategy at the crossroads of glucose and lipid metabolism

-

Review,

NA,

NA

ACLY↓,

1576-

Citrate,

Targeting citrate as a novel therapeutic strategy in cancer treatment

-

Review,

Var,

NA

TCA↓, T-Cell↝, Glycolysis↓, PKM2↓, PFK2?, SDH↓, PDH↓, β-oxidation↓, CPT1A↓, FASN↑, Casp3↑, Casp2↑, Casp8↑, Casp9↑, cl‑PARP↑, Hif1a↓, GLUT1↓, angioG↓, Ca+2↓, ROS↓, eff↓, Dose↓, eff↑, Mcl-1↓, HK2↓, IGF-1R↓, PTEN↑, citrate↓, Dose∅, eff↑, eff↑, eff↑, eff↑,

1587-

Citrate,

ATP citrate lyase: A central metabolic enzyme in cancer

-

Review,

NA,

NA

ACLY↓, other↓, PFK1↓, ATP↓, PFK2↓, Mcl-1↓, Casp3↑, Casp2↑, Casp9↑, IGF-1R↓, PI3K↓, Akt↓, p‑Akt↓, p‑ERK↓, PTEN↑, Snail↓, E-cadherin↑, ChemoSen↑,

1574-

Citrate,

Citrate Suppresses Tumor Growth in Multiple Models through Inhibition of Glycolysis, the Tricarboxylic Acid Cycle and the IGF-1R Pathway

-

in-vitro,

Lung,

A549

5,10,15mM

-

in-vitro,

Melanoma,

WM983B

-

in-vivo,

NA,

NA

4 g/kg citrate twice a day for 4 week

mice. Plasma levels in chronically treated animals were approximately 3 mM

TumCG↓, eff↑, T-Cell↑, p‑IGF-1R↓, p‑Akt↓, PTEN↑, p‑eIF2α↑, OCR↓, ROS↓, ECAR∅, IL1↑, TNF-α↑, IL10↑, IGF-1R↓, eIF2α↑, PTEN↑, TCA↓, Glycolysis↓, selectivity↑, *toxicity∅, Dose∅,

1586-

Citrate,

Extracellular Citrate Is a Trojan Horse for Cancer Cells

-

in-vitro,

Liver,

HepG2

<5mM(low), vs >10,25mM(high)

17mM

Dose?, ac‑H4↓, lipidDe↓, ACLY↓, selectivity↑, *ACLY∅, Glycolysis↓, NADH↓, OAA↑, other↑,

1577-

Citrate,

Citric acid promotes SPARC release in pancreatic cancer cells and inhibits the progression of pancreatic tumors in mice on a high-fat diet

-

in-vivo,

PC,

NA

30 mg·kg ·day citrate(injection)

mice

-

in-vitro,

PC,

PANC1

10 mmol·L citrate

-

in-vitro,

PC,

PATU-8988

-

in-vitro,

PC,

MIA PaCa-2

Apoptosis↑, TumCP↓, TumCG↑, SPARC↑, Glycolysis↓, OCR↓, pol-M1↑, pol-M2 MC↓, Weight∅, ATP↓, ECAR↓, mitResp↓, i-ATP↑, p65↓, i-Ca+2↑, eff↓,

1578-

Citrate,

Understanding the Central Role of Citrate in the Metabolism of Cancer Cells and Tumors: An Update

-

Review,

Var,

NA

10–20 mM

TCA↑, FASN↑, Glycolysis↓, glucoNG↑, PFK1↓, PFK2↓, FBPase↑, TumCP↓, eff↑, ACLY↓, Dose↑, Casp3↑, Casp2↑, Casp8↑, Casp9↑, Bcl-xL↓, Mcl-1↓, IGF-1R↓, PI3K↓, Akt↓, mTOR↓, PTEN↑, ChemoSen↑, Dose?,

1579-

Citrate,

Effect of Food Additive Citric Acid on The Growth of Human Esophageal Carcinoma Cell Line EC109

-

in-vitro,

ESCC,

Eca109

TumCP↓, e-LDH↑, MMP↓, Ca+2?, PFK↓, Glycolysis↓,

1580-

Citrate,

Citrate activates autophagic death of prostate cancer cells via downregulation CaMKII/AKT/mTOR pathway

-

in-vitro,

Pca,

PC3

(0-3 mM)

-

in-vivo,

PC,

NA

50 mg/kg/day, i.p.)

-

in-vitro,

Pca,

LNCaP

-

in-vitro,

Pca,

WPMY-1

(0-3 mM)

Apoptosis↑, Ca+2↓, Akt↓, mTOR↓, selectivity↑, TumCP↓, cl‑Casp3↑, cl‑PARP↑, LC3‑Ⅱ/LC3‑Ⅰ↑, p62↓, ATG5↑, ATG7↑, Beclin-1↑, TumAuto↑, CaMKII ↓,

1581-

Citrate,

Hypothesis proved. . .citric acid (citrate) does improve cancer:A case of a patient suffering from medullary thyroid cancer

-

Case Report,

Thyroid,

NA

OS↑, Weight↑, Dose∅, eff↑,

1582-

Citrate,

Clinical report: A patient with primary peritoneal mesothelioma that has improved after taking citric acid orally

-

Case Report,

PerC,

NA

Dose∅, Weight↑, OS↑,

1583-

Citrate,

Extracellular citrate and metabolic adaptations of cancer cells

-

Review,

NA,

NA

Warburg↓, OXPHOS↓, Dose∅, TumCP↓, ATP↓, eff↑, Apoptosis↑, TumCG↓, PFK1↓, NA↓,

1584-

Citrate,

Anticancer effects of high-dose extracellular citrate treatment in pancreatic cancer cells under different glucose concentrations

-

in-vitro,

PC,

MIA PaCa-2

-

in-vitro,

PC,

PANC1

tumCV↓, i-Ca+2↓, TumCMig↓, CD133↓, pH↑, eff↑, Ki-67↓, eff↑,

1585-

Citrate,

Sodium citrate targeting Ca2+/CAMKK2 pathway exhibits anti-tumor activity through inducing apoptosis and ferroptosis in ovarian cancer

-

in-vitro,

Ovarian,

SKOV3

15.93 mM

-

in-vitro,

Ovarian,

A2780S

16.8 mM

-

in-vitro,

Nor,

HEK293

Apoptosis↑, Ferroptosis↑, Ca+2↓, CaMKII ↓, Akt↓, mTOR↓, Hif1a↓, ROS↑, ChemoSen↑, Casp3↑, Casp9↑, BAX↑, Bcl-2↓, Cyt‑c↑, GlucoseCon↓, lactateProd↓, Pyruv↓, GLUT1↓, HK2↓, PFKP↓, Glycolysis↓, Hif1a↓, p‑Akt↓, p‑mTOR↓, Iron↑, lipid-P↑, MDA↑, ROS↑, H2O2↑, mtDam↑, GSH↓, GPx↓, GPx4↓, NADPH/NADP+↓, eff↓, FTH1↓, LC3‑Ⅱ/LC3‑Ⅰ↑, NCOA4↑, eff↓, TumCG↓,

1591-

Citrate,

The biological significance of cancer: mitochondria as a cause of cancer and the inhibition of glycolysis with citrate as a cancer treatment

-

Analysis,

NA,

NA

Glycolysis↓, PDK1↓, SDH↓,

1592-

Citrate,

Inhibition of Mcl-1 expression by citrate enhances the effect of Bcl-xL inhibitors on human ovarian carcinoma cells

-

in-vitro,

Ovarian,

SKOV3

5mM,10mM

-

in-vitro,

Ovarian,

IGROV1

eff↑, tumCV↓, Mcl-1↓, eff↑,

1593-

Citrate,

Citrate Induces Apoptotic Cell Death: A Promising Way to Treat Gastric Carcinoma?

-

in-vitro,

GC,

BGC-823

10mM

-

in-vitro,

GC,

SGC-7901

PFK↓, Glycolysis↓, tumCV↓, cl‑Casp3↑, cl‑PARP↑, Apoptosis↑, ATP↓, ChemoSen↑, Mcl-1↓, glucoNG↑, FBPase↑, OXPHOS↓, TCA↓, β-oxidation↓, HK2↓, PDH↓, ROS↑,

2315-

Citrate,

Why and how citrate may sensitize malignant tumors to immunotherapy

-

Review,

Var,

NA

Bcl-2↓, Mcl-1↓, survivin↓, Casp3↑, Casp9↑, Ferroptosis↑, lipid-P↑, Ca+2↓, Akt↓, mTOR↓, Hif1a↓, MCU↓, ATP↓, ROS↑, eff↑,

16-

CP,

Resveratrol inhibits the hedgehog signaling pathway and epithelial-mesenchymal transition and suppresses gastric cancer invasion and metastasis

-

in-vitro,

GC,

SGC-7901

HH↓, Gli1↓, EMT↓, N-cadherin↓, E-cadherin↑, Snail↓,

945-

Croc,

Characterization of the Saffron Derivative Crocetin as an Inhibitor of Human Lactate Dehydrogenase 5 in the Antiglycolytic Approach against Cancer

-

in-vitro,

Lung,

A549

114uM

-

in-vitro,

Cerv,

HeLa

113uM

LDH↓,

1595-

Cu,

The Multifaceted Roles of Copper in Cancer: A Trace Metal Element with Dysregulated Metabolism, but Also a Target or a Bullet for Therapy

-

Review,

NA,

NA

eff↑, ROS↑, eff↓,

1596-

Cu,

CDT,

Unveiling the promising anticancer effect of copper-based compounds: a comprehensive review

-

Review,

NA,

NA

TumCD↑, Apoptosis↓, ROS↑, angioG↑, Cupro↑, Paraptosis↑, eff↑, eff↓, selectivity↑, DNAdam↑, eff↑, eff↑, eff↑, eff↑, Fenton↑, H2O2↑, eff↑, eff↑, eff↑, RadioS↑, ChemoSen↑, eff↑, *toxicity↝, other↑, eff↑,

1597-

Cu,

Anticancer potency of copper(II) complexes of thiosemicarbazones

-

Review,

NA,

NA

eff↑, ROS↑,

1598-

Cu,

Targeting copper in cancer therapy: 'Copper That Cancer'

-

Review,

NA,

NA

eff↓, eff↑, Dose∅, eff↑, angioG↑, ROS↑,

1599-

Cu,

Copper in tumors and the use of copper-based compounds in cancer treatment

-

Review,

NA,

NA

ROS↑, RadioS↑,

1600-

Cu,

Cu(II) complex that synergistically potentiates cytotoxicity and an antitumor immune response by targeting cellular redox homeostasis

-

Review,

NA,

NA

ER Stress↑, ROS↑, AntiTum↑, GSH↓, Ferroptosis↑, selectivity↑, GSH/GSSG↓, *ROS∅, eff↑,

1601-

Cu,

The copper (II) complex of salicylate phenanthroline induces immunogenic cell death of colorectal cancer cells through inducing endoplasmic reticulum stress

-

in-vitro,

CRC,

NA

i-CRT↓, ICD↑, i-ATP↓, i-HMGB1↓, ER Stress↑, ROS↑, DCells↑, CD8+↑, IL12↑, IFN-γ↑, TGF-β↓,

1602-

Cu,

A simultaneously GSH-depleted bimetallic Cu(ii) complex for enhanced chemodynamic cancer therapy†

-

in-vitro,

BC,

MCF-7

3.2uM

-

in-vitro,

BC,

4T1

3.3uM

-

in-vitro,

Lung,

A549

4uM

-

in-vitro,

Liver,

HepG2

3.5uM

eff↑, GSH↓, H2O2↑, ROS↑, *BioAv↑, selectivity↑, TumCCA↑, Apoptosis↑, Fenton↑, *toxicity?,

1603-

Cu,

BP,

SDT,

Glutathione Depletion-Induced ROS/NO Generation for Cascade Breast Cancer Therapy and Enhanced Anti-Tumor Immune Response

-

in-vitro,

BC,

4T1

-

in-vivo,

NA,

NA

mice

GSH↓, Fenton↑, ROS↑, NO↑, sonoS↑, eff↑, NO↑, *toxicity∅, eff?,

1604-

Cu,

Targeting copper metabolism: a promising strategy for cancer treatment

-

Review,

NA,

NA

eff↓, eff↓, ROS↑, eff↑,

1642-

Cu,

HCAs,

Copper-assisted anticancer activity of hydroxycinnamic acid terpyridine conjugates on triple-negative breast cancer

-

in-vitro,

BC,

4T1

(IC50 ∼ 3.5 ± 2.5 μM

-

in-vitro,

Nor,

L929

IC50 ∼ 15 ± 5 μM

tumCV↓, selectivity↑,

1572-

Cu,

Recent Advances in Cancer Therapeutic Copper-Based Nanomaterials for Antitumor Therapy

-

Review,

NA,

NA

eff↑, Fenton↑, ROS↑, eff↑, mtDam↑, BAX↑, Bcl-2↓, MMP↓, Cyt‑c↑, Casp3↑, ER Stress↑, CHOP↑, Apoptosis↑, selectivity↑, eff↑, Pyro↑, Paraptosis↑, Cupro↑, ChemoSen↑, eff↑,

1571-

Cu,

Copper in cancer: From pathogenesis to therapy

-

Review,

NA,

NA

*toxicity↝, ROS↑, lipid-P↓, HNE↑, MAPK↑, JNK↑, AP-1↑, Beclin-1↑, ATG7↑, TumAuto↑, Apoptosis↑, HO-1↑, NQO1↑, mt-ROS↑, Fenton↑,

1570-

Cu,

Development of copper nanoparticles and their prospective uses as antioxidants, antimicrobials, anticancer agents in the pharmaceutical sector

-

Review,

NA,

NA

selectivity↑, antiOx↑, ROS↑, eff↑, GSH↓, lipid-P↑, Catalase↓, SOD↓, other↑,

1569-

Cu,

Copper Nanoparticles as Therapeutic Anticancer Agents

-

Review,

NA,

NA

Dose∅, Dose∅, ROS↑,

1639-

Cu,

HCAs,

Green synthesis of copper oxide nanoparticles using sinapic acid: an underpinning step towards antiangiogenic therapy for breast cancer

-

in-vitro,

BC,

MCF-7

-

in-vitro,

BC,

MDA-MB-231

angioG↓, tumCV↓, Dose↓, ROS↑,

1590-

Cuc,

ATP citrate lyase (ACLY) inhibitors: An anti-cancer strategy at the crossroads of glucose and lipid metabolism

-

Review,

NA,

NA

0.1 uM

ACLY↓,

1616-

CUR,

EA,

Kinetics of Inhibition of Monoamine Oxidase Using Curcumin and Ellagic Acid

-

in-vitro,

Nor,

NA

*MAOA↓, *Dose∅, Dose?,

1510-

CUR,

Chemo,

Combination therapy in combating cancer

-

Review,

NA,

NA

*NRF2↑, *GSH↑, *ROS↓, ChemoSideEff↓, eff↑, OS↓, chemoP↑,

1609-

CUR,

EA,

Curcumin and Ellagic acid synergistically induce ROS generation, DNA damage, p53 accumulation and apoptosis in HeLa cervical carcinoma cells

-

in-vitro,

Cerv,

NA

eff↑, Dose∅, ROS↑, DNAdam↑, P53↑, P21↑, BAX↑, Dose∅,

1809-

CUR,

Oxy,

Long-term stabilisation of myeloma with curcumin

-

Case Report,

Melanoma,

NA

*OS↑, QoL↑, Dose↑, Dose↑, IL6↓, STAT3↓, NF-kB↓, COX2↓,

1792-

CUR,

LEC,

Chondroprotective effect of curcumin and lecithin complex in human chondrocytes stimulated by IL-1β via an anti-inflammatory mechanism

-

in-vitro,

Arthritis,

RAW264.7

0.5-20 μM as curcumin) and LPS (1 μg/mL) for 48 h.

-

NA,

NA,

HCC-38

*Inflam↓, *NF-kB↓, *iNOS↓, *COX2↓, *NO↓, *PGE2↓, *MMPs↑, *TIMP1↑, *BioEnh↑,

1487-

CUR,

Relationship and interactions of curcumin with radiation therapy

-

Review,

Var,

NA

RadioS↑, ChemoSen↑,

1486-

CUR,

Curcumin and lung cancer--a review

-

Review,

Lung,

NA

RadioS↑, ChemoSen↑,

1485-

CUR,

Chemo,

Rad,

Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs

-

Review,

Var,

NA

ChemoSen↑, NF-kB↓, *STAT3↓, *COX2↓, *Akt↓, *NRF2↑, *HO-1↑, *GPx↑, *NADPH↑, *GSH↑, *ROS↓, *p300↓, radioP↑, chemoP↑, RadioS↑,

1408-

CUR,

Antiproliferative and ROS Regulation Activity of Photoluminescent Curcumin-Derived Nanodots

-

in-vitro,

Lung,

A549

ROS↓, ROS↑,

1411-

CUR,

Cisplatin,

Curcumin and its derivatives in cancer therapy: Potentiating antitumor activity of cisplatin and reducing side effects

-

Review,

Var,

NA

ChemoSen↑, *ROS↓, *NF-kB↓, TumCCA↑,

1410-

CUR,

Curcumin induces ferroptosis and apoptosis in osteosarcoma cells by regulating Nrf2/GPX4 signaling pathway

-

vitro+vivo,

OS,

MG63

tumCV↓, Apoptosis↑, TumCG↓, NRF2↓, GPx4↓, HO-1↓, xCT↓, ROS↑, MDA↑, GSH↓,

1409-

CUR,

Curcumin analog WZ26 induces ROS and cell death via inhibition of STAT3 in cholangiocarcinoma

-

in-vivo,

CCA,

Walker256

mouse

TumCG↓, ROS↑, MMP↓, STAT3↓, TumCCA↑, eff↓,

1383-

CUR,

BBR,

RES,

Regulation of GSK-3 activity by curcumin, berberine and resveratrol: Potential effects on multiple diseases

-

Review,

NA,

NA

GSK‐3β↝, ROS↑,

1418-

CUR,

Potential complementary and/or synergistic effects of curcumin and boswellic acids for management of osteoarthritis

-

Review,

Arthritis,

NA

*COX2↓, *Inflam↓, *5LO↓, *NO↓, *NF-kB↓, *TNF-α↓, *IL1↓, *IL2↑, *IL6↓, *IL8↓, *IL12↓, *MCP1↓, *PGE2↓, *MMP2↓, *MMP3↓, *MMP9↓, *NLRP3↓, *ROS↓,

1488-

CUR,

Anti-Cancer and Radio-Sensitizing Effects of Curcumin in Nasopharyngeal Carcinoma

RadioS↑, ChemoSen↑,

1505-

CUR,

Epigenetic targets of bioactive dietary components for cancer prevention and therapy

-

Review,

NA,

NA

25 μM @24hr

TumCCA↑, Apoptosis↑, DNMTs↓, HDAC↓, HATs↓, TumCP↓, p300↓, HDAC1↓, HDAC3↓, HDAC8↓, NF-kB↓,

1977-

CUR,

Synthesis and evaluation of curcumin analogues as potential thioredoxin reductase inhibitors

-

in-vitro,

BC,

MCF-7

-

in-vitro,

Cerv,

HeLa

-

in-vitro,

Lung,

A549

TrxR↓, Dose↝, eff↑,

1982-

CUR,

Inhibition of thioredoxin reductase by curcumin analogs

-

in-vitro,

NA,

NA

IC50 values from the nano to the low micromolar range.

eff↑, TrxR↓,

1978-

CUR,

Curcumin targeting the thioredoxin system elevates oxidative stress in HeLa cells

-

in-vitro,

Cerv,

HeLa

TrxR1↓, ROS↑, DNA-PK↑, eff↑, Trx↓, Trx1↓,

1979-

CUR,

Rad,

Dimethoxycurcumin, a metabolically stable analogue of curcumin enhances the radiosensitivity of cancer cells: Possible involvement of ROS and thioredoxin reductase

-

in-vitro,

Lung,

A549

eff↑, ROS↑, GSH/GSSG↓, TrxR↓, selectivity↑,

1980-

CUR,

Rad,

Thioredoxin reductase-1 (TxnRd1) mediates curcumin-induced radiosensitization of squamous carcinoma cells

-

in-vitro,

Cerv,

HeLa

10 µM

-

in-vitro,

Laryn,

FaDu

10 µM

selectivity↑, RadioS↑, TrxR↓, ROS↑, ERK↑, Dose∅, cl‑PARP↑,

1981-

CUR,

Mitochondrial targeted curcumin exhibits anticancer effects through disruption of mitochondrial redox and modulation of TrxR2 activity

-

in-vitro,

Lung,

NA

eff↑, ROS↑, mt-GSH↓, Bax:Bcl2↑, Cyt‑c↑, MMP↓, Casp3↑, Trx2↓, TrxR↓, mt-DNAdam↑,

2312-

CUR,

Dual Role of Reactive Oxygen Species and their Application in Cancer Therapy

-

Review,

Var,

NA

ROS↑, PKM2↓,

2308-

CUR,

Counteracting Action of Curcumin on High Glucose-Induced Chemoresistance in Hepatic Carcinoma Cells

-

in-vitro,

Liver,

HepG2

GlucoseCon↓, lactateProd↓, ECAR↓, NO↓, ROS↑, HK2↓, PFK1↓, GAPDH↓, PKM2↓, LDHA↓, FASN↓, GLUT1↓, MCT1↓, MCT4↓, HCAR1↓, SDH↑, ChemoSen↑, ROS↑, BioAv↑, P53↑, NF-kB↓, pH↑,

2305-

CUR,

Mitochondrial targeting nano-curcumin for attenuation on PKM2 and FASN

-

in-vitro,

BC,

MCF-7

BioAv↑, PKM2↓, FASN↓, Glycolysis↓,

2304-

CUR,

Curcumin decreases Warburg effect in cancer cells by down-regulating pyruvate kinase M2 via mTOR-HIF1α inhibition

-

in-vitro,

Lung,

H1299

0–20 μM curcumin for 24

-

in-vitro,

BC,

MCF-7

-

in-vitro,

Cerv,

HeLa

-

in-vitro,

Pca,

PC3

-

in-vitro,

Nor,

HEK293

Glycolysis↓, GlucoseCon↓, lactateProd↓, PKM2↓, mTOR↓, Hif1a↓, selectivity↑, Dose↝, tumCV↓,

2307-

CUR,

Cell-Type Specific Metabolic Response of Cancer Cells to Curcumin

-

in-vitro,

Colon,

HT29

20 μM for 24 hours

-

in-vitro,

Laryn,

FaDu

PKM2↓, Warburg↓, mTOR↓, Hif1a↓, Glycolysis↓,

2819-

CUR,

Chemo,

Curcumin as a hepatoprotective agent against chemotherapy-induced liver injury

-

Review,

Var,

NA

*hepatoP↑, *Inflam↓, *antiOx↓, *lipid-P↓, *GSH↑, *SOD↑, *Catalase↑, *GPx↑, *GSTs↑, *ROS↓, *ALAT↓, *AST↓, *MDA↓, *NRF2↑, *COX2↑, *NF-kB↓, *ICAM-1↓, *MCP1↓, *HO-1↑, CXCc↓,

2818-

CUR,

Novel Insight to Neuroprotective Potential of Curcumin: A Mechanistic Review of Possible Involvement of Mitochondrial Biogenesis and PI3/Akt/ GSK3 or PI3/Akt/CREB/BDNF Signaling Pathways

-

Review,

AD,

NA

*neuroP↑, *ROS↓, *Inflam↓, *Apoptosis↓, *cognitive↑, *cardioP↑, other↑, *COX2↓, *IL1β↓, *TNF-α↓, NF-kB↓, *PGE2↓, *iNOS↓, *NO↓, *IL2↓, *IL4↓, *IL6↓, *INF-γ↓, *GSK‐3β↓, *STAT↓, *GSH↑, *MDA↓, *lipid-P↓, *SOD↑, *GPx↑, *Catalase↑, *GSR↓, *LDH↓, *H2O2↓, *Casp3↓, *Casp9↓, *NRF2↑, *AIF↓, *ATP↑,

2817-

CUR,

Neuroprotection by curcumin: A review on brain delivery strategies

-

Review,

Nor,

NA

*BioAv↝, neuroP↑,

2816-

CUR,

NEUROPROTECTIVE EFFECTS OF CURCUMIN

-

Review,

AD,

NA

-

Review,

Park,

NA

*neuroP↑, *Inflam↓, *antiOx↑, *BioAv↓, *AP-1↓, *NF-kB↓, *HATs↓, *HDAC↑, Dose↑, *ROS↓, *cognitive↑, *Aβ↓,

2815-

CUR,

Biochemical and cellular mechanism of protein kinase CK2 inhibition by deceptive curcumin

*CK2↑,

2814-

CUR,

Curcumin in Cancer and Inflammation: An In-Depth Exploration of Molecular Interactions, Therapeutic Potentials, and the Role in Disease Management

-

Review,

Var,

NA

*BioAv↓, *Inflam↓, *antiOx↑, AntiCan↑, CK2↓, GSK‐3β↓, EGFR↓, TOP1↓, TOP2↓, NF-kB↓, COX2↓, CRP↓,

2813-

CUR,

Oxidative Metabolites of Curcumin Poison Human Type II Topoisomerases

-

Review,

NA,

NA

TOP2↑,

2812-

CUR,

Curcumin Induces High Levels of Topoisomerase I− and II−DNA Complexes in K562 Leukemia Cells

-

in-vitro,

AML,

K562

TOP1↑, TOP2↑, eff↓,

2811-

CUR,

Effect of Curcumin Supplementation During Radiotherapy on Oxidative Status of Patients with Prostate Cancer: A Double Blinded, Randomized, Placebo-Controlled Study

-

Human,

Pca,

NA

*antiOx↑, radioP↑, RadioS∅, *TAC↑, *SOD↓,

2810-

CUR,

Effect of curcuminoids on oxidative stress: A systematic review and meta-analysis of randomized controlled trials

-

Review,

Nor,

NA

*SOD↑, *lipid-P↓, *GSH↑, *Catalase↑, *ROS↓,

2809-

CUR,

Comparative absorption of curcumin formulations

-

in-vivo,

Nor,

NA

BioAv↑, BioAv↑, BioAv↑, BioAv↑, BioAv↑, BioAv↓, Half-Life↝,

2808-

CUR,

Iron chelation by curcumin suppresses both curcumin-induced autophagy and cell death together with iron overload neoplastic transformation

-

in-vitro,

Liver,

HUH7

25 μM curcumin for 48 h

Ferritin↓, IronCh↑, TumAuto↑, Apoptosis↑, eff↝, Dose↝,

2688-

CUR,

Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs

-

Review,

Var,

NA

-

Review,

AD,

NA

*ROS↓, *SOD↑, p16↑, JAK2↓, STAT3↓, CXCL12↓, IL6↓, MMP2↓, MMP9↓, TGF-β↓, α-SMA↓, LAMs↓, DNAdam↑, *memory↑, *cognitive↑, *Inflam↓, *antiOx↓, *NO↑, *MDA↓, *ROS↓, DNMT1↓, ROS↑, Casp3↑, Apoptosis↑, miR-21↓, LC3II↓, ChemoSen↑, NF-kB↓, CSCs↓, Nanog↓, OCT4↓, SOX2↓, eff↑, Sp1/3/4↓, miR-27a-3p↓, ZBTB10↑, SOX9?, ChemoSen↑, VEGF↓, XIAP↓, Bcl-2↓, cycD1↓, BioAv↑, Hif1a↓, EMT↓, BioAv↓, PTEN↑, VEGF↓, Akt↑, EZH2↓, NOTCH1↓, TP53↑, NQO1↑, HO-1↑,

2466-

CUR,

Regulatory Effects of Curcumin on Platelets: An Update and Future Directions

-

Review,

Nor,

NA

*AntiAg↑, *antiOx↑, *Inflam↓, *12LOX↑, COX1↓, COX2↓, MMP9↓, NF-kB↓,

2980-

CUR,

Inhibition of NF B and Pancreatic Cancer Cell and Tumor Growth by Curcumin Is Dependent on Specificity Protein Down-regulation

-

in-vivo,

PC,

NA

mice

TumCG↓, p50↓, p65↓, NF-kB↓, Sp1/3/4↓, MMP↓, ROS↑,

2979-

CUR,

GB,

Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death

-

in-vitro,

Lung,

H157

-

in-vitro,

Lung,

H1299

EGFR↓, Sp1/3/4↓, ERK↓, MEK↓, Akt↓, S6K↓,

2978-

CUR,

N-acetyl cysteine mitigates curcumin-mediated telomerase inhibition through rescuing of Sp1 reduction in A549 cells

-

in-vitro,

Lung,

A549

ROS↑, hTERT↓, Sp1/3/4↓, eff↓,

2977-

CUR,

Curcumin Down-Regulates Toll-Like Receptor-2 Gene Expression and Function in Human Cystic Fibrosis Bronchial Epithelial Cells

-

in-vitro,

CF,

NA

*TLR2↓, *Sp1/3/4↓,

2976-

CUR,

Curcumin suppresses the proliferation of oral squamous cell carcinoma through a specificity protein 1/nuclear factor‑κB‑dependent pathway

-

in-vitro,

Oral,

HSC3

-

in-vitro,

HNSCC,

CAL33

tumCV↓, Sp1/3/4↓, p65↓, HSF1↓, NF-kB↓,

2975-

CUR,

Curcumin inhibits proliferation, migration and neointimal formation of vascular smooth muscle via activating miR-22

-

in-vivo,

Nor,

NA

rats

*miR-22↑, *Sp1/3/4↓,

2974-

CUR,

Curcumin Suppresses Metastasis via Sp-1, FAK Inhibition, and E-Cadherin Upregulation in Colorectal Cancer

-

in-vitro,

CRC,

HCT116

0, 5, 10, and 20 μM

-

in-vitro,

CRC,

HT29

-

in-vitro,

CRC,

HCT15

-

in-vitro,

CRC,

COLO205

-

in-vitro,

CRC,

SW-620

-

in-vivo,

NA,

NA

1 g/kg once daily for 30 days

mice

TumCMig↓, TumCI↓, TumCG↓, TumMeta↓, Sp1/3/4↓, HDAC4↓, FAK↓, CD24↓, E-cadherin↑, EMT↓, TumCP↓, NF-kB↓, AP-1↝, STAT3↓, P53?, β-catenin/ZEB1↓, NOTCH1↝, Hif1a↝, PPARα↝, Rho↓, MMP2↓, MMP9↓,

3576-

CUR,

Protective Effects of Indian Spice Curcumin Against Amyloid-β in Alzheimer's Disease

-

Review,

AD,

NA

*Inflam↓, *antiOx↑, *memory↑, *Aβ↓, *BBB↑, *cognitive↑, *tau↓, *LDL↓, *AChE↓, *IL1β↓, *IronCh↑, *neuroP↑, *BioAv↝, *PI3K↑, *Akt↑, *NRF2↑, *HO-1↑, *Ferritin↑, *HO-2↓, *ROS↓, *Ach↑, *GSH↑, *Bcl-2↑, *ChAT↑,

3575-

CUR,

The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse

-

in-vivo,

AD,

NA

mice

*antiOx↓, *ROS↓, *IL1β↓, *Aβ↓, *Inflam↓, *toxicity↓,

3574-

CUR,

The effect of curcumin (turmeric) on Alzheimer's disease: An overview

-

Review,

AD,

NA

*antiOx↑, *Inflam↓, *lipid-P↓, *cognitive↑, *memory↑, *Aβ↓, *COX2↓, *ROS↓, *AP-1↓, *NF-kB↓, *TNF-α↓, *IL1β↓, *SOD↑, *GSH↑, *HO-1↑, *IronCh↑, *BioAv↓, *Half-Life↝, *Dose↝, *BBB↑, *BioAv↑, *toxicity∅, *eff↑,

2821-

CUR,

Antioxidant curcumin induces oxidative stress to kill tumor cells (Review)

-

Review,

Var,

NA

*antiOx↑, *NRF2↑, *ROS↓, *Inflam↓, ROS↑, p‑ERK↑, ER Stress↑, mtDam↑, Apoptosis↑, Akt↓, mTOR↓, HO-1↑, Fenton↑, GSH↓, Iron↑, p‑JNK↑, Cyt‑c↑, ATF6↑, CHOP↑,

2822-

CUR,

Identification of curcumin derivatives as human glyoxalase I inhibitors: A combination of biological evaluation, molecular docking, 3D-QSAR and molecular dynamics simulation studies

-

Analysis,

Nor,

NA

GLO-I↓,

2823-

CUR,

Binding of curcumin with glyoxalase I: Molecular docking, molecular dynamics simulations, and kinetics analysis

-

Study,

Nor,

NA

GLO-I↓,

2820-

CUR,

Hepatoprotective Effect of Curcumin on Hepatocellular Carcinoma Through Autophagic and Apoptic Pathways

-

in-vitro,

HCC,

HepG2

50 μM

*hepatoP↑, *ROS?, tumCV↓,

2654-

CUR,

Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence

-

Review,

Var,

NA

ROS↑, Catalase↓, SOD1↓, GLO-I↓, NADPH↓, TumCCA↑, Apoptosis↑, Akt↓, ER Stress↑, JNK↑, STAT3↓, BioAv↑,

2579-

CUR,

ART/DHA,

Curcumin-Artemisinin Combination Therapy for Malaria

-

in-vivo,

NA,

NA

IC50s for artemisinin and curcumin are 45 to 50 nM and 15 to 18 μM, respectively.

mice, Malaria

OS↑, toxicity↓,

872-

CUR,

RES,

New Insights into Curcumin- and Resveratrol-Mediated Anti-Cancer Effects

-

in-vitro,

BC,

TUBO

15uM, 15uM

-

in-vitro,

BC,

SALTO

TumCP↓, tumCV↓, p62↓, p62↑, TumAuto↑, TumAuto↓, ROS↑, ROS↓, CHOP↑,

933-

CUR,

EP,

Effective electrochemotherapy with curcumin in MDA-MB-231-human, triple negative breast cancer cells: A global proteomics study

-

in-vitro,

BC,

NA

50uM, 1200v/c,100us

Apoptosis↑, ALDOA↓, ENO2↓, LDHA↓, LDHB↓, PFKP↓, PGK1↓, PGM1↓, PGAM1↓, OXPHOS↑, TCA↑,

155-

CUR,

Osteopontin and MMP9: Associations with VEGF Expression/Secretion and Angiogenesis in PC3 Prostate Cancer Cells

-

in-vitro,

Pca,

PC3

p‑ERK↓, VEGF↓, angioS↑,

154-

CUR,

Curcumin inhibits expression of inhibitor of DNA binding 1 in PC3 cells and xenografts

-

vitro+vivo,

Pca,

PC3

Id1↓,

157-

CUR,

Curcumin induces cell cycle arrest and apoptosis of prostate cancer cells by regulating the expression of IkappaBalpha, c-Jun and androgen receptor

-

in-vitro,

Pca,

LNCaP

-

in-vitro,

Pca,

PC3

cJun↓, AR↓,

153-

CUR,

Curcumin Inhibits Prostate Cancer Bone Metastasis by Up-Regulating Bone Morphogenic Protein-7 in Vivo

-

in-vivo,

Pca,

C4-2B

PSA↓, TGF-β↓, BMPs↑,

152-

CUR,

Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer

-

in-vivo,

Pca,

NA

PLGA-CUR NPs

mice

β-catenin/ZEB1↓, AR↓, STAT3↓, p‑Akt↓, Mcl-1↓, Bcl-xL↓, cl‑PARP↑, miR-21↓, miR-205↑,

151-

CUR,

Curcumin analogues with high activity for inhibiting human prostate cancer cell growth and androgen receptor activation

-

in-vitro,

Pca,

22Rv1

-

in-vitro,

Pca,

LNCaP

AR↓,

146-

CUR,

EGCG,

Synergistic effect of curcumin on epigallocatechin gallate-induced anticancer action in PC3 prostate cancer cells

-

in-vitro,

Pca,

PC3

-

in-vitro,

Pca,

LNCaP

-

in-vitro,

Pca,

DU145

P21↑,

131-

CUR,

Modulation of AKR1C2 by curcumin decreases testosterone production in prostate cancer

-

vitro+vivo,

Pca,

LNCaP

5, 25 and 50 μM, 24, 48 and 72 h; 200 mg/kg/day, 30days

mice

-

vitro+vivo,

Pca,

22Rv1

AKR1C2↓, CYP11A1↓, HSD3B↓, DHT↓, testos↓, StAR↓, SRD5A1↑,

144-

CUR,

Bical,

Combination of curcumin and bicalutamide enhanced the growth inhibition of androgen-independent prostate cancer cells through SAPK/JNK and MEK/ERK1/2-mediated targeting NF-κB/p65 and MUC1-C

-

in-vitro,

Pca,

PC3

androgen-independent prostate cancer cells

-

in-vitro,

NA,

DU145

-

in-vitro,

NA,

LNCaP

p‑ERK↑, p‑JNK↓, MUC1↓, p65↓,

143-

CUR,

Nonautophagic cytoplasmic vacuolation death induction in human PC-3M prostate cancer by curcumin through reactive oxygen species -mediated endoplasmic reticulum stress

-

in-vitro,

Pca,

LNCaP

-

in-vitro,

Pca,

DU145

-

in-vitro,

Pca,

PC3

ER Stress↑, CHOP↑, GRP78/BiP↑, ROS↑,

141-

CUR,

Effect of curcumin on Bcl-2 and Bax expression in nude mice prostate cancer

-

in-vivo,

Pca,

PC3

100 mg/kg, 50 mg/kg, and 25 mg/kg curcumin)

nude mice

BAX↑, Bcl-2↓,

140-

CUR,

Curcumin inhibits cancer-associated fibroblast-driven prostate cancer invasion through MAOA/mTOR/HIF-1α signaling

-

in-vitro,

Pca,

PC3

25 μM

CAFs/TAFs↓, EMT↓, ROS↓, CXCR4↓, IL6↓, MAOA↓, mTOR↓, HIF-1↓,

137-

CUR,

Curcumin induces G0/G1 arrest and apoptosis in hormone independent prostate cancer DU-145 cells by down regulating Notch signaling

-

in-vitro,

Pca,

DU145

NOTCH1↓, cycD1↓, CDK2↓, P21↑, p27↑, P53↑, Bcl-2↓, Casp3↑, Casp9↑,

136-

CUR,

docx,

Combinatorial effect of curcumin with docetaxel modulates apoptotic and cell survival molecules in prostate cancer

-

in-vitro,

Pca,

DU145

5-50uM

19.2 nM(docx), 32.3 μM(CUR)

20 μM curcumin and 10 nM docetaxel significantly decrease (2.7 fold) the proliferation

-

in-vitro,

Pca,

PC3

46 nM(docx), 36.1 μM(CUR)

combined treatment decrease (3.2 fold)

Bcl-2↓, Bcl-xL↓, Mcl-1↓, BAX↑, BID↑, PARP↑, NF-kB↓, CDK1↓, COX2↓, RTK-RAS↓, PI3K/Akt↓, EGFR↓, HER2/EBBR2↓, P53↑,

135-

CUR,

Curcumin induces apoptosis and protective autophagy in castration-resistant prostate cancer cells through iron chelation

-

in-vitro,

Pca,

DU145

6-50uM

CRPC Castration-Resistant Prostrate Cancer Cell

-

in-vitro,

Pca,

PC3

TfR1/CD71↑, IRP1↑,

134-

CUR,

RES,

MEL,

SIL,

Thioredoxin 1 modulates apoptosis induced by bioactive compounds in prostate cancer cells

-

in-vitro,

Pca,

LNCaP

-

in-vitro,

Pca,

PC3

Apoptosis↑, ROS↑, Trx1↓,

133-

CUR,

Curcumin inhibits prostate cancer by targeting PGK1 in the FOXD3/miR-143 axis

-

in-vitro,

Pca,

NA

miR-143↑, PDK1↓, FOXD3↑,

132-

CUR,

Targeting multiple pro-apoptotic signaling pathways with curcumin in prostate cancer cells

-

in-vitro,

Pca,

NA

TumCCA↑, ROS↑, TumAuto↑, UPR↑,

142-

CUR,

Effect of curcumin on the interaction between androgen receptor and Wnt/β-catenin in LNCaP xenografts

-

in-vivo,

Pca,

LNCaP

500 mg/kg

AR↓, PSA↓,

170-

CUR,

Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis

-

vitro+vivo,

Pca,

PC3

mice

TRAILR↑, BAX↑, P21↑, p27↑, NF-kB↓, cycD1↓, VEGF↓, uPA↓, MMP2↓, MMP9↓, Bcl-2↓, Bcl-xL↓,

183-

CUR,

Curcumin down-regulates AR gene expression and activation in prostate cancer cell lines

-

in-vitro,

Pca,

LNCaP

-

in-vitro,

Pca,

PC3

AR↓, AP-1↓, NF-kB↓, CBP↓,

182-

CUR,

RES,

GI,

Chemopreventive anti-inflammatory activities of curcumin and other phytochemicals mediated by MAP kinase phosphatase-5 in prostate cells

-

in-vitro,

Pca,

DU145

-

in-vitro,

Pca,

PC3

-

in-vitro,

Pca,

LNCaP

-

in-vitro,

Pca,

LAPC-4

p38↓, MKP5↑,

181-

CUR,

The effects of curcumin on the invasiveness of prostate cancer in vitro and in vivo

-

vitro+vivo,

Pca,

DU145

MMP2↓, MMP9↓,

9-

CUR,

Curcumin Suppresses Malignant Glioma Cells Growth and Induces Apoptosis by Inhibition of SHH/GLI1 Signaling Pathway in Vitro and Vivo

-

vitro+vivo,

MG,

U87MG

15uM

-

vitro+vivo,

MG,

T98G

31uM 31 uM

HH↓, Shh↓, Gli1↓, cycD1↓, Bcl-2↓, Foxm1↓, Bax:Bcl2↑,

10-

CUR,

Curcumin Suppresses Lung Cancer Stem Cells via Inhibiting Wnt/β-catenin and Sonic Hedgehog Pathways

-

in-vitro,

Lung,

A549

-

in-vitro,

Lung,

H1299

HH↓, Wnt/(β-catenin)↓, Shh↓, Smo↓, Gli1↝, GLI2↝,

11-

CUR,

Curcumin inhibits hypoxia-induced epithelial‑mesenchymal transition in pancreatic cancer cells via suppression of the hedgehog signaling pathway

-

in-vitro,

PC,

PANC1

HH↓, Shh↓, Smo↓, Gli1↓, N-cadherin↓, E-cadherin↑, Vim↓,

12-

CUR,

Curcumin inhibits the Sonic Hedgehog signaling pathway and triggers apoptosis in medulloblastoma cells

-

in-vitro,

MB,

DAOY

20 uM

HH↓, Shh↓, Gli1↓, PTCH1↓, cMyc↓, n-MYC↓, cycD1↓, Bcl-2↓, NF-kB↓, Akt↓, β-catenin/ZEB1↓, survivin↓,

13-

CUR,

Role of curcumin in regulating p53 in breast cancer: an overview of the mechanism of action

-

Review,

BC,

NA

P53↑, DR5↑, JNK↑, NRF2↑, PPARγ↑, HER2/EBBR2↓, IR↓, ER(estro)↓, Fas↑, PDGF↓, TGF-β↓, FGF↓, EGFR↓, JAK↓, PAK↓, MAPK↓, ATPase↓, COX2↓, MMPs↓, IL1↓, IL2↓, IL5↓, IL6↓, IL8↓, IL12↓, IL18↓, NF-kB↓, NOTCH1↓, STAT1↓, STAT4↓, STAT5↓, STAT3↓,

14-

CUR,

Curcumin, a Dietary Component, Has Anticancer, Chemosensitization, and Radiosensitization Effects by Down-regulating the MDM2 Oncogene through the PI3K/mTOR/ETS2 Pathway

-

vitro+vivo,

Pca,

PC3

5-30 uM

PI3K/mTOR/ETS2↓, MDM2↓, P21↑,

15-

CUR,

UA,

Effects of curcumin and ursolic acid in prostate cancer: A systematic review

NF-kB↝, Akt↝, AR↝, Apoptosis↝, Bcl-2↝, Casp3↝, BAX↝, P21↝, ROS↝, Apoptosis↝, Bcl-xL↝, JNK↝, MMP2↝, P53↝, PSA↝, VEGF↝, COX2↝, cycD1↝, EGFR↝, IL6↝, β-catenin/ZEB1↝, mTOR↝, NRF2↝, p‑Akt↝, AP-1↝, Cyt‑c↝, PI3K↝, PTEN↝, Cyc↝, TNF-α↝,

158-

CUR,

Curcumin-targeting pericellular serine protease matriptase role in suppression of prostate cancer cell invasion, tumor growth, and metastasis

-

vitro+vivo,

Pca,

LNCaP

MMP9↓, Matr↓,

169-

CUR,

Curcumin inhibits the expression of vascular endothelial growth factor and androgen-independent prostate cancer cell line PC-3 in vitro

-

in-vitro,

Pca,

PC3

6-50uM/L

VEGF↓,

168-

CUR,

Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism

-

in-vitro,

Pca,

PC3

Akt↓, mTOR↓, AMPK↑, TAp63α↑,

167-

CUR,

Curcumin-induced apoptosis in PC3 prostate carcinoma cells is caspase-independent and involves cellular ceramide accumulation and damage to mitochondria

-

in-vitro,

Pca,

PC3

MAPK↑, JNK↑, Casp3↑, Casp8↑, Casp9↑, AIF↑,

165-

CUR,

Curcumin interrupts the interaction between the androgen receptor and Wnt/β-catenin signaling pathway in LNCaP prostate cancer cells

-

in-vitro,

Pca,

LNCaP

AR↓, β-catenin/ZEB1↓, p‑Akt↓, GSK‐3β↓, p‑β-catenin/ZEB1↑, cycD1↓, cMyc↓,

164-

CUR,

Anti-tumor activity of curcumin against androgen-independent prostate cancer cells via inhibition of NF-κB and AP-1 pathway in vitro

-

in-vitro,

Pca,

PC3

NF-kB↓, AP-1↓,

163-

CUR,

Epigenetic CpG Demethylation of the Promoter and Reactivation of the Expression of Neurog1 by Curcumin in Prostate LNCaP Cells

-

in-vitro,

Pca,

LNCaP

5 μM CUR for 7 days

MeCP2↓, Neurog1↑, HDAC↓,

162-

CUR,

EGCG,

SFN,

Shattering the underpinnings of neoplastic architecture in LNCap: synergistic potential of nutraceuticals in dampening PDGFR/EGFR signaling and cellular proliferation

-

in-vitro,

Pca,

LNCaP

p‑PDGF↓,

161-

CUR,

MeSA,

Enhanced apoptotic effects by the combination of curcumin and methylseleninic acid: potential role of Mcl-1 and FAK

-

in-vitro,

BC,

MDA-MB-231

-

in-vitro,

Pca,

DU145

Mcl-1↑, Mcl-1↓, MPT↑, AIF↑,

160-

CUR,

Curcumin inhibits prostate cancer metastasis in vivo by targeting the inflammatory cytokines CXCL1 and -2

CXCc↓, IκB↓, NF-kB↓, COX2↓, SPARC↓, EFEMP↓,

159-

CUR,

Crosstalk from survival to necrotic death coexists in DU-145 cells by curcumin treatment

-

in-vitro,

Pca,

DU145

ROS↑, p‑Jun↑, p‑p38↑,

129-

CUR,

Curcumin suppressed the prostate cancer by inhibiting JNK pathways via epigenetic regulation

-

vitro+vivo,

Pca,

LNCaP

JNK↓,

130-

CUR,

Maspin Enhances the Anticancer Activity of Curcumin in Hormone-refractory Prostate Cancer Cells

-

in-vitro,

Pca,

DU145

less senstive (with lower maspin expression)

-

in-vitro,

Pca,

PC3

more senstive (higher maspin expression)

BAD↝, BAX↝, eff↑,

117-

CUR,

Increased Intracellular Reactive Oxygen Species Mediates the Anti-Cancer Effects of WZ35 via Activating Mitochondrial Apoptosis Pathway in Prostate Cancer Cells

-

in-vivo,

Pca,

RM-1

-

in-vivo,

Pca,

DU145

ROS↑,

118-

CUR,

Curcumin analog WZ35 induced cell death via ROS-dependent ER stress and G2/M cell cycle arrest in human prostate cancer cells

-

in-vitro,

Pca,

PC3

2.2 μM

for WZ35 analog. For Curcumin it is 20.9μM

-

in-vitro,

Pca,

DU145

ROS↑, Bcl-2↓, PARP↑, cDC2↓, CycB↓, MDM2↓,

120-

CUR,

A randomized, double-blind, placebo-controlled trial to evaluate the role of curcumin in prostate cancer patients with intermittent androgen deprivation

-

Human,

Pca,

NA

1440 mg/day

PSA↓,

121-

CUR,

Screening for Circulating Tumour Cells Allows Early Detection of Cancer and Monitoring of Treatment Effectiveness: An Observational Study

-

in-vivo,

Pca,

NA

CTC↓,

122-

CUR,

isoFl,

Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen

-

Human,

Pca,

LNCaP

85 participants

PSA↓, AR↓,

123-

CUR,

Synthesis of novel 4-Boc-piperidone chalcones and evaluation of their cytotoxic activity against highly-metastatic cancer cells

-

in-vitro,

Colon,

LoVo

0.84–34.7 μg/mL

curcumin analog

-

in-vitro,

Colon,

COLO205

0.84–34.7 μg/mL

curcumin analog

-

in-vitro,

Pca,

PC3

17.1–22.9 μg/mL

curcumin analog

-

in-vitro,

Pca,

22Rv1

17.1–22.9 μg/mL

curcumin analog

NF-kB↓,

124-

CUR,

Curcumin-Gene Expression Response in Hormone Dependent and Independent Metastatic Prostate Cancer Cells

-

in-vitro,

Pca,

LNCaP

-

in-vitro,

Pca,

C4-2B

TGF-β↓, Wnt↓, PI3k/Akt/mTOR↓, NF-kB↓, PTEN↑, Apoptosis↑,

125-

CUR,

Bioactivity of Curcumin on the Cytochrome P450 Enzymes of the Steroidogenic Pathway

-

in-vitro,

adrenal,

H295R

10 µg/mL

CYP17A1↓, CYP19↓,

126-

CUR,

Modulation of miR-34a in curcumin-induced antiproliferation of prostate cancer cells

-

in-vitro,

Pca,

22Rv1

1, 5, 10 and 20 μM, 4 days

-

in-vitro,

Pca,

PC3

-

in-vitro,

Pca,

DU145

miR-34a↑, β-catenin/ZEB1↓, cMyc↓, P21↑, cycD1↓, PCNA↓,

127-

CUR,

The chromatin remodeling protein BRG1 links ELOVL3 trans-activation to prostate cancer metastasis

-

in-vitro,

Pca,

NA

Elvol3↓,

128-

CUR,

RES,

Evaluation of biophysical as well as biochemical potential of curcumin and resveratrol during prostate cancer

-

in-vivo,

Pca,

NA

Rats

lipid-P↓,

1108-

CUR,

Curcumin: a potent agent to reverse epithelial-to-mesenchymal transition

-

Review,

NA,

NA

EMT↓,

430-

CUR,

Curcumin suppresses tumor growth of gemcitabine-resistant non-small cell lung cancer by regulating lncRNA-MEG3 and PTEN signaling

-

vitro+vivo,

Lung,

A549

50, 100 and 150 μM, 48 h; 100 mg/kg, 3 weeks

mice

PTEN↑, MEG3↑,

424-

CUR,

Curcumin inhibits autocrine growth hormone-mediated invasion and metastasis by targeting NF-κB signaling and polyamine metabolism in breast cancer cells

-

in-vitro,

BC,

MCF-7

5, 10, 15, 20, 25 and 30 µM, 24, 48 and 72 h

-

in-vitro,

BC,

MDA-MB-231

Src↓, p‑STAT1↓, p‑Akt↓, p‑p44↓, p‑p42↓, RAS↓, Raf↓, Vim↓, β-catenin/ZEB1↓, P53↓, Bcl-2↓, Mcl-1↓, PIAS-3↑, SOCS-3↑, SOCS1↑, ROS↑, NF-kB↓, PAO↑, SSAT↑, P21↑, Bak↑,

425-

CUR,

Curcumin inhibits proliferation and promotes apoptosis of breast cancer cells

-

in-vitro,

BC,

T47D

10 and 30 µM, 24 and 48 h

-

in-vitro,

BC,

MCF-7

-

in-vitro,

BC,

MDA-MB-231

-

in-vitro,

BC,

MDA-MB-468

CDC25↓, cDC2↓, P21↑, p‑Akt↓, p‑mTOR↓, Bcl-2↓, BAX↑, Casp3↑,

404-

CUR,

Curcumin induces ferroptosis in non-small-cell lung cancer via activating autophagy

-

vitro+vivo,

Lung,

A549

mice

-

vitro+vivo,

Lung,

H1299

TumAuto↑, TumCG↓, TumCP↓, Iron↑, GSH↓, lipid-P↑, GPx↓, mtDam↑, autolysosome↑, Beclin-1↑, LC3s↑, p62↓, Ferroptosis↑,

426-

CUR,

Use of cancer chemopreventive phytochemicals as antineoplastic agents

-

in-vitro,

BC,

MDA-MB-231

5 µM, 48 h

-

in-vitro,

BC,

CAL51

Bcl-2↓, ROS↑, BAX↑, RAD51↑, γH2AX↑,

438-

CUR,

Curcumin Reduces Colorectal Cancer Cell Proliferation and Migration and Slows In Vivo Growth of Liver Metastases in Rats

-

vitro+vivo,

CRC,

CC531

15, 20, 25 and 30 µM, 24, 48 and 72 h; 200 mg/kg/day, 28 days

TumCP↓, TumVol↓, Albumin↑, ALP↑, AST↑, ALAT↑, cholinesterase↓,

427-

CUR,

Curcumin suppresses the malignancy of non-small cell lung cancer by modulating the circ-PRKCA/miR-384/ITGB1 pathway

-

in-vitro,

Lung,

H1299

10, 20 and 40 μM, 24 h

-

in-vitro,

Lung,

H460

-

vitro+vivo,

Lung,

A549

50 mg/kg, 22 days

ITGB1↓, circ-PRKCA↓, miR-384↑,

429-

CUR,

TAp63α Is Involved in Tobacco Smoke-Induced Lung Cancer EMT and the Anti-cancer Activity of Curcumin via miR-19 Transcriptional Suppression

-

in-vitro,

Lung,

H1299

2.5, 5 and 7.5 μM, 48 h

-

in-vitro,

Lung,

A549

TAp63α↑, E-cadherin↑, ZO-1↑, Vim↓, N-cadherin↓, miR-19b↓,

431-

CUR,

Curcumin suppresses the stemness of non-small cell lung cancer cells via promoting the nuclear-cytoplasm translocation of TAZ

-

in-vitro,

Lung,

A549

5, 25, 125 and 250 nM, 24, 48 and 72 h

-

in-vitro,

Lung,

H1299

ALDH1A1↓, CD133↓, EpCAM↓, OCT4↓, TAZ↓, Hippo↑, p‑TAZ↑,

432-

CUR,

Curcumin-Induced Global Profiling of Transcriptomes in Small Cell Lung Cancer Cells

-

in-vitro,

Lung,

H446

5, 10, 15 and 20 μM, 24 and 48 h

Bcl-2↓, cycF↓, LOX1↓, VEGF↓, MRGPRF↓, BAX↑, Cyt‑c↑, miR-548ah-5p↑,

433-

CUR,

Curcumin Inhibits the Migration and Invasion of Non-Small-Cell Lung Cancer Cells Through Radiation-Induced Suppression of Epithelial-Mesenchymal Transition and Soluble E-Cadherin Expression

-

in-vitro,

Lung,

A549

1, 2, 5, 10 and 20 μM, 24 and 48 h

E-cadherin↓, Vim↓, Slug↓, N-cadherin↓, Snail↓, MMP9↓, EMT↓,

434-

CUR,

Curcumin induces apoptosis in lung cancer cells by 14-3-3 protein-mediated activation of Bad

-

in-vitro,

Lung,

A549

25, 50 and 100 μM, 48h

14-3-3 proteins↓, p‑BAD↓, p‑Akt↓, Akt↓, cl‑Casp9↑, cl‑PARP↑,

435-

CUR,

Antitumor activity of curcumin by modulation of apoptosis and autophagy in human lung cancer A549 cells through inhibiting PI3K/Akt/mTOR pathway

-

in-vitro,

Lung,

A549

5, 10, 20 and 40 μM, 24, 48, 72 and 96 h

Apoptosis↑, TumAuto↑, LC3‑Ⅱ/LC3‑Ⅰ↑, Beclin-1↑, p62↓, PI3K↓, Akt↓, mTOR↓, p‑Akt↓, p‑mTOR↓, NA↓,

437-

CUR,

Anti-cancer activity of amorphous curcumin preparation in patient-derived colorectal cancer organoids

-

vitro+vivo,

CRC,

TCO1

0.6, 2, 6 and 20 µg/mL, 72 h; 20 mg/day, 21 days

-

vitro+vivo,

CRC,

TCO2

cycD1↓, cMyc↓, p‑ERK↓, CD44↓, CD133↓, LGR5↓, TumCCA↑, TumVol↓,

439-

CUR,

Curcumin suppresses LGR5(+) colorectal cancer stem cells by inducing autophagy and via repressing TFAP2A-mediated ECM pathway

-

in-vitro,

CRC,

LGR5

LGR5(+) colorectal CSCs

Apoptosis↑, TumAuto↑, GP1BB↓, COL9A3↓, COMP↓, AGRN↓, ITGB4↓, LAMA5↓, COL2A1↓, ITGB6↓, LGR5↓, TFAP2A↓, ECM/TCF↓,

436-

CUR,

Integrated microRNA and gene expression profiling reveals the crucial miRNAs in curcumin anti‐lung cancer cell invasion

-

in-vitro,

Lung,

A549

10, 20 and 40 μM, 12, 24 and 48 h

miR-25-5p↓, miR-330-5p↑, MAPK↓, Wnt↓,

423-

CUR,

Inhibition of TLR4/TRIF/IRF3 Signaling Pathway by Curcumin in Breast Cancer Cells

-

in-vitro,

BC,

MCF-7

5, 10 and 25 µM, 48 h

more efficient in MDA- MB-231 cells than MCF-7 cells owing to its greater inhibitory efficacy in the LPS- enhanced TLR4 signaling pathway.

-

in-vitro,

BC,

MDA-MB-231

TLR4↓, IRF3↓, IFN-γ↓, TRIF↓,

422-

CUR,

Curcumin induces re-expression of BRCA1 and suppression of γ synuclein by modulating DNA promoter methylation in breast cancer cell lines

-

in-vitro,

BC,

HCC-38

5 and 10 µM, 3 days

-

in-vitro,

BC,

T47D

BRCA1↑, TET1↑, DNMT3A↑, DNMT1↓, SNCG↓, miR-29b↓, miR-29b↑,

420-

CUR,

Anti-metastasis activity of curcumin against breast cancer via the inhibition of stem cell-like properties and EMT

-

in-vitro,

BC,

MCF-7

10, 15, 20, 25, 30, 35 and 40 µM, 24 and 48 h

-

in-vitro,

BC,

MDA-MB-231

Vim↓, Fibronectin↓, β-catenin/ZEB1↓, E-cadherin↓, CD44↑, CD24↓, OCT4↓, Nanog↓, SOX2↓,

417-

CUR,

Curcumin inhibits the growth of triple‐negative breast cancer cells by silencing EZH2 and restoring DLC1 expression

-

vitro+vivo,

BC,

MCF-7

20 and 40 µM, 48 h; 100 mg/kg/2 days, 21 days

mice

-

vitro+vivo,

BC,

MDA-MB-231

-

vitro+vivo,

BC,

MDA-MB-468

EZH2↓, DLC1↑, cycA1↓, CDK1↓, Bcl-2↓, Casp9↑, DLC1↑,

415-

CUR,

Curcumin inhibits proteasome activity in triple-negative breast cancer cells through regulating p300/miR-142-3p/PSMB5 axis

-

vitro+vivo,

BC,

MDA-MB-231

5, 10, 20 and 50 μM, 24 h; 25 g/kg, 4 weeks

mice

PSMB5↓, CT-I↓, miR-142-3p↑, EP300↓,

414-

CUR,

Transcriptome Investigation and In Vitro Verification of Curcumin-Induced HO-1 as a Feature of Ferroptosis in Breast Cancer Cells

-

in-vitro,

BC,

MCF-7

114 μM

-

in-vitro,

BC,

MDA-MB-231

Ferroptosis↑, Iron↑, ROS↑, lipid-P↑, MDA↑, GSH↓, HO-1↑, NRF2↑, GPx↓, ROS↑, Iron↑, GPx4↓, HSP70/HSPA5↑, ATFs↑, CHOP↑, MDA↑, FTL↑, FTH1↑, BACH1↑, REL↑, USF1↑, NFE2L2↑,

413-

CUR,

Curcumin attenuates lncRNA H19-induced epithelial-mesenchymal transition in tamoxifen-resistant breast cancer cells

-

in-vitro,

BC,

MCF-7

31.7 µM

N-cadherin↓, E-cadherin↑, H19↓,

412-

CUR,

Curcumin and Its New Derivatives: Correlation between Cytotoxicity against Breast Cancer Cell Lines, Degradation of PTP1B Phosphatase and ROS Generation

-

in-vitro,

BC,

MCF-7

-

in-vitro,

BC,

MDA-MB-231

ROS↑, PTP1B↓,

411-

CUR,

Curcumin inhibits the invasion and metastasis of triple negative breast cancer via Hedgehog/Gli1 signaling pathway

-

in-vitro,

BC,

MDA-MB-231

HH↓, EMT↓, Gli1↓,

410-

CUR,

Nrf2 depletion enhanced curcumin therapy effect in gastric cancer by inducing the excessive accumulation of ROS

-

vitro+vivo,

GC,

AGS

mice

-

vitro+vivo,

GC,

HGC27

ROS↑, NRF2↑,

409-

CUR,

Curcumin Inhibits Glyoxalase 1—A Possible Link to Its Anti-Inflammatory and Anti-Tumor Activity

-

in-vitro,

Pca,

PC3

7.9 µM

-

in-vitro,

BC,

MDA-MB-231

GLO-I↓, GSH↓, ATP↓,

408-

CUR,

Cytotoxic, chemosensitizing and radiosensitizing effects of curcumin based on thioredoxin system inhibition in breast cancer cells: 2D vs. 3D cell culture system

-

in-vitro,

BC,

MCF-7

10-100uM

Trx1↓,

407-

CUR,

Curcumin inhibited growth of human melanoma A375 cells via inciting oxidative stress

-

in-vitro,

Melanoma,

A375

80uM

Apoptosis↑, ROS↑, GSH↓, MMP↓,

406-

CUR,

Effect of curcumin on normal and tumor cells: Role of glutathione and bcl-2

-

in-vitro,

BC,

MCF-7

50 μmol/L

-

in-vitro,

Hepat,

HepG2

GSH↓, Apoptosis↑, Bcl-2↓, cMyc↓,

405-

CUR,

5-FU,

Curcumin activates a ROS/KEAP1/NRF2/miR-34a/b/c cascade to suppress colorectal cancer metastasis

-

vitro+vivo,

CRC,

HCT116

15uM

Apoptosis↑, TumCMig↓, NRF2↑, ROS↑, MET↓, NA↑,

477-

CUR,

Curcumin induces G2/M arrest and triggers autophagy, ROS generation and cell senescence in cervical cancer cells

-

in-vitro,

Cerv,

SiHa

5, 15, 30 and 50 µM, 6, 12, 24 and 48 h

TumCP↓, TumCCA↑, Apoptosis↑, TumAuto↑, CycB↓, CDC25↓, ROS↑, p62↑, LC3‑Ⅱ/LC3‑Ⅰ↑, cl‑Casp3↑, cl‑PARP↑, P53↑, P21↑,

468-

CUR,

5-FU,

Gut microbiota enhances the chemosensitivity of hepatocellular carcinoma to 5-fluorouracil in vivo by increasing curcumin bioavailability

-

vitro+vivo,

Liver,

HepG2

15 and 30 μM, 24, 48 and 72 h; 100 mg/kg/day, 14 days

-

vitro+vivo,

Liver,

402

-

vitro+vivo,

Liver,

Bel7

Apoptosis↑, TumCCA↑, PI3k/Akt/mTOR↓, p‑PI3K↓, Bacteria↑, cl‑Casp3↑,

459-

CUR,

Curcumin inhibits cell proliferation and motility via suppression of TROP2 in bladder cancer cells

-

in-vitro,

Bladder,

T24

10, 15, 20 and 25 µM, 48 and 72 h

-

in-vitro,

Bladder,

RT4

Trop2↓, Apoptosis↑, cycE1↓, p27↑, TumCCA↑,

460-

CUR,

Curcumin Suppresses microRNA-7641-Mediated Regulation of p16 Expression in Bladder Cancer

-

in-vitro,

Bladder,

T24

1, 5, 10 and 20 µM, 24, 48 and 72 h

-

in-vitro,

Bladder,

TCCSUP

-

in-vitro,

Bladder,

J82

miR-7641↓, p16↑, Apoptosis↑, TumCI↓,

461-

CUR,

Curcumin inhibits prostate cancer progression by regulating the miR-30a-5p/PCLAF axis

-

in-vitro,

Pca,

PC3

10, 20, 30, 40 and 50 µM, 12, 24 and 48 h

-

in-vitro,

Pca,

DU145

TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, miR-30a-5p↑, PCLAF↓, Bcl-2↓, Casp3↓, BAX↑, cl‑Casp3↑,

462-

CUR,

Curcumin promotes cancer-associated fibroblasts apoptosis via ROS-mediated endoplasmic reticulum stress

-

in-vitro,

Pca,

PC3

10, 20 and 30 μM, 8, 12 and 24 h

Bcl-2↓, MMP↓, cl‑Casp3↑, BAX↑, BIM↑, p‑PARP↑, PUMA↑, p‑P53↑, ROS↑, p‑ERK↑, p‑eIF2α↑, CHOP↑, ATF4↑,

463-

CUR,

Curcumin induces autophagic cell death in human thyroid cancer cells

-

in-vitro,

Thyroid,

K1

10, 12.5, 20, 25, 30, 40 and 50 µM, 24 and 72 h

-

in-vitro,

Thyroid,

FTC-133

-

in-vitro,

Thyroid,

BCPAP

-

in-vitro,

Thyroid,

8505C

TumAuto↑, LC3II↑, Beclin-1↑, p‑p38↑, p‑JNK↑, p‑ERK↑, p62↓, p‑PDK1↓, p‑Akt↓, p‑p70S6↓, p‑PIK3R1↓, p‑S6↓, p‑4E-BP1↓,

464-

CUR,

Curcumin inhibits the viability, migration and invasion of papillary thyroid cancer cells by regulating the miR-301a-3p/STAT3 axis

-

in-vitro,

Thyroid,

BCPAP

2.5, 5, 10, 20 and 40 µM, 24 h

-

in-vitro,

Thyroid,

TPC-1

TumCI↓, TumCI↓, MMP2↓, MMP9↓, EMT↓, STAT3↓, miR-301a-3p↓, STAT↓, N-cadherin↓, Vim↓, Fibronectin↓, p‑JAK↓, p‑JAK2↓, p‑JAK3↓, p‑STAT1↓, p‑STAT2↓, E-cadherin↑,

465-

CUR,

Curcumin inhibits the growth of liver cancer by impairing myeloid-derived suppressor cells in murine tumor tissues

-

vitro+vivo,

Liver,

HepG2

1.2, 2.4, 4.8 and 9.6 µg/mL, 24 and 48 h; 120 and 240 mg/kg/day, 15 days

-

vitro+vivo,

Liver,

HUH7

-

vitro+vivo,

Liver,

MHCC-97H

TumCG↓, MDSCs↓, TLR4↓, NF-kB↓, IL6↓, IL1↓, PGE2↓, COX2↓, GM-CSF↓, angioG↓, VEGF↓, CD31↓, GM-CSF↓, α-SMA↓, p‑IKKα↓, MyD88↓,

466-

CUR,

Curcumin circumvent lactate-induced chemoresistance in hepatic cancer cells through modulation of hydroxycarboxylic acid receptor-1

-

in-vitro,

Liver,

HepG2

5 and 10 μM, 24 h

-

in-vitro,

Liver,

HuT78

GlucoseCon↓, lactateProd↓, pH↑, NO↑, LAR↓, Hif1a↓, LDHA↓, MCT1↓, MDR1↓, STAT3↓, HCAR1↓,

467-

CUR,

Curcumin inhibits liver cancer by inhibiting DAMP molecule HSP70 and TLR4 signaling

-

in-vitro,

Liver,

HepG2

20, 50, 80 and 100 μM, 24, 48 and 72 h

TumCP↓, TumCI↓, TumMeta↓, Apoptosis↑, HSP70/HSPA5↓, e-HSP70/HSPA5↓, TLR4↓,

458-

CUR,

Curcumin suppresses gastric cancer by inhibiting gastrin‐mediated acid secretion

-

vitro+vivo,

GC,

SGC-7901

25 μM, 3, 5 and 7 days; 100 mg/kg, 2 weeks

Casp3↑, Apoptosis↑, TumCP↓,

469-

CUR,

The inhibitory effect of curcumin via fascin suppression through JAK/STAT3 pathway on metastasis and recurrence of ovary cancer cells

-

in-vitro,

Ovarian,

SKOV3

10, 20, 30, 40 and 50 μM, 6, 12 and 24 h

fascin↓, STAT3↓, JAK↓,

470-

CUR,

Regulation of carcinogenesis and modulation through Wnt/β-catenin signaling by curcumin in an ovarian cancer cell line

-

in-vitro,

Ovarian,

SKOV3

20 μM, 96 h

Wnt/(β-catenin)↓, EMT↓, DNMT3A↓, cycD1↓, cMyc↓, Fibronectin↓, Vim↓, E-cadherin↑, SFRP5↑,

471-

CUR,

Curcumin induces apoptotic cell death and protective autophagy by inhibiting AKT/mTOR/p70S6K pathway in human ovarian cancer cells

-

in-vitro,

Ovarian,

SKOV3

5, 10, 20, 40 and 80 μM, 24, 48 and 72 h

-

in-vitro,

Ovarian,

A2780S

Apoptosis↑, TumAuto↑, p62↓, p‑Akt↓, p‑mTOR↓, p‑P70S6K↓, Casp9↑, PARP↑, ATG3↑, Beclin-1↑, LC3‑Ⅱ/LC3‑Ⅰ↑,

472-

CUR,

Curcumin inhibits ovarian cancer progression by regulating circ-PLEKHM3/miR-320a/SMG1 axis

-

vitro+vivo,

Ovarian,

SKOV3

10, 20 and 40 μM, 24, 48 and 72 h; 15 mg/kg/2days, 5 weeks

mice

-

vitro+vivo,

Ovarian,

A2780S

TumCP↓, Apoptosis↑, PCNA↓, miR-320a↓, BAX↑, cl‑Casp3↑, circ‑PLEKHM3↑, SMG1↑,

473-

CUR,

Curcumin inhibits epithelial-mesenchymal transition in oral cancer cells via c-Met blockade

-

in-vitro,

Oral,

HSC4

15 μM, 48 h

-

in-vitro,

Oral,

Ca9-22

Vim↓, p‑cMET↓, p‑ERK↓, pro‑MMP9↓, E-cadherin↑,

474-

CUR,

Modification of radiosensitivity by Curcumin in human pancreatic cancer cell lines

-

in-vitro,

PC,

PANC1

6, 10 and 12 µM, 24 h

-

in-vitro,

PC,

MIA PaCa-2

TumCD↑, Apoptosis↑, DNAdam↑, γH2AX↑, TumCCA↑,

475-

CUR,

Curcumin induces apoptotic cell death in human pancreatic cancer cells via the miR-340/XIAP signaling pathway

-

in-vitro,

PC,

PANC1

2.5, 5, 10 and 20 µM, 72 h

Apoptosis↑, cl‑Casp3↑, miR-340↑, cl‑PARP↑, XIAP↓,

476-

CUR,

The effects of curcumin on proliferation, apoptosis, invasion, and NEDD4 expression in pancreatic cancer

-

in-vitro,

PC,

PATU-8988

5, 10, 15 and 20 μM, 48 and 72 h

-

in-vitro,

PC,

PANC1

TumCMig↓, TumCI↓, Apoptosis↑, NEDD9↓, p‑Akt↓, p‑mTOR↓, PTEN↑, p73↑, β-TRCP↑,

449-

CUR,

Curcumin Suppresses the Colon Cancer Proliferation by Inhibiting Wnt/β-Catenin Pathways via miR-130a

-

vitro+vivo,

CRC,

SW480

40 μM, 24 h; 200 mg/kg, 5 days

TumCP↓, β-catenin/ZEB1↓, TCF↓, miR-21↓, NKD2↑, miR-130a↓,

441-

CUR,

Curcumin Regulates ERCC1 Expression and Enhances Oxaliplatin Sensitivity in Resistant Colorectal Cancer Cells through Its Effects on miR-409-3p

-

in-vitro,

CRC,

HCT116

10, 20, 30 and 40 µM, 48 h

ERCC1↓, Bcl-2↓, GSTP1/GSTπ↓, MRP↓, P-gp↓, miR-409-3p↑, survivin↓,

442-

CUR,

5-FU,

Curcumin may reverse 5-fluorouracil resistance on colonic cancer cells by regulating TET1-NKD-Wnt signal pathway to inhibit the EMT progress

-

in-vitro,

CRC,

HCT116

0-40uM

Apoptosis↑, TumCP↓, TumCCA↑, TET1↑, NKD2↑, Wnt↓, EMT↓, Vim↑, E-cadherin↓, β-catenin/ZEB1↓, TCF↓, AXIN1↓,

443-

CUR,

Reduced Caudal Type Homeobox 2 (CDX2) Promoter Methylation Is Associated with Curcumin’s Suppressive Effects on Epithelial-Mesenchymal Transition in Colorectal Cancer Cells

-

in-vitro,

CRC,

SW480

DNMT1↓, DNMT3A↓, N-cadherin↓, Vim↓, Wnt↓, Snail↓, Twist↓, β-catenin/ZEB1↓, E-cadherin↑, EMT↓, CDX2↓,

444-

CUR,

Cisplatin,

LncRNA KCNQ1OT1 is a key factor in the reversal effect of curcumin on cisplatin resistance in the colorectal cancer cells

-

vitro+vivo,

CRC,

HCT8

10 μM, 48 h; 1 g/kg/week, 42 days

TumVol↓, Apoptosis↑, Bcl-2↓, Cyt‑c↑, BAX↑, cl‑Casp3↑, cl‑PARP1↑, miR-497↑, KCNQ1OT1↓,

445-

CUR,

Curcumin Regulates the Progression of Colorectal Cancer via LncRNA NBR2/AMPK Pathway

-

in-vitro,

CRC,

HCT116

10 μM, 24 h

-

in-vitro,

CRC,

HCT8

-

in-vitro,

CRC,

SW480

-

in-vitro,

CRC,

SW-620

p‑AMPK↑, p‑ACC-α↑, NBR2↑, p‑S6K↓, mTOR↓,

446-

CUR,

The Influence of Curcumin on the Downregulation of MYC, Insulin and IGF-1 Receptors: A Possible Mechanism Underlying the Anti-Growth and Anti-Migration in Chemoresistant Colorectal Cancer Cells

-

in-vitro,

CRC,

SW480

5, 10, 15, 20, 25, 30, and 50 μM, 48 and 72 h

IR↓, IGF-1↓, Myc↓, TumCMig↓, TumCP↓,

447-

CUR,

OXA,

Curcumin reverses oxaliplatin resistance in human colorectal cancer via regulation of TGF-β/Smad2/3 signaling pathway

-

vitro+vivo,

CRC,

HCT116

1, 2, 4, 8, 16, 32 and 64 μM, 48 h; 60 mg/kg, 3 weeks

4uM(Cur)+10uM(OXA)

p‑p65↓, Bcl-2↓, Casp3↑, EMT↓, p‑SMAD2↓, p‑SMAD3↓, N-cadherin↓, TGF-β↓, E-cadherin↑, TumVol↓, TumCMig↓,

448-

CUR,

Heat shock protein 27 influences the anti-cancer effect of curcumin in colon cancer cells through ROS production and autophagy activation

-

in-vitro,

CRC,

HT-29

15, 20 and 25 μM, 48 h

Apoptosis↑, TumCCA↑, p‑Akt↓, Akt↓, Bcl-2↓, p‑BAD↓, BAD↑, cl‑PARP↑, ROS↑, HSP27↑, Beclin-1↑, p62↑, GPx1↓, GPx4↓,

440-

CUR,

Curcumin Reverses NNMT-Induced 5-Fluorouracil Resistance via Increasing ROS and Cell Cycle Arrest in Colorectal Cancer Cells

-

vitro+vivo,

CRC,

SW480

10, 20, 30, 40, 50 and 60 µM, 24 h; 100 mg/kg/day, 3 weeks

-

vitro+vivo,

CRC,

HT-29

13.69 μM

NNMT↓, p‑STAT3↓, TumCP↓, TumCCA↑, ROS↑,

450-

CUR,

Curcumin may be a potential adjuvant treatment drug for colon cancer by targeting CD44

-

in-vitro,

CRC,

HCT116

2.5, 5, 10, 20 and 40 µM, 24 h

-

in-vitro,

CRC,

HCT8

TumCP↓, TumCMig↓, CD44↓,

451-

CUR,

The effect of Curcumin on multi-level immune checkpoint blockade and T cell dysfunction in head and neck cancer

-

vitro+vivo,

HNSCC,

SCC15

1, 2, 5, 10, 20, 40 and 80 µM, 1, 3, 6, 12 and 24 h; 50 mg/kg, 6 weeks

-

vitro+vivo,

HNSCC,

SNU1076

-

vitro+vivo,

HNSCC,

SNU1041

TumCMig↓, TumCG↓, PD-L1↓, PD-L2↓, Galectin-9↓, EMT↓, T-Cell↑, TILs↑, PD-1↓, TIM-3↓, CD4+↓, CD25+↓, FoxP3+↓, E-cadherin↑, CD8+↑, IFN-γ↑,

452-

CUR,

Curcumin downregulates the PI3K-AKT-mTOR pathway and inhibits growth and progression in head and neck cancer cells

-

vitro+vivo,

HNSCC,

SCC9

0, 25, 10, 5, 2.5, 1.25 and 0.75 μM, 24 and 48 h

41uM

-

vitro+vivo,

HNSCC,

FaDu

-

vitro+vivo,

HNSCC,

HaCaT

TumCCA↑, PI3k/Akt/mTOR↓, Casp3↑, EGFR↓, EGF↑, PRKCG↑, p‑Akt↓, p‑mTOR↓, RPS6KA1↓, EIF4E↓, proCasp3↓,

453-

CUR,

Cellular uptake and apoptotic properties of gemini curcumin in gastric cancer cells

-

in-vitro,

GC,

AGS

10,- 100 µM, 24, 48 and 72 h; 50 mg/kg, 6weeks

Bcl-2↓, survivin↓, BAX↑, TumCCA↑,

454-

CUR,

Curcumin-Induced DNA Demethylation in Human Gastric Cancer Cells Is Mediated by the DNA-Damage Response Pathway

-

in-vitro,

GC,

MGC803

5, 10, 15, 20, 40 and 60 μM, 24, 48 and 72 h

TumCMig↓, TumCP↓, ROS↑, mtDam↑, DNAdam↑, Apoptosis↑, ATR↑, P21↑, p‑P53↑, GADD45A↑, p‑γH2AX↑,

455-

CUR,

Curcumin Affects Gastric Cancer Cell Migration, Invasion and Cytoskeletal Remodeling Through Gli1-β-Catenin

-

in-vitro,

GC,

SGC-7901

10, 20, 40 and 80 µM, 48 h

Shh↓, Gli1↓, Foxm1↓, β-catenin/ZEB1↓, TumCMig↓, Apoptosis↑, TumCCA↑, Wnt↓, EMT↓, E-cadherin↑, Vim↓,

456-

CUR,

Curcumin Promoted miR-34a Expression and Suppressed Proliferation of Gastric Cancer Cells

-

vitro+vivo,

GC,

SGC-7901

50 μM, 24, 48 and 96 h

miR-34a↑, TumCP↓, TumCMig↓, TumCI↓, TumCCA↑, Bcl-2↓, CDK4/6↓, cycD1↓,

457-

CUR,

Curcumin regulates proliferation, autophagy, and apoptosis in gastric cancer cells by affecting PI3K and P53 signaling

-

in-vitro,

GC,

SGC-7901

10, 20 and 40 μM, 24 h

-

in-vitro,

GC,

BGC-823

TumCP↓, Apoptosis↑, TumAuto↑, P53↑, PI3K↓, P21↑, p‑Akt↓, p‑mTOR↓, Bcl-2↓, Bcl-xL↓, LC3I↓, BAX↑, Beclin-1↑, cl‑Casp3↑, cl‑PARP↑, LC3II↑, ATG3↑, ATG5↑,

1006-

CUR,

The effect of Curcuma longa extract and its active component (curcumin) on gene expression profiles of lipid metabolism pathway in liver cancer cell line (HepG2)

-

in-vitro,

Liver,

HepG2

(15, 30, 60, 125, 250, 1000, 2000 μg/ml

TumCP↓, PGC1A↑, CPT1A↑, ACOX1↑, SCD1↓, SREBF2↓, DGAT1↓,

990-

CUR,

Curcumin inhibits aerobic glycolysis and induces mitochondrial-mediated apoptosis through hexokinase II in human colorectal cancer cells in vitro

-

in-vitro,

CRC,

HCT116

-

in-vitro,

CRC,

HT-29

HK2↓, Glycolysis↓, Apoptosis↑,

1034-

CUR,

immuno,

Enhanced anti‐tumor effects of the PD‐1 blockade combined with a highly absorptive form of curcumin targeting STAT3

-

in-vivo,

NA,

NA

mice

DCells↑, T-Cell↑,

479-

CUR,

Curcumin Has Anti-Proliferative and Pro-Apoptotic Effects on Tongue Cancer in vitro: A Study with Bioinformatics Analysis and in vitro Experiments

-

in-vitro,

Tong,

CAL27

10, 25, 50 and 100 µM, 16 and 24 h

TumCP↓, TumCMig↓, Apoptosis↑, TumCCA↑, Bcl-2↓, BAX↑, cl‑Casp3↑,

478-

CUR,

Curcumin decreases epithelial‑mesenchymal transition by a Pirin‑dependent mechanism in cervical cancer cells

-

in-vitro,

Cerv,

SiHa

20 µM, 72 h

EMT↓, N-cadherin↓, Vim↓, Slug↓, Zeb1↓, PIR↓, Pirin↓, E-cadherin↑,

480-

CUR,

Curcumin exerts its tumor suppressive function via inhibition of NEDD4 oncoprotein in glioma cancer cells

-

in-vitro,

GBM,

SNB19

10, 15, 20 and 25 µM, 48 and 72 h

TumCP↓, TumCMig↓, Apoptosis↑, TumCCA↑, NEDD9↓, NOTCH1↓, p‑Akt↓,

481-

CUR,

CHr,

Api,

Flavonoid-induced glutathione depletion: Potential implications for cancer treatment

-

in-vitro,

Liver,

A549

-

in-vitro,

Pca,

PC3

-

in-vitro,

AML,

HL-60

GSH↓, mtDam↑, MMP↓, Cyt‑c↑,

482-

CUR,

PDT,

The Antitumor Effect of Curcumin in Urothelial Cancer Cells Is Enhanced by Light Exposure In Vitro

-

in-vitro,

Bladder,

RT112

0.1 to 0.4 μg/ml

-

in-vitro,

Bladder,

UMUC3

Apoptosis↑, TumCG↓, TumCP↓,

483-

CUR,

PDT,

Visible light and/or UVA offer a strong amplification of the anti-tumor effect of curcumin

-

in-vivo,

NA,

A431

0.2–1 μg/ml

mice

TumVol↓, TumCP↓, Apoptosis↑,

484-

CUR,

PDT,

Low concentrations of curcumin induce growth arrest and apoptosis in skin keratinocytes only in combination with UVA or visible light

-

in-vitro,

Melanoma,

NA

0.2-1 microg/ml

skin keratinocytes

Cyt‑c↑, Casp9↑, Casp8↑, NF-kB↓, EGFR↓,

485-

CUR,

PDT,

Red Light Combined with Blue Light Irradiation Regulates Proliferation and Apoptosis in Skin Keratinocytes in Combination with Low Concentrations of Curcumin

-

in-vitro,

Melanoma,

NA

1.25–3.12 μM

Skin Keratinocytes

NF-kB↓, Casp8↑, Casp9↑, p‑Akt↓, p‑ERK↓,

1910-

CUSP9,

A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care

-

Analysis,

GBM,

NA

Dose↝, QoL↑, Dose↝,

1871-

DAP,

Targeting PDK1 with dichloroacetophenone to inhibit acute myeloid leukemia (AML) cell growth

-

in-vitro,

AML,

U937

14.0 μM

-

in-vivo,

AML,

NA

mouse

TumCP↓, Apoptosis↑, TumCG↓, PDK1↓, cl‑PARP↑, Bcl-xL↓, Bcl-2↓, Beclin-1↓, ATG3↓, PI3K↓, Akt↓, eff↑,

1876-

DCA,

Chemo,

In vitro cytotoxicity of novel platinum-based drugs and dichloroacetate against lung carcinoid cell lines

-

in-vivo,

Lung,

H727

eff↑, TumCG↓, Glycolysis↓, mitResp↑,

1889-

DCA,

A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth

-

Review,

Var,

NA

PDKs↓, Glycolysis↓, mt-H2O2↑, Apoptosis↑, TumCP↓, TumCG↓, toxicity∅,

1887-

DCA,

GSTZ1 expression and chloride concentrations modulate sensitivity of cancer cells to dichloroacetate

-

in-vitro,

Var,

NA

GSTZ1∅, eff↓, PDKs↓, Chl∅, eff↓,

1885-

DCA,

Role of SLC5A8, a plasma membrane transporter and a tumor suppressor, in the antitumor activity of dichloroacetate

-

in-vitro,

CRC,

HCT116

These three cell lines do not express SLC5A8

-

in-vitro,

CRC,

SW-620

-

in-vitro,

CRC,

HT-29

SMCT1∅, eff↓, eff↑, eff↑, PDKs↓, MMP↓, Glycolysis↓, mitResp↑, ROS↑, eff↑,

1883-

DCA,

In vivo metabolic response of glucose to dichloroacetate in humans

-

Analysis,

Var,

NA

BG↓, glucoNG↓,

1882-

DCA,

Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer

-

Analysis,

NA,

NA

PDKs↓, PDH↑, lactateProd↓, Half-Life∅,

1881-

DCA,

Chemo,

Co-treatment of dichloroacetate, omeprazole and tamoxifen exhibited synergistically antiproliferative effect on malignant tumors: in vivo experiments and a case report

-

in-vitro,

NA,

HT1080

-

in-vitro,

NA,

WI38

-

Case Report,

Var,

NA

eff↑, selectivity↑, OS↑,

1880-

DCA,

A Novel Form of Dichloroacetate Therapy for Patients With Advanced Cancer: A Report of 3 Cases

-

Case Report,

Var,

NA

OS↑, angioG↓, Hif1a↝, pH↝, QoL↑,

1879-

DCA,

Long-term stabilization of metastatic melanoma with sodium dichloroacetate

-

Case Report,

Melanoma,

NA

OS↑, toxicity↓, Dose∅, Dose∅, Dose∅, QoL∅,

1878-

DCA,

5-FU,

Synergistic Antitumor Effect of Dichloroacetate in Combination with 5-Fluorouracil in Colorectal Cancer

-

in-vitro,

CRC,

LS174T

57mM

-

in-vitro,

CRC,

LoVo

29mM

-

in-vitro,

CRC,

SW-620

38mM

-

in-vitro,

CRC,

HT-29

47mM

tumCV↓, eff↑, PDKs↓, lactateProd↓, Glycolysis↓, mitResp↑, TumCCA↑, Bcl-2↓, BAX↑, Casp3↑,

1877-

DCA,

Non-Hodgkin′s Lymphoma Reversal with Dichloroacetate

-

Case Report,

lymphoma,

NA

Remission↑, p‑PDKs↓, Glycolysis↓, i-Ca+2↓, toxicity↓, Dose∅,

1884-

DCA,

Sal,

Dichloroacetate and Salinomycin Exert a Synergistic Cytotoxic Effect in Colorectal Cancer Cell Lines

-

in-vitro,

CRC,

DLD1

-

in-vitro,

CRC,

HCT116

eff↑, pH↓, PDKs↓, Warburg↓,

1875-

DCA,

Dichloroacetate inhibits neuroblastoma growth by specifically acting against malignant undifferentiated cells

-

in-vitro,

neuroblastoma,

NA

-

in-vivo,

NA,

NA

five mice were treated with 2.5 mg/kg/ dose of DCA, 14 mice were treated with 25 mg/kg/dose

mice

selectivity↑, AntiCan↑, TumVol↓, PDKs↓, mt-OXPHOS↑, MMP↓, Glycolysis↓, toxicity↓, Warburg↓, ROS↑, eff↑,

1874-

DCA,

Dichloroacetate induces apoptosis of epithelial ovarian cancer cells through a mechanism involving modulation of oxidative stress

-

in-vitro,

Ovarian,

SKOV3

20, 40, and 80 mg/mL DCA doses,

-

in-vitro,

Ovarian,

MDAH-2774

Apoptosis↑, MPO↓, iNOS↓, Hif1a↓, SOD↑, Casp3↑,

1873-

DCA,

Dual-targeting of aberrant glucose metabolism in glioblastoma

-

in-vitro,

GBM,

U87MG

-

in-vitro,

GBM,

U251

PDKs↓, eff↑, selectivity↑, MMP↓, ROS↑, Apoptosis↑, Warburg↓, eff↑, Dose∅, toxicity∅,

1872-

DCA,

Dichloroacetate, a selective mitochondria-targeting drug for oral squamous cell carcinoma: a metabolic perspective of treatment

-

in-vitro,

Oral,

HSC2

-

in-vitro,

Oral,

HSC3

PDKs↓, ROS↑, OCR↑, other↑,

1870-

DCA,

Rad,

Dichloroacetate (DCA) sensitizes both wild-type and over expressing Bcl-2 prostate cancer cells in vitro to radiation

-

in-vitro,

Pca,

PC3

TumCCA↑, Apoptosis↑, MMP↓, eff↑, RadioS↑,

1864-

DCA,

MET,

Dichloroacetate Enhances Apoptotic Cell Death via Oxidative Damage and Attenuates Lactate Production in Metformin-Treated Breast Cancer Cells

-

in-vitro,

BC,

MCF-7

DCA (2.5 mM) and metformin (1 mM)

-

in-vitro,

BC,

T47D

-

in-vitro,

Nor,

MCF10

PDKs↓, eff↑, ROS↑, PDK1↓, lactateProd↓, p‑PDH↑, Dose∅, OCR↑, DNA-PK↑, γH2AX↑, cl‑PARP↑, selectivity↑, *toxicity∅,

1865-

DCA,

Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo

-

in-vivo,

BC,

NA

rat

-

in-vitro,

BC,

MCF-7

-

in-vitro,

BC,

T47D

TumCG↓, TumCP↓, AntiCan↑,

1866-

DCA,

MET,

BTZ,

Targeting metabolic pathways alleviates bortezomib-induced neuropathic pain without compromising anticancer efficacy in a sex-specific manner

-

in-vivo,

NA,

NA

mice

eff↑, TumCG↓, Hif1a↓, PDH↑, lactateProd↓, TumVol↓, TumW↓, Glycolysis↑, neuroP↑,

1867-

DCA,

Chemo,

Sensitization of breast cancer cells to paclitaxel by dichloroacetate through inhibiting autophagy

-

in-vivo,

BC,

NA

mice

-

in-vitro,

BC,

NA

TumCG↓, eff↑, OS↑, PDKs↓, PDH↑,

1868-

DCA,

MET,

Long-term stabilization of stage 4 colon cancer using sodium dichloroacetate therapy

-

Case Report,

NA,

NA

eff↑, toxicity∅, MMP↓, Apoptosis↑, selectivity↑, pH↝, Dose↝, Dose↝, eff↑,

1869-

DCA,

Dichloroacetate induces autophagy in colorectal cancer cells and tumours

-

in-vitro,

CRC,

HT-29

-

in-vitro,

CRC,

HCT116

-

in-vitro,

Pca,

PC3

-

in-vitro,

CRC,

HT-29

LC3II↑, ROS↑, mTOR↓, MCT1↓, NADH:NAD↓, NAD↑, TumAuto↑, lactateProd↓, LDH↑,

1445-

Deg,

Deguelin--an inhibitor to tumor lymphangiogenesis and lymphatic metastasis by downregulation of vascular endothelial cell growth factor-D in lung tumor model

-

in-vivo,

lymphoma,

NA

(4 mg/kg) i.p.

mice

-

in-vitro,

lymphoma,

NA

Akt↓, TumCP↓, TumCMig↓, VEGF↓, TumCG↓, OS↑,

1444-

Deg,

Deguelin promotes apoptosis and inhibits angiogenesis of gastric cancer

-

in-vitro,

GC,

MKN-28

1uM 24hrs

cell line SNU-484

Casp9↑, Casp3↑, Hif1a↓, VEGF↓, TumCCA↑, TumCG↓, DNAdam↑, p‑Akt↓,

1443-

Deg,

Deguelin Action Involves c-Met and EGFR Signaling Pathways in Triple Negative Breast Cancer Cells

-

vitro+vivo,

BC,

MDA-MB-231

Deguelin at 2 mg and 4 mg (per kg body weight) daily by i.p. injection.

mice

-

in-vitro,

BC,

MDA-MB-435

(0–500 nM) for 24–72 h.

-

in-vitro,

BC,

BT549

EGFR↓, Akt↓, p‑ERK↓, NF-kB↓, p‑STAT3↓, survivin↓, Myc↓, TumCG↓, cMET↓,

1442-

Deg,

Deguelin, a novel anti-tumorigenic agent targeting apoptosis, cell cycle arrest and anti-angiogenesis for cancer chemoprevention

-

Review,

Var,

NA

PI3K/Akt↓, IKKα↓, AMP↓, mTOR↓, survivin↓, NF-kB↓, Apoptosis↑, TumCCA↑, toxicity↓, HSP90↓, Casp↑, TumCG↓, p27↑, cycE↓, angioG↓, Hif1a↓, VEGF↓, *toxicity↑,

1446-

Deg,

Efficacy and mechanism of action of Deguelin in suppressing metastasis of 4T1 cells

-

in-vitro,

BC,

4T1

250nM

cMET↓, p‑ERK↓, p‑Akt↓, TumCMig↓, TumCG↓, Weight∅, *toxicity∅, Hif1a↓, TumMeta↓,

19-

Deg,

Deguelin inhibits proliferation and migration of human pancreatic cancer cells in vitro targeting hedgehog pathway

-

in-vitro,

PC,

Bxpc-3

-

in-vitro,

PC,

PANC1

0-20uM-1wk

HH↓, Gli1↓, PTCH1↓, Sufu↓, MMP2↓, MMP9↓, PI3K/Akt↓, HIF-1↓, VEGF↓, IKKα↓, NF-kB↓, EMT↓, AMPK↑, mTOR↓, survivin↓,

1183-

DHA,

Docosahexaenoic acid inhibited the Wnt/β-catenin pathway and suppressed breast cancer cells in vitro and in vivo

-

in-vitro,

BC,

4T1

-

in-vitro,

BC,

MCF-7

-

in-vivo,

BC,

NA

5% fish oil-supplemented diet

mice

TumCG↓, TumCCA↑, β-catenin/ZEB1↓, TCF↓, LEF1↓, cMyc↓, cycD1↓, Wnt/(β-catenin)↓, TumMeta↓,

1109-

DHA,

DHA inhibits Gremlin-1-induced epithelial-to-mesenchymal transition via ERK suppression in human breast cancer cells

-

in-vitro,

BC,

NA

GREM1↓, TumCMig↓, p‑ERK↓, EMT↓,

1184-

DHA,

Syndecan-1-Dependent Suppression of PDK1/Akt/Bad Signaling by Docosahexaenoic Acid Induces Apoptosis in Prostate Cancer

-

in-vitro,

Pca,

PC3

-

in-vitro,

Pca,

LNCaP

-

in-vivo,

NA,

NA

mice

SDC1↑, p‑PCK1↓, Akt↓, BAD↓,

1035-

DHA,

Docosahexaenoic acid reverses PD-L1-mediated immune suppression by accelerating its ubiquitin-proteasome degradation

-

vitro+vivo,

NA,

NA

PD-L1↓, FASN↓,

951-

DHA,

Docosahexaenoic Acid Attenuates Breast Cancer Cell Metabolism and the Warburg Phenotype by Targeting Bioenergetic Function

-

in-vitro,

BC,

BT474

25-100uM

-

in-vitro,

BC,

MDA-MB-231

-

in-vitro,

Nor,

MCF10

Hif1a↓, GLUT1↓, LDH↓, GlucoseCon↓, lactateProd↓, ATP↓, p‑AMPK↑, ECAR↓, OCR↓, *toxicity↓,

1085-

DHA,

EPA,

DHA and EPA Down-regulate COX-2 Expression through Suppression of NF-kappaB Activity in LPS-treated Human Umbilical Vein Endothelial Cells

-

in-vitro,

Nor,

HUVECs

50-100uM

low doses (10 µM) of DHA and EPA, but not troglitozone, significantly increased the activity of NF-κB in resting HUVECs.

*COX2↓, *NF-kB↓, *PGE2↓, *IL6↓, *NF-kB↑,

1886-

Dicl,

Regulation of colonic epithelial butyrate transport: Focus on colorectal cancer

-

Review,

CRC,

NA

SMCT1↑,

2169-

dietF,

Prolonged stabilization of platinum-resistant ovarian cancer in a single patient consuming a fermented soy therapy

-

Case Report,

Ovarian,

NA

OS↑, CA125↓, eff↑,

2152-

dietFMD,

Prolonged Nightly Fasting and Breast Cancer Prognosis

-

Analysis,

BC,

NA

eff↑, Dose↓, Risk↓,

1848-

dietFMD,

Chemo,

Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial

-

Trial,

BC,

NA

ChemoSideEff↓, ChemoSen↑, eff↑,

1855-

dietFMD,

Impact of modified short-term fasting and its combination with a fasting supportive diet during chemotherapy on the incidence and severity of chemotherapy-induced toxicities in cancer patients - a controlled cross-over pilot study

-

Trial,

NA,

NA

ChemoSideEff↓, QoL↑, IGF-1↓, Insulin↓,

1854-

dietFMD,

How Far Are We from Prescribing Fasting as Anticancer Medicine?

-

Review,

Var,

NA

ChemoSideEff↓, ChemoSen↑, IGF-1↓, IGFBP1↑, adiP↑, glyC↓, E-cadherin↑, MMPs↓, Casp3↑, ROS↑, ATP↓, AMPK↑, mTOR↓, ROS↑, Glycolysis↓, NADPH↓, OXPHOS↝, eff↑, eff↑, *RAS↓, *MAPK↓, *PI3K↓, *Akt↓, eff↑, ROS↑, Akt↑, Casp3↑,

1853-

dietFMD,

Impact of Fasting on Patients With Cancer: An Integrative Review

-

Review,

Var,

NA

*toxicity∅, QoL∅, eff↑, eff↝, ChemoSideEff↓, TumCG↓, Dose↑, toxicity↝, eff↑, IGF-1↑, *OXPHOS↑, BG↓, Insulin↓, RadioS↑,

1852-

dietFMD,

Chemo,

Starvation Based Differential Chemotherapy: A Novel Approach for Cancer Treatment

-

Review,

Var,

NA

ChemoSideEff↓, *toxicity↓, mTOR↓, IGF-1↓, IGFBP1↑, BG↓, ROS↑,

1851-

dietFMD,

Chemo,

Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy

-

in-vitro,

GBM,

LN229

-

in-vitro,

neuroblastoma,

SH-SY5Y

selectivity↑, selectivity↑, ROS↑, DNAdam↑, BG↓,

1850-

dietFMD,

Fasting-mimicking diet remodels gut microbiota and suppresses colorectal cancer progression

-

in-vivo,

CRC,

NA

mice

TumCP↑, angioG↓, CD8+↑, GutMicro↑, eff↑,

1849-

dietFMD,

The emerging role of fasting-mimicking diets in cancer treatment

-

Review,

Var,

NA

TumCG↓, toxicity∅, BG↓, IGF-1↓, mTOR↓, M2 MC↓, eff↑, ChemoSen↑, QoL↑, RadioS↑, selectivity↑,

1857-

dietFMD,

Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy

-

in-vitro,

BC,

4T1

-

in-vivo,

NA,

NA

mouse

TumCG↓, ChemoSen↑, OS↑,

1847-

dietFMD,

VitC,

Synergistic effect of fasting-mimicking diet and vitamin C against KRAS mutated cancers

-

in-vitro,

PC,

PANC1

vitamin C (≥0.3 mM)

TumCG↓, ChemoSen↑, eff↑, HO-1↓, Ferritin↓, Iron↑, ROS↑, TumCD↑, IGF-1↓, eff↓, eff↓,

1846-

dietFMD,

VitC,

A fasting-mimicking diet and vitamin C: turning anti-aging strategies against cancer

-

Study,

Var,

NA

TumCG↓, ChemoSen↑, ChemoSideEff↓, ROS↑, Fenton↑, H2O2↑, eff↑, HO-1↓, DNAdam↑, eff↑,

1845-

dietFMD,

Fasting and fasting mimicking diets in cancer prevention and therapy

-

Review,

Var,

NA

eff↑, selectivity↑, ChemoSen↑,

1841-

dietFMD,

Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer

-

Trial,

Var,

NA

BG↓, AntiCan↑, IFN-γ↑, eff↑, Dose↝, CD14↓, IGF-1↓, IGFR↓, CD8+↑, NK cell↑,

1842-

dietFMD,

Safety and Feasibility of Fasting-Mimicking Diet and Effects on Nutritional Status and Circulating Metabolic and Inflammatory Factors in Cancer Patients Undergoing Active Treatment

-

Trial,

Var,

NA

Strength∅, Weight∅, IGF-1↓, IGFBP3↑, IGFBP1↑, eff↑,

1843-

dietFMD,

BTZ,

Cyclic Fasting–Mimicking Diet Plus Bortezomib and Rituximab Is an Effective Treatment for Chronic Lymphocytic Leukemia

-

in-vivo,

CLL,

NA

mouse

AntiTum↓, Apoptosis↑, IGF-1↓, eff↑, OS↑, eff↑,

1844-

dietFMD,

Unlocking the Potential: Caloric Restriction, Caloric Restriction Mimetics, and Their Impact on Cancer Prevention and Treatment

-

Review,

NA,

NA

Risk↓, AMPK↑, Akt↓, mTOR↓, SIRT1↑, Hif1a↓, NRF2↓, SOD↑, ROS↑, IGF-1↓, p‑Akt↓, PI3K↑, GutMicro↑, OS↑, eff↝, ROS↑, TumCCA↑, *DNArepair↑, DNAdam↑,

1856-

dietFMD,

immuno,

Targeting the Gut Microbiome to Improve Immunotherapy Outcomes: A Review

-

Review,

Var,

NA

GutMicro↑,

1858-

dietFMD,

Chemo,

Effect of short-term fasting on the cisplatin activity in human oral squamous cell carcinoma cell line HN5 and chemotherapy side effects

-

in-vitro,

HNSCC,

HN5

Apoptosis↑, necrosis↑,

1859-

dietFMD,

Chemo,

Fasting-Mimicking Diet Reduces HO-1 to Promote T Cell-Mediated Tumor Cytotoxicity

-

in-vitro,

BC,

4T1

-

in-vivo,

Melanoma,

B16-BL6

mice

CLP↑, CD8+↑, TumCG↓, HO-1↓, TILs↑,

1860-

dietFMD,

Chemo,

Fasting-mimicking diet blocks triple-negative breast cancer and cancer stem cell escape

-

in-vitro,

BC,

SUM159

-

in-vitro,

BC,

4T1

PI3K↑, Akt↑, mTOR↑, CDK4↑, CDK6↑, hyperG↓, TumCG↓, TumVol↓, Casp3↑, BG↓, eff↑, eff∅, PKA↓, KLF5↓, p‑GSK‐3β↑, Nanog↓, OCT4↓, KLF2↓, eff↑, ROS↑, BIM↑, ASK1↑, PI3K↑, Akt↑, mTOR↑, CDK1↓, CDK4↑, CDK6↑, eff↑,

1861-

dietFMD,

Chemo,

Fasting induces anti-Warburg effect that increases respiration but reduces ATP-synthesis to promote apoptosis in colon cancer models

-

in-vitro,

Colon,

CT26

-

in-vivo,

NA,

NA

selectivity↑, ChemoSen↑, BG↓, AminoA↓, Warburg↓, OCR↑, ATP↓, ROS↑, Apoptosis↑, GlucoseCon↓, PI3K↓, PTEN↑, GLUT1↓, GLUT2↓, HK2↓, PFK1↓, PKA↓, ATP:AMP↓, Glycolysis↓, lactateProd↓,

1862-

dietFMD,

Exceptional tumour responses to fasting-mimicking diet combined with standard anticancer therapies: A sub-analysis of the NCT03340935 trial

-

Trial,

Var,

NA

OS↑,

1863-

dietFMD,

Chemo,

Effect of fasting on cancer: A narrative review of scientific evidence

-

Review,

Var,

NA

eff↑, ChemoSideEff↓, ChemoSen↑, Insulin↓, HDAC↓, IGF-1↓, STAT5↓, BG↓, MAPK↓, HO-1↓, ATG3↑, Beclin-1↑, p62↑, SIRT1↑, LAMP2↑, OXPHOS↑, ROS↑, P53↑, DNAdam↑, TumCD↑, ATP↑, Treg lymp↓, M2 MC↓, CD8+↑, Glycolysis↓, GutMicro↑, GutMicro↑, Warburg↓, Dose↝,

2352-

dietFMD,

Glucose restriction reverses the Warburg effect and modulates PKM2 and mTOR expression in breast cancer cell lines

-

in-vitro,

BC,

MDA-MB-231

-

in-vitro,

BC,

MCF-7

Warburg↓, mTOR↓, PKM2↓,

1810-

dietKeto,

Oxy,

The Ketogenic Diet and Hyperbaric Oxygen Therapy Prolong Survival in Mice with Systemic Metastatic Cancer

-

in-vivo,

Var,

NA

mice

BG↓, TumCG↓, OS↑, eff↑, Dose∅, KeyT↑, eff↑, cachexia↓, ChemoSen↑, *ROS↓, ROS↑, lipid-P↑, selectivity↑, toxicity∅,

1893-

dietMet,

Clinical Studies of Methionine-Restricted Diets for Cancer Patients

-

Review,

Var,

NA

mice

TumCG↓, ChemoSen↑, MATs↓,

1894-

dietMet,

Long term methionine restriction: Influence on gut microbiome and metabolic characteristics

-

in-vivo,

Nor,

NA

mice

*GutMicro↓, *OS↑, Weight↓, BG↓,

1895-

dietMet,

Altering Diet Enhances Response to Cancer Treatments in Mice

-

Review,

Var,

NA

ChemoSen↑,

1896-

dietMet,

Dietary methionine links nutrition and metabolism to the efficacy of cancer therapies

-

in-vivo,

CRC,

NA

mice

TumCG↓, *GSH↓, RadioS↑, eff↑,

1897-

dietMet,

Methionine metabolism in health and cancer: a nexus of diet and precision medicine

-

Review,

Var,

NA

OS↑, TumCG↓, TumCCA↑, ChemoSen↑, RadioS↑,

2170-

dietMet,

Low Protein Intake is Associated with a Major Reduction in IGF-1, Cancer, and Overall Mortality in the 65 and Younger but Not Older Population

-

Study,

Var,

NA

OS↑, eff↝, other↝,

2264-

dietMet,

Methionine restriction for cancer therapy: From preclinical studies to clinical trials

-

Review,

Var,

NA

TumCP↓, *ROS?, ChemoSen↑, RadioS↑, eff↑, ROS↑, selectivity↑, TS↓, eff↑,

2265-

dietMet,

Cysteine supplementation reverses methionine restriction effects on rat adiposity: significance of stearoyl-coenzyme A desaturase

-

in-vivo,

Nor,

NA

Rats

*SCD1↓, *Weight↓, *Insulin↓, *IGF-1↓, *adiP↑, *eff↓,

2266-

dietMet,

Cysteine dietary supplementation reverses the decrease in mitochondrial ROS production at complex I induced by methionine restriction

-

in-vivo,

Nor,

NA

Rats

*ROS↓, eff↓,

2267-

dietMet,

Role of amino acids in regulation of ROS balance in cancer

-

Review,

Var,

NA

TumCG↓, GSH↓, ROS↑,

2268-

dietMet,

Methionine dependency and cancer treatment

-

Review,

Var,

NA

ChemoSen↑, *eff↑, selectivity↑, eff↑,

2269-

dietMet,

Mechanisms of Increased In Vivo Insulin Sensitivity by Dietary Methionine Restriction in Mice

-

in-vivo,

Nor,

NA

mice

*adiP↑, *FGF↑, *Insulin↓, *glucose↓, Akt↑, *GSH↓, PTEN↓, FGF21↑, PIP3↑,

2270-

dietMet,

Methionine-restricted diet inhibits growth of MCF10AT1-derived mammary tumors by increasing cell cycle inhibitors in athymic nude mice

-

in-vivo,

Var,

NA

mice

Weight↓, TumVol↓, P21↑, p27↑, *adiP↑, *glucose↓, *IGF-1↓, *FGF21↑, *OS↑, Ki-67↓, Casp3↑, cycD1↓,

2271-

dietMet,

A review of methionine dependency and the role of methionine restriction in cancer growth control and life-span extension

-

Review,

Nor,

NA

*eff↑, *OS↓, *ROS↓, *Weight↓,

2272-

dietMet,

Methionine restriction - Association with redox homeostasis and implications on aging and diseases

-

Review,

Nor,

NA

*OS↑, *mt-ROS↓, *H2S↑, *FGF21↑, *cognitive↑, *GutMicro↑, *IGF-1↓, *mTOR↓, *GSH↑, *SOD↑, *MDA↓, *NRF2↑, *HO-1↑, *NQO1↑, *GLUT4↑, *Glycolysis↑, *HK2↑, *PFK↑, *PKM2↑, *GlucoseCon↑, *ATF4↑, *PPARα↑, GSH↓, GSTs↑, ROS↑, *neuroP↑,

2273-

dietMet,

Methionine and cystine double deprivation stress suppresses glioma proliferation via inducing ROS/autophagy

-

in-vitro,

GBM,

U87MG

-

in-vitro,

GBM,

U251

-

in-vivo,

NA,

NA

mice

ROS↑, GSH↓, TumCP↓, TumAuto↑, LC3II↑,

2263-

dietMet,

Methionine Restriction and Cancer Biology

-

Review,

Var,

NA

AntiCan↑, TumCP↓, TumCG↓, selectivity↑, ChemoSen↓, RadioS↑, Insulin↓, *GlucoseCon↑, *ROS↓, *antiOx↑, *GSH↑, GSH↑, eff↑, polyA↓, TS↓, Raf↓, Akt↓, Casp9↑, Bak↑, P21↑, p27↑, Insulin↓, IGF-1↓,

2154-

dietP,

Ex,

American Cancer Society (ACS) Nutrition and Physical Activity Guidelines after colon cancer diagnosis and disease-free (DFS), recurrence-free (RFS), and overall survival (OS) in CALGB 89803 (Alliance)

-

Trial,

Colon,

NA

OS↑,

2155-

dietP,

Transepithelial Anti-Neuroblastoma Response to Kale among Four Vegetable Juices Using In Vitro Model Co-Culture System

-

in-vivo,

neuroblastoma,

Caco-2

-

NA,

NA,

SH-SY5Y

AntiCan↑, ROS↑, eff↑, eff↑, eff↑,

2156-

dietP,

Phytochemical-rich vegetable and fruit juice alleviates oral mucositis during concurrent chemoradiotherapy in patients with locally advanced head and neck cancer

-

Human,

HNSCC,

NA

chemoP↑, radioP↑, eff↑,

2157-

dietP,

Plant-Based Diets and Disease Progression in Men With Prostate Cancer

-

Study,

Pca,

NA

cohort study of 2062 men diagnosed with nonmetastatic prostate cancer,

TumCG↓, Risk↓, eff↑,

2158-

dietP,

Association of Animal and Plant Protein Intake With All-Cause and Cause-Specific Mortality in a Japanese Cohort

-

Human,

Nor,

NA

OS↓, Risk↓,

2159-

dietP,

Postdiagnostic Fruit and Vegetable Consumption and Breast Cancer Survival: Prospective Analyses in the Nurses' Health Studies

-

Human,

BC,

NA

Risk↑, Risk∅, OS↑, OS↓,

2160-

dietP,

Dietary proteins and protein sources and risk of death: the Kuopio Ischaemic Heart Disease Risk Factor Study

-

Trial,

Heart,

NA

Risk↓,

2161-

dietP,

Plant-Based Diets and Cancer Prognosis: a Review of Recent Research

-

Review,

NA,

NA

OS↑, eff↑, eff↑,

2162-

dietP,

Effect of low-fat diet on breast cancer survival: a meta-analysis

-

Analysis,

BC,

NA

Risk↓, OS↑,

2163-

dietP,

SFN,

Intake of Cruciferous Vegetables Modifies Bladder Cancer Survival

-

Human,

Bladder,

NA

OS↑, OS∅,

2165-

dietP,

SFN,

Broccoli sprout supplementation in patients with advanced pancreatic cancer is difficult despite positive effects—results from the POUDER pilot study

-

Trial,

PC,

NA

Dose↝, OS↑, eff↝,

1606-

EA,

Ellagic acid inhibits proliferation and induced apoptosis via the Akt signaling pathway in HCT-15 colon adenocarcinoma cells

-

in-vitro,

Colon,

HCT15

20-120 uM

TumCP↓, cycD1↓, Apoptosis↑, PI3K↓, Akt↓, ROS↑, Casp3↑, Cyt‑c↑, Bcl-2↓, TumCCA↑, Dose∅, ALP↓, LDH↓, PCNA↓, P53↑, Bax:Bcl2↑,

1617-

EA,

CUR,

The inhibition of human glutathione S-transferases activity by plant polyphenolic compounds ellagic acid and curcumin

-

in-vitro,

Nor,

NA

Dose∅, GSTs↓,

1607-

EA,

Exploring the Potential of Ellagic Acid in Gastrointestinal Cancer Prevention: Recent Advances and Future Directions

-

Review,

GC,

NA

STAT3↓, TumCP↓, Apoptosis↑, NF-kB↓, EMT↓, RadioS↑, antiOx↑, COX1↓, COX2↓, cMyc↓, Snail↓, Twist↓, MMP2↓, P90RSK↓, CDK8↓, PI3K↓, Akt↓, TumCCA↑, Casp8↑, PCNA↓, TGF-β↓, Shh↓, NOTCH↓, IL6↓, ALAT↓, ALP↓, AST↓, VEGF↓, P21↑, *toxicity∅,

1608-

EA,

Ellagic Acid from Hull Blackberries: Extraction, Purification, and Potential Anticancer Activity

-

in-vitro,

Cerv,

HeLa

35 μg/mL

-

in-vitro,

Liver,

HepG2

220ug/mL

-

in-vitro,

BC,

MCF-7

75 ug/mL

-

in-vitro,

Lung,

A549

242um/mL

-

in-vitro,

Nor,

HUVECs

258um/mL

eff↑, Dose∅, *BioAv↑, selectivity↑, TumCP↓, Casp↑, PTEN↑, TSC1↑, mTOR⇅, Akt↓, PDK1↓, E6↓, E7↓, DNAdam↑, ROS↑, *BioAv↓, *BioEnh↑, *Half-Life∅,

1610-

EA,

Anticancer Effect of Pomegranate Peel Polyphenols against Cervical Cancer

-

Review,

Cerv,

NA

TumCCA↑, STAT3↓, P21↑, IGFBP7↑, Akt↓, mTOR↓, ROS↑, DNAdam↑, P53↑, P21↑, BAX↑,

1611-

EA,

Targeting Myeloperoxidase Activity and Neutrophil ROS Production to Modulate Redox Process: Effect of Ellagic Acid and Analogues

-

in-vitro,

Mal,

NA

*BioAv↓, eff↑, *BioAv↓, ROS↑,

1612-

EA,

Negative Effect of Ellagic Acid on Cytosolic pH Regulation and Glycolytic Flux in Human Endometrial Cancer Cell

-

in-vitro,

EC,

NA

20uM

NHE1↓, i-pH↓, ROS↓, GlucoseCon↓, NHE1↓, Glycolysis↓,

1613-

EA,

Ellagitannins in Cancer Chemoprevention and Therapy

-

Review,

Var,

NA

ROS↑, angioG↓, ChemoSen↑, BAX↑, Bak↑, Bcl-2↓, Bcl-xL↓, CDK2↓, CDK4↓, CDK6↓, cycD1↓, cycE1↓, TumCG↓, VEGF↓, Hif1a↓, eff↑, COX2↓, TumCCA↑, selectivity↑, Wnt/(β-catenin)↓, *toxicity∅,

1614-

EA,

Bioavailability of ellagic acid in human plasma after consumption of ellagitannins from pomegranate (Punica granatum L.) juice

-

Human,

Nor,

NA

*BioEnh↝, *Half-Life∅,

1615-

EA,

Absorption, metabolism, and antioxidant effects of pomegranate (Punica granatum l.) polyphenols after ingestion of a standardized extract in healthy human volunteers

-

Human,

Nor,

NA

*BioAv∅, *ROS∅,

1605-

EA,

Ellagic Acid and Cancer Hallmarks: Insights from Experimental Evidence

-

Review,

Var,

NA

*BioAv↓, antiOx↓, Inflam↓, TumCP↓, TumCCA↑, cycD1↓, cycE↓, P53↑, P21↑, COX2↓, NF-kB↓, Akt↑, NOTCH↓, CDK2↓, CDK6↓, JAK↓, STAT3↓, EGFR↓, p‑ERK↓, p‑Akt↓, p‑STAT3↓, TGF-β↓, SMAD3↓, CDK6↓, Wnt/(β-catenin)↓, Myc↓, survivin↓, CDK8↓, PKCδ↓, tumCV↓, RadioS↑, eff↑, MDM2↓, XIAP↓, p‑RB1↓, PTEN↑, p‑FAK↓, Bax:Bcl2↑, Bcl-xL↓, Mcl-1↓, PUMA↑, NOXA↑, MMP↓, Cyt‑c↑, ROS↑, Ca+2↝, Endoglin↑, Diablo↑, AIF↑, iNOS↓, Casp9↑, Casp3↑, cl‑PARP↑, RadioS↑, Hif1a↓, HO-1↓, HO-2↓, SIRT1↓, selectivity↑, Dose∅, NHE1↓, Glycolysis↓, GlucoseCon↓, lactateProd↓, PDK1?, PDK1?, ECAR↝, COX1↓, Snail↓, Twist↓, cMyc↓, Telomerase↓, angioG↓, MMP2↓, MMP9↓, VEGF↓, Dose↝, PD-L1↓, eff↑, SIRT6↑, DNAdam↓,

1618-

EA,

A comprehensive review on Ellagic acid in breast cancer treatment: From cellular effects to molecular mechanisms of action

-

Review,

BC,

NA

TumCCA↑, TumCMig↓, TumCI↓, TumMeta↓, Apoptosis↑, TGF-β↓, SMAD3↓, CDK6↓, PI3K↓, Akt↓, angioG↓, VEGFR2↓, MAPK↓, NEDD9↓, NF-kB↓, eff↑, eff↑, RadioS↑, ChemoSen↑, DNAdam↑, eff↑, *toxicity∅, *toxicity∅,

1619-

EA,

CUR,

Antimutagenic Effect of the Ellagic Acid and Curcumin Combinations

-

in-vitro,

Nor,

NA

eff↑,

1620-

EA,

Rad,

Radiosensitizing effect of ellagic acid on growth of Hepatocellular carcinoma cells: an in vitro study

-

in-vitro,

Liver,

HepG2

ROS↑, P53↑, TumCCA↑, IL6↓, COX2↓, TNF-α↓, MMP↓, angioG↓, MMP9↓, BAX↑, Casp3↑, Apoptosis↑, RadioS↑, TBARS↑, GSH↓, Bax:Bcl2↑, p‑NF-kB↓, p‑STAT3↓,

1621-

EA,

The multifaceted mechanisms of ellagic acid in the treatment of tumors: State-of-the-art

-

Review,

Var,

NA

AntiCan↑, Apoptosis↑, TumCP↓, TumMeta↓, TumCI↓, TumAuto↑, VEGFR2↓, MAPK↓, PI3K↓, Akt↓, PD-1↓, NOTCH↓, PCNA↓, Ki-67↓, cycD1↓, CDK2↑, CDK6↓, Bcl-2↓, cl‑PARP↑, BAX↑, Casp3↑, DR4↑, DR5↑, Snail↓, MMP2↓, MMP9↓, TGF-β↑, PKCδ↓, β-catenin/ZEB1↓, SIRT1↓, HO-1↓, ROS↑, CHOP↑, Cyt‑c↑, MMP↓, OCR↓, AMPK↑, Hif1a↓, NF-kB↓, E-cadherin↑, Vim↓, EMT↓, LC3II↑, CIP2A↓, GLUT1↓, PDH↝, MAD↓, LDH↓, GSTs↑, NOTCH↓, survivin↓, XIAP↓, ER Stress↑, ChemoSideEff↓, ChemoSen↑,

1037-

EA,

Unripe Black Raspberry (Rubus coreanus Miquel) Extract and Its Constitute, Ellagic Acid Induces T Cell Activation and Antitumor Immunity by Blocking PD-1/PD-L1 Interaction

-

in-vivo,

CRC,

NA

25 to100 μg/mL

83.8 ± 4.7 μg/mL

humanized PD-1 mice bearing MC38 colorectal tumor

AntiTum↑, PD-L1↓,

27-

EA,

Ellagic acid inhibits human pancreatic cancer growth in Balb c nude mice

-

in-vivo,

PC,

NA

HH↓, Gli1↓, GLI2↓, cycD1↓, CDK1/2/5/9↓, p‑Akt↓, NOTCH1↓, Akt↓, Shh↓, Snail↓, MMP2↓, MMP9↓, BAX↑, E-cadherin↑, NOTCH3↓, HEY1↓,

1110-

EA,

GEM,

Ellagic Acid Resensitizes Gemcitabine-Resistant Bladder Cancer Cells by Inhibiting Epithelial-Mesenchymal Transition and Gemcitabine Transporters

-

vitro+vivo,

Bladder,

NA

TGF-β↓, SMAD2↓, SMAD3↓, SMAD4↓,

2402-

EA,

Ellagic Acid and Its Metabolites as Potent and Selective Allosteric Inhibitors of Liver Pyruvate Kinase

-

in-vitro,

NA,

NA

PKL↓,

1111-

EDM,

Evodiamine exerts inhibitory roles in non‑small cell lung cancer cell A549 and its sub‑population of stem‑like cells

-

in-vitro,

Lung,

A549

5, 7.5 or 10 µmol/l

TumCP↓, TumCMig↓, TumCI↓, EMT↓,

1022-

EDM,

Evodiamine suppresses non-small cell lung cancer by elevating CD8+ T cells and downregulating the MUC1-C/PD-L1 axis

-

in-vivo,

Lung,

H1975

Female H1975 xenograft nude mice

-

in-vitro,

Lung,

H1650

TumCG↓, Apoptosis↑, TumCCA↑, PD-L1↓, MUC1-C↓, TumVol↓,

1057-

EDM,

Evodiamine abolishes constitutive and inducible NF-kappaB activation by inhibiting IkappaBalpha kinase activation, thereby suppressing NF-kappaB-regulated antiapoptotic and metastatic gene expression, up-regulating apoptosis, and inhibiting invasion

NF-kB↓, TNF-α↓, COX2↓, cycD1↓, cMyc↓, MMP9↓, ICAM-1↓, MDR1↓, XIAP↓, Bcl-2↓, Bcl-xL↓, IAP1↓, IAP2↓, cFLIP↓, Bfl-1↓,

989-

EGCG,

Citrate,

In vitro and in vivo study of epigallocatechin-3-gallate-induced apoptosis in aerobic glycolytic hepatocellular carcinoma cells involving inhibition of phosphofructokinase activity

-

in-vitro,

HCC,

NA

EGCG (50 μM), citrate (5 mM)

-

in-vivo,

NA,

NA

10 mg/kg/ BW/day

mice

PFK↓, Glycolysis↓, lactateProd↓, GlucoseCon↓, TumCP↓, TumCCA↑, Casp3↑, cl‑PARP↑, Apoptosis↑, Casp8↑, Casp9↑, Cyt‑c↝, MMP↓, BAD↑, GLUT2↓, PKM2∅,

1036-

EGCG,

Green Tea Catechin Is an Alternative Immune Checkpoint Inhibitor that Inhibits PD-L1 Expression and Lung Tumor Growth

-

in-vitro,

Lung,

A549

10 and 50 µM

-

in-vitro,

Lung,

LU99

PD-L1↓, EGF↓, Akt↓,

1056-

EGCG,

EGCG, a major green tea catechin suppresses breast tumor angiogenesis and growth via inhibiting the activation of HIF-1α and NFκB, and VEGF expression

-

vitro+vivo,

BC,

E0771

50–100 mg/kg/d in drinking water for 4 weeks

mice

TumW↓, VEGF↓, Weight∅, Hif1a↓, NF-kB↓,

1071-

EGCG,

Green tea polyphenols modulate insulin secretion by inhibiting glutamate dehydrogenase

-

in-vitro,

Nor,

NA

*GDH↓,

1072-

EGCG,

Epigallocatechin gallate (EGCG) suppresses epithelial-Mesenchymal transition (EMT) and invasion in anaplastic thyroid carcinoma cells through blocking of TGF-β1/Smad signaling pathways

-

in-vitro,

Thyroid,

8505C

EMT↓, TumCI↓, TumCMig↓, TGF-β↓, p‑SMAD2↓, p‑SMAD3↓, SMAD4↓,

1012-

EGCG,

Inhibition of beta-catenin/Tcf activity by white tea, green tea, and epigallocatechin-3-gallate (EGCG): minor contribution of H(2)O(2) at physiologically relevant EGCG concentrations

-

in-vitro,

Nor,

HEK293

10-12uM EGCG

*H2O2↑, *β-catenin/ZEB1↓, *TCF-4↓,

937-

EGCG,

Metabolic Consequences of LDHA inhibition by Epigallocatechin Gallate and Oxamate in MIA PaCa-2 Pancreatic Cancer Cells

-

in-vitro,

Pca,

MIA PaCa-2

lactateProd↓, Glycolysis↓, GlucoseCon↓, LDHA↓,

936-

EGCG,

Bioactivity-Guided Identification and Cell Signaling Technology to Delineate the Lactate Dehydrogenase A Inhibition Effects of Spatholobus suberectus on Breast Cancer

-

in-vitro,

BC,

MCF-7

-

in-vitro,

BC,

MDA-MB-231

LDHA↓,

26-

EGCG,

QC,

docx,

Green tea and quercetin sensitize PC-3 xenograft prostate tumors to docetaxel chemotherapy

-

vitro+vivo,

Pca,

PC3

BAD↓, PARP↑, Casp7↑, IκB↓, Ki-67↓, VEGF↓, EGFR↓, FGF↓, TGF-β↓, TNF-α↓, SCF↓, Bax:Bcl2↑, NF-kB↓,

25-

EGCG,

QC,

Quercetin Increased the Antiproliferative Activity of Green Tea Polyphenol (-)-Epigallocatechin Gallate in Prostate Cancer Cells

-

in-vitro,

Pca,

PC3

5, 10, 20 uM

-

in-vitro,

Pca,

LNCaP

5, 10, 20 uM

COMT↓,

24-

EGCG,

GEN,

QC,

Targeting CWR22Rv1 prostate cancer cell proliferation and gene expression by combinations of the phytochemicals EGCG, genistein and quercetin

-

in-vitro,

Pca,

22Rv1

0.1, 1, 5, 10, 50 uM

NQO1↑, P53↑, NQO2↑,

23-

EGCG,

(-)-Epigallocatechin-3-gallate induces apoptosis and suppresses proliferation by inhibiting the human Indian Hedgehog pathway in human chondrosarcoma cells

-

in-vitro,

Chon,

SW1353

-

in-vitro,

Chon,

CRL-7891

HH↓, Gli1↓, PTCH1↓, Bcl-2↓, BAX↑,

22-

EGCG,

Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics

-

in-vitro,

PC,

CD133+

-

in-vitro,

PC,

CD44+

-

in-vitro,

PC,

CD24+

-

in-vitro,

PC,

ESA+

20-60 uM

HH↓, Smo↓, PTCH1↓, PTCH2↓, Gli1↓, GLI2↓, Gli↓, Bcl-2↓, XIAP↓, Shh↓, EMT↓, survivin↓, Nanog↓, Casp3↑, Casp7↑,

21-

EGCG,

Tea polyphenols EGCG and TF restrict tongue and liver carcinogenesis simultaneously induced by N-nitrosodiethylamine in mice

-

in-vivo,

Liver,

NA

HH↓, PTCH1↓, Smo↓, Gli1↓,

20-

EGCG,

Potential Therapeutic Targets of Epigallocatechin Gallate (EGCG), the Most Abundant Catechin in Green Tea, and Its Role in the Therapy of Various Types of Cancer

-

in-vivo,

Liver,

NA

-

in-vivo,

Tong,

NA

HH↓, Gli1↓, Smo↓, TNF-α↓, COX2↓, *antiOx↑, Hif1a↓, NF-kB↓, VEGF↓, STAT3↓, Bcl-2↓, P53↑, Akt↓, p‑Akt↓, p‑mTOR↓, EGFR↓, AP-1↓, BAX↑, ROS↑, Casp3↑, Apoptosis↑, NRF2↑, *H2O2↓, *NO↓, *SOD↑, *Catalase↑, *GPx↑, *ROS↓,

651-

EGCG,

Epigallocatechin-3-Gallate Therapeutic Potential in Cancer: Mechanism of Action and Clinical Implications

ROS↑, p‑AMPK↑, mTOR↓, FAK↓, Smo↓, Gli1↓, HH↓, TumCMig↓, TumCI↓, NOTCH↓, JAK↓, STAT↓, Bcl-2↓, Bcl-xL↓, BAX↑, Casp9↑,

665-

EGCG,

Anticancer effects of epigallocatechin-3-gallate nanoemulsion on lung cancer cells through the activation of AMP-activated protein kinase signaling pathway

-

in-vitro,

NA,

H1299

36.03 and 4.71 μM(nano)

nano particles have much lower IC50

AMPK↑, TumCP↓, TumCMig↓, TumCI↓,

652-

EGCG,

VitK2,

CUR,

Case Report of Unexpectedly Long Survival of Patient With Chronic Lymphocytic Leukemia: Why Integrative Methods Matter

-

Case Report,

CLL,

NA

1800 mg of EGCG per day

patient consumed 1000 mg of curcumin phytosome daily

Remission↑,

653-

EGCG,

Phase 2 Trial of Daily, Oral Polyphenon E in Patients with Asymptomatic, Rai Stage 0-II Chronic Lymphocytic Leukemia(CLL)

-

Trial,

CLL,

NA

2000 mg per dose) was administered twice daily.

ALC↓, Remission↑,

654-

EGCG,

MNPs,

MF,

Characterization of mesenchymal stem cells with augmented internalization of magnetic nanoparticles: The implication of therapeutic potential

-

in-vitro,

Var,

NA

human MSCs

*BioEnh↑,

655-

EGCG,

A new molecular mechanism underlying the EGCG-mediated autophagic modulation of AFP in HepG2 cells

-

in-vitro,

HCC,

HepG2

60-80uM

AFP↓, TumAuto↑, LC3II↑, TumCG↓, MMP↓,

657-

EGCG,

MNPs,

MF,

Interaction of poly-l-lysine coating and heparan sulfate proteoglycan on magnetic nanoparticle uptake by tumor cells

-

in-vitro,

GBM,

U87MG

10 µM EGCG

*BioEnh↑,

658-

EGCG,

MNPs,

MF,

Laminin Receptor-Mediated Nanoparticle Uptake by Tumor Cells: Interplay of Epigallocatechin Gallate and Magnetic Force at Nano-Bio Interface

-

in-vitro,

GBM,

LN229

*BioEnh↑,

659-

EGCG,

MNPs,

MF,

Augmented cellular uptake of nanoparticles using tea catechins: effect of surface modification on nanoparticle-cell interaction

-

in-vivo,

Nor,

NA

*BioEnh↑,

660-

EGCG,

FA,

Epigallocatechin-3-gallate Delivered in Nanoparticles Increases Cytotoxicity in Three Breast Carcinoma Cell Lines

-

in-vitro,

BC,

MDA-MB-231

10-20uM

-

in-vitro,

BC,

MCF-7

-

in-vitro,

Nor,

MCF10

Apoptosis↑, *toxicity↓, *eff↓,

661-

EGCG,

GoldNP,

Epigallocatechin-3-Gallate-Loaded Gold Nanoparticles: Preparation and Evaluation of Anticancer Efficacy in Ehrlich Tumor-Bearing Mice

-

vitro+vivo,

NA,

NA

Apoptosis↑, TumVol↓,

662-

EGCG,

Advanced Nanovehicles-Enabled Delivery Systems of Epigallocatechin Gallate for Cancer Therapy

-

Review,

Var,

NA

*BioEnh↑,

663-

EGCG,

EGCG-coated silver nanoparticles self-assemble with selenium nanowires for treatment of drug-resistant bacterial infections by generating ROS and disrupting biofilms

-

in-vitro,

NA,

NA

Bacteria

ROS↑,

664-

EGCG,

SNP,

Epigallocatechin-3-gallate-capped Ag nanoparticles: preparation and characterization

-

Analysis,

NA,

NA

other↑,

666-

EGCG,

The Role of EGCG in Breast Cancer Prevention and Therapy

-

Review,

NA,

NA

ROMO1↑, VEGF↓, TumCG↓,

650-

EGCG,

Cellular thiol status-dependent inhibition of tumor cell growth via modulation of retinoblastoma protein phosphorylation by (-)-epigallocatechin

-

in-vitro,

NA,

NA

TumCCA↑, p‑pRB↓,

649-

EGCG,

CUR,

PI,

Targeting Cancer Hallmarks with Epigallocatechin Gallate (EGCG): Mechanistic Basis and Therapeutic Targets

-

Review,

Var,

NA

*BioEnh↑, EGFR↓, HER2/EBBR2↓, IGF-1↓, MAPK↓, ERK↓, RAS↓, Raf↓, NF-kB↓, p‑pRB↓, TumCCA↑, Glycolysis↓, Warburg↓, HK2↓, Pyruv↓,

648-

EGCG,

Bioavailability of Epigallocatechin Gallate Administered With Different Nutritional Strategies in Healthy Volunteers

-

Human,

Nor,

NA

*BioAv↑,

647-

EGCG,

Food Inhibits the Oral Bioavailability of the Major Green Tea Antioxidant Epigallocatechin Gallate in Humans

-

Human,

Nor,

NA

*BioAv↑,

646-

EGCG,

PI,

Piperine enhances the bioavailability of the tea polyphenol (-)-epigallocatechin-3-gallate in mice

-

in-vivo,

Nor,

NA

*BioAv↑,

645-

EGCG,

The Effect of Ultrasound, Oxygen and Sunlight on the Stability of (−)-Epigallocatechin Gallate

-

Analysis,

NA,

NA

eff↑, pH↓,

644-

EGCG,

Citrate,

Simple Approach to Enhance Green Tea Epigallocatechin Gallate Stability in Aqueous Solutions and Bioavailability: Experimental and Theoretical Characterizations

-

Analysis,

Nor,

NA

*BioAv↑,

643-

EGCG,

New insights into the mechanisms of polyphenols beyond antioxidant properties; lessons from the green tea polyphenol, epigallocatechin 3-gallate

-

Analysis,

NA,

NA

H2O2↑, Fenton↑, PDGFR-BB↑, EGFR↓, VEGFR2↓, IGFR↓, Ca+2↑, NO↑, Sp1/3/4↓, NF-kB↓, AP-1↓, STAT1↓, STAT3↓, FOXO↓, mtDam↑, TumAuto↑,

642-

EGCG,

Prooxidant Effects of Epigallocatechin-3-Gallate in Health Benefits and Potential Adverse Effect

ROS↑, H2O2↑, Apoptosis↑, Trx↓, TrxR↓, JNK↑, HO-1↑, Fenton↑,

641-

EGCG,

Se,

Antioxidant effects of green tea

ROS↑, H2O2↑, ROS⇅,

640-

EGCG,

Epigallocatechin Gallate (EGCG) Is the Most Effective Cancer Chemopreventive Polyphenol in Green Tea

-

in-vitro,

CRC,

HCT116

20-300uM

-

in-vitro,

Colon,

SW480

TumCCA↑, Apoptosis↑,

639-

EGCG,

Immunomodulatory Effects of Green Tea Catechins and Their Ring Fission Metabolites in a Tumor Microenvironment Perspective

-

Review,

NA,

NA

TIMP3↑, MMP2↓, MMP9↓,

638-

EGCG,

MushCha,

MushReishi,

A Case of Complete and Durable Molecular Remission of Chronic Lymphocytic Leukemia Following Treatment with Epigallocatechin-3-gallate, an Extract of Green Tea

-

Case Report,

AML,

NA

epigallocatechin-3-gallate to 4 g daily

Remission↑,

637-

EGCG,

CAP,

Cancer prevention trial of a synergistic mixture of green tea concentrate plus Capsicum (CAPSOL-T) in a random population of subjects ages 40-84

-

Human,

NA,

NA

ENOX2↓,

667-

EGCG,

Anti-cancer effect of EGCG and its mechanisms

-

Review,

NA,

NA

RPSA↓,

695-

EGCG,

TFdiG,

The antioxidant and pro-oxidant activities of green tea polyphenols: a role in cancer prevention

-

in-vitro,

NA,

HL-60

24 and 22 μM

EGCG and theaflavin-3,3′-digallate (TFdiG)

ROS↑, IronCh↑, Apoptosis↑,

694-

EGCG,

Matcha green tea (MGT) inhibits the propagation of cancer stem cells (CSCs), by targeting mitochondrial metabolism, glycolysis and multiple cell signalling pathways

-

in-vitro,

BC,

MCF-7

~0.2 mg/ml, in tissue culture

Glycolysis↓, GAPDH↓, ROS↑, OCR↓, ECAR↓, mTOR↓, OXPHOS↓,

693-

EGCG,

CAP,

Phen,

Metabolite modulation of HeLa cell response to ENOX2 inhibitors EGCG and phenoxodiol

-

in-vitro,

Cerv,

HeLa

ENOX2↓, TumCG↓,

692-

EGCG,

EGCG: The antioxidant powerhouse in lung cancer management and chemotherapy enhancement

-

Review,

NA,

NA

ROS↑, Apoptosis↑, DNAdam↑, CTR1↑, JWA↑, β-catenin/ZEB1↓, P53↑, Vim↓, VEGF↓, p‑Akt↓, Hif1a↓, COX2↓, ERK↓, NF-kB↓, Akt↓, Bcl-xL↓, miR-210↓,

691-

EGCG,

Preclinical Pharmacological Activities of Epigallocatechin-3-gallate in Signaling Pathways: An Update on Cancer

-

Review,

NA,

NA

Apoptosis↑, necrosis↑, TumAuto↑, ERK↓, p38↓, NF-kB↓, VEGF↓,

690-

EGCG,

Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer

-

in-vitro,

Pca,

NA

AR↓, miR-21↓, miR-330-5p↑, TumCG↓,

689-

EGCG,

EGCG inhibited bladder cancer SW780 cell proliferation and migration both in vitro and in vivo via down regulation of NF-κB and MMP-9

-

vitro+vivo,

Bladder,

SW780

25–100 μM

Casp8↑, Casp9↑, Casp3↑, BAX↑, PARP↑, TumVol↓, NF-kB↓, MMP9↓,

688-

EGCG,

GEM,

Epigallocatechin-3-Gallate (EGCG) Suppresses Pancreatic Cancer Cell Growth, Invasion, and Migration partly through the Inhibition of Akt Pathway and Epithelial–Mesenchymal Transition: Enhanced Efficacy When Combined with Gemcitabine

-

in-vitro,

PC,

NA

Zeb1↓, β-catenin/ZEB1↓, Vim↓, Akt↓, p‑IGFR↓, TumCG↓, TumCMig↓, TumCI↓,

687-

EGCG,

Estrogen receptor-α36 is involved in epigallocatechin-3-gallate induced growth inhibition of ER-negative breast cancer stem/progenitor cells

-

in-vitro,

BC,

MDA-MB-231

-

in-vitro,

BC,

MDA-MB-468

ER-α36↓,

686-

EGCG,

Prevention effect of EGCG in rat's lung cancer induced by benzopyrene

-

in-vivo,

Lung,

NA

rats

NF-kB↓, p50↓, Ki-67↓,

685-

EGCG,

CUR,

SFN,

RES,

GEN

The “Big Five” Phytochemicals Targeting Cancer Stem Cells: Curcumin, EGCG, Sulforaphane, Resveratrol and Genistein

-

Analysis,

NA,

NA

Bcl-2↓, survivin↓, XIAP↓, EMT↓, Apoptosis↑, Nanog↓, cMyc↓, OCT4↓, Snail↓, Slug↓, Zeb1↓, TCF↓,

684-

EGCG,

Improving the anti-tumor effect of EGCG in colorectal cancer cells by blocking EGCG-induced YAP activation

-

in-vitro,

CRC,

NA

eff↑, Akt↓, VEGFR2↓, STAT3↓, P53↓, Hippo↓, YAP/TEAD↑,

683-

EGCG,

Targeting the AMP-Activated Protein Kinase for Cancer Prevention and Therapy

-

Review,

NA,

NA

AMPK↑, TumCP↓, P21↑, mTOR↓, COX2↓,

682-

EGCG,

Suppressive Effects of EGCG on Cervical Cancer

-

Review,

NA,

NA

E7↓, E6↓, PI3K/Akt↓, P53↑, p27↑, P21↑, CDK2↓, mTOR↓, HIF-1↓, IGF-1↓, EGFR↓, ERK↓, VEGF↓,

681-

EGCG,

Suppressing glucose metabolism with epigallocatechin-3-gallate (EGCG) reduces breast cancer cell growth in preclinical models

-

vitro+vivo,

BC,

NA

10-320 μM

Casp3↑, Casp8↑, Casp9↑, TumAuto↑, Beclin-1↝, ATG5↝, GlucoseCon↓, lactateProd↓, ATP↝, HK2↓, LDHA↓, Hif1a↓, GLUT1↓, TumVol↓, VEGF↓,

680-

EGCG,

Cancer preventive and therapeutic effects of EGCG, the major polyphenol in green tea

-

Review,

NA,

NA

NF-kB↓, STAT3↓, PI3K↓, HGF/c-Met↓, Akt↓, ERK↓, MAPK↓, AR↓, Casp↑, Ki-67↓, PARP↑, Bcl-2↓, BAX↑, PCNA↓, p27↑, P21↑,

679-

EGCG,

5-FU,

Epigallocatechin-3-gallate targets cancer stem-like cells and enhances 5-fluorouracil chemosensitivity in colorectal cancer

-

in-vitro,

CRC,

NA

NOTCH1↓, BMI1↓, SUZ12↓, EZH2↓, miR-34a↑, miR-200c↑, miR-145↑,

678-

EGCG,

Cancer Prevention with Green Tea and Its Principal Constituent, EGCG: from Early Investigations to Current Focus on Human Cancer Stem Cells

other↑, TumMeta↓, YMcells↑, CSCs↓,

677-

EGCG,

Induction of Endoplasmic Reticulum Stress Pathway by Green Tea Epigallocatechin-3-Gallate (EGCG) in Colorectal Cancer Cells: Activation of PERK/p-eIF2 α /ATF4 and IRE1 α

-

in-vitro,

CRC,

HT-29

ER Stress↑, GRP78/BiP↑, PERK↑, eIF2α↑, ATF4↑, IRE1↑, Apoptosis↑,

676-

EGCG,

Chemo,

The Potential of Epigallocatechin Gallate (EGCG) in Targeting Autophagy for Cancer Treatment: A Narrative Review

-

Review,

NA,

NA

PI3k/Akt/mTOR↓, Apoptosis↑, ROS↑, TumAuto↑,

675-

EGCG,

When Natural Compounds Meet Nanotechnology: Nature-Inspired Nanomedicines for Cancer Immunotherapy

-

Review,

Var,

NA

*BioAv↑,

674-

EGCG,

Biocompatible and biodegradable nanoparticles for enhancement of anti-cancer activities of phytochemicals

-

Review,

Var,

NA

*BioEnh↑,

673-

EGCG,

Iron Chelation Properties of Green Tea Epigallocatechin-3-Gallate (EGCG) in Colorectal Cancer Cells: Analysis on Tfr/Fth Regulations and Molecular Docking

-

in-vitro,

CRC,

HT-29

IronCh↑, TfR1/CD71↑, FTH1↓,

672-

EGCG,

Molecular Targets of Epigallocatechin—Gallate (EGCG): A Special Focus on Signal Transduction and Cancer

-

Review,

NA,

NA

DNMT1↓, HDAC↓, G9a↓, PRC2↓, DNMT3A↓, 67LR↓, Apoptosis↑, TumCCA↑,

671-

EGCG,

The Epigenetic Modification of Epigallocatechin Gallate (EGCG) on Cancer

other↝,

670-

EGCG,

Epigallocatechin-3-gallate and its nanoformulation in cervical cancer therapy: the role of genes, MicroRNA and DNA methylation patterns

-

Review,

NA,

NA

TumCCA↑, P53↑, ERK↓, EGFR↓, p‑ERK↑, VEGF↓, Hif1a↓, miR-203↓, miR-210↑,

669-

EGCG,

Epigallocatechin-3-gallate and cancer: focus on the role of microRNAs

-

Review,

NA,

NA

Let-7↑, KRAS↓,

668-

EGCG,

The Potential Role of Epigallocatechin-3-Gallate (EGCG) in Breast Cancer Treatment

-

Review,

BC,

MCF-7

-

Review,

BC,

MDA-MB-231

HER2/EBBR2↓, EGFR↓, mtDam↑, ROS↑, PI3K/Akt↓, P53↑, P21↑, Casp3↑, Casp9↑, BAX↑, PTEN↑, Bcl-2↓, hTERT↓, STAT3↓, TumCCA↑, Hif1a↓,

1514-

EGCG,

Preferential inhibition by (-)-epigallocatechin-3-gallate of the cell surface NADH oxidase and growth of transformed cells in culture

-

in-vitro,

Cerv,

HeLa

1-50uM

-

in-vitro,

Nor,

MCF10

selectivity↑, *toxicity∅, TumCG↓, NADHdeh?, eff↑, ENOX2↓, Dose?,

1515-

EGCG,

Phen,

Reciprocal Relationship Between Cytosolic NADH and ENOX2 Inhibition Triggers Sphingolipid-Induced Apoptosis in HeLa Cells

-

in-vitro,

Cerv,

HeLa

0.003 uM

-

in-vitro,

Nor,

MCF10

exceeded 20 uM

note IC50 not reached for normal cells

-

in-vitro,

BC,

BT20

0.01 uM

selectivity↑, ENOX2↓, NADH↑, SK↓, eff↑, aSmase↑,

1516-

EGCG,

Epigallocatechin Gallate (EGCG): Pharmacological Properties, Biological Activities and Therapeutic Potential

-

Review,

NA,

NA

*Dose∅, Half-Life∅, BioAv∅, BBB↑, toxicity∅, eff↓, Apoptosis↑, Casp3↑, Cyt‑c↑, cl‑PARP↑, DNMTs↓, Telomerase↓, angioG↓, Hif1a↓, NF-kB↓, MMPs↓, BAX↑, Bak↑, Bcl-2↓, Bcl-xL↓, P53↑, PTEN↑, IGF-1↓, H3↓, HDAC1↓, *LDH↓, *ROS↓,

1303-

EGCG,

(-)-Epigallocatechin-3-gallate induces apoptosis in human endometrial adenocarcinoma cells via ROS generation and p38 MAP kinase activation

-

in-vitro,

EC,

NA

TumCP↓, ER-α36↓, cycD1↓, ERK↑, Jun↓, BAX↑, Bcl-2↓, cl‑Casp3↑, ROS↑, p38↑,

1503-

EGCG,

Epigenetic targets of bioactive dietary components for cancer prevention and therapy

-

Review,

NA,

NA

IC50 values ranging from 0.21 to 0.47 μM

selectivity↑, DNMT1↓, RECK↑, MMPs↓, TumCI↓, angioG↓, TumMeta↓, HATs↓, IκB↑, NF-kB↓, IL6↓, COX2↓, NOS2↓, ac‑H3↑, ac‑H4↑, eff↑,

1976-

EGCG,

Epigallocatechin-3-gallate exhibits anti-tumor effect by perturbing redox homeostasis, modulating the release of pro-inflammatory mediators and decreasing the invasiveness of glioblastoma cells

-

in-vitro,

GBM,

U87MG

50-100uM

ROS↑, MMP↓, Casp3↑, Cyt‑c↑, Trx1↓, Ceru↓, IL6↓, IL8↓, MCP1↓, RANTES?, uPA↝, ROS↑,

1975-

EGCG,

Molecular bases of thioredoxin and thioredoxin reductase-mediated prooxidant actions of (-)-epigallocatechin-3-gallate

-

in-vitro,

Cerv,

HeLa

TrxR↓, Trx↓, ROS↑, Dose↑,

1974-

EGCG,

Protective Effect of Epigallocatechin-3-Gallate in Hydrogen Peroxide-Induced Oxidative Damage in Chicken Lymphocytes

-

in-vitro,

Nor,

NA

0, 22.5, 45, and 90 μM

*ROS↓, *NO↓, *MMP↑, *i-Ca+2↓, *HO-1↑, *Catalase↑, *NRF2↑, *Trx1↑, *antiOx↑, *SOD↑, *Apoptosis↓,

2468-

EGCG,

Green tea epigallocatechin-3-gallate inhibits platelet signalling pathways triggered by both proteolytic and non-proteolytic agonists

-

in-vitro,

Nor,

NA

*AntiAg↑, *Ca+2↓,

2460-

EGCG,

Tau,

Anti-fibrosis activity of combination therapy with epigallocatechin gallate, taurine and genistein by regulating glycolysis, gluconeogenesis, and ribosomal and lysosomal signaling pathways in HSC-T6 cells

-

in-vitro,

Nor,

HSC-T6

HK2↓,

2459-

EGCG,

Epigallocatechin gallate inhibits human tongue carcinoma cells via HK2‑mediated glycolysis

-

in-vitro,

Tong,

Tca8113

0-80uM

-

in-vitro,

Tong,

TSCCa

EGFR↓, Akt↓, ERK↓, HK2↓, GlucoseCon↓, lactateProd↓, Glycolysis↓,

2501-

EGCG,

A Case of Complete and Durable Molecular Remission of Chronic Lymphocytic Leukemia Following Treatment with Epigallocatechin-3-gallate, an Extract of Green Tea

-

Case Report,

AML,

NA

OS↑, Remission↑, eff↑, Dose↝,

2458-

EGCG,

QC,

Identification of plant-based hexokinase 2 inhibitors: combined molecular docking and dynamics simulation studies

-

Analysis,

Nor,

NA

HK2↓,

2395-

EGCG,

EGCG inhibits diabetic nephrophathy through up regulation of PKM2

-

Study,

Diabetic,

NA

*PKM2↑, *Apoptosis↓, *PGC-1α↑,

2309-

EGCG,

Chemo,

Targeting Glycolysis with Epigallocatechin-3-Gallate Enhances the Efficacy of Chemotherapeutics in Pancreatic Cancer Cells and Xenografts

-

in-vitro,

PC,

MIA PaCa-2

(20–100 μM) for 72 h

-

in-vitro,

Nor,

HPNE

-

in-vitro,

PC,

PANC1

-

in-vivo,

NA,

NA

mice

TumCG↓, eff↑, ROS↑, ECAR↓, ChemoSen↑, selectivity↑, Glycolysis↓, PFK↓, PKA↓, HK2∅, LDHA∅, PFKP↓, PKM2↓, H2O2↑, TumW↓,

2310-

EGCG,

Epigallocatechin-3-gallate downregulates PDHA1 interfering the metabolic pathways in human herpesvirus 8 harboring primary effusion lymphoma cells

-

in-vitro,

lymphoma,

PEL

GLUT3↑, PDHA1↓, GDH↓, ROS↑, Glycolysis↓, OXPHOS↓,

2302-

EGCG,

Flavonoids Targeting HIF-1: Implications on Cancer Metabolism

-

Review,

Var,

NA

TumCP↓, Hif1a↓, LDHA↓, PFK↓, cardioP↑, Glycolysis↓, PKM2↓,

2561-

EGCG,

ASA,

Anti-platelet effects of epigallocatechin-3-gallate in addition to the concomitant aspirin, clopidogrel or ticagrelor treatment

-

ex-vivo,

Nor,

NA

40 participants

AntiAg↑, eff↑, Half-Life↝, other∅,

2562-

EGCG,

Green Tea Epigallocatechin 3-Gallate Reduced Platelet Aggregation and Improved Anticoagulant Proteins in Patients with Transfusion-Dependent β-Thalassemia: A Randomized Placebo-Controlled Clinical Trial

-

Trial,

NA,

NA

placebo or GTE tablets (50 mg and 2 × 50 mg EGCG equivalent) every day for two months.

AntiAg↑, other↝,

2563-

EGCG,

Cardioprotective effect of epigallocatechin gallate in myocardial ischemia/reperfusion injury and myocardial infarction: a meta-analysis in preclinical animal studies

-

Review,

NA,

NA

cardioP↑, ROS↑, AntiAg↑, eff↑, COX1↓,

2993-

EGCG,

Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells

-

in-vitro,

Pca,

LNCaP

TumCG↓, PSA↓, HK2↓, AR↓, Sp1/3/4↓,

2992-

EGCG,

Effects of Epigallocatechin-3-Gallate on Matrix Metalloproteinases in Terms of Its Anticancer Activity

-

Review,

Var,

NA

AP-1↓, Sp1/3/4↓, NF-kB↓, ERK↓, P-gp↓, HSP27↓, β-catenin/ZEB1↓, MMPs↓, TNF-α↓, IL1β↓, MMP2↓,

2994-

EGCG,

Nano-Engineered Epigallocatechin Gallate (EGCG) Delivery Systems: Overcoming Bioavailability Barriers to Unlock Clinical Potential in Cancer Therapy

-

Review,

Var,

NA

BioAv↓, NF-kB↓, Casp↑, MMP9↑, Sp1/3/4↑,

3210-

EGCG,

Protective effect of epigallocatechin-3-gallate (EGCG) via Nrf2 pathway against oxalate-induced epithelial mesenchymal transition (EMT) of renal tubular cells

-

in-vitro,

Nor,

NA

renal tubular cells

*ROS↓, *NRF2↓, *Catalase↑, *antiOx↑,

3209-

EGCG,

Epigallocatechin gallate upregulates NRF2 to prevent diabetic nephropathy via disabling KEAP1

-

in-vitro,

Diabetic,

NA

*NRF2↑,

3208-

EGCG,

Induction of Endoplasmic Reticulum Stress Pathway by Green Tea Epigallocatechin-3-Gallate (EGCG) in Colorectal Cancer Cells: Activation of PERK/p-eIF2α/ATF4 and IRE1α

-

in-vitro,

Colon,

HT29

-

in-vitro,

Nor,

3T3

TumCD↓, ER Stress↑, GRP78/BiP↑, PERK↑, eIF2α↑, ATF4↑, IRE1↑, Apoptosis↑, Casp3↑, Casp7↑, Wnt↓, β-catenin/ZEB1↓, *toxicity∅, UPR↑,

3207-

EGCG,

EGCG Enhances the Chemosensitivity of Colorectal Cancer to Irinotecan through GRP78-MediatedEndoplasmic Reticulum Stress

-

in-vitro,

CRC,

RKO

-

in-vitro,

CRC,

HCT116

GRP78/BiP↑, MMP↓, ER Stress↑, ROS↓, UPR↑,

3206-

EGCG,

Insights on the involvement of (-)-epigallocatechin gallate in ER stress-mediated apoptosis in age-related macular degeneration

-

Review,

AMD,

NA

*Ca+2↓, *ROS↓, *Apoptosis↓, *GRP78/BiP↓, *CHOP↓, *PERK↓, *IRE1↓, *p‑PARP↓, *Casp3↓, *Casp12↓, *ER Stress↓, *UPR↓,

3205-

EGCG,

The Role of Epigallocatechin-3-Gallate in Autophagy and Endoplasmic Reticulum Stress (ERS)-Induced Apoptosis of Human Diseas

-

Review,

Var,

NA

-

Review,

AD,

NA

Beclin-1↑, ROS↑, Apoptosis↑, ER Stress↑, *Inflam↓, *cardioP↑, *antiOx?, *LDL↓, *NF-kB↓, *MPO↓, *glucose↓, *ROS↓, ATG5↑, LC3B↑, MMP↑, lactateProd↓, VEGF↓, Zeb1↑, Wnt↑, IGF-1R↑, Fas↑, Bak↑, BAD↑, TP53↓, Myc↓, Casp8↓, LC3II↑, NOTCH3↓, eff↑, p‑Akt↓, PARP↑, *Cyt‑c↓, *BAX↓, *memory↑, *neuroP↑, *Ca+2?, GRP78/BiP↑, CHOP↑, ATF4↑, Casp3↑, Casp8↑, UPR↑,

3204-

EGCG,

The Role of ER Stress and the Unfolded Protein Response in Cancer

-

Review,

Var,

NA

BID↓, UPR↑, ER Stress↑,

3203-

EGCG,

(-)- Epigallocatechin-3-gallate induces GRP78 accumulation in the ER and shifts mesothelioma constitutive UPR into proapoptotic ER stress

-

NA,

MM,

NA

ROS↑, Ca+2↝, GRP78/BiP↑, ATF4↑, XBP-1↑, CHOP↑, Casp3↑, Casp8↑, *GRP78/BiP↓, *UPR↓, UPR↑,

3202-

EGCG,

Epigallocatechin-3-gallate enhances ER stress-induced cancer cell apoptosis by directly targeting PARP16 activity

-

in-vitro,

Cerv,

HeLa

100uM

-

in-vitro,

HCC,

QGY-7703

PARP16↓, p‑PERK↓, Apoptosis↑, eIF2α↓, UPR↓, ER Stress↑, eff↑, GRP78/BiP↓,

3201-

EGCG,

Epigallocatechin Gallate (EGCG): Pharmacological Properties, Biological Activities and Therapeutic Potential

-

Review,

NA,

NA

*AntiCan↑, *cardioP↑, *neuroP↑, *BioAv↝, *BioAv↓, *BioAv↓, *Dose↝, *Half-Life↝, *BioAv↑, *BBB↑, *hepatoP↓, *other↓, *Inflam↓, *NF-kB↓, *AP-1↓, *iNOS↓, *COX2↓, *ROS↓, *RNS↓, *IL8↓, *JAK↓, *PDGFR-BB↓, *IGF-1R↓, *MMP2↓, *P53↓, *NRF2↑, *TNF-α↓, *IL6↓, *E2Fs↑, *SOD1↑, *SOD2↑, Casp3↑, Cyt‑c↑, PARP↑, DNMTs↓, Telomerase↓, Hif1a↓, MMPs↓, BAX↑, Bak↑, Bcl-2↓, Bcl-xL↓, P53↑, PTEN↑, TumCP↓, MAPK↓, HGF/c-Met↓, TIMP1↑, HDAC↓, MMP9↓, uPA↓, GlutMet↓, ChemoSen↑, chemoP↑,

3211-

EGCG,

Antioxidation Function of EGCG by Activating Nrf2/HO-1 Pathway in Mice with Coronary Heart Disease

-

in-vivo,

NA,

NA

0-40mg/kg

mice

*cardioP↑, *VEGF↓, *MMP2↓, *SOD↑, *ROS↓, *HO-1↑, *NQO1↑, *NRF2↑,

3238-

EGCG,

Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications

-

Review,

Var,

NA

Telomerase↓, DNMTs↓, cycD1↓, cycE↓, CDK2↓, CDK4↓, CDK6↓, HATs↓, HDAC↓, selectivity↑, uPA↓, NF-kB↓, TNF-α↓, *ROS↓, *antiOx↑, Hif1a↓, VEGF↓, MMP2↓, MMP9↓, FAK↓, TIMP2↑, Mcl-1↓, survivin↓, XIAP↓, PCNA↓, p16↑, P21↑, p27↑, pRB↑, P53↑, MDM2↑, ROS↑, Casp3↑, Casp8↑, Casp9↑, Cyt‑c↑, Diablo↑, BAX⇅, cl‑PPARα↓, PDGF↓, EGFR↓, FOXO↑, AP-1↓, JNK↓, COX2↓, angioG↓,

3229-

EGCG,

Epigallocatechin-3-gallate (EGCG) Alters Histone Acetylation and Methylation and Impacts Chromatin Architecture Profile in Human Endothelial Cells

-

in-vitro,

Nor,

HMEC

-

in-vitro,

Nor,

HUVECs

HDAC↓,

3230-

EGCG,

Green Tea Polyphenol Epigallocatechin 3-Gallate, Contributes to the Degradation of DNMT3A and HDAC3 in HCT 116 Human Colon Cancer Cells

-

in-vitro,

CRC,

HCT116

50 μM to 150 μM

-

in-vitro,

CRC,

HT29

HDAC↓, DNMTs↓,

3231-

EGCG,

Epigallocatechin-3-gallate restores mitochondrial homeostasis impairment by inhibiting HDAC1-mediated NRF1 histone deacetylation in cardiac hypertrophy

-

in-vitro,

Nor,

NA

*HDAC↓, *cardioP↑, *Nrf1↑, *PGC-1α↓,

3232-

EGCG,

(−)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer׳s disease model mice by upregulating neprilysin expression

-

in-vivo,

AD,

NA

HDAC1↓, *HDAC1↓, *Aβ↓, *cognitive↑,

3233-

EGCG,

Epigallocatechin gallate inhibits HeLa cells by modulation of epigenetics and signaling pathways

-

in-vitro,

Cerv,

HeLa

DNMTs↓, DNMT1↓, DNMT3A↓, HDAC2↓, HDAC3↓, HDAC4↓, EZH2↓, PI3K↓, Wnt↓, MAPK↓, hTERT↓, MMP2↓, MMP7↓, IL6↓, MDM2↓, MMP-10↓, TP53↑, PTEN↑,

3234-

EGCG,

Rad,

EGCG, a tea polyphenol, as a potential mitigator of hematopoietic radiation injury in mice

-

in-vivo,

Nor,

NA

*DNMTs↓, *radioP↑, *HDAC↑,

3235-

EGCG,

(-)-Epigallocatechin-3-gallate reverses the expression of various tumor-suppressor genes by inhibiting DNA methyltransferases and histone deacetylases in human cervical cancer cells

-

in-vivo,

Cerv,

HeLa

DNMTs↓, HDAC↓,

3236-

EGCG,

BA,

Molecular mechanisms for inhibition of colon cancer cells by combined epigenetic-modulating epigallocatechin gallate and sodium butyrate

-

in-vitro,

Colon,

RKO

-

in-vitro,

Colon,

HCT116

-

in-vitro,

Colon,

HT29

Apoptosis↑, TumCCA?, HDAC1↓, DNMT1↓, survivin↓, HDAC↓, P21↑, NF-kB↑, γH2AX↑, ac‑H3↑, DNAdam↑,

3237-

EGCG,

(-)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer's disease model mice by upregulating neprilysin expression

-

in-vivo,

AD,

NA

intragastric administration of low- and high-dose EGCG (5 and 15 mg/kg, respectively) for 60 day

*HDAC↓, *Aβ↓, cognitive↑,

3212-

EGCG,

EGCG maintained Nrf2-mediated redox homeostasis and minimized etoposide resistance in lung cancer cells

-

in-vitro,

Lung,

A549

-

in-vivo,

Lung,

NCIH23

NRF2⇅, eff↑, SOD1↑, SOD1↓, MMP2⇅, MMP9⇅,

3239-

EGCG,

(−)-Epigallocatechin Gallate, A Major Constituent of Green Tea, Poisons Human Type II Topoisomerases

*TOP2↑,

3240-

EGCG,

Green tea constituents (−)-epigallocatechin-3-gallate (EGCG) and gallic acid induce topoisomerase I– and topoisomerase II–DNA complexes in cells mediated by pyrogallol-induced hydrogen peroxide

-

in-vitro,

AML,

K562

TOP1↑, TOP2↑,

3241-

EGCG,

Epigallocatechin gallate triggers apoptosis by suppressing de novo lipogenesis in colorectal carcinoma cells

-

in-vitro,

CRC,

HCT116

0.5 ± 0.05 mm

-

in-vitro,

CRC,

HT29

0.8 ± 0.06 mm

-

in-vitro,

Liver,

HepG2

> 1 mm

-

in-vitro,

Liver,

HUH7

> 1 mm

tumCV↓, mtDam↑, Apoptosis↑, ATP↓, lipoGen↓, eff↑,

3242-

EGCG,

Epigallocatechin gallate has pleiotropic effects on transmembrane signaling by altering the embedding of transmembrane domains

ITGB3↓,

3243-

EGCG,

(−)-Epigallocatechin-3-Gallate Inhibits Colorectal Cancer Stem Cells by Suppressing Wnt/β-Catenin Pathway

CD133↓, CSCs↓, TumCP↓, Apoptosis↑, Wnt↓, β-catenin/ZEB1↓,

3244-

EGCG,

Novel epigallocatechin gallate (EGCG) analogs activate AMP-activated protein kinase pathway and target cancer stem cells

AMPK↑, TumCP↓, P21↑, mTOR↓, CSCs↓, CD44↓, CD24↓,

3245-

EGCG,

(−)-Epigallocatechin-3-gallate protects PC12 cells against corticosterone-induced neurotoxicity via the hedgehog signaling pathway

-

in-vitro,

Nor,

PC12

*neuroP↑, *Shh↑, *Gli1↑, *n-MYC↑, *Dose↝,

3246-

EGCG,

Epigallocatechin gallate suppresses hepatic cholesterol synthesis by targeting SREBP-2 through SIRT1/FOXO1 signaling pathway

-

in-vitro,

Nor,

NA

rat

*MDA↓, *SOD↑, *SIRT1↑, *FOXO1↑, *SREBP2↓,

3227-

EGCG,

Epigallocatechin-3-gallate treatment to promote neuroprotection and functional recovery after nervous system injury

-

NA,

Nor,

NA

*Rho↓, *IL1↓, *IL6↓, *TNF-α↓,

3213-

EGCG,

Rad,

Epigallocatechin-3-gallate Enhances Radiation Sensitivity in Colorectal Cancer Cells Through Nrf2 Activation and Autophagy

-

in-vitro,

CRC,

HCT116

12.5 μM EGCG

RadioS↑, TumCP↓, NRF2↑,

3214-

EGCG,

EGCG-induced selective death of cancer cells through autophagy-dependent regulation of the p62-mediated antioxidant survival pathway

-

in-vitro,

Nor,

MRC-5

-

in-vitro,

Cerv,

HeLa

-

in-vitro,

Nor,

HEK293

-

in-vitro,

BC,

MDA-MB-231

-

in-vitro,

CRC,

HCT116

mTOR↓, AMPK↑, selectivity↑, ROS↑, selectivity↑, HO-1↓, *NRF2↑, NRF2↓, *HO-1↑,

3215-

EGCG,

Epigallocatechin gallate modulates ferroptosis through downregulation of tsRNA-13502 in non-small cell lung cancer

-

in-vitro,

NSCLC,

A549

111.1 μM

-

in-vitro,

NSCLC,

H1299

5.564 μM

TumCP↓, Ki-67↓, GPx4↓, ACSL4↑, Iron↑, MDA↑, ROS↑, Ferroptosis↑, eff↑, NRF2↑, HO-1↑,

3216-

EGCG,

Epigallocatechin-3-gallate suppresses hemin-aggravated colon carcinogenesis through Nrf2-inhibited mitochondrial reactive oxygen species accumulation

-

NA,

Colon,

Caco-2

NRF2↑, TumCP↓, mt-ROS↓, Keap1↓,

3217-

EGCG,

Epigallocatechin-3-gallate promotes angiogenesis via up-regulation of Nfr2 signaling pathway in a mouse model of ischemic stroke

-

in-vivo,

Stroke,

NA

*angioG↑, *neuroG↑, *NRF2↑,

3218-

EGCG,

Comparative efficacy of epigallocatechin-3-gallate against H2O2-induced ROS in cervical cancer biopsies and HeLa cell lines

-

in-vitro,

Cerv,

HeLa

SOD↑, GPx↑, *antiOx↑, ROS↓,

3219-

EGCG,

Nano-chemotherapeutic efficacy of (−) -epigallocatechin 3-gallate mediating apoptosis in A549 cells: Involvement of reactive oxygen species mediated Nrf2/Keap1signaling

-

in-vitro,

Lung,

A549

ROS↑, RNS↓, MMP↓, NRF2↑, Keap1↓,

3220-

EGCG,

Dual Roles of Nrf2 in Cancer

-

in-vitro,

Lung,

A549

NRF2↑, eff↓,

3221-

EGCG,

EGCG upregulates phase-2 detoxifying and antioxidant enzymes via the Nrf2 signaling pathway in human breast epithelial cells

-

in-vitro,

Nor,

MCF10

*antiOx↑, *GSTA1↑, *NRF2↑,

3222-

EGCG,

Epigallocatechin gallate and mitochondria—A story of life and death

-

Review,

Nor,

NA

*lipid-P↓, *SOD↑, *Catalase↑, GPx↑, *GR↑, *GSTs↑, *GSH↑, *SIRT1↑, *PGC1A↑, *other↑,

3223-

EGCG,

The Effects of Green Tea Catechins in Hematological Malignancies

-

Review,

AML,

NA

Prx↓, ROS↑,

3224-

EGCG,

Epigallocatechin-3-Gallate Prevents Acute Gout by Suppressing NLRP3 Inflammasome Activation and Mitochondrial DNA Synthesis

-

in-vitro,

Nor,

NA

mice

*Casp1↓, *NLRP3↓, *Inflam↓,

3225-

EGCG,

Epigallocatechin‐3‐Gallate Ameliorates Diabetic Kidney Disease by Inhibiting the TXNIP/NLRP3/IL‐1β Signaling Pathway

-

in-vitro,

Nor,

NA

Human podocytes

-

in-vivo,

Nor,

NA

mice

*RenoP↑, *NLRP3↓, *TXNIP↓, *ASC↓, *Casp1↓, *IL1β↓, *ROS↓, *TNF-α↓, *IL6↓, *IL18↓,

3226-

EGCG,

Epigallocatechin-3-gallate, a green-tea polyphenol, suppresses Rho signaling in TWNT-4 human hepatic stellate cells

-

in-vitro,

Nor,

NA

TWNT-4

*Rho↓, other↑,

3228-

EGCG,

Targeting fibrotic signaling pathways by EGCG as a therapeutic strategy for uterine fibroids

*cycD1↓, *COL1A1↓, *ACTA2↓, *α-SMA↓,

3428-

EGCG,

Thymoquinone Is a Multitarget Single Epidrug That Inhibits the UHRF1 Protein Complex

-

Review,

Var,

NA

TumCCA↑, UHRF1↓, DNMT1↓, p16↑,

2422-

EMD,

Anti-Cancer Effects of Emodin on HepG2 Cells as Revealed by 1H NMR Based Metabolic Profiling

-

in-vitro,

HCC,

HepG2

HK2↓, PKM2↓, LDHA↓, Glycolysis↓, TumCCA↑, ROS↓, glut↓, Hif1a↓,

2345-

EMD,

Emodin ameliorates antioxidant capacity and exerts neuroprotective effect via PKM2-mediated Nrf2 transactivation

-

in-vitro,

AD,

PC12

*PKM2↓, *neuroP↑,

988-

EMD,

Emodin Induced Necroptosis and Inhibited Glycolysis in the Renal Cancer Cells by Enhancing ROS

-

in-vitro,

RCC,

NA

Necroptosis↑, p‑RIP1↑, MLKL↑, ROS↑, Glycolysis↓, GLUT1↓, PI3K↓, Akt↓,

950-

EMD,

Emodin Decreases Hepatic Hypoxia-Inducible Factor-1[Formula: see text] by Inhibiting its Biosynthesis

-

in-vivo,

NA,

NA

mice

-

in-vitro,

Liver,

HepG2

modin inhibited HIF-1 expression in human HepG2 hepatic cells

HIF-1↓,

1319-

EMD,

Emodin treatment of papillary thyroid cancer cell lines in vitro inhibits proliferation and enhances apoptosis via downregulation of NF‑κB and its upstream TLR4 signaling

-

in-vitro,

Thyroid,

TPC-1

20 and 40 µM emodin for 24 h

-

in-vitro,

Thyroid,

IHH4

NF-kB↓, TLR4↓, TumCI↓, TumCMig↓,

1318-

EMD,

Aloe-emodin Induces Apoptosis in Human Liver HL-7702 Cells through Fas Death Pathway and the Mitochondrial Pathway by Generating Reactive Oxygen Species

-

in-vitro,

Nor,

HL7702

*TumCCA↑, *ROS↑, *MMP↓, *Fas↑, *P53↑, *P21↓, *Bax:Bcl2↑, *cl‑Casp3↑, *cl‑Casp8↑, *cl‑Casp9↑, *cl‑PARP↑,

1320-

EMD,

SRF,

Emodin Sensitizes Hepatocellular Carcinoma Cells to the Anti-Cancer Effect of Sorafenib through Suppression of Cholesterol Metabolism

-

vitro+vivo,

HCC,

HepG2

-

in-vitro,

HCC,

Hep3B

-

in-vitro,

HCC,

HUH7

-

vitro+vivo,

Hepat,

SK-HEP-1

SREBF2↓, Akt↓, TumCCA↑, TumCG↓, STAT3↓,

1321-

EMD,

Antitumor effects of emodin on LS1034 human colon cancer cells in vitro and in vivo: roles of apoptotic cell death and LS1034 tumor xenografts model

-

in-vitro,

CRC,

LS1034

-

in-vivo,

NA,

NA

mice

tumCV↓, TumCCA↑, ROS↑, Ca+2↑, MMP↓, Apoptosis↑, Cyt‑c↑, Casp9↑, Bax:Bcl2↑,

1322-

EMD,

The versatile emodin: A natural easily acquired anthraquinone possesses promising anticancer properties against a variety of cancers

-

Review,

Var,

NA

7.22 μg/mL

Apoptosis↑, TumCP↓, ROS↑, TumAuto↑, EMT↓, TGF-β↓, DNAdam↑, ER Stress↑, TumCCA↑, ATP↓, NF-kB↓, CYP1A1↑, STAC2↓, JAK↓, PI3K↓, Akt↓, MAPK↓, FASN↓, HER2/EBBR2↓, ChemoSen↑, eff↑, ChemoSen↑, angioG↓, VEGF↓, MMP2↓, eNOS↓, FOXD3↑, MMP9↓, TIMP1↑,

1247-

EMD,

Emodin exerts antitumor effects in ovarian cancer cell lines by preventing the development of cancer stem cells via epithelial mesenchymal transition

-

vitro+vivo,

Ovarian,

SKOV3

-

in-vitro,

Ovarian,

A2780S

TumCP↓, TumCMig↓, TumCI↓, EMT↓, N-cadherin↓, Vim↓, E-cadherin↑, TumCG↓, CD133↓, OCT4↓, CSCs↓,

1246-

EMD,

Emodin reduces Breast Cancer Lung Metastasis by suppressing Macrophage-induced Breast Cancer Cell Epithelial-mesenchymal transition and Cancer Stem Cell formation

-

in-vivo,

BC,

NA

mouse

TGF-β↓, EMT↓, CSCs↓,

1323-

EMD,

Anticancer action of naturally occurring emodin for the controlling of cervical cancer

-

Review,

Cerv,

NA

56.7 µmol/L

TumCCA↑, DNAdam↑, mTOR↓, Casp3↑, Casp8↑, Casp9↑, TGF-β↑, SMAD3↓, p‑SMAD4↓, ROS↑, MMP↓, CXCR4↓, HER2/EBBR2↓, ER Stress↓, TumAuto↑, NOTCH1↓,

1245-

EMD,

Emodin Exhibits Strong Cytotoxic Effect in Cervical Cancer Cells by Activating Intrinsic Pathway of Apoptosis

-

in-vitro,

Cerv,

HeLa

10-50 μM

20uM@48hr

TumCG↓, TumCP↓, Apoptosis↑, ROS↑, Casp3↑, Casp9↑, MMP↓, DNAdam↑, GSH↓,

1324-

EMD,

Is Emodin with Anticancer Effects Completely Innocent? Two Sides of the Coin

-

Review,

Var,

NA

2–10 μM

*toxicity↑, *BioAv↓, Akt↓, ERK↓, ROS↑, MMP↓, Bcl-2↓, BAX↑, TumCCA↑,

1325-

EMD,

PacT,

Emodin enhances antitumor effect of paclitaxel on human non-small-cell lung cancer cells in vitro and in vivo

-

vitro+vivo,

Lung,

A549

10 μM emodin combined with 4 μM PTX

TumCP↓, Apoptosis↑, BAX↑, Casp3↑, Bcl-2↓, p‑Akt↓, p‑ERK↓, ChemoSideEff∅, ChemoSen↑,

1326-

EMD,

Emodin induces a reactive oxygen species-dependent and ATM-p53-Bax mediated cytotoxicity in lung cancer cells

-

in-vitro,

Lung,

A549

Apoptosis↑, ROS↑, P53↑, BAX↑, ATM↑,

1327-

EMD,

Emodin induces apoptosis in human lung adenocarcinoma cells through a reactive oxygen species-dependent mitochondrial signaling pathway

-

in-vitro,

Lung,

A549

50uM

Cyt‑c↑, Casp2↑, Casp3↑, Casp9↑, ERK↓, Akt↓, ROS↑, MMP↓, Bcl-2↓, BAX↑,

1328-

EMD,

Emodin induces apoptosis of human tongue squamous cancer SCC-4 cells through reactive oxygen species and mitochondria-dependent pathways

-

in-vitro,

Tong,

SCC4

TumCCA↑, P21↑, Chk2↑, CycB↓, cDC2↓, Apoptosis↑, Cyt‑c↑, Casp9↑, Casp3↑, ROS↑, MMP↓, Bax:Bcl2↑, ER Stress↑,

1332-

EMD,

Induction of Apoptosis in HepaRG Cell Line by Aloe-Emodin through Generation of Reactive Oxygen Species and the Mitochondrial Pathway

-

in-vivo,

Nor,

HepaRG

rata

*tumCV↓, *ROS↑, *MMP↓, *Fas↑, *P53↑, *P21↑, *Bax:Bcl2↑, *Casp3↑, *Casp8↑, *Casp9↑, *cl‑PARP↑, *TumCCA↑, *P21↑, *cycE↑, *cycA1↓, *CDK2↓,

1296-

EMD,

Emodin inhibits LOVO colorectal cancer cell proliferation via the regulation of the Bcl-2/Bax ratio and cytochrome c

-

in-vitro,

CRC,

LoVo

BAX↑, Bcl-2↓, MMP↓, Cyt‑c↑,

1329-

EMD,

Aloe-emodin induces cell death through S-phase arrest and caspase-dependent pathways in human tongue squamous cancer SCC-4 cells

-

in-vitro,

Tong,

SCC4

30 microM

TumCCA↑, eff↓, P53↑, P21↑, p27↑, cycA1↓, cycE↓, TS↓, CDC25↓, AIF↑, proCasp9↓, Cyt‑c↑, MMP↓, Bax:Bcl2↑, Casp3↑, Casp9↑,

1330-

EMD,

Aloe emodin-induced apoptosis in t-HSC/Cl-6 cells involves a mitochondria-mediated pathway

-

in-vitro,

NA,

NA

12.5, 25, or 50 microM

tumCV↓, Casp3↑, Casp9↑, MMP↓, Cyt‑c↑, BAX↑, Bax:Bcl2↑,

1331-

EMD,

Aloe-emodin induces apoptosis of human nasopharyngeal carcinoma cells via caspase-8-mediated activation of the mitochondrial death pathway

-

in-vitro,

NPC,

NA

TumCCA↑, CycB↑, DNAdam↑, Casp3↑, cl‑PARP↑, MMP↓, Ca+2↑, ROS↑,

3460-

EP,

Picosecond pulsed electric fields induce apoptosis in HeLa cells via the endoplasmic reticulum stress and caspase-dependent signaling pathways

-

in-vitro,

Cerv,

HeLa

tumCV↓, Apoptosis↑, TumCCA↑, GRP78/BiP↑, GRP94↑, CEBPA↑, CHOP↑, Ca+2↑, Casp12↑, Casp9↑, Casp3↑, Cyt‑c↑, BAX↑, Bcl-2↓, ER Stress↑, MMP↓,

2455-

erastin,

Discovery of the Inhibitor Targeting the SLC7A11/xCT Axis through In Silico and In Vitro Experiments

-

in-vitro,

Cerv,

HeLa

xCT↓, GSH↓, ROS↑, TumCMig↓,

2204-

erastin,

Regulation of ferroptotic cancer cell death by GPX4

-

in-vitro,

fibroS,

HT1080

GSH↓, Ferroptosis↑, ROS↑, GPx↓, GPx4↓, lipid-P↑, eff↓, eff↑,

975-

Est,

Estrogen inhibits autophagy and promotes growth of endometrial cancer by promoting glutamine metabolism

-

vitro+vivo,

UEC,

NA

GLS↑, cMyc↑, GlutMet↑, tumCV↑, TumAuto↓,

2143-

Ex,

The association between physical activity and bladder cancer: systematic review and meta-analysis

-

Review,

Bladder,

NA

Risk↓, Dose↝,

2144-

Ex,

Physical activity, hormone replacement therapy and breast cancer risk: A meta-analysis of prospective studies

-

Analysis,

NA,

NA

Risk↓, Dose?, eff↑,

2145-

Ex,

Leisure time physical activity and cancer risk: evaluation of the WHO's recommendation based on 126 high-quality epidemiological studies

-

Analysis,

Var,

NA

Risk↓, Dose↝, eff↑,

2146-

Ex,

A systematic review and meta-analysis of physical activity and endometrial cancer risk

-

Review,

Endo,

NA

Risk↓, eff↑,

2147-

Ex,

The association between physical activity and gastroesophageal cancer: systematic review and meta-analysis

-

Review,

GC,

NA

Risk↓,

2148-

Ex,

Effects of Exercise on Cancer Treatment Efficacy: A Systematic Review of Preclinical and Clinical Studies

-

Review,

Var,

NA

ChemoSen↑,

2149-

Ex,

Physical activity and exercise training in cancer patients

-

Analysis,

Var,

NA

eff↑, Dose↑,

2150-

Ex,

Roles and molecular mechanisms of physical exercise in cancer prevention and treatment

-

Review,

Var,

NA

eff↓, Dose↝, TumCP↓, Apoptosis↓, ChemoSen↑, chemoP↑,

2151-

Ex,

The effects of physical activity on overall survival among advanced cancer patients: a systematic review and meta-analysis

-

Review,

Var,

NA

eff↑, eff↝,

2153-

Ex,

The Impact of Exercise on Cancer Mortality, Recurrence, and Treatment-Related Adverse Effects

-

Review,

Var,

NA

eff↑, BMD↑, cognitive↑, OS↑, Remission↑, eff↑,

1038-

F,

immuno,

Fucoidan enhances the anti-tumor effect of anti-PD-1 immunotherapy by regulating gut microbiota.

-

in-vivo,

BC,

NA

GutMicro↑, T-Cell↑, Treg lymp↓,

1039-

F,

Anti-Proliferative and Pro-Apoptotic vLMW Fucoidan Formulas Decrease PD-L1 Surface Expression in EBV Latency III and DLBCL Tumoral B-Cells by Decreasing Actin Network

-

in-vitro,

NA,

NA

TumCP↓, Apoptosis↑, PD-L1↓,

1114-

F,

The Potential Effect of Fucoidan on Inhibiting Epithelial-to-Mesenchymal Transition, Proliferation, and Increase in Apoptosis for Endometriosis Treatment: In Vivo and In Vitro Study

-

vitro+vivo,

NA,

NA

tumCV↓, TumCMig↓, VEGF↓, EMT↓, Apoptosis↑,

1155-

F,

The anti-cancer effects of fucoidan: a review of both in vivo and in vitro investigations

-

Review,

NA,

NA

100 μg/mL

*toxicity↓, Casp3↑, Casp7↑, Casp8↑, Casp9↑, VEGF↓, angioG↓, PI3K↓, Akt↓, PARP↑, Bak↑, BID↑, Fas↑, Mcl-1↓, survivin↓, XIAP↓, ERK↓, EMT↓, EM↑, IM↓, Snail↓, Slug↓, Twist↓,

948-

F,

Low Molecular Weight Fucoidan Inhibits Tumor Angiogenesis through Downregulation of HIF-1/VEGF Signaling under Hypoxia

-

vitro+vivo,

Bladder,

T24

80-300mg/kg/day

mice

-

in-vitro,

Nor,

HUVECs

p‑PI3k/Akt/mTOR↓, p‑p70S6↓, p‑4E-BP1↓, angioG↓, Hif1a↓, VEGF↑, TumCG↓, TumVol↓, TumW↓, Iron∅, ROS↓,

1112-

FA,

Ferulic acid exerts antitumor activity and inhibits metastasis in breast cancer cells by regulating epithelial to mesenchymal transition

-

in-vitro,

BC,

MDA-MB-231

-

in-vivo,

BC,

NA

mouse

tumCV↓, Apoptosis↑, AntiTum↑, TumMeta↓, EMT↓, TumVol↓, TumW↓,

2173-

FA,

VitB12,

Elevated serum homocysteine levels associated with poor recurrence-free and overall survival in patients with colorectal cancer

-

Study,

CRC,

NA

Risk↓, eff↝, eff↝, homoC↓,

2176-

FA,

VitB12,

Hyperhomocysteinemia and Cancer: The Role of Natural Products and Nutritional Interventions

-

Review,

Var,

NA

homoC↓, eff↝,

2174-

FA,

VitB12,

-

Analysis,

Var,

NA

homoC↓, eff↑, eff↑, eff↑, eff↝, homoC↝, other?,

1289-

FA,

Cytotoxic and Apoptotic Effects of Ferulic Acid on Renal Carcinoma Cell Line (ACHN)

-

in-vitro,

RCC,

NA

10, 20, 40, 80, and 160 μM) for 24, 48, and 72 hours

30 μM at 72 hours

Bcl-2↓, BAX↑, Apoptosis↑,

1656-

FA,

Ferulic Acid: A Natural Phenol That Inhibits Neoplastic Events through Modulation of Oncogenic Signaling

-

Review,

Var,

NA

tyrosinase↓, CK2↓, TumCP↓, TumCMig↓, FGF↓, FGFR1↓, PI3K↓, Akt↓, VEGF↓, FGFR1↓, FGFR2↓, PDGF↓, ALAT↓, AST↓, TumCCA↑, CDK2↓, CDK4↓, CDK6↓, BAX↓, Bcl-2↓, MMP2↓, MMP9↓, P53↑, PARP↑, PUMA↑, NOXA↑, Casp3↑, Casp9↑, TIMP1↑, lipid-P↑, mtDam↑, EMT↓, Vim↓, E-cadherin↓, p‑STAT3↓, COX2↓, CDC25↓, RadioS↑, ROS↑, DNAdam↑, γH2AX↑, PTEN↑, LC3II↓, Beclin-1↓, SOD↓, Catalase↓, GPx↓, Fas↑, *BioAv↓, cMyc↓, Beclin-1↑, LC3‑Ⅱ/LC3‑Ⅰ↓,

1655-

FA,

Ferulic acid inhibiting colon cancer cells at different Duke’s stages

-

in-vitro,

Colon,

SW480

0−400 μg/mL up to 72 h

176.41 ± 16.77ug/mL

-

in-vitro,

Colon,

Caco-2

179.19 ± 25.71ug/mL

-

in-vitro,

Colon,

HCT116

165.46 ± 5.87ug/mL

TumCP↓, TumCMig↓, TumCCA↑, Apoptosis↑, ATM↑, Chk2↑, ATR↑, CHK1↑, CK2↓, cycA1↑, CDK4↓, CDK6↓, cycD1↓, cycE↓, P53↑, P21↑,

1654-

FA,

Molecular mechanism of ferulic acid and its derivatives in tumor progression

-

Review,

Var,

NA

AntiCan↑, Inflam↓, RadioS↑, ROS↑, Apoptosis↑, TumCCA↑, TumCMig↑, TumCI↓, angioG↓, ChemoSen↑, ChemoSideEff↓, P53↑, cycD1↓, CDK4↓, CDK6↓, TumW↓, miR-34a↑, Bcl-2↓, Casp3↑, BAX↑, β-catenin/ZEB1↓, cMyc↓, Bax:Bcl2↑, SOD↓, GSH↓, LDH↓, ERK↑, eff↑, JAK2↓, STAT6↓, NF-kB↓, PYCR1↓, PI3K↓, Akt↓, mTOR↓, Ki-67↓, VEGF↓, FGFR1↓, EMT↓, CAIX↓, LC3II↑, p62↑, PKM2↓, Glycolysis↓, *BioAv↓,

1622-

FA,

Folate and Its Impact on Cancer Risk

-

Review,

NA,

NA

eff↓,

1623-

FA,

Folic acid: friend or foe in cancer therapy

-

Review,

Var,

NA

Risk↝,

2497-

Fenb,

In vitro anti-tubulin effects of mebendazole and fenbendazole on canine glioma cells

-

in-vitro,

GBM,

NA

Dose?, selectivity↑, TumCD↑, α-tubulin↓,

2496-

Fenb,

Impairment of the Ubiquitin-Proteasome Pathway by Methyl N-(6-Phenylsulfanyl-1H-benzimidazol-2-yl)carbamate Leads to a Potent Cytotoxic Effect in Tumor Cells

-

in-vitro,

NSCLC,

A549

1.6 μm

-

in-vitro,

NSCLC,

H460

1.2 uM

TumCG↓, selectivity↑, P53↑, IKKα↑, ER Stress↑, GRP78/BiP↑, CHOP↑, ATF3↑, IRE1↑, NOXA↑, ROS↑, MMP↓, Cyt‑c↑, selectivity↑, eff↝,

2495-

Fenb,

Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells

-

in-vitro,

Melanoma,

A375

FBZ (1 and 2 μM)

P53↑, P21↑, TumCCA↑, MDM2↓, MDMX↓, eff↑,

2494-

Fenb,

Oral Fenbendazole for Cancer Therapy in Humans and Animals

-

Review,

Var,

NA

Glycolysis↓, GlucoseCon↓, ROS↑, Apoptosis↑, BioAv↓, eff↑, toxicity↓, BioAv↑, BioAv↑, hepatoP↓, eff↑,

2499-

Fenb,

VitE,

Effects of fenbendazole and vitamin E succinate on the growth and survival of prostate cancer cells

-

in-vitro,

Pca,

PC3

TumCP∅, TumCP↓, toxicity↓, eff↑,

2498-

Fenb,

Unexpected Antitumorigenic Effect of Fenbendazole when Combined with Supplementary Vitamins

-

in-vivo,

lymphoma,

NA

mice

eff↓, eff↑, TumVol↓, antiOx↑, Hif1a↓,

1915-

Fer,

Vascular Imaging With Ferumoxytol as a Contrast Agent

-

Analysis,

Var,

NA

eff↑, toxicity↓, other?,

1914-

Fer,

VitC,

TMZ,

Rad,

Pharmacologic Ascorbate and Ferumoxytol Combined with Temozolomide and Radiation Therapy for the Treatment of Newly Diagnosed Glioblastoma

-

Trial,

GBM,

NA

eff↑,

2844-

FIS,

Fisetin, a dietary flavonoid induces apoptosis via modulating the MAPK and PI3K/Akt signalling pathways in human osteosarcoma (U-2 OS) cells

-

in-vitro,

OS,

U2OS

tumCV↓, Apoptosis↑, Casp3↑, Casp8↑, Casp9↑, BAX↑, BAD↑, Bcl-2↓, Bcl-xL↓, PI3K↓, Akt↓, ERK↓, p‑JNK↑, p‑cJun↑, p‑p38↑, ROS↑, MMP↓, mTORC1↓, PTEN↑, p‑GSK‐3β↓, GSK‐3β↑, NF-kB↓, IKKα↑, Cyt‑c↑,

2850-

FIS,

Fisetin regulates TPA-induced breast Cancer cell invasion by suppressing matrix metalloproteinase-9 activation via the PKC/ROS/MAPK pathways

-

in-vitro,

BC,

MCF-7

TumCI↓, PKCδ↓, ROS↓, ERK↑, p38↓, NF-kB↓, MMP9↓,

2845-

FIS,

Fisetin: A bioactive phytochemical with potential for cancer prevention and pharmacotherapy

-

Review,

Var,

NA

PI3K↓, Akt↓, mTOR↓, p38↓, *antiOx↑, *neuroP↑, Casp3↑, Bcl-2↓, Mcl-1↓, BAX↑, BIM↑, BAD↑, AMPK↑, ACC↑, DNAdam↑, MMP↓, eff↑, ROS↑, cl‑PARP↑, Cyt‑c↑, Diablo↑, P53↑, p65↓, Myc↓, HSP70/HSPA5↓, HSP27↓, COX2↓, Wnt↓, EGFR↓, NF-kB↓, TumCCA↑, CDK2↓, CDK4↓, cycD1↓, cycA1↓, P21↑, MMP2↓, MMP9↓, TumMeta↓, MMP1↓, MMP3↓, MMP7↓, MET↓, N-cadherin↓, Vim↓, Snail↓, Fibronectin↓, E-cadherin↑, uPA↓, ChemoSen↑, EMT↓, Twist↓, Zeb1↓, cFos↓, cJun↓, EGF↓, angioG↓, VEGF↓, eNOS↓, *NRF2↑, HO-1↑, NRF2↓, GSTs↓, ATF4↓,

2846-

FIS,

Fisetin protects against cardiac cell death through reduction of ROS production and caspases activity

-

in-vitro,

Nor,

NA

0, 5, 10, 15, 20, 30, 40, 60, 80 and 100 μM

concentration of 15 μM of fisetin in the subsequent experiments

*cardioP↑, *ROS↓, *Casp↓, *DNAdam↓,

2847-

FIS,

Fisetin-induced cell death, apoptosis, and antimigratory effects in cholangiocarcinoma cells

-

in-vitro,

CCA,

NA

tumCV↓, ChemoSen↑, TumCMig↓, ROS↑, TumCI↓, angioG↓, CDK2↓, PI3K↓, Akt↓, mTOR↓, EGFR↓, Casp↑, mTORC1↓, mTORC2↑, cycD1↓, cycE↓, MMP2↓, MMP9↓, ER Stress↑, Ca+2↑, eff↓,

2848-

FIS,

Fisetin alleviates cellular senescence through PTEN mediated inhibition of PKCδ-NOX1 pathway in vascular smooth muscle cells

-

in-vitro,

Nor,

NA

*ROS↓, *PTEN↑, *PKCδ↑, *Inflam↓,

2849-

FIS,

Activation of reactive oxygen species/AMP activated protein kinase signaling mediates fisetin-induced apoptosis in multiple myeloma U266 cells

-

in-vitro,

Melanoma,

U266

40 μg/ml

TumCD↑, TumCCA↑, Casp3↑, Bcl-2↓, Mcl-1↓, BAX↑, BIM↑, BAD↑, AMPK↑, ACC↑, p‑Akt↓, p‑mTOR↓, ROS↑, eff↓,

2851-

FIS,

Apoptosis induction in breast cancer cell lines by the dietary flavonoid fisetin

-

in-vitro,

BC,

MDA-MB-468

-

in-vitro,

BC,

MDA-MB-231

-

in-vitro,

BC,

MCF-7

-

in-vitro,

BC,

T47D

-

in-vitro,

BC,

SkBr3

-

in-vitro,

Nor,

NA

tumCV↓, selectivity↑, TumCCA↑, Apoptosis↑, ROS∅,

2852-

FIS,

A comprehensive view on the fisetin impact on colorectal cancer in animal models: Focusing on cellular and molecular mechanisms

-

Review,

CRC,

NA

Risk↓, P53↑, MDM2↓, COX2↓, Wnt↓, NF-kB↓, CDK2↓, CDK4↓, p‑RB1↓, cycE↓, P21↑, NRF2↓, ROS↑, Casp8↑, Fas↑, TRAIL↑, DR5↑, MMP↓, Cyt‑c↑, selectivity↑, P450↝, GSTs↝, RadioS↑, Inflam↓, β-catenin/ZEB1↓, EGFR↓, TumCCA↑, ChemoSen↑,

2853-

FIS,

Fisetin Inhibits Cell Proliferation and Induces Apoptosis via JAK/STAT3 Signaling Pathways in Human Thyroid TPC 1 Cancer Cells

-

in-vitro,

Thyroid,

TPC-1

Apoptosis↑, ROS↑, MMP↓, TumCCA↑, Casp3↑, Casp8↑, Casp9↑, JAK1↓, STAT3↓,

2854-

FIS,

New Perspectives for Fisetin

-

Review,

Var,

NA

-

Review,

Stroke,

NA

Inflam↓, ChemoSen↑, chemoP↑, eff↑, memory↑, neuroP↑, *Dose↑, BioAv↓, BBB↑,

2855-

FIS,

Fisetin Induces Apoptosis Through p53-Mediated Up-Regulation of DR5 Expression in Human Renal Carcinoma Caki Cells

-

in-vitro,

RCC,

Caki-1

TumCCA↑, cl‑PARP↑, Apoptosis↑, Casp↑, P53↑, DR5↑, CHOP↑, ROS↑, ER Stress↑, ATF4↑, XBP-1↑, eff∅,

2856-

FIS,

N -acetyl- L -cysteine enhances fisetin-induced cytotoxicity via induction of ROS-independent apoptosis in human colonic cancer cells

-

in-vitro,

Colon,

COLO205

eff↑, ROS↑, tumCV↓, Casp3↑, Bcl-2↓, MMP↓, eff↑,

2857-

FIS,

A review on the chemotherapeutic potential of fisetin: In vitro evidences

-

Review,

Var,

NA

COX2↓, PGE2↓, EGFR↓, Wnt↓, β-catenin/ZEB1↓, TCF↑, Apoptosis↑, Casp3↑, cl‑PARP↑, Bcl-2↓, Mcl-1↓, BAX↑, BIM↑, BAD↑, Akt↓, mTOR↓, ACC↑, Cyt‑c↑, Diablo↑, cl‑Casp8↑, Fas↑, DR5↑, TRAIL↑, Securin↓, CDC2↓, CDC25↓, HSP70/HSPA5↓, CDK2↓, CDK4↓, cycD1↓, MMP2↓, uPA↓, NF-kB↓, cFos↓, cJun↓, MEK↓, p‑ERK↓, N-cadherin↓, Vim↓, Snail↓, Fibronectin↓, E-cadherin↓, NF-kB↑, ROS↑, DNAdam↑, MMP↓, CHOP↑, eff↑, ChemoSen↑,

2858-

FIS,

Fisetin inhibits cell migration via inducing HO-1 and reducing MMPs expression in breast cancer cell lines

-

in-vitro,

BC,

4T1

HO-1↑, NRF2↑, MMP2↓, MMP9↓,

2859-

FIS,

The Natural Flavonoid Fisetin Inhibits Cellular Proliferation of Hepatic, Colorectal, and Pancreatic Cancer Cells through Modulation of Multiple Signaling Pathways

-

in-vitro,

Liver,

HepG2

3.2μM

-

NA,

Colon,

Caco-2

16.4 μM

TumCG↓, other↝, Casp3↑, Casp7↑, PGE2↓, GSTs↓, Wnt↓, EGFR↓, NF-kB↓, COX2↓, P53↑, P21↑, P450↓,

2860-

FIS,

Fisetin induces autophagy in pancreatic cancer cells via endoplasmic reticulum stress- and mitochondrial stress-dependent pathways

-

in-vitro,

PC,

PANC1

-

in-vitro,

PC,

Bxpc-3

-

in-vitro,

Nor,

hTERT-HPNE

-

in-vivo,

NA,

NA

mice

AMPK↑, mTOR↑, UPR↑, ER Stress↑, selectivity↑, TumCP↓, PERK↑, ATF4↑, ATF6↑,

2861-

FIS,

The neuroprotective effects of fisetin, a natural flavonoid in neurodegenerative diseases: Focus on the role of oxidative stress

-

Review,

Nor,

NA

-

Review,

Stroke,

NA

-

Review,

Park,

NA

*antiOx↑, *ROS↓, *neuroP↑, *NO↑, BioAv↝, *BBB↑, *toxicity↑, *eff↑, *GSH↑, *SOD↑, *Aβ↓, *12LOX↓, *COX2↓, *Catalase↑, *Inflam↓, *TNF-α↓, *IL6↑, *lipid-P↓, NF-kB↓, IL1β↓, NRF2↑, HO-1↑, GSTs↑, cognitive↑,

2862-

FIS,

Fisetin averts oxidative stress in pancreatic tissues of streptozotocin-induced diabetic rat

-

in-vivo,

Diabetic,

NA

*BG↓, *NF-kB↓, *IL1β↓, *NO↓, *Insulin↑, *SOD↑, *Catalase↑, *GPx↑, *GSTs↑,

2842-

FIS,

Fisetin inhibits cellular proliferation and induces mitochondria-dependent apoptosis in human gastric cancer cells

-

in-vitro,

GC,

AGS

TumCCA↑, CDK2↓, P53↑, selectivity↑, MMP↓, DNAdam↑, cl‑PARP↑, mt-ROS↑, eff↓, survivin↓,

2824-

FIS,

Fisetin in Cancer: Attributes, Developmental Aspects, and Nanotherapeutics

-

Review,

Var,

NA

*antiOx↑, *Inflam↓, angioG↓, BioAv↓, BioAv↑, TumCP↓, TumCI↓, TumCMig↓, *neuroP↑, EMT↓, ROS↑, selectivity↑, EGFR↓, NF-kB↓, VEGF↓, MMP9↓, MMP↓, cl‑PARP↑, Casp7↑, Casp8↑, Casp9↑, *ROS↓, uPA↓, MMP1↓, Wnt↓, Akt↓, PI3K↓, ERK↓, Half-Life↝,

2825-

FIS,

Exploring the molecular targets of dietary flavonoid fisetin in cancer

-

Review,

Var,

NA

*Inflam↓, *antiOx↓, *ERK↑, *p‑cMyc↑, *NRF2↑, *GSH↑, *HO-1↑, mTOR↓, PI3K↓, Akt↓, TumCCA↑, cycD1↓, cycE↓, CDK2↓, CDK4↓, CDK6↓, P21↑, p27↑, JNK↑, MMP2↓, MMP9↓, uPA↓, NF-kB↓, cFos↓, cJun↓, E-cadherin↑, Vim↓, N-cadherin↓, EMT↓, MMP↓, Cyt‑c↑, Diablo↑, Casp↑, cl‑PARP↑, P53↑, COX2↓, PGE2↓, HSP70/HSPA5↓, HSP27↓, DNAdam↑, Casp3↑, Casp9↑, ROS↑, AMPK↑, NO↑, Ca+2↑, mTORC1↓, p70S6↓, ROS↓, ER Stress↑, IRE1↑, ATF4↑, GRP78/BiP↑, eff↑, eff↑, eff↑, RadioS↑, ChemoSen↑, Half-Life↝,

2826-

FIS,

Fisetin induces apoptosis in breast cancer MDA-MB-453 cells through degradation of HER2/neu and via the PI3K/Akt pathway

-

in-vitro,

BC,

MDA-MB-453

0, 20, 40, 60, 80, and 100 uM

Apoptosis↑, p‑ENO1↓, DNAdam↑, PI3K↑, p‑Akt↑, HER2/EBBR2↓,

2827-

FIS,

The Potential Role of Fisetin, a Flavonoid in Cancer Prevention and Treatment

-

Review,

Var,

NA

*antiOx↑, *Inflam↓, neuroP↑, hepatoP↑, RenoP↑, cycD1↓, TumCCA↑, MMPs↓, VEGF↓, MAPK↓, NF-kB↓, angioG↓, Beclin-1↑, LC3s↑, ATG5↑, Bcl-2↓, BAX↑, Casp↑, TNF-α↓, Half-Life↓, MMP↓, mt-ROS↑, cl‑PARP↑, CDK2↓, CDK4↓, Cyt‑c↑, Diablo↑, DR5↑, Fas↑, PCNA↓, Ki-67↓, p‑H3↓, chemoP↑, Ca+2↑, Dose↝, CDC25↓, CDC2↓, CHK1↑, Chk2↑, ATM↑, PCK1↓, RAS↓, p‑p38↓, Rho↓, uPA↓, MMP7↓, MMP13↓, GSK‐3β↑, E-cadherin↑, survivin↓, VEGFR2↓, IAP2↓, STAT3↓, JAK1↓, mTORC1↓, mTORC2↓, NRF2↑,

2828-

FIS,

Fisetin, a Potent Anticancer Flavonol Exhibiting Cytotoxic Activity against Neoplastic Malignant Cells and Cancerous Conditions: A Scoping, Comprehensive Review

-

Review,

Var,

NA

*neuroP↑, *antiOx↑, *Inflam↓, RenoP↑, COX2↓, Wnt↓, EGFR↓, NF-kB↓, Casp3↑, Ca+2↑, Casp8↑, TumCCA↑, CDK1↓, PI3K↓, Akt↓, mTOR↓, MAPK↓, *P53↓, *P21↓, *p16↓, mTORC1↓, mTORC2↓, P53↑, P21↑, cycD1↓, cycA1↓, CDK2↓, CDK4↓, BAX↑, Bcl-2↓, PCNA↓, HER2/EBBR2↓, Cyt‑c↑, MMP↓, cl‑Casp9↑, MMP2↓, MMP9↓, cl‑PARP↑, uPA↓, DR4↑, DR5↑, ROS↓, AIF↑, CDC25↓, Dose↑, CHOP↑, ROS↑, cMyc↓, cardioP↑,

2829-

FIS,

Fisetin: An anticancer perspective

-

Review,

Var,

NA

TumCP↓, TumCI↓, TumCCA↑, TumCG↓, Apoptosis↑, cl‑PARP↑, PKCδ↓, ROS↓, ERK↓, NF-kB↓, survivin↓, ROS↑, PI3K↓, Akt↓, mTOR↓, MAPK↓, p38↓, HER2/EBBR2↓, EMT↓, PTEN↑, HO-1↑, NRF2↑, MMP2↓, MMP9↓, MMP↓, Casp8↑, Casp9↑, TRAILR↑, Cyt‑c↑, XIAP↓, P53↑, CDK2↓, CDK4↓, CDC25↓, CDC2↓, VEGF↓, DNAdam↑, TET1↓, CHOP↑, CD44↓, CD133↓, uPA↓,

2830-

FIS,

Biological effects and mechanisms of fisetin in cancer: a promising anti-cancer agent

-

Review,

Var,

NA

TumCG↓, angioG↓, *ROS↓, TumCMig↓, VEGF↓, MAPK↑, NF-kB↓, PI3K↓, Akt↓, mTOR↓, NRF2↑, HO-1↑, ROS↓, Inflam↓, ER Stress↑, ROS↑, TumCP↓, ChemoSen↑, PTEN↑, P53↑, Casp3↑, Casp8↑, Casp9↑, COX2↓, Wnt↓, EGFR↓, Mcl-1↓, survivin↓, IAP1↓, IAP2↓, PGE2↓, β-catenin/ZEB1↓, DR5↑, MMP2↓, MMP9↓, FAK↓, uPA↓, EMT↓, ERK↓, JNK↑, p38↑, PKCδ↓, BioAv↓, BioAv↑, BioAv↑,

2831-

FIS,

Fisetin as a chemoprotective and chemotherapeutic agent: mechanistic insights and future directions in cancer therapy

-

Review,

Var,

NA

TumCG↓, ER Stress↑, antiOx↓, ROS↓, ChemoSen↑,

2832-

FIS,

Fisetin's Promising Antitumor Effects: Uncovering Mechanisms and Targeting for Future Therapies

-

Review,

Var,

NA

MMP↓, mtDam↑, Cyt‑c↑, Diablo↑, Casp↑, cl‑PARP↑, Bak↑, BIM↑, Bcl-xL↓, Bcl-2↓, P53↑, ROS↑, AMPK↑, Casp9↑, Casp3↑, BID↑, AIF↑, Akt↓, mTOR↓, MAPK↓, Wnt↓, β-catenin/ZEB1↓, TumCCA↑, P21↑, p27↑, cycD1↓, cycE↓, CDK2↓, CDK4↓, CDK6↓, TumMeta↓, uPA↓, E-cadherin↑, Vim↓, EMT↓, Twist↓, DNAdam↑, ROS↓, COX2↓, PGE2↓, HSF1↓, cFos↓, cJun↓, AP-1↓, Mcl-1↓, NF-kB↓, IRE1↑, ER Stress↑, ATF4↑, GRP78/BiP↑, MMP2↓, MMP9↓, TCF-4↓, MMP7↓, RadioS↑, TOP1↓, TOP2↓,

2833-

FIS,

SNP,

Glucose-capped fisetin silver nanoparticles induced cytotoxicity and ferroptosis in breast cancer cells: A molecular perspective

-

in-vitro,

BC,

MDA-MB-231

11.275 ± 0.197 μg/mL

MMP↓, ROS↑, NRF2↑, NOX↑, selectivity↑,

2838-

FIS,

Fisetin induces apoptosis in colorectal cancer cells by suppressing autophagy and down-regulating nuclear factor erythroid 2-related factor 2 (Nrf2)

cl‑Casp3↑, cl‑PARP↑, MMP↓, Cyt‑c↑, ROS↑, NRF2↓,

2839-

FIS,

Dietary flavonoid fisetin for cancer prevention and treatment

-

Review,

Var,

NA

DNAdam↑, ROS↑, Apoptosis↑, Bcl-2↓, BAX↑, cl‑Casp9↑, cl‑Casp3↑, Cyt‑c↑, lipid-P↓, TumCG↓, TumCA↓, TumCMig↓, TumCI↓, uPA↓, ERK↓, MMP9↓, NF-kB↓, cFos↓, cJun↓, AP-1↓, TumCCA↑, AR↓, mTORC1↓, mTORC2↓, TSC2↑, EGF↓, TGF-β↓, EMT↓, P-gp↓, PI3K↓, Akt↓, mTOR↓, eff↑, ROS↓, ER Stress↑, IRE1↑, ATF4↑, GRP78/BiP↑, ChemoSen↑, CDK2↓, CDK4↓, cycE↓, cycD1↓, P21↑, COX2↓, Wnt↓, EGFR↓, β-catenin/ZEB1↓, TCF-4↓, MMP7↓, RadioS↑, eff↑,

2840-

FIS,

Fisetin-induced cell death, apoptosis, and antimigratory effects in cholangiocarcinoma cells

-

NA,

CCA,

NA

50 μM.

ROS↑, TumCMig↓, TumCP↓,

2841-

FIS,

Fisetin, an Anti-Inflammatory Agent, Overcomes Radioresistance by Activating the PERK-ATF4-CHOP Axis in Liver Cancer

-

in-vitro,

Nor,

RAW264.7

LPS-induced Raw264.7 cells

-

in-vitro,

Liver,

HepG2

10, 25, 100, and 200 μM, 24 h

-

in-vitro,

Liver,

Hep3B

-

in-vitro,

Liver,

HUH7

*Inflam↓, *TNF-α↓, *IL1β↓, *IL6↓, Apoptosis↓, ER Stress↑, Ca+2↑, PERK↑, ATF4↑, CHOP↑, GRP78/BiP↑, tumCV↓, LDH↑, Casp3↑, cl‑Casp3↑, cl‑Casp8↑, cl‑Casp9↑, p‑eIF2α↑, RadioS↑,

2843-

FIS,

Fisetin and Quercetin: Promising Flavonoids with Chemopreventive Potential

-

Review,

Var,

NA

NRF2↑, Keap1↓, ChemoSen↑, BioAv↓, Cyt‑c↑, Casp3↑, Casp9↑, BAX↑, tumCV↓, Mcl-1↓, cl‑PARP↑, IGF-1↓, Akt↓, CDK6↓, TumCCA↑, P53?, cycD1↓, cycE↓, CDK2↓, CDK4↓, CDK6↓, MMP2↓, MMP9↓, MMP1↓, MMP7↓, MMP3↓, VEGF↓, PI3K↓, mTOR↓, COX2↓, Wnt↓, EGFR↓, NF-kB↓, ERK↓, ROS↑, angioG↓, TNF-α↓, PGE2↓, iNOS↓, NO↓, IL6↓, HSP70/HSPA5↝, HSP27↝,

1113-

FIS,

Fisetin suppresses migration, invasion and stem-cell-like phenotype of human non-small cell lung carcinoma cells via attenuation of epithelial to mesenchymal transition

-

in-vitro,

Lung,

A549

-

in-vitro,

Lung,

H1299

TumCI↓, TumCMig↓, EMT↓, E-cadherin↑, ZO-1↑, Vim↓, N-cadherin↓, MMP2↓, CD44↓, CD133↓, β-catenin/ZEB1↓, NF-kB↓, EGFR↓, STAT3↓,

949-

FIS,

ATAGJ,

Cisplatin,

Ai-Tong-An-Gao-Ji and Fisetin Inhibit Tumor Cell Growth in Rat CIBP Models by Inhibiting the AKT/HIF-1α Signaling Pathway

-

in-vivo,

BC,

Walker256

10,20,30g/day

-

in-vitro,

BC,

Walker256

10,20,30uM and 5uM(Cis)

indicating that the cisplatin group could substantially inhibit the migration of Walker 256 cells in both low and high dose fisetin groups

Akt↓, Hif1a↓, p‑Akt↓,

2313-

Flav,

Flavonoids against the Warburg phenotype—concepts of predictive, preventive and personalised medicine to cut the Gordian knot of cancer cell metabolism

-

Review,

Var,

NA

Warburg↓, antiOx↑, angioG↓, Glycolysis↓, PKM2↓, PKM2:PKM1↓, β-catenin/ZEB1↓, cMyc↓, HK2↓, Akt↓, mTOR↓, GLUT1↓, Hif1a↓,

2642-

Flav,

QC,

Api,

KaempF,

MCT

In Vitro–In Vivo Study of the Impact of Excipient Emulsions on the Bioavailability and Antioxidant Activity of Flavonoids: Influence of the Carrier Oil Type

-

in-vitro,

Nor,

NA

-

in-vivo,

Nor,

NA

rat

*BioAv↑, *eff↝, BioEnh↑,

2401-

Flav,

In vitro effects of some flavonoids and phenolic acids on human pyruvate kinase isoenzyme M2

-

in-vitro,

Nor,

NA

cells not specified

PKM2↓,

1773-

GA,

Impact of Gallic Acid on Gut Health: Focus on the Gut Microbiome, Immune Response, and Mechanisms of Action

-

Review,

Var,

NA

antiOx↑, AntiCan↑, Inflam↑, GutMicro↑, BioAv↝, BioAv↓, BioAv↑, TumMeta↓,

1300-

GA,

PacT,

carbop,

Gallic acid potentiates the apoptotic effect of paclitaxel and carboplatin via overexpression of Bax and P53 on the MCF-7 human breast cancer cell line

-

in-vitro,

BC,

MCF-7

TumCCA↑, Apoptosis↑, P53↑, BAX↑, Casp3↑, Bcl-2↓,

1283-

GA,

immuno,

Gallic acid induces T-helper-1-like Treg cells and strengthens immune checkpoint blockade efficacy

-

vitro+vivo,

CRC,

NA

p‑STAT3↓, Treg lymp↓, FOXP3↓, CD8+↑, IFN-γ↑,

1624-

GA,

Anticancer Effect of Pomegranate Peel Polyphenols against Cervical Cancer

-

in-vitro,

Cerv,

NA

ROS↑, Dose∅, MMP↓, GSH↑,

1065-

GA,

Gallic acid, a phenolic acid, hinders the progression of prostate cancer by inhibition of histone deacetylase 1 and 2 expression

-

vitro+vivo,

Pca,

NA

mice

tumCV↓, MMP↓, DNAdam↑, HDAC1↓, HDAC2↓, PCNA↓, cycD1↓, cycE1↓, P21↑, TumVol↓,

1086-

GA,

Anti-leukemic effects of gallic acid on human leukemia K562 cells: downregulation of COX-2, inhibition of BCR/ABL kinase and NF-κB inactivation

-

in-vitro,

AML,

K562

tumCV↓, TumCCA↑, P21↑, p27↑, cycD1↓, cycE↓, Bax:Bcl2↑, Cyt‑c↑, cl‑PARP↓, DNAdam↑, Casp3↑, FASN↓, Casp8↑,

987-

GA,

Targeting Aerobic Glycolysis: Gallic Acid as Promising Anticancer Drug

-

in-vitro,

GBM,

AMGM

1-100uM

1uM->90% growth inhibition @72hr

-

in-vitro,

Cerv,

HeLa

-

in-vitro,

BC,

MCF-7

LDH↓, TumCG↓,

997-

GA,

The Inhibitory Mechanisms of Tumor PD-L1 Expression by Natural Bioactive Gallic Acid in Non-Small-Cell Lung Cancer (NSCLC) Cells

-

in-vitro,

Lung,

A549

400 μM @48hrs

-

in-vitro,

Lung,

H292

100 μM@48hrs

-

in-vitro,

Nor,

HUVECs

400 μM GA inducing around 8% cell death which indicated that this concentration does not make much toxicity in normal cells ****

PD-L1↓, p‑EGFR↓, p‑PI3K↓, p‑Akt↓, P53↑, miR-34a↑, *toxicity↓,

1115-

GA,

Gallic acid alleviates gastric precancerous lesions through inhibition of epithelial mesenchymal transition via Wnt/β-catenin signaling pathway

-

in-vivo,

GC,

GES-1

mice,induced precancerous lesions of gastric cancer cells (MC)

TumCP↓, TumCCA↑, Wnt/(β-catenin)↓, EMT↓,

1091-

GA,

Gallic acid reduces cell viability, proliferation, invasion and angiogenesis in human cervical cancer cells

-

in-vitro,

Cerv,

HeLa

-

in-vitro,

Cerv,

HTB-35

tumCV↓, TumCP↓, ADAM17↓, EGFR↓, p‑Akt↓, p‑ERK↓,

947-

GA,

Gallic acid, a phenolic compound, exerts anti-angiogenic effects via the PTEN/AKT/HIF-1α/VEGF signaling pathway in ovarian cancer cells

-

in-vitro,

Ovarian,

OVCAR-3

0, 5, 10, or 20 μM GA for 24 h

-

in-vitro,

Melanoma,

A2780S

-

in-vitro,

Nor,

IOSE364

40uM

Notably, GA did not have a significant inhibitory effect on the normal cell line (IOSE-364) at 40 μM. ****

-

Human,

NA,

NA

8-10uM / 800mg oral GA

~8–10 μM of GA was detected in the serum of healthy volunteers, after oral intake of a combination of a dietary herbal supplement and 800 mg GA

TumCG↓, VEGF↓, angioG↓, p‑Akt↓, Hif1a↓, PTEN↑, BioAv↑, *toxicity↓,

935-

Gallo,

Galloflavin, a new lactate dehydrogenase inhibitor, induces the death of human breast cancer cells with different glycolytic attitude by affecting distinct signaling pathways

-

in-vitro,

BC,

MCF-7

-

in-vitro,

BC,

MDA-MB-231

LDH↓, ROS↑,

934-

Gallo,

Galloflavin (CAS 568-80-9): a novel inhibitor of lactate dehydrogenase

-

Analysis,

NA,

NA

calculated Ki values for pyruvate were 5.46 μM (LDH-A) and 15.06 μM (LDH-B)

LDH↓, Glycolysis↓, Apoptosis↑,

2426-

GamB,

Anti-cancer natural products isolated from chinese medicinal herbs

-

Review,

Var,

NA

(IC50) lower than 1 μM

TfR1/CD71↓, MMP2↓, MMP9↓, ChemoSen↑,

1968-

GamB,

Gambogic Acid Shows Anti-Proliferative Effects on Non-Small Cell Lung Cancer (NSCLC) Cells by Activating Reactive Oxygen Species (ROS)-Induced Endoplasmic Reticulum (ER) Stress-Mediated Apoptosis

-

in-vitro,

Lung,

A549

0, 0.5, and 1.0 μmol/l

tumCV↓, ROS↑, GRP78/BiP↑, CHOP↑, ATF6↑, Casp12↑, p‑PERK↑,

1973-

GamB,

Gambogic acid deactivates cytosolic and mitochondrial thioredoxins by covalent binding to the functional domain

-

in-vitro,

Liver,

SMMC-7721 cell

Apoptosis↑, ROS↑, Trx↓, Trx1↓, Trx2↓, Mich↑,

1972-

GamB,

doxoR,

Gambogic acid sensitizes resistant breast cancer cells to doxorubicin through inhibiting P-glycoprotein and suppressing survivin expression

-

in-vitro,

BC,

NA

eff↑, P-gp↓, ROS↑, survivin↓, p38↑,

1971-

GamB,

Gambogic acid triggers vacuolization-associated cell death in cancer cells via disruption of thiol proteostasis

-

in-vitro,

Nor,

MCF10

-

in-vitro,

BC,

MDA-MB-435

1.5 μM

-

in-vitro,

BC,

MDA-MB-468

2.35 μM

-

in-vivo,

NA,

NA

injections of saline or GA (4 or 8 mg/kg) twice

mice

Paraptosis↑, ER Stress↑, MMP↓, eff↓, selectivity↑, p‑ERK↑, p‑JNK↑, eff↓,

1970-

GamB,

Gambogic acid-induced autophagy in nonsmall cell lung cancer NCI-H441 cells through a reactive oxygen species pathway

-

NA,

Lung,

NCI-H441

TumCG↓, TumAuto↑, Beclin-1↑, LC3‑Ⅱ/LC3‑Ⅰ↑, ROS↑, eff↓,

1969-

GamB,

Gambogic acid promotes apoptosis and resistance to metastatic potential in MDA-MB-231 human breast carcinoma cells

-

in-vitro,

BC,

MDA-MB-231

3 and 6 µmol/L

-

in-vivo,

NA,

NA

mice

AntiTum↑, TumCI↓, Apoptosis↑, ROS↑, Cyt‑c↑, Akt↓, mTOR↓, TumCG↓, TumMeta↓,

1967-

GamB,

Gambogic acid induces apoptotic cell death in T98G glioma cells

-

in-vitro,

GBM,

T98G

BAX↑, AIF↑, Cyt‑c↑, cl‑Casp3↑, cl‑Casp8↑, cl‑Casp9↑, cl‑PARP↓, Bcl-2↓, ROS↑,

2060-

GamB,

Gambogenic acid induces apoptosis and autophagy through ROS-mediated endoplasmic reticulum stress via JNK pathway in prostate cancer cells

-

in-vitro,

Pca,

NA

TumCP↓, TumAuto↑, eff↑, ROS↑, ER Stress↑, JNK↑,

1954-

GamB,

Gambogic acid induces apoptosis in hepatocellular carcinoma SMMC-7721 cells by targeting cytosolic thioredoxin reductase

-

in-vitro,

HCC,

SMMC-7721 cell

1.2 uM

AntiTum↑, TrxR↓, TrxR1↓, ROS↑, Apoptosis↑, Dose∅, Dose?,

1955-

GamB,

Gambogic acid inhibits thioredoxin activity and induces ROS-mediated cell death in castration-resistant prostate cancer

-

in-vitro,

Pca,

NA

185nM

ROS↑, Apoptosis↑, Ferroptosis↑, Trx↓, eff↑, TrxR↓, Dose∅, MMP↓, eff↑,

1956-

GamB,

Gambogic Acid Inhibits Malignant Melanoma Cell Proliferation Through Mitochondrial p66shc/ROS-p53/Bax-Mediated Apoptosis

-

in-vitro,

Melanoma,

A375

1-10 μg/ml

tumCV↓, Apoptosis↑, ROS↑, p66Shc↑,

1957-

GamB,

Nanoscale Features of Gambogic Acid Induced ROS-Dependent Apoptosis in Esophageal Cancer Cells Imaged by Atomic Force Microscopy

-

in-vitro,

ESCC,

EC9706

0-2uM

~1.4uM

AntiCan↑, toxicity↓, TumCP↓, Apoptosis↑, TumCCA↑, MMP↓, ROS↑, eff↓, RadioS↑,

1958-

GamB,

Gambogenic acid induces apoptosis and autophagy through ROS-mediated endoplasmic reticulum stress via JNK pathway in prostate cancer cells

-

in-vitro,

Pca,

NA

-

in-vivo,

NA,

NA

AntiCan↑, TumCP↓, TumAuto↑, eff↑, JNK↑, ROS↑, ER Stress↑, eff↓, TumCG↓,

1959-

GamB,

Gambogic acid induces GSDME dependent pyroptotic signaling pathway via ROS/P53/Mitochondria/Caspase-3 in ovarian cancer cells

-

in-vitro,

Ovarian,

NA

-

in-vivo,

NA,

NA

mice

AntiCan↑, Pyro↑, tumCV?, CellMemb↓, cl‑Casp3↑, GSDME-N↑, ROS?, p‑P53↑, eff↓, MMP↓, Bcl-2↓, BAX↑, mtDam↑, Cyt‑c↑, TumCG↓, CD4+↑, CD8+↑,

1961-

GamB,

Effects of gambogic acid on the activation of caspase-3 and downregulation of SIRT1 in RPMI-8226 multiple myeloma cells via the accumulation of ROS

-

in-vitro,

Melanoma,

RPMI-8226

0-2.5uM

2uM

TumCG↓, Apoptosis↑, ROS↑, Casp3↑, cl‑PARP↑, SIRT1↓, eff↓,

1962-

GamB,

HCQ,

Gambogic acid induces autophagy and combines synergistically with chloroquine to suppress pancreatic cancer by increasing the accumulation of reactive oxygen species

-

in-vitro,

PC,

NA

LC3II↑, Beclin-1↑, p62↓, MMP↓, ROS↑, TumAuto↑, eff↑,

1963-

GamB,

Gambogic acid exhibits promising anticancer activity by inhibiting the pentose phosphate pathway in lung cancer mouse model

-

in-vitro,

Lung,

NA

lung cancer mouse model was constructed

ROS↑, 6PGD↓, PPP↓,

1964-

GamB,

Gambogic acid suppresses the pentose phosphate pathway by covalently inhibiting 6PGD protein in cancer cells

-

in-vitro,

NA,

NA

PPP↓, 6PGD↓,

1965-

GamB,

doxoR,

Gambogic acid sensitizes ovarian cancer cells to doxorubicin through ROS-mediated apoptosis

-

in-vitro,

Ovarian,

SKOV3

eff↑, AntiCan↑, ROS↑, ChemoSen↑,

1966-

GamB,

Cisplatin,

Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-κB and MAPK/HO-1 signalling

-

in-vitro,

Lung,

A549

-

in-vitro,

Lung,

NCIH1299

TumCCA↑, PARP↑, eff↑, ROS↑, ChemoSen↑,

1960-

GamB,

Vem,

Calcium channel blocker verapamil accelerates gambogic acid-induced cytotoxicity via enhancing proteasome inhibition and ROS generation

-

in-vitro,

Liver,

HepG2

-

in-vitro,

AML,

K562

Proteasome↓, eff↑, Casp↑, ER Stress↑, ROS↑, eff↑,

1636-

GAR,

Dangerous dietary supplements: Garcinia cambogia-associated hepatic failure requiring transplantation

-

Case Report,

Obesity,

NA

*Dose∅, *other↑,

1632-

GAR,

Garcinia Cambogia, Either Alone or in Combination with Green Tea Causes Moderate to Severe Liver Injury

-

Human,

LiverDam,

NA

HLA↑, other↑,

808-

GAR,

CUR,

Synergistic effect of garcinol and curcumin on antiproliferative and apoptotic activity in pancreatic cancer cells

-

in-vitro,

PC,

Bxpc-3

10uM(Gar), 5uM(Cur)

combination of garcinol and curcumin was 2 to 10 fold that of the individual agents

-

in-vitro,

PC,

PANC1

tumCV↓, Apoptosis↑, Casp3↑, Casp9↑,

832-

GAR,

Rad,

Garcinol, a Histone Acetyltransferase Inhibitor, Radiosensitizes Cancer Cells by Inhibiting Non-Homologous End Joining

-

in-vitro,

Lung,

A549

-

in-vitro,

NA,

HeLa

HATs↓, other↑,

831-

GAR,

CUR,

Induction of apoptosis by garcinol and curcumin through cytochrome c release and activation of caspases in human leukemia HL-60 cells

-

in-vitro,

AML,

HL-60

20 microM

9.4uM(Gar), 19.5uM(Cur)

Apoptosis↑, Casp3↑, MMP↓, Cyt‑c↑, proCasp9↑, Bcl-2↓, BAX↑, PARP↓, DNAdam↑, DFF45↓,

830-

GAR,

Garcinol modulates tyrosine phosphorylation of FAK and subsequently induces apoptosis through down-regulation of Src, ERK, and Akt survival signaling in human colon cancer cells

-

in-vitro,

CRC,

HT-29

10uM

TumCI↓, TumCMig↓, Apoptosis↑, p‑FAK↓, Src↓, MAPK↓, ERK↓, PI3K/Akt↓, Bax:Bcl2↑, Cyt‑c↑, MMP7↓,

817-

GAR,

Garcinol inhibits esophageal cancer metastasis by suppressing the p300 and TGF-β1 signaling pathways

-

vitro+vivo,

SCC,

KYSE150

5-15uM

mouse 20 mg/kg

-

vitro+vivo,

SCC,

KYSE450

HATs↓, TumCCA↑, Apoptosis↑, TumCMig↓, TumCI↓, CBP↓, p300↓, TGF-β↓, Ki-67↓, SMAD2↓, SMAD3↓,

826-

GAR,

Inhibition of STAT3 dimerization and acetylation by garcinol suppresses the growth of human hepatocellular carcinoma in vitro and in vivo

-

vitro+vivo,

HCC,

HepG2

-

vitro+vivo,

Liver,

HUH7

STAT3↓, TumCP↓, cycD1↓, Bcl-2↓, Bcl-xL↓, Mcl-1↓, survivin↓, VEGF↓, TumCCA↑, TumVol↓,

825-

GAR,

Garcinol-induced apoptosis in prostate and pancreatic cancer cells is mediated by NF- kappaB signaling

-

in-vitro,

Pca,

LNCaP

-

in-vitro,

Pca,

Bxpc-3

-

in-vitro,

Pca,

PC3

-

in-vitro,

Pca,

C4-2B

TumCG↓, Apoptosis↑, NF-kB↓,

824-

GAR,

Garcinol A Novel Inhibitor of Platelet Activation and Apoptosis

-

in-vitro,

NA,

NA

33 µM, 30 min

exposed murine blood platelets to garcinol

AntiAg↓,

823-

GAR,

Garcinol Potentiates TRAIL-Induced Apoptosis through Modulation of Death Receptors and Antiapoptotic Proteins

-

in-vitro,

BC,

MCF-7

-

in-vitro,

Nor,

MCF10

-

in-vitro,

CRC,

HCT116

Casp3↑, Casp9↑, Casp8↑, DR5↑, survivin↓, Bcl-2↓, XIAP↓, cFLIP↓, BAX↑, Cyt‑c↑, ROS↑, GSH↓, *eff↓,

822-

GAR,

Garcinol, a Polyisoprenylated Benzophenone Modulates Multiple Proinflammatory Signaling Cascades Leading to the Suppression of Growth and Survival of Head and Neck Carcinoma

-

vitro+vivo,

HNSCC,

NA

0-50uM/L

ROS↑, STAT3↓, cSrc↓, JAK1↓, JAK2↓, NF-kB↓, TGF-β↓, TumCG↓,

821-

GAR,

Garcinol inhibits cell growth in hepatocellular carcinoma Hep3B cells through induction of ROS-dependent apoptosis

-

in-vitro,

Liver,

Hep3B

ROS↑, CHOP↑, MMP↓, Bax:Bcl2↑, Casp8↑, Casp3↑, Casp9↑, cl‑PARP↑, DFF45↑,

820-

GAR,

Garcinol in gastrointestinal cancer prevention: recent advances and future prospects

-

Review,

NA,

NA

Fas↑, TRAIL↑, PARP↑, BAX↑, Bcl-2↓, ROS↑, STAT3↓, Apoptosis↑, MMP2↓, MMP9↓,

819-

GAR,

Enhanced Hsa-miR-181d/p-STAT3 and Hsa-miR-181d/p-STAT5A Ratios Mediate the Anticancer Effect of Garcinol in STAT3/5A-Addicted Glioblastoma

-

in-vivo,

GBM,

U87MG

also mouse model

-

in-vitro,

GBM,

GBM

OCT4↓, SOX2↓, TumCG↓,

818-

GAR,

GB,

Garcinol Sensitizes NSCLC Cells to Standard Therapies by Regulating EMT-Modulating miRNAs

-

in-vitro,

Lung,

A549

miR-205↑, Let-7↑, Apoptosis↑, miR-200b↑, miR-218↑,

828-

GAR,

Cisplatin,

Garcinol Alone and in Combination With Cisplatin Affect Cellular Behavior and PI3K/AKT Protein Phosphorylation in Human Ovarian Cancer Cells

-

in-vitro,

Ovarian,

OVCAR-3

tumCV↓, cl‑PARP↑, cl‑Casp3↑, BAX↑, p‑PI3K↓, p‑Akt↓, NF-kB↓,

816-

GAR,

Garcinol downregulates Notch1 signaling via modulating miR-200c and suppresses oncogenic properties of PANC-1 cancer stem-like cells

-

in-vitro,

PC,

PANC1

significantly suppressed the stem-like properties

Mcl-1↓, EZH2↓, ABCG2↓, Gli1↓, NOTCH1↓, miR-200c↑,

815-

GAR,

Garcinol from Garcinia indica Downregulates Cancer Stem-like Cell Biomarker ALDH1A1 in Nonsmall Cell Lung Cancer A549 Cells through DDIT3 Activation

-

vitro+vivo,

Lung,

A549

mouse

ALDH1A1↓, CHOP↑,

814-

GAR,

PacT,

Garcinol sensitizes breast cancer cells to Taxol through the suppression of caspase-3/iPLA2 and NF-κB/Twist1 signaling pathways in a mouse 4T1 breast tumor model

-

in-vivo,

BC,

NA

Taxol (5 mg kg-1, i.p.) and garcinol (1 mg kg-1, i.g.)

mouse

Apoptosis↑, TumCCA↑, EMT↓, TumCI↓,

813-

GAR,

GEM,

Dietary Garcinol Arrests Pancreatic Cancer in p53 and K-ras Conditional Mutant Mouse Model

-

in-vivo,

PC,

NA

mouse

TumCG↓, OS↑,

812-

GAR,

Anti-proliferative and anti-invasive effects of garcinol from Garcinia indica on gallbladder carcinoma cells

-

in-vitro,

Gall,

GBC-SD

-

in-vitro,

Gall,

NOZ

TumCG↓, TumCI↓, MMP2↓, MMP9↓,

811-

GAR,

Garcinol exhibits anti-proliferative activities by targeting microsomal prostaglandin E synthase-1 in human colon cancer cells

-

in-vitro,

CRC,

HT-29

mPGES-1↓, Hif1a↓, VEGF↓, CXCR4↓, MMP2↓, MMP9↓, Casp3↑, TumCP↓, PGE2↓,

810-

GAR,

GEM,

Garcinol sensitizes human pancreatic adenocarcinoma cells to gemcitabine in association with microRNA signatures

-

in-vitro,

PC,

NA

Garcinol synergizes with gemcitabine to inhibit cell proliferation and induce apoptosis

TumCP↓, Apoptosis↑, PARP↝, VEGF↝, MMPs↝, Casp↝, NF-kB↝, miR-21↝,

809-

GAR,

High-Throughput Screen of Natural Product Libraries for Hsp90 Inhibitors

-

Review,

NA,

NA

4uM

IC50 MCF7

HRI↓, HSP90↓,

807-

GAR,

Garcinol inhibits cell proliferation and promotes apoptosis in pancreatic adenocarcinoma cells

-

in-vitro,

PC,

PANC1

0-40 μM

-

in-vitro,

PC,

Bxpc-3

TumCG↓, Apoptosis↑, TumCCA↑,

829-

GAR,

The Role of T-Cadherin (CDH13) in Treatment Options with Garcinol in Melanoma

-

vitro+vivo,

Melanoma,

NA

827-

GAR,

Garcinol Is an HDAC11 Inhibitor

-

in-vitro,

NA,

NA

HDAC11↓,

794-

GAR,

Garcinol Enhances TRAIL-Induced Apoptotic Cell Death through Up-Regulation of DR5 and Down-Regulation of c-FLIP Expression

-

in-vitro,

RCC,

NA

-

in-vitro,

Lung,

A549

-

in-vitro,

Nor,

NA

garcinol plus TRAIL did not alter cell viability in normal cells

DR5↑, cFLIP↓, *toxicity↓,

806-

GAR,

Garcinol exerts anti-cancer effect in human cervical cancer cells through upregulation of T-cadherin

-

vitro+vivo,

Pca,

HeLa

0, 5, 10, and 25 uM

-

vitro+vivo,

Cerv,

SiHa

TumCI↓, TumCMig↓, TumCCA↑, Apoptosis↑, T-cadherin↑,

795-

GAR,

Garcinol—A Natural Histone Acetyltransferase Inhibitor and New Anti-Cancer Epigenetic Drug

-

Review,

NA,

NA

0-50uM

HATs↓, BAX↑, PARP↑, Bcl-2↓, Casp3↑, Casp9↑, DR5↑, cFLIP↓, MMP2↓, MMP9↓, STAT3↓, p‑Akt↓,

796-

GAR,

Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression

-

vitro+vivo,

Pca,

HeLa

7uM

HATs↓, PCAF↓, Apoptosis↑,

797-

GAR,

CUR,

Differential effects of garcinol and curcumin on histone and p53 modifications in tumour cells

-

in-vitro,

BC,

MCF-7

-

in-vitro,

OS,

U2OS

-

in-vitro,

OS,

SaOS2

TumCP↓, H3K18↓, DNAdam↑,

798-

GAR,

Garcinol, an acetyltransferase inhibitor, suppresses proliferation of breast cancer cell line MCF-7 promoted by 17β-estradiol

-

in-vitro,

BC,

MCF-7

TumCP↓, TumCCA↑, Apoptosis↑, ac‑H3↑, ac‑H4∅, NF-kB↓, ac‑p65↑, cycD1↓, Bcl-2↓, Bcl-xL↓,

793-

GAR,

Garcinol inhibits tumour cell proliferation, angiogenesis, cell cycle progression and induces apoptosis via NF-κB inhibition in oral cancer

-

in-vitro,

SCC,

SCC9

did not show toxic effect on normal cells

-

in-vitro,

SCC,

SCC4

-

in-vitro,

SCC,

SCC25

TumCG↓, Apoptosis↑, TumCCA↑, NF-kB↓, COX2↓, VEGF↓,

799-

GAR,

Apoptosis-inducing effect of garcinol is mediated by NF-kappaB signaling in breast cancer cells

-

in-vitro,

BC,

MCF-7

-

in-vitro,

BC,

MDA-MB-231

-

in-vitro,

NMSC,

MCF10

no effect on non-tumorigenic MCF-10A cells

TumCG↓, Apoptosis↑, NF-kB↓,

800-

GAR,

Garcinol Regulates EMT and Wnt Signaling Pathways In Vitro and In Vivo, Leading to Anticancer Activity against Breast Cancer Cells

-

in-vitro,

BC,

MDA-MB-231

-

in-vitro,

BC,

BT549

-

in-vivo,

NA,

NA

xenograft mouse model where garcinol was found to inhibit NF-κB, miRNAs, vimentin, and nuclear β-catenin

EMT↓, MET↑, E-cadherin↑, Vim↓, Zeb1↓, ZEB2↑, miR-200c↑, Let-7↑, p‑β-catenin/ZEB1↓, NF-kB↓,

801-

GAR,

Cisplatin,

Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers

-

in-vivo,

HNSCC,

NA

0.5 mg/kg

mouse

Apoptosis↑, cycD1↓, Bcl-2↓, survivin↓, VEGF↓, TumCG↓, Ki-67↓, CD31↓,

802-

GAR,

Garcinol acts as an antineoplastic agent in human gastric cancer by inhibiting the PI3K/AKT signaling pathway

-

in-vitro,

GC,

HGC27

TumCP↓, TumCI↓, Apoptosis↑, PI3K/Akt↓, Akt↓, p‑mTOR↓, cycD1↓, MMP2↓, MMP9↓, BAX↑, Bcl-2↓,

803-

GAR,

Induction of p21(Waf1/Cip1) by garcinol via downregulation of p38-MAPK signaling in p53-independent H1299 lung cancer

-

in-vitro,

Lung,

H1299

-

in-vitro,

Lung,

H460

TumCP↓, TumCCA↑, CDK2↓, CDK4↓, cycD1↓, CycD3↓, cycE↑, CDK6↑, P21↑, p27↑, ERK↓, MAPK↓,

804-

GAR,

Garcinol inhibits the proliferation of endometrial cancer cells by inducing cell cycle arrest

-

in-vitro,

EC,

HEC1B

-

in-vitro,

EC,

ISH

TumCP↓, TumCCA↑, P53↑, P21↑, CDK2↓, CDK4↓, cycD1↓, CycB↓, p‑cJun↑,

805-

GAR,

Cisplatin,

PacT,

Garcinol Exhibits Anti-Neoplastic Effects by Targeting Diverse Oncogenic Factors in Tumor Cells

-

Review,

NA,

NA

ERK↓, PI3K/Akt↓, Wnt/(β-catenin)↓, STAT3↓, NF-kB↓, ChemoSen↑, COX2↓, Casp3↑, Casp9↑, BAX↑, Bcl-2↓, VEGF↓, TGF-β↓, HATs↓, E-cadherin↑, Vim↓, Zeb1↓, ZEB2↓, Let-7↑, MMP9↓, TumCCA↑, ROS↑, MMP↓, IL6↓, NOTCH1↓,

1190-

GB,

Extract of Ginkgo biloba exacerbates liver metastasis in a mouse colon cancer Xenograft model

-

in-vivo,

CRC,

SW-620

EGb solution daily for 5 wks with a dose of 35 mg/kg body weight (3.5 mg/mL EGb diluted in PBS)

mice

TumMeta↑, Ki-67↑,

1186-

GB,

Ginkgolic acid suppresses the development of pancreatic cancer by inhibiting pathways driving lipogenesis

-

in-vitro,

PC,

NA

-

in-vitro,

Nor,

HUVECs

-

in-vivo,

PC,

NA

tumCV↓, *toxicity∅, TumCMig↓, TumCI↓, Apoptosis↑, AMPK↑, lipoGen↓, ACC↓, FASN↓,

1187-

GB,

Ginkgolic Acid C 17:1, Derived from Ginkgo biloba Leaves, Suppresses Constitutive and Inducible STAT3 Activation through Induction of PTEN and SHP-1 Tyrosine Phosphatase

-

in-vitro,

Melanoma,

U251

-

in-vitro,

Melanoma,

MM.1S

STAT3↓, PTEN↑, Apoptosis↑, PTPN6↑,

1188-

GB,

The potential of Ginkgo biloba in the treatment of human diseases and the relationship to Nrf2-mediated antioxidant protection

-

Review,

NA,

NA

*NRF2↑, *ROS↓,

1189-

GB,

New insight into the mechanisms of Ginkgo biloba leaves in the treatment of cancer

-

Review,

NA,

NA

Apoptosis↑, TumCP↓, TumCI↓, TumCMig↓, Inflam↓, antiOx↑, angioG↓,

1117-

GB,

Ginkgobiloba leaf extract mitigates cisplatin-induced chronic renal interstitial fibrosis by inhibiting the epithelial-mesenchymal transition of renal tubular epithelial cells mediated by the Smad3/TGF-β1 and Smad3/p38 MAPK pathways

-

vitro+vivo,

Kidney,

HK-2

rats

α-SMA↓, COL1↓, TGF-β↓, SMAD2↓, SMAD3↓, p‑SMAD2↓, p‑SMAD3↓, p38↓, p‑p38↓, Vim↓, TIMP1↓, CTGF↓, E-cadherin↑, MMP1:TIMP1↑,

1118-

Ge,

Grape Seed Proanthocyanidins Inhibit Migration and Invasion of Bladder Cancer Cells by Reversing EMT through Suppression of TGF- β Signaling Pathway

-

in-vitro,

Bladder,

T24

-

in-vitro,

Bladder,

5637

TumCMig↓, TumCI↓, MMP2↓, MMP9↓, EMT↓, N-cadherin↓, Vim↓, Slug↓, E-cadherin↑, ZO-1↑, p‑SMAD2↓, p‑SMAD3↓, p‑Akt↓, p‑ERK↓, p‑p38↓,

792-

GE,

The role of germanium in diseases: exploring its important biological effects

other↓,

791-

GE,

Germanium Sesquioxide Organic Germanium

other↝,

790-

GE,

A Toxicological Evaluation of Germanium Sesquioxide (Organic Germanium)

-

vitro+vivo,

NA,

NA

mice, rats

other↓,

789-

GE,

Complete remission of pulmonary spindle cell carcinoma after treatment with oral germanium sesquioxide

-

Case Report,

SCC,

NA

Remission↑,

1241-

Ge,

PACs,

Grape seed proanthocyanidins inhibit angiogenesis via the downregulation of both vascular endothelial growth factor and angiopoietin signaling

-

in-vitro,

Nor,

NA

*VEGF↓, *MMP2↓, *MMP9↓, *p‑VEGFR2↓,

1240-

Ge,

PACs,

Grape Seed Proanthocyanidins Inhibit Melanoma Cell Invasiveness by Reduction of PGE2 Synthesis and Reversal of Epithelial-to-Mesenchymal Transition

-

in-vitro,

Melanoma,

A375

-

in-vitro,

Melanoma,

Hs294T

TumCMig↓, TumCI↓, COX2↓, PGE2↓, NF-kB↓, EMT↓, E-cadherin↑, Vim↓, Fibronectin↓, N-cadherin↓,

1292-

Ge,

EGCG,

Antiproliferative and Apoptotic Effects Triggered by Grape Seed Extract (GSE) versus Epigallocatechin and Procyanidins on Colon Cancer Cell Lines

-

in-vitro,

Colon,

Caco-2

100ug/L

-

in-vitro,

CRC,

HCT8

TumCG↓, Apoptosis↑,

1435-

GEN,

SFN,

The Effects of Combinatorial Genistein and Sulforaphane in Breast Tumor Inhibition: Role in Epigenetic Regulation

-

in-vitro,

BC,

MDA-MB-231

-

in-vitro,

BC,

MCF-7

DNMTs↓, HDAC↓, eff↑, TumCCA↑, HMTs↓, HDAC2↓, HDAC3↓, KLF4↓, hTERT↓,

1504-

GEN,

Epigenetic targets of bioactive dietary components for cancer prevention and therapy

-

Review,

NA,

NA

DNMTs↓, P21↑, p16↑, ac‑H3↑, ac‑H4↑, TumCCA↑, Casp↑, Apoptosis↑, hTERT↓, BTG3↑,

927-

GEN,

PacT,

Bioenhancers from mother nature and their applicability in modern medicine

-

Review,

Nor,

NA

*BioAv↑,

28-

GEN,

Genistein decreases the breast cancer stem-like cell population through Hedgehog pathway

-

in-vivo,

BC,

MCF-7

15-30 uM 20-50mg/kg(2wks)

HH↓, Smo↓, Gli1↓,

29-

GEN,

Genistein inhibits the stemness properties of prostate cancer cells through targeting Hedgehog-Gli1 pathway

-

in-vivo,

Pca,

NA

HH↓, Gli1↓,

2997-

GEN,

Genistein Inhibition of Topoisomerase IIα Expression Participated by Sp1 and Sp3 in HeLa Cell

-

in-vitro,

Cerv,

HeLa

75 μM for 48 h

TOP2↓, Sp1/3/4↓, Apoptosis↑, TumCCA↑,

2998-

GEN,

Cellular and Molecular Mechanisms Modulated by Genistein in Cancer

-

Review,

Var,

NA

Hif1a↓, VEGF↓, PDGF↓, uPA↓, MMP2↓, MMP9↓, chemoP↑, TumCI↓, TumMeta↓, NF-kB↓, AP-1↓, IKKα↓, PI3K↓, Akt↓, EMT↓, CSCs↓,

30-

Ger,

A sesquiterpene lactone from Siegesbeckia glabrescens suppresses Hedgehog/Gli-mediated transcription in pancreatic cancer cells

-

in-vitro,

PC,

PANC1

(IC 50) values of 6,.9 uM

-

in-vitro,

PC,

AsPC-1

5.1 uM

HH↓, Gli1↓, Shh↓, cycD1↓,

1005-

GI,

Ginger Constituent 6-Shogaol Inhibits Inflammation- and Angiogenesis-Related Cell Functions in Primary Human Endothelial Cells

-

vitro+vivo,

Nor,

HUVECs

30uM

*NF-kB↓, *p65↓, *TLR4∅, *angioG↓, *TumCP↓, *VEGF↓, *Inflam↓, *ICAM-1↓, *VCAM-1↓, *E-sel↓, *p‑JNK↓, *HO-1↑,

1116-

GI,

6-Shogaol Inhibits the Cell Migration of Colon Cancer by Suppressing the EMT Process Through the IKKβ/NF-κB/Snail Pathway

-

in-vitro,

Colon,

Caco-2

20, 40, 60, 80, and 100 µM

86.63 µM

-

in-vitro,

CRC,

HCT116

45.25 µM

TumCG↓, Apoptosis↑, TumCMig↓, MMP2↓, N-cadherin↓, IKKα↓, p‑NF-kB↓, Snail↓, VEGF↓,

2464-

GI,

The Effect of Ginger (Zingiber officinale) on Platelet Aggregation: A Systematic Literature Review

-

Review,

Nor,

NA

*Inflam↓, *antiOx↑, *LDL↓, *AntiAg↑, *AntiAg∅,

2465-

GI,

Effect of daily ginger consumption on platelet aggregation

-

Trial,

Nor,

NA

Forty healthy male and female participants were randomized (1:1) to consume ginger tea four gram once daily vs. twice daily for five consecutive days

AntiAg↝, Dose∅,

31-

GlaB,

Gli1/DNA interaction is a druggable target for Hedgehog-dependent tumors

-

in-vitro,

BCC,

NA

HH↓, Gli1↓, PTCH1↓,

32-

GlaB,

Gli1/DNA interaction is a druggable target for Hedgehog-dependent tumors

-

in-vivo,

MB,

NA

HH↓, Gli1↓, PTCH1↓,

401-

GoldNP,

MF,

In vitro evaluation of electroporated gold nanoparticles and extremely-low frequency electromagnetic field anticancer activity against Hep-2 laryngeal cancer cells

-

in-vitro,

Laryn,

HEp2

50mT/15mins

4.79 μg/mL IC50 for Au-NP

Casp3↑, P53↑, BAX↑, Bcl-2↓,

1407-

GoldNP,

Z,

The antioxidant effects of silver, gold, and zinc oxide nanoparticles on male mice in in vivo condition

-

in-vivo,

NA,

NA

mice

ROS↑, GPx↓, Catalase↓,

1901-

GoldNP,

Rad,

The role of thioredoxin reductase in gold nanoparticle radiosensitization effects

-

in-vitro,

Lung,

A549

10nm, 50 ug Au/ml

MMP↓, ROS↑, RadioS↑, TrxR↓,

1904-

GoldNP,

SNP,

Unveiling the Potential of Innovative Gold(I) and Silver(I) Selenourea Complexes as Anticancer Agents Targeting TrxR and Cellular Redox Homeostasis

-

in-vitro,

Lung,

H157

-

in-vitro,

BC,

MCF-7

-

in-vitro,

Colon,

HCT15

-

in-vitro,

Melanoma,

A375

TrxR↓, selectivity↑, eff↑, eff↝, ROS↑, MMP↓, Apoptosis↑, eff↑,

3526-

GoldNP,

Rad,

Advances in nanoparticle-based radiotherapy for cancer treatment

-

Review,

Var,

NA

RadioS↑, EPR↑, ROS↑, TumCCA↑,

941-

Gos,

Rad,

The Lactate Dehydrogenase Inhibitor Gossypol Inhibits Radiation-Induced Pulmonary Fibrosis

-

in-vivo,

NA,

NA

mice, injection to mice starting at week 4 postirradiation at a dose of 5 mg/kg in 30 μl volume

lactateProd↓, other↓, TGF-β↓,

849-

Gra,

Annona muricata silver nanoparticles exhibit strong anticancer activities against cervical and prostate adenocarcinomas through regulation of CASP9 and the CXCL1/CXCR2 genes axis

-

in-vitro,

Pca,

PC3

48.17μg/ml

-

in-vitro,

Nor,

PNT1A

7.8x higher

normal health cells

-

in-vitro,

NA,

HeLa

Casp9↑, CXCL1↓, *toxicity↓,

851-

Gra,

Antiproliferation Activity and Apoptotic Mechanism of Soursop (Annona muricata L.) Leaves Extract and Fractions on MCF7 Breast Cancer Cells

-

in-vitro,

BC,

MCF-7

f 5.3, 2.86, 3.08, and 48.31 µg/mL

ethanol extract, ethyl acetate, n-hexane, and water fractions of A. muricata leaves

-

in-vitro,

Nor,

CV1

Bcl-2↓, Casp9↑, Casp3↑, other↑, *toxicity↓,

848-

Gra,

SNP,

Synthesis, Characterization and Evaluation of Antioxidant and Cytotoxic Potential of Annona muricata Root Extract-derived Biogenic Silver Nanoparticles

-

in-vitro,

CRC,

HCT116

ROS↑, PUMA↝, Casp3↑, Casp8↑, Casp9↑, Apoptosis↑,

847-

Gra,

Natural substances (acetogenins) from the family Annonaceae are powerful inhibitors of mitochondrial NADH dehydrogenase (Complex I).

NADHdeh↓,

846-

Gra,

Cytotoxic effect of Annona muricata Linn leaves extract on Capan-1 cells

-

in-vitro,

NA,

Ca9-22

IC25 varied ~7.8-8μg/ml and ~0.9-1.0μg/ml respectively.

other↑,

845-

Gra,

A Review on Annona muricata and Its Anticancer Activity

-

Review,

NA,

NA

GlucoseCon↓, ATP↓, HIF-1↓, GLUT1↓, GLUT4↓, HK2↓, LDHA↓, ERK↓, Akt↓, Apoptosis↑, NF-kB↓, ROS↑, Bax:Bcl2↑, MMP↓, Casp3↑, Casp9↑, p‑JNK↓,

844-

Gra,

Annona muricata Leaf Extract Triggered Intrinsic Apoptotic Pathway to Attenuate Cancerous Features of Triple Negative Breast Cancer MDA-MB-231 Cells

-

in-vitro,

BC,

MDA-MB-231

0-200ug/mL

-

in-vitro,

BC,

MCF-7

tumCV↓, TumCI↓, ROS↑,

843-

Gra,

Graviola (Annona muricata) Exerts Anti-Proliferative, Anti-Clonogenic and Pro-Apoptotic Effects in Human Non-Melanoma Skin Cancer UW-BCC1 and A431 Cells In Vitro: Involvement of Hedgehog Signaling

-

in-vitro,

NMSC,

A431

3.5 µg/mL

DCM fraction proved to be by far the most potent in inhibiting the proliferation

-

in-vitro,

NMSC,

UW-BCC1

4.0 µg/mL

-

in-vitro,

Nor,

NHEKn

38.8 µg/mL

10-fold higher than in noncancerous NHEKn cells

TumCG↓, TumCCA↑, Cyc↓, Apoptosis↑, cl‑Casp3↑, cl‑Casp8↑, cl‑PARP↑, HH↓, Smo↓, Gli1↓, GLI2↓, Shh↓, Sufu↑, BAX↑, Bcl-2↓, *toxicity↓,

842-

Gra,

Phytochemical screening, anti-oxidant activity and in vitro anticancer potential of ethanolic and water leaves extracts of Annona muricata (Graviola)

-

in-vitro,

NA,

NA

200-335ug/mL

-

in-vitro,

Nor,

NA

no cytotoxic effect

no cytotoxic effect on normal spleen cells

other↓, *toxicity↓,

841-

Gra,

The Chemopotential Effect of Annona muricata Leaves against Azoxymethane-Induced Colonic Aberrant Crypt Foci in Rats and the Apoptotic Effect of Acetogenin Annomuricin E in HT-29 Cells: A Bioassay-Guided Approach

-

in-vitro,

CRC,

HT-29

1.62ug/ml@48hr

-

in-vitro,

Nor,

CCD841

32.51μg/ml@48 h

normal human colon cells

PCNA↓, Bcl-2↓, BAX↑, *MDA↓, lipid-P↓, TumCG↓, MMP↓, Cyt‑c↑, Casp3↑, Casp7↑, Casp9↑, *ROS↓, LDH↓, *toxicity↓, selectivity↑,

840-

Gra,

Evaluation of cytotoxicity of aqueous extract of Graviola leaves on squamous cell carcinoma cell-25 cell lines by 3-(4,5-dimethylthiazol-2-Yl) -2,5-diphenyltetrazolium bromide assay and determination of percentage of cell inhibition at G2M phase of cell cycle by flow cytometry: An in vitro study

-

in-vitro,

SCC,

SCC25

TumCCA↑, ATP↓,

839-

Gra,

Functional proteomic analysis revels that the ethanol extract of Annona muricata L. induces liver cancer cell apoptosis through endoplasmic reticulum stress pathway

-

in-vitro,

Liver,

HepG2

tumCV↓, Apoptosis↑, HSP70/HSPA5↑, GRP94↑, ER Stress↑, p‑PERK↑, p‑eIF2α↑, GRP78/BiP↑, CHOP↑,

838-

Gra,

Antiproliferative activity of aqueous leaf extract of Annona muricata L. on the prostate, BPH-1 cells, and some target genes

-

in-vitro,

Pca,

BPH1

1.36 mg/mL

BPH cells and rats

BAX↑, Bcl-2↓, TumVol↓,

837-

Gra,

Quantitative assessment of the relative antineoplastic potential of the n-butanolic leaf extract of Annona muricata Linn. in normal and immortalized human cell lines

-

in-vitro,

BC,

MDA-MB-435

29.2 μg

-

in-vitro,

Nor,

WRL68

52.4 μg

-

in-vitro,

Nor,

HaCaT

30.1 μg

human immortalized keratinocyte cells

*toxicity↓,

836-

Gra,

Graviola: A Novel Promising Natural-Derived Drug That Inhibits Tumorigenicity and Metastasis of Pancreatic Cancer Cells In Vitro and In Vivo Through Altering Cell Metabolism

-

vitro+vivo,

PC,

NA

mice

Hif1a↓, NF-kB↓, GLUT1↓, GLUT4↓, HK2↓, LDHA↓, TumCCA↑, TumMeta↓, GlucoseCon↓, ATP↓, necrosis↑, Casp∅, p‑FAK↓, MMP9↓, MUC4↓,

835-

Gra,

Annona muricata leaves induced apoptosis in A549 cells through mitochondrial-mediated pathway and involvement of NF-κB

-

in-vitro,

Lung,

A549

5ug/mL @72hr

ROS↑, MMP↓, BAX↑, Bcl-2↓, Cyt‑c↑, Casp9↑, Casp3↑, Apoptosis↑, TumCCA↑,

834-

Gra,

Anticancer Properties of Graviola (Annona muricata): A Comprehensive Mechanistic Review

-

Review,

NA,

NA

EGFR↓, PI3K/Akt↓, NF-kB↓, JAK↓, STAT↓, Hif1a↓, GLUT1↓, GLUT4↓, ROS↑, Catalase↑, SOD↑, HO-1↑,

833-

Gra,

Cytotoxic Effect of Annona muricata leaf extracts on tumor cell lines in vitro

-

in-vitro,

BC,

MDA-MB-231

134.6 mg/ml

-

in-vitro,

Lung,

A549

124.6 mg/ml

Apoptosis↑,

850-

Gra,

Selective cytotoxic and anti-metastatic activity in DU-145 prostate cancer cells induced by Annona muricata L. bark extract and phytochemical, annonacin

-

in-vitro,

PC,

PC3

0.1uM(Annonacin) 55ug/mL(EAB)

without impacting RWPE-1 normal prostate cells

-

in-vitro,

Pca,

DU145

ROS∅, MMP∅, Casp3↑, Casp7↑, VEGF↓,

852-

Gra,

Silver Nanoparticles from Annona muricata Peel and Leaf Extracts as a Potential Potent, Biocompatible and Low Cost Antitumor Tool

-

in-vitro,

BC,

MCF-7

2-3ug/mL

AgNPs-PE, AgNPs-LE

-

in-vitro,

Colon,

HCT116

2ug/mL

AgNPs-PE, AgNPs-LE

-

in-vitro,

Melanoma,

A375

3-8ug/mL

AgNPs-PE, AgNPs-LE

tumCV↓,

853-

Gra,

SNP,

Solid lipid nanoparticles of Annona muricata fruit extract: formulation, optimization and in vitro cytotoxicity studies

other↑,

854-

Gra,

SNP,

Green Synthesis of Silver Nanoparticles Using Annona muricata Extract as an Inducer of Apoptosis in Cancer Cells and Inhibitor for NLRP3 Inflammasome via Enhanced Autophagy

-

vitro+vivo,

AML,

THP1

17.34 µg/mL

-

in-vitro,

AML,

AMJ13

-

vitro+vivo,

lymphoma,

HBL

TumCP↓, TumAuto↑, IL1↓, NLRP3↓, Apoptosis↑, mtDam↑, P53↑, LDH↓,

855-

Gra,

Antiproliferative activity of ionic liquid-graviola fruit extract against human breast cancer (MCF-7) cell lines using flow cytometry techniques

-

in-vitro,

BC,

MCF-7

4.75 μg/mL

TumCG↓, TumCP↓, TumCCA↑, Apoptosis↑,

856-

Gra,

https://pubmed.ncbi.nlm.nih.gov/33048613/

-

in-vitro,

BC,

MCF-7

85.55 µg/mL

TumCCA↑, ROS↑, Casp↑,

857-

Gra,

The Value of Caspase-3 after the Application of Annona muricata Leaf Extract in COLO-205 Colorectal Cancer Cell Line

-

in-vitro,

CRC,

COLO205

Casp3↑, tumCV↓,

858-

Gra,

Annona muricata leaves induce G₁ cell cycle arrest and apoptosis through mitochondria-mediated pathway in human HCT-116 and HT-29 colon cancer cells

-

in-vitro,

CRC,

HT-29

11.43 µg/ml

-

in-vitro,

CRC,

HCT116

8.98 µg/ml

TumCCA↑, Apoptosis↑, ROS↑, MMP↓, Cyt‑c↑, Casp↑, BAX↑, Bcl-2↓, TumCMig↓, TumCI↓,

2437-

Gra,

Graviola inhibits hypoxia-induced NADPH oxidase activity in prostate cancer cells reducing their proliferation and clonogenicity

-

in-vitro,

Pca,

LNCaP

1–5 μg/ml

-

in-vitro,

Pca,

22Rv1

-

in-vitro,

Pca,

PC3

-

in-vitro,

Nor,

PWR-1E

NOX↓, selectivity↑,

2438-

Gra,

Emerging therapeutic potential of graviola and its constituents in cancers

-

Review,

Var,

NA

Hif1a↓, GLUT1↓, GLUT4↓, HK2↓, LDHA↓, MUC4↓, TumCCA↑, MMP↓, NF-kB↓, ROS↓, Bax:Bcl2↑, ER(estro)↓, cycD1↓, chemoP↑, hepatoP↑,

1232-

Gra,

Graviola: A Systematic Review on Its Anticancer Properties

-

Review,

NA,

NA

oral 100mg/kg

EGFR↓, cycD1↓, Bcl-2↓, TumCCA↑, Apoptosis↑, ROS↑, MMP↓, BAX↑, Cyt‑c↑, Hif1a↓, NF-kB↓, GLUT1↓, GLUT4↓, HK2↓, LDHA↓, ATP↓,

1233-

Gra,

THERAPEUTIC ELIGIBILITY OF GRAVIOLA VERSUS 5-FLUOROURACIL: APOPTOTIC EFFICACY ON HEAD AND NECK SQUAMOUS CELL CARCINOMA AND NORMAL EPITHELIUM CELLS

-

in-vitro,

HNSCC,

NA

(200 μg/ml, 400 μg/ml, 600 μg/ml, 800 μg/ml, and 1000 μg/m

103ug/ml @48hr

Apoptosis↑, MMP↓,

1234-

Gra,

Graviola attenuates DMBA-induced breast cancer possibly through augmenting apoptosis and antioxidant pathway and downregulating estrogen receptors

-

in-vivo,

BC,

NA

200 mg/kg body mass

rats

Apoptosis↑, BAX↑, P53↑, Casp3↑, ER-α36↓, lipid-P↓,

108-

GSL,

A sesquiterpene lactone from Siegesbeckia glabrescens suppresses Hedgehog/Gli-mediated transcription in pancreatic cancer cells

-

in-vitro,

PC,

PANC1

6.9 uM

-

in-vitro,

PC,

AsPC-1

5.1 uM

-

in-vitro,

PC,

C3H10T1/2

35.7 uM

HH↓, Gli1↓, cycD1↓,

2503-

H2,

Brain Metastases Completely Disappear in Non-Small Cell Lung Cancer Using Hydrogen Gas Inhalation: A Case Report

-

Case Report,

Lung,

NA

TumVol↓, OS↑, Dose↝, Dose↝, CEA↓, CA125↓, CYFRA21-1↓, SIRT1↓, COX2↓, IL1β↓, IL6↓, TNF-α↓, HMGB1↓, NF-kB↓, EP2↓,

2504-

H2,

Hydrogen gas activates coenzyme Q10 to restore exhausted CD8+ T cells, especially PD-1+Tim3+terminal CD8+ T cells, leading to better nivolumab outcomes in patients with lung cancer

-

Trial,

Lung,

NA

A total of 42 of 56 patients with lung cancer treated with nivolumab received hydrogen gas

CD8+↑, OS↑, eff↝, CoQ10↑, PDT+↓, PGC-1α↑, Dose↝, *toxicity∅,

2505-

H2,

Hydrogen gas restores exhausted CD8+ T cells in patients with advanced colorectal cancer to improve prognosis

-

Trial,

CRC,

NA

55 patients with histologically and clinically diagnosed stage IV colorectal carcinoma were enrolled between July 2014 and July 2017

PGC-1α↑, Dose↝, CD8+↑, OS↑,

2506-

H2,

Molecular hydrogen suppresses activated Wnt/β-catenin signaling

-

in-vivo,

Arthritis,

NA

Rats

*Wnt↓, *β-catenin/ZEB1↓, *Dose↝,

2525-

H2,

Hydrogen-Rich Saline Attenuates Cardiac and Hepatic Injury in Doxorubicin Rat Model by Inhibiting Inflammation and Apoptosis

-

in-vivo,

NA,

NA

rats

OS↓, cardioP↑, *AST↓, ALAT↓, *ROS↓, *MDA↓, *hepatoP↑, *Inflam↓, chemoP↑,

2508-

H2,

Molecular hydrogen is a promising therapeutic agent for pulmonary disease

-

Review,

Var,

NA

-

Review,

Sepsis,

NA

*ROS↓, eff↝, *Inflam?, *NRF2↑, *HO-1↑, *SOD↑, *Catalase↑, *MPO↑, *ASK1↓, *NADPH↓, *Sepsis↓, *HMGB1↓, ROS↑, NLRP3↑, GSDMD↑, chemoP↑, eff↑,

2524-

H2,

Protective effect of hydrogen-rich water on liver function of colorectal cancer patients treated with mFOLFOX6 chemotherapy

-

Trial,

NA,

NA

152 patients with CRC

hepatoP↑, ALAT↓, AST↓, Dose↝, Dose↝,

2523-

H2,

Prospects of molecular hydrogen in cancer prevention and treatment

-

Review,

Var,

NA

ROS↓, TumCP↓, TumMeta↓, AntiTum↑, GutMicro↑, Inflam↓, OS↑, radioP↑, selectivity↑, SOD↑, IL1β↑, IL8↑, TNF-α↑, neuroP↑,

2522-

H2,

A Systematic Review of Molecular Hydrogen Therapy in Cancer Management

-

Review,

Var,

NA

chemoP↑, OS↑, QoL↑, TumVol↑, ROS↑, AntiTum↑, other↝,

2521-

H2,

Oxyhydrogen Gas: A Promising Therapeutic Approach for Lung, Breast and Colorectal Cancer

-

Review,

CRC,

NA

-

Review,

Lung,

NA

-

Review,

BC,

NA

Inflam↑, ROS↓, ChemoSen↑, p‑PI3K↓, p‑Akt↓, QoL↑, GutMicro↑, chemoP↑, radioP↑, *NRF2↑, *Catalase↑, *GPx↑, *HO-1↑, *SOD↑, *TNF-α↓, *IL4↓, *IL6↓, ChemoSen↑, Appetite↑, cognitive↑, Pain↓, Sleep↑, other?,

2520-

H2,

The Impact of Molecular Hydrogen on Mitochondrial ROS and Apoptosis in Colorectal Cancer Cells

-

in-vitro,

CRC,

NA

mt-ROS↓, ChemoSen↑, other↝,

2519-

H2,

Hydrogen: an advanced and safest gas option for cancer treatment

-

Review,

Var,

NA

antiOx↑, neuroP↓, BBB↑, toxicity∅, TumCP↓, Apoptosis↓, ROS↑, Hif1a↓, NF-kB↓, P53?, OS↑, chemoP↑,

2518-

H2,

Hydrogen Therapy Reverses Cancer-Associated Fibroblasts Phenotypes and Remodels Stromal Microenvironment to Stimulate Systematic Anti-Tumor Immunity

-

in-vitro,

BC,

4T1

CaCO3 nanoparticles-coated magnesium system (Mg-CaCO3) is developed.

-

in-vitro,

Nor,

3T3

TumCD↑, CD4+↑, ROS↓,

2517-

H2,

Molecular Hydrogen Enhances Proliferation of Cancer Cells That Exhibit Potent Mitochondrial Unfolded Protein Response

-

in-vitro,

Var,

A549

-

in-vitro,

NA,

HCT116

-

in-vitro,

NA,

HeLa

-

in-vitro,

NA,

HepG2

-

in-vitro,

NA,

HT1080

-

in-vitro,

NA,

PC3

-

in-vitro,

NA,

SH-SY5Y

TumCP↓, other↝, eff↝, mt-UPR↑,

2515-

H2,

Recent Advances in Studies of Molecular Hydrogen against Sepsis

-

Review,

Sepsis,

NA

*Sepsis↓, *Inflam↓, *antiOx↑, *ROS↓, *NADPH↓,

2507-

H2,

Hydrogen protects against chronic intermittent hypoxia induced renal dysfunction by promoting autophagy and alleviating apoptosis

-

in-vivo,

NA,

NA

Sprague-Dawley rats

*RenoP↑, *ROS↓, *Apoptosis↓, *ER Stress↓, *CHOP↓, *Casp12↓, *GRP78/BiP↓, *LC3‑Ⅱ/LC3‑Ⅰ↑, *Beclin-1↑, *p62↓, *mTOR↓,

2509-

H2,

Hydrogen inhibits endometrial cancer growth via a ROS/NLRP3/caspase-1/GSDMD-mediated pyroptotic pathway

-

in-vitro,

Endo,

AN3CA

-

in-vivo,

Endo,

NA

endometrial tumors in a xenograft mouse model.

selectivity↑, mt-ROS↑, ROS↑, TumW↓, GSDMD↑, Pyro↑, Dose↝, eff↓, TumVol↓,

2510-

H2,

Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals

-

in-vivo,

Stroke,

NA

acute rat model

*ROS↓, *antiOx↑,

2511-

H2,

Molecular hydrogen suppresses glioblastoma growth via inducing the glioma stem-like cell differentiation

-

in-vivo,

GBM,

U87MG

mice

TumCG↓, OS↑, CD133↓, Ki-67↓, angioG↓, Diff↑, TumCMig↓, TumCI↓, Dose↝, BBB↑, mt-ROS↑,

2512-

H2,

Hydrogen Attenuates Allergic Inflammation by Reversing Energy Metabolic Pathway Switch

-

in-vivo,

asthmatic,

NA

selectivity↑, lactateProd↓, ATP↑, HK2↓, PFK↓, Hif1a↓, PGC-1α↑, Glycolysis↓, OXPHOS↑, Dose↝,

2513-

H2,

Hydrogen therapy: from mechanism to cerebral diseases

-

Review,

Stroke,

NA

*BBB?, *antiOx↑, *Inflam↓, *Apoptosis↓, *NF-kB↓, *Dose↝,

2514-

H2,

Hydrogen: A Novel Option in Human Disease Treatment

-

Review,

NA,

NA

*Inflam↓, *IL1β↓, *IL6↓, *IL8↓, *IL10↓, *TNF-α↓, *ROS↓, *HO-1↓, *NRF2↑, *ER Stress↓, H2O2↑,

2516-

H2,

Hydrogen Gas in Cancer Treatment

-

Review,

Var,

NA

*Half-Life↓, *ROS↓, *selectivity↑, *SOD↑, *HO-1↑, *NRF2↑, *chemoP↑, *radioP↑, ROS↑, *Inflam↓, eff↑, *TNF-α↓, *IL6↓, *cl‑Casp8↑, *Bax:Bcl2↓, *Apoptosis↓, *cardioP↑, *hepatoP↑, *RenoP↑, *chemoP↑, eff↝, chemoP↑, radioP↑, eff↑, TumCG↓, Ki-67↓, VEGF↓, selectivity↑,

2526-

H2,

Influence of hydrogen-occluding-silica on migration and apoptosis in human esophageal cells in vitro

-

in-vitro,

ESCC,

KYSE-510

we investigated solidified hydrogen-occluding-silica (H2-silica) that can release molecular hydrogen into cell culture medium

*ROS↓, selectivity↑, ROS↓,

2527-

H2,

The healing effect of hydrogen-rich water on acute radiation-induced skin injury in rats

-

in-vivo,

Wounds,

NA

Rats

*Dose↝, *SOD↑, *EGF↑, *antiOx↑, *Inflam↓, *Dose↝,

2528-

H2,

Local generation of hydrogen for enhanced photothermal therapy

-

in-vitro,

Var,

NA

eff↑, ROS↓, selectivity↑, ROS↑, other↝, ROS↑,

2529-

H2,

Guidelines for the selection of hydrogen gas inhalers based on hydrogen explosion accidents

-

Analysis,

Nor,

NA

other↑, eff↝, eff↝, other↝, other↝, other↝, other↝, other↝,

2530-

H2,

Improvement of psoriasis-associated arthritis and skin lesions by treatment with molecular hydrogen: A report of three cases

-

Case Report,

PSA,

NA

eff↑, Dose↝, eff↑, IL6↓, eff↑,

3152-

H2,

VitC,

Rad,

Hydrogen and Vitamin C Combination Therapy: A Novel Method of Radioprotection

-

in-vitro,

Nor,

HUVECs

-

in-vivo,

NA,

NA

AntiTum↑, OS↑, QoL↑, TumVol↓, radioP↑, Dose↑, Dose↝, eff↑,

1412-

HCA,

Identification of ATP Citrate Lyase as a Positive Regulator of Glycolytic Function in Glioblastomas

-

in-vitro,

GBM,

U87MG

-

in-vitro,

GBM,

LN229

ACLY↓, TumCMig↓,

1413-

HCA,

Effects of acute (-)-hydroxycitrate supplementation on substrate metabolism at rest and during exercise in humans

-

Human,

Nor,

NA

3.1 mL/kg body wt of an HCA solution (19 g/L)

*toxicity↓,

1414-

HCA,

Bioefficacy of a novel calcium-potassium salt of (-)-hydroxycitric acid

-

Human,

Nor,

NA

*BioAv↑,

1415-

HCA,

Hydroxycitrate delays early mortality in mice and promotes muscle regeneration while inducing a rich hepatic energetic status

-

in-vivo,

Nor,

NA

mice

*OS↑, *toxicity↓, *AST∅, *ALAT∅, *Strength↑, *memory∅, *other↑, *other↑, *other↑,

1628-

HCA,

ALA,

Addition of Hydroxy Citrate improves effect of ALA

-

Review,

Var,

NA

ACLY↓, other↓, ROS↑, eff↑, PDKs↓,

1629-

HCA,

Tam,

Hydroxycitric acid reverses tamoxifen resistance through inhibition of ATP citrate lyase

-

in-vitro,

BC,

MCF-7

ACLY↓, eff↓, tumCV↓, eff↑, Casp3↑, BAX↑, Bcl-2↓,

1630-

HCA,

Chemistry and biochemistry of (-)-hydroxycitric acid from Garcinia

-

Review,

NA,

NA

ACLY↓, FASN↓, lipoGen↓, Weight↓,

1631-

HCA,

An overview of the safety and efficacy of a novel, natural(-)-hydroxycitric acid extract (HCA-SX) for weight management

-

Review,

Obesity,

NA

*ACLY↓, *toxicity∅, *Dose∅,

1633-

HCA,

Hydroxycitric Acid Alleviated Lung Ischemia-Reperfusion Injury by Inhibiting Oxidative Stress and Ferroptosis through the Hif-1α Pathway

-

in-vivo,

NA,

NA

mice, Lung ischemia-reperfusion injury (LIRI)

-

in-vitro,

Nor,

HUVECs

*other↓, *Inflam↓, *MDA↓, *ROS↓, *Iron↓, *SOD↓, *Hif1a↓, *HO-1↓,

1634-

HCA,

Hydroxycitrate: a potential new therapy for calcium urolithiasis

-

Human,

Nor,

NA

*other↑, *eff↑,

1627-

HCA,

Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance

-

Review,

Var,

NA

ChemoSen↑, eff↑, ACLY↓, LC3‑Ⅱ/LC3‑Ⅰ↑,

1635-

HCA,

Hydroxycitric acid prevents hyperoxaluric-induced nephrolithiasis and oxidative stress via activation of the Nrf2/Keap1 signaling pathway

-

vitro+vivo,

Nor,

NA

*other↓, *ROS↓, *SOD↑, *Catalase↑, *MDA↓, *NRF2↑,

1625-

HCA,

In S. cerevisiae hydroxycitric acid antagonizes chronological aging and apoptosis regardless of citrate lyase

-

Review,

Nor,

NA

aged yeast cells

CRM↑, ACLY↓, TumAuto↑, Inflam↓, TumCG↓, toxicity∅, lipoGen↓, *ROS↓, *OCR↓,

1637-

HCA,

OLST,

Orlistat and Hydroxycitrate Ameliorate Colon Cancer in Rats: The Impact of Inflammatory Mediators

-

in-vivo,

Colon,

NA

32 mg/kg/day(or)+(135 mg/kg/day(HCA)

rats

TumVol↓, OS↑, *IL6↓, *NF-kB↓, *eff↑, *Casp3↓, *TNF-α↓, *Catalase↑, *NO↓, *ROS↓, *Inflam↓, *Apoptosis↓,

1589-

HCA,

ATP citrate lyase (ACLY) inhibitors: An anti-cancer strategy at the crossroads of glucose and lipid metabolism

-

Review,

NA,

NA

ACLY↓, eff↑,

286-

HCA,

ALA,

Adding a combination of hydroxycitrate and lipoic acid (METABLOC™) to chemotherapy improves effectiveness against tumor development: experimental results and case report

OS↑,

294-

HCA,

In Vitro and In Vivo Toxicity of Garcinia or Hydroxycitric Acid: A Review

293-

HCA,

Tam,

Hydroxycitric acid potentiates the cytotoxic effect of tamoxifen in MCF-7 breast cancer cells through inhibition of ATP citrate lyase

-

in-vitro,

BC,

MCF-7

TumCG↓, Apoptosis↑, ACLY↓, ACC-α↓, Fas↓,

292-

HCA,

Hydroxycitric Acid Inhibits Chronic Myelogenous Leukemia Growth through Activation of AMPK and mTOR Pathway

-

in-vitro,

AML,

K562

11.34 mM

ACLY↓, AMPK↑, mTOR↑, eIF2α↑, ATFs↑, TumCG↓,

602-

HCAs,

Prooxidant activity of hydroxycinnamic acids on DNA damage in the presence of Cu(II) ions: mechanism and structure-activity relationship

-

Analysis,

NA,

NA

ROS↑, DNAdam↑,

2400-

HCAs,

The Mixture of Ferulic Acid and P-Coumaric Acid Suppresses Colorectal Cancer through lncRNA 495810/PKM2 Mediated Aerobic Glycolysis

-

in-vitro,

CRC,

NA

-

in-vivo,

CRC,

NA

mice

PKM2↓, Glycolysis↓, TumCG↓,

2407-

HCAs,

2'-hydroxycinnamaldehyde inhibits cancer cell proliferation and tumor growth by targeting the pyruvate kinase M2

-

in-vitro,

Pca,

DU145

-

in-vitro,

Pca,

LNCaP

p‑PKM2↓, TumCG↓,

1641-

HCAs,

Lung cancer induced by Benzo(A)Pyrene: ChemoProtective effect of sinapic acid in swiss albino mice

-

in-vitro,

Lung,

A549

50 µM

-

in-vivo,

Lung,

NA

mice

AntiCan↑, Igs↓, lipid-P↓, ROS↑, Casp3↑, Casp9↑, ChemoSideEff↓, Dose∅,

1638-

HCAs,

Anticancer potential of hydroxycinnamic acids: mechanisms, bioavailability, and therapeutic applications

-

Review,

Nor,

NA

*BioAv↓, Inflam↓, COX2↓, TumCCA↑, ChemoSen↑, RadioS↑, selectivity↑, ROS↑, DNAdam↑, antiOx↑, SOD↑, Catalase↑, GPx↑, GSH↑, NRF2↑, NF-kB↓, Cyc↓, CDK1↑, P21↑, p27↑, P53↑, VEGF↓, MAPK↓,

1644-

HCAs,

PBG,

Artepillin C (3,5-diprenyl-4-hydroxycinnamic acid) sensitizes LNCaP prostate cancer cells to TRAIL-induced apoptosis

-

in-vitro,

Pca,

LNCaP

NF-kB↓, TRAILR↑, Casp8↑, Casp3↑, MMP↓, Dose?,

1643-

HCAs,

Mechanisms involved in the anticancer effects of sinapic acid

-

Review,

Var,

NA

*BioAv↓, *toxicity↓, Dose∅, ROS⇅, ROS↑, Igs↑, TumCCA↑, TumAuto↑, eff↑, angioG↓, TumCI↓, TumMeta↓, EMT↓, Vim↓, MMP9↓, MMP2↓, Snail↓, E-cadherin↑, p‑Akt↓, GSK‐3β↓, TumCP↓, ChemoSen↑,

1657-

HCAs,

Anticancer Activity of Sinapic Acid by Inducing Apoptosis in HT-29 Human Colon Cancer Cell Line 2023

-

in-vitro,

CRC,

HT-29

200 μM

317.5 μM for 24 hours

cl‑Casp3↑, BAX↑, cl‑PARP↑, γH2AX↑, Cyt‑c↑,

1649-

HCAs,

Anticancer Properties of Hydroxycinnamic Acids -A Review

-

Review,

Var,

NA

*antiOx↑, MMP2↓, MMP9↓, VEGF↓, TGF-β↓, Bax:Bcl2↑, TumCCA↑, COX2↓, NF-kB↓,

1645-

HCAs,

Chapter 8 - Hydroxycinnamic Acids: Natural Sources, Biosynthesis, Possible Biological Activities, and Roles in Islamic Medicine

-

Review,

Nor,

NA

Dose∅, ROS⇅, Dose∅,

8-

HCO3,

Hedgehog/GLI-mediated transcriptional inhibitors from Zizyphus cambodiana

-

in-vitro,

PC,

HaCaT

-

in-vitro,

Pca,

PANC1

HH↓, Gli1↓, PTCH1↓, Bcl-2↓,

1439-

HCQ,

Acidic extracellular pH neutralizes the autophagy-inhibiting activity of chloroquine

-

in-vitro,

Melanoma,

NA

CQ (25, 50, 100 μM)

-

in-vitro,

CRC,

HCT116

TumAuto↓, eff↓, other↓,

1438-

HCQ,

Chemo,

Adding Chloroquine to Conventional Treatment for Glioblastoma Multiforme

-

Trial,

GBM,

NA

Chloroquine tablets 150 mg, were commercially purchased 150 mg/d, starting on day 5 after surgery, and was continued for 12 months

30 patients

OS↑, *toxicity∅,

1441-

HCQ,

Chemo,

Case report: stage 4 pancreatic cancer to remission using paricalcitol and hydroxychloroquine in addition to traditional chemotherapy

-

Case Report,

GBM,

NA

hydroxychloroquine (600 mg BID)

TumAuto↓, Remission↑,

1912-

HCQ,

TMZ,

Chloroquine enhances temozolomide cytotoxicity in malignant gliomas by blocking autophagy

-

in-vivo,

GBM,

U87MG

mice

LC3B-II↑, CHOP↑, cl‑PARP↑,

1160-

HibSad,

Hibiscus sabdariffa anthocyanins are potential modulators of estrogen receptor alpha activity with favourable toxicology: a computational analysis using molecular docking, ADME/Tox prediction, 2D/3D QSAR and molecular dynamics simulation

-

Analysis,

NA,

NA

ER(estro)↓,

1153-

HNK,

Honokiol Eliminates Glioma/Glioblastoma Stem Cell-Like Cells via JAK-STAT3 Signaling and Inhibits Tumor Progression by Targeting Epidermal Growth Factor Receptor

-

in-vitro,

GBM,

U251

-

in-vitro,

GBM,

U87MG

-

in-vivo,

NA,

NA

mice + zebrafish

tumCV↓, Apoptosis↑, TumCMig↓, TumCI↓, Bcl-2↓, EGFR↓, CD133↓, Nestin↓, Akt↓, ERK↓, Casp3↑, p‑STAT3↓, TumCG↓,

1154-

HNK,

MET,

Honokiol inhibits the growth of hormone-resistant breast cancer cells: its promising effect in combination with metformin

-

in-vitro,

BC,

MCF-7

20uM

-

in-vitro,

BC,

SkBr3

12.1± 1.3uM

-

in-vitro,

BC,

MDA-MB-231

17uM

cl‑PARP↑, Bcl-2↓, ERα↓,

1120-

HNK,

Honokiol suppresses renal cancer cells' metastasis via dual-blocking epithelial-mesenchymal transition and cancer stem cell properties through modulating miR-141/ZEB2 signaling

-

vitro+vivo,

RCC,

NA

EMT↓, CSCs↓, TumCG↓, miR-141↑,

1119-

HNK,

Honokiol inhibits epithelial—mesenchymal transition in breast cancer cells by targeting signal transducer and activator of transcription 3/Zeb1/E‐cadherin axis

-

vitro+vivo,

BC,

NA

EMT↓, MSCmark↓, EM↑, STAT3↓, Zeb1↓, E-cadherin↑,

1087-

HNK,

Honokiol Inhibits Non-Small Cell Lung Cancer Cell Migration by Targeting PGE2-Mediated Activation of β-Catenin Signaling

-

in-vitro,

Lung,

A549

-

in-vitro,

Lung,

H1299

-

in-vitro,

Lung,

H460

-

in-vitro,

Lung,

H226

TumCMig↓, COX2↓, PGE2↓, NF-kB↓, p65↓, β-catenin/ZEB1↓, MMP2↓, MMP9↓,

960-

HNK,

Honokiol Inhibits HIF-1α-Mediated Glycolysis to Halt Breast Cancer Growth

-

vitro+vivo,

BC,

MCF-7

HNK (diluted in DMSO, 25 mg/kg/day

mice

-

vitro+vivo,

BC,

MDA-MB-231

0-40uM/24hr

OCR↑, ECAR↓, GlucoseCon↓, lactateProd↓, ATP↓, Glycolysis↓, Hif1a↓, GLUT1↓, HK2↓, PDK1↓, Apoptosis↑, LDHA↓,

1021-

HNK,

Honokiol suppress the PD-L1 expression to improve anti-tumor immunity in lung cancer

-

in-vivo,

Lung,

NA

PD-L1↓, T-Cell↑, CD4+↑, CD8+↑, TumCG↓,

1004-

HNK,

RAPA,

Honokiol downregulates PD-L1 expression and enhances antitumor effects of mTOR inhibitors in renal cancer cells

-

in-vitro,

RCC,

NA

Apoptosis↑, TumCCA↑, ROS↑, PD-L1↓, IFN-γ↓,

2079-

HNK,

Honokiol Microemulsion Causes Stage-Dependent Toxicity Via Dual Roles in Oxidation-Reduction and Apoptosis through FoxO Signaling Pathway

-

in-vitro,

Nor,

PC12

*toxicity↝, *ROS↓, *ROS↑, *Dose⇅, *BioAv↑, *BioAv↓, *ROS⇅, *SOD↓, *toxicity↑,

2080-

HNK,

Honokiol Induces Ferroptosis by Upregulating HMOX1 in Acute Myeloid Leukemia Cells

-

in-vitro,

AML,

THP1

20 μM

-

in-vitro,

AML,

U937

35 μM

-

in-vitro,

AML,

SK-HEP-1

30 μM

tumCV↓, TumCCA↑, Ferroptosis↑, lipid-P↑, HO-1↑, GPx4∅,

2081-

HNK,

Honokiol induces ferroptosis in colon cancer cells by regulating GPX4 activity

-

in-vitro,

Colon,

RKO

11.42 μM

-

in-vitro,

Colon,

HCT116

47.65 μM

-

in-vitro,

Colon,

SW48

-

in-vitro,

Colon,

HT-29

-

in-vitro,

Colon,

LS174T

-

in-vitro,

Colon,

HCT8

-

in-vitro,

Colon,

SW480

-

in-vivo,

NA,

NA

mice

tumCV↓, ROS↑, Iron↑, GPx4↓, mtDam↑, Ferroptosis↑, TumVol↓, TumW↓,

2082-

HNK,

Revealing the role of honokiol in human glioma cells by RNA-seq analysis

-

in-vitro,

GBM,

U87MG

36.27 μM

In U87-MG cells, the optimum concentration of honokiol was 20 µM, and the optimum time was 48 h

-

in-vitro,

GBM,

U251

59.53 μM

n U251-MG cells, the optimum concentration of honokiol was 40 µM, and the optimum time was 48 h

AntiCan↑, TumCP↑, TumAuto↑, Apoptosis↑, *BioAv↑, *neuroP↑, *NF-kB↑, MAPK↑, GPx4↑, Tf↑, BAX↑, Bcl-2↓, antiOx↑, Hif1a↓, Ferroptosis↑,

1286-

HNK,

The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells

-

in-vitro,

CLL,

NA

Apoptosis↑, Casp3↑, Casp8↑, Casp9↑, cl‑PARP↑, Bcl-2↓, BAX↑,

2073-

HNK,

Honokiol induces apoptosis and autophagy via the ROS/ERK1/2 signaling pathway in human osteosarcoma cells in vitro and in vivo

-

in-vitro,

OS,

U2OS

21.5 μM

-

in-vivo,

NA,

NA

40 mg/kg

TumCD↑, TumAuto↑, Apoptosis↑, TumCCA↑, GRP78/BiP↑, ROS↑, eff↓, p‑ERK↑, selectivity↑, Ca+2↑, MMP↓, Casp3↑, Casp9↑, cl‑PARP↑, Bcl-2↓, Bcl-xL↓, survivin↓, LC3B-II↑, ATG5↑, TumVol↓, TumW↓, ER Stress↑,

2072-

HNK,

Honokiol Suppresses Cell Proliferation and Tumor Migration through ROS in Human Anaplastic Thyroid Cancer Cells

-

in-vitro,

Thyroid,

NA

ROS↑, eff↓,

2071-

HNK,

Identification of senescence rejuvenation mechanism of Magnolia officinalis extract including honokiol as a core ingredient

-

Review,

Nor,

HaCaT

10 μg/ml

0.625 μg/ml was selected as the optimal concentration of M. officinalis extract since it was the lowest concentration that causes cell proliferation

*ROS↓, *antiOx↑, *AntiAge↑, *MMP↑, *ECAR↓, *Glycolysis↓, *PAR-2↓, *CXCL12↑, *BMAL1↑, *mt-ROS↓, *OXPHOS↓,

2894-

HNK,

Pharmacological features, health benefits and clinical implications of honokiol

-

Review,

Var,

NA

-

Review,

AD,

NA

*BioAv↓, *neuroP↑, *BBB↑, *ROS↓, *Keap1↑, *NRF2↑, *Casp3↓, *SIRT3↑, *Rho↓, *ERK↓, *NF-kB↓, angioG↓, RAS↓, PI3K↓, Akt↓, mTOR↓, *memory↑, *Aβ↓, *PPARγ↑, *PGC-1α↑, NF-kB↓, Hif1a↓, VEGF↓, HO-1↓, Foxm1↓, p27↑, P21↑, CDK2↓, CDK4↓, CDK6↓, cycD1↓, Twist↓, MMP2↓, Rho↑, ROCK1↑, TumCMig↓, cFLIP↓, BMPs↑, OCR↑, ECAR↓, *AntiAg↑, *cardioP↑, *antiOx↑, *ROS↓, P-gp↓,

2881-

HNK,

Honokiol Suppressed Pancreatic Cancer Progression via miR-101/Mcl-1 Axis

-

in-vitro,

PC,

PANC1

50 µM

tumCV↓, Casp3↑, Apoptosis↑, TumCCA↑, TumCI↓, Mcl-1↓, EMT↓,

2882-

HNK,

Honokiol Suppresses Perineural Invasion of Pancreatic Cancer by Inhibiting SMAD2/3 Signaling

-

in-vitro,

PC,

PANC1

TumCI↓, TumCMig↓, p‑SMAD2↓, p‑SMAD3↓, EMT↓, N-cadherin↓, Vim↓, E-cadherin↑, Snail↓, Slug↓, Rho↓, ROCK1↓,

2883-

HNK,

Honokiol targets mitochondria to halt cancer progression and metastasis

-

Review,

Var,

NA

ChemoSen↑, BBB↓, Ca+2↑, Cyt‑c↑, Casp3↑, chemoP↑, OCR↓, mitResp↓, Apoptosis↑, RadioS↑, NF-kB↓, Akt↓, TNF-α↓, PGE2↓, VEGF↓, NO↝, COX2↓, RAS↓, EMT↓, Snail↓, N-cadherin↓, β-catenin/ZEB1↓, E-cadherin↑, ER Stress↑, p‑STAT3↓, EGFR↓, mTOR↓, mt-ROS↑, PI3K↓, Wnt↓,

2884-

HNK,

Honokiol inhibits EMT-mediated motility and migration of human non-small cell lung cancer cells in vitro by targeting c-FLIP

-

in-vitro,

Lung,

A549

-

in-vitro,

Lung,

H460

EMT↓, cFLIP↓, N-cadherin↓, Snail↓, p‑SMAD2↓, p‑SMAD3↓, IKKα↑, TumCMig↓, NA↑,

2885-

HNK,

Honokiol: a novel natural agent for cancer prevention and therapy

NF-kB↓, STAT3↓, EGFR↓, mTOR↓, BioAv↝, Inflam↓, TumCP↓, angioG↓, TumCI↓, TumMeta↓, cSrc↓, JAK1↓, JAK2↓, ERK↓, Akt↓, PTEN↑, ChemoSen↑, chemoP↑, COX2↓, PGE2↓, TNF-α↓, IL1β↓, IL6↓, Casp3↑, Casp8↑, Casp9↑, cl‑PARP↑, DNAdam↑, Cyt‑c↑, RadioS↑, RAS↓, BBB↑, BioAv↓, Half-Life↝, Half-Life↝, toxicity↓,

2886-

HNK,

Liposomal honokiol inhibits non-small cell lung cancer progression and enhances PD-1 blockade via suppressing M2 macrophages polarization

-

in-vitro,

Lung,

A549

-

in-vitro,

Lung,

H460

-

in-vivo,

NA,

NA

mouse Lewis lung cancer cell line (LL2

eff↑, BioAv↑, eff↑, PI3K↓, Akt↓,

2887-

HNK,

Honokiol Restores Microglial Phagocytosis by Reversing Metabolic Reprogramming

-

in-vitro,

AD,

BV2

*Glycolysis↑, *ATP↑, *ROS↓, *MMP↑, *OXPHOS↑, *PPARα↑, *PGC-1α↑,

2888-

HNK,

Honokiol mediated inhibition of PI3K/mTOR pathway: A potential strategy to overcome immunoresistance in glioma, breast and prostate carcinoma without impacting T cell function

-

in-vitro,

Var,

PC3

-

in-vitro,

BC,

BT549

PI3K↓, mTOR↓, Inflam↓,

2889-

HNK,

doxoR,

Honokiol, an activator of Sirtuin-3 (SIRT3) preserves mitochondria and protects the heart from doxorubicin-induced cardiomyopathy in mice

-

in-vivo,

Nor,

NA

mice

*SIRT3↑, chemoP↑, *cardioP↑, mtDam↑, ROS↑, *ROS↓, *MMP↑,

2890-

HNK,

SIRT3 activation promotes enteric neurons survival and differentiation

*SIRT3↑, *antiOx↑, *neuroP↑,

2892-

HNK,

Honokiol Induces Apoptosis, G1 Arrest, and Autophagy in KRAS Mutant Lung Cancer Cells

-

in-vitro,

Lung,

A549

30.42

-

in-vitro,

Lung,

H460

50.58

-

in-vitro,

Lung,

H385

59.38 ± 6.75 μM

-

in-vitro,

Nor,

BEAS-2B

TumCCA↑, Apoptosis↑, SIRT3↑, Hif1a↓, selectivity↑, p‑mTOR↓, p70S6↓,

2893-

HNK,

doxoR,

Honokiol protects against doxorubicin cardiotoxicity via improving mitochondrial function in mouse hearts

-

in-vivo,

Nor,

NA

rat

*mitResp↑, *PPARγ↑, *cardioP↑, *SIRT3↑, *ROS↓, *GSH↑, *SOD2↑,

2902-

HNK,

Rad,

Honokiol Mitigates Ionizing Radiation-Induced Injury by Maintaining the Redox Balance of the TrxR/Trx System

-

in-vitro,

Nor,

BEAS-2B

*TrxR1↑, *Trx↑, *radioP↑, *ROS↓,

2895-

HNK,

Mitochondria-Targeted Honokiol Confers a Striking Inhibitory Effect on Lung Cancer via Inhibiting Complex I Activity

-

in-vitro,

Lung,

PC9

0.26 μM

eff↑, TumCP↓, mt-ROS↑, Prx3↑, mt-STAT3↓, *toxicity∅, selectivity↑, ChemoSen↑,

2896-

HNK,

Honokiol inhibits hypoxia-inducible factor-1 pathway

-

in-vivo,

Colon,

CT26

subcutaneous murine colon carcinoma, CT26

Hif1a↓, RadioS↑,

2897-

HNK,

Honokiol Inhibits Proliferation, Invasion and Induces Apoptosis Through Targeting Lyn Kinase in Human Lung Adenocarcinoma Cells

-

in-vitro,

Lung,

PC9

0, 20, 40, 60, and 80 μM

41uM@48h

-

in-vitro,

Lung,

A549

52uM@48h

TumCP↓, Apoptosis↑, EGFR↓, PI3K↓, Akt↓, STAT3↓, TumCI↓, TNF-α↑, NF-kB↓, VEGF↓, MMP9↓, COX2↓,

2898-

HNK,

Honokiol Suppression of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Cell Biological Activity and Its Mechanism

-

in-vitro,

GC,

AGS

-

in-vitro,

GC,

NCI-N87

-

in-vitro,

BC,

MGC803

-

in-vitro,

GC,

SGC-7901

TumCP↓, Apoptosis↑, TumCI↓, TumCMig↓, HER2/EBBR2↓, TumCCA↑, PI3K↓, Akt↓, MMP9↓, P21↑,

2899-

HNK,

SIRT3 activator honokiol ameliorates surgery/anesthesia-induced cognitive decline in mice through anti-oxidative stress and anti-inflammatory in hippocampus

-

in-vivo,

Nor,

NA

Adult C57BL/6 mice

*memory↑, *Inflam↓, *ROS↓, neuroP↑, SIRT3↑, ac‑SOD2↓,

2891-

HNK,

Honokiol, an Active Compound of Magnolia Plant, Inhibits Growth, and Progression of Cancers of Different Organs

-

Review,

Var,

NA

AntiCan↑, Inflam↓, antiOx↑, selectivity↑, *toxicity↓, cycD1↓, cycE↓, CDK2↓, CDK4↓, TumMeta↓, NADPH↓, MMP2↓, MMP9↓, p‑mTOR↓, EGFR↓, EMT↓, SIRT1↑, SIRT3↑, EZH2↓, Snail↓, Vim↓, N-cadherin↓, E-cadherin↑, COX2↓, NF-kB↓, *ROS↓, Ca+2↑, ROS↑,

2900-

HNK,

The Role and Therapeutic Perspectives of Sirtuin 3 in Cancer Metabolism Reprogramming, Metastasis, and Chemoresistance

-

Review,

Var,

NA

SIRT3↑, Hif1a↓, ChemoSen↑, chemoP↑,

2901-

HNK,

doxoR,

Honokiol protects against doxorubicin cardiotoxicity via improving mitochondrial function in mouse hearts

-

in-vivo,

Nor,

NA

mice

*mitResp↑, *PPARγ↑, *Inflam↓, *ROS↓, *cardioP↑, *SOD2↑, *LDH↓,

2879-

HNK,

Honokiol Inhibits Lung Tumorigenesis through Inhibition of Mitochondrial Function

-

in-vitro,

Lung,

H226

-

in-vivo,

NA,

NA

mouse

tumCV↓, selectivity↑, TumCP↓, TumCCA↑, Apoptosis↑, mt-ROS↑, Casp3↑, Casp7↑, OCR↓, Cyt‑c↑, ATP↓, mitResp↓, AMP↑, AMPK↑,

2880-

HNK,

Honokiol inhibits breast cancer cell metastasis by blocking EMT through modulation of Snail/Slug protein translation

-

in-vitro,

BC,

MCF-7

-

in-vitro,

BC,

MDA-MB-231

-

in-vitro,

BC,

4T1

-

in-vivo,

NA,

NA

50 mg/kg every day, intraperitoneal (i.p.), 6 times per week for 30 days

mouse

tumCV↓, E-cadherin↑, Snail↓, Slug↓, Vim↓, TumMeta↓, p‑eIF2α↑,

2863-

HNK,

Honokiol induces paraptosis-like cell death through mitochondrial ROS-dependent endoplasmic reticulum stress in hepatocellular carcinoma Hep3B cells

-

in-vitro,

Liver,

Hep3B

ER Stress↑, Ca+2↑, mtDam↑, PTEN↑, PARK2↑, Alix/AIP‑1↓, ROS↑, mt-ROS↑,

2864-

HNK,

Honokiol: A Review of Its Anticancer Potential and Mechanisms

-

Review,

Var,

NA

TumCCA↑, CDK2↓, EMT↓, MMPs↓, AMPK↑, TumCI↓, TumCMig↓, TumMeta↓, VEGFR2↓, *antiOx↑, *Inflam↓, *BBB↑, *neuroP↑, *ROS↓, Dose↝, selectivity↑, Casp3↑, Casp9↑, NOTCH1↓, cycD1↓, cMyc↓, P21?, DR5↑, cl‑PARP↑, P53↑, Mcl-1↑, p65↓, NF-kB↓, ROS↑, JNK↑, NRF2↑, cJun↑, EF-1α↓, MAPK↓, PI3K↓, mTORC1↓, CSCs↓, OCT4↓, Nanog↓, SOX4↓, STAT3↓, CDK4↓, p‑RB1↓, PGE2↓, COX2↓, β-catenin/ZEB1↑, IKKα↓, HDAC↓, HATs↑, H3↑, H4↑, LC3II↑, c-Raf↓, SIRT3↑, Hif1a↓, ER Stress↑, GRP78/BiP↑, cl‑CHOP↑, MMP↓, PCNA↓, Zeb1↓, NOTCH3↓, CD133↓, Nestin↓, ATG5↑, ATG7↑, survivin↓, ChemoSen↑, SOX2↓, OS↑, P-gp↓, Half-Life↓, Half-Life↝, eff↑, BioAv↓,

2865-

HNK,

Liposomal Honokiol induces ROS-mediated apoptosis via regulation of ERK/p38-MAPK signaling and autophagic inhibition in human medulloblastoma

-

in-vitro,

MB,

DAOY

-

vitro+vivo,

NA,

NA

BioAv↓, BioAv↓, TumCP↓, selectivity↑, P53↑, P21↑, CDK4↓, cycD1↓, mtDam↑, ROS↑, eff↓, Casp3↑, BAX↑, LC3II↑, Beclin-1↑, ATG7↑, p62↑, eff↑, ChemoSen↑, *toxicity↓,

2866-

HNK,

Honokiol and its analogues as anticancer compounds: Current mechanistic insights and structure-activity relationship

-

Review,

Var,

NA

EMT↓, TumMeta↓, BioAv↑, BBB↑,

2867-

HNK,

Honokiol ameliorates oxidative stress-induced DNA damage and apoptosis of c2c12 myoblasts by ROS generation and mitochondrial pathway

-

in-vitro,

Nor,

C2C12

*antiOx↑, *ROS↓, *Bcl-2↑, *BAX↓, Casp9∅, Casp3∅, cl‑PARP∅, Cyt‑c?,

2868-

HNK,

Honokiol: A review of its pharmacological potential and therapeutic insights

-

Review,

Var,

NA

-

Review,

Sepsis,

NA

*P-gp↓, *ROS↓, *TNF-α↓, *IL10↓, *IL6↓, eIF2α↑, CHOP↑, GRP78/BiP↑, BAX↑, cl‑Casp9↑, p‑PERK↑, ER Stress↑, Apoptosis↑, MMPs↓, cFLIP↓, CXCR4↓, Twist↓, HDAC↓, BMPs↑, p‑STAT3↓, mTOR↓, EGFR↓, NF-kB↓, Shh↓, VEGF↓, tumCV↓, TumCMig↓, TumCI↓, ERK↓, Akt↓, Bcl-2↓, Nestin↓, CD133↓, p‑cMET↑, RAS↑, chemoP↑, *NRF2↑, *NADPH↓, *p‑Rac1↓, *ROS↓, *IKKα↑, *NF-kB↓, *COX2↓, *PGE2↓, *Casp3↓, *hepatoP↑, *antiOx↑, *GSH↑, *Catalase↑, *RenoP↑, *ALP↓, *AST↓, *ALAT↓, *neuroP↑, *cardioP↑, *HO-1↑, *Inflam↓,

2869-

HNK,

Nature's neuroprotector: Honokiol and its promise for Alzheimer's and Parkinson's

-

Review,

AD,

NA

-

Review,

Park,

NA

*neuroP↑, *Inflam↓, *motorD↑, *Aβ↓, *p‑tau↓, *cognitive↑, *memory↑, *ERK↑, *p‑Akt↑, *PPARγ↑, *PGC-1α↑, *MMP↑, *mt-ROS↓, *SIRT3↑, *IL1β↓, *TNF-α↓, *GRP78/BiP↓, *CHOP↓, *NF-kB↓, *GSK‐3β↓, *β-catenin/ZEB1↑, *Ca+2↓, *AChE↓, *SOD↑, *Catalase↑, *GPx↑,

2870-

HNK,

Honokiol attenuates oxidative stress and vascular calcification via the upregulation of heme oxygenase-1 in chronic kidney disease

-

in-vitro,

CKD,

NA

*HO-1↑, *ROS↓,

2872-

HNK,

Honokiol alleviated neurodegeneration by reducing oxidative stress and improving mitochondrial function in mutant SOD1 cellular and mouse models of amyotrophic lateral sclerosis

-

in-vivo,

ALS,

NA

mice

-

NA,

Stroke,

NA

-

NA,

AD,

NA

-

NA,

Park,

NA

*eff↑, *ROS↓, *GSH↑, *NRF2↑, *motorD↑, *OS↑, *neuroP↑, *BBB↑, *cognitive↑, *eff↑, *antiOx↑, *Cyt‑c↑, *PGC-1α↑,

2873-

HNK,

Honokiol Alleviates Oxidative Stress-Induced Neurotoxicity via Activation of Nrf2

-

in-vitro,

Nor,

PC12

*neuroP↑, *GSH↑, *HO-1↑, *NADPH↑, *Trx1↑, *TrxR1↑, *NRF2↑, *ROS↓, *antiOx↑, *BBB↑, Dose↓,

2874-

HNK,

Suppressing migration and invasion of H1299 lung cancer cells by honokiol through disrupting expression of an HDAC6‐mediated matrix metalloproteinase 9

-

in-vitro,

Lung,

H1299

0-10uM

MMP9↓, α-tubulin↑, TumCI↓, HDAC6↓, HSP90↓, TumCMig↓, EGFR↓,

2875-

HNK,

Inhibition of class I histone deacetylases in non-small cell lung cancer by honokiol leads to suppression of cancer cell growth and induction of cell death in vitro and in vivo

-

in-vitro,

Lung,

A549

20, 40 and 60 µM

-

in-vitro,

Lung,

H1299

-

in-vitro,

Lung,

H460

-

in-vitro,

SCC,

H226

HDAC↓, tumCV↓, TumCCA↑, cycD1↓, ac‑H3↑, ac‑H4↑, selectivity↑, CDK2↓, CDK4↓,

2876-

HNK,

Honokiol from Magnolia spp. induces G1 arrest via disruption of EGFR stability through repressing HDAC6 deacetylated Hsp90 function in lung cancer cells

-

in-vitro,

Lung,

A549

0, 5, 10, 15, 20 and 40 µM) for 24, 48, and 72 h.

23.55 ± 1.18 µM

-

in-vitro,

Lung,

H23

-

in-vitro,

Lung,

HCC827

EGFR↓, HSP90↓,

2877-

HNK,

Targeting histone deacetylase-3 blocked epithelial-mesenchymal plasticity and metastatic dissemination in gastric cancer

-

in-vitro,

GC,

AGS

HDAC3↓, NF-kB↓, CEBPB↓, ER Stress↑, EMT↓, Wnt↓, β-catenin/ZEB1↓,

2878-

HNK,

Suppressing migration and invasion of H1299 lung cancer cells by honokiol through disrupting expression of an HDAC6-mediated matrix metalloproteinase 9

-

in-vitro,

Lung,

H1299

TumCMig↓, TumCI↓, MMP9↓, α-tubulin↑, HDAC6↓, HSP90↓,

2871-

HNK,

Antihyperalgesic Properties of Honokiol in Inflammatory Pain Models by Targeting of NF-κB and Nrf2 Signaling

-

in-vivo,

Nor,

NA

honokiol 10 mg/kg i.p.

adult male BALB/c mic

*TNF-α↓, *IL1β↓, *IL6↓, *VEGF↓, *NRF2↑, *SOD2↑, *HO-1↑, *Inflam↓, *Pain↓, *NO↓, toxicity↓,

886-

HPT,

Impact of hyper- and hypothermia on cellular and whole-body physiology

-

Analysis,

NA,

NA

MMP↓, OXPHOS↓, ATP↓, ROS↑, Apoptosis↑, Cyt‑c↑,

601-

HTyr,

Dihydroxyphenylethanol induces apoptosis by activating serine/threonine protein phosphatase PP2A and promotes the endoplasmic reticulum stress response in human colon carcinoma cells

-

in-vivo,

NA,

HT-29

TumCG↓, Apoptosis↑, ER Stress↑, UPR↑, CHOP↑, JNK↑, TNF-α↓, PPP2R1A↑,

1278-

I3C,

Indole-3-carbinol inhibits prostate cancer cell migration via degradation of beta-catenin

-

in-vivo,

Pca,

DU145

100 microM

TumCMig↓, β-catenin/ZEB1↓,

1277-

I3C,

GEN,

Modulation of the constitutive activated STAT3 transcription factor in pancreatic cancer prevention: effects of indole-3-carbinol (I3C) and genistein

-

in-vitro,

PC,

PANC1

>10uM

STAT3↓, Apoptosis↑,

33-

InA,

Inoscavin A, a pyrone compound isolated from a Sanghuangporus vaninii extract, inhibits colon cancer cell growth and induces cell apoptosis via the hedgehog signaling pathway

-

vitro+vivo,

Colon,

NA

HH↓, Smo↓,

1293-

Ins,

Inositol Hexaphosphate Inhibits Growth and Induces G1 Arrest and Apoptotic Death of Androgen-Dependent Human Prostate Carcinoma LNCaP Cells

-

vitro+vivo,

Pca,

LNCaP

TumCG↓, TumCCA↑, P21↑, CDK4↓, cycD1↓, RB1↑, E2Fs↓,

2172-

iod,

A prospective study of iodine status, thyroid function, and prostate cancer risk: follow-up of the First National Health and Nutrition Examination Survey

-

Study,

Pca,

NA

Risk↓,

1088-

IP6,

Preventive Inositol Hexaphosphate Extracted from Rice Bran Inhibits Colorectal Cancer through Involvement of Wnt/β-Catenin and COX-2 Pathways

-

in-vivo,

CRC,

NA

rats

AntiTum↑, β-catenin/ZEB1↓, COX2↓,

2180-

itraC,

Repurposing Drugs in Oncology (ReDO)—itraconazole as an anti-cancer agent

-

Review,

Var,

NA

Dose↝, toxicity↝, BioAv↑, Half-Life↝, BioAv↑, Dose↝, HH↓, TumAuto↑, Akt↓, mTOR↓, angioG↓, MDR1↓, TumCP↓, eff↑,

2179-

itraC,

Repurposing itraconazole for the treatment of cancer

-

Review,

Var,

NA

HH↓, angioG↓, TumCCA↑, MDR1↓, P-gp↓, mTOR↓, VEGF↓, Smo↓, Gli1↓, OS↑, PSA↓,

2178-

itraC,

Itraconazole inhibits tumor growth via CEBPB-mediated glycolysis in colorectal cancer

-

in-vivo,

CRC,

HCT116

xenograft model in tumor-bearing mice

TumCG↓, Glycolysis↓, CEBPB?, ENO1↓, LDHA↓, PKM2↓, GAPDH↓, ECAR↓, OCR↓,

2177-

itraC,

Itraconazole improves survival outcomes in patients with colon cancer by inducing autophagic cell death and inhibiting transketolase expression

-

Study,

Colon,

NA

present study analyzed extensive data from patients diagnosed with colon cancer using itraconazole between January 2011 and December 2015

-

in-vitro,

CRC,

COLO205

-

in-vitro,

CRC,

HCT116

OS↑, tumCV↓, Casp3↑, TumCCA↑, HH↓, TumAuto↑, LC3B↑, p62↑, TKT↓,

1166-

IVM,

The importin α/β-specific inhibitor Ivermectin affects HIF-dependent hypoxia response pathways

-

in-vitro,

NA,

NA

importin α/β↓, Hif1a↓,

1167-

IVM,

The river blindness drug Ivermectin and related macrocyclic lactones inhibit WNT-TCF pathway responses in human cancer

-

vitro+vivo,

NA,

NA

Wnt↓, TCF↓, TumCP↓, Apoptosis↑, β-catenin/ZEB1↓, cycD1↓,

1168-

IVM,

SRF,

Ivermectin synergizes sorafenib in hepatocellular carcinoma via targeting multiple oncogenic pathways

-

in-vitro,

HCC,

NA

TumMeta↓, mTOR↓, EMT↓, CSCsMark↓, STAT3↓,

1175-

IVM,

PDT,

Drug induced mitochondria dysfunction to enhance photodynamic therapy of hypoxic tumors

-

in-vitro,

Var,

NA

Hypoxia↓, mitResp↓, ROS↑,

1070-

IVM,

Ivermectin accelerates autophagic death of glioma cells by inhibiting glycolysis through blocking GLUT4 mediated JAK/STAT signaling pathway activation

-

vitro+vivo,

GBM,

NA

10 mg/kg IVM

rat

TumCG↓, LC3II↑, p62↓, ATP↓, Pyruv↓, GlucoseCon↑, HK2↓, PFK1↓, GLUT4↓, Glycolysis↓, JAK2↓, p‑STAT3↓, p‑STAT5↓,

974-

JG,

Juglone down-regulates the Akt-HIF-1α and VEGF signaling pathways and inhibits angiogenesis in MIA Paca-2 pancreatic cancer in vitro

-

in-vitro,

PC,

MIA PaCa-2

100nM-10uM

Hif1a↓, VEGF↓, p‑Akt↓, TumCP↓, TumCI↓,

1121-

JG,

Juglone suppresses epithelial-mesenchymal transition in prostate cancer cells via the protein kinase B/glycogen synthase kinase-3β/Snail signaling pathway

-

in-vitro,

Pca,

LNCaP

E-cadherin↑, N-cadherin↓, Vim↓, Snail↓, GSK‐3β↑,

1918-

JG,

ROS -mediated p53 activation by juglone enhances apoptosis and autophagy in vivo and in vitro

-

in-vitro,

Liver,

HepG2

1-30uM

-

in-vivo,

NA,

NA

4mg/kg

mice were intraperitoneally injected with 10% dimethyl sulfoxide (DMSO) or JG (4 mg/kg) every other day for ten times in tota

TumCG↓, TumCP↓, Apoptosis↑, TumAuto↑, AMPK↑, mTOR↑, P53↑, H2O2↑, ROS↑, toxicity↝, p62↓, DR5↑, Casp8↑, PARP↑, cl‑Casp3↑,

1927-

JG,

Juglone-induced apoptosis in human gastric cancer SGC-7901 cells via the mitochondrial pathway

-

in-vitro,

GC,

SGC-7901

5, 10, 15 and 20 μmol/L 24h

36.51 μmol/L (24h) and 25.37 μmol/L (48 h)

Apoptosis↑, ROS↑, Bcl-2↓, BAX↑, MMP↓, Cyt‑c↑, Casp3?, Bax:Bcl2↑,

1926-

JG,

Mechanism of juglone-induced apoptosis of MCF-7 cells by the mitochondrial pathway

-

in-vitro,

BC,

MCF-7

11.99 μM

TumCG↓, ROS↑, MMP↓, i-Ca+2↑, BAX↑, Bcl-2↓, Cyt‑c↑, Casp3?,

1925-

JG,

Redox regulation of mitochondrial functional activity by quinones

-

in-vitro,

NA,

NA

other↓, ROS↑, MMP↓, eff↝,

1917-

JG,

Inhibition of human leukemia cells growth by juglone is mediated via autophagy induction, endogenous ROS production, and inhibition of cell migration and invasion

-

in-vitro,

AML,

HL-60

0-80uM

selectivity↑, LC3I↑, LC3II↑, Beclin-1↑, ROS↑, tumCV↓, Dose↝, TumAuto↑,

1919-

JG,

The Anti-Glioma Effect of Juglone Derivatives through ROS Generation

-

in-vitro,

GBM,

U87MG

IC50 for U87 was 3.99, 3.28, 7.60, and 11.84 μM

-

in-vitro,

GBM,

U251

IC50 was 7.00, 5.43, 8.64, and 18.05 μM, respectively

ROS↑, Apoptosis↑, eff↓, eff↓,

1920-

JG,

TQ,

Plum,

Natural quinones induce ROS-mediated apoptosis and inhibit cell migration in PANC-1 human pancreatic cancer cell line

-

in-vitro,

PC,

PANC1

ROS↑, TumCMig↓, MMP9↓,

1921-

JG,

Juglone induces ferroptotic effect on hepatocellular carcinoma and pan-cancer via the FOSL1-HMOX1 axis

-

in-vitro,

PC,

NA

-

vitro+vivo,

PC,

NA

TumCG↓, Ferroptosis↑, ROS↑, Iron↑, lipid-P↑, MDA↑, GSH↓, FOSL1↑, HO-1↑,

1922-

JG,

Juglone induces apoptosis of tumor stem-like cells through ROS-p38 pathway in glioblastoma

-

in-vitro,

GBM,

U87MG

(0, 10, 20, and 40 μM)

tumCV↓, TumCP↓, ROS↑, p‑p38↑, eff↓, Apoptosis↑, OS↑,

1923-

JG,

Mechanism of Juglone-Induced Cell Cycle Arrest and Apoptosis in Ishikawa Human Endometrial Cancer Cells

-

in-vitro,

Endo,

NA

20.81 μM

TumCP↓, TumCCA↑, cycA1↓, ROS↑, P21↑, CDK2↓, CDK1↓, CDC25↓, Bcl-2↓, Bcl-xL↓, BAX↑, BAD↑, Cyt‑c↑,

1924-

JG,

Juglone triggers apoptosis of non-small cell lung cancer through the reactive oxygen species -mediated PI3K/Akt pathway

-

in-vitro,

Lung,

A549

2-8uM

9.47 μM@24h

TumCMig↓, TumCI↓, TumCCA↑, Apoptosis↑, cl‑Casp3↑, BAX↑, Cyt‑c↑, ROS↑, MDA↑, GPx4↓, SOD↓, PI3K↓, Akt↓, eff↓,

2390-

KaempF,

Kaempferol Can Reverse the 5-Fu Resistance of Colorectal Cancer Cells by Inhibiting PKM2-Mediated Glycolysis

-

in-vitro,

CRC,

HCT8

eff↑, GlucoseCon↓, lactateProd↓, PKM2↓, Glycolysis↓, glucose↑,

1272-

LA,

Lactobacillus johnsonii N6.2 Modulates the Host Immune Responses: A Double-Blind, Randomized Trial in Healthy Adults

-

Trial,

Nor,

NA

*Pain↓, *other↑,

1243-

LA,

Lactobacilli Modulate Hypoxia-Inducible Factor (HIF)-1 Regulatory Pathway in Triple Negative Breast Cancer Cell Line

-

in-vitro,

BC,

MDA-MB-231

Hif1a↓, HSP90↓, GLUT1↓, VHL↓, SHARP↑,

865-

Lae,

Amygdalin: A Review on Its Characteristics, Antioxidant Potential, Gastrointestinal Microbiota Intervention, Anticancer Therapeutic and Mechanisms, Toxicity, and Encapsulation

*toxicity↝, other↝,

867-

Lae,

Effects of the Gut microbiota on Amygdalin and its use as an anti-cancer therapy: Substantial review on the key components involved in altering dose efficacy and toxicity

-

Review,

NA,

NA

other↑,

866-

Lae,

Amygdalin from Apricot Kernels Induces Apoptosis and Causes Cell Cycle Arrest in Cancer Cells: An Updated Review

-

Review,

NA,

NA

BAX↑, Casp3↑, Bcl-2↓, TumCCA↑,

864-

Lae,

Can Amygdalin Provide any Benefit in Integrative Anticancer Treatment?

-

Review,

NA,

NA

TumCCA↑, COX2↝, E-cadherin↑, other∅, other∅,

863-

Lae,

Amygdalin inhibits the growth of renal cell carcinoma cells in vitro

-

in-vitro,

RCC,

NA

TumCG↓, TumCP↓, TumCCA↑, CDK1↓, CycB↓, E-cadherin↝, N-cadherin↝,

862-

Lae,

Molecular mechanism of amygdalin action in vitro: review of the latest research

-

Review,

NA,

NA

BAX↑, Casp3↑, Bcl-2↓, Akt↓, mTOR↓, p19↑, TumCCA↑, other↓,

861-

Lae,

Chit,

SNP,

Synthesis of polygonal chitosan microcapsules for the delivery of amygdalin loaded silver nanoparticles in breast cancer therapy

other↑,

859-

Lae,

Vitamin B17 and its Proposed Application in Treating Cancer

-

Analysis,

NA,

NA

other↑,

870-

Lae,

Physician Beware: Severe Cyanide Toxicity from Amygdalin Tablets Ingestion

-

Case Report,

NA,

NA

other↑,

868-

Lae,

The Postulated Mechanism of Action of Amygdalin (Vitamin B17) on Cancer Cells

-

Review,

NA,

NA

other∅,

860-

Lae,

Amygdalin as a Promising Anticancer Agent: Molecular Mechanisms and Future Perspectives for the Development of New Nanoformulations for Its Delivery

-

Review,

NA,

NA

eff↑, Casp3↑, Bcl-2↓,

869-

Lae,

Recent updates and future perspectives about amygdalin as a potential anticancer agent: A review

TumCD↑,

2351-

lamb,

Anti-Warburg effect via generation of ROS and inhibition of PKM2/β-catenin mediates apoptosis of lambertianic acid in prostate cancer cells

-

in-vitro,

Pca,

DU145

-

in-vitro,

Pca,

PC3

proCasp3↓, proPARP↓, LDHA↓, Glycolysis↓, HK2↓, PKM2↓, lactateProd↓, p‑STAT3↓, cycD1↓, cMyc↓, β-catenin/ZEB1↓, p‑GSK‐3β↓, ROS↑, eff↓,

2453-

LE,

The Promoting Role of HK II in Tumor Development and the Research Progress of Its Inhibitors

-

Review,

Var,

NA

HK2↓, PI3K↓, Akt↓, TumCP↓, Glycolysis↓,

1040-

LE,

Licorice extract inhibits growth of non-small cell lung cancer by down-regulating CDK4-Cyclin D1 complex and increasing CD8+ T cell infiltration

-

in-vivo,

Lung,

H1975

5400 μg/mL

mice

TumCCA↑, CDK4↓, cycD1↓, PD-L1↑, TumVol↓,

1266-

LE,

Glycyrrhizin suppresses epithelial-mesenchymal transition by inhibiting high-mobility group box1 via the TGF-β1/Smad2/3 pathway in lung epithelial cells

-

in-vitro,

Lung,

A549

-

in-vitro,

Nor,

BEAS-2B

HMGB1↓, EMT↓, TumCMig↓, p‑SMAD2↓, p‑SMAD3↓,

1306-

LE,

Modulations of the Bcl-2/Bax family were involved in the chemopreventive effects of licorice root (Glycyrrhiza uralensis Fisch) in MCF-7 human breast cancer cell

-

in-vitro,

BC,

MCF-7

50 microg/mL

Bcl-2↓, BAX↑, Apoptosis↑, TumCCA↑,

1788-

LE,

Activation of rapid signaling pathways and the subsequent transcriptional regulation for the proliferation of breast cancer MCF-7 cells by the treatment with an extract of Glycyrrhiza glabra root

-

in-vitro,

BC,

MCF-7

0.1–100 lg/ml for the extract and 0.1–100 lM for glycyrrhizin)

TumCG↑,

1787-

LE,

Licorice and cancer

-

Review,

Var,

NA

Inflam↓, AntiCan↓, DNAdam↓, LOX1↓, COX2↓, PKCδ↓, EGFR↓,

1790-

LEC,

DHA,

Dietary Crude Lecithin Increases Systemic Availability of Dietary Docosahexaenoic Acid with Combined Intake in Rats

-

in-vivo,

Nor,

NA

rats

*eff↑, other↑,

1796-

LEC,

A comprehensive review on pleiotropic effects and therapeutic potential of soy lecithin

-

Review,

NA,

NA

BioAv↑, antiOx↑, LDL↓, memory↑,

1795-

LEC,

Chit,

Self-assembled lecithin-chitosan nanoparticles improve the oral bioavailability and alter the pharmacokinetics of raloxifene

-

in-vivo,

Nor,

NA

Rats

eff↑, BioAv↑,

1789-

LEC,

Lecithin Supplements and Breast Cancer Risk

-

Analysis,

NA,

NA

AntiCan↑, Risk↓,

1794-

LEC,

Effects of abomasal infusion of soybean or sunflower lecithin on nutrient digestibility and milk production in lactating dairy cows

-

in-vivo,

NA,

NA

Cows

BioAv↑, other↑,

1793-

LEC,

Unmasking Sunflower Lecithin: Does Science Support the Claims?

-

Review,

NA,

NA

BioEnh↑, memory↑, Inflam↓, GutMicro↑, antiOx↑,

1791-

LEC,

Vegetable lecithins: A review of their compositional diversity, impact on lipid metabolism and potential in cardiometabolic disease prevention

-

Review,

Nor,

NA

*BioEnh↑, *antiOx↑, *BioEnh↑, *LDL↓, *HDL∅, *Obesity↓, eff↑, GutMicro↝,

1122-

LF,

MTX,

Lactoferrin Reverses Methotrexate Driven Epithelial Barrier Defect by Inhibiting TGF-β Mediated Epithelial to Mesenchymal Transition

-

in-vivo,

Colon,

Caco-2

0.8 mg/ml (10 µM)

mouse

TGF-β↓, EMT↓,

1200-

LT,

Inhibition of Fatty Acid Synthase by Luteolin Post-Transcriptionally Downregulates c-Met Expression Independent of Proteosomal/Lysosomal Degradation

-

in-vitro,

Pca,

DU145

luteolin could act as a novel HGF/c-Met inhibitor

FASN↓, cMET↓, HGF/c-Met↓,

1100-

LT,

Luteolin, a flavonoid, as an anticancer agent: A review

-

Review,

NA,

NA

TumCP↓, TumCCA↑, Apoptosis↑, EMT↓, E-cadherin↑, N-cadherin↓, Snail↓, Vim↓, ROS↑, ER Stress↑, mtDam↑, p‑eIF2α↝, p‑PERK↝, p‑CHOP↝, p‑ATF4↝, cl‑Casp12↝,

1171-

LT,

The inhibition of β-catenin activity by luteolin isolated from Paulownia flowers leads to growth arrest and apoptosis in cholangiocarcinoma

-

in-vitro,

CCA,

NA

Wnt↓, TumCCA↑, Apoptosis↑, TumCMig↓, β-catenin/ZEB1↓, cMyc↓, cycD1↓,

1125-

LT,

Luteolin suppresses epithelial-mesenchymal transition and migration of triple-negative breast cancer cells by inhibiting YAP/TAZ activity

-

in-vitro,

BC,

NA

YAP/TEAD↓, TAZ↓, MSCmark↓, EM↑, TumCMig↓,

979-

LT,

Luteolin Regulation of Estrogen Signaling and Cell Cycle Pathway Genes in MCF-7 Human Breast Cancer Cells

-

in-vitro,

BC,

MCF-7

17.5 μM

TumCP↓,

982-

LT,

Inhibitory effect of luteolin on estrogen biosynthesis in human ovarian granulosa cells by suppression of aromatase (CYP19)

-

in-vitro,

Ovarian,

KGN

CYP19↓,

1064-

LT,

Cisplatin,

Inhibition of cell survival, invasion, tumor growth and histone deacetylase activity by the dietary flavonoid luteolin in human epithelioid cancer cells

-

vitro+vivo,

Lung,

LNM35

25-200μM

intraperitoneal injection (20mg/kg/day for 18days)

-

in-vitro,

CRC,

HT-29

-

in-vitro,

Liver,

HepG2

-

in-vitro,

BC,

MCF-7

-

in-vitro,

BC,

MDA-MB-231

Casp3↑, Casp7↑, HDAC↓,

986-

LT,

doxoR,

Luteolin as a glycolysis inhibitor offers superior efficacy and lesser toxicity of doxorubicin in breast cancer cells

-

in-vitro,

BC,

4T1

100 microM

could reverse tumor resistance to Dox and promote death of tumor cells under hypoxia.

-

in-vitro,

BC,

MCF-7

SOD↓, Catalase↓, Glycolysis↓,

973-

LT,

Luteolin impairs hypoxia adaptation and progression in human breast and colon cancer cells

-

in-vitro,

CRC,

HCT116

-

in-vitro,

BC,

MDA-MB-231

Apoptosis↑, necrosis↑, TumAuto↑, HIF-1↓,

1025-

LT,

Api,

Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer

-

in-vivo,

Lung,

NA

H358 xenograft and Lewis lung carcinoma model in vivo,

TumCG↓, Apoptosis↑, PD-L1↓, p‑STAT3↓,

1060-

LT,

BTZ,

Luteolin inhibits the TGF-β signaling pathway to overcome bortezomib resistance in multiple myeloma

-

vitro+vivo,

Melanoma,

NA

ALDH1A1↓, TGF-β↓, ChemoSen↑,

1084-

LT,

CHr,

Luteolin and chrysin differentially inhibit cyclooxygenase-2 expression and scavenge reactive oxygen species but similarly inhibit prostaglandin-E2 formation in RAW 264.7 cells

-

in-vitro,

Nor,

RAW264.7

*COX2↓, *COX2∅, *PGE2↓, *ROS↓,

2346-

LT,

Luteolin suppressed PKM2 and promoted autophagy for inducing the apoptosis of hepatocellular carcinoma cells

-

in-vitro,

HCC,

HepG2

TumCP↓, Apoptosis↓, PKM2↓, TumAuto↑,

2915-

LT,

Luteolin promotes apoptotic cell death via upregulation of Nrf2 expression by DNA demethylase and the interaction of Nrf2 with p53 in human colon cancer cells

-

in-vitro,

Colon,

HT29

30 μM

-

in-vitro,

CRC,

SNU-407

30 μM

-

in-vitro,

Nor,

FHC

65 μM

DNMTs↓, TET1↑, NRF2↑, HDAC↓, tumCV↓, BAX↑, Casp9↑, Casp3↑, Bcl-2↓, ROS↓, GSS↑, Catalase↑, HO-1↑, DNMT1↓, DNMT3A↓, TET1↑, TET3↑, TET2↓, P53↑, P21↑,

2916-

LT,

Antioxidative and Anticancer Potential of Luteolin: A Comprehensive Approach Against Wide Range of Human Malignancies

-

Review,

Var,

NA

-

Review,

AD,

NA

-

Review,

Park,

NA

proCasp9↓, CDC2↓, CycB↓, Casp9↑, Casp3↑, Cyt‑c↑, cycA1↑, CDK2↓, APAF1↑, TumCCA↑, P53↑, BAX↑, VEGF↓, Bcl-2↓, Apoptosis↑, p‑Akt↓, p‑EGFR↓, p‑ERK↓, p‑STAT3↓, cardioP↑, Catalase↓, SOD↓, *BioAv↓, *antiOx↓, *ROS↓, *NO↓, *GSTs↑, *GSR↑, *SOD↑, *Catalase↑, *lipid-P↓, PI3K↓, Akt↓, CDK2↓, BNIP3↑, hTERT↓, DR5↑, Beclin-1↑, TNF-α↓, NF-kB↓, IL1↓, IL6↓, EMT↓, FAK↓, E-cadherin↑, MDM2↓, NOTCH↓, MAPK↑, Vim↓, N-cadherin↓, Snail↓, MMP2↓, Twist↓, MMP9↓, ROS↑, MMP↓, *AChE↓, *MMP↑, *Aβ↓, *neuroP↑, Trx1↑, ROS↓, *NRF2↑, NRF2↓, *BBB↑, ChemoSen↑, GutMicro↑,

2917-

LT,

Rad,

Luteolin acts as a radiosensitizer in non‑small cell lung cancer cells by enhancing apoptotic cell death through activation of a p38/ROS/caspase cascade

-

in-vitro,

Lung,

NA

Bcl-2↓, Casp3↑, Casp8↑, Casp9↑, p‑p38↑, ROS↑, RadioS↑,

2918-

LT,

Luteolin inhibits melanoma growth in vitro and in vivo via regulating ECM and oncogenic pathways but not ROS

-

in-vitro,

Melanoma,

A375

-

in-vivo,

Melanoma,

NA

-

in-vitro,

Melanoma,

SK-MEL-28

TumCG↓, ROS↑, ECM/TCF↓,

2919-

LT,

Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence

-

Review,

Var,

NA

RadioS↑, ChemoSen↑, chemoP↑, *lipid-P↓, *Catalase↑, *SOD↑, *GPx↑, *GSTs↑, *GSH↑, *TNF-α↓, *IL1β↓, *Casp3↓, *IL10↑, NRF2↓, HO-1↓, NQO1↓, GSH↓, MET↓, p‑MET↓, p‑Akt↓, HGF/c-Met↓, NF-kB↓, Bcl-2↓, SOD2↓, Casp8↑, Casp3↑, PARP↑, MAPK↓, NLRP3↓, ASC↓, Casp1↓, IL6↓, IKKα↓, p‑p65↓, p‑p38↑, MMP2↓, ICAM-1↓, EGFR↑, p‑PI3K↓, E-cadherin↓, ZO-1↑, N-cadherin↓, CLDN1↓, β-catenin/ZEB1↓, Snail↓, Vim↑, ITGB1↓, FAK↓, p‑Src↓, Rac1↓, Cdc42↓, Rho↓, PCNA↓, Tyro3↓, AXL↓, CEA↓, NSE↓, SOD↓, Catalase↓, GPx↓, GSR↓, GSTs↓, GSH↓, VitE↓, VitC↓, CYP1A1↓, cFos↑, AR↓, AIF↑, p‑STAT6↓, p‑MDM2↓, NOTCH1↓, VEGF↓, H3↓, H4↓, HDAC↓, SIRT1↓, ROS↑, DR5↑, Cyt‑c↑, p‑JNK↑, PTEN↓, mTOR↓, CD34↓, FasL↑, Fas↑, XIAP↓, p‑eIF2α↑, CHOP↑, LC3II↑, PD-1↓, STAT3↓, IL2↑, EMT↓, cachexia↓, BioAv↑, *Half-Life↝, *eff↑,

2920-

LT,

Formulation, characterization, in vitro and in vivo evaluations of self-nanoemulsifying drug delivery system of luteolin

-

in-vitro,

Nor,

NA

-

in-vivo,

Nor,

NA

BioAv↑, eff↑,

2921-

LT,

Luteolin as a potential hepatoprotective drug: Molecular mechanisms and treatment strategies

-

Review,

Nor,

NA

*hepatoP↑, *AMPK↑, *SIRT1↑, *ROS↑, STAT3↓, TNF-α↓, NF-kB↓, *IL2↓, *IFN-γ↓, *GSH↑, *SREBP1↓, *ZO-1↑, *TLR4↓, BAX↑, Bcl-2↓, XIAP↓, Fas↑, Casp8↑, Beclin-1↑, *TXNIP↓, *Casp1↓, *IL1β↓, *IL18↓, *NLRP3↓, *MDA↓, *SOD↑, *NRF2↑, *ER Stress↓, *ALAT↓, *AST↓, *iNOS↓, *IL6↓, *HO-1↑, *NQO1↑, *PPARα↑, *ATF4↓, *CHOP↓, *Inflam↓, *antiOx↑, *GutMicro↑,

2922-

LT,

Combination of transcriptomic and proteomic approaches helps unravel the mechanisms of luteolin in inducing liver cancer cell death via targeting AKT1 and SRC

-

in-vitro,

Liver,

HUH7

12.68 µM

Half-Life↝, TumCCA↑, AKT1↓, ATF2↓, NF-kB↓, GSK‐3β↓, cMyc↓, GSTs↓, TrxR1↓, ROS↑,

2923-

LT,

Luteolin induces apoptosis through endoplasmic reticulum stress and mitochondrial dysfunction in Neuro-2a mouse neuroblastoma cells

-

in-vitro,

NA,

NA

Apoptosis↑, TumCD↑, Casp12↑, Casp9↑, Casp3↑, ER Stress↑, CHOP↑, GRP78/BiP↑, GRP94↑, cl‑ATF6↑, p‑eIF2α↑, MMP↓, JNK↓, p38↑, ERK↑, Cyt‑c↑,

2924-

LT,

Luteolin selectively kills STAT3 highly activated gastric cancer cells through enhancing the binding of STAT3 to SHP-1

-

in-vitro,

GC,

NA

-

in-vivo,

NA,

NA

p‑STAT3↓, STAT3↓, Mcl-1↓, survivin↓, Bcl-xL↓, HSP90↓,

2925-

LT,

Luteolin Induces Carcinoma Cell Apoptosis through Binding Hsp90 to Suppress Constitutive Activation of STAT3

-

in-vitro,

Cerv,

HeLa

-

in-vitro,

Nor,

HEK293

-

in-vitro,

BC,

MCF-7

HSP90↓, p‑STAT3↓, Apoptosis↑, selectivity↑,

2926-

LT,

Luteolin ameliorates rat myocardial ischemia-reperfusion injury through peroxiredoxin II activation: LUT's cardioprotection through PRX II

-

in-vitro,

Nor,

H9c2

*cardioP↑, *PrxII↑,

2927-

LT,

Luteolin Causes 5′CpG Demethylation of the Promoters of TSGs and Modulates the Aberrant Histone Modifications, Restoring the Expression of TSGs in Human Cancer Cells

-

in-vitro,

Cerv,

HeLa

5, 10, and 20 µM of luteolin for 48 h

TumCMig↓, DNMTs↓, HDAC↓, HATs↓, ac‑H3↓, ac‑H4↓, MMP2↓, MMP9↓, HO-1↓, E-cadherin↑, EZH2↓, HER2/EBBR2↓, IL18↓, IL8↓, IL2↓,

2928-

LT,

Luteolin-mediated increase in miR-26a inhibits prostate cancer cell growth and induces cell cycle arrest targeting EZH2

EZH2↓, cycD1↓, cycE↓, CDK4↓, CDK6↓,

2929-

LT,

Loss of BRCA1 in the cells of origin of ovarian cancer induces glycolysis: A window of opportunity for ovarian cancer chemoprevention

-

in-vitro,

Ovarian,

NA

HK2↓, Myc↓, Glycolysis↓,

2930-

LT,

Luteolin confers renoprotection against ischemia–reperfusion injury via involving Nrf2 pathway and regulating miR320

-

in-vitro,

Nor,

NA

rats

*RenoP↑, *ROS↓, *antiOx↑, *NRF2↓,

2913-

LT,

Luteolin induces apoptosis by impairing mitochondrial function and targeting the intrinsic apoptosis pathway in gastric cancer cells

-

in-vitro,

GC,

HGC27

0, 10, 20, 30, 40, 50, 60, 70, and 80 µM) for 24 h or 48 h

-

in-vitro,

BC,

MCF-7

-

in-vitro,

GC,

MKN45

TumCP↓, MMP↓, Apoptosis↑, ROS↑, SOD↓, ATP↓, Bax:Bcl2↑, TumCCA↑,

2914-

LT,

Therapeutic Potential of Luteolin on Cancer

-

Review,

Var,

NA

3–50 µM in vitro

*antiOx↑, *IronCh↑, *toxicity↓, *BioAv↓, *BioAv↑, DNAdam↑, TumCP↓, DR5↑, P53↑, JNK↑, BAX↑, cl‑Casp3↑, cl‑Casp8↑, cl‑Casp9↑, cl‑PARP↑, survivin↓, cycD1↓, CycB↓, CDC2↓, P21↑, angioG↓, MMP2↓, AEG1↓, VEGF↓, VEGFR2↓, MMP9↓, CXCR4↓, PI3K↓, Akt↓, ERK↓, TumAuto↑, LC3B-II↑, EMT↓, E-cadherin↑, N-cadherin↓, Wnt↓, ROS↑, NICD↓, p‑GSK‐3β↓, iNOS↓, COX2↓, NRF2↑, Ca+2↑, ChemoSen↑, ChemoSen↓, IFN-γ↓, RadioS↑, MDM2↓, NOTCH1↓, AR↓, TIMP1↑, TIMP2↑, ER Stress↑, CDK2↓, Telomerase↓, p‑NF-kB↑, p‑cMyc↑, hTERT↓, RAS↓, YAP/TEAD↓, TAZ↓, NF-kB↓, NRF2↓, HO-1↓, MDR1↓,

2903-

LT,

Luteolin induces apoptosis by ROS/ER stress and mitochondrial dysfunction in gliomablastoma

-

in-vitro,

GBM,

U251

-

in-vitro,

GBM,

U87MG

-

in-vivo,

NA,

NA

mouse

ER Stress↑, ROS↑, PERK↑, eIF2α↑, ATF4↑, CHOP↑, Casp12↑, eff↓, UPR↑, MMP↓, Cyt‑c↑, Bcl-2↓, BAX↑, TumCG↓, Weight∅, ALAT∅, AST∅,

2904-

LT,

Luteolin from Purple Perilla mitigates ROS insult particularly in primary neurons

-

in-vitro,

Park,

SK-N-SH

-

in-vitro,

AD,

NA

*ROS↓, *neuroP↑, *MMP↑, *Catalase↑, *GSH↑, selectivity↑, *eff↑, *Cyt‑c↓,

2905-

LT,

Luteolin blocks the ROS/PI3K/AKT pathway to inhibit mesothelial-mesenchymal transition and reduce abdominal adhesions

-

in-vivo,

NA,

HMrSV5

C57/BL6 mice were used in vivo experiments

*ROS↓, *p‑Akt↓, *Vim↓, *E-cadherin↑, *PI3K↓,

2906-

LT,

Luteolin, a flavonoid with potentials for cancer prevention and therapy

-

Review,

Var,

NA

*Inflam↓, AntiCan↑, antiOx⇅, Apoptosis↑, TumCP↓, TumMeta↓, angioG↓, PI3K↓, Akt↓, NF-kB↓, XIAP↓, P53↑, *ROS↓, *GSTA1↑, *GSR↑, *SOD↑, *Catalase↑, *other↓, ROS↑, Dose↝, chemoP↑, NF-kB↓, JNK↑, p27↑, P21↑, DR5↑, Casp↑, Fas↑, BAX↑, MAPK↓, CDK2↓, IGF-1↓, PDGF↓, EGFR↓, PKCδ↓, TOP1↓, TOP2↓, Bcl-xL↓, FASN↓, VEGF↓, VEGFR2↓, MMP9↓, Hif1a↓, FAK↓, MMP1↓, Twist↓, ERK↓, P450↓, CYP1A1↓, CYP1A2↓, TumCCA↑,

2907-

LT,

Protective effect of luteolin against oxidative stress‑mediated cell injury via enhancing antioxidant systems

-

in-vitro,

Nor,

NA

Chinese hamster lung fibroblasts (V79-4)

*ROS↓, *Casp9↓, *Casp3↓, *Bcl-2↑, *BAX↓, *GSH↑, *SOD↑, *Catalase↑, *GPx↑, *HO-1↑, *antiOx↑, *lipid-P↓, *p‑γH2AX↓, eff↑,

2908-

LT,

Luteolin attenuates neutrophilic oxidative stress and inflammatory arthritis by inhibiting Raf1 activity

-

in-vitro,

Arthritis,

NA

*ROS↓, *p‑ERK↓, *p‑MEK↓, *Raf↓,

2909-

LT,

Revisiting luteolin: An updated review on its anticancer potential

-

Review,

Var,

NA

Apoptosis↑, TumCCA↑, angioG↓, TumMeta↓, TumCP↓, chemoP↑, MDR1↓,

2910-

LT,

FA,

Folic acid-modified ROS-responsive nanoparticles encapsulating luteolin for targeted breast cancer treatment

-

in-vitro,

BC,

4T1

-

in-vivo,

NA,

NA

mice

BioAv↓, BioAv↑, eff↑, tumCV↓, e-H2O2↓, i-H2O2∅,

2911-

LT,

Luteolin targets MKK4 to attenuate particulate matter-induced MMP-1 and inflammation in human keratinocytes

-

in-vitro,

Nor,

HaCaT

*MMP1↓, *COX2↓, *IL6↓, *AP-1↓, *NF-kB↓, *ROS↓, *p‑MKK4↑, *p‑JNK↓, *p‑p38↓,

2912-

LT,

Luteolin: a flavonoid with a multifaceted anticancer potential

-

Review,

Var,

NA

ROS↑, TumCCA↑, TumCP↓, angioG↓, ER Stress↑, mtDam↑, PERK↑, ATF4↑, eIF2α↑, cl‑Casp12↑, EMT↓, E-cadherin↑, N-cadherin↓, Vim↓, *neuroP↑, NF-kB↓, PI3K↓, Akt↑, XIAP↓, MMP↓, Ca+2↑, BAX↑, Casp3↑, Casp9↑, Bcl-2↓, Cyt‑c↑, IronCh↑, SOD↓, *ROS↓, *LDHA↑, *SOD↑, *GSH↑, *BioAv↓, Telomerase↓, cMyc↓, hTERT↓, DR5↑, Fas↑, FADD↑, BAD↑, BOK↑, BID↑, NAIP↓, Mcl-1↓, CDK2↓, CDK4↓, MAPK↓, AKT1↓, Akt2↓, *Beclin-1↓, Hif1a↓, LC3II↑, Beclin-1↑,

2595-

LT,

Regulation of Nrf2/ARE Pathway by Dietary Flavonoids: A Friend or Foe for Cancer Management?

-

Review,

Var,

NA

*NRF2↑, NRF2↓, NRF2⇅,

2589-

LT,

Chemo,

Luteolin Inhibits Breast Cancer Stemness and Enhances Chemosensitivity through the Nrf2-Mediated Pathway

-

in-vitro,

BC,

MDA-MB-231

1 to 2 μM) of luteolin for 48 h

NRF2↓, HO-1↓, ChemoSen↑, CSCs↓, SIRT1↓,

2588-

LT,

Chemo,

Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway

-

in-vitro,

CRC,

HCT116

NRF2↓, NQO1↓, HO-1↓, GSH↓, ChemoSen↑,

2587-

LT,

Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs

-

in-vitro,

Lung,

A549

1-20uM

NRF2↓, GSH↓, ChemoSen↑, HO-1↓,

1275-

LT,

Mechanism of luteolin induces ferroptosis in nasopharyngeal carcinoma cells

-

in-vitro,

Laryn,

NA

Ferroptosis↑, MDA↑, Iron↑, SOD↓, GSH↓, GPx4↓, SOX4↓, GDF15↓,

1317-

LT,

Luteolin Suppresses Teratoma Cell Growth and Induces Cell Apoptosis via Inhibiting Bcl-2

-

vitro+vivo,

Ovarian,

PA1

10uM

Bcl-2↓, BAX↑, Apoptosis↑, TumCG↓,

1534-

LT,

Api,

EGCG,

RES,

Plant polyphenol induced cell death in human cancer cells involves mobilization of intracellular copper ions and reactive oxygen species generation: a mechanism for cancer chemopreventive action

-

in-vitro,

Nor,

MCF10

-

in-vitro,

BC,

MDA-MB-231

-

in-vitro,

BC,

MDA-MB-468

-

in-vitro,

PC,

Bxpc-3

TumCP↓, Apoptosis↑, eff↓, *toxicity↑, Dose?, eff↓, eff↓,

1721-

Lyco,

RES,

VitC,

Lycopene, resveratrol, vitamin C and FeSO4 increase damage produced by pro-oxidant carcinogen 4-nitroquinoline-1-oxide in Drosophila melanogaster: Xenobiotic metabolism implications.

-

in-vitro,

Pca,

PC3

-

in-vitro,

Lung,

A549

-

in-vitro,

Cerv,

HeLa

-

in-vitro,

BC,

MCF-7

-

in-vitro,

Liver,

HepG2

ROS↑,

1720-

Lyco,

Antioxidant and Pro-oxidant Activities of Carotenoids

-

Review,

Nor,

NA

ROS↑,

1719-

Lyco,

Lycopene for the prevention and treatment of prostate disease.

-

Review,

Var,

NA

ROS⇅,

1718-

Lyco,

The role of carotenoids in the prevention of human pathologies

-

Review,

Var,

NA

ROS⇅, ROS↑,

1717-

Lyco,

Potential Role of Carotenoids as Antioxidants in Human Health and Disease

-

Review,

Var,

NA

antiOx↑, ROS⇅, ROS↑,

1716-

Lyco,

Anti-inflammatory Activity of β-Carotene, Lycopene and Tri-n-butylborane, a Scavenger of Reactive Oxygen Species

-

in-vitro,

AML,

RAW264.7

antiOx↑, lipid-P↓, ROS↑, Dose↑,

1715-

Lyco,

Pro-oxidant Actions of Carotenoids in Triggering Apoptosis of Cancer Cells: A Review of Emerging Evidence

-

Review,

Var,

NA

antiOx↑, ROS↑, ChemoSen↑, selectivity↑, eff↓, Casp3↑, Casp7↑, Casp9↑, P53↑, BAX↑, DNAdam↑, mtDam↑, eff↑,

1714-

Lyco,

Lycopene reduces ovarian tumor growth and intraperitoneal metastatic load

-

in-vitro,

Ovarian,

OV-MZ-6

-

in-vivo,

NA,

NA

mice

ChemoSen↑, CA125↓, ITGA5↓, ITGB1↓, MMP9↓, FAK↓, EMT↓, MAPK↓, MMP9↓, antiOx↑, Ki-67↓, MAPK↓,

1713-

Lyco,

Lycopene: A Potent Antioxidant with Multiple Health Benefits

-

Review,

Nor,

NA

*antiOx↑, *ROS⇅, *Dose↝, *eff↑, *LDL↓, *RenoP↑, *Inflam↓, neuroP↑, Rho↓,

1712-

Lyco,

Lycopene Protects against Smoking-Induced Lung Cancer by Inducing Base Excision Repair

-

in-vitro,

Lung,

A549

ROS↓, ROS↑, eff↑,

1711-

Lyco,

Nutritional Importance of Carotenoids and Their Effect on Liver Health: A Review

-

Review,

Var,

NA

ROS↑, Dose↓, Dose↑, antiOx↑, P450↓, TNF-α↓, IL1β↓, IL12↓,

1710-

Lyco,

Lycopene: A Natural Arsenal in the War against Oxidative Stress and Cardiovascular Diseases

-

Review,

CardioV,

NA

antiOx↓, ROS↓, BP↓, LDL↓, *toxicity∅, eff↑, ROS↑, *Half-Life↑, *BioAv↓, *BioAv↑, *antiOx↑,

1709-

Lyco,

Lycopene prevents carcinogen-induced cutaneous tumor by enhancing activation of the Nrf2 pathway through p62-triggered autophagic Keap1 degradation

-

in-vitro,

Nor,

JB6

mouse cell line

*antiOx↑, *NRF2↑, *GSH/GSSG↓, *Catalase↝, *GR↝, *SOD↝, *GPx↝, *GSH↑, *Keap1↓, *p62↑,

1708-

Lyco,

The Anti-Cancer Activity of Lycopene: A Systematic Review of Human and Animal Studies

-

Review,

Var,

NA

OS↑, ChemoSen↑, QoL↑, PSA∅, eff↑, AntiCan↑, AntiCan↑, angioG↓, VEGF↓, Hif1a↓, SOD↑, Catalase↑, GPx↑, GSH↑, GPx↑, GR↑, MDA↓, NRF2↑, HO-1↑, COX2↓, PGE2↓, NF-kB↓, IL4↑, IL10↑, IL6↓, TNF-α↓, PPARγ↑, TumCCA↑, FOXO3↓, Casp3↑, IGF-1↓, p27↑, STAT3↓, CDK2↓, CDK4↓, P21↑, PCNA↓, MMP7↓, MMP9↓,

1013-

Lyco,

Lycopene induces apoptosis by inhibiting nuclear translocation of β-catenin in gastric cancer cells

-

in-vitro,

GC,

AGS

Apoptosis↑, DNAdam↑, Bax:Bcl2↑, ROS↓, β-catenin/ZEB1↓, p‑GSK‐3β↓, APC↑, β-TRCP↑, cMyc↓, cycD1↓,

1041-

Lyco,

immuno,

Lycopene improves the efficiency of anti-PD-1 therapy via activating IFN signaling of lung cancer cells

-

in-vivo,

Lung,

NA

mice

TumVol↓, TumW↓, eff↑, IL1↑, IFN-γ↑, IL4↓, IL10↓,

1126-

Lyco,

Lycopene Inhibits Epithelial–Mesenchymal Transition and Promotes Apoptosis in Oral Cancer via PI3K/AKT/m-TOR Signal Pathway

-

vitro+vivo,

Oral,

NA

TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, EMT↓, PI3K↓, Akt↓, mTOR↓, E-cadherin↓, BAX↑, N-cadherin↓, p‑PI3K↓, p‑Akt↓, p‑mTOR↓, Bcl-2↓,

3533-

Lyco,

Chemo,

Lycopene and chemotherapy toxicity

-

Review,

Var,

NA

*ROS↓, *antiOx↑, *chemoP↑, *Inflam↓,

3528-

Lyco,

The Importance of Antioxidant Activity for the Health-Promoting Effect of Lycopene

-

Review,

Nor,

NA

-

Review,

AD,

NA

-

Review,

Park,

NA

*antiOx↑, *ROS↓, *BioAv↝, *Half-Life↑, *BioAv↓, *BioAv↑, *cardioP↑, *neuroP↑, *H2O2↓, *VitC↑, *VitE↑, *GPx↑, *GSH↑, *MPO↓, *GSTs↓, *SOD↑, *NF-kB↓, *IL1β↓, *IL6↓, *IL10↑, *MAPK↓, *Akt↓, *COX2↓, *TNF-α↓, *TGF-β1↑, *NO↓, *GSR↑, *NRF2↑, *HO-1↑, *TAC↑, *Inflam↓, *BBB↑, *neuroP↑, *memory↑,

3529-

Lyco,

The antioxidant and anti-inflammatory properties of lycopene in mice lungs exposed to cigarette smoke

-

in-vivo,

Nor,

NA

mice

*antiOx↑, *Inflam↓, *ROS↓, *TNF-α↓, *IFN-γ↓, IL10↓,

3530-

Lyco,

Lycopene Scavenges Cellular ROS, Modulates Autophagy and Improves Survival through 7SK snRNA Interaction in Smooth Muscle Cells

-

in-vitro,

Stroke,

NA

*ROS↓, *antiOx↑, *TNF-α↓,

3531-

Lyco,

Lycopene attenuates the inflammation and apoptosis in aristolochic acid nephropathy by targeting the Nrf2 antioxidant system

-

in-vivo,

Nor,

NA

rats

*NRF2↑, *HO-1↑, *NQO1↑, *ROS↓, *mtDam↓, *Bcl-2↑, *BAX↓, *Casp9↓, *Casp3↓, *Apoptosis↓, *RenoP↑, *lipid-P↓, *SOD↑, *GPx↑, *Inflam↓, *TNF-α↓, *IL6↓, *IL10↓,

3532-

Lyco,

Lycopene alleviates oxidative stress via the PI3K/Akt/Nrf2pathway in a cell model of Alzheimer’s disease

-

in-vitro,

AD,

NA

Chinese hamster ovary (CHO) cell line

*ROS↓, *PI3K↑, *Akt↑, *NRF2↑, *antiOx↑, *Aβ↓, *Apoptosis↓, *neuroP↑,

3277-

Lyco,

Recent trends and advances in the epidemiology, synergism, and delivery system of lycopene as an anti-cancer agent

-

Review,

Var,

NA

antiOx↑, TumCP↓, Apoptosis↑, TumMeta↑, ChemoSen↑, BioAv↓, Dose↝, BioAv↓, BioAv↑, SOD↑, Catalase↑, GPx↑, IL2↑, IL4↑, IL1↑, TNF-α↑, GSH↑, GPx↑, GSTA1↑, GSR↑, PPARγ↑, Casp3↑, NF-kB↓, COX2↓, Bcl-2↑, BAX↓, P53↓, CHK1↓, Chk2↓, γH2AX↓, DNAdam↓, ROS↓, P21↑, PCNA↓, β-catenin/ZEB1↓, PGE2↓, ERK↓, cMyc↓, cycE↓, JAK1↓, STAT3↓, SIRT1↑, cl‑PARP↑, cycD1↓, TNF-α↓, IL6↓, p65↓, MMP2↓, MMP9↓, Wnt↓,

3260-

Lyco,

Lycopene in human health

-

Review,

NA,

NA

*BioAv↝, *BioAv↓, *ROS⇅, *BioAv↝,

3278-

Lyco,

Anti-inflammatory effect of lycopene in SW480 human colorectal cancer cells

-

in-vitro,

Colon,

SW480

(0–30 µM) for 0, 24, 48, and 96 h

TNF-α↓, IL1β↓, IL6↓, iNOS↓, COX2↓, PGE2↓, NO↓, NF-kB↓, JNK↓, Inflam↓, MPO↓,

3279-

Lyco,

The role of lycopene and its derivatives in the regulation of transcription systems: implications for cancer prevention

-

Review,

Var,

NA

chemoP↑,

3280-

Lyco,

Lycopene as A Carotenoid Provides Radioprotectant and Antioxidant Effects by Quenching Radiation-Induced Free Radical Singlet Oxygen: An Overview

-

Review,

Var,

NA

*radioP↑, *antiOx↑, *lipid-P↓,

3281-

Lyco,

Chemo,

Lycopene Supplementation for Patients Under Cancer Therapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

-

Review,

Var,

NA

eff↑, cardioP↑, eff?, PSA↓, RenoP↑,

3285-

Lyco,

Comparative evaluation of antiplatelet effect of lycopene with aspirin and the effect of their combination on platelet aggregation: An in vitro study

-

in-vitro,

Nor,

NA

*AntiAg↑, *eff↑,

3286-

Lyco,

Inhibitory effects of lycopene on in vitro platelet activation and in vivo prevention of thrombus formation

-

in-vitro,

Nor,

NA

*AntiAg↑,

3287-

Lyco,

Recent technological strategies for enhancing the stability of lycopene in processing and production

-

Review,

NA,

NA

*eff↑,

3276-

Lyco,

Lycopene modulates cellular proliferation, glycolysis and hepatic ultrastructure during hepatocellular carcinoma

-

in-vivo,

HCC,

NA

Female BALB/c mice

G6PD↓, PCNA↓, cycD1↓, P21↑, Hif1a↓, Glycolysis↓,

3275-

Lyco,

Multifaceted Effects of Lycopene: A Boulevard to the Multitarget-Based Treatment for Cancer

-

Review,

Var,

NA

TumCCA↑, cycD1↓, cycE↓, CDK2↓, CDK4↓, P21↑, P53↑, GSK‐3β↓, p27↓, Akt↓, mTOR↓, ROS↓, MMPs↓, TumCI↓, TumCMig↓, NF-kB↓, *iNOS↓, *COX2↓, lipid-P↓, GSH↑, NRF2↑,

3274-

Lyco,

Lycopene enhances the sensitivity of castration-resistant prostate cancer to enzalutamide through the AKT/EZH2/ androgen receptor signaling pathway

-

in-vitro,

Pca,

22Rv1

-

in-vitro,

Pca,

C4-2B

Akt↓, EZH2↓,

3273-

Lyco,

Lycopene

-

Review,

Var,

NA

antiOx↑, ChemoSen↓, RadioS↓,

3268-

Lyco,

Lycopene as a Natural Antioxidant Used to Prevent Human Health Disorders

-

Review,

AD,

NA

*BioAv↓, *AntiCan↑, *ROCK1↓, *Ki-67↓, *ICAM-1↓, *cardioP↑, *antiOx↑, *NQO1↑, *HO-1↑, *TNF-α↓, *IL22↓, *NRF2↑, *NF-kB↓, *MDA↓, *Catalase↑, *SOD↑, *GSH↑, *cognitive↑, *tau↓, *hepatoP↑, *MMP2↑, *AST↓, *ALAT↓, *P450↑, *DNAdam↓, *ROS↓, *neuroP↑, *memory↑, *Ca+2↓, *Dose↝, *Dose↑, *Dose↝, *toxicity∅, PGE2↓, CDK2↓, CDK4↓, STAT3↓, NOX↓, NOX4↓, ROS↓, *SREBP1↓, *FASN↓, *ACC↓,

3267-

Lyco,

Lycopene inhibits angiogenesis both in vitro and in vivo by inhibiting MMP-2/uPA system through VEGFR2-mediated PI3K-Akt and ERK/p38 signaling pathways

-

in-vitro,

Nor,

HUVECs

*VEGF↓, *MMP2↓, *uPA↓, *Rac1↑, *TIMP2↑, *p38↓, *Akt↓, *angioG↓,

3266-

Lyco,

Effects of lycopene on number and function of human peripheral blood endothelial progenitor cells cultivated with high glucose

-

in-vitro,

Nor,

NA

10, 30, and 50 µg/mL

peripheral blood endothelial progenitor cells cultivated with high glucose

*p38↓, *MAPK↓,

3265-

Lyco,

Lycopene inhibits pyroptosis of endothelial progenitor cells induced by ox-LDL through the AMPK/mTOR/NLRP3 pathway

-

in-vitro,

Nor,

NA

*AMPK↑, *mTOR↓, *NLRP3↓, *Pyro↓,

3264-

Lyco,

Pharmacological potentials of lycopene against aging and aging‐related disorders: A review

-

Review,

Var,

NA

-

Review,

AD,

NA

-

Review,

Stroke,

NA

*antiOx↑, *ROS↓, *SOD↑, *Catalase↑, *GSH↑, *GSTs↑, *MDA↓, *lipid-P↓, *NRF2↑, *HO-1↑, *iNOS↓, *NO↓, *TAC↑, *NOX4↓, *Inflam↓, *IL1↓, *IL6↓, *IL8↓, *IL1β↓, *TNF-α↓, *TLR2↓, *TLR4↓, *VCAM-1↓, *ICAM-1↓, *STAT3↓, *NF-kB↓, *ERK↓, *BP↓, ROS↓, PGE2↓, cardioP↑, *neuroP↑, *creat↓, *RenoP↑,

3263-

Lyco,

Lycopene protects against myocardial ischemia-reperfusion injury by inhibiting mitochondrial permeability transition pore opening

-

in-vitro,

Nor,

H9c2

-

in-vitro,

Stroke,

NA

*Apoptosis↓, *MMP↑, *Cyt‑c↓, *APAF1↓, *cl‑Casp9↓, *cl‑Casp3↓, *Bcl-2↑, *BAX↓, cardioP↑,

3262-

Lyco,

Lycopene inhibits matrix metalloproteinase-9 expression and down-regulates the binding activity of nuclear factor-kappa B and stimulatory protein-1

-

in-vitro,

adrenal,

SK-HEP-1

TumCI↓, MMP9↓, NF-kB↓, Sp1/3/4↓, IGF-1R↓, i-ROS↓,

3261-

Lyco,

Lycopene and Vascular Health

-

Review,

Stroke,

NA

endothelial cells

*Inflam↓, *antiOx↑, *AntiAg↑, *cardioP↑, *SOD↑, *Catalase↑, *ROS↓, *mtDam↓, *cardioP↑, *NF-kB↓, *NO↓, *COX2↓, *LDL↓, *eff↑, *ER Stress↓, *BioAv↑, *eff↑, *MMPs↓, *COX2↓, *RAGE↓,

2547-

M-Blu,

SDT,

The effect of dual-frequency ultrasound waves on B16F10 melanoma cells: Sonodynamic therapy using nanoliposomes containing methylene blue

-

in-vitro,

Melanoma,

B16-BL6

tumCV↓, ROS↑, mtDam↑,

2542-

M-Blu,

In Vitro Methylene Blue and Carboplatin Combination Triggers Ovarian Cancer Cells Death

-

in-vitro,

Ovarian,

OV1369

-

in-vitro,

Ovarian,

OV1946

-

in-vitro,

Nor,

ARPE-19

BioAv↝, TumCP↓, GlutaM↓, Warburg↓, OCR↑, Glycolysis↓, ATP↓, BioAv↝, ROS↑,

2543-

M-Blu,

The use of methylene blue to control the tumor oxygenation level

-

in-vivo,

Lung,

NA

mouse Lewis lung carcinoma (LLC) model

OCR↑, OXPHOS↑, Half-Life↝, AntiTum↑,

2544-

M-Blu,

Methylene blue and its importance in medicine

-

Review,

NA,

NA

*ROS↓, antiOx↑, BBB↑, neuroP↑, GSR↓, tau↓,

2545-

M-Blu,

Reversing the Warburg Effect as a Treatment for Glioblastoma

-

in-vitro,

GBM,

U87MG

1-10uM

-

NA,

AD,

NA

-

in-vitro,

GBM,

A172

-

in-vitro,

GBM,

T98G

Warburg↓, OCR↑, lactateProd↓, TumCP↓, TumCCA↑, AMPK↑, ACC↓, Cyc↓, neuroP↑, Cyt‑c↝, Glycolysis↓, ECAR↓, TumCG↓, other↓,

2541-

M-Blu,

Spectroscopic Study of Methylene Blue Interaction with Coenzymes and its Effect on Tumor Metabolism

-

in-vivo,

Var,

NA

mice model of Ehrlich carcinoma

TumCG↓, Glycolysis↓, OXPHOS↑, ROS↑, OCR↑, GlucoseCon↑, lactateProd↓,

2546-

M-Blu,

SDT,

The sonodynamic antitumor effect of methylene blue on sarcoma180 cells in vitro

-

in-vitro,

sarcoma,

S180

1,10,100uM 0.24 W/cm(2) for 30 seconds

TumCD↑,

2540-

M-Blu,

Alternative mitochondrial electron transfer for the treatment of neurodegenerative diseases and cancers: Methylene blue connects the dots

-

Review,

Var,

NA

-

Review,

AD,

NA

*OCR↑, *Glycolysis↓, *GlucoseCon↑, neuroP↑, Warburg↓, mt-OXPHOS↑, TumCCA↑, TumCP↓, ROS⇅, *cognitive↑, *mTOR↓, *mt-antiOx↑, *memory↑, *BBB↑, *eff↝, *ECAR↓, eff↑, lactateProd↓, NADPH↓, OXPHOS↑, AMPK↑, selectivity↑,

2535-

M-Blu,

SDT,

Apoptosis of ovarian cancer cells induced by methylene blue-mediated sonodynamic action

-

in-vitro,

Ovarian,

HO-8910

tumCV↓, ROS↑,

2534-

M-Blu,

doxoR,

PDT,

Methylene Blue-Mediated Photodynamic Therapy in Combination With Doxorubicin: A Novel Approach in the Treatment of HT-29 Colon Cancer Cells

-

in-vitro,

CRC,

HT-29

LDH↑, ROS↑,

2533-

M-Blu,

PDT,

Methylene blue-mediated photodynamic therapy enhances apoptosis in lung cancer cells

-

in-vitro,

Lung,

A549

MMP↓, p‑MAPK↑, ROS↑, cl‑PARP↑, Bcl-2↓, Mcl-1↓, eff↓,

2532-

M-Blu,

PDT,

Methylene blue in anticancer photodynamic therapy: systematic review of preclinical studies

-

Review,

Var,

NA

AntiCan↑,

2531-

M-Blu,

Anticancer activity of methylene blue via inhibition of heat shock protein 70

-

in-vitro,

Lung,

A549

2.5uM

-

in-vivo,

NA,

NA

mice

tumCV↓, HSP70/HSPA5↓, LDH↓, SOD↑,

1314-

MAG,

Magnolol induces apoptosis via activation of both mitochondrial and death receptor pathways in A375-S2 cells

-

in-vitro,

Melanoma,

A375

TumCP↓, Casp3↑, Casp8↑, Casp9↑, Bcl-2↓, BAX↑,

1089-

MAG,

Magnolol potently suppressed lipopolysaccharide-induced iNOS and COX-2 expression via downregulating MAPK and NF-κB signaling pathways

-

in-vitro,

AML,

RAW264.7

p‑IκB↓, NF-kB↓, p‑ERK↓, p‑JNK↓, p‑PI3K↓, p‑Akt↓, iNOS↓, COX2↓,

1198-

MAG,

Mitochondria-targeted magnolol inhibits OXPHOS, proliferation, and tumor growth via modulation of energetics and autophagy in melanoma cells

-

in-vivo,

Melanoma,

NA

Mito-MGN potently inhibits (IC50 = =0.3 μM)

OXPHOS↓, TumCP↓,

1197-

MAG,

Magnolol as STAT3 inhibitor for treating multiple sclerosis by restricting Th17 cells

-

in-vivo,

MS,

NA

mice

Weight↑, Th17↓, STAT3↓,

1196-

MAG,

2-O-Methylmagnolol, a Magnolol Derivative, Suppresses Hepatocellular Carcinoma Progression via Inhibiting Class I Histone Deacetylase Expression

-

in-vitro,

HCC,

NA

TumCG↓, TumCMig↓, TumCI↓, TumCCA↑, HDAC↓,

972-

MAG,

Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells

-

vitro+vivo,

Bladder,

T24

angioG↓, VEGF↓, H2O2↓, Hif1a↓, VEGFR2↓, Akt↓, mTOR↓, P70S6K↓, 4E-BP1↓, TumCG↓, CD31↓, CA↓,

2450-

Matr,

The Promoting Role of HK II in Tumor Development and the Research Progress of Its Inhibitors

-

Review,

Var,

NA

HK2↓, eff↓,

2643-

MCT,

Medium Chain Triglycerides enhances exercise endurance through the increased mitochondrial biogenesis and metabolism

-

Review,

Nor,

NA

*Akt↑, *AMPK↓, *TGF-β↓, eff↑, *BioEnh↑, *ATP↑, *PGC-1α↑, *p‑mTOR↑, *SMAD3↓,

2644-

MCT,

The Effects of Medium-Chain Triglyceride Oil Supplementation on Endurance Performance and Substrate Utilization in Healthy Populations: A Systematic Review

-

Review,

Nor,

NA

*KeyT↑, *Dose↝, eff↑,

2500-

meben,

Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme

-

in-vitro,

GBM,

U87MG

0.1 to 0.3 µM

-

in-vivo,

GBM,

NA

Female C57BL/6 mice

α-tubulin↓, AntiCan↑, TumCG↓, OS↑, VEGF↓, Hif1a↓,

1898-

MeJa,

Methyl jasmonate and its potential in cancer therapy

-

Review,

Var,

NA

ROS↑, selectivity↑, toxicity↝,

1899-

MeJa,

Methyl jasmonate induces production of reactive oxygen species and alterations in mitochondrial dynamics that precede photosynthetic dysfunction and subsequent cell death

-

in-vitro,

NA,

NA

100 mM

Plants

ROS↑, MMP↓, eff↓, H2O2?,

1784-

MEL,

Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta-analysis of randomized trials

-

Review,

NA,

NA

Remission↑,

1783-

MEL,

The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials

-

Review,

Var,

NA

Dose∅, Remission↑, OS↑, radioP↑,

1785-

MEL,

Antitumoral melatonin-loaded nanostructured lipid carriers

-

in-vitro,

Var,

NA

selectivity↑, TumCD↑,

1786-

MEL,

What is known about melatonin, chemotherapy and altered gene expression in breast cancer (Review)

-

Review,

NA,

NA

AntiTum↑, Risk↓, ChemoSen↑,

1782-

MEL,

Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities

-

Review,

Var,

NA

AntiCan↑, Apoptosis↑, TumCP↓, TumCG↑, TumMeta↑, ChemoSideEff↓, radioP↑, ChemoSen↑, *ROS↓, *SOD↑, *GSH↑, *GPx↑, *Catalase↑, Dose∅, VEGF↓, eff↑, Hif1a↓, GLUT1↑, GLUT3↑, CAIX↑, P21↑, p27↑, PTEN↑, Warburg↓, PI3K↓, Akt↓, NF-kB↓, cycD1↓, CDK4↓, CycB↓, CDK4↓, MAPK↑, IGF-1R↓, STAT3↓, MMP9↓, MMP2↓, MMP13↓, E-cadherin↑, Vim↓, RANKL↓, JNK↑, Bcl-2↓, P53↑, Casp3↑, Casp9↑, BAX↑, DNArepair↑, COX2↓, IL6↓, IL8↓, NO↓, T-Cell↑, NK cell↑, Treg lymp↓, FOXP3↓, CD4+↑, TNF-α↑, Th1 response↑, BioAv↝, RadioS↑, OS↑,

1781-

MEL,

Melatonin in patients with cancer receiving chemotherapy: a randomized, double-blind, placebo-controlled trial

-

Trial,

Lung,

NA

QoL↑, OS∅, selectivity↑,

1780-

MEL,

Utilizing Melatonin to Alleviate Side Effects of Chemotherapy: A Potentially Good Partner for Treating Cancer with Ageing

-

Review,

Var,

NA

*antiOx↑, *toxicity↓, ChemoSen↑, *eff↑, *mitResp↑, *ATP↑, *ROS↓, *CardioT↓, *GSH↑, *NOS2↓, *lipid-P↓, eff↑, *HO-1↑, *NRF2↑, *NF-kB↑, TumCP↓, eff↑, neuroP↑,

1779-

MEL,

Therapeutic Potential of Melatonin Counteracting Chemotherapy-Induced Toxicity in Breast Cancer Patients: A Systematic Review

-

Review,

BC,

NA

QoL↑, OS↑, Dose∅, antiOx↑, ROS↑, SOD↑, Catalase↑, GPx↑, Risk↓, NK cell↑, IL1β↓, IL6↓, TNF-α↓, radioP↑, chemoP↑, TumVol↓, TumMeta↓, angioG↓, ChemoSen↑, eff↑,

1778-

MEL,

Melatonin: a well-documented antioxidant with conditional pro-oxidant actions

-

Review,

Var,

NA

-

Review,

AD,

NA

*ROS↓, *antiOx↓, ROS↑, selectivity↑, Dose↑, *mitResp↑, *ATP↑, *ROS↓, eff↑, ROS↑, Dose↑, *toxicity∅, ROS↑, eff↓, ROS↝, Dose↑, other↑,

1777-

MEL,

Melatonin as an antioxidant: under promises but over delivers

-

Review,

NA,

NA

*ROS↓, *Fenton↓, *antiOx↑, *toxicity∅, *GPx↑, *GSR↑, *GSH↑, *NO↓, *Iron↓, *Copper↓, *IL1β↓, *iNOS↓, *Casp3↓, *BBB↑, *RenoP↑, chemoP↑, *Ca+2↝, eff↑, *PKCδ?, ChemoSen↑, eff↑, Akt↓, DR5↑, selectivity↑, ROS↑, eff↑,

1776-

MEL,

Therapeutic strategies of melatonin in cancer patients: a systematic review and meta-analysis

-

Review,

NA,

NA

Remission↑, OS↑, neuroP↑, VEGF↓, KISS1↑, TumCP↓, ChemoSideEff↓, radioP↑, Dose∅, *ROS↓, DNArepair↑, ROS↑,

1775-

MEL,

Chemo,

Rad,

A Systematic Review of the Chemo/Radioprotective Effects of Melatonin against Ototoxic Adverse Effects Induced by Chemotherapy and Radiotherapy

-

Review,

Var,

NA

chemoP↑, radioP↑, antiOx↑, Inflam↑,

971-

MEL,

Melatonin down-regulates HIF-1 alpha expression through inhibition of protein translation in prostate cancer cells

-

in-vitro,

Pca,

DU145

-

in-vitro,

Pca,

PC3

-

in-vitro,

Pca,

LNCaP

Hif1a↓, VEGF↓, p‑p70S6↓,

995-

MEL,

Melatonin Treatment Triggers Metabolic and Intracellular pH Imbalance in Glioblastoma

-

vitro+vivo,

GBM,

NA

1.5 and 3.0 mM

five glioma tumor initiating cell lines (GBM1A [15], QNS120, GBM612, GBM965, and QNS108

LDHA↓, MCT4↓, lactateProd↓, i-pH↓, ROS↑, ATP↓, TumCD↑, TumCCA↑, PDH↓, Glycolysis↓, GlucoseCon↓, TumCG↓,

1063-

MEL,

HDAC1 inhibition by melatonin leads to suppression of lung adenocarcinoma cells via induction of oxidative stress and activation of apoptotic pathways

-

in-vitro,

Lung,

A549

-

in-vitro,

Lung,

PC9

AntiCan↑, TumCMig↓, GSH↓, Casp3↑, Apoptosis↑, ROS↑, HDAC1↓, Ac-histone H3↑, PUMA↑, BAX↑, PCNA↓, Bcl-2↓,

1042-

MEL,

Melatonin Downregulates PD-L1 Expression and Modulates Tumor Immunity in KRAS-Mutant Non-Small Cell Lung Cancer

-

in-vitro,

Lung,

A549

-

in-vitro,

Lung,

H460

-

in-vitro,

Lung,

LLC1

PD-L1↓, YAP/TEAD↓, TAZ↓, TumCG↓,

994-

MET,

Tumor metabolism destruction via metformin-based glycolysis inhibition and glucose oxidase-mediated glucose deprivation for enhanced cancer therapy

-

in-vitro,

Var,

NA

Glycolysis↓, HK2↓, ATP↓, AMPK↑, P53↑, Warburg↓, Apoptosis↑,

1066-

MET,

Metformin increases PDH and suppresses HIF-1α under hypoxic conditions and induces cell death in oral squamous cell carcinoma

-

in-vitro,

SCC,

NA

PDH↑, Hif1a↓, TumCMig↓, Casp3↑, P53∅,

970-

MET,

Metformin suppresses HIF-1α expression in cancer-associated fibroblasts to prevent tumor-stromal cross talk in breast cancer

CAFs/TAFs↝, p‑AMPK↑, PHDs↑, Hif1a↓, TumCI↓,

1043-

MET,

immuno,

Metformin reduces PD-L1 on tumor cells and enhances the anti-tumor immune response generated by vaccine immunotherapy

-

in-vitro,

NA,

NA

eff↑, PD-L1↓, Ki-67↑, TIM-3↑, L-sel↑,

1204-

MET,

Metformin induces ferroptosis through the Nrf2/HO-1 signaling in lung cancer

-

in-vitro,

Lung,

A549

-

in-vitro,

Lung,

H1299

MDA↑, ROS↑, Iron↑, GSH↓, T-SOD↓, Catalase↓, GPx4↓, xCT↓, NRF2↓, HO-1↓,

2457-

MET,

Metformin Impairs Glucose Consumption and Survival in Calu-1 Cells by Direct Inhibition of Hexokinase-II

-

in-vitro,

Lung,

Calu-1

0-10mM

HK1↓, HK2↓, GlucoseCon↓, MMP↓, ATP↓,

2456-

MET,

Direct inhibition of hexokinase activity by metformin at least partially impairs glucose metabolism and tumor growth in experimental breast cancer

-

in-vitro,

BC,

MDA-MB-231

-

in-vivo,

NA,

NA

GlucoseCon↓, TumCG↓, HK2↓, p‑AMPK↑, TXNIP↓, *toxicity↓,

2491-

MET,

Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase

-

in-vivo,

Nor,

NA

Rats

*glucoNG↓, *glucose↓, *mitResp↓,

2492-

MET,

The Metformin Mechanism on Gluconeogenesis and AMPK Activation: The Metabolite Perspective

-

Review,

Nor,

NA

*glucose↓, *glucoNG↓, *AMPK↑,

2493-

MET,

Metformin Inhibits Gluconeogenesis by a Redox-Dependent Mechanism In Vivo

-

in-vivo,

Nor,

NA

glucoNG↓, glucose↓,

2371-

MET,

The role of pyruvate kinase M2 in anticancer therapeutic treatments

-

Review,

Var,

NA

ChemoSen↑, PKM2↓, Hif1a↓, EMT↓,

2386-

MET,

Mechanisms of metformin inhibiting cancer invasion and migration

-

Review,

Var,

NA

OS↑, AMPK↑, EMT↓, TGF-β↓, mTOR↓, P70S6K↓, PKM2↓, Hif1a↓, ChemoSen↑,

2385-

MET,

Metformin activates chaperone-mediated autophagy and improves disease pathologies in an Alzheimer disease mouse model

-

in-vitro,

AD,

H4

-

in-vitro,

NA,

HEK293

-

in-vivo,

NA,

NA

APP/PS1 mice develop AD-like cognitive deficits

-

in-vitro,

NA,

SH-SY5Y

*HK2↓, *PKM2↓, *Dose↝, IKKα↑, memory↑, p‑Hsc70↑, APP↓,

2384-

MET,

Integration of metabolomics and transcriptomics reveals metformin suppresses thyroid cancer progression via inhibiting glycolysis and restraining DNA replication

-

in-vitro,

Thyroid,

BCPAP

BCPAP cell lines were treated with 10 and 20 mM metformin for 24 h in subsequent experiments

-

in-vivo,

NA,

NA

nude mice

-

in-vitro,

Thyroid,

TPC-1

Glycolysis↓, OXPHOS↑, tumCV↓, TumCI↓, TumCMig↓, EMT↓, Apoptosis↑, TumCCA↑, LDHA↓, PKM2↓, IDH1↑, TumCG↓,

2387-

MET,

GEM,

Metformin Increases the Response of Cholangiocarcinoma Cells to Gemcitabine by Suppressing Pyruvate Kinase M2 to Activate Mitochondrial Apoptosis

-

in-vitro,

CCA,

HCC9810

eff↑, tumCV↓, TumCMig↓, TumCI↓, Apoptosis↑, PKM2↓, PDHB↓,

2383-

MET,

Activation of AMPK by metformin promotes renal cancer cell proliferation under glucose deprivation through its interaction with PKM2

-

in-vitro,

RCC,

A498

AMPK↑, TumCP↓, eff↓, eff↑,

2379-

MET,

Down‐regulation of PKM2 enhances anticancer efficiency of THP on bladder cancer

-

in-vitro,

Bladder,

T24

-

in-vitro,

BC,

UMUC3

PKM2↓, p‑STAT3↓, TumCG↓, eff↑, chemoP↑, AMPK↑,

2378-

MET,

Metformin inhibits epithelial-mesenchymal transition of oral squamous cell carcinoma via the mTOR/HIF-1α/PKM2/STAT3 pathway

-

in-vitro,

SCC,

CAL27

0, 2.5, 5, 10, 20, 40, 80 and 160 mM) for 24 h

-

in-vivo,

NA,

NA

Xenograft mouse

TumCP↓, TumCMig↓, TumCI↓, EMT↓, mTOR↓, Hif1a↓, PKM2↓, STAT3↓, E-cadherin↑, Vim↓, Snail↓, STAT3↓,

2377-

MET,

Metformin Inhibits TGF-β1-Induced Epithelial-to-Mesenchymal Transition via PKM2 Relative-mTOR/p70s6k Signaling Pathway in Cervical Carcinoma Cells

-

in-vitro,

Cerv,

HeLa

-

in-vitro,

Cerv,

SiHa

EMT↓, P70S6K↓, mTOR↓, PKM2↓, Warburg↓, AMPK↑,

2376-

MET,

Metformin Inhibits Epithelial-to-Mesenchymal Transition of Keloid Fibroblasts via the HIF-1α/PKM2 Signaling Pathway

-

in-vitro,

Nor,

NA

10, 15, 20 mM

*Hif1a↓, *EMT↓, *p‑P70S6K↓, *PKM2↓,

2375-

MET,

Metformin inhibits gastric cancer via the inhibition of HIF1α/PKM2 signaling

-

in-vitro,

GC,

SGC-7901

0-50mM

tumCV↓, TumCI↓, TumCMig↓, Apoptosis↑, PARP↓, PI3K↓, Akt↓, Hif1a↓, PKM2↓, COX2↓,

2436-

MET,

Metformin alleviates nickel-induced autophagy and apoptosis via inhibition of hexokinase-2, activating lipocalin-2, in human bronchial epithelial cells

-

in-vitro,

Nor,

BEAS-2B

*HK2↓,

2374-

MET,

Metformin Induces Apoptosis and Downregulates Pyruvate Kinase M2 in Breast Cancer Cells Only When Grown in Nutrient-Poor Conditions

-

in-vitro,

BC,

MCF-7

-

in-vitro,

BC,

SkBr3

-

in-vitro,

BC,

MDA-MB-231

eff↑, Apoptosis↑, Glycolysis↓, PKM2↓, mTOR↓, PARP↓,

2486-

metroC,

capec,

Sustained complete response of advanced hepatocellular carcinoma with metronomic capecitabine: a report of three cases

-

Case Report,

HCC,

NA

OS↑, eff↝, Dose↝, AFP↓, Dose↝, TumVol↓, AFP↓,

2487-

metroC,

Metronomic Chemotherapy: Possible Clinical Application in Advanced Hepatocellular Carcinoma

-

Review,

HCC,

NA

toxicity↓, toxicity↓, eff↝, angioG↓, CSCs↓, TSP-1↑, Hif1a↓, VEGF↓, eff↑,

2488-

metroC,

Metronomic S-1 Chemotherapy and Vandetanib: An Efficacious and Nontoxic Treatment for Hepatocellular Carcinoma

-

in-vitro,

HCC,

HUH7

-

in-vivo,

HCC,

NA

Male 5-week-old nude mice

TumCG↓, toxicity↓, OS↑, TSP-1↑, Dose↓, Dose↓,

2489-

metroC,

capec,

Long-lasting response with metronomic capecitabine in advanced hepatocellular carcinoma

-

Case Report,

HCC,

NA

Dose↝, OS↑, TumVol↓, AFP↓,

2490-

metroC,

Durable complete response of hepatocellular carcinoma after metronomic capecitabine

-

Case Report,

HCC,

NA

angioG↓, TumVol↓, Remission↑,

3566-

MF,

Positive and Negative Effects of Administering a Magnetic Field to Patients with Rheumatoid Arthritis (RA)

-

Study,

Arthritis,

NA

39 patients with RA, who were randomly assigned to two groups: SMF—static magnetic field (n = 18) and PEMF

*Inflam↓, *QoL↑, *Pain↓, *motorD↑, *toxicity↓, *Cartilage↑, *Inflam↓,

3568-

MF,

The Efficacy of Pulsed Electromagnetic Fields on Pain, Stiffness, and Physical Function in Osteoarthritis: A Systematic Review and Meta-Analysis

-

Review,

Arthritis,

NA

OA patients treated with PEMF

*eff↑, *Pain↓, *motorD↑,

3569-

MF,

Current Evidence Using Pulsed Electromagnetic Fields in Osteoarthritis: A Systematic Review

-

Review,

Arthritis,

NA

*Pain↓, *QoL↑, *motorD↑,

2247-

MF,

Effects of Pulsed Electromagnetic Field Treatment on Skeletal Muscle Tissue Recovery in a Rat Model of Collagenase-Induced Tendinopathy: Results from a Proteome Analysis

-

in-vivo,

Nor,

NA

Sprague Dawley rats

*Glycolysis↓, *LDHB↑, *NAD↑, *ATP↑, *antiOx↑, *ROS↑, *YAP/TEAD↑, *PGC-1α↑, *TCA↑, *FAO↑, *OXPHOS↑,

2257-

MF,

HPT,

HSP70 Inhibition Synergistically Enhances the Effects of Magnetic Fluid Hyperthermia in Ovarian Cancer

-

in-vitro,

Ovarian,

NA

eff↑, eff↑,

2246-

MF,

The Use of Pulsed Electromagnetic Field to Modulate Inflammation and Improve Tissue Regeneration: A Review

-

in-vitro,

Nor,

NA

5.1hz, 0.04mT, 5 min

PEMF treatment for 15 min at 15 Hz and 2 mT sine wave

*Inflam↓, *IL1↓, *IL6↓, IL17↓, *TNF-α↓,

2245-

MF,

Quantum based effects of therapeutic nuclear magnetic resonance persistently reduce glycolysis

-

in-vitro,

Nor,

NIH-3T3

Warburg↓, Hif1a↓, *Hif1a∅, Glycolysis↓, *lactateProd↓, *ADP:ATP↓, Pyruv↓, ADP:ATP↓, *PPP↓, *mt-ROS↑, *ROS↓, RPM↑, *ECAR↓,

2244-

MF,

Little strokes fell big oaks: The use of weak magnetic fields and reactive oxygen species to fight cancer

-

Review,

Var,

NA

RPM↑, Glycolysis∅, ROS↑, ChemoSen↑, RadioS↑, selectivity↑,

2243-

MF,

Pulsed electromagnetic fields increase osteogenetic commitment of MSCs via the mTOR pathway in TNF-α mediated inflammatory conditions: an in-vitro study

-

in-vitro,

Nor,

NA

mesenchymal stem cells (MSCs)

*eff↑, *mTOR↑, *Akt↑, *PKA↑, *MAPK↑, *ERK↑, *BMP2↑, *Diff↑, *PKCδ↓, *VEGF↑, *IL10↑,

2242-

MF,

Electromagnetic stimulation increases mitochondrial function in osteogenic cells and promotes bone fracture repair

-

in-vitro,

Nor,

NA

2.5G, 5G, 10G, 15G, and 20G

*MMP↑, *Diff↑, *OXPHOS↑, *BMD↑, ATP∅,

2241-

MF,

Pulsed electromagnetic therapy in cancer treatment: Progress and outlook

-

Review,

Var,

NA

other↝, p‑ERK↝, P53↝, Cyt‑c↝, OXPHOS↑, Apoptosis↑, ROS↑,

2240-

MF,

Pulsed electromagnetic field induces Ca2+-dependent osteoblastogenesis in C3H10T1/2 mesenchymal cells through the Wnt-Ca2+/Wnt-β-catenin signaling pathway

-

in-vitro,

Nor,

C3H10T1/2

30 Hz, 1 mT, 2 h/day

PEMF output waveform consisted of a 400 kV/m pulsed burst (pulse width 0.2 m s; pulse wait 0.02 m s; burst width 5 m s; burst wait 60 m s; pulse rise 0.3 m s; pulse fall 2.0 m s) repeated at 30 Hz.

*Ca+2↑, *Diff↑, *BMD↑, *Wnt↑, *β-catenin/ZEB1↑, *eff↝,

2239-

MF,

Time-varying magnetic fields increase cytosolic free Ca2+ in HL-60 cells

-

in-vitro,

AML,

HL-60

Ca+2↑, eff↝,

2238-

MF,

Electromagnetic fields act via activation of voltage-gated calcium channels to produce beneficial or adverse effects

-

Review,

Var,

NA

*BMD↑, *VGCC↑, *Ca+2↑, *NO↑, *eff↓,

2237-

MF,

The Effect of Pulsed Electromagnetic Field Stimulation of Live Cells on Intracellular Ca2+ Dynamics Changes Notably Involving Ion Channels

-

in-vitro,

AML,

KG-1

40 mins

10 Hz [DC: 30%, intensity:26.2 mT], 30 Hz [DC: 30%, intensity:20.3 mT], and 50 Hz [DC: 30%, 15 mT].

-

in-vitro,

Nor,

HUVECs

Ca+2↑, selectivity↑, *Inflam↓, *TNF-α↓, *NF-kB↓, *Ca+2↓,

2236-

MF,

Changes in Ca2+ release in human red blood cells under pulsed magnetic field

-

in-vitro,

Nor,

NA

0.27 T at a transition time of 102 μs with pulse intervals of 1 Hz.

human red blood cells

*Ca+2↓, *eff↓, *ROS↓,

2235-

MF,

Increase of intracellular Ca2+ concentration in Listeria monocytogenes under pulsed magnetic field

-

in-vitro,

Inf,

NA

~7mT, us duration, repeat every second

Ca+2↑, TumCD↑,

2260-

MF,

Alternative magnetic field exposure suppresses tumor growth via metabolic reprogramming

-

in-vitro,

GBM,

U87MG

18 mT at the center

-

in-vitro,

GBM,

LN229

-

in-vivo,

NA,

NA

AMF for 30 min daily, for a total of five sessions.

mice

TumCP↓, TumCG↓, OS↑, ROS↑, SOD2↑, eff↓, ECAR↓, OCR↑, selectivity↑, *toxicity∅, TumVol↓, PGC-1α↑, OXPHOS↑, Glycolysis↓, PKM2↓,

2261-

MF,

Tumor-specific inhibition with magnetic field

-

in-vitro,

Nor,

GP-293

5 mT, 2h/day, 3 days

-

in-vitro,

Liver,

HepG2

-

in-vitro,

Lung,

A549

ROS↑, Ca+2↓, Apoptosis↑, *selectivity↑, TumCG↓, *i-Ca+2↓, i-Ca+2↑,

2248-

MF,

Magnetic fields modulate metabolism and gut microbiome in correlation with Pgc-1α expression: Follow-up to an in vitro magnetic mitohormetic study

-

in-vivo,

Nor,

NA

1.5 mT, 10 min/week

mice

*PGC-1α↑, *GutMicro↑, *FAO↓, *Insulin↓,

2249-

MF,

Pulsed electromagnetic fields modulate energy metabolism during wound healing process: an in vitro model study

-

in-vitro,

Nor,

L929

4mT, 80 Hz

pulsed burst (burst width, 2 ms; pulse width, 10.5 ms).

*TumCMig↑, *tumCV↑, *Glycolysis↑, *ROS↓, *mitResp↓, *other↝, *OXPHOS↓, *pH↑, *antiOx↑, *PFKM↑, *PFKL↑, *PKM2↑, *HK2↑, *GLUT1↑, *GPx1↑, *GPx4↑, *SOD1↑,

2250-

MF,

MNPs,

Confronting stem cells with surface-modified magnetic nanoparticles and low-frequency pulsed electromagnetic field

-

Review,

NA,

NA

1.3 mT, 15 Hz,3 h per day for 20 day

*Ca+2↑, *Dose↝, *BioAv↓,

2251-

MF,

Rad,

BEMER Electromagnetic Field Therapy Reduces Cancer Cell Radioresistance by Enhanced ROS Formation and Induced DNA Damage

-

in-vitro,

Lung,

A549

0 μT to 35 μT and a mattress applicator

-

in-vitro,

HNSCC,

UTSCC15

-

in-vitro,

CRC,

DLD1

-

in-vitro,

PC,

MIA PaCa-2

RadioS↑, DNAdam↑, ROS↑, ChemoSen∅, Pyruv↓, ADP:ATP↓, ROS↑,

2252-

MF,

HPT,

Cellular Response to ELF-MF and Heat: Evidence for a Common Involvement of Heat Shock Proteins?

-

Review,

NA,

NA

HSPs∅, *HSPs↑, eff↝, *eff↑, eff↑, eff↓,

2253-

MF,

Low-frequency pulsed electromagnetic field promotes functional recovery, reduces inflammation and oxidative stress, and enhances HSP70 expression following spinal cord injury

-

in-vivo,

Nor,

NA

50 Hz frequency and 2.5 mT

spinal cord-injured rats.

*Inflam↓, *TNF-α↓, *IL1β↓, *NF-kB↓, *iNOS↓, *ROS↓, Catalase↑, *SOD↑, *HSP70/HSPA5↑, *neuroP↑, *motorD↑, *antiOx↑,

2256-

MF,

HPT,

Effects of exposure to repetitive pulsed magnetic stimulation on cell proliferation and expression of heat shock protein 70 in normal and malignant cells

-

in-vitro,

BC,

MCF-7

34mT, 50Hz 2-s bursts and 1-s rests.

-

in-vitro,

Cerv,

HeLa

-

in-vitro,

Nor,

HBL-100

HSP70/HSPA5↑, HSP70/HSPA5∅,

2255-

MF,

Pulsed Electromagnetic Fields Induce Skeletal Muscle Cell Repair by Sustaining the Expression of Proteins Involved in the Response to Cellular Damage and Oxidative Stress

-

in-vitro,

Nor,

SkMC

1.5 mT PEMF for four hours repeated for two days

*HSP70/HSPA5↑, *Apoptosis↓, *Inflam↓, *Trx↓, *PONs↓, *SOD2↓, *TumCG↑, *Diff↑, *HIF2a↑, *Cyt‑c↑, P21↑,

2254-

MF,

Effect of 60 Hz electromagnetic fields on the activity of hsp70 promoter: an in vivo study

-

in-vivo,

Nor,

NA

80uT, 60Hz,2 h daily for 7 days

BALB/c mice

*HSP70/HSPA5↑, HSP70/HSPA5↑,

3500-

MF,

Moderate Static Magnet Fields Suppress Ovarian Cancer Metastasis via ROS-Mediated Oxidative Stress

-

in-vitro,

Ovarian,

SKOV3

SMFs of ~0.5 T

ROS↑, CSCs↓, CD44↓, SOX2↓, cMyc↓, TumMeta↓, TumCI↓, TumCMig↓, CD133↓, Nanog↓,

3536-

MF,

Targeting Mesenchymal Stromal Cells/Pericytes (MSCs) With Pulsed Electromagnetic Field (PEMF) Has the Potential to Treat Rheumatoid Arthritis

-

Review,

Arthritis,

NA

-

Review,

Stroke,

NA

*Inflam↓, *Diff↑, *toxicity∅, *other↑, *SOX9↑, *COL2A1↑, *NO↓, *PGE2↓, *NF-kB↓, *TNF-α↓, *IL1β↓, *IL6↓, *IL10↑, *angioG↑, *MSCs↑, *VEGF↑, *TGF-β↑, *angioG↝, *VEGF↓, Ca+2↝,

3501-

MF,

Unveiling the Power of Magnetic-Driven Regenerative Medicine: Bone Regeneration and Functional Reconstruction

-

Review,

NA,

NA

*VEGF↑, *BMPs↓, *SMAD4↑, *SMAD5↑, *Ca+2↑,

3498-

MF,

Effect of Static Magnetic Field on Oxidant/Antioxidant Parameters in Cancerous and Noncancerous Human Gastric Tissues

-

in-vitro,

GC,

NA

Twenty-four cancerous gastric tissues and 24 noncancerous adjacent gastric tissues were obtained from patients with gastric cancer by surgical operation

*SOD↑, *MDA↓, SOD↓, GPx↓, MDA↑, Catalase↑,

3487-

MF,

Rad,

High-specificity protection against radiation-induced bone loss by a pulsed electromagnetic field

-

Review,

Var,

NA

radioP↑, *Ca+2↑, RAS↑, MAPK↓,

3486-

MF,

Pulsed electromagnetic field potentiates etoposide-induced MCF-7 cell death

-

in-vitro,

NA,

NA

ChemoSen↑, tumCV↓, cl‑PARP↑, Casp7↑, Casp9↑, survivin↓, BAX↑, DNAdam↑, ROS↑, eff↓,

3485-

MF,

Cytoprotective effects of low-frequency pulsed electromagnetic field against oxidative stress in glioblastoma cells

-

in-vitro,

GBM,

U87MG

*antiOx↑, *ROS↓, *cytoP↑,

3484-

MF,

Extremely low frequency pulsed electromagnetic fields cause antioxidative defense mechanisms in human osteoblasts via induction of •O2 − and H2O2

-

in-vitro,

Nor,

NA

*GPx↑, *SOD2↑, *Catalase↑, *GSR↑, *ROS↓,

3483-

MF,

Pulsed Electromagnetic Fields Protect Against Brain Ischemia by Modulating the Astrocytic Cholinergic Anti-inflammatory Pathway

-

NA,

Stroke,

NA

*Inflam↓, *STAT3↓, *p‑STAT3↓,

3482-

MF,

Pulsed Electromagnetic Fields Increase Angiogenesis and Improve Cardiac Function After Myocardial Ischemia in Mice

-

in-vitro,

NA,

NA

mice

*cardioP↑, *VEGF↑, *VEGFR2↑, *Hif1a↑, *FGF↑, *ITGB1↑, *angioG↑,

3481-

MF,

No effects of pulsed electromagnetic fields on expression of cell adhesion molecules (integrin, CD44) and matrix metalloproteinase-2/9 in osteosarcoma cell lines

-

in-vitro,

OS,

MG63

-

in-vitro,

OS,

SaOS2

ITGA1∅, ITGB1∅, ITGA5∅, ITGB3∅, ITGB4∅, MMP2∅, MMP9∅, eff↑,

3470-

MF,

Pulsed electromagnetic fields inhibit IL-37 to alleviate CD8+ T cell dysfunction and suppress cervical cancer progression

-

in-vitro,

Cerv,

HeLa

TNF-α↑, IL6↑, ROS↑, Apoptosis↑, TumCP↓, TumCMig↓, TumCI↓,

3457-

MF,

Cellular stress response to extremely low‐frequency electromagnetic fields (ELF‐EMF): An explanation for controversial effects of ELF‐EMF on apoptosis

-

Review,

Var,

NA

Apoptosis↑, H2O2↑, ROS↑, eff↑, eff↑, Ca+2↑, MAPK↑, *Catalase↑, *SOD1↑, *GPx1↑, *GPx4↑, *NRF2↑, TumAuto↑, ER Stress↑, HSPs↑, SIRT3↑, ChemoSen↑, UPR↑, other↑, PI3K↓, JNK↑, p38↑, eff↓, *toxicity?,

3458-

MF,

Magnetic Control of Protein Expression via Magneto-mechanical Actuation of ND-PEGylated Iron Oxide Nanocubes for Cell Therapy

-

in-vitro,

GBM,

NA

65 mT and 50 Hz for 30 min

ER Stress↑, UPR↑, Ca+2↑, TRAIL↓, GRP78/BiP↑,

3459-

MF,

EFFECT OF PULSED ELECTROMAGNETIC FIELDS ON ENDOPLASMIC RETICULUM STRESS

-

in-vitro,

Cerv,

HeLa

GRP78/BiP↑, GRP94↑, CHOP↑, ER Stress↓,

3462-

MF,

The Effect of a Static Magnetic Field on microRNA in Relation to the Regulation of the Nrf2 Signaling Pathway in a Fibroblast Cell Line That Had Been Treated with Fluoride Ions

-

in-vitro,

Nor,

NA

Normal Human Dermal Fibroblasts

*NRF2↑, *Keap1↓, *SOD↑, *GPx↑, *ROS↓, *MDA↓, *SOD1↑, *SOD2↑, *GSR↑,

3463-

MF,

Pulsed Electromagnetic Fields Alleviates Hepatic Oxidative Stress and Lipids Accumulation in db/db mice

-

in-vivo,

NA,

NA

2 h of pulsed electromagnetic fields (15.38 Hz, 2 mT)

db/db mice

*hepatoP↑, *MDA↓, *GSSG↓, *GSH↑, *GPx↑, *antiOx↑, *SREBP1↓,

3468-

MF,

An integrative review of pulsed electromagnetic field therapy (PEMF) and wound healing

-

Review,

NA,

NA

*other↑, *necrosis↓, *IL6↑, *TGF-β↑, *iNOS↑, *MMP2↑, *MCP1↑, *HO-1↑, *Inflam↓, *IL1β↓, *IL6↓, *TNF-α↓, *BioAv↑, eff⇅, DNAdam↑, Apoptosis↑, ROS↑, TumCP↓, *ROS↓, *FGF↑,

3469-

MF,

Pulsed Electromagnetic Fields (PEMF)—Physiological Response and Its Potential in Trauma Treatment

-

Review,

NA,

NA

*eff↑, *eff↝, *other↑, Ca+2↑, ROS↑, HSP70/HSPA5↑, *NOTCH↑, *HEY1↑, *p38↑, *MAPK↑,

3480-

MF,

Cellular and Molecular Effects of Magnetic Fields

-

Review,

NA,

NA

ROS↑, *Ca+2↑, *Inflam↓, *Akt↓, *mTOR↓, selectivity↑, *memory↑, *MMPs↑, *VEGF↑, *FGF↑, *PDGF↑, *TNF-α↑, *HGF/c-Met↑, *IL1↑,

3471-

MF,

The prevention effect of pulsed electromagnetic fields treatment on senile osteoporosis in vivo via improving the inflammatory bone microenvironment

-

in-vivo,

Nor,

NA

PEMF with 40 min/day, five days per week

24 Sprague Dawley (SD) rats

*BMD↑, *NLRP3↓, *proCasp1↓, *cl‑Casp1↓, *IL1β↓, *GSDMD↓,

3472-

MF,

Pulsed electromagnetic field alleviates synovitis and inhibits the NLRP3/Caspase-1/GSDMD signaling pathway in osteoarthritis rats

-

in-vivo,

ostP,

NA

3.82 mT, 8 Hz, 40 min/day, 5 days a week, for 12 weeks.

three-month-old Sprague-Dawley (SD)

*Inflam↓, *NLRP3↓, *Casp1↓, *GSDMD?,

3473-

MF,

Therapeutic use of pulsed electromagnetic field therapy reduces prostate volume and lower urinary tract symptoms in benign prostatic hyperplasia

-

Human,

BPH,

NA

Magcell®Microcirc, Physiomed Elektromedizin). PEMF was delivered on perineal area 5 minutes twice daily for 28 days,

27 naive patients with BPH and lower urinary tract symptoms (LUTS)

*Inflam↓, *Dose↝, *other?,

3474-

MF,

Pulsed electromagnetic fields potentiate the paracrine function of mesenchymal stem cells for cartilage regeneration

-

in-vitro,

Nor,

NA

2 mT and 3 mT amplitudes

mesenchymal stem cell (MSC

*Inflam↓, *Apoptosis↓, *other↑, *PGE2↓, *COX2↓, *IL6↓, *IL8↓, *cAMP↑, *IL10↑,

3475-

MF,

A Pulsed Electromagnetic Field Protects against Glutamate-Induced Excitotoxicity by Modulating the Endocannabinoid System in HT22 Cells

-

in-vitro,

Nor,

HT22

-

Review,

AD,

NA

*Apoptosis↓, *LDH↓, *neuroP↑, *toxicity∅, *IL1β↓, *Inflam↓, *IL10↑, *TNF-α↓,

3476-

MF,

Pulsed Electromagnetic Fields Stimulate HIF-1α-Independent VEGF Release in 1321N1 Human Astrocytes Protecting Neuron-like SH-SY5Y Cells from Oxygen-Glucose Deprivation

-

in-vitro,

Stroke,

1321N1

1.5 ± 0.2 mT, pulse duration of 1.3 ms and frequency of 75 Hz, yielding a 0.1 duty cycle

-

in-vitro,

Park,

NA

*VEGF↑, *eff↑, *neuroP↑, *other↑, *eff↑, *Inflam↓, *Hif1a∅,

3477-

MF,

Electromagnetic fields regulate calcium-mediated cell fate of stem cells: osteogenesis, chondrogenesis and apoptosis

-

Review,

NA,

NA

*Ca+2↑, *VEGF↑, *angioG↑, Ca+2↑, ROS↑, Necroptosis↑, TumCCA↑, Apoptosis↑, *ATP↑, *FAK↑, *Wnt↑, *β-catenin/ZEB1↑, *ROS↑, p38↑, MAPK↑, β-catenin/ZEB1↓, CSCs↓, TumCP↓, ROS↑, RadioS↑, Ca+2↑, eff↓, NO↑,

3478-

MF,

One Month of Brief Weekly Magnetic Field Therapy Enhances the Anticancer Potential of Female Human Sera: Randomized Double-Blind Pilot Study

-

Trial,

BC,

NA

-

in-vitro,

BC,

MCF-7

-

in-vitro,

Nor,

C2C12

TumCP↓, TumCMig↓, TumCI↓, *toxicity∅, TGF-β↓, Twist↓, Slug↓, β-catenin/ZEB1↓, Vim↓, p‑SMAD2↓, p‑SMAD3↓, angioG↓, VEGF↓, selectivity↑, LIF↑,

3479-

MF,

Evaluation of Pulsed Electromagnetic Field Effects: A Systematic Review and Meta-Analysis on Highlights of Two Decades of Research In Vitro Studies

-

Review,

NA,

NA

*eff↓, eff↝, *Hif1a↑, *VEGF↑, *TIMP1↑, *E2Fs↑, *MMP2↑, *MMP9↑, Apoptosis↑,

1762-

MF,

Fe,

Triggering the apoptosis of targeted human renal cancer cells by the vibration of anisotropic magnetic particles attached to the cell membrane

-

in-vitro,

RCC,

NA

low frequencies (∼20 Hz) and in weak magnetic fields (∼30 mT)

Dose∅, Apoptosis↑, Casp↑, tumCV↓, Casp3↑, Casp7↑, Ca+2↑, Cyt‑c↑,

493-

MF,

Extremely low-frequency electromagnetic field induces acetylation of heat shock proteins and enhances protein folding

-

in-vitro,

NA,

HEK293

10uT, 3h

-

in-vitro,

Liver,

AML12

mouse source

ATP↑, HSP70/HSPA5↓, HSP90↓,

504-

MF,

Effect of Magnetic Fields on Tumor Growth and Viability

-

in-vivo,

NA,

NA

100 mT, 1-Hz, half-sine-wave unipolar magnetic fields, 60-360min/d

mice

TumCG↓,

494-

MF,

Effects of Various Densities of 50 Hz Electromagnetic Field on Serum IL-9, IL-10, and TNF-α Levels

-

in-vivo,

NA,

NA

1 and 100 µT 50 Hz 2h/d, 60days

rats

IL9↓, TNF-α↓,

495-

MF,

How a High-Gradient Magnetic Field Could Affect Cell Life

-

in-vitro,

NA,

HeLa

1T static

+ Cancer cells

Apoptosis↑, CellMemb↑,

496-

MF,

Low-Frequency Magnetic Fields (LF-MFs) Inhibit Proliferation by Triggering Apoptosis and Altering Cell Cycle Distribution in Breast Cancer Cells

-

in-vitro,

BC,

MCF-7

1mT, 200Hz, 24h

200 Hz reached the optimum inhibition effect

-

in-vitro,

BC,

ZR-75-1

-

in-vitro,

BC,

T47D

-

in-vitro,

BC,

MDA-MB-231

ROS↑, PI3K↓, Akt↓, GSK‐3β↑, Apoptosis↑, cl‑PARP↑, cl‑Casp3↑, BAX↑, Bcl-2↓, CycB↓, TumCCA↑, p‑Akt↓, p‑Akt↓,

497-

MF,

In Vitro and in Vivo Study of the Effect of Osteogenic Pulsed Electromagnetic Fields on Breast and Lung Cancer Cells

-

vitro+vivo,

NA,

MCF-7

-

vitro+vivo,

NA,

A549

TumCG↓, TumVol↓, Casp3↑, Casp7↑, Apoptosis↑, DNAdam↑, TumCCA↑, ChemoSen↑, EPR↑,

498-

MF,

Stimulation of osteogenic differentiation in human osteoprogenitor cells by pulsed electromagnetic fields: an in vitro study

-

in-vitro,

NA,

NA

5 Hz, 0.1mT EM field, consisting of 5-millisecond bursts

human bone marrow-derived stromal cell (BMSC)

Calcium↑, MMP1↑, MMP3↑, BMPs↑,

499-

MF,

The Effect of Pulsed Electromagnetic Fields on Angiogenesis

-

Review,

NA,

NA

normal cells

angioG↑, VEGF↑, VGCC↑,

500-

MF,

Anti-Oxidative and Immune Regulatory Responses of THP-1 and PBMC to Pulsed EMF Are Field-Strength Dependent

-

in-vitro,

AML,

THP1

wkEMF (<50 μT), mdEMF (<250 μT) and stEMF (<4.8 mT), 16.7Hz

compared to healty blood cells

ROS↑, Prx6↑, DHCR24↑, IL10↑,

501-

MF,

Low Intensity and Frequency Pulsed Electromagnetic Fields Selectively Impair Breast Cancer Cell Viability

-

in-vitro,

BC,

MCF-7

2-5mT, 10-50Hz, 30-90min/d

harmless to non-malignant cell types

-

in-vitro,

Nor,

MCF10

Apoptosis↑, *toxicity↓, ChemoSen↑, chemoP↑, selectivity↑, DNAdam↑,

502-

MF,

Electromagnetic field investigation on different cancer cell lines

-

in-vitro,

BC,

MDA-MB-231

50 Hz with RMS value of 10 mT

apoptosis (55% and 20%)

-

in-vitro,

Colon,

SW480

apoptosis (11% and 6%),

-

in-vitro,

CRC,

HCT116

apoptosis (2% and 3%)

TumCG↓, Apoptosis↑,

503-

MF,

Effects of acute and chronic low frequency electromagnetic field exposure on PC12 cells during neuronal differentiation

-

in-vitro,

NA,

PC12

0.1-1.0 mT

rat cells

ROS↑, Ca+2↑,

526-

MF,

Inhibition of Cancer Cell Growth by Exposure to a Specific Time-Varying Electromagnetic Field Involves T-Type Calcium Channels

-

in-vitro,

BC,

MDA-MB-231

Thomas-EMF is a low-intensity, frequency-modulated (25-6 Hz) EMF pattern.

Thomas-EMF used in our experiments is a complex time-modulated pattern (25–6 HZ)

-

in-vitro,

BC,

MCF-7

-

in-vitro,

Pca,

HeLa

-

vitro+vivo,

Melanoma,

B16-BL6

-

in-vitro,

Nor,

HEK293

TumCG↓, Ca+2↑, selectivity↑, *Ca+2∅, ROS↑, HSP70/HSPA5↑, AntiCan↑,

492-

MF,

Weak electromagnetic fields (50 Hz) elicit a stress response in human cells

-

in-vitro,

AML,

HL-60

10-140uT, 30mins

human fibroblasts

HSP70/HSPA5↑,

491-

MF,

Pre-exposure of neuroblastoma cell line to pulsed electromagnetic field prevents H2 O2 -induced ROS production by increasing MnSOD activity

-

in-vitro,

neuroblastoma,

SH-SY5Y

2 ± 0.2 mT; 75 ± 2 Hz for 10 min, 4 times/week

*Dose∅, *ROS↓,

490-

MF,

Extremely Low Frequency Magnetic Field (ELF-MF) Exposure Sensitizes SH-SY5Y Cells to the Pro-Parkinson's Disease Toxin MPP(.)

-

in-vitro,

Park,

SH-SY5Y

50 Hz, 1 mT for 24/48/72 h

ROS↑,

489-

MF,

Time-varying magnetic fields of 60 Hz at 7 mT induce DNA double-strand breaks and activate DNA damage checkpoints without apoptosis

-

in-vitro,

NA,

HeLa

60 Hz, 7 mT for 10–60 min

-

in-vitro,

NA,

IMR90

DNAdam↑,

488-

MF,

Repetitive exposure to a 60-Hz time-varying magnetic field induces DNA double-strand breaks and apoptosis in human cells

-

in-vitro,

NA,

HeLa

60 Hz, 6 mT for 30 min every 24 h for 3 days

-

in-vitro,

NA,

IMR90

DNAdam↑, p‑γH2AX↑, Chk2↑, p38↑, Apoptosis↑,

487-

MF,

Extremely Low-Frequency Electromagnetic Fields Cause G1 Phase Arrest through the Activation of the ATM-Chk2-p21 Pathway

-

in-vitro,

NMSC,

HaCaT

60 Hz, 1.5 mT for 144 h

ATM↑, Chk2↑, P21↑, TumCCA↑,

486-

MF,

mTOR Activation by PI3K/Akt and ERK Signaling in Short ELF-EMF Exposed Human Keratinocytes

-

in-vitro,

Nor,

HaCaT

50 Hz, 1 mT for 1 h

*mTOR↑, *PI3K↑, *Akt↑, *p‑ERK↑, *other↑, *p‑JNK↑, *p‑P70S6K↑,

582-

MF,

immuno,

VitC,

Magnetic field boosted ferroptosis-like cell death and responsive MRI using hybrid vesicles for cancer immunotherapy

-

in-vitro,

Pca,

TRAMP-C1

As shown in Fig. 1a, once AA is released under the MF, ferric ions in IONCs are reduced by AA increasing ferrous ions, which are a stronger inducer for Fenton reaction compared with ferric ions

-

in-vivo,

NA,

NA

TRAMP-C1 tumor-bearing mice

Fenton↑, Ferroptosis↑, ROS↑, TumCG↓, Iron↑, GPx4↓,

585-

MF,

VitC,

Impact of pulsed magnetic field treatment on enzymatic inactivation and quality of cloudy apple juice

other↓,

587-

MF,

VitC,

Effect of stationary magnetic field strengths of 150 and 200 mT on reactive oxygen species production in soybean

ROS↑, SOD↓, other↓,

590-

MF,

VitC,

Sub-millitesla magnetic field effects on the recombination reaction of flavin and ascorbic acid radicals

-

in-vitro,

NA,

NA

<1 mT

RPM↑,

592-

MF,

VitC,

Alternative radical pairs for cryptochrome-based magnetoreception

RPM↑,

594-

MF,

VitC,

Static Magnetic Field Effect on the Fremy's Salt-Ascorbic Acid Chemical Reaction Studied by Continuous-Wave Electron Paramagnetic Resonance

-

Analysis,

NA,

NA

RPM↑,

535-

MF,

Electromagnetic Fields Trigger Cell Death in Glioblastoma Cells through Increasing miR-126-5p and Intracellular Ca2+ Levels

-

in-vitro,

Pca,

PC3

2.4GHz

-

in-vitro,

GBM,

A172

-

in-vitro,

Pca,

HeLa

Apoptosis↑, miR-129-5p↑, Ca+2↑, eff↝,

523-

MF,

MTX,

Extremely low-frequency magnetic fields significantly enhance the cytotoxicity of methotrexate and can reduce migration of cancer cell lines via transiently induced plasma membrane damage

-

in-vitro,

AML,

THP1

10uM(MTX), 0.1 and 0.6 μT

-

in-vitro,

NA,

PC12

pheocrmomocytoma (PC12) Pheochromocytoma is a type of tumor

-

in-vivo,

Cerv,

HeLa

H2O2↑, TumCD↑, CellMemb↑, eff↑,

527-

MF,

Effects of Fifty-Hertz Electromagnetic Fields on Granulocytic Differentiation of ATRA-Treated Acute Promyelocytic Leukemia NB4 Cells

-

in-vitro,

AML,

APL NB4

2mT, 50Hz

ROS↑, other↑, p‑ERK↑, TumCP↓,

528-

MF,

Caff,

Pulsed electromagnetic fields affect the intracellular calcium concentrations in human astrocytoma cells

-

in-vitro,

GBM,

U373MG

3mT, 50Hz

Ca+2↑, TumCP∅, TumCD∅, eff↑,

524-

MF,

Inhibition of Angiogenesis Mediated by Extremely Low-Frequency Magnetic Fields (ELF-MFs)

-

vitro+vivo,

PC,

MS-1

2mT, 50Hz

mouse cell line injected in mice

-

vitro+vivo,

PC,

HUVECs

other↓, TumCP↓, TumCMig↓, VEGFR2↓, TumVol↓, HSP70/HSPA5↓, HSP90↓, TumCCA↑, angioG↓,

539-

MF,

Pulsed Magnetic Field Improves the Transport of Iron Oxide Nanoparticles through Cell Barriers

-

in-vitro,

NA,

NA

eff↑,

538-

MF,

The extremely low frequency electromagnetic stimulation selective for cancer cells elicits growth arrest through a metabolic shift

-

in-vitro,

BC,

MDA-MB-231

-

in-vitro,

Melanoma,

MSTO-211H

TumCG↓, Ca+2↑, COX2↓, ATP↑, MMP↑, ROS↑, OXPHOS↑, mitResp↑,

537-

MF,

immuno,

Integrating electromagnetic cancer stress with immunotherapy: a therapeutic paradigm

-

Review,

Var,

NA

Apoptosis↑, ROS↑, TumAuto↑, Ca+2↑, ATP↓, eff↑, eff↑,

536-

MF,

Comparison of pulsed and continuous electromagnetic field generated by WPT system on human dermal and neural cells

-

in-vitro,

Nor,

SH-SY5Y

87–207 kHz, 1.01–1.05 kW, 1.3–1.7 mT

-

in-vitro,

GBM,

T98G

-

in-vitro,

Nor,

HDFa

other∅,

522-

MF,

Low Magnetic Field Exposure Alters Prostate Cancer Cell Properties

-

in-vitro,

Pca,

PC3

20nT, 4hr

MMP2↑, MMP9↑, miR-21↑, miR-155↑, miR-210↑, miR-200c↓, miR-126↓,

534-

MF,

Effect of extremely low frequency electromagnetic field parameters on the proliferation of human breast cancer

-

in-vitro,

BC,

MCF-7

0.5,1mT 8-39Hz

square wave

-

in-vitro,

BC,

MDA-MB-231

-

in-vivo,

Nor,

MCF10

Ca+2↑, Apoptosis↑, eff↝, eff↑, selectivity↑, eff↝, eff↝,

505-

MF,

Amplitude-modulated electromagnetic fields for the treatment of cancer: Discovery of tumor-specific frequencies and assessment of a novel therapeutic approach

-

Case Report,

NA,

NA

Pain↓, OS↑,

533-

MF,

Effects of extremely low-frequency magnetic fields on human MDA-MB-231 breast cancer cells: proteomic characterization

-

in-vitro,

BC,

MDA-MB-231

1mT, 50Hz for 4 h

-

in-vitro,

Nor,

MCF10

TumCD↑, necrosis↑, mt-ROS↑, other↑, *STAT3↓, STAT3↑,

532-

MF,

A 50 Hz magnetic field influences the viability of breast cancer cells 96 h after exposure

-

in-vitro,

BC,

MDA-MB-231

0.1 mT and 1.0 mT, 50Hz, 96h

-

in-vitro,

BC,

MCF-7

-

in-vitro,

Nor,

MCF10

TumCP↓, MMP↓, ROS↑, eff↝, selectivity↑,

531-

MF,

6-mT 0-120-Hz magnetic fields differentially affect cellular ATP levels

-

in-vitro,

Cerv,

HeLa

6mT, 0,50,120Hz

-

in-vitro,

CRC,

HCT116

-

in-vitro,

BC,

MCF-7

-

in-vitro,

Lung,

A549

-

in-vitro,

Nor,

RPE-1

-

in-vitro,

Nor,

GP-293

ATP⇅,

530-

MF,

Low frequency sinusoidal electromagnetic fields promote the osteogenic differentiation of rat bone marrow mesenchymal stem cells by modulating miR-34b-5p/STAC2

-

in-vivo,

Nor,

NA

15 Hz, 0.4 -1 mT

rat bone marrow mesenchymal stem cells

*miR-34b-5p↓, *ALP↑, *RUNX2↑, *BMP2↑, *OCN↑, *OPN↑, *β-catenin/ZEB1↑, *STAC2↑, *Diff↑, *BMD↑,

529-

MF,

Low-frequency magnetic field therapy for glioblastoma: Current advances, mechanisms, challenges and future perspectives

-

Review,

GBM,

NA

Ca+2↑, ROS↑, ChemoSen↑, QoL↑, OS↑,

514-

MF,

Therapeutic electromagnetic field effects on angiogenesis and tumor growth

-

in-vivo,

NA,

NA

0, 10 mT, 15 mT or 20 mT, 120pulse/s, 10mins/d

mice

TumVol↓,

506-

MF,

doxoR,

Pulsed Electromagnetic Field Stimulation Promotes Anti-cell Proliferative Activity in Doxorubicin-treated Mouse Osteosarcoma Cells

-

in-vitro,

OS,

LM8

5 mT, 200 Hz

x2 fold improved

The IC50 for combined PEMF and doxorubicin was about 2-fold lower than that of doxorubicin alone, suggesting that PEMF enhanced the antiproliferative activity of doxorubicin.

TumCP↓, p‑CHK1↓, Ca+2↑, Casp3↓, Casp7↓, p‑BAD↓, ChemoSen↑,

507-

MF,

Effects of extremely low frequency electromagnetic fields on the tumor cell inhibition and the possible mechanism

-

in-vitro,

Liver,

HepG2

5 mT and 20 Hz

adherence inhibition rate for Hepg2 and A549 estimated at 18% and 30% respectively

-

in-vitro,

Lung,

A549

-

in-vitro,

Nor,

GP-293

MMP↓, TumCG↓, ROS↑, *Ca+2↓, Ca+2↑, selectivity↑, i-pH↑,

508-

MF,

doxoR,

Synergistic cytotoxic effects of an extremely low-frequency electromagnetic field with doxorubicin on MCF-7 cell line

-

in-vitro,

BC,

MCF-7

50 Hz; 20 mT

2uM goes to 0.25uM with PEMF

ROS↑, Apoptosis↑, TumCCA↑,

509-

MF,

Is extremely low frequency pulsed electromagnetic fields applicable to gliomas? A literature review of the underlying mechanisms and application of extremely low frequency pulsed electromagnetic fields

-

Review,

NA,

NA

Ca+2↑, TumAuto↑, Apoptosis↑, angioG↓, ROS↑,

510-

MF,

Effect of a 9 mT pulsed magnetic field on C3H/Bi female mice with mammary carcinoma. A comparison between the 12 Hz and the 460 Hz frequencies

-

in-vivo,

NA,

NA

9 mT, 12 Hz, 10mins, 3d/wk

mice

OS↑,

511-

MF,

Optimization of a therapeutic electromagnetic field (EMF) to retard breast cancer tumor growth and vascularity

-

in-vivo,

NA,

NA

20mT for 10 minutes twice a day

mice

TumVol↓,

512-

MF,

Pulsed Electromagnetic Fields (PEMFs) Trigger Cell Death and Senescence in Cancer Cells

-

in-vitro,

BC,

MCF-7

11mT, 8Hz, square wave, 2x/d 30mins, 5 d

-

in-vitro,

BC,

MDA-MB-231

-

in-vitro,

Nor,

FF95

TumCP↓, *toxicity↓, ChemoSen↑, RadioS↑, selectivity↑,

513-

MF,

Exposure to a specific time-varying electromagnetic field inhibits cell proliferation via cAMP and ERK signaling in cancer cells

-

in-vitro,

BC,

MDA-MB-231

Thomas-EMF, a low-intensity, frequency-modulated (25-6 Hz) EMF pattern

-

in-vitro,

BC,

MDA-MB-468

-

in-vitro,

BC,

MCF-7

-

in-vivo,

Pca,

HeLa

TumCG↓, p‑ERK↑, cAMP⇅,

515-

MF,

Pulsed Low-Frequency Magnetic Fields Induce Tumor Membrane Disruption and Altered Cell Viability

-

in-vitro,

Lung,

A549

sequential 50- and 385-Hz oscillating magnetic fields, 10min, 20mT

CellMemb↑, TumCP↓,

525-

MF,

Pulsed electromagnetic fields regulate metabolic reprogramming and mitochondrial fission in endothelial cells for angiogenesis

-

in-vitro,

Nor,

HUVECs

4mT, 80 Hz

*angioG↑, *GPx1↑, *GPx4↑, *SOD↑, *PFKM↑, *PFKL↑, *PKM2↑, *PFKP↑, *HK2↑, *GLUT1↑, *GLUT4↑, *ROS↓, *MMP↝, *Glycolysis↑, *OXPHOS↓,

517-

MF,

Rad,

Therapeutic Electromagnetic Field (TEMF) and gamma irradiation on human breast cancer xenograft growth, angiogenesis and metastasis

-

in-vivo,

NA,

MDA-MB-231

15mT, 120 pulse/s

in mice

TumMeta↓, TumCG↓,

518-

MF,

Moderate and strong static magnetic fields directly affect EGFR kinase domain orientation to inhibit cancer cell proliferation

-

in-vitro,

NA,

HCT116

Static MF 0.7T

EGFR↓, p‑EGFR↓,

519-

MF,

Effects of 50-Hz magnetic field exposure on superoxide radical anion formation and HSP70 induction in human K562 cells

-

in-vitro,

AML,

K562

50-Hz sine wave; 1 h; 0.025-0.10 mT

HSP70/HSPA5↑,

520-

MF,

Exposure to a 50-Hz magnetic field induced mitochondrial permeability transition through the ROS/GSK-3β signaling pathway

-

in-vitro,

Nor,

NA

50 Hz, 0.4 mT, 60mins

Human amniotic epithelial cells

*MPT↑, *Cyt‑c↑, *ROS↑, *p‑GSK‐3β↑, *eff↓, *MMP∅, *BAX↓, *Bcl-2∅,

521-

MF,

Magnetic field effects in biology from the perspective of the radical pair mechanism

-

Analysis,

NA,

NA

RPM↑,

197-

MF,

A mechanism for action of oscillating electric fields on cells

196-

MF,

Mechanism for action of electromagnetic fields on cells

194-

MF,

Electromagnetic Field as a Treatment for Cerebral Ischemic Stroke

-

Review,

Stroke,

NA

*BAD↓, *BAX↓, *Casp3↓, *Bcl-xL↑, *p‑Akt↑, *MMP9↓, *p‑ERK↑, *HIF-1↓, *ROS↓, *VEGF↑, *Ca+2↓, *SOD↑, *IL2↑, *p38↑, *HSP70/HSPA5↑, *Apoptosis↓, *ROS↓, *NO↓,

192-

MF,

The use of magnetic fields in treatment of patients with rheumatoid arthritis. Review of the literature

-

Review,

Arthritis,

NA

2 mT, 12 Hz

15 to 30 minutes, and the treatments are performed 1–2 times per day for several weeks

*Dose↝,

188-

MFrot,

Spinning magnetic field patterns that cause oncolysis by oxidative stress in glioma cells

-

in-vitro,

GBM,

GBM115

0.4-58mT pulsed

~ 137 Hz and was large enough to generate a peak-topeak amplitude (PPA) of ~ 5 mT

-

in-vitro,

GBM,

DIPG

ROS↑, SDH↓, eff↓, RPM↑, eff↓, eff↑, eff↝, eff↝, Casp3↑, eff↝, SOD↓,

219-

MFrot,

The expression and intranuclear distribution of nucleolin in HL-60 and K-562 cells after repeated, short-term exposition to rotating magnetic fields

-

in-vitro,

AML,

HL-60

10,20mT, 35-50hz 30mins/day 4days

-

in-vitro,

AML,

K562

nucleolin↑,

189-

MFrot,

Cancer treatment by magneto-mechanical effect of particles, a review

-

vitro+vivo,

Var,

NA

CellMemb↑, lysoMP↑, ERK↑, Apoptosis↑,

187-

MFrot,

Method for noninvasive whole-body stimulation with spinning oscillating magnetic fields and its safety in mice

-

in-vivo,

GBM,

NA

healthy mice

selectivity↑, ROS↑, *ROS∅, *toxicity∅,

190-

MFrot,

The efficacy and safety of low-frequency rotating static magnetic field therapy combined with chemotherapy on advanced lung cancer patients: a randomized, double-blinded, controlled clinical trial

-

Human,

Lung,

NA

human trial

*IP-10/CXCL-10↑, *GM-CSF↑, *TREM-1↓,

191-

MFrot,

Early exposure of rotating magnetic fields promotes central nervous regeneration in planarian Girardia sinensis

-

in-vivo,

Nor,

NA

6 Hz 0.02 T RMFs.

planarian Girardia sinensis worm

*EGR4↑, *Netrins↑, *NSE↑, *NPY↑,

193-

MFrot,

Rotating Magnetic Field Mitigates Ankylosing Spondylitis Targeting Osteocytes and Chondrocytes via Ameliorating Immune Dysfunctions

-

in-vivo,

Arthritis,

NA

Ankylosing Spondylitis arthritis: Mouse model

BMD↑, Cartilage↑, IL17↓, IL22↓, IL23↓, IL28↓, CD4+↓, CD8+↓, LAMB3↑, COL4↓, THBS2↓, ITGA11↓, PPARγ↑, ACAA1↓, PLIN1↓, FABP4↓, PCK1↓, UCP1↓, TNF-α↓,

195-

MFrot,

Application of Rotating Magnetic Fields Increase the Activity of Antimicrobials Against Wound Biofilm Pathogens

-

Human,

Wounds,

NA

198-

MFrot,

Biological effects of rotating magnetic field: A review from 1969 to 2021

-

Review,

Var,

NA

AntiCan↑, breath↑, Pain↓, Appetite↑, Strength↑, BowelM↑, TumMeta↓, TumCCA↑,

199-

MFrot,

Modulation of Cellular Response to Different Parameters of the Rotating Magnetic Field (RMF)—An In Vitro Wound Healing Study

-

in-vivo,

Wounds,

L929

f = 30 Hz; B from 5.9 to 28.4 mT

-

NA,

NA,

HaCaT

*ROS↑, *Ca+2↓, *other↝, *other↝, *other↝, *other↝, *other↝, *other?,

200-

MFrot,

Moderate intensity low frequency rotating magnetic field inhibits breast cancer growth in mice

-

in-vivo,

BC,

MDA-MB-231

0–0.15 T. rotating frequency 2.5 Hz, 3.3 Hz and 4.2 Hz

mice; inhibit tumor growth 30%

-

in-vivo,

BC,

MCF-7

ALAT↓, TumVol↓,

201-

MFrot,

Gradient Rotating Magnetic Fields Impairing F-Actin-Related Gene CCDC150 to Inhibit Triple-Negative Breast Cancer Metastasis by Inactivating TGF-β1/SMAD3 Signaling Pathway

-

in-vitro,

BC,

MDA-MB-231

5 Hz, 0.41 T

-

in-vitro,

BC,

BT549

-

in-vitro,

BC,

MDA-MB-468

CCDC150↓, TGF-β↓, SMAD3↓,

202-

MFrot,

Systematic simulation of tumor cell invasion and migration in response to time-varying rotating magnetic field

-

Analysis,

Var,

MDA-MB-231

also used physical magnets

TumCG↓, MMPs↓, ECM/TCF↓,

203-

MFrot,

Rotating Magnetic Field Induced Oscillation of Magnetic Particles for in vivo Mechanical Destruction of Malignant Glioma

-

vitro+vivo,

GBM,

U87MG

1T

lysoMP↓, TumVol↓, eff↑, Apoptosis↑, Ca+2↑,

204-

MFrot,

Rotating magnetic field improved cognitive and memory impairments in a sporadic ad model of mice by regulating microglial polarization

-

in-vivo,

AD,

NA

0.2T, 4Hz

reduced aluminum deposition in the brains of AD mice

*NF-kB↓, *MAPK↓, *TLR4↓, *memory↑, *cognitive↑, *TGF-β1↑, *ARG↑, *IL4↑, *IL10↑, *IL6↓, *IL1↓, *TNF-α↓, *iNOS↓, *ROS↓, *NO↓, *MyD88↓, *p‑IKKα↓, *p‑IκB↓, *p‑p65↓, *p‑JNK↓, *p‑p38↓, *ERK↓, *neuroP↑,

205-

MFrot,

Intermittent F-actin Perturbations by Magnetic Fields Inhibit Breast Cancer Metastasis

-

vitro+vivo,

BC,

MDA-MB-231

0.1-T and 0.4-T (~4.2 Hz)

mouse

OS↑, F-actin↓, TumCI↓, TumCMig↓, Rho↓, selectivity↑,

185-

MFrot,

Case Report: End-Stage Recurrent Glioblastoma Treated With a New Noninvasive Non-Contact Oncomagnetic Device

-

Human,

GBM,

NA

>1mT

TumVol↓, Dose↝, cognitive↑,

218-

MFrot,

Extremely low frequency magnetic fields inhibit adipogenesis of human mesenchymal stem cells

-

in-vitro,

Nor,

NA

7.5 Hz, 0.4 T

human umbilical cord MSCs

*PPARγ↓, *p‑JNK↑, *Wnt↑, *ALP∅, *COL1∅, *RUNX2∅, *OCN∅, *FABP4↓, *p‑JNK↑, *Diff↓,

220-

MFrot,

Effect of low frequency magnetic fields on melanoma: tumor inhibition and immune modulation

-

in-vitro,

Melanoma,

B16-F10

0.4 T, 7.5 Hz

mouse cell line

OS↑, DCells↑, T-Cell↑, Apoptosis↑, IL1↑, IFN-γ↓, IL10↑, TumCG↓, ROS↑,

209-

MFrot,

The effect of a rotating magnetic field on the antioxidant system in healthy volunteers - preliminary study

-

Human,

NA,

NA

30 healthy volunteers

*SOD↑, *Catalase↑, *ROMO1↑, *MDA↓, *TAC↑, *ROS↓,

221-

MFrot,

Low Frequency Magnetic Fields Enhance Antitumor Immune Response against Mouse H22 Hepatocellular Carcinoma

-

in-vivo,

Liver,

NA

0.4T, 7.5Hz

mice

OS↑, TumCG↓, IL6↓, GM-CSF↓, CXCc↓, Macrophages↑, DCells↑, CD4+↑, CD8+↑, IL12↑,

222-

MFrot,

LF-MF inhibits iron metabolism and suppresses lung cancer through activation of P53-miR-34a-E2F1/E2F3 pathway

-

in-vitro,

Lung,

A549

0.4T, 7.5 Hz

inhibits iron metabolism

TumCG↓, OS↑, miR-34a↑, E2Fs↓, P53↑, TfR1/CD71↓, Ferritin↓,

223-

MFrot,

The effect of rotating magnetic fields on the growth of Deal's guinea pig sarcoma transplanted subcutaneously in guinea pigs

-

in-vivo,

NA,

NA

3hrs, 2x daily

guinea pig sarcoma: RMF inhibited the growth of DGPS cells in experimental guinea pigs compared to control animals

TumCG↓,

224-

MFrot,

A pilot study of extremely low-frequency magnetic fields in advanced non-small cell lung cancer: Effects on survival and palliation of general symptoms

-

Human,

NSCLC,

NA

420 r/min, 0.4-T:2 h per day, 5 days per week for 6–10 weeks

13 advanced NSCLC patients

PleEff↓, breath↑, Pain↓, Appetite↑, Strength↑, BowelM↑, OS↑,

225-

MFrot,

Extremely low frequency magnetic fields regulate differentiation of regulatory T cells: Potential role for ROS-mediated inhibition on AKT

-

vitro+vivo,

Lung,

NA

0.4 T, 7.5 Hz: 2 h/day for 27 days.

mice

MMP2↓, MMP9↓, FOXP3↓, ROS↑, p‑Akt↓,

226-

MFrot,

Involvement of midkine expression in the inhibitory effects of low-frequency magnetic fields on cancer cells

-

in-vitro,

NA,

A549

0.4-T, 7.5 Hz

-

in-vitro,

NA,

LoVo

TumCP↓, eff↝,

227-

MFrot,

Low Frequency Magnetic Fields Induce Autophagy-associated Cell Death in Lung Cancer through miR-486-mediated Inhibition of Akt/mTOR Signaling Pathway

-

in-vivo,

Lung,

A549

0.4T, 7.5 Hz, 4 h/day

mouse

-

in-vitro,

Lung,

A549

TumCG↓, miR-486↑, BCAP↓, Apoptosis↑, ROS↑, TumAuto↑, LC3II↑, ATG5↑, Beclin-1↑, p62↑, TumCP↓,

228-

MFrot,

Rotating magnetic field ameliorates experimental autoimmune encephalomyelitis by promoting T cell peripheral accumulation and regulating the balance of Treg and Th1/Th17

-

NA,

MS,

NA

*CD4+↑, *MCP1↓, RANTES↓, *MIP‑1α↓, *Treg lymp↓, *IFN-γ↓, *IL17↓, *CXCc↓,

229-

MFrot,

Molecular mechanism of effect of rotating constant magnetic field on organisms

-

in-vivo,

Nor,

NA

New Zealand rabbits, rotating constant magnetic field on organisms

*NO↑, *5HT↓, *eff↝, *eff↝, *β-Endo↑, *other↓,

230-

MFrot,

Study on the Effect of Rotating Magnetic Field on Cellular Response of Mammalian Cells

-

in-vitro,

Nor,

L929

1-10mT, 50hz, 8hrs

*ALDH↑,

217-

MFrot,

Effect of low-frequency rotary magnetic fields on advanced gastric cancer

-

in-vivo,

GC,

HL-60

420 r/min, 0.4-T

-

in-vivo,

GC,

SK-HEP-1

OS↑, Pain↓, ChemoSideEff↓, Weight↑, Strength↑, Sleep↑,

216-

MFrot,

Elongated Nanoparticle Aggregates in Cancer Cells for Mechanical Destruction with Low Frequency Rotating Magnetic Field

-

in-vitro,

GBM,

U87MG

15 Hz and 40 mT

motor was used to produce the magnets rotation at 15 Hz and the cell-culture dish was placed above the station

lysoMP↓, CellMemb↑,

215-

MFrot,

Magneto-mechanical destruction of cancer-associated fibroblasts using ultra-small iron oxide nanoparticles and low frequency rotating magnetic fields

-

in-vitro,

PC,

CAF

1 Hz and 40 mT

superparamagnetic iron oxide nanoparticles

TumVol↓, lysoMP↑, CAFs/TAFs↓, eff↑,

214-

MFrot,

Modification of bacterial cellulose through exposure to the rotating magnetic field

-

in-vitro,

Nor,

NA

B=34mT,50hz, for 72h at 28°C

bacterial cellulose

CellMemb↑, GlucoseCon↓,

213-

MFrot,

Rotating Magnetic Field-Assisted Reactor Enhances Mechanisms of Phage Adsorption on Bacterial Cell Surface

-

in-vitro,

NA,

NA

B = 30 mT, f = 50 Hz

E. coli cells

CellMemb↑,

212-

MFrot,

Rotating magnetic field inhibits Aβ protein aggregation and alleviates cognitive impairment in Alzheimer’s disease mice

-

in-vivo,

AD,

SH-SY5Y

0.4T, 4.2 Hz

mice

*β-Amyloid↓, *cognitive↑, *motorD↑, *ROS↓, *memory↑,

184-

MFrot,

Rotating Magnetic Fields Inhibit Mitochondrial Respiration, Promote Oxidative Stress and Produce Loss of Mitochondrial Integrity in Cancer Cells

-

in-vitro,

GBM,

GBM

80mT pulsed

ROS↑, mitResp↓, mtDam↑, Dose↝, MMP?, OCR↓, mt-H2O2↑, eff↓, SDH↓, Thiols↓, GSH↓, TumCD↑, Casp3↑, Casp7↑, MPT↑, Cyt‑c↑, selectivity↑, GSH/GSSG↓,

186-

MFrot,

Selective induction of rapid cytotoxic effect in glioblastoma cells by oscillating magnetic fields

-

in-vitro,

GBM,

GBM

new device that generates oscillating magnetic fields (OMF) by rapid rotation of strong permanent magnets in specially designed patterns of frequency and timing

-

in-vitro,

Lung,

NA

mt-ROS↑, Casp3↑, selectivity↑, TumCD↑,

595-

MFrot,

VitC,

The Effect of Alternating Magnetic Field Exposure and Vitamin C on Cancer Cells

-

in-vitro,

PC,

MIA PaCa-2

4mT, 1000rpm

51% reduction

reduces IC50 value of cells treated with Vit C and magnetic field

-

in-vitro,

CRC,

SW-620

23% reduction

-

in-vitro,

NA,

HT1080

37% reduction

-

in-vitro,

Pca,

PC3

40% reduction

-

in-vitro,

OS,

U2OS

46% reduction

-

in-vitro,

BC,

MCF-7

33% reduction

-

in-vitro,

Nor,

CCD-18Co

-7% reduction

health normal colon cells *****

TumCD↑, eff↑, *TumCG∅,

516-

MFrot,

immuno,

Anti-tumor effect of innovative tumor treatment device OM-100 through enhancing anti-PD-1 immunotherapy in glioblastoma growth

-

vitro+vivo,

GBM,

U87MG

1mT, 120Hz (7200rpm), 24, 48, and 72 h

OM‑100 device (motor driven pulses)

TumCP↓, Apoptosis↑, TumCMig↓, ROS↑, PD-L1↑, TumVol↓, eff↑, *toxicity∅, eff↑, *toxicity∅, Dose↝, tumCV↓, TumCI↓,

3489-

MFrot,

Rotating magnetic field inhibits Aβ protein aggregation and alleviates cognitive impairment in Alzheimer's disease mice.

-

in-vivo,

AD,

NA

mice

*Aβ↓, *motorD↑, *cognitive↑, *memory↑, *ROS↓,

3535-

MFrot,

Pulsed Electromagnetic Field Stimulation in Osteogenesis and Chondrogenesis: Signaling Pathways and Therapeutic Implications

-

Review,

Nor,

NA

*eff↑, *COL2A1↑, *SOX9↑, *Ca+2↑, *FAK↑, *F-actin↑, *Inflam↓, *other↑, *Diff↑, *BMD↑,

3497-

MFrot,

The Effect of a Rotating Magnetic Field on the Regenerative Potential of Platelets

-

Human,

Nor,

NA

30 healthy female and male volunteers

*PDGFR-BB↑, *TGF-β↑, *IGF-1↑, *FGF↑, *angioG↑, *Inflam↓, *ROS↓,

3488-

MFrot,

Rotating magnetic field improves cognitive and memory impairments in APP/PS1 mice by activating autophagy and inhibiting the PI3K/AKT/mTOR signaling pathway

-

in-vivo,

AD,

NA

2 h/day, 0.2 T, 4 Hz) for a duration of 6 months.

APP/PS1 mice

*cognitive↑, *memory↑, *neuroP↑, *Aβ↓, *PI3K↓, *Akt↓, *mTOR↓,

3499-

MFrot,

Rotating magnetic field delays human umbilical vein endothelial cell aging and prolongs the lifespan of Caenorhabditis elegans

-

in-vitro,

Nor,

HUVECs

*AntiAge↑, *AMPK↑, *mPGES-1↓, *Ca+2↑, *ER Stress↑, *OS↑, *ROS↓,

3491-

MFrot,

Magnetically controlled cyclic microscale deformation of in vitro cancer invasion models

-

in-vitro,

BC,

MDA-MB-231

Ca+2↑, ATF3↑, FOSB↑,

3492-

MFrot,

Chemo,

Synergistic Effect of Chemotherapy and Magnetomechanical Actuation of Fe-Cr-Nb-B Magnetic Particles on Cancer Cells

eff↑, TumCD↑,

3493-

MFrot,

Mechanical nanosurgery of chemoresistant glioblastoma using magnetically controlled carbon nanotubes

-

in-vivo,

GBM,

NA

20 ± 2 mT and a rotating frequency of 20 Hz

TumCD↑, MMP↓, Cyt‑c↑, Apoptosis↑, OS↑, DNAdam↑,

3494-

MFrot,

Magnetically switchable mechano-chemotherapy for enhancing the death of tumour cells by overcoming drug-resistance

-

in-vitro,

Var,

NA

eff↑, TumCD↑,

3495-

MFrot,

Synthesis of urchin-like nickel nanoparticles with enhanced rotating magnetic field-induced cell necrosis and tumor inhibition

-

in-vivo,

BC,

NA

mouse

TumCG↓,

3496-

MFrot,

GoldNP,

Enhancement of chemotherapy effects by non-lethal magneto-mechanical actuation of gold-coated magnetic nanoparticles

-

in-vitro,

Cerv,

HeLa

eff↑, tumCV↓,

3567-

MFrot,

The Effect of Extremely Low-Frequency Magnetic Field on Stroke Patients: A Systematic Review

-

Review,

Stroke,

NA

*eff↑, *ROS↓, *Inflam↓, *cognitive↑, *Catalase↑, *SOD↑, *SOD1↑, *SOD2↑, *GPx1↑, *GPx4↑, *IL1β↑, *neuroP↑, *toxicity∅,

2262-

MFrot,

Effects of 0.4 T Rotating Magnetic Field Exposure on Density, Strength, Calcium and Metabolism of Rat Thigh Bones

-

in-vivo,

ostP,

NA

0.4T, 8Hz, 30min/day, 30days

Rat

*BMD↑, *eff↓, *ALP↑, *other↑,

2258-

MFrot,

EXTH-68. ONCOMAGNETIC TREATMENT SELECTIVELY KILLS GLIOMA CANCER CELLS BY INDUCING OXIDATIVE STRESS AND DNA DAMAGE

-

in-vitro,

GBM,

GBM

-

in-vitro,

Nor,

SVGp12

TumVol↓, OS↑, γH2AX↑, DNAdam↑, selectivity↑, ROS↑, TumCD↑, eff↑, eff↓,

2259-

MFrot,

Method and apparatus for oncomagnetic treatment

-

in-vitro,

GBM,

NA

Oncomagnetic patent

MMP↓, Bcl-2↓, BAX↑, Bak↑, Cyt‑c↑, Casp3↑, Casp9↑, DNAdam↑, ROS↑, lactateProd↑, Apoptosis↑, MPT↑, *selectivity↑, eff↑, MMP↓, selectivity↑, TCA?, H2O2↑, eff↑, *antiOx↑, H2O2↑, eff↓, GSH/GSSG↓, *toxicity∅, OS↑,

2311-

MFrot,

Magnetic fields as a potential therapy for diabetic wounds based on animal experiments and clinical trials

-

in-vivo,

Nor,

HaCaT

diabetic wounds based on animal experiments

*COX2↓, *Inflam↓, *MMP9↑, *GPx↑, *Diff↑,

1737-

MFrot,

Fe,

Feature Matching of Microsecond-Pulsed Magnetic Fields Combined with Fe3O4 Particles for Killing A375 Melanoma Cells

-

in-vitro,

MB,

A375

Dose∅, tumCV↓,

777-

Mg,

Biodegradable Mg Implants Suppress the Growth of Ovarian Tumor

-

vitro+vivo,

Ovarian,

SKOV3

mice

TumCG↓, Apoptosis↑,

769-

Mg,

Magnesium and cancer: more questions than answers

-

Review,

NA,

NA

Risk↓,

770-

Mg,

Magnesium and cancer: a dangerous liason

-

Analysis,

NA,

NA

Risk↓,

771-

Mg,

Magnesium Ion: A New Switch in Tumor Treatment

TumCG↓,

772-

Mg,

https://pmc.ncbi.nlm.nih.gov/articles/PMC4759402/

-

Analysis,

NA,

NA

OS↑,

773-

Mg,

Methyl Jasmonate-induced Increase in Intracellular Magnesium Promotes Apoptosis in Breast Cancer Cells

-

in-vitro,

BC,

MCF-7

TRPM7↓, ROS↑, ER Stress↑, MAPK↑, ATP↓,

774-

Mg,

Calc,

Chemo,

Dietary Intake of Magnesium or Calcium and Chemotherapy-Induced Peripheral Neuropathy in Colorectal Cancer Patients

-

Analysis,

NA,

NA

ChemoSideEff↓,

775-

Mg,

The Supplement of Magnesium Element to Inhibit Colorectal Tumor Cells

-

vitro+vivo,

CRC,

DLD1

30mM

After 72 h treatment, the cell viability decreased by 71.7% in the 30 mM Mg2+ group

TumCCA↑, Apoptosis↑, Casp3↑, TumCG↓,

787-

Mg,

Magnesium and Human Health: Perspectives and Research Directions

VitD↑, other↓,

776-

Mg,

Magnesium intake is associated with a reduced risk of incident liver cancer, based on an analysis of the NIH-American Association of Retired Persons (NIH-AARP) Diet and Health Study prospective cohort

Risk↓,

778-

Mg,

Magnesium and the inflammatory response: potential physiopathological implications

*ROS↓,

779-

Mg,

Mg alloys with antitumor and anticorrosion properties for orthopedic oncology: A review from mechanisms to application strategies

TumCG↓,

780-

Mg,

Degradable magnesium implants inhibit gallbladder cancer

-

vitro+vivo,

Gall,

NA

high-purity Mg wires on gallbladder cancer

TumCG↓, Apoptosis↑, TumCCA↑,

781-

Mg,

Hypomagnesemia in the Cancer Patient

-

Analysis,

NA,

NA

other↓,

782-

Mg,

Oral magnesium supplements for cancer treatment‐induced hypomagnesemia: Results from a pilot randomized trial

-

Trial,

Var,

NA

*BioAv↑,

783-

Mg,

Magnesium intake and incidence of pancreatic cancer: the VITamins and Lifestyle study

Risk↓,

784-

Mg,

Direct and indirect associations between dietary magnesium intake and breast cancer risk

-

Analysis,

NA,

NA

Risk↓, CRP↓,

785-

Mg,

Magnesium: The overlooked electrolyte in blood cancers?

-

Analysis,

NA,

NA

Risk↓,

786-

Mg,

VitC,

A narrative review on the role of magnesium in immune regulation, inflammation, infectious diseases, and cancer

Risk↓, *VitD↑, *pH↝, *ROS↓, TumCG↓, eff↑,

788-

Mg,

Timeline (Bioavailability) of Magnesium Compounds in Hours: Which Magnesium Compound Works Best?

other↑, other↑,

1890-

MGO,

The Dual-Role of Methylglyoxal in Tumor Progression – Novel Therapeutic Approaches

-

Review,

Var,

NA

AntiCan?, TumCG↓, GAPDH↓, Apoptosis↑, TumCCA↑, MAPK↑, Bcl-2↓, MMP9↓, eff↑,

1892-

MGO,

Role of Glyoxalase 1 (Glo1) and methylglyoxal (MG) in behavior: recent advances and mechanistic insights

-

Review,

NA,

NA

MGO↑, ROS↑, other↝, GABA↑, other∅,

1891-

MGO,

Methylglyoxal induces mitochondria-dependent apoptosis in sarcoma

-

in-vitro,

SCC,

NA

NADH↓, MMP↓, Cyt‑c↑, selectivity↑, Apoptosis↑, ROS↑, ATP↓,

656-

MNPs,

MF,

Effects of combined delivery of extremely low frequency electromagnetic field and magnetic Fe3O4 nanoparticles on hepatic cell lines

-

in-vitro,

HCC,

HepG2

-

in-vitro,

Nor,

HL7702

BioAv↑, Apoptosis↑, *toxicity↓,

929-

Moringa,

Bioenhancers from mother nature and their applicability in modern medicine

-

Review,

Nor,

NA

*BioEnh↑,

1203-

MSM,

Methylsulfonylmethane Suppresses Breast Cancer Growth by Down-Regulating STAT3 and STAT5b Pathways

-

vitro+vivo,

BC,

MDA-MB-231

tumCV↓, STAT3↓, STAT5↓, IGF-1↓, Hif1a↓, VEGF↓, Brk/PTK6↓, IGF-1R↓,

1170-

MushCha,

Chaga mushroom extract suppresses oral cancer cell growth via inhibition of energy metabolism

-

in-vitro,

Oral,

HSC4

0, 160, 200, 400, and 800 μg/mL

tumCV↓, TumCP↓, TumCCA↑, STAT3↓, Glycolysis↓, MMP↓, TumAuto↑, p38↑, NF-kB↑,

1182-

MushCha,

Ergosterol peroxide from Chaga mushroom (Inonotus obliquus) exhibits anti-cancer activity by down-regulation of the β-catenin pathway in colorectal cancer

-

in-vitro,

CRC,

HCT116

-

in-vitro,

CRC,

HT-29

-

in-vitro,

CRC,

SW-620

-

in-vitro,

CRC,

DLD1

Apoptosis↑, TumCG↓, FASN↓, β-catenin/ZEB1↓, cMyc↓, cycD1↓, CDK8↓, Ki-67↓,

2484-

mushLions,

Neurotrophic and Neuroprotective Effects of Hericium erinaceus

-

Review,

Stroke,

NA

-

Review,

AD,

NA

-

Review,

Park,

NA

*eff↑, *BBB↑, *Dose↝, *neuroP↑, *cognitive↑, *toxicity∅,

1573-

MushReishi,

Ganoderma lucidum (Reishi mushroom) for cancer treatment

-

Review,

NA,

NA

A total of five RCTs with 373 subjects were included in this review

ChemoSen↑, CR3↝, eff↑, NK cell↑, T-Cell↑, QoL↑,

930-

MushShi,

Active Hexose Correlated Compound (AHCC) Inhibits the Proliferation of Ovarian Cancer Cells by Suppressing Signal Transducer and Activator of Transcription 3 (STAT3) Activation

-

in-vitro,

Ovarian,

NA

p‑STAT3↓, PTPN6↑, cycD1↓, Bcl-2↓, Mcl-1↓, survivin↓, VEGF↓,

2-

MushShi,

The Effects of Active Hexose Correlated Compound (AHCC) on Levels of CD4+ and CD8+ in Patients with Epithelial Ovarian Cancer or Peritoneal Cancer Receiving Platinum Based Chemotherapy

CD8+↑,

3-

MushShi,

AHCC Activation and Selection of Human Lymphocytes via Genotypic and Phenotypic Changes to an Adherent Cell Type: A Possible Novel Mechanism of T Cell Activation

LAT↑, FLRT2↑, GIT1↑, T-Cell↑,

1128-

Myr,

Myricetin suppresses TGF-β-induced epithelial-to-mesenchymal transition in ovarian cancer

-

vitro+vivo,

Ovarian,

NA

MAPK↓, ERK↓, PI3K↓, Akt↓, p‑PARP↑, cl‑Casp3↑, Bax:Bcl2↑, TumCMig↓, SMAD3↓,

1141-

Myr,

Myricetin: targeting signaling networks in cancer and its implication in chemotherapy

-

Review,

NA,

NA

*PI3K↑, *Akt↑, p‑Akt↓, SIRT3↑, p‑ERK↓, p38↓, VEGF↓, MEK↓, MKK4↓, MMP9↓, Raf↓, F-actin↓, MMP2↓, COX2↓, BMP2↓, cycD1↓, Bax:Bcl2↑, EMT↓, EGFR↓, TumAuto↑,

1044-

Myr,

Myricetin inhibits interferon-γ-induced PD-L1 and IDO1 expression in lung cancer cells

-

in-vitro,

Lung,

NA

PD-L1↓, IDO1↓,

1273-

Myr,

Myricetin Induces Ferroptosis and Inhibits Gastric Cancer Progression by Targeting NOX4

-

vitro+vivo,

GC,

NA

Ferroptosis↑, MDA↑, Iron↑, GSH↓, NOX4↑, NRF2↓, GPx4↓,

1998-

Myr,

CUR,

Thioredoxin-dependent system. Application of inhibitors

-

Review,

Var,

NA

TrxR↓, ROS↑,

1997-

Myr,

QC,

Inhibition of Mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity

-

in-vitro,

Lung,

A549

50, 75, and 100 umol/L

<1uM

TrxR↓, eff↑, TumCCA↑, eff↓, ROS↑,

116-

Myrrh,

The Role of Myrrh Metabolites in Cancer, Inflammation, and Wound Healing: Prospects for a Multi-Targeted Drug Therapy

-

in-vitro,

AML,

HL-60

26ug/mL

moderate cytotoxic

-

in-vitro,

AML,

K562

88ug/mL

moderate cytotoxic

-

in-vitro,

BC,

KAIMRC1

95ug/mL

ROS↑,

2939-

NAD,

Rad,

NMN ameliorated radiation induced damage in NRF2-deficient cell and mice via regulating SIRT6 and SIRT7

-

in-vitro,

Nor,

NA

*SIRT6↑, *DNAdam↓, *radioP↑, *ROS↓,

2938-

NAD,

NAD+ supplementation limits triple-negative breast cancer metastasis via SIRT1-P66Shc signaling

-

in-vivo,

BC,

NA

TumMeta↓, SIRT1↑,

2937-

NAD,

High-Dosage NMN Promotes Ferroptosis to Suppress Lung Adenocarcinoma Growth through the NAM-Mediated SIRT1-AMPK-ACC Pathway

-

in-vitro,

Lung,

A549

SIRT1↑, Dose↝, TumCP⇅, Ferroptosis↑, lipid-P↑, AMPK↑, ACC↑,

2936-

NAD,

The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update

*ROS↓, *DNAdam↓, *neuroP↑, *Inflam↓, *BioAv↑, *SIRT1↑, BioAv↝,

2935-

NAD,

Long-term NMN treatment increases lifespan and healthspan in mice in a sex dependent manner

-

in-vitro,

Nor,

NA

mice

*GutMicro↑, *OS↑,

2934-

NAD,

The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial

-

Trial,

Nor,

NA

80 participants

*Dose↑, *Strength↑,

2932-

NAD,

Neuroprotective effects and mechanisms of action of nicotinamide mononucleotide (NMN) in a photoreceptor degenerative model of retinal detachment

-

in-vitro,

Nor,

NA

using 661W cells

*SIRT1↑, *HO-1↑, *neuroP↑, *Apoptosis↓, *Inflam↓, *ROS↓, *antiOx↑, *toxicity↓,

2931-

NAD,

NAD+ Repletion Rescues Female Fertility during Reproductive Aging

-

in-vivo,

Nor,

NA

NMN in drinking water (2 g/L)

mice

*eff↑, *SIRT2↑, *other↑, *Dose↝,

2933-

NAD,

Nicotinamide mononucleotide (NMN) as an anti-aging health product – Promises and safety concerns

-

Review,

Nor,

NA

-

NA,

AD,

NA

-

NA,

Diabetic,

NA

-

NA,

Stroke,

NA

-

NA,

LiverDam,

NA

-

NA,

Park,

NA

*mtDam↓, *BioAv↝, *BioAv↑, *OS↑, *eff↑, *eff↑, *cognitive↑, *DNAdam↓, *SIRT1↑, *cardioP↑, *ROS↓, *Dose↝, *BioAv↑, *hepatoP↑, *eff↑, *BG↓, *creat↓,

981-

NarG,

QC,

Anti-estrogenic and anti-aromatase activities of citrus peels major compounds in breast cancer

-

in-vivo,

NA,

NA

30 mg/kg dissolved in Tween 80

mice

TumVol↓, CYP19↓,

1015-

NarG,

Naringin induces endoplasmic reticulum stress-mediated apoptosis, inhibits β-catenin pathway and arrests cell cycle in cervical cancer cells

-

in-vitro,

Cerv,

SiHa

764uM

-

in-vitro,

Cerv,

HeLa

793 uM

-

in-vitro,

Cerv,

C33A

745uM

ER Stress↑, p‑eIF2α↑, CHOP↑, PARP1↑, Casp3↑, β-catenin/ZEB1↓, GSK‐3β↓, p‑β-catenin/ZEB1↓, p‑GSK‐3β↓, TumCCA↑, P21↑, p27↑,

1129-

NarG,

Naringenin Attenuated Prostate Cancer Invasion via Reversal of Epithelial-to-Mesenchymal Transition and Inhibited uPA Activity

-

in-vitro,

Pca,

PC3

E-cadherin↓, Vim↓, Snail↓, Twist↓, EMT↓, uPA↓,

928-

NarG,

PacT,

Bioenhancers from mother nature and their applicability in modern medicine

-

Review,

Nor,

NA

*BioEnh↑,

1311-

NarG,

Rad,

Naringenin sensitizes lung cancer NCI-H23 cells to radiation by downregulation of akt expression and metastasis while promoting apoptosis

-

in-vitro,

Lung,

H23

tumCV↓, ROS↑, Casp3↑, p‑Akt↓, Akt↓, MMP2↓, P21↓,

1800-

NarG,

Naringenin

-

Human,

Nor,

NA

CYP19↓,

1808-

NarG,

Intake of flavonoids and lung cancer

-

Analysis,

NA,

NA

AntiCan↑, CYP1A1↓,

1807-

NarG,

A Systematic Review of the Preventive and Therapeutic Effects of Naringin Against Human Malignancies

-

Review,

NA,

NA

AntiTum↑, TumCP↓, tumCV↓, TumCCA↑, Mcl-1↓, RAS↓, e-Raf↓, VEGF↓, AntiAg↑, MMP2↓, MMP9↓, TIMP2↑, TIMP1↑, p38↓, Wnt↓, β-catenin/ZEB1↑, Casp↑, P53↑, BAX↑, COX2↓, GLO-I↓, CYP1A1↑, lipid-P↓, p‑Akt↓, p‑mTOR↓, VCAM-1↓, P-gp↓, survivin↓, Bcl-2↓, ROS↑, ROS↑, MAPK↑, STAT3↓, chemoP↑,

1806-

NarG,

Naringin: Nanotechnological Strategies for Potential Pharmaceutical Applications

-

Review,

NA,

NA

Inflam↓, antiOx↓, AntiCan↑, BioAv↓, BioAv↓, BioAv↑, INF-γ↓, IL6↓, TNF-α↓, IL10↑, CRP↓,

1805-

NarG,

Naringenin suppresses epithelial ovarian cancer by inhibiting proliferation and modulating gut microbiota

-

in-vitro,

Ovarian,

A2780S

200 μM

-

in-vivo,

NA,

NA

mice

TumCP↓, TumCMig↓, PI3K↓, TumVol↓, TumW↓, BioAv↑, GutMicro↑, Dose∅, eff↑, EGFR↓, cycD1↓, toxicity∅,

1804-

NarG,

Beneficial effects of citrus flavanones naringin and naringenin and their food sources on lipid metabolism: An update on bioavailability, pharmacokinetics, and mechanisms

-

Review,

NA,

NA

GutMicro↝, BioAv↝,

1803-

NarG,

Naringin and naringenin as anticancer agents and adjuvants in cancer combination therapy: Efficacy and molecular mechanisms of action, a comprehensive narrative review

-

Review,

Var,

NA

JAK↓, STAT↓, PI3K↓, Akt↓, mTOR↓, NF-kB↓, COX2↓, NOTCH↓, TumCCA↑,

1802-

NarG,

ATV,

Bioenhancing effects of naringin on atorvastatin

-

in-vivo,

Nor,

NA

AST along with naringin (15 and 30 mg/kg)

Rats

BioEnh↑, LDL↓, P450↓, P-gp↓,

1801-

NarG,

A Narrative Review on Naringin and Naringenin as a Possible Bioenhancer in Various Drug-Delivery Formulations

-

Review,

Var,

NA

AntiCan↓, CYP19↓, PI3K↓, Akt↓, TumAuto↑, eff↑, BioEnh↑, NA↓,

1799-

NarG,

Naringenin as potent anticancer phytocompound in breast carcinoma: from mechanistic approach to nanoformulations based therapeutics

-

Review,

NA,

NA

TumCCA↑, BioAv↑, Half-Life∅, TNF-α↓, Casp8↑, BAX↑, Bak↑, EGF↓, mTOR↓, PI3K↓, ERK↓, Akt↓, NF-kB↓, VEGF↓, angioG↓, antiOx↑, EMT↓, OS↑, MAPK↓, ChemoSen↑, MMP9↓, MMP2↓, ROS↑, ROS↑, GSH↓, Casp3↑, ROS↑,

1798-

NarG,

Naringenin: A potential flavonoid phytochemical for cancer therapy

-

Review,

NA,

NA

*Inflam↓, *antiOx↓, neuroP↑, hepatoP↑, AntiCan↑, Apoptosis↑, TumCCA↑, angioG↓, ROS↝, SOD↑, TGF-β↓, Treg lymp↓, IL1β↓, *BioAv↝, ChemoSen↑, cardioP↑,

1797-

NarG,

Naringin inhibits growth potential of human triple-negative breast cancer cells by targeting β-catenin signaling pathway

-

in-vitro,

BC,

MDA-MB-231

TumCG↓, β-catenin/ZEB1↓, AntiTum↑, Apoptosis↑, TumCCA↑, P21↑, survivin↓,

1271-

NCL,

Niclosamide inhibits ovarian carcinoma growth by interrupting cellular bioenergetics

-

vitro+vivo,

Ovarian,

SKOV3

Wnt/(β-catenin)↓, mTOR↓, STAT3↓, NF-kB↓, NOTCH↓, TumCG↓, Apoptosis↑, MEK↓, ERK↓, mitResp↓, Glycolysis↓, ROS↑, JNK↑,

1270-

NCL,

Rad,

Niclosamide enhances the antitumor effects of radiation by inhibiting the hypoxia-inducible factor-1α/vascular endothelial growth factor signaling pathway in human lung cancer cells

-

in-vivo,

Lung,

NA

Hif1a↓, VEGF↓,

1269-

NCL,

Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway

-

in-vitro,

Pca,

DU145

STAT3↓, TumCG↓, Apoptosis↑, TumCCA↑, cycD1↓, cMyc↓, Bcl-xL↓,

1268-

NCL,

carbop,

Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer

-

in-vitro,

Ovarian,

NA

0.1 to 5 μM

Wnt/(β-catenin)↓, ALDH1A1↓, LRP6↓,

1267-

NCL,

Niclosamide suppresses migration of hepatocellular carcinoma cells and downregulates matrix metalloproteinase-9 expression

-

in-vitro,

HCC,

NA

1-10uM

TumCP↓, cycD1↓, MMP9↓, TumCMig↓,

946-

Nimb,

Nimbolide retards T cell lymphoma progression by altering apoptosis, glucose metabolism, pH regulation, and ROS homeostasis

-

in-vivo,

NA,

NA

murine model of T cell lymphoma : tumor bearing mice

Apoptosis↑, Bcl-2↓, P53↑, cl‑Casp3↑, Cyt‑c↑, ROS↑, SOD↓, Catalase↓, Glycolysis↓, GLUT3↓, LDHA↓, MCT1↓, NHE1↓, ATPase↓, CAIX↓,

1911-

Nos,

Noscapine inhibits tumor growth in TMZ-resistant gliomas

-

in-vitro,

GBM,

NA

-

in-vivo,

GBM,

NA

animals

TumCG↓, TumCI↓, OS↑,

150-

NRF,

CUR,

docx,

Subverting ER-Stress towards Apoptosis by Nelfinavir and Curcumin Coexposure Augments Docetaxel Efficacy in Castration Resistant Prostate Cancer Cells

-

in-vitro,

Pca,

C4-2B

NFR (5 µM), CUR (5 µM),DTX 10nM

CRPC

p‑Akt↓, p‑eIF2α↑, ER Stress↑, ATFs↑, CHOP↑, TRIB3↑,

991-

OA,

Blockade of glycolysis-dependent contraction by oroxylin a via inhibition of lactate dehydrogenase-a in hepatic stellate cells

-

in-vivo,

NA,

NA

40 mg/kg

fibrotic mice

-

in-vivo,

Nor,

NA

cultured human HSCs

*Glycolysis↓, *GlucoseCon↓, *lactateProd↓, *ECAR↓, *HK2↓, *PFK↓, *PKM2↓, *LDHA↓,

968-

OA,

Oroxylin A inhibits glycolysis-dependent proliferation of human breast cancer via promoting SIRT3-mediated SOD2 transcription and HIF1α destabilization

-

vitro+vivo,

BC,

MDA-MB-231

mice

-

in-vitro,

BC,

MBT-2

Hif1a↓, SIRT3↑, SOD2↑, GlucoseCon↓, Glycolysis↓, TumCG↓,

1130-

OA,

Oroxylin A Suppresses the Cell Proliferation, Migration, and EMT via NF-κB Signaling Pathway in Human Breast Cancer Cells

-

in-vitro,

BC,

MDA-MB-231

TumCP↓, TumCI↓, TumCMig↓, E-cadherin↑, N-cadherin↓, Vim↓, NF-kB↓,

1229-

OA,

Review of the Clinical Effect of Orlistat

-

Review,

NA,

NA

NPC1L1↓, FASN↓, ER Stress↑, angioG↓, TumCG↓,

1228-

OLST,

Orlistat Mitigates Oxidative Stress-Linked Myocardial Damage via NF-κβ- and Caspase-Dependent Activities in Obese Rats

-

in-vivo,

Obesity,

NA

10 mg/kg/day

*ROS↓, *NF-kB↓,

1227-

OLST,

Anti-Obesity Drug Orlistat Alleviates Western-Diet-Driven Colitis-Associated Colon Cancer via Inhibition of STAT3 and NF-κB-Mediated Signaling

-

in-vivo,

CRC,

NA

mice

OS↑, Inflam↓, TumCG↓, STAT3↓, NF-kB↓, β-catenin/ZEB1↓, Slug↓, XIAP↓, CDK4↓, cycD1↓, Bcl-2↓,

1226-

OLST,

Knockdown of PGM1 enhances anticancer effects of orlistat in gastric cancer under glucose deprivation

-

vitro+vivo,

GC,

NA

PGM1∅, FASN↓, Apoptosis↑, lipidLev↑, GlucoseCon↑, eff↑,

1225-

OLST,

Orlistat Induces Ferroptosis in Pancreatic Neuroendocrine Tumors by Inactivating the MAPK Pathway

-

vitro+vivo,

PC,

NA

TumCMig↓, TumCI↓, Ferroptosis↑, MAPK↓,

1045-

OLST,

Fatty acid synthase inhibitor orlistat impairs cell growth and down-regulates PD-L1 expression of a human T-cell leukemia line

-

in-vitro,

ALL,

Jurkat

FASN↓, TumCG↓, PD-L1↓,

969-

OLST,

Orlistat as a FASN inhibitor and multitargeted agent for cancer therapy

-

Review,

NA,

NA

FASN↓,

1812-

Oxy,

Hyperbaric oxygen suppressed tumor progression through the improvement of tumor hypoxia and induction of tumor apoptosis in A549-cell-transferred lung cancer

-

in-vitro,

Lung,

A549

-

in-vivo,

Lung,

NA

mouse

-

in-vitro,

NA,

BEAS-2B

TumCG↓, CD31↑, P53↓, Dose∅, other↑, Apoptosis↑, Hif1a↑, selectivity↑,

1811-

Oxy,

Hyperbaric oxygen therapy and cancer—a review

-

Review,

NA,

NA

toxicity∅, AntiTum↑, MAPK↑, ERK↓, ChemoSen↑, ChemoSen↑, RadioS↑,

1814-

Oxy,

Hyperbaric oxygen therapy for malignancy: a review

-

Review,

Var,

NA

ROS↑, SOD↑, OS↑, ChemoSen↑, RadioS↑, BioAv↑,

1813-

Oxy,

Advances in hyperbaric oxygen to promote immunotherapy through modulation of the tumor microenvironment

-

Review,

Var,

NA

ChemoSen↑, RadioS↑, PD-L1↓, Hif1a↓, ROS↑,

2451-

PA,

The Promoting Role of HK II in Tumor Development and the Research Progress of Its Inhibitors

-

Review,

Var,

NA

HK2↓, ATP↓, ROS↑,

2452-

PA,

Targeting Pyruvate Kinase M2 and Hexokinase II, Pachymic Acid Impairs Glucose Metabolism and Induces Mitochondrial Apoptosis

-

in-vitro,

BC,

SkBr3

HK2↓, GlucoseCon↓, lactateProd↓, mtDam↑, ATP↓, ROS↑, PKM2↑,

2396-

PACs,

PKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinoma

-

in-vitro,

HCC,

HCCLM3

80.59 μM

-

in-vitro,

HCC,

SMMC-7721 cell

76.32 μM

-

in-vitro,

HCC,

Bel-7402

-

in-vitro,

HCC,

HUH7

-

in-vitro,

HCC,

HepG2

-

in-vitro,

Nor,

L02

TumCP↓, TumCCA↓, Apoptosis↑, GlucoseCon↓, lactateProd↓, PKM2↓, Glycolysis↓, HK2↓, PFK↓, OXPHOS↑, ChemoSen↑, HSP90↓, Hif1a↓,

1239-

PACs,

Cranberry proanthocyanidins inhibit MMP production and activity

-

in-vitro,

Nor,

NA

*MMPs↓, *MMP1↓, *MMP9↓, *NF-kB↓,

959-

PACs,

Grape seed extract inhibits VEGF expression via reducing HIF-1α protein expression

-

in-vitro,

GBM,

U251

GSE 10 μg/ml

The GSE preparation contains ∼19, 36, 8 and 22 ng/μg of procyanidins B1, B2, B3 and B4, respectively.

-

in-vitro,

BC,

MDA-MB-231

Hif1a↓, p‑Akt↓, p‑S6K↓, p‑S6↓, VEGF↓,

1988-

Part,

Parthenolide Induces ROS-Mediated Apoptosis in Lymphoid Malignancies

-

in-vitro,

lymphoma,

NCI-H929

0.1 µM and 100 µM

(IC50) ranging between 1 µM and 10 µM.

NF-kB↓, ROS↑, GSH↓, MMP↓, GPx1↓,

1996-

Part,

Critical roles of intracellular thiols and calcium in parthenolide-induced apoptosis in human colorectal cancer cells

-

in-vitro,

CRC,

COLO205

Apoptosis↑, GSH↓, ROS↑, Ca+2↑, GRP78/BiP↑, ER Stress↑, eff↓, eff↑, Thiols↓,

1995-

Part,

The protective effect of parthenolide in an in vitro model of Parkinson's disease through its regulation of nuclear factor-kappa B and oxidative stress

-

in-vitro,

Park,

SH-SY5Y

*Apoptosis↓, *ROS↓, *BAX↓, *NF-kB↓, *P53↓, *p‑NF-kB↓,

1994-

Part,

Parthenolide Inhibits Tumor Cell Growth and Metastasis in Melanoma A2058 Cells

-

in-vitro,

Melanoma,

A2058

20uM

-

in-vitro,

Nor,

L929

27uM

tumCV↓, selectivity?, ROS?, BAX↑, TumCCA?, MMP2↓, MMP9↓, TumCMig↓, eff↑,

1993-

Part,

Parthenolide induces apoptosis and autophagy through the suppression of PI3K/Akt signaling pathway in cervical cancer

-

in-vitro,

Cerv,

HeLa

6 µM

tumCV↓, TumAuto↑, Casp3↑, BAX↑, Beclin-1↑, ATG3↑, ATG5↑, Bcl-2↓, mTOR↓, PI3K↓, Akt↓, PTEN↑, ROS↑, MMP↓,

1992-

Part,

Parthenolide induces ROS-dependent cell death in human gastric cancer cell

-

in-vitro,

BC,

MGC803

TumCCA↑, Casp↑, Apoptosis↑, Necroptosis↑, RIP1↓, RIP3↑, MLKL↑, ROS↑, eff↓,

1991-

Part,

A novel SLC25A1 inhibitor, parthenolide, suppresses the growth and stemness of liver cancer stem cells with metabolic vulnerability

-

in-vitro,

Liver,

HUH7

17.02 μM

liver cancer stem cells (LCSCs).

TumCCA↑, Apoptosis↑, CSCs↓, ROS↑, OXPHOS↓, MMP↓, SLC25A1↓, IDH2↓,

1990-

Part,

Parthenolide alleviates cognitive dysfunction and neurotoxicity via regulation of AMPK/GSK3β(Ser9)/Nrf2 signaling pathway

-

in-vitro,

AD,

PC12

*Apoptosis↓, *ROS↓, *MMP↓, *memory↑, *eff↑,

1989-

Part,

Parthenolide and Its Soluble Analogues: Multitasking Compounds with Antitumor Properties

-

Review,

Var,

NA

eff↑, NF-kB↓, STAT↓, ROS↑, Inflam↓, Wnt↓, TCF-4↓, LEF1↓, GSH↓, MMP↓, Casp↑, eff↓, CSCs↓,

1987-

Part,

Rad,

A NADPH oxidase dependent redox signaling pathway mediates the selective radiosensitization effect of parthenolide in prostate cancer cells

-

in-vitro,

Pca,

PC3

-

in-vitro,

Nor,

PrEC

selectivity↑, RadioS↑, ROS↑, *ROS∅, NADPH↑, Trx↓, PI3K↑, Akt↑, p‑FOXO3↓, SOD2↓, Catalase↓, radioP↑, *NADPH∅, *GSH↑, *GSH/GSSG↑, *NRF2↑,

1986-

Part,

Modulation of Cell Surface Protein Free Thiols: A Potential Novel Mechanism of Action of the Sesquiterpene Lactone Parthenolide

-

in-vitro,

NA,

NA

JNK↑, ROS↑, eff↓, NF-kB↓, Trx↓,

1985-

Part,

KEAP1 Is a Redox Sensitive Target That Arbitrates the Opposing Radiosensitive Effects of Parthenolide in Normal and Cancer Cells

-

in-vitro,

Pca,

LNCaP

-

in-vitro,

Pca,

DU145

-

in-vitro,

Nor,

PrEC

-

in-vivo,

NA,

NA

mice

ROS↑, NADPH↑, RadioS↑, radioP↑, Trx↓, *ox-Keap1↑, ox-Keap1↓, rd-Keap1↑, *NRF2↑, NRF2∅, NF-kB↓,

1984-

Part,

Targeting Thioredoxin Reductase by Parthenolide Contributes to Inducing Apoptosis of HeLa Cells

-

in-vitro,

Cerv,

HeLa

∼3 μm

AntiCan↑, TrxR1↓, TrxR2↓, ROS↑, Apoptosis↑, eff↓, eff↑,

1983-

Part,

Targeting thioredoxin reductase by micheliolide contributes to radiosensitizing and inducing apoptosis of HeLa cells

-

in-vitro,

Cerv,

HeLa

eff↑, TrxR↓, ROS↑, RadioS↑,

2031-

PB,

Phenylbutyrate is a multifaceted drug that exerts neuroprotective effects and reverses the Alzheimer´s disease-like phenotype of a commonly used mouse model

-

in-vivo,

AD,

NA

In Tg2576 mice administered PBA or NaBu for 3 weeks,

*neuroP↑, *HDAC↓, *ChemChap↑,

2036-

PB,

Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate

-

in-vitro,

Pca,

NA

-

in-vivo,

NA,

NA

Copenhagen rats

TumCG↓, eff↑, Diff↑,

2037-

PB,

Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria

-

in-vitro,

GBM,

NA

-

in-vivo,

GBM,

NA

rats bearing intracranial gliomas

AntiTum↑, *toxicity↓, selectivity↑, TumCG↓,

2035-

PB,

Sodium Phenylbutyrate Controls Neuroinflammatory and Antioxidant Activities and Protects Dopaminergic Neurons in Mouse Models of Parkinson’s Disease

-

in-vitro,

Nor,

glial

-

in-vivo,

NA,

NA

mice

*ROS↓, *Inflam↑, *P21↓, *antiOx↑, *GSH↑, *NF-kB↓, *neuroP↑, *HDAC↓, *iNOS↓, *TNF-α↓, *IL1β↓, *LDL↓, ROS↓,

2034-

PB,

Protective effects of 4-phenylbutyrate derivatives on the neuronal cell death and endoplasmic reticulum stress

-

in-vitro,

Nor,

SH-SY5Y

*ER Stress↓, *ChemChap↓, *cytoP↑, *cellD↓, *neuroP↑,

2033-

PB,

Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model

-

in-vivo,

AD,

NA

established mouse model

*p‑tau↑, *GSK‐3β↓, *ac‑Histones↑, *neuroP↑,

2032-

PB,

Phenylbutyric acid reduces amyloid plaques and rescues cognitive behavior in AD transgenic mice

-

in-vivo,

AD,

NA

AD transgenic mic

*cognitive↑, *memory↑, *neuroP↑,

2062-

PB,

Sodium 4-phenylbutyrate induces apoptosis of human lung carcinoma cells through activating JNK pathway

-

in-vitro,

Lung,

H460

-

in-vitro,

Lung,

H1792

-

in-vitro,

Lung,

A549

-

in-vitro,

Lung,

SK-LU-1

-

in-vitro,

Nor,

HBE4-E6/E7

JNK↓, ERK↓,

2049-

PB,

Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors

-

Review,

Var,

NA

HDAC↓, ac‑H3↑, ac‑H4↑, ac‑H3↑, eff↝, toxicity↓,

2061-

PB,

Chemo,

Complementary effects of HDAC inhibitor 4-PB on gap junction communication and cellular export mechanisms support restoration of chemosensitivity of PDAC cells

-

in-vitro,

PC,

PANC1

-

in-vitro,

PC,

COLO357

-

in-vitro,

PC,

Bxpc-3

HDAC↓, Apoptosis↑, eff↑, selectivity↑, TumCCA↑, eff↑, selectivity↑,

2059-

PB,

Gambogenic acid induces apoptosis and autophagy through ROS-mediated endoplasmic reticulum stress via JNK pathway in prostate cancer cells

2058-

PB,

Induction of Human-Lung-Cancer-A549-Cell Apoptosis by 4-Hydroperoxy-2-decenoic Acid Ethyl Ester through Intracellular ROS Accumulation and the Induction of Proapoptotic CHOP Expression

-

in-vitro,

Lung,

A549

ER Stress↓,

2057-

PB,

Trichomonas vaginalis induces apoptosis via ROS and ER stress response through ER–mitochondria crosstalk in SiHa cells

-

in-vitro,

Cerv,

SiHa

4-PBA (0, 0.2, 1, 2 mM)

ROS↓, tumCV∅, cl‑PARP↓, cl‑Casp3↓, MMP∅, ER Stress↓,

2056-

PB,

Endoplasmic Reticulum Stress Induces ROS Production and Activates NLRP3 Inflammasome Via the PERK-CHOP Signaling Pathway in Dry Eye Disease

-

in-vitro,

Nor,

HCE-2

*ROS↓, *NLRP3↓, *IL1β↓, *TXNIP↑, *ER Stress↓,

2055-

PB,

The Effects of Butyric Acid on the Differentiation, Proliferation, Apoptosis, and Autophagy of IPEC-J2 Cells

-

in-vitro,

Nor,

IPEC-J2

0.2-0.4 mM BT

also (0.5 mM or higher)

*Diff↑, *TumCP↓, *TumCCA↑, *ROS↑, *Casp3↑, *TNF-α↑,

2054-

PB,

Sodium butyrate induces ferroptosis in endometrial cancer cells via the RBM3/SLC7A11 axis

-

in-vitro,

EC,

ISH

-

in-vitro,

EC,

HEC1B

Ferroptosis↑, xCT↓, RBM3↑, HDAC↓, ROS↑,

2053-

PB,

4-Phenyl butyric acid prevents glucocorticoid-induced osteoblast apoptosis by attenuating endoplasmic reticulum stress

-

in-vitro,

ostP,

3T3

*ER Stress↓, *mtDam↓, *Apoptosis↓, eff↑,

2052-

PB,

Lipid-regulating properties of butyric acid and 4-phenylbutyric acid: Molecular mechanisms and therapeutic applications

-

Review,

NA,

NA

*HDAC↓, *Half-Life↑, *Half-Life↑, *lipoGen↓, *ER Stress↓, *FAO↑, *ROS↓, *BioAv↑,

2051-

PB,

Beneficial Effects of Sodium Phenylbutyrate Administration during Infection with Salmonella enterica Serovar Typhimurium

-

in-vivo,

Inf,

NA

mice

*Inf↓, *GutMicro↑, *IL17↑, *Inflam↓, *ER Stress↓, *ROS↓, *OS↑, *Bacteria↓, *Neut↑, *toxicity↓,

2038-

PB,

A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies

-

Trial,

Var,

NA

Dose∅, *toxicity↝, BioAv↑, SD↑,

2048-

PB,

Sodium Phenylbutyrate Inhibits Tumor Growth and the Epithelial-Mesenchymal Transition of Oral Squamous Cell Carcinoma In Vitro and In Vivo

-

in-vitro,

OS,

CAL27

4mM

-

in-vitro,

Oral,

HSC3

3.7mM

-

in-vitro,

OS,

SCC4

3mM

-

in-vivo,

NA,

NA

*NH3↓, *HDAC↓, *ER Stress↓, Apoptosis?, Bcl-2↓, cl‑Casp3↑, TGF-β↑, N-cadherin↓, E-cadherin↑, TumVol↓, eff↑,

2046-

PB,

Sodium butyrate promotes apoptosis in breast cancer cells through reactive oxygen species (ROS) formation and mitochondrial impairment

-

in-vitro,

BC,

MCF-7

0.1–20 mM) for 24, 48, 72 h

-

in-vitro,

BC,

MDA-MB-468

-

in-vitro,

Nor,

MCF10

Apoptosis↑, i-ROS?, Casp↑, MMP?, selectivity↑, *ROS∅, HDAC↓, DNArepair↓, Casp3↑, Casp8↑, *toxicity↓, TumCCA↑,

2045-

PB,

Phenylbutyrate—a pan-HDAC inhibitor—suppresses proliferation of glioblastoma LN-229 cell line

-

in-vitro,

GBM,

LN229

0.5 to 15 mmol/L

1.21

-

in-vitro,

GBM,

LN-18

1.92 mmol/L,

HDAC↓, TumCG↓, TumCCA↑, P21↑, Bcl-2↓, Bcl-xL↓, BioAv↑,

2044-

PB,

DCA,

Differential inhibition of PDKs by phenylbutyrate and enhancement of pyruvate dehydrogenase complex activity by combination with dichloroacetate

-

in-vivo,

NA,

NA

mice

PDK1↓, PDKs↓, eff↑, PDH↑,

2043-

PB,

Cisplatin,

Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin

-

in-vitro,

HNSCC,

UM-SCC-1

2 mM phenylbutyrate for 5 days

ChemoSen↑, eff↑, HDAC↓, BRCA1↓, RadioS↑,

2042-

PB,

Phenylbutyrate, a histone deacetylase inhibitor, protects against Adriamycin-induced cardiac injury

-

in-vitro,

Nor,

NA

mouse

*HDAC↓, *toxicity↓, *LDH↓, *SOD2↑, *ROS↓, *cardioP↑, *antiOx↑,

2041-

PB,

The Effect of Glucose Concentration and Sodium Phenylbutyrate Treatment on Mitochondrial Bioenergetics and ER Stress in 3T3-L1 Adipocytes

-

in-vitro,

Nor,

3T3

*mitResp↓, *ER Stress↓, MMP↓, GlucoseCon↓, OCR↓, CHOP↑,

2063-

PB,

Rad,

Phenylbutyrate sensitizes human glioblastoma cells lacking wild-type p53 function to ionizing radiation

-

in-vitro,

GBM,

U87MG

2 mM

-

NA,

NA,

U251

RadioS↑, eff↝, P53↝,

2039-

PB,

TXNIP mediates the differential responses of A549 cells to sodium butyrate and sodium 4‐phenylbutyrate treatment

-

in-vitro,

Lung,

A549

-

in-vitro,

Nor,

HEK293

TXNIP↑, Casp3↑, Casp7↑, mt-ROS↑, GlucoseCon↓, TumCP↓, TumCD↑, IGF-2↑, HDAC↓, ROS⇅,

2029-

PB,

Phenylbutyric Acid: simple structure - multiple effects

-

Review,

Var,

NA

NH3↓, HDAC↓, ChemChap↑,

2030-

PB,

4-Phenylbutyric acid protects against neuronal cell death by primarily acting as a chemical chaperone rather than histone deacetylase inhibitor

-

Review,

Nor,

NA

*HDAC↓, *neuroP↑, *ChemChap↑,

2074-

PB,

Chemo,

The effect of combined treatment with sodium phenylbutyrate and cisplatin, erlotinib, or gefitinib on resistant NSCLC cells

-

in-vitro,

Lung,

A549

10uM

-

in-vitro,

Lung,

Calu-6

8.53uM

-

in-vitro,

Lung,

H1650

4.53uM

TumCG↓, eff↑, ChemoSen↑, HDAC↓,

2075-

PB,

Chemo,

Preliminary Findings on the Use of Targeted Therapy in Combination with Sodium Phenylbutyrate in Colorectal Cancer after Failure of Second-Line Therapy—A Potential Strategy for Improved Survival

-

Trial,

CRC,

NA

OS↑, HDAC↓,

2076-

PB,

Sodium Butyrate Induces Endoplasmic Reticulum Stress and Autophagy in Colorectal Cells: Implications for Apoptosis

-

in-vitro,

CRC,

HCT116

0-5mM

-

in-vitro,

CRC,

HT29

TumCP↓, TumAuto↑, Apoptosis↑, ER Stress↑, BID↑, CHOP↑, PDI↑, IRE1↓, LC3‑Ⅱ/LC3‑Ⅰ↑, LC3B↑, Beclin-1↑, other↝, other↝,

2070-

PB,

Phenylbutyrate-induced apoptosis is associated with inactivation of NF-kappaB IN HT-29 colon cancer cells

-

in-vitro,

CRC,

HT-29

TumCG↓, Apoptosis↑, MMP↓, Casp3↑, PARP↓, NF-kB↓, eff↑,

2069-

PB,

Toxic and metabolic effect of sodium butyrate on SAS tongue cancer cells: role of cell cycle deregulation and redox changes

-

in-vitro,

Tong,

NA

TumCG↓, ROS↑, P21↑, CycB↓, cDC2↓, CDC25↓, eff↓, TumCCA↑, Apoptosis↑,

2068-

PB,

Phenylbutyrate-induced glutamine depletion in humans: effect on leucine metabolism

-

in-vivo,

Nor,

NA

glut↓, NH3↓, eff↝,

2067-

PB,

Histone Deacetylase (HDAC) Inhibitors: Current Evidence for Therapeutic Activities in Pancreatic Cancer

-

in-vitro,

PC,

NA

HDAC↓, HATs↑,

2066-

PB,

Rad,

Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas

-

in-vitro,

GBM,

U251

RadioS↑,

2065-

PB,

TMZ,

Inhibition of Mitochondria- and Endoplasmic Reticulum Stress-Mediated Autophagy Augments Temozolomide-Induced Apoptosis in Glioma Cells

-

in-vitro,

GBM,

NA

eff↑, ROS↑, MMP↓, ER Stress↑, CHOP↑, GRP78/BiP↑, pro‑Casp12↓, eff↝, Ca+2↝,

2064-

PB,

Rad,

Phenylbutyrate Attenuates the Expression of Bcl-XL, DNA-PK, Caveolin-1, and VEGF in Prostate Cancer Cells

-

in-vitro,

Pca,

PC3

2 or 5 mM PB

-

in-vitro,

Pca,

DU145

-

in-vitro,

Pca,

LNCaP

Bcl-xL↓, Cav1↓, VEGF↓, RadioS↑, chemoP↑, HDAC↓, *toxicity↓, Diff↑, Prot↓,

2025-

PB,

Complete response of a recurrent, multicentric malignant glioma in a patient treated with phenylbutyrate

-

Case Report,

GBM,

NA

Dose↝, OS↑,

2026-

PB,

Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: A dose escalation and pharmacologic study

-

Trial,

GBM,

NA

Twenty-three patients with supratentorial recurrent malignant gliomas were enrolled on this dose escalation trial

Dose↝, Dose↑, Dose↝, OS↑, HDAC↓, TumCCA↑, P21↑, other↝, BioAv↑, eff↑,

2027-

PB,

Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors

-

Trial,

Var,

NA

TumCG↓, Dose↝, toxicity↓, Dose↝, HDAC↓, OS↑,

2028-

PB,

Potential of Phenylbutyrate as Adjuvant Chemotherapy: An Overview of Cellular and Molecular Anticancer Mechanisms

-

Review,

Var,

NA

HDAC↓, TumCCA↑, P21↑, Dose↝, Telomerase↓, IGFBP3↑, p‑p38↑, JNK↑, ERK↑, BAX↑, Casp3↑, Bcl-2↓, Cyt‑c↝, FAK↓, survivin↓, VEGF↓, angioG↓, DNArepair↓, TumMeta↓, HSP27↑, ASK1↑, ROS↑, eff↑, ER Stress↓, GRP78/BiP↓, CHOP↑, AR↓, other?,

2078-

PB,

Butyrate-induced apoptosis in HCT116 colorectal cancer cells includes induction of a cell stress response

-

in-vitro,

CRC,

HCT116

0-20mM

p38↑, ER Stress↑, Casp3↑, Casp7↑, TumCD↑, Apoptosis↑, TumCP↑, HSP27↓,

2077-

PB,

Butyrate induces ROS-mediated apoptosis by modulating miR-22/SIRT-1 pathway in hepatic cancer cells

-

in-vitro,

Liver,

HUH7

5mM

miR-22↑, SIRT1↓, ROS↑, Cyt‑c↑, Casp3↑, eff↓, TumCG↓, TumCP↓, HDAC↓, SIRT1↓, CD44↓, proMMP2↓, MMP↓, SOD↓,

2421-

PB,

Sodium butyrate inhibits aerobic glycolysis of hepatocellular carcinoma cells via the c‐myc/hexokinase 2 pathway

-

in-vitro,

HCC,

HCCLM3

3.91mM

-

in-vivo,

NA,

NA

mouse xenograft model

-

in-vitro,

HCC,

Bel-7402

2.61mM

-

in-vitro,

HCC,

SMMC-7721 cell

4.18mM

-

in-vitro,

Nor,

L02

19.68 mM

Glycolysis↓, Apoptosis↑, TumCP↓, lactateProd↓, GlucoseCon↓, HK2↓, ChemoSen↑, *toxicity↓, cMyc↓, PFK1↓, LDHA↓, cMyc↓, ChemoSen↑,

2429-

PB,

Impact of butyrate on PKM2 and HSP90β expression in human colon tissues of different transformation stages: a comparison of gene and protein data

-

in-vitro,

Colon,

NA

PKM2↓, *HSP90↑, HSP90∅,

998-

PB,

Phenyl butyrate inhibits pyruvate dehydrogenase kinase 1 and contributes to its anti-cancer effect

-

in-vivo,

NA,

NA

zebrafish and wild type mice

p‑PDH↓, PDH↑, PDK1↓, HDAC↓, Glycolysis↓, MMP↓, Apoptosis↑,

1664-

PBG,

Anticancer Activity of Propolis and Its Compounds

-

Review,

Var,

NA

Apoptosis↑, TumCMig↓, TumCCA↑, TumCP↓, angioG↓, P21↑, p27↑, CDK1↓, p‑CDK1↓, cycA1↓, CycB↓, P70S6K↓, CLDN2↓, HK2↓, PFK↓, PKM2↓, LDHA↓, TLR4↓, H3↓, α-tubulin↓, ROS↑, Akt↓, GSK‐3β↓, FOXO3↓, NF-kB↓, cycD1↓, MMP↓, ROS↑, i-Ca+2↑, lipid-P↑, ER Stress↑, UPR↑, PERK↑, eIF2α↑, GRP78/BiP↑, BAX↑, PUMA↑, ROS↑, MMP↓, Cyt‑c↑, cl‑Casp8↑, cl‑Casp8↑, cl‑Casp3↑, cl‑PARP↑, eff↑, eff↑, RadioS↑, ChemoSen↑, eff↑,

1670-

PBG,

Lung response to propolis treatment during experimentally induced lung adenocarcinoma

-

in-vivo,

Lung,

NA

rats

GSH↑, SOD↑, MDA↓, selectivity↑, Inflam↓, TumW↓,

1665-

PBG,

Evidence on the Health Benefits of Supplemental Propolis

-

Review,

Nor,

NA

*antiOx↑, *Inflam↓, *toxicity↑, *Dose?,

1666-

PBG,

Molecular and Cellular Mechanisms of Propolis and Its Polyphenolic Compounds against Cancer

-

Review,

Var,

NA

ChemoSen↑, TumCCA↑, TumCP↓, Apoptosis↑, antiOx↓, ROS↑, COX2↑, ER(estro)↓, cycA1↓, CycB↓, CDK2↓, P21↑, p27↑, hTERT↓, HDAC↓, ROS⇅, Dose?, ROS↓, ROS↑, DNAdam↑, ChemoSen↑, LOX1↓, lipid-P↓, NO↑, Igs↑, NK cell↑, MMPs↓, VEGF↓, Hif1a↓, GLUT1↓, HK2↓, selectivity↑, RadioS↑, GlucoseCon↓, lactateProd↓, eff↓, *BioAv↓,

1667-

PBG,

Ethanolic extract of Brazilian green propolis sensitizes prostate cancer cells to TRAIL-induced apoptosis

-

in-vitro,

Pca,

LNCaP

NF-kB↓, Apoptosis↑, MMP↓,

1668-

PBG,

Propolis: A Detailed Insight of Its Anticancer Molecular Mechanisms

-

Review,

Var,

NA

antiOx↑, Inflam↓, AntiCan↑, TumCP↓, Apoptosis↑, eff↝, MMPs↓, TNF-α↓, iNOS↓, COX2↓, IL1β↑, *BioAv↓, BAX↑, Casp3↑, Cyt‑c↑, Bcl-2↓, eff↑, selectivity↑, P53↑, ROS↑, Casp↑, eff↑, ERK↓, Dose∅, TRAIL↑, NF-kB↑, ROS↑, Dose↑, MMP↓, DNAdam↑, TumAuto↑, LC3II↑, p62↓, EGF↓, Hif1a↓, VEGF↓, TLR4↓, GSK‐3β↓, NF-kB↓, Telomerase↓, ChemoSen↑, ChemoSideEff↓,

1669-

PBG,

Chemo,

Antioxidant and anti-inflammatory effects of oral propolis in patients with breast cancer treated with chemotherapy: a Randomized controlled trial

-

Trial,

BC,

NA

250 mg/ twice daily for 3 months

Breast cancer patients receiving chemotherapy were randomly assigned to two groups; a week prior to chemotherapy, the first group received Propolis (250 mg/ twice daily for 3 months) and the second group received a placebo daily.

antiOx↑, Inflam↓,

1672-

PBG,

The Potential Use of Propolis as an Adjunctive Therapy in Breast Cancers

-

Review,

BC,

NA

ChemoSen↓, RadioS↑, Inflam↓, AntiCan↑, Dose∅, mtDam↑, Apoptosis?, OCR↓, ATP↓, ROS↑, ROS↑, LDH↓, TP53↓, Casp3↓, BAX↓, P21↓, ROS↑, eNOS↑, iNOS↑, eff↑, hTERT↓, cycD1↓, eff↑, eff↑, eff↑, eff↑, STAT3↓, TIMP1↓, IL4↓, IL10↓, OS↑, Dose∅, ER Stress↑, ROS↑, NF-kB↓, p65↓, MMP↓, TumAuto↑, LC3II↑, p62↓, TLR4↓, mtDam↑, LDH↓, ROS↑, Glycolysis↓, HK2↓, PFK↓, PKM2↓, LDH↓, IL10↓, HDAC8↓, eff↑, eff↑, P21↑,

1663-

PBG,

Propolis and Their Active Constituents for Chronic Diseases

-

Review,

Var,

NA

NF-kB↓, Casp↓, Fas↓, DNAdam↑, Casp3↑, P53↝, MMP↝, ROS↑, mtDam↑, Dose?, angioG↓, TumCP↓, TumCMig↓, BAX↑, selectivity↑, MMP↓, LDH↓, IL6↓, IL1β↓, TNF-α↓,

1662-

PBG,

The immunomodulatory and anticancer properties of propolis

-

Review,

Var,

NA

IL6↓, IL12↓, IL10↑, CSCs↓, PAK1↓, VEGF↓, MMP2↓, MMP9↓, NF-kB↓, Hif1a↓, ChemoSen↑, RadioS↑,

1661-

PBG,

Propolis: a natural compound with potential as an adjuvant in cancer therapy - a review of signaling pathways

-

Review,

Var,

NA

JNK↓, ERK↓, Akt↓, NF-kB↓, FAK↓, MAPK↓, PI3K↓, Akt↓, P21↑, p27↑, TRAIL↑, BAX↑, P53↑, ERK↓, ChemoSen↑, RadioS↑, Glycolysis↓, HK2↓, PKM2↓, LDHA↓, PFK↓,

1660-

PBG,

Emerging Adjuvant Therapy for Cancer: Propolis and its Constituents

-

Review,

Var,

NA

MMPs↓, angioG↓, TumMeta↓, TumCCA↑, Apoptosis↑, ChemoSideEff↓, eff∅, HDAC↓, PTEN↑, p‑PTEN↓, p‑Akt↓, Casp3↑, p‑ERK↑, p‑FAK↑, Dose?, Akt↓, GSK‐3β↓, FOXO3↓, eff↑, IL2↑, IL10↑, NF-kB↓, VEGF↓, mtDam↑, ER Stress↑, AST↓, ALAT↓, ALP↓, COX2↓, eff↑, Bax:Bcl2↑,

1659-

PBG,

Improvement of insulin resistance, blood pressure and interstitial pH in early developmental stage of insulin resistance in OLETF rats by intake of propolis extracts

-

in-vivo,

Nor,

NA

rats

pH↑, BP↓, BG↓,

1658-

PBG,

Body Fluid pH Balance in Metabolic Health and Possible Benefits of Dietary Alkaline Foods

-

Review,

Var,

NA

pH↑, GFR↑,

1648-

PBG,

Contribution of Green Propolis to the Antioxidant, Physical, and Sensory Properties of Fruity Jelly Candies Made with Sugars or Fructans

-

Review,

Nor,

NA

Dose∅, Dose∅, eff↓, antiOx↑,

1647-

PBG,

CA,

Antioxidant Properties and Phenolic Composition of Greek Propolis Extracts

-

Analysis,

Nor,

NA

Dose?, antiOx↑, other↑,

1671-

PBG,

Importance of pH Homeostasis in Metabolic Health and Diseases: Crucial Role of Membrane Proton Transport

-

Review,

Nor,

NA

pH↑,

1682-

PBG,

Honey, Propolis, and Royal Jelly: A Comprehensive Review of Their Biological Actions and Health Benefits

-

Review,

Var,

NA

i-LDH↓, Akt↓, MAPK↓, NF-kB↓, IL1β↓, IL6↓, TNF-α↓, iNOS↓, COX2↓, ROS↓, Bcl-2↓, PARP↓, P53↑, BAX↑, Casp3↑, TumCCA↑, Cyt‑c↑, MMP↓, eff↑,

1681-

PBG,

Propolis: Its Role and Efficacy in Human Health and Diseases

-

Review,

Nor,

NA

*Inflam↓, *AntiCan↑, *antiOx↑, *hyperG↓, *BG↓, *HbA1c↓, *NF-kB↓, *ROS↓, *TGF-β↑, *selectivity↑,

1683-

PBG,

Rad,

Protective effect of propolis in protecting against radiation-induced oxidative stress in the liver as a distant organ

-

in-vivo,

Nor,

NA

rats

GPx↑, SOD↓, RadioS↑,

1684-

PBG,

Antitumor Activity of Chinese Propolis in Human Breast Cancer MCF-7 and MDA-MB-231 Cells

-

in-vitro,

BC,

MCF-7

25, 50, 100, and 200 μg/mL

-

in-vitro,

BC,

MDA-MB-231

-

in-vitro,

Nor,

HUVECs

Apoptosis?, ANXA7↑, ROS↑, NF-kB↓, MMP↓, selectivity↑,

1685-

PBG,

Antitumor Activity of Chinese Propolis in Human Breast Cancer MCF-7 and MDA-MB-231 Cells

-

in-vitro,

BC,

MCF-7

25, 50, 100, and 200 μg/mL

ANXA7↑, ROS↑, NF-kB↓, MMP↓, selectivity↑, Dose⇅, ROS⇅,

1686-

PBG,

Different propolis samples, phenolic content, and breast cancer cell lines: Variable cytotoxicity ranging from ineffective to potent

-

in-vitro,

BC,

MCF-7

-

in-vitro,

BC,

SkBr3

-

in-vitro,

BC,

MDA-MB-231

TumCP↓,

1680-

PBG,

Protection against Ultraviolet A-Induced Skin Apoptosis and Carcinogenesis through the Oxidative Stress Reduction Effects of N-(4-bromophenethyl) Caffeamide, a Propolis Derivative

-

in-vitro,

Nor,

HS68

*ROS↓, *NRF2↑, *HO-1↑, *cJun↓, *MMP1↓, *MMP2↓, *p‑cJun↓, *cFos↓, *BAX↓, *Casp3↓, *DNAdam↓, *iNOS↓, *COX2↓, *IL6↓, *PGE2↓, *NO↓,

1679-

PBG,

Constituents of Propolis: Chrysin, Caffeic Acid, p-Coumaric Acid, and Ferulic Acid Induce PRODH/POX-Dependent Apoptosis in Human Tongue Squamous Cell Carcinoma Cell (CAL-27)

-

in-vitro,

SCC,

CAL27

tumCV↓, P53↑, Casp9↑, Casp3↑, GSH↓, proline↓,

1678-

PBG,

5-FU,

sericin,

In vitro and in vivo anti-colorectal cancer effect of the newly synthesized sericin/propolis/fluorouracil nanoplatform through modulation of PI3K/AKT/mTOR pathway

-

in-vitro,

CRC,

Caco-2

-

in-vivo,

NA,

NA

105 in bred- albino mice

PI3K↓, Akt↓, mTOR↓, TumCP↓, Bcl-2↓, BAX↑, Casp3↑, Casp9↑, ROS↓, FOXO1↑, *toxicity∅, eff↑,

1673-

PBG,

An Insight into Anticancer Effect of Propolis and Its Constituents: A Review of Molecular Mechanisms

-

Review,

Var,

NA

TumCP↓, Apoptosis↑, TumCCA↑, MALAT1↓, P53↑, RadioS↑, OS↑, ROS↑, NF-kB↓, p65↑, MMP↓, ROS↑, MMP9↓, β-catenin/ZEB1↓, Vim↓, E-cadherin↓, VEGF↓, EMT↓,

1674-

PBG,

SDT,

HPT,

Study on the effect of a triple cancer treatment of propolis, thermal cycling-hyperthermia, and low-intensity ultrasound on PANC-1 cells

-

in-vitro,

PC,

PANC1

-

in-vitro,

Nor,

H6c7

tumCV↓, ROS↑, eff↑, Dose∅, selectivity↑, MMP↓, mtDam↑, cl‑PARP↑, p‑ERK↓, p‑JNK↑, p‑p38↑, eff↓, ChemoSen↑,

1675-

PBG,

Portuguese Propolis Antitumoral Activity in Melanoma Involves ROS Production and Induction of Apoptosis

-

in-vitro,

Melanoma,

A375

-

in-vitro,

Melanoma,

WM983B

tumCV↓, ROS↑, antiOx↑, Apoptosis↑, BAX↑, P53↑, Casp3↑, Casp9↑,

1676-

PBG,

Use of Stingless Bee Propolis and Geopropolis against Cancer—A Literature Review of Preclinical Studies

-

Review,

Var,

NA

20-250ug/mL

ROS↑, MMP↓, Bcl-2↓, eff↑, tumCV↓, TumCCA↑, angioG↓, PAK1↓, HDAC1↓, HDAC2↓, P53↑, PCNA↓, cycD1↓, cycE↓, P21?, BAX↑, cl‑Casp3↑, cl‑PARP↑, ChemoSen↑,

1677-

PBG,

Propolis Inhibits UVA-Induced Apoptosis of Human Keratinocyte HaCaT Cells by Scavenging ROS

-

in-vitro,

Nor,

HaCaT

5 and 10 μg/mL

*Dose∅, *AP-1↓, *MMP↑, *Casp3↓, *ROS↓,

1231-

PBG,

Caffeic acid phenethyl ester inhibits MDA-MB-231 cell proliferation in inflammatory microenvironment by suppressing glycolysis and lipid metabolism

-

in-vitro,

BC,

MDA-MB-231

TumCP↓, TumCMig↓, TumCI↓, MMP↓, TLR4↓, TNF-α↓, NF-kB↓, IL1β↓, IL6↓, IRAK4↓, GLUT1↓, GLUT3↓, HK2↓, PFK↓, PKM2↓, LDHA↓, ACC↓, FASN↓, eff↓,

2382-

PBG,

Integration with Transcriptomic and Metabolomic Analyses Reveals the In Vitro Cytotoxic Mechanisms of Chinese Poplar Propolis by Triggering the Glucose Metabolism in Human Hepatocellular Carcinoma Cells

-

in-vitro,

HCC,

HepG2

TumCP↓, Glycolysis↓, GlucoseCon↓, lactateProd↓, GLUT1↓, GLUT2↓, LDHA↓, HK2↓, PKM2↓, PFK↓, Dose↝,

2381-

PBG,

Chinese Poplar Propolis Inhibits MDA-MB-231 Cell Proliferation in an Inflammatory Microenvironment by Targeting Enzymes of the Glycolytic Pathway

-

in-vitro,

BC,

MDA-MB-231

0-100ug/mL

TumCP↓, TumCMig↓, TumCI↓, angioG↓, TNF-α↓, IL1β↓, IL6↓, NLRP3↓, Glycolysis↓, HK2↓, PFK↓, PKM2↓, LDHA↓, ROS↑, MMP↓,

2380-

PBG,

Potential Strategies for Overcoming Drug Resistance Pathways Using Propolis and Its Polyphenolic/Flavonoid Compounds in Combination with Chemotherapy and Radiotherapy

-

Review,

Var,

NA

Hif1a↓, Glycolysis↓, PKM2↓, LDHA↓, GLUT2↓, HK2↓, PFK1↓, PDK1↓, chemoP↓, radioP↑,

2430-

PBG,

The cytotoxic effects of propolis on breast cancer cells involve PI3K/Akt and ERK1/2 pathways, mitochondrial membrane potential, and reactive oxygen species generation

-

in-vitro,

BC,

MDA-MB-231

TumCP↓, TP53↓, Casp3↓, BAX↓, P21↓, ROS↑, eff↓, MMP↓, LDH↑, ATP↓, Ca+2↑,

3250-

PBG,

Allergic Inflammation: Effect of Propolis and Its Flavonoids

-

Review,

NA,

NA

*SOD↑, *GPx↑, *Catalase↑, *Prx↑, *HO-1↑, *Inflam↓, *TNF-α↓, *IL1β↓, *IL4↑, *IL10↑, *TLR4↓, *LOX1↓, *COX1↓, *COX2↓, *NF-kB↓, *AP-1↓, *ROS↓, *GSH↑, *TGF-β↓, *IL8↓, *MMP9↓, *α-SMA↓, *MDA↓,

3249-

PBG,

Can Propolis Be a Useful Adjuvant in Brain and Neurological Disorders and Injuries? A Systematic Scoping Review of the Latest Experimental Evidence

-

Review,

Var,

NA

*Inflam↓, *ROS↓, *MDA↓, *TNF-α↓, *NO↓, *iNOS↓, *SOD↑, *GPx↑, *GSR↓, *GSH↑, *neuroP↑, *IL6↓, *MMP2↓, *MMP9↓, *MCP1↓, *HSP70/HSPA5↑, *motorD↑, *Pain↓, *VCAM-1↓, *NF-kB↓, *MAPK↓, *JNK↓, *IL1β↓, *AChE↓, *toxicity∅, cognitive↑,

3251-

PBG,

The Antioxidant and Anti-Inflammatory Effects of Flavonoids from Propolis via Nrf2 and NF-κB Pathways

-

Review,

AD,

NA

-

Review,

Diabetic,

NA

-

Review,

Var,

NA

-

in-vitro,

Nor,

H9c2

To induce oxidative stress, H9c2 cells were exposed to multiple H2O2 concentrations (0, 50, 100, 150, 200, and 250 μM) for 1 h

*antiOx↑, *Inflam↓, *ROS↓, *SOD↑, *Catalase↑, *HO-1↑, *NO↓, *NOS2↓, *NF-kB↓, *NRF2↑, *hepatoP↑, *MDA↓, *mtDam↓, *GSH↑, *p65↓, *TNF-α↓, *IL1β↓, *NRF2↑, *NRF2↓, *ROS⇅, *BioAv↓, *BioAv↑,

3252-

PBG,

Propolis Extract and Its Bioactive Compounds—From Traditional to Modern Extraction Technologies

-

Review,

NA,

NA

*Inflam↓, *TNF-α↓, *NF-kB↓, *MAPK↓, *ERK↓, *antiOx↑, *NRF2↑, *cardioP↑, *Glycolysis↑, *Ca+2↓, *HO-1↑, *NRF2↑, *neuroP↑,

3253-

PBG,

Brazilian red propolis extract enhances expression of antioxidant enzyme genes in vitro and in vivo

-

in-vitro,

Nor,

HEK293

-

in-vivo,

Nor,

NA

*NRF2↑, *ROS↓,

3254-

PBG,

Brazilian green propolis water extract up-regulates the early expression level of HO-1 and accelerates Nrf2 after UVA irradiation

-

in-vitro,

Nor,

NA

Normal human skin fibroblast (NB1-RGB) cells

*HO-1↑, *NRF2↑,

3255-

PBG,

Propolis reversed cigarette smoke-induced emphysema through macrophage alternative activation independent of Nrf2

-

in-vivo,

Nor,

NA

Eight-week-old male C57BL/6 mice

*IGF-1↓, *MMP2↑, *ROS↓, *Inflam↓, *IL10↓, *NRF2∅,

3256-

PBG,

Mechanisms of Apoptosis and Cell Cycle Arrest Induced by Propolis in Cancer Therapy

-

Review,

Var,

NA

TumCCA↑, CDK2↓, CDK4↓, cycA1↓, CycB↓,

3257-

PBG,

The Potential Use of Propolis as a Primary or an Adjunctive Therapy in Respiratory Tract-Related Diseases and Disorders: A Systematic Scoping Review

-

Review,

Var,

NA

CDK4↓, CDK6↓, pRB↓, ROS↓, TumCCA↑, P21↑, PI3K↓, Akt↓, EMT↓, E-cadherin↑, Vim↓, *COX2↓, *MPO↓, *MDA↓, *TNF-α↓, *IL6↓, *Catalase↑, *SOD↑, *AST↓, *ALAT↓, *IL1β↓, *IL10↓, *GPx↓, *TLR4↓, *Sepsis↓, *IFN-γ↑, *GSH↑, *NRF2↑, *α-SMA↓, *TGF-β↓, *IL5↓, *IL6↓, *IL8↓, *PGE2↓, *NF-kB↓, *MMP9↓,

3259-

PBG,

Propolis and its therapeutic effects on renal diseases: A review

-

Review,

Nor,

NA

*Inflam↓, *COX2↓, *ROS↓, *NO↓, *NF-kB↓, TumCP↓, angioG↓, VEGF↓, STAT↓, Hif1a↓, RenoP↑, TLR4↓, *MDA↓, *GSH↑, *SOD↑, *Catalase↑, *toxicity∅,

3248-

PBG,

Propolis as a promising functional ingredient: A comprehensive review on extraction, bioactive properties, bioavailability, and industrial applications

-

Review,

NA,

NA

*BioAv↓, *Half-Life↓,

3247-

PBG,

Bioavailability and In Vivo Antioxidant Activity of a Standardized Polyphenol Mixture Extracted from Brown Propolis

-

Review,

NA,

NA

Half-Life↝, BioAv↓, Half-Life↝, BioAv↓,

34-

PFB,

Naturally occurring small-molecule inhibitors of hedgehog/GLI-mediated transcription

-

in-vitro,

PC,

PANC1

HH↓, Gli1↓, GLI2↓, PTCH1↓, Bcl-2↓,

1774-

PG,

Geno- and cytotoxicity of propyl gallate food additive

-

in-vitro,

Lung,

A549

TumCG↓, Dose∅, DNAdam↑,

1763-

PG,

Generation of Hydrogen Peroxide in Cancer Cells: Advancing Therapeutic Approaches for Cancer Treatment

-

Review,

NA,

NA

*antiOx↑, *ROS↓, *ROS↑,

1764-

PG,

Cu,

DNA strand break induction and enhanced cytotoxicity of propyl gallate in the presence of copper(II)

-

in-vitro,

Nor,

GM05757

*DNAdam↑, *ROS↑, *Dose∅, *DNAdam∅,

1766-

PG,

Propyl gallate induces human pulmonary fibroblast cell death through the regulation of Bax and caspase-3

-

in-vitro,

Nor,

NA

PG (100–1,600 μM)

TumCCA↑, MMP↓,

1767-

PG,

Propyl gallate induces cell death in human pulmonary fibroblast through increasing reactive oxygen species levels and depleting glutathione

-

in-vitro,

Nor,

NA

800 µM at 24 h

*ROS↑, *GSH↓, *SOD↓, *Catalase↓, eff↓,

1768-

PG,

Propyl gallate reduces the growth of lung cancer cells through caspase‑dependent apoptosis and G1 phase arrest of the cell cycle

-

in-vitro,

Lung,

Calu-6

-

in-vitro,

Lung,

A549

TumCG↓, TumCCA↓, Dose∅, Bcl-2↓, cl‑PARP↑, MMP↓, Casp3↑, Casp8↑,

1769-

PG,

The Anti-Apoptotic Effects of Caspase Inhibitors in Propyl Gallate-Treated Lung Cancer Cells Are Related to Changes in Reactive Oxygen Species and Glutathione Levels

-

in-vitro,

Lung,

Calu-6

-

in-vitro,

Lung,

A549

TumCP↓, eff↑, ROS↑, GSH↑,

1770-

PG,

Propyl gallate sensitizes human lung cancer cells to cisplatin-induced apoptosis by targeting heme oxygenase-1 for TRC8-mediated degradation

-

in-vitro,

Lung,

NA

antiOx↑, Inflam↓, HO-1↓, eff↑, ChemoSen↑,

1771-

PG,

Pharmacokinetic and toxicological overview of propyl gallate food additive

-

Human,

Nor,

NA

*toxicity∅,

1772-

PG,

Propyl gallate decreases the proliferation of Calu-6 and A549 lung cancer cells via affecting reactive oxygen species and glutathione levels

-

in-vitro,

Lung,

Calu-6

PG (100–1,600 μM)

-

in-vitro,

Lung,

A549

ROS⇅, TumCP↓, GSH↓,

1765-

PG,

Enhanced cell death effects of MAP kinase inhibitors in propyl gallate-treated lung cancer cells are related to increased ROS levels and GSH depletion

-

in-vitro,

Lung,

A549

800 uM at 24 h

-

in-vitro,

Lung,

Calu-6

TumCD↑, MMP↓, ROS↑, GSH↓, Dose∅, eff↑,

1258-

PI,

Piperlongumine Alleviates Mouse Colitis and Colitis-Associated Colorectal Cancer

-

in-vivo,

CRC,

NA

mouse

COX2↓, IL6↓, EMT↓, β-catenin/ZEB1↓, Snail↓, Symptoms∅,

1254-

PI,

VitC,

Piperlongumine combined with vitamin C as a new adjuvant therapy against gastric cancer regulates the ROS–STAT3 pathway

-

in-vivo,

GC,

NA

15 µM PL and 3 mM

tumour xenograft

STAT3⇅, eff↑, ROS↑, Apoptosis↑,

1255-

PI,

ALA,

Antileukemic effects of piperlongumine and alpha lipoic acid combination on Jurkat, MEC1 and NB4 cells in vitro

-

in-vitro,

CLL,

NA

PL alone (5, 15, 30 μM) and in combination (30 μ M) with ALA (200 μ M)

COX2↓, Casp3↑,

1256-

PI,

Hypoxia potentiates the cytotoxic effect of piperlongumine in pheochromocytoma models

-

in-vitro,

adrenal,

PHEO

0, 1, 5, 10, and 15μM PL

6.04μM @48hr

-

in-vivo,

NA,

NA

24mg/kg/day

Apoptosis↑, ROS↑, TumCMig↓, TumCI↓, EMT↓, angioG↓, Necroptosis↑, MAPK↑, ERK↑,

1257-

PI,

Piperlongumine attenuates bile duct ligation-induced liver fibrosis in mice via inhibition of TGF-β1/Smad and EMT pathways

-

ex-vivo,

LiverDam,

NA

*Fibronectin↓, *α-SMA↓, *COL1↓, *COL3A1↓, *TGF-β↓, *EMT↓, *MMP2↓, *α-SMA↓, *Smad7↑, *E-cadherin↑, *Vim↓, *hepatoP↑, *antiOx↑, *GSH↑, *ROS↓,

1016-

PI,

Piperine suppresses the Wnt/β-catenin pathway and has anti-cancer effects on colorectal cancer cells

-

in-vitro,

CRC,

HCT116

50 and 100 μM

34 μM

-

in-vitro,

CRC,

SW480

-

in-vitro,

CRC,

DLD1

β-catenin/ZEB1↓, Wnt↓, TumCP↓, TumCMig↓,

1059-

PI,

Piperine Inhibits TGF-β Signaling Pathways and Disrupts EMT-Related Events in Human Lung Adenocarcinoma Cells

-

in-vitro,

Lung,

A549

198 uM

-

in-vitro,

BC,

MDA-MB-231

238 uM

-

in-vitro,

Liver,

HepG2

214uM

EMT↓, p‑ERK↓, p‑SMAD2↓,

925-

PI,

Bioenhancers from mother nature and their applicability in modern medicine

-

Review,

Nor,

NA

*BioEnh↑,

1164-

PI,

Inhibition of T cell activation by the phytochemical piperine

-

in-vitro,

Nor,

NA

*other↓, *CD25+↓, *IFN-γ↓, *IL2↓, *IL4↓, *IL17↓, *CD69↓, *CTLA-4↓, *p‑ERK↓, *IKKα↓,

1131-

PI,

Piperlongumine‑loaded nanoparticles inhibit the growth, migration and invasion and epithelial‑to‑mesenchymal transition of triple‑negative breast cancer cells

-

in-vitro,

BC,

MDA-MB-231

-

in-vitro,

BC,

BT549

TumCG↓, tumCV↓, TumCMig↓, TumCI↓, MMP2↓, Slug↓, N-cadherin↓, β-catenin/ZEB1↓, SMAD3↓, E-cadherin↑, EMT↓,

1163-

PI,

The Effect of Piperine on MMP-9, VEGF, and E-cadherin Expression in Breast Cancer MCF-7 Cell Line

-

in-vitro,

BC,

MC38

(5, 10, 25, 50, 75, and 100 μM) for 24 hours

tumCV↓, VEGF↓, MMP9↓, E-cadherin↓,

1165-

PI,

Piperine inhibits IL-1β-induced IL-6 expression by suppressing p38 MAPK and STAT3 activation in gastric cancer cells

-

in-vitro,

GC,

TMK-1

p38↓, IL6↓, STAT3↓,

1162-

PI,

Piperine Inhibits the Activities of Platelet Cytosolic Phospholipase A2 and Thromboxane A2 Synthase without Affecting Cyclooxygenase-1 Activity: Different Mechanisms of Action Are Involved in the Inhibition of Platelet Aggregation and Macrophage Inflammatory Response

-

in-vitro,

NA,

NA

Rabbit platelets and murine macrophage RAW264.7 cells were treated with piperine

*cPLA2↓, TXA2↓, COX2↓, PGE2↓, PGD2↓,

992-

PL,

Piperlongumine based nanomedicine impairs glycolytic metabolism in triple negative breast cancer stem cells through modulation of GAPDH & FBP1

-

in-vivo,

BC,

NA

zebrafish and nude mice

EPR↓, Glycolysis↓, GAPDH↓, GSTP1/GSTπ↝, FBPase↑,

2649-

PL,

Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence

-

Review,

Var,

NA

AntiCan↑, ROS↑, GSH↓, TrxR↓, Trx↓, Apoptosis↑, TumCCA↑, ER Stress↑, DNAdam↑, ChemoSen↑, BioAv↓,

2972-

PL,

Piperlongumine Is an NLRP3 Inhibitor With Anti-inflammatory Activity

-

in-vitro,

AML,

THP1

NLRP3↓, IL1β↓, LDH↓, cl‑Casp1↓, Inflam↓,

2963-

PL,

Piperlongumine activates Sirtuin1 and improves cognitive function in a murine model of Alzheimer’s disease

-

in-vitro,

AD,

HEK293

50 mg/kg/day for 2.5 months

mice

*SIRT1↑, *cognitive↑, *Aβ↓, *Inflam↓, *neuroP↑, memory↑, Dose↓, NAD↑,

2964-

PL,

Preformulation Studies on Piperlongumine

-

Analysis,

Nor,

NA

*BioAv↓, *BioAv↑, *other↝, *eff↓,

2995-

PL,

Piperlongumine overcomes osimertinib resistance via governing ubiquitination-modulated Sp1 turnover

-

in-vitro,

Lung,

H1975

-

in-vitro,

Lung,

PC9

-

in-vivo,

NA,

NA

Sp1/3/4↓, cMET↓, Apoptosis↑, Cyt‑c↑, p‑ERK↓, p‑Akt↓, TumCG↓,

2996-

PL,

Application of longinamide in inhibiting the activation of NLRP3 inflammasome

-

NA,

AD,

NA

-

NA,

Park,

NA

*NLRP3↓,

2999-

PL,

Piperlongumine alleviates corneal allograft rejection via suppressing angiogenesis and inflammation

-

in-vivo,

Nor,

HUVECs

*Inflam↓, *angioG↓, *Hif1a↓, *VEGF↓, *ICAM-1↓, *VCAM-1↓, *neuroP↑,

3000-

PL,

Biological and physical approaches on the role of piplartine (piperlongumine) in cancer

-

in-vitro,

Nor,

HUVECs

-

in-vitro,

Laryn,

HEp2

Inflam↓, AntiTum↑, *α-tubulin↓, selectivity↑, HIF2a↓, MCP1↓,

2965-

PL,

docx,

Piperlongumine for enhancing oral bioavailability and cytotoxicity of docetaxel in triple negative breast cancer

-

Analysis,

Var,

NA

BioEnh↑, eff↑,

2962-

PL,

Synthesis of Piperlongumine Analogues and Discovery of Nuclear Factor Erythroid 2‑Related Factor 2 (Nrf2) Activators as Potential Neuroprotective Agents

-

in-vitro,

Nor,

PC12

*GSH↑, *NQO1↑, *Trx↑, *TrxR↑, *NRF2↑, *NRF2⇅, *eff↑, *BioAv↑, *ROS↓,

2966-

PL,

A strategy to improve the solubility and bioavailability of the insoluble drug piperlongumine through albumin nanoparticles

-

in-vitro,

LiverDam,

NA

*Half-Life↑, *BioAv↑, eff↑, ROS↑,

2967-

PL,

Piperlongumine and its derivatives against cancer: A recent update and future prospective

-

Review,

Var,

NA

BioAv↓, BioAv↑,

2968-

PL,

Chit,

Preparation of piperlongumine-loaded chitosan nanoparticles for safe and efficient cancer therapy

-

in-vitro,

GC,

AGS

eff↑, Dose↝, ROS↑, BioAv↑,

2969-

PL,

Piperlongumine induces autophagy by targeting p38 signaling

-

in-vitro,

OS,

U2OS

-

in-vitro,

Cerv,

HeLa

p38↑, ROS↑, GPx1∅, SOD∅, Catalase∅,

2970-

PL,

Piperlongumine induces apoptosis and autophagy in leukemic cells through targeting the PI3K/Akt/mTOR and p38 signaling pathways

-

in-vitro,

AML,

NA

AntiAg↑, TumCG↓, Apoptosis↑, PI3K↓, Akt↓, mTOR↓, p38↑, Casp3↑,

2971-

PL,

Piperlongumine attenuates IL-1β-induced inflammatory response in chondrocytes

-

NA,

OS,

NA

*NO↓, *PGE2↓, *iNOS↓, *COX2↓, *MMP3↑, *MMP13↓, *Inflam↓,

2973-

PL,

The Natural Alkaloid Piperlongumine Inhibits Metastatic Activity and Epithelial-to-Mesenchymal Transition of Triple-Negative Mammary Carcinoma Cells

-

in-vitro,

BC,

MDA-MB-231

-

in-vitro,

BC,

4T1

MMP2↓, MMP9↓, IL6↓, E-cadherin↑, ROS↑, EMT↓, Zeb1↓, Slug↓, TumMeta↓, selectivity↑, NA↑, GSH↓,

2961-

PL,

Piperlongumine inhibits esophageal squamous cell carcinoma in vitro and in vivo by triggering NRF2/ROS/TXNIP/NLRP3-dependent pyroptosis

-

in-vitro,

ESCC,

KYSE-30

28.55 μM

Pyro↑, TumCP↓, TumCMig↓, TumCI↓, ASC↑, cl‑Casp1↑, NLRP3↑, GSDMD↑, ROS↑, NRF2↓, TXNIP↑,

2960-

PL,

Synthesis of Piperlongumine Analogues and Discovery of Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Activators as Potential Neuroprotective Agents

-

Analysis,

Nor,

NA

NRF2↑, neuroP↑,

2959-

PL,

Piperlongumine mitigates LPS-induced inflammation and lung injury via targeting MD2/TLR4

-

in-vivo,

Nor,

NA

*Inflam↓,

2958-

PL,

Natural product piperlongumine inhibits proliferation of oral squamous carcinoma cells by inducing ferroptosis and inhibiting intracellular antioxidant capacity

-

in-vitro,

Oral,

HSC3

14.71 µM (48 hr),

TumCP↓, lipid-P↑, ROS↑, DNMT1↑, FTH1↓, GPx4↓, eff↓, GSH↓, Ferroptosis↑, MDA↓,

2957-

PL,

Piperlongumine Induces Cell Cycle Arrest via Reactive Oxygen Species Accumulation and IKKβ Suppression in Human Breast Cancer Cells

-

in-vitro,

BC,

MCF-7

10–40 μM

TumCP↓, TumCMig↓, TumCCA↑, ROS↑, H2O2↑, GSH↓, IKKα↓, NF-kB↓, P21↑, eff↓,

2956-

PL,

Piperlongumine rapidly induces the death of human pancreatic cancer cells mainly through the induction of ferroptosis

-

in-vitro,

PC,

NA

ROS↑, Ferroptosis↓, GSH↓, GPx↓, cl‑PARP∅, cl‑Casp3∅, eff↑, eff↑,

2955-

PL,

Heme Oxygenase-1 Determines the Differential Response of Breast Cancer and Normal Cells to Piperlongumine

-

in-vitro,

BC,

MCF-7

-

in-vitro,

Nor,

MCF10

ROS?, *ROS∅, other⇅, HO-1↑, *HO-1↑, NRF2↑, Keap1↓, cl‑PARP↑, selectivity↑, GSH↓, GSSG↑,

2954-

PL,

The metabolites from traditional Chinese medicine targeting ferroptosis for cancer therapy

-

Review,

Var,

NA

NRF2↑, ROS↑, ER Stress↑, MAPK↑, CHOP↑, selectivity↑, Keap1↝, HO-1↑, Ferroptosis↑,

2953-

PL,

Piperlongumine Acts as an Immunosuppressant by Exerting Prooxidative Effects in Human T Cells Resulting in Diminished TH17 but Enhanced Treg Differentiation

-

in-vitro,

Nor,

NA

10 μM PL up to 24 h

nvestigated the effects of PL on the survival and function of primary human peripheral blood T cells (PBTs

*ROS↑, *GSTA1↓, eff↝, *toxicity↓, ROS↑, *Hif1a↓,

2952-

PL,

Piperlongumine suppresses bladder cancer invasion via inhibiting epithelial mesenchymal transition and F-actin reorganization

-

in-vitro,

Bladder,

T24

2.5, 5, 10 and 20 μM, 24 h

10–20 μM

-

in-vivo,

Bladder,

NA

TumCP↓, TumCCA↑, TumCMig↓, TumCI↓, ROS↑, Slug↓, β-catenin/ZEB1↓, Zeb1↓, N-cadherin↓, F-actin↓, GSH↓, EMT↓, CLDN1↓, ZO-1↓,

2951-

PL,

Aur,

Synergistic Dual Targeting of Thioredoxin and Glutathione Systems Irrespective of p53 in Glioblastoma Stem Cells

-

in-vitro,

GBM,

U87MG

GSH↓, eff↑, GSTP1/GSTπ↓,

2950-

PL,

Overview of piperlongumine analogues and their therapeutic potential

-

Review,

Var,

NA

AntiAg↑, neuroP↑, Inflam↓, NO↓, PGE2↓, MMP3↓, MMP13↓, TumCMig↓, TumCI↓, p38↑, JNK↑, NF-kB↑, ROS↑, Foxm1↓, TrxR1↓, GSH↓, Trx↓, cMyc↓, Casp3↑, Bcl-2↓, Mcl-1↓, STAT3↓, AR↓, DNAdam↑,

2949-

PL,

Piperlongumine selectively kills glioblastoma multiforme cells via reactive oxygen species accumulation dependent JNK and p38 activation

-

in-vitro,

GBM,

LN229

5, 10 and 20 uM

-

in-vitro,

GBM,

U87MG

selectivity↑, ROS↑, JNK↑, p38↑, GSH↓, eff↓,

2948-

PL,

The promising potential of piperlongumine as an emerging therapeutics for cancer

-

Review,

Var,

NA

tumCV↓, TumCP↓, TumCI↓, angioG↓, EMT↓, TumMeta↓, *hepatoP↑, *lipid-P↓, *GSH↑, cardioP↑, CycB↓, cycD1↓, CDK2↓, CDK1↓, CDK4↓, CDK6↓, PCNA↓, Akt↓, mTOR↓, Glycolysis↓, NF-kB↓, IKKα↓, JAK1↓, JAK2↓, STAT3↓, ERK↓, cFos↓, Slug↓, E-cadherin↑, TOP2↓, P53↑, P21↑, Bcl-2↓, BAX↑, Casp3↑, Casp7↑, Casp8↑, p‑HER2/EBBR2↓, HO-1↑, NRF2↑, BIM↑, p‑FOXO3↓, NA↓, Sp1/3/4↓, cMyc↓, EGFR↓, survivin↓, cMET↓, NQO1↑, SOD2↑, TrxR↓, MDM2↓, p‑eIF2α↑, ATF4↑, CHOP↑, MDA↑, Ki-67↓, MMP9↓, Twist↓, SOX2↓, Nanog↓, OCT4↓, N-cadherin↓, Vim↓, Snail↓, TumW↓, TumCG↓, HK2↓, RB1↓, IL6↓, IL8↓, SOD1↑, RadioS↑, ChemoSen↑, toxicity↓, Sp1/3/4↓, GSH↓, SOD↑,

2947-

PL,

Piperlongumine: the amazing amide alkaloid from Piper in the treatment of breast cancer

-

Review,

Var,

NA

TumCP↓, Apoptosis↑, TumCCA↑, ROS↑,

2946-

PL,

Piperlongumine, a potent anticancer phytotherapeutic: Perspectives on contemporary status and future possibilities as an anticancer agent

-

Review,

Var,

NA

ROS↑, GSH↓, DNAdam↑, ChemoSen↑, RadioS↑, BioEnh↑, selectivity↑, BioAv↓, eff↑, p‑Akt↓, mTOR↓, GSK‐3β↓, β-catenin/ZEB1↓, HK2↓, Glycolysis↓, Cyt‑c↑, Casp9↑, Casp3↑, Casp7↑, cl‑PARP↑, TrxR↓, ER Stress↑, ATF4↝, CHOP↑, Prx4↑, NF-kB↓, cycD1↓, CDK4↓, CDK6↓, p‑RB1↓, RAS↓, cMyc↓, TumCCA↑, selectivity↑, STAT3↓, NRF2↑, HO-1↑, PTEN↑, P-gp↓, MDR1↓, MRP1↓, survivin↓, Twist↓, AP-1↓, Sp1/3/4↓, STAT1↓, STAT6↓, SOX4↑, XBP-1↑, P21↑, eff↑, Inflam↓, COX2↓, IL6↓, MMP9↓, TumMeta↓, TumCI↓, ICAM-1↓, CXCR4↓, VEGF↓, angioG↓, Half-Life↝, BioAv↑,

2945-

PL,

Piperlongumine induces ROS mediated cell death and synergizes paclitaxel in human intestinal cancer cells

-

in-vitro,

CRC,

HCT116

ROS↑, SMAD4↑, ChemoSen↑, P53↑, P21↑, BAX↑, Bcl-2↓, survivin↓, TumCMig↓,

2944-

PL,

Piperlongumine, a Potent Anticancer Phytotherapeutic, Induces Cell Cycle Arrest and Apoptosis In Vitro and In Vivo through the ROS/Akt Pathway in Human Thyroid Cancer Cells

-

in-vitro,

Thyroid,

IHH4

2 and 3 μM

-

in-vitro,

Thyroid,

8505C

-

in-vivo,

NA,

NA

10 mg/kg

Nude mice

ROS↑, selectivity↑, tumCV↓, TumCCA↑, Apoptosis↑, ERK↑, Akt↓, mTOR↓, neuroP↑, Bcl-2↓, Casp3↑, PARP↑, JNK↑, *toxicity↓, eff↓, TumW↓,

2943-

PL,

Piperlongumine Inhibits Thioredoxin Reductase 1 by Targeting Selenocysteine Residues and Sensitizes Cancer Cells to Erastin

-

in-vitro,

CRC,

HCT116

-

in-vitro,

Lung,

A549

-

in-vitro,

BC,

MCF-7

TrxR1?, TumCD↑, ROS↑, GSH↓, eff↑,

2942-

PL,

Piperlongumine increases sensitivity of colorectal cancer cells to radiation: Involvement of ROS production via dual inhibition of glutathione and thioredoxin systems

-

in-vitro,

CRC,

CT26

-

in-vitro,

CRC,

DLD1

-

in-vivo,

CRC,

CT26

CT26 tumor-bearing mice

ROS↑, GSH↓, TrxR↓, RadioS↑, DNAdam↑, TumCCA↑, mitResp↓, GSTs↓, OS↑,

2941-

PL,

Selective killing of cancer cells by a small molecule targeting the stress response to ROS

-

in-vivo,

BC,

MDA-MB-231

mice

-

in-vitro,

OS,

U2OS

-

in-vitro,

BC,

MDA-MB-453

ROS↑, Apoptosis↑, selectivity↑, *ROS∅, GSH↓, GSSG↑, H2O2↑, NO↑, Half-Life?,

2940-

PL,

Piperlongumine Induces Reactive Oxygen Species (ROS)-dependent Downregulation of Specificity Protein Transcription Factors

-

in-vitro,

PC,

PANC1

5-15 μM

-

in-vitro,

Lung,

A549

-

in-vitro,

Kidney,

786-O

-

in-vitro,

BC,

SkBr3

ROS↑, TumCP↓, Apoptosis↑, eff↓, Sp1/3/4↓, cycD1↓, survivin↓, cMyc↓, EGFR↓, cMET↓,

1950-

PL,

Increased Expression of FosB through Reactive Oxygen Species Accumulation Functions as Pro-Apoptotic Protein in Piperlongumine Treated MCF7 Breast Cancer Cells

-

in-vitro,

BC,

MCF-7

-

in-vitro,

Lung,

A549

selectivity↑, ROS↑, SETBP1↓, cl‑Casp9↑, eff↓, FOSB↑,

1938-

PL,

Piperlongumine regulates epigenetic modulation and alleviates psoriasis-like skin inflammation via inhibition of hyperproliferation and inflammation

-

Study,

PSA,

NA

-

in-vivo,

NA,

NA

Mice: 10 (PL = PPL low dose) and 30 (PH = PPL high dose) mg/kg dose of PPL was fixed for topical intervention

ROS↑, Apoptosis↑, MMP↓, TumCCA↑, DNAdam↑, STAT3↓, Akt↓, PCNA↓, Ki-67↓, cycD1↓, Bcl-2↓, K17↓, HDAC↓, ROS↑, *IL1β↓, *IL6↓, *TNF-α↓, *IL17↓, *IL22↓,

1939-

PL,

Piperlongumine selectively kills hepatocellular carcinoma cells and preferentially inhibits their invasion via ROS-ER-MAPKs-CHOP

-

in-vitro,

HCC,

HepG2

5-20 μM

-

in-vitro,

HCC,

HUH7

-

in-vivo,

NA,

NA

(1.5 mg/kg

mice

TumCMig↓, TumCI↓, ER Stress↑, selectivity↑, tumCV↓, ROS↑, GSH↓, eff↓, Ca+2↑, MAPK↑, CHOP↑, Dose↝,

1940-

PL,

Piperlongumine Inhibits Migration of Glioblastoma Cells via Activation of ROS-Dependent p38 and JNK Signaling Pathways

-

in-vitro,

GBM,

LN229

1, 2, or 5 μM, 10uM

-

in-vitro,

GBM,

U87MG

ROS↑, GSH↓, p38↑, JNK↑, IKKα↑, NF-kB↓, eff↓,

1941-

PL,

Piperlongumine selectively kills cancer cells and increases cisplatin antitumor activity in head and neck cancer

-

in-vitro,

HNSCC,

NA

selectivity↑, eff↑, ROS↑, toxicity↑, GSH↓, GSSG↑, *GSSG∅, cl‑PARP↑, PUMA↑, GSTP1/GSTπ↓, ChemoSen↑,

1942-

PL,

Piperlongumine inhibits antioxidant enzymes, increases ROS levels, induces DNA damage and G2/M cell cycle arrest in breast cell lines

-

in-vitro,

BC,

MCF-7

ROS↑, SOD1↑, Trx1↓, Catalase↓, PrxII↓, ROS↑, GADD45A↑, P21↑, DNAdam↑, TumCCA↑,

1943-

PL,

Piperlongumine treatment inactivates peroxiredoxin 4, exacerbates endoplasmic reticulum stress, and preferentially kills high-grade glioma cells

-

in-vitro,

GBM,

NA

0-10 μM

-

in-vivo,

NA,

NA

mice

selectivity↑, ROS↑, selectivity↑, Prx4↓, *Prx4∅, ER Stress↑, CHOP↑, UPR↑,

1944-

PL,

Piperlongumine, a Novel TrxR1 Inhibitor, Induces Apoptosis in Hepatocellular Carcinoma Cells by ROS-Mediated ER Stress

-

in-vitro,

HCC,

HUH7

0.625, 2.5, 5, 10, 15, 20, 30, 40, and 50 µM

-

in-vitro,

HCC,

HepG2

ER Stress↑, TrxR1↓, ROS↑, eff↓, Bcl-2↓, proCasp3↓, BAX↓, cl‑Casp3↑, TumCCA↑, p‑PERK↑, ATF4↑, TumCG↓, lipid-P↑, selectivity↑,

1945-

PL,

SANG,

The Synergistic Effect of Piperlongumine and Sanguinarine on the Non-Small Lung Cancer

-

in-vitro,

Lung,

A549

1-8uM(PL), 0-2uM(SAN)

ic50, 8.03µM for PL and 2.19 µM for SAN

toxicity∅, Apoptosis↑, TumMeta↓, ROS↑, TumCCA↑,

1946-

PL,

PI,

Piperlonguminine and Piperine Analogues as TrxR Inhibitors that Promote ROS and Autophagy and Regulate p38 and Akt/mTOR Signaling

-

in-vitro,

Liver,

NA

eff↑, toxicity↓, TrxR↓, ROS↑, MMP↓, p38↑, Akt↓, mTOR↓,

1947-

PL,

Piperlongumine as a direct TrxR1 inhibitor with suppressive activity against gastric cancer

-

in-vitro,

GC,

SGC-7901

-

in-vitro,

GC,

NA

TrxR1↓, ROS↑, ER Stress↑, mtDam↑, selectivity↑, NO↑, TumCCA↑, mt-ROS↑, Casp9↑, Bcl-2↓, Bcl-xL↓, cl‑PARP↑, eff↓, lipid-P↑,

1948-

PL,

born,

Natural borneol serves as an adjuvant agent to promote the cellular uptake of piperlongumine for improving its antiglioma efficacy

-

in-vitro,

GBM,

NA

selectivity↑, ROS↑, BioAv↓, BioAv↑, Apoptosis↑, TumCCA↑, eff↑,

1949-

PL,

Design, synthesis, and biological evaluation of a novel indoleamine 2,3-dioxigenase 1 (IDO1) and thioredoxin reductase (TrxR) dual inhibitor

-

in-vitro,

CRC,

HCT116

-

in-vitro,

Cerv,

HeLa

TrxR↓, selectivity↑, ROS↑, IDO1↓,

1951-

PL,

Piperlongumine Analogs Promote A549 Cell Apoptosis through Enhancing ROS Generation

-

in-vitro,

Lung,

A549

ROS↑, lipid-P↑, MMP↓, TumCCA↑, TrxR↓, eff↑,

1952-

PL,

5-FU,

Piperlongumine induces ROS accumulation to reverse resistance of 5-FU in human colorectal cancer via targeting TrxR

-

in-vivo,

CRC,

HCT8

10uM

mice

ROS↑, TrxR↓, eff↑, p‑Akt↓,

1953-

PL,

Designing piperlongumine-directed anticancer agents by an electrophilicity-based prooxidant strategy: A mechanistic investigation

-

in-vitro,

Lung,

A549

-

in-vitro,

Nor,

WI38

ROS↑, selectivity↑, TrxR↓, TumCCA↑, GSH?, H2O2↑,

2004-

Plum,

Plumbagin Inhibits Proliferative and Inflammatory Responses of T Cells Independent of ROS Generation But by Modulating Intracellular Thiols

-

in-vivo,

Var,

NA

5 µM

mice

TumCP↓, TumCG↓, NF-kB↓, ROS↑, GSH↓, eff↓, i-Thiols↓, GSH/GSSG↓, *GSH↓, *ROS↑,

2006-

Plum,

Plumbagin induces apoptosis in human osteosarcoma through ROS generation, endoplasmic reticulum stress and mitochondrial apoptosis pathway

-

in-vitro,

OS,

MG63

-

in-vitro,

Nor,

hFOB1.19

tumCV↓, selectivity↑, mtDam↑, Ca+2↓, ER Stress↑, ROS↑, Casp3↑, Casp9↑, Apoptosis↑, eff↓,

2005-

Plum,

Plumbagin induces apoptosis in lymphoma cells via oxidative stress mediated glutathionylation and inhibition of mitogen-activated protein kinase phosphatases (MKP1/2)

-

in-vivo,

Nor,

EL4

mouse

-

in-vitro,

AML,

Jurkat

JNK↑, Cyt‑c↑, FasL↑, BAX↑, ROS↑, *ROS↑, MKP1↓, MKP2↓, selectivity∅, tumCV↑, Cyt‑c↑, Casp3↑, GSH/GSSG↓, ROS↑, mt-ROS↑, *ROS↑, eff↓,

2651-

Plum,

Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence

-

Review,

Var,

NA

ROS↑, TrxR↓, GSR↓, ER Stress↓, TumCCA↑, MMP↓, NF-kB↓, PI3K↓, Akt↓, mTOR↓, MKP1↓, MKP2↓, ChemoSen↑,

1046-

ProBio,

immuno,

Combination Therapy of Bifidobacterium longum RAPO With Anti-PD-1 Treatment Enhances Anti-tumor Immune Response in Association With Gut Microbiota Modulation

-

in-vivo,

NA,

NA

mice

TumVol↓, GutMicro↑,

2408-

PS,

Pterostilbene suppresses the growth of esophageal squamous cell carcinoma by inhibiting glycolysis and PKM2/STAT3/c-MYC signaling pathway

-

in-vitro,

ESCC,

NA

TumCP↓, TumCMig↓, PKA↓, GlucoseCon↓, lactateProd↓, PKM2↓, STAT3↓, cMyc↓,

2409-

PS,

Pterostilbene Induces Pyroptosis in Breast Cancer Cells through Pyruvate Kinase 2/Caspase-8/Gasdermin C Signaling Pathway

-

in-vitro,

BC,

EMT6

0, 20, 40, 60, and 80 µM of PTE for 24, 48, and 72 h

-

in-vitro,

BC,

4T1

-

in-vitro,

Nor,

HC11

Pyro↑, Glycolysis↓, *toxicity∅, selectivity↑, GSDMC↑, PKM2↓, PKM1↑, GlucoseCon↓, lactateProd↓, ATP↓, TumCG↓,

1236-

PS,

Pterostilbene inhibits the metastasis of TNBC via suppression of β-catenin-mediated epithelial to mesenchymal transition and stemness

-

in-vitro,

BC,

MCF-7

20, 30 and 40 µM

-

in-vitro,

BC,

MDA-MB-231

-

in-vitro,

BC,

MDA-MB-468

TumMeta↓, EMT↓, E-cadherin↑, Zeb1↓, Snail↓, β-catenin/ZEB1↓, CD44↓, MMPs↓,

1237-

PS,

Pterostilbene induces cell apoptosis and inhibits lipogenesis in SKOV3 ovarian cancer cells by activation of AMPK-induced inhibition of Akt/mTOR signaling cascade

-

in-vitro,

Ovarian,

SKOV3

50 µM

TumCMig↓, TumCI↓, MDA↑, ROS↑, BAX↑, Casp3↑, Bcl-2↓, SREBP1↓, FASN↓, AMPK↓, p‑AMPK↑, p‑P53↑, p‑TSC2↑, p‑Akt↓, p‑mTOR↓, p‑S6K↓, p‑4E-BP1↓,

1238-

PS,

Pterostilbene suppresses gastric cancer proliferation and metastasis by inhibiting oncogenic JAK2/STAT3 signaling: In vitro and in vivo therapeutic intervention

-

in-vitro,

GC,

NA

-

in-vivo,

NA,

NA

xenograft tumor model

TumCCA↑, TumCP↓, TumCMig↓, TumCI↓, TumVol↓, TumW↓, Weight∅, JAK2↓, STAT3↓,

1493-

QC,

New quercetin-coated titanate nanotubes and their radiosensitization effect on human bladder cancer

-

NA,

Bladder,

NA

RadioS↑, ChemoSen↑,

980-

QC,

Dietary Quercetin Exacerbates the Development of Estrogen-Induced Breast Tumors in Female ACI Rats

-

in-vivo,

BC,

NA

2.5 g/kg foo

rats (QC did not protect rats, and may exacerbate carcinogenesis)

COMT↓, ROS∅,

1201-

QC,

Quercetin: a silent retarder of fatty acid oxidation in breast cancer metastasis through steering of mitochondrial CPT1

-

in-vivo,

BC,

NA

female breast cancer mice (BALB/c) model.

mitResp↓, Glycolysis↓, ATP↓, ROS↑, GSH↓, TumMeta↓, Apoptosis↑, FAO↓,

74-

QC,

EGCG,

Prospective randomized trial evaluating blood and prostate tissue concentrations of green tea polyphenols and quercetin in men with prostate cancer

-

Human,

Pca,

NA

Orally, 400 mg/twice daily

66-

QC,

Emerging impact of quercetin in the treatment of prostate cancer

-

in-vitro,

Pca,

NA

CycB↓, CDK1↓, EMT↓, PI3K↓, MAPK↓, Wnt/(β-catenin)↓, PSA↓, VEGF↓, PARP↑, Casp3↑, Casp9↑, DR5↑, ROS⇅, Shh↓, P53↑, P21↑, EGFR↓,

67-

QC,

RES,

Overexpression of c-Jun induced by quercetin and resverol inhibits the expression and function of the androgen receptor in human prostate cancer cells

-

in-vitro,

Pca,

LNCaP

50 or 100 uM

-

in-vitro,

Pca,

LAPC-4

cJun↑, AR↓, NA↓,

68-

QC,

BaP,

Differential protein expression of peroxiredoxin I and II by benzo(a)pyrene and quercetin treatment in 22Rv1 and PrEC prostate cell lines

-

in-vitro,

Pca,

22Rv1

1, 5, 10 uM

-

in-vitro,

Pca,

PrEC

PrxI∅, PrxII∅, *toxicity↓, ROS↓, ROS↑, ROS∅, chemoP↑, PrxII↑, i-H2O2↓,

69-

QC,

Quercetin enhances TRAIL-induced apoptosis in prostate cancer cells via increased protein stability of death receptor 5

-

in-vitro,

Pca,

DU145

10, 50, 100 uM

-

in-vitro,

Pca,

PC3

-

in-vitro,

Pca,

LNCaP

TRAIL↑, Casp3↑, Casp9↑, Casp8↑, DR5↑,

70-

QC,

Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells

-

in-vitro,

Pca,

LNCaP

-

in-vitro,

Pca,

LAPC-4

PSA↓, AR↓, NKX3.1↓, HK2↓,

71-

QC,

Role of Bax in quercetin-induced apoptosis in human prostate cancer cells

-

in-vitro,

Pca,

LNCaP

10, 30, 50 100 uM

-

in-vitro,

Pca,

PrEC

-

in-vitro,

Pca,

YPEN-1

-

in-vitro,

Pca,

HCT116

Casp8↑, Casp9↑, PARP↑, BAD↓, BAX↑, PI3K/Akt↓,

72-

QC,

Selenium- or quercetin-induced retardation of DNA synthesis in primary prostate cells occurs in the presence of a concomitant reduction in androgen-receptor activity

-

in-vitro,

Pca,

PECs

10, 50, 100 uM

-

in-vitro,

Pca,

LNCaP

-

in-vitro,

Pca,

NIH-3T3

cells

AR↓,

73-

QC,

The dietary bioflavonoid, quercetin, selectively induces apoptosis of prostate cancer cells by down-regulating the expression of heat shock protein 90

-

in-vitro,

Pca,

LNCaP

5, 10, 25, 50, 100 uM

Normal prostate epithelial cells

-

in-vitro,

Pca,

DU145

-

in-vitro,

Pca,

PC3

HSP90↓, Casp3↑, Casp9↑,

64-

QC,

Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts

-

in-vitro,

Colon,

HT-29

30 umol/L

-

in-vitro,

Colon,

SW-620

-

in-vitro,

Colon,

Caco-2

cells

Cyt‑c↑, BAX↑, Casp3↑,

75-

QC,

Quercetin targets hnRNPA1 to overcome enzalutamide resistance in prostate cancer cells

-

in-vitro,

Pca,

HEK293

2.5, 5, 10, 20, 50 umol/L

-

in-vitro,

NA,

22Rv1

22Rv1-Enza-R

-

in-vitro,

NA,

C4-2B

C4-2B-Enza-R

hnRNPA1↓, PSA↓, NKX3.1↓, FKBP5↓, UBE2C↓, AR-FL↓, AR-V7↑, AR↓,

76-

QC,

Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy

-

in-vitro,

Pca,

PC3

100, 150 uM

aSmase↝, Diablo↝, Fas↝, Hsc70↝, Hif1a↝, Mcl-1↝, HSP90↝, FLT4↝, EphB4↝, DNA-PK↝, PARP1↝, ATM↝, XIAP↝, PLC↝, GnT-V↝, heparanase↝, NM23↝, CSR1↝, SPP1↝, DNMT1↝, HDAC4↝, CXCR4↝, β-catenin/ZEB1↝, FBXW7↝, AMACR↝, cycD1↝, IGF-1R↝, IMPDH1↝, IMPDH2↝, HEC1↝, NHE1↝, NOS2↝,

77-

QC,

EGCG,

The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition

-

in-vitro,

Pca,

CD44+

20 uM

CD44+ and CD133+ CSCs can be isolated from PC-3 and LNCaP

-

in-vitro,

NA,

CD133+

-

in-vitro,

NA,

PC3

-

in-vitro,

NA,

LNCaP

Casp3↑, Casp7↑, Bcl-2↓, survivin↓, XIAP↓, EMT↓, Vim↓, Slug↓, Snail↓, β-catenin/ZEB1↓, LEF1↓, TCF↓, Nanog↓,

78-

QC,

Effects of quercetin on insulin-like growth factors (IGFs) and their binding protein-3 (IGFBP-3) secretion and induction of apoptosis in human prostate cancer cells

-

in-vitro,

Pca,

PC3

25, 50, 75 and 100 uM

IGF-1↓, IGF-2↓, IGFBP3↑, Bcl-2↓, Bcl-xL↓, Casp3↑,

79-

QC,

Chemopreventive Effect of Quercetin in MNU and Testosterone Induced Prostate Cancer of Sprague-Dawley Rats

-

in-vivo,

Pca,

NA

200 mg/kg/3x/week

rats

GSH↑, SOD↑, Catalase↑, GPx↑, GSR↑,

80-

QC,

Quercetin reverses EGF-induced epithelial to mesenchymal transition and invasiveness in prostate cancer (PC-3) cell line via EGFR/PI3K/Akt pathway

-

in-vitro,

Pca,

PC3

25, 50, 75, 100, 125 uM

Vim↓, ERK↓, Snail↓, Slug↓, Twist↓, EGFR↓, p‑Akt↓, EGFR↓, N-cadherin↓,

81-

QC,

EGCG,

Enhanced inhibition of prostate cancer xenograft tumor growth by combining quercetin and green tea

-

in-vivo,

Pca,

NA

0.2%, 0.4%

COMT↓, MRP1↓, Ki-67↓, Bax:Bcl2↑, AR↓, Akt↓, p‑ERK↓, COMT↓, eff↑,

57-

QC,

Quercetin inhibits angiogenesis through thrombospondin-1 upregulation to antagonize human prostate cancer PC-3 cell growth in vitro and in vivo

-

vitro+vivo,

PC,

NA

25,50 and 100 uM

TSP-1↑,

49-

QC,

Plasma rich in quercetin metabolites induces G2/M arrest by upregulating PPAR-γ expression in human A549 lung cancer cells

-

in-vitro,

Lung,

A549

CDK1↓, CycB↓, PPARγ↑,

50-

QC,

Anticancer effect and mechanism of polymer micelle-encapsulated quercetin on ovarian cancer

-

vitro+vivo,

Ovarian,

A2780S

Casp3↑, Casp9↑, Mcl-1↓, Bcl-2↓, BAX↑, angioG↓,

51-

QC,

Effect of Quercetin on Cell Cycle and Cyclin Expression in Ovarian Carcinoma and Osteosarcoma Cell Lines

-

in-vitro,

Ovarian,

SKOV3

50 uM

cycD1↓,

52-

QC,

Effect of Quercetin on Cell Cycle and Cyclin Expression in Ovarian Carcinoma and Osteosarcoma Cell Lines

-

in-vitro,

BC,

MCF-7

Bcl-2↓, BAX↑, PI3K/Akt↓,

53-

QC,

Quercetin regulates β-catenin signaling and reduces the migration of triple negative breast cancer

-

in-vitro,

BC,

NA

TNBC

E-cadherin↑, Vim↓, cycD1↓, cMyc↓, EMT↓,

54-

QC,

Quercetin‑3‑methyl ether suppresses human breast cancer stem cell formation by inhibiting the Notch1 and PI3K/Akt signaling pathways

-

in-vitro,

BC,

MCF-7

0-20 uM

EMT↓, E-cadherin↑, Vim↓, MMP2↓, NOTCH1↓, PI3K/Akt↓, PI3k/Akt/mTOR↓, p‑Akt↓, EZH2↓,

55-

QC,

Quercetin inhibits the growth of human gastric cancer stem cells by inducing mitochondrial-dependent apoptosis through the inhibition of PI3K/Akt signaling

-

in-vitro,

GC,

GCSCs

Bcl-2↓, BAX↑, Cyt‑c↑, MMP↓, PI3K/Akt↓, Casp3↑, Casp9↑,

56-

QC,

Quercetin inhibits epithelial–mesenchymal transition, decreases invasiveness and metastasis, and reverses IL-6 induced epithelial–mesenchymal transition, expression of MMP by inhibiting STAT3 signaling in pancreatic cancer cells

-

in-vitro,

PC,

PANC1

245uM

-

in-vitro,

PC,

PATU-8988

131 uM

EMT↓, MMPs↓, MMP2↓, MMP7↓, STAT3↓,

65-

QC,

Hsp27 participates in the maintenance of breast cancer stem cells through regulation of epithelial-mesenchymal transition and nuclear factor-κB

-

in-vitro,

BC,

NA

50, 25 or 12.5 uM

HSP27↓, EMT↓, NF-kB↓, Snail↓, Vim↓, E-cadherin↑,

58-

QC,

doxoR,

Quercetin induces cell cycle arrest and apoptosis in CD133+ cancer stem cells of human colorectal HT29 cancer cell line and enhances anticancer effects of doxorubicin

-

in-vitro,

CRC,

HT-29

75 uM

-

in-vitro,

NA,

CD133+

CSC

Bcl-2↓,

59-

QC,

Quercetin Inhibits Breast Cancer Stem Cells via Downregulation of Aldehyde Dehydrogenase 1A1 (ALDH1A1), Chemokine Receptor Type 4 (CXCR4), Mucin 1 (MUC1), and Epithelial Cell Adhesion Molecule (EpCAM)

-

in-vitro,

BC,

MDA-MB-231

50 uM

BCSC

ALDH1A1↓, CXCR4↓, MUC1↓, EpCAM↓,

60-

QC,

EGCG,

isoFl,

isoFl,

isoFl

The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition

-

in-vitro,

Pca,

pCSCs

20 uM

Casp3↑, Casp7↑, Bcl-2↓, survivin↓, XIAP↓, EMT↓, Slug↓, Snail↓, β-catenin/ZEB1↓, LEF1↓,

61-

QC,

Midkine downregulation increases the efficacy of quercetin on prostate cancer stem cell survival and migration through PI3K/AKT and MAPK/ERK pathway

-

in-vitro,

Pca,

PC3

40 uM

-

in-vitro,

Pca,

LNCaP

LNCap and ARPE-19 cells

-

in-vitro,

Pca,

ARPE-19

LNCap and ARPE-19 cells

p‑PI3K↓, p‑Akt↓, p‑ERK↓, NF-kB↓, p38↓, ABCG2↓,

62-

QC,

GoldNP,

Gold nanoparticles-conjugated quercetin induces apoptosis via inhibition of EGFR/PI3K/Akt-mediated pathway in breast cancer cell lines (MCF-7 and MDA-MB-231)

-

in-vitro,

BC,

MCF-7

50 uM

-

in-vitro,

BC,

MDA-MB-231

100 uM

EGFR↓, PI3k/Akt/mTOR↓, GSK‐3β↓,

63-

QC,

Quercetin facilitates cell death and chemosensitivity through RAGE/PI3K/AKT/mTOR axis in human pancreatic cancer cells

-

in-vitro,

Pca,

NA

RAGE↓, PI3K↓, mTOR↓, Akt↓, Apoptosis↑, TumAuto↑,

83-

QC,

Quercetin induces p53-independent apoptosis in human prostate cancer cells by modulating Bcl-2-related proteins: a possible mediation by IGFBP-3

-

in-vitro,

Pca,

PC3

25, 50, 75, 100 uM

Bcl-2↓, Bcl-xL↓, BAX↑, IGFBP3↑,

41-

QC,

Quercetin induces mitochondrial-derived apoptosis via reactive oxygen species-mediated ERK activation in HL-60 leukemia cells and xenograft

-

vitro+vivo,

AML,

HL-60

Casp8↑, Casp9↑, Casp3↑, ROS↑, ERK↑, PARP↑, MMP↓,

100-

QC,

Inhibition of Prostate Cancer Cell Colony Formation by the Flavonoid Quercetin Correlates with Modulation of Specific Regulatory Genes

-

in-vitro,

Pca,

PC3

0-50 uM

-

in-vitro,

Pca,

DU145

-

in-vitro,

Pca,

LNCaP

cycD1↓, cycE↓, CDK2↓, CDK4/6↓, E2Fs↓, PCNA↓, cDC2↓, PTEN↑, MSH2↑, P21↑, EP300↑, BRCA1↑, NF2↑, TSC1↑, TGFβR1↑, P53↑, RB1↑, AKT1↓, cMyc↓, CDC7↓, cycF↓, CDC16↓, CUL4B↑, CBP↑, TSC2↑, HER2/EBBR2↓, BCR↓,

48-

QC,

Quercetin Potentiates Apoptosis by Inhibiting Nuclear Factor-kappaB Signaling in H460 Lung Cancer Cells

-

in-vitro,

NSCLC,

H460

TRAILR↑, Casp10↑, DFF45↑, TNFR 1↑, Fas↑, NF-kB↓, IKKα↓,

47-

QC,

Induction of death receptor 5 and suppression of survivin contribute to sensitization of TRAIL-induced cytotoxicity by quercetin in non-small cell lung cancer cells

-

in-vitro,

NSCLC,

H460

-

in-vitro,

NSCLC,

A549

TRAIL↑, DR5↑, survivin↓,

46-

QC,

Quercetin, but Not Its Glycosidated Conjugate Rutin, Inhibits Azoxymethane-Induced Colorectal Carcinogenesis in F344 Rats

-

in-vitro,

Colon,

F344

10g/kg diet

rats

β-catenin/ZEB1↓,

45-

QC,

Quercetin Inhibit Human SW480 Colon Cancer Growth in Association with Inhibition of Cyclin D1 and Survivin Expression through Wnt/β-Catenin Signaling Pathway

-

in-vitro,

Colon,

CX-1

-

in-vitro,

Colon,

SW480

80 micromol/L

-

in-vitro,

Colon,

HT-29

-

in-vitro,

Colon,

HCT116

cycD1↓, survivin↓, Wnt/(β-catenin)↓,

44-

QC,

Preclinical Colorectal Cancer Chemopreventive Efficacy and p53-Modulating Activity of 3′,4′,5′-Trimethoxyflavonol, a Quercetin Analog

-

in-vivo,

CRC,

HCT116

P53↑,

43-

QC,

Investigation of the anti-cancer effect of quercetin on HepG2 cells in vivo

-

in-vivo,

Liver,

HepG3

cycD1↓,

42-

QC,

Quercetin induces apoptosis by activating caspase-3 and regulating Bcl-2 and cyclooxygenase-2 pathways in human HL-60 cells

-

in-vitro,

AML,

HL-60

61.11 uM

Bcl-2↓, BAX↑, Casp3↑, COX2↓,

99-

QC,

Quercetin Inhibits Epithelial-to-Mesenchymal Transition (EMT) Process and Promotes Apoptosis in Prostate Cancer via Downregulating lncRNA MALAT1

-

in-vitro,

Pca,

PC3

50 uM; 75mg/kg/every other day

EMT↓, E-cadherin↑, N-cadherin↓, Ki-67↓, PI3K/Akt↓, MALAT1↓,

40-

QC,

Quercetin arrests G2/M phase and induces caspase-dependent cell death in U937 cells

-

in-vitro,

lymphoma,

U937

cycD1↓, cycE↓, E2Fs↓, CycB↑, Casp↑,

39-

QC,

A Comprehensive Analysis and Anti-Cancer Activities of Quercetin in ROS-Mediated Cancer and Cancer Stem Cells

-

Analysis,

NA,

NA

ROS↑, GSH↓, IL6↓, COX2↓, IL8↓, iNOS↓, TNF-α↓, MAPK↑, ERK↑, SOD↑, ATP↓, Casp↑, PI3K/Akt↓, mTOR↓, NOTCH1↓, Bcl-2↓, BAX↑, IFN-γ↓, TumCP↓, TumCCA↑, Akt↓, P70S6K↓, *Keap1↓, *GPx↑, *Catalase↑, *HO-1↑, *NRF2↑, NRF2↑, eff↑, HIF-1↓,

38-

QC,

Quercetin inhibits prostate cancer by attenuating cell survival and inhibiting anti-apoptotic pathways

-

in-vitro,

Pca,

DU145

(PI3K/Akt down regulate)

-

in-vitro,

Pca,

PC3

(PI3K/Akt up regulate)

ROS↑, GSH↓, PI3K/Akt⇅,

37-

QC,

Low Concentrations of Flavonoids Are Protective in Rat H4IIE Cells Whereas High Concentrations Cause DNA Damage and Apoptosis

-

in-vivo,

Hepat,

H4IIE

1-2g=10-50uM/L

rat

DNAdamC↑, Casp1↑,

36-

QC,

Quercetin induces G2 phase arrest and apoptosis with the activation of p53 in an E6 expression-independent manner in HPV-positive human cervical cancer-derived cells

-

in-vitro,

Cerv,

HeLa

125 uM

-

in-vitro,

Cerv,

SiHa

140 uM

P53↑, P21↑, BAX↑, Casp3↑, Casp7↑, TumCCA↑, ROS↑,

35-

QC,

Quercetin may act as a cytotoxic prooxidant after its metabolic activation to semiquinone and quinoidal product

ROS↑, GSH↓,

138-

QC,

CUR,

Sensitization of androgen refractory prostate cancer cells to anti-androgens through re-expression of epigenetically repressed androgen receptor - Synergistic action of quercetin and curcumin

-

in-vitro,

Pca,

DU145

-

in-vitro,

Pca,

PC3

DNMTs↓,

98-

QC,

Quercetin postconditioning attenuates myocardial ischemia/reperfusion injury in rats through the PI3K/Akt pathway

-

in-vivo,

Stroke,

NA

rats

*Bcl-2↑, *BAX↓, *Bax:Bcl2↓, *cardioP↑, *Akt↑, *PI3K↑, *LDH↓,

84-

QC,

Quercetin-induced growth inhibition and cell death in prostatic carcinoma cells (PC-3) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression

-

in-vitro,

Pca,

PC3

25, 50, 75, 100 uM

P21↑, cDC2↓, CDK1↓, CycB↓, Casp3↑, Bcl-2↓, Bcl-xL↓, BAX↑, pRB↓,

85-

QC,

Quercetin inhibits invasion, migration and signalling molecules involved in cell survival and proliferation of prostate cancer cell line (PC-3)

-

in-vitro,

Pca,

PC3

25-125 uM

uPA↓, uPAR↓, EGFR↓, NRAS↓, Jun↓, NF-kB↓, β-catenin/ZEB1↓, p38↑, MAPK↑, cJun↓, cFos↓, Raf↓,

86-

QC,

Quercetin regulates insulin like growth factor signaling and induces intrinsic and extrinsic pathway mediated apoptosis in androgen independent prostate cancer cells (PC-3)

-

in-vitro,

Pca,

PC3

25, 50, 75, 100, 125 uM

BAD↑, IGFBP3↑, Cyt‑c↑, cl‑Casp9↑, Casp10↑, cl‑PARP↑, Casp3↑, IGF-1R↓, PI3K↓, p‑Akt↓, cycD1↓, IGF-1↓, IGF-2↓, IGF-1R↓,

87-

QC,

Quercetin inhibits prostate cancer by attenuating cell survival and inhibiting anti-apoptotic pathways

-

in-vitro,

Pca,

LNCaP

5, 10, 20, 40, 80, 160 uM

ROS↓

-

in-vitro,

Pca,

DU145

ROS↑

-

in-vitro,

Pca,

PC3

ROS↓

ROS⇅, BAX↑, PUMA⇅, β-catenin/ZEB1↓, Shc↓, TAp63α↑, MAPK↑, p‑p42↑, p‑p44↑, BIM↑,

88-

QC,

PacT,

Quercetin Enhanced Paclitaxel Therapeutic Effects Towards PC-3 Prostate Cancer Through ER Stress Induction and ROS Production

-

vitro+vivo,

Pca,

PC3

7.5, 15, 30, 60, 120 uM; 50mg/kg/every other day

mice

ROS↑, ER Stress↑,

89-

QC,

doxoR,

Quercetin reverses the doxorubicin resistance of prostate cancer cells by downregulating the expression of c-met

-

in-vitro,

Pca,

PC3

10 uM

PC3/R

PI3K/Akt↓, cMET↓, Casp3↑, Casp9↑, MMP↓,

90-

QC,

HP,

Combination of quercetin and hyperoside inhibits prostate cancer cell growth and metastasis via regulation of microRNA‑21

-

in-vitro,

Pca,

PC3

0-60 ug/ml

12.4 ug/ml

ROS↑, cl‑Casp3↑, cl‑PARP↑, miR-21↓, PDCD4↑,

91-

QC,

The roles of endoplasmic reticulum stress and mitochondrial apoptotic signaling pathway in quercetin-mediated cell death of human prostate cancer PC-3 cells

-

in-vitro,

Pca,

PC3

50-200 uM

CDK2↓, cycE↓, cycD1↓, ATFs↑, GRP78/BiP↑, Bcl-2↓, BAX↑, Casp3↑, Casp8↑, Casp9↑, ER Stress↑, CHOP↑,

92-

QC,

Quercetin Inhibits Angiogenesis Mediated Human Prostate Tumor Growth by Targeting VEGFR- 2 Regulated AKT/mTOR/P70S6K Signaling Pathways

-

vitro+vivo,

Pca,

HUVECs

10, 20, 30, 40 umol/L;

-

vitro+vivo,

Pca,

PC3

20mg/kg/day

VEGF↓, HemoG↓, Akt↓, mTOR↓, P70S6K↓,

93-

QC,

Chemical Proteomics Identifies Heterogeneous Nuclear Ribonucleoprotein (hnRNP) A1 as the Molecular Target of Quercetin in Its Anti-cancer Effects in PC-3 Cells

-

in-vitro,

Pca,

PC3

30 nM: 25, 50, 75, 100 uM

hnRNPA1↓, Casp3↑, Casp7↑,

94-

QC,

HPT,

Effects of quercetin on the heat-induced cytotoxicity of prostate cancer cells

-

in-vitro,

Pca,

LNCaP

12.5, 25, 50, 100 umol/L

-

in-vitro,

Pca,

PC3

-

in-vitro,

Pca,

JCA-1

HSP70/HSPA5↓,

95-

QC,

Quercetin, a natural dietary flavonoid, acts as a chemopreventive agent

-

in-vitro,

Pca,

PC3

10, 50, 100 uM

p‑ERK↓, p‑STAT3↓, p‑Akt↓, N-cadherin↓, Vim↓, cycD1↓, Snail↓, Slug↓, Twist↓, PCNA↓,

96-

QC,

docx,

Quercetin reverses docetaxel resistance in prostate cancer via androgen receptor and PI3K/Akt signaling pathways

-

vitro+vivo,

Pca,

LNCaP

5, 10, 20, 50, 100, 150, 200 uM; 75mg/kg/every other day

-

in-vitro,

Pca,

PC3

PI3K/Akt↓, Ki-67↓, BAX↑, Bcl-2↓, EpCAM↓, Twist↓, E-cadherin↑, P-gp↓,

97-

QC,

HPT,

Effects of the flavonoid drug Quercetin on the response of human prostate tumours to hyperthermia in vitro and in vivo

-

in-vitro,

Pca,

PC3

0-400 uM; 150mg/kg/day

HSP72↑,

82-

QC,

AG,

Arctigenin in combination with quercetin synergistically enhances the anti-proliferative effect in prostate cancer cells

-

in-vitro,

Pca,

NA

AR↓, PI3K/Akt↓, miR-21↓, STAT3↓, BAD↓, PRAS40↓, GSK‐3β↓, PSA↓, NKX3.1↑, Bax:Bcl2↑, miR-19b↓, miR-148a↓, AMPKα↓,

912-

QC,

2DG,

Selected polyphenols potentiate the apoptotic efficacy of glycolytic inhibitors in human acute myeloid leukemia cell lines. Regulation by protein kinase activities

Apoptosis↑, ROS↓, GSH∅, other↑,

913-

QC,

Effects of low dose quercetin: Cancer cell-specific inhibition of cell cycle progression

-

in-vitro,

BC,

SkBr3

-

in-vitro,

BC,

MDA-MB-435

TumCP↓, TumCCA↑, DNAdam↑, Chk2↑, CycB↓, CDK1↓, tumCV↓, p‑RB1↓, P21↑,

914-

QC,

Quercetin and Cancer Chemoprevention

-

Review,

NA,

NA

GSH↓, ROS↑, TumCCA↑, Ca+2↑, MMP↓, Casp3↑, Casp8↑, Casp9↑, β-catenin/ZEB1↓, AMPKα↑, ASK1↑, p38↑, TRAIL↑, DR5↑, cFLIP↓, Apoptosis↑,

915-

QC,

Hormesis and synergy: pathways and mechanisms of quercetin in cancer prevention and management

-

Review,

NA,

NA

1-40uM

ROS↑,

916-

QC,

Quercetin and cancer: new insights into its therapeutic effects on ovarian cancer cells

-

Review,

Ovarian,

NA

COX2↓, CRP↓, ER Stress↑, Apoptosis↑, GRP78/BiP↑, CHOP↑, p‑STAT3↓, PI3K↓, Akt↓, mTOR↓, cMyc↓, cycD1↓, cFLIP↓, IL6↓, IL10↓,

917-

QC,

BML,

Pap,

Quercetin: A Versatile Flavonoid

-

Review,

Nor,

NA

*BioEnh↑,

918-

QC,

CUR,

VitC,

Anti- and pro-oxidant effects of oxidized quercetin, curcumin or curcumin-related compounds with thiols or ascorbate as measured by the induction period method

-

Analysis,

NA,

NA

ROS↑, ROS↑,

919-

QC,

Quercetin Regulates Sestrin 2-AMPK-mTOR Signaling Pathway and Induces Apoptosis via Increased Intracellular ROS in HCT116 Colon Cancer Cells

-

in-vitro,

CRC,

HCT116

25,50uM 6hr

Apoptosis↑, ROS↑, SESN2↑, P53↑, AMPKα↑, mTOR↓,

920-

QC,

Interfering with ROS Metabolism in Cancer Cells: The Potential Role of Quercetin

-

Review,

NA,

NA

GSH↓, ROS↑,

921-

QC,

Essential requirement of reduced glutathione (GSH) for the anti-oxidant effect of the flavonoid quercetin

-

in-vitro,

lymphoma,

U937

ROS↑, GSH↓,

922-

QC,

Quercetin and ovarian cancer: An evaluation based on a systematic review

-

Review,

NA,

NA

ROS↑,

923-

QC,

Quercetin as an innovative therapeutic tool for cancer chemoprevention: Molecular mechanisms and implications in human health

-

Review,

Var,

NA

ROS↑, GSH↓, Ca+2↝, MMP↓, Casp3↑, Casp8↑, Casp9↑, other↓, *ROS↓, *NRF2↑, HO-1↑, TumCCA↑, Inflam↓, STAT3↓, DR5↑, P450↓, MMPs↓, IFN-γ↓, IL6↓, COX2↓, IL8↓, iNOS↓, TNF-α↓, cl‑PARP↑, Apoptosis↑, P53↑, Sp1/3/4↓, survivin↓, TRAILR↑, Casp10↑, DFF45↑, TNFR 1↑, Fas↑, NF-kB↓, IKKα↓, cycD1↓, Bcl-2↓, BAX↑, PI3K↓, Akt↓, E-cadherin↓, Vim↓, β-catenin/ZEB1↓, cMyc↓, EMT↓, MMP2↓, NOTCH1↓, MMP7↓, angioG↓, TSP-1↑, CSCs↓, XIAP↓, Snail↓, Slug↓, LEF1↓, P-gp↓, EGFR↓, GSK‐3β↓, mTOR↓, RAGE↓, HSP27↓, VEGF↓, TGF-β↓, COL1↓, COL3A1↓,

926-

QC,

PacT,

doxoR,

Tam,

Bioenhancers from mother nature and their applicability in modern medicine

-

Review,

Nor,

NA

*BioEnh↑, BioEnh↑, BioEnh↑, BioEnh↑, BioEnh↑, BioEnh↑, BioEnh↑, P-gp↓,

910-

QC,

The Anti-Cancer Effect of Quercetin: Molecular Implications in Cancer Metabolism

tumCV↓, Apoptosis↑, PI3k/Akt/mTOR↓, Wnt/(β-catenin)↓, MAPK↝, ERK↝, TumCCA↑, H2O2↑, ROS↑, TumAuto↑, MMPs↓, P53↑, Casp3↑, Hif1a↓, cFLIP↓, IL6↓, IL10↓, lactateProd↓, Glycolysis↓, PKM2↓, GLUT1↓, COX2↓, VEGF↓, OCR↓, ECAR↓, STAT3↓, MMP2↓, MMP9:TIMP1↓, mTOR↓,

894-

QC,

The antioxidant, rather than prooxidant, activities of quercetin on normal cells: quercetin protects mouse thymocytes from glucose oxidase-mediated apoptosis

-

in-vitro,

Nor,

NA

50uM

protected mouse thymocytes from glucose oxidase (GO)-mediated apoptosis

Apoptosis↑, *NF-kB↓, *AP-1↓, *P53↝, *ROS↓,

873-

QC,

RES,

CUR,

PI,

Combination Effects of Quercetin, Resveratrol and Curcumin on In Vitro Intestinal Absorption

-

in-vitro,

Nor,

NA

*BioEnh↑,

889-

QC,

The multifaceted role of quercetin derived from its mitochondrial mechanism

-

vitro+vivo,

Var,

NA

MMP↓, ATP↝, OXPHOS↝, ROS↑,

890-

QC,

PROOXIDANT ACTIVITIES OF ANTIOXIDANTS AND THEIR IMPACT ON HEALTH

-

Review,

Var,

NA

ROS↑,

891-

QC,

Chapter 9 - Quercetin: Prooxidant Effect and Apoptosis in Cancer

-

in-vitro,

Var,

NA

ROS↑, AntiTum↑,

892-

QC,

Antioxidant vs. pro-oxidant activities of quercetin in aqueous phase: A Density Functional Theory study

-

Analysis,

Var,

NA

ROS↑,

893-

QC,

Quercetin: Prooxidant Effect and Apoptosis in Cancer

-

Analysis,

Var,

NA

ROS↑,

911-

QC,

SFN,

Pilot study evaluating broccoli sprouts in advanced pancreatic cancer (POUDER trial) - study protocol for a randomized controlled trial

TumCG↓, Risk↓,

895-

QC,

Theoretical Study of the Antioxidant Activity of Quercetin Oxidation Products

-

Analysis,

Var,

NA

ROS⇅,

896-

QC,

Antioxidant and pro-oxidant actions of the plant phenolics quercetin, gossypol and myricetin: Effects on lipid peroxidation, hydroxyl radical generation and bleomycin-dependent damage to DNA

-

in-vivo,

Var,

NA

ROS↑,

897-

QC,

Anti- and prooxidant effects of chronic quercetin administration in rats

-

in-vivo,

Nor,

NA

Rats

*MDA↓, *GSH↓, *ROS↑,

898-

QC,

Anti- and pro-oxidant activity of rutin and quercetin derivatives

-

Analysis,

Var,

NA

ROS↑,

899-

QC,

Intracellular metabolism and bioactivity of quercetin and its in vivo metabolites

-

in-vivo,

Var,

NA

<10uM

ROS↑, GSH↓,

900-

QC,

Quercetin Affects Erythropoiesis and Heart Mitochondrial Function in Mice

-

in-vivo,

Nor,

NA

50 mg/kg

mice

*Weight↓, *TAC∅, *ROS↑,

909-

QC,

Exploring the therapeutic potential of quercetin in cancer treatment: Targeting long non-coding RNAs

-

Review,

NA,

NA

other↓, other↑,

908-

QC,

Molecular Targets Underlying the Anticancer Effects of Quercetin: An Update

-

Review,

NA,

NA

AntiCan↑, ROS↑,

907-

QC,

A Comprehensive Study on the Anti-cancer Effects of Quercetin and Its Epigenetic Modifications in Arresting Progression of Colon Cancer Cell Proliferation

-

Review,

NA,

NA

AntiCan↑,

906-

QC,

The interplay between reactive oxygen species and antioxidants in cancer progression and therapy: a narrative review

-

Review,

NA,

NA

ROS↑,

905-

QC,

Anti- and pro-oxidant effects of quercetin in copper-induced low density lipoprotein oxidation. Quercetin as an effective antioxidant against pro-oxidant effects of urate

-

Analysis,

NA,

NA

ROS↑,

904-

QC,

Antioxidant and prooxidant effects of quercetin on glyceraldehyde-3-phosphate dehydrogenase

-

Analysis,

NA,

NA

ROS↑, H2O2↑,

903-

QC,

Potential toxicity of quercetin: The repression of mitochondrial copy number via decreased POLG expression and excessive TFAM expression in irradiated murine bone marrow

-

in-vivo,

NA,

NA

mice

ROS⇅,

902-

QC,

Prooxidant activities of quercetin, p-courmaric acid and their derivatives analysed by quantitative structure–activity relationship

-

Analysis,

NA,

NA

ROS↑,

901-

QC,

Antioxidant/prooxidant effects of α-tocopherol, quercetin and isorhamnetin on linoleic acid peroxidation induced by Cu(II) and H2O2

-

Analysis,

Var,

NA

investigated in aerated and incubated emulsions

ROS↑,

2431-

QC,

The Protective Effect of Quercetin against the Cytotoxicity Induced by Fumonisin B1 in Sertoli Cells

-

in-vitro,

Nor,

TM4

*Apoptosis↓, *ROS↓, *antiOx↓, *MMP↑, *GPI↑, *HK2↑, *ALDOA↑, *PKM1↑, *LDHA↑, *PFKL↑,

2300-

QC,

Flavonoids Targeting HIF-1: Implications on Cancer Metabolism

-

Review,

Var,

NA

AntiTum↑, Hif1a↓, *Hif1a↑, Glycolysis↓, HK2↓, PDK3↓, PFKP?,

2343-

QC,

Pharmacological Activity of Quercetin: An Updated Review

-

Review,

Nor,

NA

*ROS↓, *GSH↓, *Catalase↑, *SOD↑, *MDA↓, *GPx↑, *Copper↓, *Iron↓, Apoptosis↓, TumCCA↑, MMP2↓, MMP9↓, GlucoseCon↓, lactateProd↓, PKM2↓, GLUT1↓, LDHA↓, ROS↑,

2342-

QC,

Quercetin Inhibits the Proliferation of Glycolysis-Addicted HCC Cells by Reducing Hexokinase 2 and Akt-mTOR Pathway

-

in-vitro,

HCC,

Bel-7402

-

in-vitro,

HCC,

SMMC-7721 cell

-

in-vivo,

NA,

NA

mouse

TumCP↓, HK2↓, Akt↓, mTOR↓, GlucoseCon↓, lactateProd↓, Glycolysis↓,

2303-

QC,

doxoR,

Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing effects on HIF-1α in tumor and normal cells

-

in-vitro,

BC,

4T1

100uM

51.42 uM

-

in-vivo,

NA,

NA

quercetin 100 mg/kg day or DOX 5 mg/kg

mice

cardioP↑, hepatoP↑, TumCG↓, OS↑, ChemoSen↑, chemoP↑, Hif1a↓, *Hif1a↑, selectivity↑, TumVol↓, OS↑,

2344-

QC,

Quercetin: A natural solution with the potential to combat liver fibrosis

-

Review,

Nor,

NA

*HK2↓, *PFKP↓, *PKM2↓, *hepatoP↑, *ALAT↓, *AST↓, *Glycolysis↓, *lactateProd↓, *GlucoseCon↓, *CXCL1↓, *Inflam↓,

2341-

QC,

Quercetin suppresses the mobility of breast cancer by suppressing glycolysis through Akt-mTOR pathway mediated autophagy induction

-

in-vitro,

BC,

MCF-7

30μM

-

in-vitro,

BC,

MDA-MB-231

-

in-vivo,

NA,

NA

intraperitoneally injected with 50 mg/kg quercetin twice daily for a month

mice

MMP2↓, MMP9↓, VEGF↓, Glycolysis↓, lactateProd↓, PKM2↓, GLUT1↓, LDHA↓, TumAuto↑, Akt↓, mTOR↓, TumMeta↓, MMP3↓, eff↓, GlucoseCon↓, lactateProd↓, TumAuto↑, LC3B-II↑,

2340-

QC,

Oral Squamous Cell Carcinoma Cells with Acquired Resistance to Erlotinib Are Sensitive to Anti-Cancer Effect of Quercetin via Pyruvate Kinase M2 (PKM2)

-

in-vitro,

OS,

NA

TumCG↓, GlucoseCon↓, TumCI↓, GLUT1↓, PKM2↓, LDHA↓, Glycolysis↓, lactateProd↓, HK2↓, eff↑,

2339-

QC,

Quercetin protects against LPS-induced lung injury in mice via SIRT1-mediated suppression of PKM2 nuclear accumulation

-

in-vivo,

Nor,

NA

endotoxin-induced ALI mouse model

*Inflam↓, *antiOx↑, *NLRP3↓, *Sepsis↓, *PKM2↓, *SIRT1↓,

2338-

QC,

Quercetin: A Flavonoid with Potential for Treating Acute Lung Injury

-

Review,

Nor,

NA

*SIRT1↑, *NLRP3↓, *Inflam↓, *TNF-α↓, *IL1β↓, *IL6↓, *PKM2↓, *HO-1↑, *ROS↓, *NO↓, *MDA↓, *antiOx↑, *COX2↓, *HMGB1↓, *iNOS↓, *NF-kB↓,

3534-

QC,

Lyco,

Synergistic protection of quercetin and lycopene against oxidative stress via SIRT1-Nox4-ROS axis in HUVEC cells

-

in-vitro,

Nor,

HUVECs

*ROS↓, *NOX4↓, *Inflam↓, *NF-kB↓, *p65↓, *SIRT1↑, *cardioP↑, *IL6↓, *COX2↓,

3352-

QC,

A review of quercetin: Antioxidant and anticancer properties

-

Review,

Var,

NA

*antiOx↑, *lipid-P↓, *TNF-α↓, *NF-kB↓, *COX2↓, *IronCh↑, P53↓, TumCCA↑, HSPs↓, P21↓, RAS↓, ER(estro)↑, OS?,

3361-

QC,

Quercetin ameliorates testosterone secretion disorder by inhibiting endoplasmic reticulum stress through the miR-1306-5p/HSD17B7 axis in diabetic rats

-

in-vivo,

Nor,

NA

40 male Sprague Dawley rats, which were subsequently administered with 20 or 50 mg/kg of quercetin.

-

in-vitro,

NA,

NA

Leydig cells of rat testes were treated by high glucose (HG) followed by 5 or 10 μM quercetin.

*BG↓, *ROS↓, *SOD↑, *MDA↓, *ER Stress↓, *iNOS↓, *CHOP↓, *GRP78/BiP↓, *antiOx↓, *Inflam↓, *JAK2↑, *STAT3?,

3353-

QC,

Quercetin triggers cell apoptosis-associated ROS-mediated cell death and induces S and G2/M-phase cell cycle arrest in KON oral cancer cells

-

in-vitro,

Oral,

KON

0, 1.5625, 3.125, 6.25, 12.5, 25, 50, 100, and 400 µg/mL

50ug/L @ 72h

-

in-vitro,

Nor,

MRC-5

tumCV↓, selectivity↑, TumCCA↑, TumCMig↓, TumCI↓, Apoptosis↑, TumMeta↓, Bcl-2↓, BAX↑, TIMP1↑, MMP2↓, MMP9↓, *Inflam↓, *neuroP↑, *cardioP↑, p38↓, MAPK↓, Twist↓, P21↓, cycD1↓, Casp3↑, Casp9↑, p‑Akt↓, p‑ERK↓, CD44↓, CD24↓, ChemoSen↑, MMP↓, Cyt‑c↑, AIF↑, ROS↑, Ca+2↑, Hif1a↓, VEGF↓,

3354-

QC,

Quercetin: Its Main Pharmacological Activity and Potential Application in Clinical Medicine

-

Review,

Var,

NA

*ROS↓, *IronCh↓, *lipid-P↓, *GSH↑, *NRF2↑, TumCCA↑, ER Stress↑, P53↑, CDK2↓, cycA1↓, CycB↓, cycE↓, cycD1↓, PCNA↓, P21↑, p27↑, PI3K↓, Akt↓, mTOR↓, STAT3↓, cFLIP↓, cMyc↓, survivin↓, DR5↓, *Inflam↓, *IL6↓, *IL8↓, COX2↓, 5LO↓, *cardioP↑, *FASN↓, *AntiAg↑, *MDA↓,

3355-

QC,

Quercetin exhibits cytotoxicity in cancer cells by inducing two-ended DNA double-strand breaks

-

in-vitro,

Cerv,

HeLa

DNAdam↑, ROS↑, *antiOx↑, TOP2↓, γH2AX↑,

3356-

QC,

Targeting DNA methyltransferases for cancer therapy

-

Review,

Var,

NA

DNMTs↓,

3357-

QC,

The polyphenol quercetin induces cell death in leukemia by targeting epigenetic regulators of pro-apoptotic genes

-

in-vitro,

AML,

HL-60

-

NA,

NA,

U937

DNMT1↓, DNMT3A↓, HDAC↓, ac‑H3↑, ac‑H4↑, BAX↑, APAF1↑, BNIP3↑, STAT3↑,

3358-

QC,

Effects of quercetin on the DNA methylation pattern in tumor therapy: an updated review

-

Review,

NA,

NA

TET1↑, DNMTs↓,

3359-

QC,

Quercetin modifies 5′CpG promoter methylation and reactivates various tumor suppressor genes by modulating epigenetic marks in human cervical cancer cells

-

in-vitro,

Cerv,

HeLa

DNMTs↓, HDAC↓, HMTs↓, DNMT3A↓, EZH2↓, HDAC1↓, HDAC2↓, HDAC6↓, HDAC11↓, G9a↓, TIMP3↑, PTEN↑, SOCS1↑,

3360-

QC,

Role of Flavonoids as Epigenetic Modulators in Cancer Prevention and Therapy

-

Review,

Var,

NA

HDAC↓, DNMTs↓, HMTs↓, Let-7↑, NOTCH↓,

3340-

QC,

Quercetin regulates inflammation, oxidative stress, apoptosis, and mitochondrial structure and function in H9C2 cells by promoting PVT1 expression

-

in-vitro,

Nor,

H9c2

2, 4, and 6 h) after treatment with 50 μM

*Inflam↓, *ROS↓, *Apoptosis↓,

3351-

QC,

Quercetin Exerts Differential Neuroprotective Effects Against H2O2 and Aβ Aggregates in Hippocampal Neurons: the Role of Mitochondria

-

Review,

AD,

NA

*ROS↓, *neuroP↑,

3350-

QC,

Quercetin and the mitochondria: A mechanistic view

-

Review,

NA,

NA

*antiOx↑, *Inflam↓, *NRF2↑, ROS⇅, *NRF2↑, *HO-1↑, *PPARα↑, *PGC-1α↑, *SIRT1↑, *ATP↑, ATP↓, ERK↓, cl‑PARP↑, Casp9↑, Casp8↑, BAX↑, MMP↓, Cyt‑c↑, Casp3↑, HSP27↓, HSP72↓, RAS↓, Raf↓,

3349-

QC,

Quercetin Exerted Protective Effects in a Rat Model of Sepsis via Inhibition of Reactive Oxygen Species (ROS) and Downregulation of High Mobility Group Box 1 (HMGB1) Protein Expression

-

in-vivo,

Sepsis,

NA

rats

*Sepsis↓, *ROS↓, *SOD↑, *Catalase↑, *HMGB1↓, *Inflam↓, *TAC↑,

3348-

QC,

Quercetin and iron metabolism: What we know and what we need to know

-

Review,

NA,

NA

*IronCh↑, *ROS↓, *AntiAg↑, *Fenton↓, *lipid-P↓, *hepatoP↑, *RenoP↑, HIF-1↑, ROS↑,

3347-

QC,

Recent Advances in Potential Health Benefits of Quercetin

-

Review,

Var,

NA

-

Review,

AD,

NA

*antiOx↑, *ROS↓, *Inflam?, TumCP↓, Apoptosis↑, *cardioP↑, *BP↓, TumMeta↓, MDR1↓, NADPH↓, ChemoSen↑, MMPs↓, TIMP2↑, *NLRP3↓, *IFN-γ↑, *COX2↓, *NF-kB↓, *MAPK↓, *CRP↓, *IL6↓, *TNF-α↓, *IL1β↓, *TLR4↑, *PKCδ↓, *AP-1↓, *ICAM-1↓, *NRF2↑, *HO-1↑, *lipid-P↓, *neuroP↑, *eff↑, *memory↑, *cognitive↑, *AChE↓, *BioAv↑, *BioAv↑, *BioAv↑, *BioAv↑, *BioAv↑,

3346-

QC,

Regulation of the Intracellular ROS Level Is Critical for the Antiproliferative Effect of Quercetin in the Hepatocellular Carcinoma Cell Line HepG2

-

in-vitro,

Liver,

HepG2

-

in-vitro,

Liver,

HUH7

TumCCA↑, Apoptosis↑, P53↑, TumCP↓, ROS↓, antiOx↑, HO-1↑, CDK1↓,

3344-

QC,

Quercetin induced ROS production triggers mitochondrial cell death of human embryonic stem cells

-

in-vitro,

Nor,

hESC

mt-ROS↑, selectivity↑, P53↑, ROS⇅,

3343-

QC,

Quercetin, a Flavonoid with Great Pharmacological Capacity

-

Review,

Var,

NA

-

Review,

AD,

NA

-

Review,

Arthritis,

NA

*antiOx↑, *ROS↓, *angioG↓, *Inflam↓, *BioAv↓, *Half-Life↑, *GSH↑, *SOD↑, *Catalase↑, *Nrf1↑, *BP↓, *cardioP↑, *IL10↓, *TNF-α↓, *Aβ↓, *GSK‐3β↓, *tau↓, *neuroP↑, *Pain↓, *COX2↓, *NRF2↑, *HO-1↑, *IL1β↓, *IL17↓, *MCP1↓, PKCδ↓, ERK↓, BAX↓, cMyc↓, KRAS↓, ROS↓, selectivity↑, tumCV↓, Apoptosis↑, TumCCA↑, eff↑, P-gp↓, eff↑, eff↑, eff↑, eff↑, CycB↓, CDK1↓, CDK4↓, CDK2↓, TOP2↓, Cyt‑c↑, cl‑PARP↑, MMP↓, HSP70/HSPA5↓, HSP90↓, MDM2↓, RAS↓, eff↑,

3342-

QC,

Quercetin modulates OTA-induced oxidative stress and redox signalling in HepG2 cells — up regulation of Nrf2 expression and down regulation of NF-κB and COX-2

-

in-vitro,

Nor,

HepG2

*ROS↓, *Ca+2↓, *NF-kB↓, *NRF2↑, *COX2↓, *Inflam↓,

3341-

QC,

Antioxidant Activities of Quercetin and Its Complexes for Medicinal Application

-

Review,

Var,

NA

-

Review,

Stroke,

NA

*antiOx↑, *BioAv↑, *GSH↑, *AChE↓, *BChE↓, *H2O2↓, *lipid-P↓, *SOD↑, *SOD2↑, *Catalase↑, *GPx↑, *neuroP↑, *HO-1↑, *cardioP↑, *MDA↓, *NF-kB↓, *IKKα↓, *ROS↓, *PI3K↑, *Akt↑, *hepatoP↑, P53↑, BAX↑, IGF-1R↓, Akt↓, AR↓, TumCP↓, GSH↑, SOD↑, Catalase↑, lipid-P↓, *TNF-α↓, *Ca+2↓,

3372-

QC,

FIS,

KaempF,

Anticancer Potential of Selected Flavonols: Fisetin, Kaempferol, and Quercetin on Head and Neck Cancers

-

Review,

HNSCC,

NA

ROCK1↑, TumCCA↓, HSPs↓, RAS↓, ROS↑, Ca+2↑, MMP↓, Cyt‑c↑, Endon↑, MMP9↓, MMP2↓, MMP7↓, MMP-10↓, VEGF↓, NF-kB↓, p65↓, iNOS↓, COX2↓, uPA↓, PI3K↓, FAK↓, MEK↓, ERK↓, JNK↓, p38↓, cJun↓, FOXO3↑,

3381-

QC,

Quercetin induces cell death in cervical cancer by reducing O-GlcNAcylation of adenosine monophosphate-activated protein kinase

-

in-vitro,

Cerv,

HeLa

SREBP1↓, TumCP↓, TumCD↑, AMPK↑, SREBP1↓, FASN↓, ACC↓,

3380-

QC,

Quercetin as a JAK–STAT inhibitor: a potential role in solid tumors and neurodegenerative diseases

-

Review,

Var,

NA

-

Review,

Park,

NA

-

Review,

AD,

NA

JAK↓, STAT↓, Inflam↓, NO↓, COX2↓, CRP↓, selectivity↑, *neuroP↑, STAT3↓, cycD1↓, MMP2↓, STAT4↓, JAK2↓, TumCP↓, Diff↓, *eff↑, *IL6↓, *TNF-α↓, *IL1β↓, *Aβ↓,

3379-

QC,

The Effect of Quercetin Nanosuspension on Prostate Cancer Cell Line LNCaP via Hedgehog Signaling Pathway

-

in-vitro,

Pca,

LNCaP

tumCV↓, HH↓,

3378-

QC,

CK2 and PI3K are direct molecular targets of quercetin in chronic lymphocytic leukaemia

-

in-vitro,

AML,

NA

CK2↓, PI3K↓, TumCD↑, Akt↓, Mcl-1↓, PTEN↑,

3377-

QC,

Quercetin inhibits a large panel of kinases implicated in cancer cell biology

PDGF↓, FLT3↓, JAK3↓, MET↓, RET↓, FGFR2↓, other↓,

3376-

QC,

Inhibiting CDK6 Activity by Quercetin Is an Attractive Strategy for Cancer Therapy

-

in-vitro,

BC,

MCF-7

-

in-vitro,

Lung,

A549

CDK6↓, tumCV↓, Apoptosis↑, ROS↓, eff↑,

3375-

QC,

Quercetin Mediated TET1 Expression Through MicroRNA-17 Induced Cell Apoptosis in Melanoma Cells

-

in-vitro,

Melanoma,

B16-BL6

TET1↑, TumCI↓,

3374-

QC,

Therapeutic effects of quercetin in oral cancer therapy: a systematic review of preclinical evidence focused on oxidative damage, apoptosis and anti-metastasis

-

Review,

Oral,

NA

-

Review,

AD,

NA

α-SMA↓, α-SMA↑, TumCP↓, tumCV↓, TumVol↓, TumCI↓, TumMeta↓, TumCMig↓, ROS↑, Apoptosis↑, BioAv↓, *neuroP↑, *antiOx↑, *Inflam↓, *Aβ↓, *cardioP↑, MMP↓, Cyt‑c↑, MMP2↓, MMP9↓, EMT↓, MMPs↓, Twist↓, Slug↓, Ca+2↑, AIF↑, Endon↑, P-gp↓, LDH↑, HK2↓, PKA↓, Glycolysis↓, GlucoseCon↓, lactateProd↓, GRP78/BiP↑, Casp12↑, CHOP↑,

3373-

QC,

The Effect of Quercetin in the Yishen Tongluo Jiedu Recipe on the Development of Prostate Cancer through the Akt1-related CXCL12/ CXCR4 Pathway

-

in-vitro,

Pca,

DU145

TumCP↓, Casp3↑, Bcl-2↓, Apoptosis↑, TumCI↓, TumCMig↓, CXCL12↓, CXCR4↓,

3362-

QC,

The effect of quercetin on cervical cancer cells as determined by inducing tumor endoplasmic reticulum stress and apoptosis and its mechanism of action

-

in-vitro,

Cerv,

HeLa

Apoptosis↑, cycD1↓, Casp3↑, GRP78/BiP↑, CHOP↑, tumCV↓, IRE1↑, p‑PERK↑, c-ATF6↑, ER Stress↑,

3371-

QC,

Quercetin induces MGMT+ glioblastoma cells apoptosis via dual inhibition of Wnt3a/β-Catenin and Akt/NF-κB signaling pathways

-

in-vitro,

GBM,

T98G

TIMP2↑, TumCG↓, TumCMig↓, Apoptosis↑, TumCCA↑, MMP↓, ROS↑, Bax:Bcl2↑, cl‑Casp9↑, cl‑Casp3↑, DNAdam↑, γH2AX↑, MGMT↓, cl‑PARP↑,

3370-

QC,

Quercetin downregulates matrix metalloproteinases 2 and 9 proteins expression in prostate cancer cells (PC-3)

-

in-vitro,

Pca,

PC3

50 and 100 microM), for 24 h period

MMP2↓, MMP9↓,

3369-

QC,

Pharmacological basis and new insights of quercetin action in respect to its anti-cancer effects

-

Review,

Pca,

NA

FAK↓, TumCCA↑, p‑pRB↓, CDK2↑, CycB↓, CDK1↓, EMT↓, PI3K↓, MAPK↓, Wnt↓, ROS↑, miR-21↑, Akt↓, NF-kB↓, FasL↑, Bak↑, BAX↑, Bcl-2↓, Casp3↓, Casp9↑, P53↑, p38↑, MAPK↑, Cyt‑c↑, PARP↓, CHOP↑, ROS↓, LDH↑, GRP78/BiP↑, ERK↑, MDA↓, SOD↑, GSH↑, NRF2↑, VEGF↓, PDGF↓, EGF↓, FGF↓, TNF-α↓, TGF-β↓, VEGFR2↓, EGFR↓, FGFR1↓, mTOR↓, cMyc↓, MMPs↓, LC3B-II↑, Beclin-1↑, IL1β↓, CRP↓, IL10↓, COX2↓, IL6↓, TLR4↓, Shh↓, HER2/EBBR2↓, NOTCH↓, DR5↑, HSP70/HSPA5↓, CSCs↓, angioG↓, MMP2↓, MMP9↓, IGFBP3↑, uPA↓, uPAR↓, RAS↓, Raf↓, TSP-1↑,

3368-

QC,

The potential anti-cancer effects of quercetin on blood, prostate and lung cancers: An update

-

Review,

Var,

NA

*Inflam↓, *antiOx↑, *AntiCan↑, Casp3↓, p‑Akt↓, p‑mTOR↓, p‑ERK↓, β-catenin/ZEB1↓, Hif1a↓, AntiAg↓, VEGFR2↓, EMT↓, EGFR↓, MMP2↓, MMP↓, TumMeta↓, MMPs↓, Akt↓, Snail↓, N-cadherin↓, Vim↓, E-cadherin↑, STAT3↓, TGF-β↓, ROS↓, P53↑, BAX↑, PKCδ↓, PI3K↓, COX2↓, cFLIP↓, cycD1↓, cMyc↓, IL6↓, IL10↓, Cyt‑c↑, TumCCA↑, DNMTs↓, HDAC↓, ac‑H3↑, ac‑H4↑, Diablo↑, Casp3↑, Casp9↑, PARP1↑, eff↑, PTEN↑, VEGF↓, NO↓, iNOS↓, ChemoSen↑, eff↑, eff↑, eff↑, uPA↓, CXCR4↓, CXCL12↓, CLDN2↓, CDK6↓, MMP9↓, TSP-1↑, Ki-67↓, PCNA↓, ROS↑, ER Stress↑,

3367-

QC,

Targeting Nrf2 signaling pathway by quercetin in the prevention and treatment of neurological disorders: An overview and update on new developments

-

Review,

Stroke,

NA

-

Review,

AD,

NA

*NRF2↑, *neuroP↑, *motorD↑, *Inflam↓, *cognitive↑,

3366-

QC,

Quercetin Attenuates Endoplasmic Reticulum Stress and Apoptosis in TNBS-Induced Colitis by Inhibiting the Glucose Regulatory Protein 78 Activation

-

in-vivo,

IBD,

NA

24 Wistar Albino rats

*Apoptosis↓, *Inflam↓, *ROS↓, *ER Stress↓, *TNF-α↓, *MPO↓, *p‑JNK↓, *Casp12↓, *GRP78/BiP↓, *antiOx↑, *NF-kB↓,

3365-

QC,

Quercetin attenuates sepsis-induced acute lung injury via suppressing oxidative stress-mediated ER stress through activation of SIRT1/AMPK pathways

-

in-vivo,

Sepsis,

NA

*ER Stress↓, *PDI↓, *CHOP↓, *GRP78/BiP↓, *ATF6↓, *PERK↓, *IRE1↓, *MMP↑, *SOD↑, *ROS↓, *MDA↓, *SIRT1↑, *AMPK↑, *Sepsis↓,

3364-

QC,

Quercetin Protects Human Thyroid Cells against Cadmium Toxicity

-

in-vitro,

Nor,

NA

*MDA↓, *GRP78/BiP↓,

3363-

QC,

The Protective Effect of Quercetin on Endothelial Cells Injured by Hypoxia and Reoxygenation

-

in-vitro,

Nor,

HBMECs

(0.1, 0.5, 1 μmol/L)

*Apoptosis↓, *angioG↑, *NRF2↑, *Keap1↓, *ATF6↓, *GRP78/BiP↓, *CLDN5↑, *ZO-1↑, *MMP↑, *BBB↑, *ROS↓, *ER Stress↓,

3338-

QC,

Quercetin: Its Antioxidant Mechanism, Antibacterial Properties and Potential Application in Prevention and Control of Toxipathy

-

Review,

Var,

NA

-

Review,

Stroke,

NA

*antiOx↑, *GSH↑, *ROS↓, *Dose↑, *NADPH↓, *AMP↓, *NF-kB↓, *p38↑, *MAPK↑, *SOD↑, *MDA↓, *iNOS↓, *Catalase↑, *PI3K↑, *Akt↑, *lipid-P↓, *memory↑, *radioP↑, *neuroP↑, *MDA↓,

3337-

QC,

Endoplasmic Reticulum Stress-Relieving Effect of Quercetin in Thapsigargin-Treated Hepatocytes

-

in-vitro,

NA,

HepG2

*Inflam↓, *UPR↓, *GRP58↓, *XBP-1↓, *ER Stress↓, *antiOx↑, TNF-α↓, p‑eIF2α↓, p‑IRE1↓, p‑JNK↓, CHOP↓,

3336-

QC,

Neuroprotective Effects of Quercetin in Alzheimer’s Disease

-

Review,

AD,

NA

*neuroP↑, *lipid-P↓, *antiOx↑, *Aβ↓, *Inflam↓, *BBB↓, *NF-kB↓, *iNOS↓, *memory↑, *cognitive↑, *AChE↓, *MMP↑, *ROS↓, *ATP↑, *AMPK↑, *NADPH↓, *p‑tau↓,

3335-

QC,

Recent advances on the improvement of quercetin bioavailability

-

Review,

NA,

NA

*BioAv↓,

3334-

QC,

Pharmacokinetics of Quercetin Absorption from Apples and Onions in Healthy Humans

-

Trial,

Nor,

NA

*Half-Life↑,

3339-

QC,

Quercetin suppresses ROS production and migration by specifically targeting Rac1 activation in gliomas

-

in-vitro,

GBM,

C6

(25 μM, 50 μM, 100 μM, and 200 µM) for different time points (12, 24, 48, or 72 h)

-

in-vitro,

GBM,

IMR32

BBB↑, tumCV↓, TumCMig↓, Rac1↓, p66Shc↓, ROS↓,

156-

Ralox,

Tam,

GEN,

CUR,

Modulators of estrogen receptor inhibit proliferation and migration of prostate cancer cells

-

in-vitro,

Pca,

DU145

-

in-vitro,

Pca,

PC3

ERβ↑,

101-

RES,

Resveratrol inhibits the hedgehog signaling pathway and epithelial-mesenchymal transition and suppresses gastric cancer invasion and metastasis

-

in-vitro,

GC,

SGC-7901

10 uM

HH↓, Gli1↓, EMT↓, Snail↓, N-cadherin↓, E-cadherin↑,

102-

RES,

Effect of resveratrol on proliferation and apoptosis of human pancreatic cancer MIA PaCa-2 cells may involve inhibition of the Hedgehog signaling pathway

-

in-vitro,

PC,

MIA PaCa-2

HH↓, PTCH1↓, Smo↓, HH↓, EMT↓, PI3K/Akt↓, NF-kB↓,

103-

RES,

CUR,

QC,

The effect of resveratrol, curcumin and quercetin combination on immuno-suppression of tumor microenvironment for breast tumor-bearing mice

-

vitro+vivo,

BC,

4T1

Mice: 24 mg/kg Res, 24 mg/kg Cur, 12 mg/kg Que Translated into an edible human dose of 738 mg/day (including 295.2 mg Res, 295.2 mg Cur, and 147.6 mg Que)

8.5mg/L

mice

ROS↑, MMP↓, Bcl-2↓, BAX↑, Casp9↑, T-Cell↑, TGF-β↓,

104-

RES,

QC,

Resveratrol and Quercetin in Combination Have Anticancer Activity in Colon Cancer Cells and Repress Oncogenic microRNA-27a

-

in-vitro,

Colon,

HT-29

18.7 ug/mL

Casp3↑, PARP↑, survivin↓, miR-27a-3p↓, Sp1/3/4↓, ZBTB10↑,

105-

RES,

QC,

The Effect of Resveratrol and Quercetin on Epithelial-Mesenchymal Transition in Pancreatic Cancer Stem Cell

-

in-vitro,

Pca,

CD133+

10 uM

CSCS (CD133-)

N-cadherin↓, TNF-α↓, ACTA2↓,

967-

RES,

Resveratrol binds and inhibits transcription factor HIF-1α in pancreatic cancer

-

Analysis,

PC,

NA

silico approach

Hif1a↓,

1047-

RES,

Resveratrol induces PD-L1 expression through snail-driven activation of Wnt pathway in lung cancer cells

-

in-vitro,

Lung,

H1299

below 5 μM

-

in-vitro,

Lung,

A549

-

in-vitro,

Lung,

H460

PD-L1↑, Snail↑, E-cadherin↓, N-cadherin↑, Fibronectin↑, Vim↑, Axin2↓,

993-

RES,

Resveratrol reverses the Warburg effect by targeting the pyruvate dehydrogenase complex in colon cancer cells

-

in-vitro,

CRC,

Caco-2

10 µM, 48 hr

-

in-vivo,

Nor,

HCEC 1CT

TumCG↓, Glycolysis↓, PPP↓, ATP↑, PDH↑, Ca+2↝, TumCP↓, lactateProd↓, OCR↑, ECAR↓, *ECAR∅, *other?, cycE↑, cycA1↑, TumCCA↑, cycD1↑, OXPHOS↑,

871-

RES,

CUR,

QC,

The effect of resveratrol, curcumin and quercetin combination on immuno-suppression of tumor microenvironment for breast tumor-bearing mice

-

in-vitro,

BC,

4T1

8.55mg/L

Res:Cur:Que = 1:1:0.5

-

in-vivo,

BC,

4T1

tumor bearing mice- subcutaneous injection of 4T1 breast cancer cells

T-Cell↑, Neut↓, Macrophages↓, ROS↑, MMP↓, other↓, AntiTum↑, TumVol↓,

924-

RES,

Resveratrol sequentially induces replication and oxidative stresses to drive p53-CXCR2 mediated cellular senescence in cancer cells

-

in-vitro,

OS,

U2OS

-

in-vitro,

Lung,

A549

TumCCA↑, ROS↑, γH2AX↑, ATM↑, p‑CHK1↑, cellSen↑, CXCR2↑,

877-

RES,

Resveratrol Inhibits Invasion and Metastasis of Colorectal Cancer Cells via MALAT1 Mediated Wnt/β-Catenin Signal Pathway

-

in-vitro,

CRC,

LoVo

55uM

-

in-vitro,

CRC,

HCT116

MALAT1↓, Wnt/(β-catenin)↓, TumCI↓, TumMeta↓,

878-

RES,

Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression

-

vitro+vivo,

CRC,

LoVo

12.5uM, 150 mg/Kg

mice

TumMeta↓, E-cadherin↑, Vim↓, TGF-β↓, SMAD2↓, EMT↓, SMAD3↓,

879-

RES,

Evidence that TNF-β induces proliferation in colorectal cancer cells and resveratrol can down-modulate it

-

in-vitro,

CRC,

HCT116

TumCP↓, NF-kB↓,

880-

RES,

Forkhead Proteins Are Critical for Bone Morphogenetic Protein-2 Regulation and Anti-tumor Activity of Resveratrol

-

in-vitro,

BC,

MDA-MB-231

other↓, TumW↓, FOXO↑, BMP2↑,

881-

RES,

Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein

-

in-vitro,

BC,

MDA-MB-231

-

in-vitro,

PC,

PANC1

-

in-vitro,

Pca,

DU145

TumCCA↑, cycD1↓, Bcl-xL↓, Mcl-1↓, other↓,

882-

RES,

Resveratrol: A Double-Edged Sword in Health Benefits

-

Review,

NA,

NA

AntiTum↑, Casp3↑, Casp9↑, BAX↑, Bcl-2↓, Bcl-xL↓, P53↑, NAF1↓, NRF2↑, ROS↑, Apoptosis↑, HDAC↓, TumCCA↑, TumAuto↑, angioG↓, iNOS↓,

883-

RES,

Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy

HDAC↓, TumCCA↑, Apoptosis↑, angioG↓, ROS↑,

884-

RES,

PS,

Resveratrol and Pterostilbene Exhibit Anticancer Properties Involving the Downregulation of HPV Oncoprotein E6 in Cervical Cancer Cells

-

in-vitro,

Cerv,

HeLa

pterostilbene displayed a 1.97-fold lower IC50 when compared to resveratrol (42.3 µM vs. 83.5 µM

TumCD↑, TumCCA↑, E6↓, Casp3↑, P53↑,

885-

RES,

Resveratrol induces intracellular Ca2 + rise via T-type Ca2 + channels in a mesothelioma cell line

-

in-vitro,

RCC,

REN

EC50 = 2.7 μM

-

in-vitro,

Nor,

MeT5A

EC50 = 4.9 μM

as normal cell model

TumCG↓, Ca+2↑, *toxicity↓,

1506-

RES,

Epigenetic targets of bioactive dietary components for cancer prevention and therapy

-

Review,

NA,

NA

DNMTs↓, BRCA1↑, HDAC↓, SIRT1↑, p300↓, survivin↓, HDAC1↓, HDAC3↓, HDAC8↓,

1391-

RES,

BBR,

Effects of Resveratrol, Berberine and Their Combinations on Reactive Oxygen Species, Survival and Apoptosis in Human Squamous Carcinoma (SCC-25) Cells

-

in-vitro,

Tong,

SCC25

10μg/ml each

ROS↑, eff↑,

1492-

RES,

Resveratrol: Biological and pharmaceutical properties as anticancer molecule

-

Review,

Var,

NA

RadioS↑, ChemoSen↑,

1491-

RES,

Resveratrol Augments Doxorubicin and Cisplatin Chemotherapy: A Novel Therapeutic Strategy

RadioS↑, ChemoSen↑,

1490-

RES,

Anticancer Potential of Resveratrol, β-Lapachone and Their Analogues

-

Review,

Var,

NA

TumCCA↑, ROS↑, Ca+2↑, MMP↓, ATP↓, TOP1?, P53↑, p53 Wildtype∅, Akt↓, mTOR↓, EMT↓, *BioAv↓,

1489-

RES,

Molecular mechanisms of resveratrol as chemo and radiosensitizer in cancer

-

Review,

Var,

NA

RadioS↑, ChemoSen↑, *BioAv↓, *BioAv↑, Ferroptosis↑, lipid-P↑, xCT↓, GPx4↓, *BioAv↑, COX2↓, cycD1↓, FasL↓, FOXP3↓, HLA↑, p‑NF-kB↓, BAX↑, Bcl-2↓, MALAT1↓,

1511-

RES,

Chemo,

Combination therapy in combating cancer

-

Review,

NA,

NA

eff↑, *NRF2↓, *GSH↑, *ROS↓, chemoP↑, ChemoSideEff↓,

1282-

RES,

Resveratrol Inhibits CD4+ T Cell Activation by Enhancing the Expression and Activity of Sirt1

-

vitro+vivo,

NA,

NA

T-Cell↓, SIRT1↑, CD4+↓,

2328-

RES,

Resveratrol Inhibits Cancer Cell Metabolism by Down Regulating Pyruvate Kinase M2 via Inhibition of Mammalian Target of Rapamycin

-

in-vitro,

Cerv,

HeLa

50 µM resveratrol for 48 hour

-

in-vitro,

Liver,

HepG2

-

in-vitro,

BC,

MCF-7

PKM2↓, mTOR↓, GlucoseCon↓, lactateProd↓,

2329-

RES,

Resveratrol induces apoptosis in human melanoma cell through negatively regulating Erk/PKM2/Bcl-2 axis

-

in-vitro,

Melanoma,

A375

P53↑, Bcl-2↓, BAX↑, Cyt‑c↑, ERK↓, PKM2↓, Apoptosis↑, γH2AX↑, Casp3↑, cl‑PARP1↑,

2330-

RES,

Resveratrol Induces Cancer Cell Apoptosis through MiR-326/PKM2-Mediated ER Stress and Mitochondrial Fission

-

in-vitro,

CRC,

DLD1

75uM

-

in-vitro,

Cerv,

HeLa

50uM

-

in-vitro,

BC,

MCF-7

50uM

TumCP↓, Apoptosis↑, PKM2↓, ER Stress↑,

2331-

RES,

Resveratrol improves follicular development of PCOS rats via regulating glycolysis pathway and targeting SIRT1

-

in-vivo,

Nor,

NA

PCOS rat model

*LDHA↑, *PKM2↑, *SIRT1↑, *Glycolysis↝,

2332-

RES,

Resveratrol’s Anti-Cancer Effects through the Modulation of Tumor Glucose Metabolism

-

Review,

Var,

NA

Glycolysis↓, GLUT1↓, PFK1↓, Hif1a↓, ROS↑, PDH↑, AMPK↑, TumCG↓, TumCI↓, TumCP↓, p‑NF-kB↓, SIRT1↑, SIRT3↑, LDH↓, PI3K↓, mTOR↓, PKM2↓, R5P↝, G6PD↓, TKT↝, talin↓, HK2↓, GRP78/BiP↑, GlucoseCon↓, ER Stress↑, Warburg↓, PFK↓,

2333-

RES,

Resveratrol regulates insulin resistance to improve the glycolytic pathway by activating SIRT2 in PCOS granulosa cells

-

in-vitro,

Nor,

NA

SD rats received a high-fat diet and letrozole for 30 days to establish the PCOS model

*glucose↓, *Insulin↓, *IGFR↓, *IGF-1↓, *LDHA↑, *HK2↑, *PKM2↑, *Glycolysis↝, *SIRT2↑,

2334-

RES,

Glut 1 in Cancer Cells and the Inhibitory Action of Resveratrol as A Potential Therapeutic Strategy

-

Review,

Var,

NA

GLUT1↓, GlucoseCon↓, lactateProd↓, Akt↓, mTOR↓, Dose↝, SIRT6↑, PKM2↓, HK2↓, PFK1↓, ChemoSen↑,

2650-

RES,

Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence

-

Review,

Var,

NA

ROS↑, Dose↝, NRF2↑, NAF1↓, ChemoSen↑, BioAv↓,

2568-

RES,

Resveratrol: A Miracle Drug for Vascular Pathologies

-

Review,

Var,

NA

antiOx↑, Inflam↓, cardioP↑,

2564-

RES,

Effect of resveratrol on platelet aggregation by fibrinogen protection

-

in-vitro,

NA,

NA

500uM

RSV 15 mM

AntiAg↑, antiOx↓, COX2↓,

2565-

RES,

https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2007.06788.x

-

in-vitro,

NA,

NA

-

in-vivo,

NA,

NA

mice

AntiAg↑, TXA2↑, PKCδ↑, Dose↝,

2566-

RES,

A comprehensive review on the neuroprotective potential of resveratrol in ischemic stroke

-

Review,

Stroke,

NA

*neuroP↑, *NRF2↑, *SIRT1↑, *PGC-1α↑, *FOXO↑, *HO-1↑, *NQO1↑, *ROS↓, *BP↓, *BioAv↓, *Half-Life↝, *AMPK↑, *GSK‐3β↓, *eff↑, *AntiAg↑, *BBB↓, *Inflam↓, *MPO↓, *TLR4↓, *NF-kB↓, *p65↓, *MMP9↓, *TNF-α↓, *IL1β↓, *PPARγ↑, *MMP↑, *ATP↑, *Cyt‑c∅, *mt-lipid-P↓, *H2O2↓, *HSP70/HSPA5↝, *Mets↝, *eff↑, *eff↑, *motorD↑, *MDA↓, *NADH:NAD↑, eff↑, eff↑,

2567-

RES,

Neuroprotective Effects of Resveratrol in Ischemic Brain Injury

-

Review,

Stroke,

NA

*eff↑, *neuroP↑, *antiOx↑, *Inflam↓, *cardioP↑, *AntiAg↑,

2687-

RES,

Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs

-

Review,

NA,

NA

-

Review,

AD,

NA

NF-kB↓, P450↓, COX2↓, Hif1a↓, VEGF↓, *SIRT1↑, SIRT1↓, SIRT2↓, ChemoSen⇅, cardioP↑, *memory↑, *angioG↑, *neuroP↑, STAT3↓, CSCs↓, RadioS↑, Nestin↓, Nanog↓, TP53↑, P21↑, CXCR4↓, *BioAv↓, EMT↓, Vim↓, Slug↓, E-cadherin↑, AMPK↑, MDR1↓, DNAdam↑, TOP2↓, PTEN↑, Akt↓, Wnt↓, β-catenin/ZEB1↓, cMyc↓, MMP7↓, MALAT1↓, TCF↓, ALDH↓, CD44↓, Shh↓, IL6↓, VEGF↓, eff↑, HK2↓, ROS↑, MMP↓,

2471-

RES,

Resveratrol Regulates Glucose and Lipid Metabolism in Diabetic Rats by Inhibition of PDK1/AKT Phosphorylation and HIF-1α Expression

-

in-vivo,

Diabetic,

NA

rats

*p‑PDK1↓, *p‑Akt↓, *Hif1a↓, *GLUT1↓,

2443-

RES,

Health Benefits and Molecular Mechanisms of Resveratrol: A Narrative Review

-

Review,

Var,

NA

*antiOx↑, *ROS↓, *PTEN↑, *Akt↓, *Catalase↑, *SOD↑, *ERK↓, *GSH↑, *AMPK↑, *FOXO1↝, *RNS↓, *Catalase↑, *cardioP↑, *PI3K↑, *eNOS↑, hepatoP↑,

2442-

RES,

High absorption but very low bioavailability of oral resveratrol in humans

-

in-vitro,

Nor,

NA

BioAv↝, Half-Life↝, BioAv↓, eff↝,

2441-

RES,

Anti-Cancer Properties of Resveratrol: A Focus on Its Impact on Mitochondrial Functions

-

Review,

Var,

NA

*toxicity↓, *BioAv↝, *Dose↝, *hepatoP↑, *neuroP↑, *AntiAg↑, *COX2↓, *antiOx↑, *ROS↓, *ROS↑, PI3K↓, Akt↓, NF-kB↓, Wnt↓, β-catenin/ZEB1↓, NRF2↑, GPx↑, HO-1↑, BioEnh?, PTEN↑, ChemoSen↑, eff↑, mt-ROS↑, Warburg↓, Glycolysis↓, GlucoseCon↓, GLUT1↓, lactateProd↓, HK2↓, EGFR↓, cMyc↓, ROS↝, MMPs↓, MMP7↓, survivin↓, TumCP↓, TumCMig↓, TumCI↓,

2440-

RES,

Resveratrol inhibits Hexokinases II mediated glycolysis in non-small cell lung cancer via targeting Akt signaling pathway

-

in-vitro,

Lung,

H460

-

in-vivo,

Lung,

NA

xenograft mouse model

-

in-vitro,

Lung,

H1650

-

in-vitro,

Lung,

HCC827

AntiTum↑, Glycolysis↓, HK2↓, EGFR↓, Akt↓, ERK↓, GlucoseCon↓, lactateProd↓, TumCG↓, Ki-67↓,

2439-

RES,

By reducing hexokinase 2, resveratrol induces apoptosis in HCC cells addicted to aerobic glycolysis and inhibits tumor growth in mice

-

in-vitro,

HCC,

HCCLM3

59.46uM

-

in-vitro,

Nor,

L02

-

in-vitro,

HCC,

SMMC-7721 cell

-

in-vitro,

HCC,

Bel-7402

81.57uM

-

in-vitro,

HCC,

HUH7

111.37 μM

HK2↓, ChemoSen↑, other↑, Glycolysis↓, lactateProd↓, TumCP↓, Casp3↑, cl‑PARP↑, PKM2↓,

2467-

RES,

Resveratrol inhibits Ca2+ signals and aggregation of platelets

-

in-vitro,

Nor,

NA

12.5 μM

*AntiAg↑, Ca+2↓,

2472-

RES,

Resveratrol Restores Sirtuin 1 (SIRT1) Activity and Pyruvate Dehydrogenase Kinase 1 (PDK1) Expression after Hemorrhagic Injury in a Rat Model

-

in-vivo,

Nor,

NA

rat

*SIRT1↑, *PGC-1α↑, *cMyc↑, *PDK1↓,

3069-

RES,

Resveratrol Inhibits NLRP3 Inflammasome-Induced Pyroptosis and miR-155 Expression in Microglia Through Sirt1/AMPK Pathway

-

in-vitro,

Nor,

N9

*antiOx↑, *Inflam↓, *ROS↓, *NF-kB↓, *AMPK↑, *SIRT1↑, *miR-155↓, *NLRP3↓,

3080-

RES,

Resveratrol: A miraculous natural compound for diseases treatment

-

Review,

Var,

NA

SIRT1↑, ROCK1↓, AMPK↑, *lipid-P↓, Aβ↓, COX2↓, angioG↓, Hif1a↓, VEGF↓,

3068-

RES,

Resveratrol decreases the expression of genes involved in inflammation through transcriptional regulation

-

in-vitro,

lymphoma,

U937

p65↓, SOD2↓, Prx↓, Catalase↓, Trx↓, TNF-α↓, IL8↓, MCP1↓, SIRT1↑,

3070-

RES,

Resveratrol inhibits tumor progression by down-regulation of NLRP3 in renal cell carcinoma

-

in-vitro,

RCC,

ACHN

0-100uM

-

in-vitro,

RCC,

786-O

-

in-vivo,

NA,

NA

nude mice

TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, NLRP3↓,

3071-

RES,

Resveratrol and Its Anticancer Effects

-

Review,

Var,

NA

chemoP↑, SIRT1↑, Hif1a↓, VEGF↓, STAT3↓, NF-kB↓, COX2↓, PI3K↓, mTOR↓, NRF2↑, NLRP3↓, H2O2↑, ROS↑, P53↑, PUMA↑, BAX↑,

3072-

RES,

Resveratrol ameliorates glioblastoma inflammatory response by reducing NLRP3 inflammasome activation through inhibition of the JAK2/STAT3 pathway

-

in-vitro,

GBM,

LN229

17.90 μM

-

in-vitro,

GBM,

U87MG

25 μM

tumCV↓, TumCP↓, TumCMig↓, Apoptosis↑, NLRP3↓, JAK2↓, STAT3↓, IL1β↓, IL18↓, IL6↓, TNF-α↓, Inflam↓,

3073-

RES,

Resveratrol inhibits NLRP3 inflammasome activation by preserving mitochondrial integrity and augmenting autophagy

-

in-vitro,

Nor,

NA

*NLRP3↓, *mtDam↓, *p38↑,

3074-

RES,

Possible therapeutic targets for NLRP3 inflammasome-induced breast cancer

-

Review,

BC,

NA

NLRP3↓, SIRT1↑,

3075-

RES,

Rad,

The Protection Effect of Resveratrol Against Radiation-Induced Inflammatory Bowel Disease via NLRP-3 Inflammasome Repression in Mice

-

in-vivo,

Nor,

NA

100 mg/kg

Male C57/6 mice

*SIRT1↑, *radioP↑, *NLRP3↓, *Weight↑, *IL1β↓,

3076-

RES,

Resveratrol for targeting the tumor microenvironment and its interactions with cancer cells

-

Review,

Var,

NA

IL6↓, MMPs↓, MMP2↓, MMP9↓, BioAv↓, Half-Life↑, BioAv↑, Dose↝, angioG↓, IL10↓, VEGF↓, NF-kB↓, COX2↓, SIRT1↑, Wnt↓, cMyc↓, STAT3↓, PTEN↑, ROS↑, RadioS↑, Hif1a↓, E-cadherin↓, Vim↓, angioG↓,

3077-

RES,

Resveratrol attenuates matrix metalloproteinase-9 and -2-regulated differentiation of HTB94 chondrosarcoma cells through the p38 kinase and JNK pathways

-

in-vitro,

Chon,

HTB94

MMP2↓, MMP9↓, SOX9↑, MMPs↓, p‑p38↑, p‑JNK↓, NF-kB↓, HO-1↓,

3078-

RES,

The Effects of Resveratrol on Prostate Cancer through Targeting the Tumor Microenvironment

-

Review,

Pca,

NA

*ROS↓, ROS↑, DNAdam↑, Apoptosis↑, Hif1a↑, Casp3↑, Casp9↑, Cyt‑c↑, Dose↝, MMPs↓, MMP2↓, MMP9↓, EMT↓, E-cadherin↑, N-cadherin↓, AR↓,

3079-

RES,

Therapeutic role of resveratrol against hepatocellular carcinoma: A review on its molecular mechanisms of action

-

Review,

Var,

NA

angioG↓, TumMeta↓, ChemoSen↑, NADPH↑, SIRT1↑, NF-kB↓, NLRP3↓, Dose↝, COX2↓, MMP9↓, PGE2↓, TIMP1↑, TIMP2↑, Sp1/3/4↓, p‑JNK↓, uPAR↓, ROS↓, CXCR4↓, IL6↓, Gli1↓, *ROS↓, *GSTs↑, *SOD↑, *Catalase↑, *GPx↑, *lipid-P↓, *GSH↑, eff↑, eff↑, eff↑,

3052-

RES,

Resveratrol-Induced Downregulation of NAF-1 Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine via the ROS/Nrf2 Signaling Pathways

-

in-vitro,

PC,

PANC1

0, 25, 50, 100, and 200 μM) for 24 h, 48 h, and 72 h,

-

in-vitro,

PC,

MIA PaCa-2

-

in-vitro,

PC,

Bxpc-3

NAF1↓, ROS↑, NRF2↑, eff↑, TumCG↓,

3067-

RES,

Proteomic Profiling Reveals That Resveratrol Inhibits HSP27 Expression and Sensitizes Breast Cancer Cells to Doxorubicin Therapy

-

in-vitro,

BC,

MCF-7

Apoptosis↑, MMP↓, Cyt‑c↑, Casp3↑, Casp9↑, HSP27↓,

3066-

RES,

Resveratrol triggers ER stress-mediated apoptosis by disrupting N-linked glycosylation of proteins in ovarian cancer cells

GSK‐3β↑, Akt↓, CHOP↑, ER Stress↑, PERK↑, ATF6↑, UPR↑, GlucoseCon↓,

3065-

RES,

Resveratrol-induced cytotoxicity in human Burkitt's lymphoma cells is coupled to the unfolded protein response

-

in-vitro,

lymphoma,

NA

0-200uM

UPR↑, IRE1↑, p‑eIF2α↑, PERK↑, ATF6↑, GRP78/BiP↑, GRP94↑, CHOP↑, GADD34↑, ATF4↑, XBP-1↑, Ca+2↑, ER Stress↑,

3064-

RES,

Resveratrol Suppresses Cancer Cell Glucose Uptake by Targeting Reactive Oxygen Species–Mediated Hypoxia-Inducible Factor-1α Activation

-

in-vitro,

CRC,

HT-29

-

in-vitro,

BC,

T47D

-

in-vitro,

Lung,

LLC1

FDG↓, ROS↓, Hif1a↓, GLUT1↓, lactateProd↓,

3063-

RES,

Resveratrol: A Review of Pre-clinical Studies for Human Cancer Prevention

-

Review,

Var,

NA

*Inflam↓, *antiOx↑, *AntiAg↑, *chemoP↑, ChemoSen↑, BioAv↑, Half-Life↝, COX2↓, cycD1↓, CDK2↓, CDK4↓, CDK6↓, P21↑, MMP9↓, NF-kB↓, Telomerase↓, PSA↓, MAPK↑, P53↑,

3062-

RES,

Resveratrol enhances post-injury muscle regeneration by regulating antioxidant and mitochondrial biogenesis

-

in-vivo,

Nor,

NA

450 mg/kg body weight (BW) of resveratrol per mouse each day.

Sixteen male C57BL/6 adult mice (3 months old)

*antiOx↑, *Keap1↓, *NRF2↑, *HO-1↑, *GPx↑, *SOD↑,

3061-

RES,

The Anticancer Effects of Resveratrol: Modulation of Transcription Factors

-

Review,

Var,

NA

AhR↓, NRF2↑, *NQO1↑, *HO-1↑, *GSH↑, P53↑, Cyt‑c↑, Diablo↑, Bcl-2↓, Bcl-xL↓, survivin↓, XIAP↓, FOXO↑, p‑PI3K↓, p‑Akt↓, BIM↑, DR4↑, DR5↑, p27↑, cycD1↓, SIRT1↑, NF-kB↓, ATF3↑,

3060-

RES,

Resveratrol targeting NRF2 disrupts the binding between KEAP1 and NRF2-DLG motif to ameliorate oxidative stress damage in mice pulmonary infection

-

in-vitro,

Nor,

RAW264.7

-

in-vivo,

NA,

NA

*NRF2↑, *antiOx↑, *ROS↓,

3059-

RES,

Resveratrol, an Nrf2 activator, ameliorates aging-related progressive renal injury

-

in-vivo,

Nor,

HK-2

Male 18-month-old C57BL/6 mice were used

*RenoP↑, *Inflam↓, *NRF2↑, *HO-1↑, *SIRT1↑, *ROS↓, AntiAge↑,

3058-

RES,

Resveratrol inhibits estrogen-induced breast carcinogenesis through induction of NRF2-mediated protective pathways

-

in-vivo,

NA,

NA

Resveratrol was given as a 50mg subcutaneous pellet every other month

Irish rats, estrogen-induced breast carcinogenesis

*Nrf1?,

3057-

RES,

The therapeutic effect of resveratrol: Focusing on the Nrf2 signaling pathway

-

Review,

Var,

NA

-

Review,

AD,

NA

-

Review,

Stroke,

NA

*NRF2↑, *Keap1↓, *ROS↓, *Apoptosis↓, *Inflam↓, *antiOx↑, *hepatoP↑, *neuroP↑, *cardioP↑, *RenoP↑, *AntiCan↑, *memory↑, *SOD↑, *GPx↑, *Catalase↑, *MDA↓, *NRF2↑, *HO-1↑, *ROS↓, *Aβ↓, *iNOS↓, *COX2↓, *GSH↑, *HO-1⇅, *SIRT1↑,

3056-

RES,

Less is more for cancer chemoprevention: evidence of a non-linear dose response for the protective effects of resveratrol in humans and mice

-

in-vivo,

Nor,

NA

humans and mice

*AMPK↑, *P21↑, *Dose↓, *chemoP↑,

3055-

RES,

Resveratrol and Tumor Microenvironment: Mechanistic Basis and Therapeutic Targets

-

Review,

Var,

NA

BioAv↓, BioAv↓, Dose↑, eff↑, eff↑, Dose↑, BioAv↑, ROS↑, MMP↓, P21↑, p27↑, TumCCA↑, ChemoSen↑, COX2↓, 5LO↓, VEGF↓, IL1↓, IL6↓, IL8↓, AR↓, PSA↓, MAPK↓, Hif1a↓, Glycolysis↓, miR-21↓, PTEN↑, Half-Life↝, *IGF-1↓, *IGFBP3↑, Half-Life↓,

3054-

RES,

Resveratrol induced reactive oxygen species and endoplasmic reticulum stress-mediated apoptosis, and cell cycle arrest in the A375SM malignant melanoma cell line

-

in-vitro,

Melanoma,

A375

(1 and 10 µM

TumCG↓, P21↑, p27↑, CycB↓, ROS↑, ER Stress↑, p‑p38↑, P53↑, p‑eIF2α↑, EP4↑, CHOP↑, Bcl-2↓, BAX↓, TumCCA↑, NRF2↓, ChemoSen↑, GSH↓,

3053-

RES,

Resveratrol represses estrogen-induced mammary carcinogenesis through NRF2-UGT1A8-estrogen metabolic axis activation

-

in-vitro,

NA,

NA

MCF-10A cells were transfected with siRNA of NRF2 (siNRF2) virus plasmid

NRF2↑, DNAdam↓,

3082-

RES,

Resveratrol Ameliorates the Malignant Progression of Pancreatic Cancer by Inhibiting Hypoxia-induced Pancreatic Stellate Cell Activation

-

in-vitro,

PC,

PANC1

-

in-vitro,

PC,

MIA PaCa-2

-

in-vivo,

NA,

NA

mice

VEGF↓, CXCL12↓, IL6↓, α-SMA↓, Hif1a↓, TumCI↓, EMT↓,

2981-

RES,

Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways

-

in-vitro,

Colon,

HT-29

100-150 μM

-

in-vitro,

Colon,

SW48

TumCCA↑, p27↑, cycD1↓, TumCP↓, IGF-1R↓, Akt↓, Wnt↓, P53↑, Apoptosis↑, Sp1/3/4↓, cl‑PARP↑, β-catenin/ZEB1↓, MDM2↓,

2982-

RES,

The flavonoid resveratrol suppresses growth of human malignant pleural mesothelioma cells through direct inhibition of specificity protein 1

-

in-vitro,

Melanoma,

MSTO-211H

IC50 for Res was 17 µM in MSTO-211H cells.

tumCV↓, Apoptosis↑, Sp1/3/4↓, p27↓, P21↓, cycD1↓, Mcl-1↓, survivin↓,

2983-

RES,

Resveratrol Improves Diabetic Retinopathy via Regulating MicroRNA-29b/Specificity Protein 1/Apoptosis Pathway by Enhancing Autophagy

-

in-vitro,

Nor,

NA

retinal Müller cells (RMCs)

*Beclin-1↑, *p62↓, *Sp1/3/4↓, *Apoptosis↓,

2984-

RES,

Involvement of miR-539-5p in the inhibition of de novo lipogenesis induced by resveratrol in white adipose tissue

-

in-vivo,

Nor,

NA

Male Wistar rats were fed (6 weeks) an obesogenic diet: a control group and a group treated with resveratrol (30 mg kg(-1) d(-1))

*Sp1/3/4↓, *SREBP1↓, *FASN↓,

2985-

RES,

Resveratrol Inhibits Diabetic-Induced Müller Cells Apoptosis through MicroRNA-29b/Specificity Protein 1 Pathway

-

in-vivo,

Nor,

NA

Retina was obtained from normal and diabetic rats with or without RSV (5 and 10 mg/kg/day)

-

vitro+vivo,

Diabetic,

NA

*Sp1/3/4↓, *miR-29b↑,

2986-

RES,

Effect of the natural compound trans‑resveratrol on human MCM4 gene transcription

-

in-vitro,

Cerv,

HeLa

-

in-vitro,

AML,

HL-60

Sp1/3/4↑,

2987-

RES,

Resveratrol ameliorates myocardial damage by inducing vascular endothelial growth factor-angiogenesis and tyrosine kinase receptor Flk-1

-

in-vivo,

Nor,

NA

demonstrated in rat myocardial infarction (MI) model

*VEGF↑, *iNOS↑, *NF-kB↑, *Sp1/3/4↑, *cardioP↑,

2988-

RES,

The Antimetastatic Effects of Resveratrol on Hepatocellular Carcinoma through the Downregulation of a Metastasis-Associated Protease by SP-1 Modulation

-

in-vitro,

HCC,

HUH7

TumCMig↓, TumCI↓, uPA↓, Sp1/3/4↓,

2989-

RES,

Resveratrol Represses Pokemon Expression in Human Glioma Cells

-

in-vitro,

GBM,

NA

FBI-1↓, Sp1/3/4↓,

2990-

RES,

Resveratrol reduces cerebral edema through inhibition of de novo SUR1 expression induced after focal ischemia

-

in-vivo,

Stroke,

NA

Male Wistar rats

*OS↑, *antiOx↑, Sp1/3/4↓,

2991-

RES,

Chemo,

Synergistic anti-cancer effects of resveratrol and chemotherapeutic agent clofarabine against human malignant mesothelioma MSTO-211H cells

-

in-vitro,

Melanoma,

MSTO-211H

-

in-vitro,

Nor,

MeT5A

eff↑, selectivity↑, Sp1/3/4↓,

3100-

RES,

Neuroprotective effects of resveratrol in Alzheimer disease pathology

-

Review,

AD,

NA

*neuroP↑, *BioAv↓, *Half-Life↓, *BioAv↑, *BBB↑, *NRF2↑, *BioAv↓, *BioAv↑, *SIRT1↑, *cognitive↑, *lipid-P↓, *HO-1↑, *SOD↑, *GSH↑, *GPx↑, *G6PD↑, *PPARγ↑, *AMPK↑, *Aβ↓,

3099-

RES,

Resveratrol and cognitive decline: a clinician perspective

-

Review,

Nor,

NA

-

NA,

AD,

NA

*antiOx↑, *ROS↓, *cognitive↑, *neuroP↑, *SIRT1↑, *AMPK↑, *GPx↑, *HO-1↑, *GSK‐3β↑, *COX2↓, *PGE2↓, *NF-kB↓, *NO↓, *Casp3↓, *MMP3↓, *MMP9↓, *MMP↑, *GSH↑, *other↑, *BioAv↑, *memory↑, *GlutMet↑, *BioAv↓, *Half-Life↓, *toxicity∅,

3098-

RES,

Regulation of Cell Signaling Pathways and miRNAs by Resveratrol in Different Cancers

-

Review,

Var,

NA

NOTCH2↓, Wnt↓, β-catenin/ZEB1↓, p‑SMAD2↓, p‑SMAD3↓, PTCH1↓, Smo↓, Gli1↓, E-cadherin↑, NOTCH⇅, TAC?, NKG2D↑, DR4↑, survivin↓, DR5↑, BAX↑, p27↑, cycD1↓, Bcl-2↓, STAT3↓, STAT5↓, JAK↓, DNAdam↑, γH2AX↑,

3097-

RES,

Resveratrol Induces Notch2-mediated Apoptosis and Suppression of Neuroendocrine Markers in Medullary Thyroid Cancer

-

in-vitro,

Thyroid,

TT

25 μM, 50 μM, and 100 μM

TumCG↓, cl‑Casp3↑, p‑PARP↑, NOTCH2↑,

3096-

RES,

Identification of potential target genes of non-small cell lung cancer in response to resveratrol treatment by bioinformatics analysis

-

in-vitro,

Lung,

A549

-

in-vitro,

Lung,

H1299

TumCP↓, Apoptosis↑, Akt↓, mTOR↓, p38↑, MAPK↑, STAT3↓, ROS↑, SIRT1↑, SOX2↓,

3095-

RES,

Resveratrol suppresses migration, invasion and stemness of human breast cancer cells by interfering with tumor-stromal cross-talk

-

in-vitro,

BC,

NA

TumCP↓, TumCMig↓, TumCI↓, cycD1↓, cMyc↓, MMP2↓, MMP9↓, SOX2↓, Akt↓, STAT3↓, α-SMA↓,

3094-

RES,

Resveratrol suppresses growth of cancer stem-like cells by inhibiting fatty acid synthase

-

in-vitro,

BC,

MCF-7

-

in-vitro,

BC,

MDA-MB-231

CSCs↓, tumCV↓, FASN↑, BNIP3↑, *cardioP↑, *antiOx↑, NF-kB↓, COX2↓, MMP9↓, IGF-1↓, ERK↓, lipid-P↓, CD24↓,

3093-

RES,

Pro-Oxidant Effect of Resveratrol on Human Breast Cancer MCF-7 Cells is Associated with CK2 Inhibition

-

in-vitro,

BC,

MCF-7

ROS↑, CK2↓,

3092-

RES,

Resveratrol in breast cancer treatment: from cellular effects to molecular mechanisms of action

-

Review,

BC,

MDA-MB-231

-

Review,

BC,

MCF-7

TumCP↓, tumCV↓, TumCI↓, TumMeta↓, *antiOx↑, *cardioP↑, *Inflam↑, *neuroP↑, *Keap1↓, *NRF2↑, *ROS↓, p62↓, IL1β↓, CRP↓, VEGF↓, Bcl-2↓, MMP2↓, MMP9↓, FOXO4↓, POLD1↓, CK2↓, MMP↓, ROS↑, Apoptosis↑, TumCCA↑, Beclin-1↓, Ki-67↓, ATP↓, GlutMet↓, PFK↓, TGF-β↓, SMAD2↓, SMAD3↓, Vim?, Snail↓, Slug↓, E-cadherin↑, EMT↓, Zeb1↓, Fibronectin↓, IGF-1↓, PI3K↓, Akt↓, HO-1↑, eff↑, PD-1↓, CD8+↑, Th1 response↑, CSCs↓, RadioS↑, SIRT1↑, Hif1a↓, mTOR↓,

3091-

RES,

Protein kinase CK2 modulates apoptosis induced by resveratrol and epigallocatechin-3-gallate in prostate cancer cells

-

in-vitro,

Pca,

PC3

-

in-vitro,

Pca,

ALVA-41

CK2↓, Apoptosis↑,

3090-

RES,

The Effects of Resveratrol Targeting MicroRNA-4325P/PDGF-B to Regulate Tumor Angiogenesis in Osteosarcoma Microenvironment

-

in-vitro,

OS,

MG63

0, 5, 10, 20 µM) of resveratrol for 48 h

PDGFR-BB↓, angioG↓,

3089-

RES,

The Role of Resveratrol in Cancer Therapy

-

Review,

Var,

NA

angioG↓, VEGF↓, EGFR↓, FGF↑, TumCMig↓, TumCI↓, TIMP1↑, MMP2↓, MMP9↓, NF-kB↓, Hif1a↓, PI3K↓, Akt↓, MAPK↓, EMT↓, AR↓,

3088-

RES,

Notch signaling mediated repressive effects of resveratrol in inducing caspasedependent apoptosis in MCF-7 breast cancer cells

-

in-vitro,

BC,

MCF-7

NOTCH1↓, BAX↑, CDK4↝, Casp3↑, P21↑,

3087-

RES,

Resveratrol cytotoxicity is energy-dependent

-

Review,

Var,

NA

OXPHOS↓, eff↝, eff↑,

3086-

RES,

Resveratrol inhibits the tumor migration and invasion by upregulating TET1 and reducing TIMP2/3 methylation in prostate carcinoma cells

-

in-vitro,

Pca,

LNCaP

136.1uM± 1.043 μM

-

in-vitro,

Pca,

PC3

-

in-vitro,

Pca,

DU145

162.5uM± 1.122 μM at 48 hours,

TET1↑, TumCMig↓, TumCI↓, TIMP2↑, TIMP3↑, MMP2↓, MMP9↓,

3085-

RES,

Resveratrol interrupts Wnt/β-catenin signalling in cervical cancer by activating ten-eleven translocation 5-methylcytosine dioxygenase 1

-

in-vitro,

Cerv,

NA

TET1↑, Wnt↓, β-catenin/ZEB1↓,

3084-

RES,

Resveratrol inhibits the proliferation of estrogen receptor-positive breast cancer cells by suppressing EZH2 through the modulation of ERK1/2 signaling

-

in-vitro,

BC,

MCF-7

-

in-vitro,

BC,

T47D

TumCP↓, EZH2↓, p‑ERK↓,

3083-

RES,

Resveratrol suppresses breast cancer cell invasion by inactivating a RhoA/YAP signaling axis

-

in-vitro,

BC,

MDA-MB-231

-

in-vitro,

BC,

MDA-MB-468

YAP/TEAD↓, Rho↓, FAK↓, MMP9↓, ChemoSen↑, RAS↓, ROCK1↓, TumCI↓, TumMeta↓,

3081-

RES,

Resveratrol and p53: How are they involved in CRC plasticity and apoptosis?

-

Review,

CRC,

NA

NF-kB↓, FAK↓, Ki-67↓, MMP9↓, CSCs↓, CD44↓, CD133↓, ALDH1A1↓, EMT↓, ChemoSen↑, Hif1a↓, ITGB1↓, Inflam↓,

3490-

RF,

Multidimensional insights into the repeated electromagnetic field stimulation and biosystems interaction in aging and age-related diseases

-

Review,

AD,

NA

-

Review,

Park,

NA

*OS↑, *memory↑, *cognitive↑, *memory↑, *Aβ↓, *eff↑, *HSF1↑, *HSP70/HSPA5↑,

3461-

RF,

Electromagnetic Field Stimulation Therapy for Alzheimer’s Disease

-

Review,

AD,

NA

Repeated Electromagnetic Field Stimulation (REMFS) at 50 MHz is 2.0678–7 eV, at 64 MHz it is 2.64–7 eV, and at 915 MHz it is 3.7841–6 eV;

*Aβ↓, *HSF1↑, *ROS↓, *Inflam↓, *cognitive↑, *memory↑, *eff↑,

3033-

RosA,

Rosemary (Rosmarinus officinalis) Extract Modulates CHOP/GADD153 to Promote Androgen Receptor Degradation and Decreases Xenograft Tumor Growth

-

in-vitro,

Pca,

22Rv1

0 and 50 µg/ml of rosemary extract for 24 hrs.

13.3 µg/ml

-

in-vitro,

Pca,

LNCaP

27 µg/ml

-

vitro+vivo,

NA,

NA

Athymic nude mice

ER Stress↑, selectivity↑, AR↓, TumCG↓, TumCCA↑, CHOP↑, PERK↓, GRP78/BiP↑, PSA↓,

3020-

RosA,

Protective Effect of Rosmarinic Acid on Endotoxin-Induced Neuronal Damage Through Modulating GRP78/PERK/MANF Pathway

-

in-vivo,

Nor,

NA

20 and 40 mg/kg RA

mice

-

in-vitro,

NA,

SH-SY5Y

*cognitive↑, *PERK↓, *GRP78/BiP↓, *ER Stress↓,

3029-

RosA,

Rosmarinic Acid, a Component of Rosemary Tea, Induced the Cell Cycle Arrest and Apoptosis through Modulation of HDAC2 Expression in Prostate Cancer Cell Lines

-

in-vitro,

Pca,

PC3

-

in-vitro,

Pca,

DU145

TumCP↓, tumCV↓, Apoptosis↑, HDAC2↓, PCNA↓, cycD1↓, cycE↓, P21↑, DNAdam↑, Casp3↑,

3028-

RosA,

Network pharmacology mechanism of Rosmarinus officinalis L.(Rosemary) to improve cell viability and reduces apoptosis in treating Alzheimer’s disease

-

in-vitro,

AD,

HT22

-

in-vivo,

NA,

NA

*Aβ↓, *Apoptosis↓, *antiOx↓, *neuroP↑, *eff↑, *IGF-1↑, *MMP9↑, *Src↓, *MAPK↓, *MMP↑,

3027-

RosA,

Rosmarinic acid inhibits proliferation and invasion of hepatocellular carcinoma cells SMMC 7721 via PI3K/AKT/mTOR signal pathway

-

in-vitro,

HCC,

SMMC-7721 cell

0, 20, 50, 100 μmol/L)

TumCP↓, TumCCA↑, Apoptosis↑, EMT↓, TumCI↓, PI3K↓, Akt↓, mTOR↓, TumCMig↓, MMPs↓, Vim↓,

3026-

RosA,

Modulatory Effect of Rosmarinic Acid on H2O2-Induced Adaptive Glycolytic Response in Dermal Fibroblasts

-

in-vitro,

Nor,

NA

0–100 μM

dermal fibroblasts

*ROS↑, *ATP↑, *NADPH↓, *HK2↓, *PFK2↓, *LDHA↓, *GSR↑, *GPx↑, *Prx↑, *Trx↑, *antiOx↑, *GSH↑, *ROS↓, *GlucoseCon↓, *lactateProd↓, *Glycolysis↝, *ATP↑, *NADPH↓, *PPP↓,

3025-

RosA,

Rosmarinic acid alleviates intestinal inflammatory damage and inhibits endoplasmic reticulum stress and smooth muscle contraction abnormalities in intestinal tissues by regulating gut microbiota

-

in-vivo,

IBD,

NA

*GutMicro↑, *ROCK1↓, *Rho↓, *CaMKII ↓, *Zeb1↓, *ZO-1↓, *E-cadherin↓, *IL1β↓, *IL6↓, *TNF-α↓, *GRP78/BiP↓, *PERK↓, *IRE1↓, *ATF6↓, *CHOP↓, *Casp12↓, *Casp9↓, *BAX↓, *Casp3↓, *Cyt‑c↓, *RIP1↓, *MLKL↓, *IL10↑, *Bcl-2↑, *ER Stress↓,

3024-

RosA,

rmMANF prevents sepsis-associated lung injury via inhibiting endoplasmic reticulum stress-induced ferroptosis in mice

-

in-vivo,

Sepsis,

NA

*Ferroptosis↓, *GRP78/BiP↓, *PERK↓, *ATF4↓, *Sepsis↓, *GSH↑, *SOD↑, *Catalase↑,

3023-

RosA,

Rosmarinic acid alleviates septic acute respiratory distress syndrome in mice by suppressing the bronchial epithelial RAS-mediated ferroptosis

-

in-vivo,

Sepsis,

NA

*GPx4↑, *Inflam↓, *ER Stress↓, *Ferroptosis↓, *Sepsis↓, *GRP78/BiP↓, *IRE1↓, JNK↓,

3022-

RosA,

Rosmarinic acid against cognitive impairment via RACK1/HIF-1α regulated microglial polarization in sepsis-surviving mice

-

in-vitro,

Sepsis,

NA

mice

*cognitive↑, *neuroP↑, *GlucoseCon↑, *Hif1a↓,

3021-

RosA,

Rosmarinic acid ameliorates septic-associated mortality and lung injury in mice via GRP78/IRE1α/JNK pathway

-

in-vivo,

Sepsis,

NA

mice

*eff↑, *SOD↑, *MDA↓, *GRP78/BiP↓, *IRE1↓, *JNK↓, *Sepsis↓,

3030-

RosA,

Anticancer Activity of Rosmarinus officinalis L.: Mechanisms of Action and Therapeutic Potentials

-

Review,

Var,

NA

ROS⇅, *NRF2↑, *GSH↑, HDAC2↓,

3019-

RosA,

Orally administered rosmarinic acid is present as the conjugated and/or methylated forms in plasma, and is degraded and metabolized to conjugated forms of caffeic acid, ferulic acid and m-coumaric acid

-

in-vivo,

Nor,

NA

rats

*BioAv↝, *Half-Life↝, *Half-Life↑, *Half-Life↝, *BioAv↑,

3018-

RosA,

Rosemary (Rosmarinus officinalis L.) polyphenols and inflammatory bowel diseases: Major phytochemicals, functional properties, and health effects

-

Review,

IBD,

NA

*Inflam↓, *GutMicro↑, *antiOx↑, *NF-kB↓, *NLRP3↓, *STAT3↓, *NRF2↑,

3017-

RosA,

Per,

Molecular Mechanism of Antioxidant and Anti-Inflammatory Effects of Omega-3 Fatty Acids in Perilla Seed Oil and Rosmarinic Acid Rich Fraction Extracted from Perilla Seed Meal on TNF-α Induced A549 Lung Adenocarcinoma Cells

-

in-vitro,

Lung,

A549

TumCD∅, ROS↓, IL1β↓, IL6↓, IL8↓, TNF-α↓, COX2↓, SOD2↓, FOXO1↓, NF-kB↓, JNK↓, antiOx↑, tumCV∅,

3016-

RosA,

Rosmarinic Acid Inhibits Cell Growth and Migration in Head and Neck Squamous Cell Carcinoma Cell Lines by Attenuating Epidermal Growth Factor Receptor Signaling

-

in-vitro,

HNSCC,

UM-SCC-6

-

in-vitro,

HNSCC,

UM-SCC-10B

chemoP↓, EGF↓, tumCV↓, TumCMig↓, ROS↓, PI3K↓, Akt↓, ERK↓, antiOx↑, p‑EGFR↓,

3015-

RosA,

Rad,

Rosmarinic Acid Prevents Radiation-Induced Pulmonary Fibrosis Through Attenuation of ROS/MYPT1/TGFβ1 Signaling Via miR-19b-3p

-

in-vivo,

Nor,

IMR90

(60 mg/kg

rats

*radioP↑, *Inflam↓, *ROS↓, *NF-kB↓, *Rho↓, *ROCK1↓, *other↓,

3014-

RosA,

Rosmarinic Acid Supplementation Acts as an Effective Antioxidant for Restoring the Antioxidation/Oxidation Balance in Wistar Rats with Cadmium-Induced Toxicity

-

in-vivo,

Nor,

NA

rats

*antiOx↑, *Thiols↑, *GSH↑, *TAC↑, *SOD↑, *GPx↑, *Catalase↑, *ALP↓, *ALAT↓, *AST↓, *creat↓, *BUN↓, *H2O2↓, *MDA↓, *ROS↓, cardioP↑, hepatoP↑, neuroP↑,

3013-

RosA,

Rosmarinic acid inhibits angiogenesis and its mechanism of action in vitro

-

in-vitro,

NA,

NA

*BioAv↑, *antiOx↑, *Inflam↑, *ROS↓, *VEGF↓, *IL8↓,

3012-

RosA,

Rad,

Rosmarinic Acid Prevents Radiation-Induced Pulmonary Fibrosis Through Attenuation of ROSMYPT1TGFβ1 Signaling Via miR-19b-3p

-

in-vitro,

Nor,

IMR90

*Inflam↓, *ROS↓, *p‑NF-kB↓, *Rho↓, *ROCK1↓, *radioP↑, *MCP1↓, *RANTES↓, *ICAM-1↓, *PGC1A↑, *NOX4↓, *Dose↝,

3010-

RosA,

Exploring the mechanism of rosmarinic acid in the treatment of lung adenocarcinoma based on bioinformatics methods and experimental validation

-

in-vitro,

Lung,

A549

-

in-vivo,

NA,

NA

TumCG↓, Ki-67↓, FABP4↑, PPARα↑, ROS↑, Apoptosis↑, MMP9↓, IGFBP3↓, MMP2↓, EMT↓, TumCI↓, PI3K↓, Akt↓, mTOR↓, Gli1↓, PPARγ↑, Cyt‑c↑,

3001-

RosA,

Therapeutic Potential of Rosmarinic Acid: A Comprehensive Review

-

Review,

Var,

NA

TumCP↓, Apoptosis↑, TumMeta↓, Inflam↓, *antiOx↑, *AntiAge↑, *ROS↓, BioAv↑, Dose↝, NRF2↑, P-gp↑, ATP↑, MMPs↓, cl‑PARP↓, Hif1a↓, GlucoseCon↓, lactateProd↓, Warburg↓, TNF-α↓, COX2↓, IL6↓, HDAC2↓, GSH↑, ROS↓, ChemoSen↑, *BG↓, *IL1β↓, *TNF-α↓, *IL6↓, *p‑JNK↓, *p38↓, *Catalase↑, *SOD↑, *GSTs↑, *VitC↑, *VitE↑, *GSH↑, *GutMicro↑, *cardioP↑, *ROS↓, *MMP↓, *lipid-P↓, *NRF2↑, *hepatoP↑, *neuroP↑, *P450↑, *HO-1↑, *AntiAge↑, *motorD↓,

3002-

RosA,

Anticancer Effects of Rosemary (Rosmarinus officinalis L.) Extract and Rosemary Extract Polyphenols

-

Review,

Var,

NA

TumCG↓, TumCP↓, TumCCA↑, ChemoSen↑, NRF2↑, PERK↑, SESN2↑, HO-1↑, cl‑Casp3↑, ROS↑, UPR↑, ER Stress↑, CHOP↑, HER2/EBBR2↓, ER-α36↓, PSA↓, BAX↑, AR↓, P-gp↓, Cyt‑c↑, HSP70/HSPA5↑, eff↑, p‑Akt↓, p‑mTOR↓, p‑P70S6K↓, cl‑PARP↑, eff↑,

3003-

RosA,

Comprehensive Insights into Biological Roles of Rosmarinic Acid: Implications in Diabetes, Cancer and Neurodegenerative Diseases

-

Review,

Var,

NA

-

Review,

AD,

NA

-

Review,

Park,

NA

*Inflam↓, *antiOx↑, *neuroP↑, *IL6↓, *IL1β↓, *NF-kB↓, *PGE2↓, *COX2↓, *MMP↑, *memory↑, *ROS↓, *Aβ↓, *HMGB1↓, TumCG↓, MARK4↓, Zeb1↓, MDM2↓, BNIP3↑, ASC↑, NLRP3↓, PI3K↓, Akt↓, Casp1↓, E-cadherin↑, STAT3↓, TLR4↓, MMP↓, ICAM-1↓, AMPK↓, IL6↑, MMP2↓, Warburg↓, Bcl-xL↓, Bcl-2↓, TumCCA↑, EMT↓, TumMeta↓, mTOR↓, HSP27↓, Casp3↑, GlucoseCon↓, lactateProd↓, VEGF↓, p‑p65↓, GIT1↓, Foxm1↓, cycD1↓, CDK4↓, MMP9↓, HDAC2↓,

3004-

RosA,

Rosmarinic acid counteracts activation of hepatic stellate cells via inhibiting the ROS-dependent MMP-2 activity: Involvement of Nrf2 antioxidant system

-

in-vitro,

Nor,

HSC-T6

*GSH↓, *MMP2↓, *ROS↓, *lipid-P↓, *NRF2↑,

3005-

RosA,

Nanoformulated rosemary extract impact on oral cancer: in vitro study

-

in-vitro,

Laryn,

HEp2

TumCCA↑, ROS↑, Bcl-2↓, BAX↑, Casp3↑, P53↑, necrosis↑, eff↑, BioAv↑,

3006-

RosA,

Rosmarinic acid attenuates glioblastoma cells and spheroids’ growth and EMT/stem-like state by PTEN/PI3K/AKT downregulation and ERK-induced apoptosis

-

in-vitro,

GBM,

U87MG

-

in-vitro,

GBM,

LN229

TumCG↓, EMT↓, SIRT1↓, FOXO1↓, NF-kB↓, angioG↓, ROS↓, PTEN↓, PI3K↓, Akt↓, *Inflam↓, *cardioP↑, *hepatoP↑, *neuroP↑, Warburg↓,

3007-

RosA,

Hepatoprotective effects of rosmarinic acid: Insight into its mechanisms of action

-

Review,

NA,

NA

*ROS↓, *lipid-P↓, *Inflam↓, *neuroP↑, *angioG↓, *eff↑, *AST↓, *ALAT↓, *GSSG↓, *eNOS↓, *iNOS↓, *NO↓, *NF-kB↓, *MMP2↓, *MDA↓, *TNF-α↓, *GSH↑, *SOD↑, *IL6↓, *PGE2↓, *COX2↓, *mTOR↑,

3008-

RosA,

Rosmarinic acid decreases viability, inhibits migration and modulates expression of apoptosis-related CASP8/CASP3/NLRP3 genes in human metastatic melanoma cells

-

in-vitro,

Melanoma,

SK-MEL-28

tumCV↓, TumCMig↓, ROS↓, Casp3↑, selectivity↑, Casp8↑, NLRP3↓,

3009-

RosA,

Rosmarinic acid sensitizes cell death through suppression of TNF-alpha-induced NF-kappaB activation and ROS generation in human leukemia U937 cells

-

in-vitro,

AML,

U937

TNF-α↓, NF-kB↓, ROS↓, IAP1↓, IAP2↓, XIAP↓,

3011-

RosA,

Rosmarinic Acid Exhibits Anticancer Effects via MARK4 Inhibition

-

in-vitro,

GBM,

SH-SY5Y

MARK4 activity (IC50 = 6.204 µM)

-

in-vitro,

Lung,

A549

-

in-vitro,

Nor,

HEK293

-

in-vitro,

Nor,

MCF10

MARK4↓, p‑tau↓, selectivity↑, *toxicity∅,

3039-

RosA,

Rosmarinic acid liposomes suppress ferroptosis in ischemic brain via inhibition of TfR1 in BMECs

-

in-vivo,

Nor,

NA

mice

-

in-vivo,

Stroke,

NA

*Ferroptosis↓, *GPx4↑, *ACSL4↓, *BBB↑, *IronCh↑, *TfR1/CD71↓, *neuroP↑,

3038-

RosA,

Prooxidant action of rosmarinic acid: transition metal-dependent generation of reactive oxygen species

-

in-vitro,

Nor,

NA

Yeast cells

IronCh↑, ROS↑,

3037-

RosA,

Unraveling rosmarinic acid anticancer mechanisms in oral cancer malignant transformation

-

in-vitro,

Oral,

SCC9

-

in-vitro,

Oral,

HSC3

survivin↓, AntiCan↑, Vim↓, Snail↓, SOX9↓, EMT↓, MMP2↓, MMP9↓, P-gp↓, TumCG↓, ROS↑, MMP↓, GSH↓, P-gp↓, ATP↓,

3036-

RosA,

Anti-Warburg effect of rosmarinic acid via miR-155 in colorectal carcinoma cells

-

in-vitro,

CRC,

HCT8

-

in-vitro,

CRC,

HCT116

-

in-vitro,

CRC,

LS174T

GlucoseCon↓, lactateProd↓, Hif1a↓, Inflam↓, miR-155↓, STAT3↓, Glycolysis↓, IL6↓, Warburg↓,

3035-

RosA,

Rosmarinic Acid Decreases the Malignancy of Pancreatic Cancer Through Inhibiting Gli1 Signaling

-

in-vitro,

PC,

NA

-

in-vivo,

NA,

NA

Gli1↓, TumCCA↑, TumCMig↓, TumCI↓, CDK2↓, cycE↓, P21↑, p27↑,

3034-

RosA,

RES,

Ba,

The effect of dietary polyphenols on the epigenetic regulation of gene expression in MCF7 breast cancer cells

-

in-vitro,

BC,

MCF-7

DNMTs↓, eff↑, eff↝,

3031-

RosA,

Effects of rosmarinic acid against aflatoxin B1 and ochratoxin-A-induced cell damage in a human hepatoma cell line (Hep G2)

-

in-vitro,

Liver,

HepG2

ROS↓,

106-

RosA,

Rutin, a Quercetin Glycoside, Restores Chemosensitivity in Human Breast Cancer Cells

-

in-vivo,

BC,

MCF-7

1048-

RosA,

Ger,

Rosmarinic acid in combination with ginsenoside Rg1 suppresses colon cancer metastasis via co-inhition of COX-2 and PD1/PD-L1 signaling axis

-

in-vivo,

Colon,

MC38

RA (50, 100, 150 μM)

mice

TumCMig↓, TumCI↓, PD-1↓, COX2↓, PD-L1↓,

1749-

RosA,

Rosmarinic Acid and Related Dietary Supplements: Potential Applications in the Prevention and Treatment of Cancer

-

Review,

Var,

NA

antiOx↑, eff↑, *toxicity↝, *BioAv↑, *ROS↓, SOD↑, Catalase↑, GPx↑, lipid-P↓, P450↓, chemoP↑, hepatoP↑, ChemoSen↑,

1742-

RosA,

Rosmarinic acid, a natural polyphenol, has a potential pro-oxidant risk via NADH-mediated oxidative DNA damage

-

Analysis,

Var,

NA

ROS↑, eff↑, eff↑, eff↑, eff↑, eff↓, Dose↝, Dose↝,

1743-

RosA,

New insights into the competition between antioxidant activities and pro-oxidant risks of rosmarinic acid

-

Analysis,

Var,

NA

ROS↑, Fenton↑, eff↑, antiOx↑, Iron↓, ROS↑,

1744-

RosA,

Therapeutic Applications of Rosmarinic Acid in Cancer-Chemotherapy-Associated Resistance and Toxicity

-

Review,

Var,

NA

chemoR↓, ChemoSideEff↓, RadioS↑, ROS↓, ChemoSen↑, BioAv↑, Half-Life↝, antiOx↑, ROS↑, Fenton↑, DNAdam↑, Apoptosis↑, CSCs↓, HH↓, Bax:Bcl2↑, MDR1↓, P-gp↓, eff↑, eff↑, FOXO4↑, *eff↑, *ROS↓, *JNK↓, *ERK↓, *GSH↑, *H2O2↑, *MDA↓, *SOD↓, *HO-1↑, *CardioT↓, selectivity↑,

1745-

RosA,

Rosmarinic acid and its derivatives: Current insights on anticancer potential and other biomedical applications

-

Review,

Var,

NA

-

Review,

AD,

NA

ChemoSideEff↓, ChemoSen↑, antiOx↑, MMP2↓, MMP9↓, p‑AMPK↑, DNMTs↓, tumCV↓, COX2↓, E-cadherin↑, Vim↓, N-cadherin↓, EMT↓, Casp3↑, Casp9↓, ROS↓, GSH↑, ERK↓, Akt↓, ROS↓, NF-kB↓, p‑IκB↓, p50↓, p65↓, neuroP↑, Dose↝,

1746-

RosA,

Rosmarinic acid sensitizes cell death through suppression of TNF-α-induced NF-κB activation and ROS generation in human leukemia U937 cells

-

in-vitro,

AML,

U937

TNF-α↓, ROS↓, Casp↑, NF-kB↓, IκB↓, p50↓, p65↓, IAP1↓, IAP2↓, XIAP↓, Apoptosis↑,

1747-

RosA,

Molecular Pathways of Rosmarinic Acid Anticancer Activity in Triple-Negative Breast Cancer Cells: A Literature Review

-

Review,

BC,

MDA-MB-231

-

Review,

BC,

MDA-MB-468

TumCCA↑, TNF-α↑, GADD45A↑, BNIP3↑, survivin↓, Bcl-2↓, BAX↑, HH↓, eff↑, ChemoSen↑, RadioS↑, TumCP↓, TumCMig↓, Apoptosis↑, RenoP↑, CardioT↓,

1748-

RosA,

The Role of Rosmarinic Acid in Cancer Prevention and Therapy: Mechanisms of Antioxidant and Anticancer Activity

-

Review,

Var,

NA

AntiCan↑, *BioAv↝, *CardioT↓, *Iron↓, *ROS↓, *SOD↑, *Catalase↑, *GPx↑, *NRF2↑, MARK4↓, MMP9↓, TumCCA↑, Bcl-2↓, BAX↑, Apoptosis↑, E-cadherin↑, N-cadherin↓, Vim↓, Gli1↓, HDAC2↓, Warburg↓, Hif1a↓, miR-155↓, p‑PI3K↑, ROS↑, *IronCh↑,

1251-

RT,

OLST,

Rutin and orlistat produce antitumor effects via antioxidant and apoptotic actions

-

in-vitro,

BC,

MCF-7

-

in-vitro,

PC,

PANC1

-

in-vivo,

NA,

NA

EAC, mice

TumVol↓, *CEA↓, *FASN↓, *ROS↓, *MDA↓, *GSH↑, Apoptosis↑,

966-

RT,

Antioxidant Mechanism of Rutin on Hypoxia-Induced Pulmonary Arterial Cell Proliferation

-

vitro+vivo,

Nor,

NA

hypoxia-induced

*ROS↓, *NOX4↓, *Hif1a↓, *α-tubulin↓,

1132-

RT,

Rutin Promotes Proliferation and Orchestrates Epithelial–Mesenchymal Transition and Angiogenesis in MCF-7 and MDA-MB-231 Breast Cancer Cells

-

in-vitro,

BC,

MDA-MB-231

>100uM

rutin may act as a breast-cancer-promoting phytoestrogen.

-

in-vitro,

BC,

MCF-7

Vim↑, N-cadherin↑, E-cadherin↓, TumCP↑, TumCMig↑, tumCV↑, MKI67↑,

2040-

SAHA,

The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin

-

in-vitro,

Pca,

LNCaP

7.5 μM

-

in-vitro,

CRC,

T24

-

in-vitro,

BC,

MCF-7

HDAC↓, TumCG↓, Diff↑, Apoptosis↑, TXNIP↑,

323-

Sal,

SNP,

Combination of salinomycin and silver nanoparticles enhances apoptosis and autophagy in human ovarian cancer cells: an effective anticancer therapy

-

in-vitro,

BC,

MDA-MB-231

Sal (3 µM), AgNPs (4 µg/mL)

IC25 values of both Sal and AgNPs (3.0 µM and 4 µg/mL)

-

in-vitro,

Ovarian,

A2780S

TumCD↑, LDH↓, MDA↑, SOD↓, ROS↑, GSH↓, Catalase↓, MMP↓, P53↑, P21↑, BAX↑, Bcl-2↓, Casp3↑, Casp9↑, Apoptosis↑, TumAuto↑,

1210-

SANG,

Sanguinarine combats hypoxia-induced activation of EphB4 and HIF-1α pathways in breast cancer

-

in-vitro,

BC,

NA

EphB4↓, Hif1a↓, STAT3↓, MAPK↓, ERK↓,

1209-

SANG,

Sanguinarine is a novel VEGF inhibitor involved in the suppression of angiogenesis and cell migration

-

in-vitro,

Lung,

A549

VEGF↓, TumCMig↓, Akt↓, p38↓,

1208-

SANG,

Sanguinarine induces apoptosis in osteosarcoma by attenuating the binding of STAT3 to the single-stranded DNA-binding protein 1 (SSBP1) promoter region

-

in-vitro,

OS,

NA

SSBP1↑, mtDam↑, Apoptosis↑, JAK↓, STAT3↓, PI3k/Akt/mTOR↓, ROS↑, MMP↓,

1134-

SANG,

Sanguinarine inhibits epithelial–mesenchymal transition via targeting HIF-1α/TGF-β feed-forward loop in hepatocellular carcinoma

-

in-vitro,

HCC,

HepG2

0.4-50uM

4uM

impairs the proliferation of nine kinds of HCC cell lines

-

in-vitro,

HCC,

Hep3B

4.5uM

-

in-vitro,

HCC,

HUH7

3uM

Hif1a↓, EMT↓, Snail↓, PI3K↓, Akt↓, SMAD2↓, SMAD3↓,

1090-

SANG,

Sanguinarine inhibits invasiveness and the MMP-9 and COX-2 expression in TPA-induced breast cancer cells by inducing HO-1 expression.

-

in-vitro,

BC,

MCF-7

MMP9↓, COX2↓, PGE2↓, NF-kB↓, AP-1↓, p‑Akt↓, p‑ERK↓, HO-1↑,

1307-

SANG,

Sanguinarine induces apoptosis of HT-29 human colon cancer cells via the regulation of Bax/Bcl-2 ratio and caspase-9-dependent pathway

-

in-vitro,

CRC,

HT-29

Apoptosis↑, BAX↑, Bcl-2↓, Casp3↑, Casp9↑,

1388-

Sco,

Scoulerine promotes cell viability reduction and apoptosis by activating ROS-dependent endoplasmic reticulum stress in colorectal cancer cells

-

in-vitro,

CRC,

NA

tumCV↓, Apoptosis↑, Casp3↑, Casp7↑, BAX↑, Bcl-2↓, ROS↑, GSH↓, SOD↓, ER Stress↑, GRP78/BiP↑, CHOP↑, eff↓,

1403-

SDT,

BBR,

From 2D to 3D In Vitro World: Sonodynamically-Induced Prooxidant Proapoptotic Effects of C60-Berberine Nanocomplex on Cancer Cells

-

in-vitro,

Cerv,

HeLa

1 MHz, 1 W/cm2 US and 20 µM C60-Ber for 24 h

-

in-vitro,

Lung,

LLC1

eff↑, tumCV↓, ATP↓, ROS↑, Casp3↑, Casp7↑, mtDam↑,

2548-

SDT,

Sonoporation, a Novel Frontier for Cancer Treatment: A Review of the Literature

-

Review,

Var,

NA

sonoP↑, Dose↝, eff↓, Dose↝, BioEnh↑, toxicity↝,

2537-

SDT,

Design and Challenges of Sonodynamic Therapy System for Cancer Theranostics: From Equipment to Sensitizers

-

Review,

Var,

NA

Dose↝, eff↑, eff↑, eff↑, eff↑,

2536-

SDT,

Sonodynamic Therapy: Rapid Progress and New Opportunities for Non-Invasive Tumor Cell Killing with Sound

-

Review,

Var,

NA

ROS↑, eff↑, Dose?,

2549-

SDT,

Landscape of Cellular Bioeffects Triggered by Ultrasound-Induced Sonoporation

-

Review,

Var,

NA

sonoP↑, tumCV↓, MMP↓, ROS↑, Ca+2↑, eff↝, eff↑, selectivity↑, Half-Life↝, Dose↝, P-gp↓, ER Stress↑, other↑,

2550-

SDT,

Intracellular Delivery and Calcium Transients Generated in Sonoporation Facilitated by Microbubbles

-

in-vitro,

Nor,

NA

Rat cardiomyoblast (H9c2) cells

*Ca+2↑, sonoP↑, BioEnh↑,

2551-

SDT,

Sonoporation: Past, Present, and Future

-

Review,

Var,

NA

other↝, sonoP↑, Dose↝,

2140-

Se,

Selenium Exposure and Cancer Risk: an Updated Meta-analysis and Meta-regression

-

Review,

Var,

NA

Risk↓, antiOx↑, eff↑, eff↝,

2141-

Se,

Selenium and cancer risk: Wide-angled Mendelian randomization analysis

-

Review,

NA,

NA

Dose↝, Risk↝,

2142-

Se,

A U-shaped association between selenium intake and cancer risk

-

Review,

NA,

NA

*Risk↝, Dose↝, *Risk↓,

1698-

Se,

Association between Dietary Zinc and Selenium Intake, Oxidative Stress-Related Gene Polymorphism, and Colorectal Cancer Risk in Chinese Population - A Case-Control Study

-

Human,

CRC,

NA

A total of 493 cases and 498 sex and age-matched controls were randomly selected from an ongoing case-control study.

Risk↓,

1697-

Se,

Calc,

Calcium intake may explain the reduction of colorectal cancer odds by dietary selenium - a case-control study in Poland

-

Human,

CRC,

NA

Risk↓, Risk↓, Dose∅, AntiCan↑,

1687-

Se,

Selenium for preventing cancer

-

Analysis,

Var,

NA

eff∅, AntiCan∅,

1688-

Se,

Potential Role of Selenium in the Treatment of Cancer and Viral Infections

-

Review,

Var,

NA

IL2↑, INF-γ↑, Th1 response↑, Th2↑, Dose↑, AntiCan∅, Risk↑, chemoP↑, Hif1a↓, VEGF↓, selectivity↑, *GADD45A↑, NRF2↓, *NRF2↑, ChemoSen↑, angioG↓, PrxI↓, ChemoSideEff↓, eff↑,

1689-

Se,

Selenium and breast cancer - An update of clinical and epidemiological data

-

Analysis,

BC,

NA

OS↑, eff↑, Dose∅, *toxicity↝, eff↑,

1690-

Se,

Selenium and cancer: a story that should not be forgotten-insights from genomics

-

Review,

Var,

NA

Dose↓, other↝,

1691-

Se,

The influence of selenium and selenoprotein gene variants on colorectal cancer risk

-

Analysis,

CRC,

NA

Risk↓,

1692-

Se,

Association of Selenoprotein and Selenium Pathway Genotypes with Risk of Colorectal Cancer and Interaction with Selenium Status

-

Analysis,

CRC,

NA

Risk↓,

1693-

Se,

Prediagnostic selenium status, selenoprotein gene variants and association with breast cancer risk in a European cohort study

-

Analysis,

BC,

NA

Risk↓, other∅,

1694-

Se,

Expression of Selenoprotein Genes and Association with Selenium Status in Colorectal Adenoma and Colorectal Cancer

-

Analysis,

CRC,

NA

AntiCan↑, selenoP↓,

1695-

Se,

Serum Selenium Concentration as a Potential Diagnostic Marker for Early-Stage Colorectal Cancer: A Comparative Study

-

Trial,

CRC,

NA

49 patients diagnosed with colorectal cancer at our institution.

Risk↓, selm↑, Dose↓, antiOx↑, Dose↑, Dose↝,

1696-

Se,

Selenium dietary intake and survival among CRC patients

-

Human,

CRC,

NA

OS↑,

1707-

Se,

A Diet Lacking Selenium, but Not Zinc, Copper or Manganese, Induces Anticancer Activity in Mice with Metastatic Cancers

-

in-vivo,

Ovarian,

NA

mice

-

in-vivo,

BC,

NA

mice

OS↓,

1706-

Se,

Selenium in Prostate Cancer: Prevention, Progression, and Treatment

-

Review,

Pca,

NA

Risk∅, ChemoSen↑, Risk↓, toxicity↝, Risk↑, eff↑, *toxicity↑, RadioS↑, eff↓, eff↑, ChemoSen↑, ChemoSideEff↓,

1705-

Se,

Serum Selenium Level and 10-Year Survival after Melanoma

-

Study,

Melanoma,

NA

10-year survival of 375 melanoma patients depending on their serum selenium levels.

OS↑,

1704-

Se,

Prospective study of toenail selenium levels and cancer among women

-

Study,

Var,

NA

Risk∅,

1703-

Se,

An Assessment of Serum Selenium Concentration in Women with Endometrial Cancer

-

Study,

EC,

NA

A total of 306 women participated in the study

Risk↓, selm↝,

1702-

Se,

Supplemental Selenium May Decrease Ovarian Cancer Risk in African-American Women

-

Human,

Ovarian,

NA

Risk↓, eff∅,

1701-

Se,

An Assessment of Serum Selenium Concentration in Women with Ovarian Cancer

-

Human,

Ovarian,

NA

314 women (157 diseased patients and 157 healthy ones)

Risk↓, Risk↓, Dose∅,

1700-

Se,

Metabolism of Selenium, Selenocysteine, and Selenoproteins in Ferroptosis in Solid Tumor Cancers

-

Review,

Var,

NA

Dose↝, Risk↑, Dose↝, Risk↓,

1699-

Se,

Vegetarianism and colorectal cancer risk in a low-selenium environment: effect modification by selenium status? A possible factor contributing to the null results in British vegetarians

-

Analysis,

CRC,

NA

Dose↑, eff↓, Dose↓,

984-

Sel,

Effects of selenite on estrogen receptor-alpha expression and activity in MCF-7 breast cancer cells

-

in-vitro,

BC,

MCF-7

1 uM of sodium selenite

ERα↓, PR↑, pS2/TFF1↑, Catalase↑,

1018-

Sel,

Selenite-induced autophagy antagonizes apoptosis in colorectal cancer cells in vitro and in vivo

-

vitro+vivo,

CRC,

HCT116

injected i.p. with sodium selenite (2 mg/kg/day

-

vitro+vivo,

CRC,

SW480

TumAuto↑, LC3s↑, TumW↓, Weight∅, Beclin-1↑, p62↓, ROS↑,

1003-

Sel,

Sodium selenite inhibits proliferation of lung cancer cells by inhibiting NF-κB nuclear translocation and down-regulating PDK1 expression which is a key enzyme in energy metabolism expression

-

vitro+vivo,

Lung,

NA

NF-kB↓, PDK1↓, p‑p65↑, p‑IκB↑, BAX↑, lactateProd↓, MMP↓, Cyt‑c↑, mitResp↑, Apoptosis↑,

1002-

Sel,

Osi,

Adag,

Selenite as a dual apoptotic and ferroptotic agent synergizes with EGFR and KRAS inhibitors with epigenetic interference

-

in-vitro,

Lung,

H1975

7uM@72hr

-

in-vitro,

Lung,

H385

6uM@72hr

Apoptosis↑, Ferroptosis↑, DNMT1↓, TET1↑, TumCCA↑, cl‑PARP↑, cl‑Casp3↑, Cyt‑c↑, BIM↑, NOXA↑, Apoptosis↑, ROS↑, ER Stress↑, UPR↑,

1062-

Sel,

Sodium Selenite Decreased HDAC Activity, Cell Proliferation and Induced Apoptosis in Three Human Glioblastoma Cells

-

in-vitro,

GBM,

LN229

-

in-vitro,

GBM,

T98G

-

in-vitro,

GBM,

U87MG

HDAC↓, TumCP↓, TumCCA↑, Apoptosis↑, Casp3↝, MMP2↓, *BioAv↝,

1017-

Sel,

Selenite induces apoptosis in colorectal cancer cells via AKT-mediated inhibition of β-catenin survival axis

-

vitro+vivo,

CRC,

NA

Akt↓, β-catenin/ZEB1↓, cycD1↓, survivin↓, Apoptosis↑, ROS↑,

1135-

Selenate,

Selenate induces epithelial-mesenchymal transition in a colorectal carcinoma cell line by AKT activation

-

in-vitro,

CRC,

DLD1

880uM

EMT↑, Akt↑, Twist↑, Vim↑, E-cadherin↓,

1136-

SFN,

Sulforaphane inhibits epithelial-mesenchymal transition by activating extracellular signal-regulated kinase 5 in lung cancer cells

-

in-vitro,

Lung,

NA

-

in-vivo,

NA,

NA

Xenograft model

TumCMig↓, E-cadherin↑, ZO-1↑, N-cadherin↓, Snail↓, ERK5↑, EMT↓,

963-

SFN,

Sulforaphane inhibits hypoxia-induced HIF-1α and VEGF expression and migration of human colon cancer cells

-

in-vitro,

CRC,

HCT116

12.5-50 µM sulforaphane

-

in-vitro,

GC,

AGS

Hif1a↓, VEGF↓, angioG↓, Akt∅, ERK∅,

1061-

SFN,

Relevance of the natural HDAC inhibitor sulforaphane as a chemopreventive agent in urologic tumors

-

vitro+vivo,

NA,

NA

AntiTum↑, HDAC↓,

1014-

SFN,

Sulforaphane Modulates Cell Migration and Expression of β-Catenin and Epithelial Mesenchymal Transition Markers in Breast Cancer Cells

-

in-vitro,

BC,

MDA-MB-231

5, 10, 20, 30 and 40 μM

Zeb1↓, Apoptosis↑, Fibronectin↓, CLDN1↓, β-catenin/ZEB1↓, EMT↓,

110-

SFN,

Sulforaphane regulates self-renewal of pancreatic cancer stem cells through the modulation of Sonic hedgehog-GLI pathway

-

in-vivo,

PC,

NA

20 mg/kg

HH↓, Smo↓, Gli1↓, GLI2↓, Shh↓, VEGF↓, PDGFRA↓, EMT↓, Zeb1↓, Bcl-2↓, XIAP↓, E-cadherin↑, OCT4↓,

111-

SFN,

Sulforaphene Interferes with Human Breast Cancer Cell Migration and Invasion through Inhibition of Hedgehog Signaling

-

in-vitro,

BC,

SUM159

TNBC

HH↓, Gli1↓, MMP2↓, MMP9↓,

2552-

SFN,

Chemo,

Chemopreventive activity of sulforaphane

-

Review,

Var,

NA

chemoP↑, TumCG↓, *ROS↓, *Inflam↓, *Dose↝, *NRF2↑, *HO-1↑, *NQO1↑, NF-kB↓, ROS↑,

2553-

SFN,

Mechanistic review of sulforaphane as a chemoprotective agent in bladder cancer

-

Review,

Bladder,

NA

antiOx↓, Inflam↓, ChemoSen↑, ROS⇅, *NRF2↑, *GSH↑, Catalase↑, HO-1↑, NAD↑, chemoP↑,

2554-

SFN,

Sulforaphane (SFN): An Isothiocyanate in a Cancer Chemoprevention Paradigm

-

Review,

Var,

NA

Dose↝, chemoP↑, *NQO1↑, *GSTA1↑, HDAC↓, NF-kB↓,

2555-

SFN,

Chemopreventive functions of sulforaphane: A potent inducer of antioxidant enzymes and apoptosis

-

Review,

Var,

NA

chemoP↑, HDAC↓, TumCCA↑, Apoptosis↑, Mets↑, *NRF2↑, ROS⇅,

2556-

SFN,

The role of Sulforaphane in cancer chemoprevention and health benefits: a mini-review

-

Review,

Var,

NA

chemoP↑, HDAC↓, Hif1a↓, angioG↓, CYP1A1↓, eff↑, BioAv↑,

3180-

SFN,

Exploring the therapeutic effects of sulforaphane: an in-depth review on endoplasmic reticulum stress modulation across different disease contexts

-

Review,

Var,

NA

*cardioP↑, *ER Stress↓, GRP78/BiP↑, XBP-1↑, Apoptosis↑, *NRF2↑, UPR↑,

3200-

SFN,

Sulforaphane suppresses the activity of sterol regulatory element-binding proteins (SREBPs) by promoting SREBP precursor degradation

-

in-vitro,

Liver,

HUH7

FASN↓, ACC↓, SREBP1↓,

3199-

SFN,

Sulforaphane improves chemotherapy efficacy by targeting cancer stem cell-like properties via the miR-124/IL-6R/STAT3 axis

-

in-vitro,

GC,

NA

CSCs↓, CD133↓, BMI1↓, Nanog↓, Nestin↓,

3198-

SFN,

Sulforaphane and TRAIL induce a synergistic elimination of advanced prostate cancer stem-like cells

-

in-vitro,

Pca,

NA

Nanog↓, SOX2↓, E-cadherin↓, Snail↓, VEGFR2↓, Diff↓, TumCMig↓, EMT↓, CXCR4↓, NOTCH1↓, ALDH1A1↓, CSCs↓, eff↑,

3197-

SFN,

Sulforaphane Inhibits Self-renewal of Lung Cancer Stem Cells Through the Modulation of Polyhomeotic Homolog 3 and Sonic Hedgehog Signaling Pathways

-

in-vitro,

Lung,

A549

-

in-vitro,

Lung,

H460

TumCP↓, CSCs↓, Shh↓, Smo↓, Gli1↓,

3196-

SFN,

Sulforaphane eradicates pancreatic cancer stem cells by NF-κB

-

Review,

PC,

NA

CSCs↓, NF-kB↓,

3195-

SFN,

AKT1/HK2 Axis-mediated Glucose Metabolism: A Novel Therapeutic Target of Sulforaphane in Bladder Cancer

-

in-vitro,

Bladder,

UMUC3

ATP↓, Glycolysis↓, OXPHOS↓, HK2↓, PDH↓, AKT1↓, p‑Akt↓,

3194-

SFN,

Sulforaphane impedes mitochondrial reprogramming and histone acetylation in polarizing M1 (LPS) macrophages

-

in-vitro,

Nor,

NA

*OXPHOS↑, *M1↓, *IL1β↓, *IL6↓, *NOS2↓, *TNF-α↓, *ROS↓, *NO↓, *ACC↑,

3193-

SFN,

Epigenetic Therapeutics Targeting NRF2/KEAP1 Signaling in Cancer Oxidative Stress

-

Review,

Var,

NA

DNMTs↓, HDAC↑, NRF2↑, DNMT1↓, DNMT3A↓, NQO1↑, COMT↑, TumCG↓, *toxicity↓,

3192-

SFN,

Transcriptome analysis reveals a dynamic and differential transcriptional response to sulforaphane in normal and prostate cancer cells and suggests a role for Sp1 in chemoprevention

-

in-vitro,

Pca,

PC3

15 μM SFN

Sp1/3/4↓, selectivity↑, NRF2↑, HDAC↓, DNMTs↓, TumCCA↑, selectivity↑, HO-1↑, NQO1↑, CDK2↓, TumCP↓, BID↑, Smad1↑, Diablo↑, ICAD↑, Cyt‑c↑, IAP1↑, HSP27↑, *Cyt‑c↓, *IAP1↓, *HSP27↓, survivin↓, CDK4↓, VEGF↓, AR↓,

3191-

SFN,

Sulforaphane exhibits potent renoprotective effects in preclinical models of kidney diseases: A systematic review and meta-analysis

-

Review,

NA,

NA

Prot↝, RenoP↑,

3189-

SFN,

Sulforaphane Inhibits TNF-α-Induced Adhesion Molecule Expression Through the Rho A/ROCK/NF-κB Signaling Pathway

-

in-vitro,

Nor,

ECV304

*ICAM-1↓, *IL1β↓, *IL6↓, *IL8↓, *p‑IKKα↓, *Rho↓, *ROCK1↓, *ERK↓, *Inflam↓,

3188-

SFN,

Sulforaphane inhibited tumor necrosis factor-α induced migration and invasion in estrogen receptor negative human breast cancer cells

-

in-vitro,

BC,

NA

1,5,10uM

TNF-α↓, TumCI↓, TumMeta↓, MMPs↓, MMP2↓, MMP9↓, MMP13↓,

3187-

SFN,

Sulforaphane inhibits the expression of interleukin-6 and interleukin-8 induced in bronchial epithelial IB3-1 cells by exposure to the SARS-CoV-2 Spike protein

-

in-vitro,

Nor,

IB3-1

*IL6↓, *IL8↓, *Inflam↓,

3186-

SFN,

A pharmacological inhibitor of NLRP3 inflammasome prevents non-alcoholic fatty liver disease in a mouse model induced by high fat diet

-

in-vivo,

Nor,

NA

30 mg/kg/day

mice

*NLRP3↓, *ASC↓, *Casp1↓, *IL1β↓, *ALAT↓, *AST↓, *AMPK↑, *mTOR↓, *P70S6K↓,

3185-

SFN,

Sulforaphane decreases oxidative stress and inhibits NLRP3 inflammasome activation in a mouse model of ulcerative colitis

-

in-vivo,

Nor,

RAW264.7

mice

*IL18↓, *IL1β↓, *NLRP3↓, *Inflam↓,

3184-

SFN,

The Integrative Role of Sulforaphane in Preventing Inflammation, Oxidative Stress and Fatigue: A Review of a Potential Protective Phytochemical

-

Review,

Nor,

NA

*NRF2↑, *Inflam↓, *NF-kB↓, *ROS↓, *BioAv↝, *BioAv↝, *BioAv↝, *BioAv↝, *cardioP↑, *GPx↑, *SOD↑, *Catalase↑, *GPx↑, *HO-1↑, *NADPH↑, *NQO1↑, *LDH↓, *hepatoP↑, *ALAT↓, *AST↓, *IL6↓,

3183-

SFN,

Sulforaphane potentiates the efficacy of chemoradiotherapy in glioblastoma by selectively targeting thioredoxin reductase 1

-

in-vitro,

GBM,

NA

RadioS↑, TrxR1↓, ROS↑, ChemoSen↑, Prx↓,

3182-

SFN,

Sulforaphane Modulates AQP8-Linked Redox Signalling in Leukemia Cells

-

in-vitro,

AML,

NA

10 and 30 μM SFN

B1647 cell line

Prx↓, AQPs↓, NOX↓, tumCV↓, AntiCan↑, cardioP↑, neuroP↑, Inflam↓, chemoP↑, angioG↓, TumMeta↓, selectivity↑, ROS↓,

3181-

SFN,

Effect of sulforaphane on protein expression of Bip/GRP78 and caspase-12 in human hapetocelluar carcinoma HepG-2 cells

-

in-vitro,

HCC,

HepG2

GRP78/BiP↑, Casp12↑, Apoptosis↑, ER Stress↑,

3190-

SFN,

Sulforaphane inhibits TGF-β-induced fibrogenesis and inflammation in human Tenon’s fibroblasts

-

in-vitro,

Nor,

NA

*Fibronectin↓, *α-SMA↓, *ITGB1↓, *ITGA5↓, *IL6↓, *IL8↓, Inflam↓,

2447-

SFN,

Sulforaphane Bioavailability from Glucoraphanin-Rich Broccoli: Control by Active Endogenous Myrosinase

-

Review,

Nor,

NA

*BioAv↓, *BioAv↓, *BioAv↓, *BioAv↝,

2403-

SFN,

Reversal of the Warburg phenomenon in chemoprevention of prostate cancer by sulforaphane

-

in-vitro,

Pca,

LNCaP

5 and 10 µM SFN

-

in-vitro,

Pca,

22Rv1

-

in-vitro,

Pca,

PC3

-

in-vivo,

NA,

NA

mouse

ECAR↓, HK2↓, PKM2↓, LDHA↓, Glycolysis↓, Warburg↓,

2404-

SFN,

Prostate cancer chemoprevention by sulforaphane in a preclinical mouse model is associated with inhibition of fatty acid metabolism

-

in-vitro,

Pca,

LNCaP

5 and 10 μM

-

in-vitro,

Pca,

22Rv1

-

in-vivo,

NA,

NA

TRAMP mice

ACC1↓, FASN↓, CPT1A↓, β-oxidation↓, SREBP1?, HK2↓, PKM2↓, LDHA↓, Glycolysis↓,

2449-

SFN,

Optimization of a blanching step to maximize sulforaphane synthesis in broccoli florets

-

Study,

Nor,

NA

BioAv↑,

2448-

SFN,

Sulforaphane and bladder cancer: a potential novel antitumor compound

-

Review,

Bladder,

NA

Apoptosis↑, TumCG↓, TumCI↓, TumMeta↓, glucoNG↓, ChemoSen↑, TumCCA↑, Casp3↑, Casp7↑, cl‑PARP↑, survivin↓, EGFR↓, HER2/EBBR2↓, ATP↓, Glycolysis↓, mt-OXPHOS↓, AKT1↓, HK2↓, Hif1a↓, ROS↑, NRF2↑, EMT↓, COX2↓, MMP2↓, MMP9↓, Zeb1↓, Snail↓, HDAC↓, HATs↓, MMP↓, Cyt‑c↓, Shh↓, Smo↓, Gli1↓, BioAv↝, BioAv↝, Dose↝,

2405-

SFN,

Sulforaphane Targets the TBX15/KIF2C Pathway to Repress Glycolysis and Cell Proliferation in Gastric Carcinoma Cells

-

in-vitro,

GC,

SGC-7901

-

in-vitro,

GC,

BGC-823

TumCP↓, Glycolysis↓, TBX15↑, GlucoseCon↓, lactateProd↓, tumCV↓, PKM2↓, KIF2C↓,

2446-

SFN,

CAP,

The Molecular Effects of Sulforaphane and Capsaicin on Metabolism upon Androgen and Tip60 Activation of Androgen Receptor

-

in-vitro,

Pca,

LNCaP

10uM

AR↓, Bcl-xL↓, TumCP↓, Glycolysis↓, HK2↓, PKA↓, Hif1a↓, PSA↓, ECAR↓, BioAv↑, BioAv↓, *toxicity↓,

2445-

SFN,

Sulforaphane-Induced Cell Cycle Arrest and Senescence are accompanied by DNA Hypomethylation and Changes in microRNA Profile in Breast Cancer Cells

-

in-vitro,

BC,

MCF-7

-

in-vitro,

BC,

MDA-MB-231

-

in-vitro,

BC,

SkBr3

TumCCA↑, P21↑, p27↑, NO↑, Akt↓, ATP↓, AMPK↑, TumAuto↑, DNMT1↓, HK2↓, PKM2↓, HDAC3↓, HDAC4↓, HDAC8↓,

2444-

SFN,

Sulforaphane Delays Fibroblast Senescence by Curbing Cellular Glucose Uptake, Increased Glycolysis, and Oxidative Damage

-

in-vitro,

Nor,

MRC-5

Human fetal lung MRC-5 fibroblasts and human foreskin BJ

*GlucoseCon↓, *ROS↓, *Trx↓, *HK2↓, *NRF2↑, *Catalase↓, *TXNIP↑, *PFKFB2↓, *G6PD↑,

2406-

SFN,

Sulforaphane and Its Protective Role in Prostate Cancer: A Mechanistic Approach

-

Review,

Pca,

NA

HK2↓, PKM2↓, LDHA↓, Glycolysis↓, LAMP2↑, Hif1a↓, DNAdam↓, DNArepair↓, Dose↝,

1733-

SFN,

Sonic Hedgehog Signaling Inhibition Provides Opportunities for Targeted Therapy by Sulforaphane in Regulating Pancreatic Cancer Stem Cell Self-Renewal

-

in-vitro,

PC,

PanCSC

-

in-vitro,

Nor,

HPNE

-

in-vitro,

Nor,

HNPSC

CSCs↓, Shh↓, Gli↓, Nanog↓, OCT4↓, PDGFRA↓, cycD1↑, Apoptosis↑, Casp↑, Smo↓, Gli1↓, GLI2↓, Bcl-2↓, Casp3↑, Casp7↑,

1722-

SFN,

Sulforaphane as an anticancer molecule: mechanisms of action, synergistic effects, enhancement of drug safety, and delivery systems

-

Review,

Var,

NA

TumCCA↑, CYP1A1↓, CYP3A4↓, Cyt‑c↑, Casp9↑, Apoptosis↑, ROS↑, MAPK↑, P53↑, BAX↑, ChemoSen↑, HDAC↓, GSH↓, HO-1↑,

1725-

SFN,

Anticancer Activity of Sulforaphane: The Epigenetic Mechanisms and the Nrf2 Signaling Pathway

-

Review,

Var,

NA

*toxicity∅, AntiCan↑, antiOx↑, NRF2↑, DNMTs↓, HDAC↓, Hif1a↓, VEGF↓, P21↑, TumCCA↑, ac‑H3↑, ac‑H4↑, DNAdam↑, Dose↝,

1732-

SFN,

Sulforaphane, a Dietary Component of Broccoli/Broccoli Sprouts, Inhibits Breast Cancer Stem Cells

-

in-vitro,

BC,

MCF-7

1~5 μM

16 μM

-

in-vitro,

BC,

SUM159

10 μM

-

in-vivo,

NA,

NA

Daily injection with 50 mg/kg

mice

TumCD↑, CSCs↓, Wnt↓, β-catenin/ZEB1↓, *BioAv↑, angioG↓, VEGF↓, Hif1a↓, MMP2↓, MMP9↓, Casp3↑, *Half-Life∅,

1734-

SFN,

Sulforaphane Inhibits Nonmuscle Invasive Bladder Cancer Cells Proliferation through Suppression of HIF-1α-Mediated Glycolysis in Hypoxia

-

in-vitro,

Bladder,

RT112

selectivity↑, TumCP↓, Glycolysis↓, Hif1a↓,

1735-

SFN,

Activation of multiple molecular mechanisms for apoptosis in human malignant glioblastoma T98G and U87MG cells treated with sulforaphane

-

in-vitro,

GBM,

T98G

20 μM and 40 μM SFN for 24 h

-

in-vitro,

GBM,

U87MG

Apoptosis↑, Ca+2↑, Bax:Bcl2↑, cal2↑, Casp12↑, Casp9↑, Cyt‑c↑,

1736-

SFN,

Antitumor and antimetastatic effects of dietary sulforaphane in a triple-negative breast cancer models

-

in-vitro,

BC,

NA

-

in-vivo,

BC,

NA

TumCG↓, selectivity↓,

1731-

SFN,

Targeting cancer stem cells with sulforaphane, a dietary component from broccoli and broccoli sprouts

-

Review,

Var,

NA

CSCs↓, ChemoSen↑, NF-kB↓, Shh↓, Smo↓, Gli1↓, GLI2↓, PI3K↓, Wnt↓, β-catenin/ZEB1↓, Nanog↓, COX2↓, Zeb1↓, Snail↓, ChemoSideEff↓, eff↑, *BioAv↑,

1730-

SFN,

Sulforaphane: An emergent anti-cancer stem cell agent

-

Review,

Var,

NA

BioAv↓, BioAv↑, GSTA1↑, P450↓, TumCCA↑, HDAC↓, P21↑, p27↑, DNMT1↓, DNMT3A↓, cycD1↑, DNAdam↑, BAX↑, Cyt‑c↑, Apoptosis↑, ROS↑, AIF↑, CDK1↑, Casp3↑, Casp8↑, Casp9↑, NRF2↑, NF-kB↓, TNF-α↓, IL1β↓, CSCs↓, CD133↓, CD44↓, ALDH↓, Nanog↓, OCT4↓, hTERT↓, MMP2↓, EMT↓, ALDH1A1↓, Wnt↓, NOTCH↓, ChemoSen↑, *Ki-67↓, *HDAC3↓, *HDAC↓,

1729-

SFN,

Discovery and development of sulforaphane as a cancer chemopreventive phytochemical

-

Review,

Nor,

NA

eff↑, angioG↓, VEGF↓, MMP9↓, MMP2↓,

1728-

SFN,

Broccoli sprouts: An exceptionally rich source of inducers of enzymes that protect against chemical carcinogens

-

Review,

Nor,

NA

eff↑, eff↓,

1727-

SFN,

Glucoraphanin, sulforaphane and myrosinase activity in germinating broccoli sprouts as affected by growth temperature and plant organs

-

Analysis,

Nor,

NA

eff↑, eff↓,

1726-

SFN,

Sulforaphane: A Broccoli Bioactive Phytocompound with Cancer Preventive Potential

-

Review,

Var,

NA

Dose↝, eff↝, IL1β↓, IL6↓, IL12↓, TNF-α↓, COX2↓, CXCR4↓, MPO↓, HSP70/HSPA5↓, HSP90↓, VCAM-1↓, IKKα↓, NF-kB↓, HO-1↑, Casp3↑, Casp7↑, Casp8↑, Casp9↑, cl‑PARP↑, Cyt‑c↑, Diablo↑, CHOP↑, survivin↓, XIAP↓, p38↑, Fas↑, PUMA↑, VEGF↓, Hif1a↓, Twist↓, Zeb1↓, Vim↓, MMP2↓, MMP9↓, E-cadherin↑, N-cadherin↓, Snail↓, CD44↓, cycD1↓, cycA1↓, CycB↓, cycE↓, CDK4↓, CDK6↓, p50↓, P53↑, P21↑, GSH↑, SOD↑, GSTs↑, mTOR↓, Akt↓, PI3K↓, β-catenin/ZEB1↓, IGF-1↓, cMyc↓,

1724-

SFN,

Sulforaphane: A review of its therapeutic potentials, advances in its nanodelivery, recent patents, and clinical trials

-

Review,

Var,

NA

antiOx↑, NRF2↑, HDAC↓, neuroP↑,

1723-

SFN,

Sulforaphane as a potential remedy against cancer: Comprehensive mechanistic review

-

Review,

Var,

NA

*NRF2↑, ROS↑, MMP↓, Cyt‑c↑, cl‑PARP↑, Apoptosis↑, AMPK↑, GSH↓,

1494-

SFN,

doxoR,

Sulforaphane potentiates anticancer effects of doxorubicin and attenuates its cardiotoxicity in a breast cancer model

-

in-vivo,

BC,

NA

rats

-

in-vitro,

BC,

MCF-7

-

in-vitro,

Nor,

MCF10

CardioT↓, *GSH↑, *ROS↓, *NRF2↑, NRF2∅, HDAC↓, DNMTs↓, Casp3↑, ER-α36↓, Remission↑, eff↑, ROS↑, selectivity?,

1455-

SFN,

Sulforaphane Activates a lysosome-dependent transcriptional program to mitigate oxidative stress

-

in-vitro,

Cerv,

HeLa

SFN (10 or 15 μM) for 9 h

-

in-vitro,

Nor,

1321N1

*ROS↓, *BioAv↑, LC3II↑, LAMP1?, TumAuto↑, TFEB↑, ROS↑, eff↓,

1482-

SFN,

Sulforaphane induces apoptosis in T24 human urinary bladder cancer cells through a reactive oxygen species-mediated mitochondrial pathway: the involvement of endoplasmic reticulum stress and the Nrf2 signaling pathway

-

in-vitro,

Bladder,

T24

tumCV↓, Apoptosis↑, Cyt‑c↑, Bax:Bcl2↑, Casp9↑, Casp3↑, Casp8∅, cl‑PARP↑, ROS↑, MMP↓, eff↓, ER Stress↑, p‑NRF2↑, HO-1↑,

1483-

SFN,

Targeting p62 by sulforaphane promotes autolysosomal degradation of SLC7A11, inducing ferroptosis for osteosarcoma treatment

-

in-vitro,

OS,

143B

0-10uM

-

in-vitro,

Nor,

HEK293

-

in-vivo,

OS,

NA

25-50mg/kg

subcutaneous tumor-bearing nude mouse model

AntiCan↑, *toxicity∅, Ferroptosis↑, ROS↑, lipid-P↑, GSH↓, p62↑, SLC12A5↓, eff↓, GPx4↓, i-Iron↑, eff↓, MDA↑, TumVol↓, TumW↓, Ki-67↓, LC3B↑, *Weight∅,

1484-

SFN,

Sulforaphane’s Multifaceted Potential: From Neuroprotection to Anticancer Action

-

Review,

Var,

NA

-

Review,

AD,

NA

neuroP↑, AntiCan↑, NRF2↑, HDAC↓, eff↑, *ROS↓, neuroP↑, HDAC↓, *toxicity∅, BioAv↑, eff↓, cycD1↓, CDK4↓, p‑RB1↓, Glycolysis↓, miR-30a-5p↑, TumCCA↑, TumCG↓, TumMeta↓, eff↑, ChemoSen↑, RadioS↑, CardioT↓, angioG↓, Hif1a↓, VEGF↓, *BioAv?, *Half-Life∅,

1430-

SFN,

Sulforaphane bioavailability and chemopreventive activity in women scheduled for breast biopsy

-

Trial,

BC,

NA

250 μM GFN glucoraphanin

*HDAC3↓, HDAC↓, *toxicity↓,

1429-

SFN,

Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast

-

in-vivo,

Nor,

NA

-

Human,

Nor,

NA

200 mumol

eight healthy women undergoing reduction mammoplasty were given a single dose of a broccoli sprout preparation containing 200 mumol of sulforaphane.

*NADPH↑, *NQO1↑, *HO-1↑, *Risk↑,

1428-

SFN,

Broccoli or Sulforaphane: Is It the Source or Dose That Matters?

-

Review,

NA,

NA

HDAC↓, NRF2↑,

1454-

SFN,

Absorption and chemopreventive targets of sulforaphane in humans following consumption of broccoli sprouts or a myrosinase-treated broccoli sprout extract

-

Human,

Nor,

NA

Subjects consumed fresh broccoli sprouts or the BSE, each providing 200 μmol SFN daily, as a single dose and as two 100-μmol doses taken 12 h apart.

*HDAC↓, *eff↑, *eff↑, *eff↑, *BioAv↑, *BioAv↑,

1453-

SFN,

Sulforaphane Reduces Prostate Cancer Cell Growth and Proliferation In Vitro by Modulating the Cdk-Cyclin Axis and Expression of the CD44 Variants 4, 5, and 7

-

in-vitro,

Pca,

DU145

1–20 µM

14-32uM

Other investigators have calculated the IC50 value for SFN to be 14 µM for DU145 versus 32 µM for PC3

-

in-vitro,

Pca,

PC3

TumCG↓, TumCP↓, TumCCA↑, H3↑, H4↑, HDAC↓, CDK1↑, CDK2↑, p19↑, *BioAv↑,

1452-

SFN,

Sulforaphane Suppresses the Nicotine-Induced Expression of the Matrix Metalloproteinase-9 via Inhibiting ROS-Mediated AP-1 and NF-κB Signaling in Human Gastric Cancer Cells

-

in-vitro,

GC,

AGS

MMP9↓, p38↓, ERK↓, AP-1↓, ROS↓, NF-kB↓, TumCI↓, MMP9↓, HDAC↓, Glycolysis↓, Hif1a↓, *memory↑, *cognitive↑,

1432-

SFN,

Evaluation of biodistribution of sulforaphane after administration of oral broccoli sprout extract in melanoma patients with multiple atypical nevi

-

Human,

Melanoma,

NA

50-200uM

Seventeen patients who each had at least 2 atypical nevi and a prior history of melanoma were randomly allocated to 50, 100, or 200 µmol oral BSE-SFN daily for 28 days.

other↑, decorin↑, *toxicity↓, IP-10/CXCL-10↓, MCP1↓, CXCL9↓, MIP-1β↓, IFN-γ↓,

1434-

SFN,

GEM,

Sulforaphane Potentiates Gemcitabine-Mediated Anti-Cancer Effects against Intrahepatic Cholangiocarcinoma by Inhibiting HDAC Activity

-

in-vitro,

CCA,

HuCCT1

SFN (0–80 μM) or GEM (0–10 μM) for 24 h

27.4uM(SFN),0.57 μM(GEM)

-

in-vitro,

CCA,

HuH28

34.2 μM(SFN), 0.71um(GEM)

-

in-vivo,

NA,

NA

50 mg/kg/day

tumors of SFN- and GEM-treated mice

HDAC↓, ac‑H3↑, ChemoSen↑, tumCV↓, TumCP↓, TumCCA↑, Apoptosis↑, cl‑Casp3↑, TumCI↓, VEGF↓, VEGFR2↓, Hif1a↓, eNOS↓, EMT?, TumCG↓, Ki-67↓, TUNEL↑, P21↑, p‑Chk2↑, CDC25↓, BAX↑, *ROS↓, NQO1?,

1481-

SFN,

docx,

Combination of Low-Dose Sulforaphane and Docetaxel on Mitochondrial Function and Metabolic Reprogramming in Prostate Cancer Cell Lines

-

in-vitro,

Pca,

LNCaP

6.55 µM SFN and 0.0675 µM DCT

Prostate cancer cell lines LNCaP and PC-3 were treated with individual IC50 doses of SFN and DCT and half-reduced IC50 values for the SFN:DCT combination.

-

in-vitro,

Pca,

PC3

1.1 µM SFN and 0.0005 µM DCT

ChemoSen↑, Casp3↑, ROS↑, Casp8↑, Cyt‑c↑, Glycolysis↓, GSH↓, GSH/GSSG↓, *toxicity↓,

1495-

SFN,

doxoR,

Sulforaphane protection against the development of doxorubicin-induced chronic heart failure is associated with Nrf2 Upregulation

-

in-vivo,

Nor,

NA

Rats

*CardioT↓, *NRF2↑, *eff↓, *ROS↓,

1496-

SFN,

VitD3,

Association between histone deacetylase activity and vitamin D-dependent gene expressions in relation to sulforaphane in human colorectal cancer cells

-

in-vitro,

CRC,

Caco-2

24 h to vitamin D (100 nmol L-1 ) either alone or in combination with SFN and trichostatin A (20 and 1 μmol L-1 , respectively)

eff↑, VDR↑, CYP11A1↓, HDAC↓,

1497-

SFN,

Differential effects of sulforaphane on histone deacetylases, cell cycle arrest and apoptosis in normal prostate cells versus hyperplastic and cancerous prostate cells

-

in-vitro,

Nor,

PrEC

-

in-vitro,

Pca,

LNCaP

15 µM SFN

-

in-vitro,

Pca,

PC3

HDAC↓, selectivity↑, TumCCA↑, Apoptosis↑, selectivity↑, H3↑, P21↑, selectivity↑,

1498-

SFN,

Prolonged sulforaphane treatment activates survival signaling in nontumorigenic NCM460 colon cells but apoptotic signaling in tumorigenic HCT116 colon cells

-

in-vitro,

CRC,

HCT116

-

in-vitro,

Nor,

NCM460

selectivity↑, TumCCA↑, Apoptosis↑, *p‑ERK↑, cMYB↓, selectivity↑, selectivity↑,

1499-

SFN,

Sulforaphane suppresses metastasis of triple-negative breast cancer cells by targeting the RAF/MEK/ERK pathway

-

in-vitro,

BC,

NA

TumCMig↓, TumCI↓, FAK↓, p‑MEK↓, p‑ERK↓,

1500-

SFN,

A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase

-

in-vitro,

Nor,

HEK293

-

in-vitro,

CRC,

HCT116

HDAC↓, P21↑, TOPflash↑,

1501-

SFN,

The Inhibitory Effect of Sulforaphane on Bladder Cancer Cell Depends on GSH Depletion-Induced by Nrf2 Translocation

-

in-vitro,

CRC,

T24

2.5 µM vs >10uM

Dose↝, NRF2↑, GSH↓, eff↑,

1502-

SFN,

Epigenetic targets of bioactive dietary components for cancer prevention and therapy

-

Review,

NA,

NA

HDAC↓, AntiCan↑, DNMTs↓, hTERT↓, selectivity↑,

1436-

SFN,

PacT,

docx,

Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells

-

in-vivo,

BC,

SUM159

mouse

NF-kB↓, ChemoSen↑, IL6↓, IL8↑,

1437-

SFN,

Dietary Sulforaphane in Cancer Chemoprevention: The Role of Epigenetic Regulation and HDAC Inhibition

-

Review,

NA,

NA

HDAC↓, HDAC1↓, HDAC2↓, HDAC3↓, HDAC8↓, eff↑, ac‑HSP90↑, DNMT1↓, DNMT3A↓, hTERT↓, NRF2↑, HO-1↑, NQO1↑, miR-155↓, miR-200c↑, SOX9↓, *toxicity↓,

1468-

SFN,

Cellular responses to dietary cancer chemopreventive agent D,L-sulforaphane in human prostate cancer cells are initiated by mitochondrial reactive oxygen species

-

in-vitro,

Pca,

LNCaP

-

in-vitro,

Pca,

PC3

ROS↑, DNAdam↑, MMP↓, Cyt‑c↑, TumCCA↑,

1456-

SFN,

Sulforaphane regulates cell proliferation and induces apoptotic cell death mediated by ROS-cell cycle arrest in pancreatic cancer cells

-

in-vitro,

PC,

MIA PaCa-2

0, 7.5, and 15 µM

-

in-vitro,

PC,

PANC1

tumCV↓, TumCP↓, cl‑PARP↑, cl‑Casp3↑, TumCCA↑, ROS↑, MMP↓, γH2AX↑, eff↓, *toxicity↓,

1457-

SFN,

Sulforaphane Inhibits IL-1β-Induced IL-6 by Suppressing ROS Production, AP-1, and STAT3 in Colorectal Cancer HT-29 Cells

-

in-vitro,

CRC,

HT-29

0–10 μM

IL6↓, ROS↓, TumCP↓, TumCI↓, p38↓, AP-1↓,

1458-

SFN,

Sulforaphane Impact on Reactive Oxygen Species (ROS) in Bladder Carcinoma

-

Review,

Bladder,

NA

HDAC↓, eff↓, TumW↓, TumW↓, angioG↓, *toxicity↓, GutMicro↝, AntiCan↑, ROS↑, MMP↓, Cyt‑c↑, Bax:Bcl2↑, Casp3↑, Casp9↑, Casp8∅, cl‑PARP↑, TRAIL↑, DR5↑, eff↓, NRF2↑, ER Stress↑, COX2↓, EGFR↓, HER2/EBBR2↓, ChemoSen↑, NF-kB↓, TumCCA?, p‑Akt↓, p‑mTOR↓, p70S6↓, p19↑, P21↑, CD44↓,

1459-

SFN,

Aur,

Auranofin Enhances Sulforaphane-Mediated Apoptosis in Hepatocellular Carcinoma Hep3B Cells through Inactivation of the PI3K/Akt Signaling Pathway

-

in-vitro,

Liver,

Hep3B

auranofin (0.5, 1, 1.5, and 2 μM) or sulforaphane (2.5, 5, 7.5, and 10 μM)

-

in-vitro,

Liver,

HepG2

eff↑, TumCCA↑, Apoptosis↑, MMP↓, BAX↑, cl‑PARP↑, Casp3↑, Casp8↑, Casp9↑, ROS↑, eff↓, PI3K↓, Akt↓, TrxR↓, BAX↑, Bcl-2∅,

1460-

SFN,

High levels of EGFR prevent sulforaphane-induced reactive oxygen species-mediated apoptosis in non-small-cell lung cancer cells

-

in-vitro,

Lung,

NA

ROS↑, EGFR↓, eff↓, TumCCA↑, γH2AX↑, DNAdam↑, eff↓,

1461-

SFN,

Targets and mechanisms of sulforaphane derivatives obtained from cruciferous plants with special focus on breast cancer - contradictory effects and future perspectives

-

Review,

BC,

NA

TumCP↓, Apoptosis↑, TumCCA↑, antiOx↑, NA↑,

1462-

SFN,

Epithelial-mesenchymal transition, a novel target of sulforaphane via COX-2/MMP2, 9/Snail, ZEB1 and miR-200c/ZEB1 pathways in human bladder cancer cells

-

in-vitro,

Bladder,

T24

EMT↓, TumCI↓, TumCMig↓, E-cadherin↑, Zeb1↓, Snail↓, COX2↝, MMP2↝, MMP9↝,

1463-

SFN,

Sulforaphane induces reactive oxygen species-mediated mitotic arrest and subsequent apoptosis in human bladder cancer 5637 cells

-

in-vitro,

Bladder,

5637

tumCV↓, CycB↑, p‑CDK1↑, Apoptosis↑, Casp8↑, Casp9↑, Casp3↑, cl‑PARP↑, ROS↑, eff↓,

1464-

SFN,

d,l-Sulforaphane Induces ROS-Dependent Apoptosis in Human Gliomablastoma Cells by Inactivating STAT3 Signaling Pathway

-

in-vitro,

GBM,

NA

Apoptosis↑, Casp3↑, BAX↑, Bcl-2↓, ROS↑, p‑STAT3↓, JAK2↓, eff↓,

1465-

SFN,

TRAIL attenuates sulforaphane-mediated Nrf2 and sustains ROS generation, leading to apoptosis of TRAIL-resistant human bladder cancer cells

-

NA,

Bladder,

NA

eff↑, Apoptosis↑, Casp↑, MMP↓, BID↑, DR5↑, ROS↑, NRF2↑, eff↑, eff↓,

1466-

SFN,

Sulforaphane inhibits thyroid cancer cell growth and invasiveness through the reactive oxygen species-dependent pathway

-

vitro+vivo,

Thyroid,

FTC-133

10.8 to 19.6 μM

mice

TumCP↓, TumCCA↑, Apoptosis↑, TumCMig↓, TumCI↓, EMT↓, Slug↓, Twist↓, MMP2↓, MMP9↓, TumCG↓, p‑Akt↓, P21↑, ERK↑, p38↑, ROS↑, *toxicity∅, MMP↓, eff↓,

1467-

SFN,

Sulforaphane generates reactive oxygen species leading to mitochondrial perturbation for apoptosis in human leukemia U937 cells

-

in-vitro,

AML,

U937

Apoptosis↑, ROS↑, MMP↓, Casp3↑, Bcl-2↓, eff↓,

1480-

SFN,

Sulforaphane Induces Cell Death Through G2/M Phase Arrest and Triggers Apoptosis in HCT 116 Human Colon Cancer Cells

-

in-vitro,

CRC,

HCT116

tumCV↓, TumCCA↑, Apoptosis↑, cycA1↑, CycB↑, CDC25↓, CDK1↓, ROS↑, eff↓, Cyt‑c↑, AIF↑, ER Stress↑,

1469-

SFN,

Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis

-

in-vitro,

Pca,

PC3

-

in-vitro,

Pca,

LNCaP

-

in-vivo,

Pca,

NA

orthotopically implanted PC-3 tumors

eff↑, ROS↑, MMP↓, Casp3↑, Casp9↑, DR4↑, DR5↑, BAX↑, Bak↑, BIM↑, NOXA↑, Bcl-2↓, Bcl-xL↓, Mcl-1↓, eff↓, TumCG↓, TumCP↓, eff↑, NF-kB↓, PI3K↓, Akt↓, MEK↓, ERK↓, angioG↓, FOXO3↑,

1470-

SFN,

Rad,

Sulforaphane induces ROS mediated induction of NKG2D ligands in human cancer cell lines and enhances susceptibility to NK cell mediated lysis

-

in-vitro,

BC,

MCF-7

-

in-vitro,

BC,

MDA-MB-231

-

in-vitro,

Lung,

A549

-

in-vitro,

lymphoma,

U937

eff↓, ROS↑, NKG2D↑,

1471-

SFN,

ROS-mediated activation of AMPK plays a critical role in sulforaphane-induced apoptosis and mitotic arrest in AGS human gastric cancer cells

-

in-vitro,

GC,

AGS

TumCP↓, Apoptosis↑, TumCCA↑, CycB↑, P21↑, p‑H3↑, p‑AMPK↑, eff↓, MMP↓, Cyt‑c↑, ROS↑, eff↓,

1472-

SFN,

Sulforaphane Inhibits Autophagy and Induces Exosome-Mediated Paracrine Senescence via Regulating mTOR/TFE3

-

in-vitro,

ESCC,

NA

TumCP↓, ROS↑, DNAdam↑,

1431-

SFN,

Induction of the phase 2 response in mouse and human skin by sulforaphane-containing broccoli sprout extracts

-

in-vivo,

Nor,

NA

Topical application of an extract delivering 100 nmol sulforaphane/cm(2)

mice and human

*NADPH↑, *NQO1↑, *GSTA1↑, *HO-1↑,

1474-

SFN,

Sulforaphane induces p53‑deficient SW480 cell apoptosis via the ROS‑MAPK signaling pathway

-

in-vitro,

Colon,

SW480

5, 10, 15 and 20 µM

TumCG↓, Apoptosis↑, MMP↓, Bax:Bcl2↑, Casp3↑, Casp7↑, Casp9↑, ROS↑, e-ERK↑, p38↑, P53∅, eff↓, ChemoSen↑,

1475-

SFN,

Form,

Combination of Formononetin and Sulforaphane Natural Drug Repress the Proliferation of Cervical Cancer Cells via Impeding PI3K/AKT/mTOR Pathway

-

in-vitro,

Cerv,

HeLa

0-50 µM

TumCP↓, PI3K↓, Akt↓, mTOR↓, eff↑, ROS↑,

1476-

SFN,

PDT,

Enhancement of cytotoxic effect on human head and neck cancer cells by combination of photodynamic therapy and sulforaphane

-

in-vitro,

HNSCC,

NA

eff↑, tumCV↓, ROS↑, eff↓, Casp↑,

1477-

SFN,

Sulforaphane Induces Oxidative Stress and Death by p53-Independent Mechanism: Implication of Impaired Glutathione Recycling

-

in-vitro,

OS,

MG63

>10 μM

tumCV↓, Apoptosis↑, Casp3↑, ROS↑, GSR↓, GPx↓,

1478-

SFN,

acet,

Anti-inflammatory and anti-oxidant effects of combination between sulforaphane and acetaminophen in LPS-stimulated RAW 264.7 macrophage cells

-

in-vitro,

Nor,

NA

eff↑, NO↓, iNOS↓, COX2↓, IL1β↓, ROS↓,

1479-

SFN,

Sulforaphane triggers Sirtuin 3-mediated ferroptosis in colorectal cancer cells via activating the adenosine 5'-monophosphate (AMP)-activated protein kinase/ mechanistic target of rapamycin signaling pathway

-

in-vitro,

CRC,

HCT116

Ferroptosis↑, SIRT3↑, AMPK↑, mTOR↑, tumCV↓, ROS↑, MDA↑, Iron↑,

1315-

SFN,

Sulforaphane Induces Apoptosis of Acute Human Leukemia Cells Through Modulation of Bax, Bcl-2 and Caspase-3

-

in-vitro,

AML,

K562

TumCP↓, BAX↑, Casp3↑, Bcl-2↓,

2164-

SFN,

dietP,

Broccoli Sprouts Delay Prostate Cancer Formation and Decrease Prostate Cancer Severity with a Concurrent Decrease in HDAC3 Protein Expression in Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) Mice

-

in-vitro,

Pca,

NA

mouse prostate (TRAMP) model

HDAC↓, Dose↝, Risk↓, TumCP↓, H3↓,

2166-

SFN,

Sulforaphane targets cancer stemness and tumor initiating properties in oral squamous cell carcinomas via miR-200c induction

-

in-vitro,

Oral,

NA

-

in-vivo,

NA,

NA

CSCs↓, selectivity↑, TumCMig↓, TumCI↓,

2167-

SFN,

The dietary isothiocyanate sulforaphane targets pathways of apoptosis, cell cycle arrest, and oxidative stress in human pancreatic cancer cells and inhibits tumor growth in severe combined immunodeficient mice

-

in-vitro,

PC,

MIA PaCa-2

-

in-vitro,

PC,

PANC1

Casp8↑, MMP↓, Casp3↑, Apoptosis↑, GSH↓, GSH↑,

2168-

SFN,

Amelioration of Alzheimer's disease by neuroprotective effect of sulforaphane in animal model

-

in-vivo,

AD,

NA

Aβ-induced AD acute mouse models

*NRF2↑, *cognitive↑, other↓,

1508-

SFN,

Nrf2 targeting by sulforaphane: A potential therapy for cancer treatment

-

Review,

Var,

NA

*BioAv↑, HDAC↓, TumCCA↓, eff↓, Wnt↓, β-catenin/ZEB1↓, Casp12?, Bcl-2↓, cl‑PARP↑, Bax:Bcl2↑, IAP1↓, Casp3↑, Casp9↑, Telomerase↓, hTERT↓, ROS?, DNMTs↓, angioG↓, VEGF↓, Hif1a↓, cMYB↓, MMP1↓, MMP2↓, MMP9↓, ERK↑, E-cadherin↑, CD44↓, MMP2↓, eff↑, IL2↑, IFN-γ↑, IL1β↓, IL6↓, TNF-α↓, NF-kB↓, ERK↓, NRF2↑, RadioS↑, ChemoSideEff↓,

1513-

SFN,

acetaz,

Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis

-

in-vitro,

BrCC,

H720

AZ, SFN, and AZ+SFN (10 μM, 20 μM, and 40 μM)

-

in-vivo,

BrCC,

NA

AZ (20 mg/kg), SFN (40 mg/kg), and a combination of AZ (20 mg/kg) plus SFN (40 mg/kg), daily for two weeks

mice

-

in-vitro,

BrCC,

H727

eff↑, tumCV↓, Apoptosis↑, P21↑, PI3K↓, Akt↓, mTOR↓, 5HT↓, NRF2↑,

1509-

SFN,

Combination therapy in combating cancer

-

Review,

NA,

NA

NRF2↑, ChemoSideEff↓, eff↑, TumCP↓, Apoptosis↑, TumCCA↑, eff↑, PSA↓, P53↑, Hif1a↓, CAIX↓, chemoR↓, 5HT↓,

1507-

SFN,

Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects

-

in-vivo,

Colon,

NA

7.5 mumol per animal for 21 days

-

Human,

Nor,

NA

68 g BroccoSprouts

TumCG↓, HDAC↓, *BioAv↑, Dose∅, Half-Life∅,

1316-

SIL,

Chemo,

Silymarin and Cancer: A Dual Strategy in Both in Chemoprevention and Chemosensitivity

-

Analysis,

Var,

NA

TumCCA↑, p42↓, P450↓, OATPs↓, chemoP↑, ChemoSen↑,

1276-

SIL,

Silibinin inhibits TPA-induced cell migration and MMP-9 expression in thyroid and breast cancer cells

-

in-vitro,

BC,

NA

-

in-vitro,

Thyroid,

NA

TumCMig↓, MMP9↓, p‑MEK↓, p‑ERK↓,

109-

SIL,

Silibinin induces apoptosis through inhibition of the mTOR-GLI1-BCL2 pathway in renal cell carcinoma

-

vitro+vivo,

RCC,

769-P

-

in-vitro,

RCC,

786-O

-

in-vitro,

RCC,

ACHN

-

in-vitro,

RCC,

OS-RC-2

(50-200 uM) 200mg/kg vivo

HH↓, Gli1↓, GLI2↓, mTOR↓, Bcl-2↓,

1127-

SIL,

Silibinin suppresses epithelial–mesenchymal transition in human non-small cell lung cancer cells by restraining RHBDD1

-

in-vitro,

Lung,

A549

TumCP↓, TumCMig↓, TumCI↓, EMT↓, RHBDD1↓,

1140-

SIL,

Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth

-

in-vitro,

PC,

AsPC-1

10 μM to 250 μM

~75uM

-

in-vivo,

PC,

NA

mouse

-

in-vitro,

PC,

MIA PaCa-2

-

in-vitro,

PC,

PANC1

-

in-vitro,

PC,

Bxpc-3

TumCG↓, Glycolysis↓, cMyc↓, STAT3↓, TumCP↓, Weight∅, Strength↑, DNAdam↑, Casp3↑, Casp9↑, GLUT1↓, HK2↓, LDHA↓, GlucoseCon↓, lactateProd↓, PPP↓, Ki-67↓, p‑STAT3↓, cachexia↓,

1001-

SIL,

Silibinin down-regulates PD-L1 expression in nasopharyngeal carcinoma by interfering with tumor cell glycolytic metabolism

-

in-vitro,

NA,

NA

0–200µM

100µM@72hr

LMP-1+ NPC tumor cells (C666–1),

TumCG↓, Glycolysis↓, OXPHOS↑, LDHA↓, lactateProd↓, i-citrate↑, Hif1a↓, PD-L1↓,

964-

SIL,

Silibinin inhibits hypoxia-induced HIF-1α-mediated signaling, angiogenesis and lipogenesis in prostate cancer cells: In vitro evidence and in vivo functional imaging and metabolomics

-

vitro+vivo,

Pca,

LNCaP

25,50uM

-

in-vitro,

Pca,

22Rv1

200 mg/kg

mice

TumCP↓, Hif1a↓, NADPH↓, angioG↓, FASN↓, ACC↓,

978-

SIL,

A comprehensive evaluation of the therapeutic potential of silibinin: a ray of hope in cancer treatment

-

Review,

NA,

NA

10uM

200 to 570 μM

PI3K↓, Akt↓, NF-kB↓, Wnt/(β-catenin)↓, MAPK↓, TumCP↓, TumCCA↑, Apoptosis↑, p‑EGFR↓, JAK2↓, STAT5↓, cycD1↓, hTERT↓, AP-1↓, MMP9↓, miR-21↓, miR-155↓, Casp9↑, BID↑, ERK↓, Akt2↓, DNMT1↓, P53↑, survivin↓, Casp3↑, ROS↑,

2410-

SIL,

Autophagy activated by silibinin contributes to glioma cell death via induction of oxidative stress-mediated BNIP3-dependent nuclear translocation of AIF

-

in-vitro,

GBM,

U87MG

-

in-vitro,

GBM,

U251

-

in-vivo,

NA,

NA

nude mice

TumAuto↑, ATP↓, Glycolysis↓, H2O2↑, P53↑, GSH↓, xCT↓, BNIP3↝, MMP↑, mt-ROS↑, mtDam↑, HK2↓, PFKP↓, PKM2↓, TumCG↓,

2306-

SIL,

CUR,

RES,

EA,

Identification of Natural Compounds as Inhibitors of Pyruvate Kinase M2 for Cancer Treatment

-

in-vitro,

BC,

MDA-MB-231

PKM2↓, Dose↝, Dose↝,

3301-

SIL,

Critical review of therapeutic potential of silymarin in cancer: A bioactive polyphenolic flavonoid

-

Review,

Var,

NA

Inflam↓, TumCCA↑, Apoptosis↓, TumMeta↓, TumCG↓, angioG↓, chemoP↑, radioP↑, p‑ERK↓, p‑p38↓, p‑JNK↓, P53↑, Bcl-2↓, Bcl-xL↓, TGF-β↓, MMP2↓, MMP9↓, E-cadherin↑, Wnt↓, Vim↓, VEGF↓, IL6↓, STAT3↓, *ROS↓, IL1β↓, PGE2↓, CDK1↓, CycB↓, survivin↓, Mcl-1↓, Casp3↑, Casp9↑, cMyc↓, COX2↓, Hif1a↓, CXCR4↓, CSCs↓, EMT↓, N-cadherin↓, PCNA↓, cycD1↓, ROS↑, eff↑, eff↑, eff↑, HER2/EBBR2↓,

3282-

SIL,

Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions

-

Review,

NA,

NA

hepatoP↑, AntiCan↑, TumCMig↓, Hif1a↓, selectivity↑, toxicity∅, *antiOx↑, *Inflam↓, *NA↓, TumCCA↑, P21↑, CDK4↓, NF-kB↓, ERK↓, PSA↓, TumCG↓, p27↑, COX2↓, IL1↓, VEGF↓, IGFBP3↑, AR↓, STAT3↓, Telomerase↓, Cyt‑c↑, Casp↑, eff↝, HDAC↓, HATs↑, Zeb1↓, E-cadherin↑, miR-203↑, NHE1↓, MMP2↓, MMP9↓, PGE2↓, Vim↓, Wnt↓, angioG↓, VEGF↓, *TIMP1↓, EMT↓, TGF-β↓, CD44↓, EGFR↓, PDGF↓, *IL8↓, SREBP1↓, MMP↓, ATP↓, uPA↓, PD-L1↓, NOTCH↓, *SIRT1↑, SIRT1↓, CA↓, Ca+2↑, chemoP↑, cardioP↑, Dose↝, Half-Life↝, BioAv↓, BioAv↓, BioAv↓, toxicity↝, Half-Life↓, ROS↓, FAK↓,

3302-

SIL,

Protective effects of silymarin in glioblastoma cancer cells through redox system regulation

-

in-vitro,

GBM,

U87MG

264.6 μM

NRF2↑, HO-1↑, Trx↑, antiOx↑,

3303-

SIL,

Exploring the anti-cancer and antimetastatic effect of Silymarin against lung cancer

-

Review,

Var,

NA

chemoP↑, radioP↑,

3304-

SIL,

Silymarin induces inhibition of growth and apoptosis through modulation of the MAPK signaling pathway in AGS human gastric cancer cells

-

in-vitro,

GC,

AGS

0, 20, 40, 60, 80, 100 and 120 µg/ml for 24 h

-

in-vivo,

NA,

NA

100 mg/kg silymarin injection group mice

BAX↑, p‑JNK↑, p‑p38↑, cl‑PARP↑, Bcl-2↓, p‑ERK↓, TumVol↓, Apoptosis↑, tumCV↓,

3305-

SIL,

Silymarin inhibits proliferation of human breast cancer cells via regulation of the MAPK signaling pathway and induction of apoptosis

-

in-vitro,

BC,

MDA-MB-231

0, 25, 50, 75, 100, 150 or 200 µg/ml silymarin for 24 h

-

in-vitro,

BC,

MCF-7

-

in-vivo,

NA,

NA

mice

TumCP↓, tumCV↓, BAX↑, cl‑PARP↑, Casp9↑, p‑JNK↑, Bcl-2↓, p‑p38↓, p‑ERK↓, *toxicity∅, Dose↝, *hepatoP↑, Inflam↓, AntiCan↑,

3306-

SIL,

Rad,

Radioprotective and radiosensitizing properties of silymarin/silibinin in response to ionizing radiation

-

Review,

Var,

NA

radioP↑, RadioS↑, TumCMig↓, TumCI↓, angioG↓, Apoptosis↑, DNAdam↓, ROS↑, *ROS↓, *Inflam↓,

3307-

SIL,

Flavolignans from Silymarin as Nrf2 Bioactivators and Their Therapeutic Applications

-

Review,

Var,

NA

*NRF2↑, *antiOx↑, *chemoP↑, *Inflam↓, *BioAv↑, eff↑, *NQO1↑, TNF-α↓, IL6↓, *GSH↑, *ROS↓, *MDA↓, eff↑, *hepatoP↑, *GPx↑, *SOD↑, *Catalase↑, *HO-1↑, *neuroP↑,

3308-

SIL,

Structural basis of Nrf2 activation by flavonolignans from silymarin

-

Analysis,

NA,

NA

*antiOx↑, *chemoP↑, *NRF2↑,

3309-

SIL,

Silymarin as a Natural Antioxidant: An Overview of the Current Evidence and Perspectives

-

Review,

NA,

NA

*ROS↓, *IronCh↑, *MMP↑, *NRF2↑, *Inflam↓, *hepatoP↑, *HSPs↑, *Trx↑, *SIRT2↑, *GSH↑, *ROS↑, *NADPH↓, *iNOS↓, *NF-kB↓, *BioAv↓, *Dose↝, *BioAv↑,

3310-

SIL,

Silymarin attenuates paraquat-induced lung injury via Nrf2-mediated pathway in vivo and in vitro

-

in-vitro,

Lung,

A549

Inflam↓, MPO↓, NO↓, iNOS↓, ROS↓, MDA↑, SOD↑, Catalase↑, GPx↑, NRF2↑, HO-1↑, NADPH↑,

3311-

SIL,

Silymarin protects against acrylamide-induced neurotoxicity via Nrf2 signalling in PC12 cells

-

in-vitro,

Nor,

PC12

*antiOx↑, *Inflam↓, AntiCan↑, *ROS↓, *MDA↓, *GSH↓, *NRF2↑, *GPx↑, *GCLC↑, *GCLM↑,

3300-

SIL,

Toward the definition of the mechanism of action of silymarin: activities related to cellular protection from toxic damage induced by chemotherapy

-

Review,

Var,

NA

*ROS↓, *SOD↑, *hepatoP↑, *AST↓, *ALAT↓, *lipid-P↓, *GSH↑, *Catalase↑, *GSTs↑, *GSR↑, *TNF-α↓, *IFN-γ↓, *IL4↓, *IL2↓, *NF-kB↓, *IL10↑, *Inflam↓, COX2↓, Apoptosis↑, ChemoSen↑, PGE2↓, VEGF↓,

3288-

SIL,

Silymarin in cancer therapy: Mechanisms of action, protective roles in chemotherapy-induced toxicity, and nanoformulations

-

Review,

Var,

NA

Inflam↓, lipid-P↓, TumMeta↓, angioG↓, chemoP↑, EMT↓, HDAC↓, HATs↑, MMPs↓, uPA↓, PI3K↓, Akt↓, VEGF↓, CD31↓, Hif1a↓, VEGFR2↓, Raf↓, MEK↓, ERK↓, BIM↓, BAX↑, Bcl-2↓, Bcl-xL↓, Casp↑, MAPK↓, P53↑, LC3II↑, mTOR↓, YAP/TEAD↓, *BioAv↓, MMP↓, Cyt‑c↑, PCNA↓, cMyc↓, cycD1↓, β-catenin/ZEB1↓, survivin↓, APAF1↑, Casp3↑, MDSCs↓, IL10↓, IL2↑, IFN-γ↑, hepatoP↑, cardioP↑, GSH↑, neuroP↑,

3315-

SIL,

Silymarin alleviates docetaxel-induced central and peripheral neurotoxicity by reducing oxidative stress, inflammation and apoptosis in rats

-

in-vivo,

Nor,

NA

rats

neuroP↑, *NRF2↑, *HO-1↑, *lipid-P↓, *GSH↑, *SOD↑, *Catalase↑, *GPx↑, *NF-kB↓, *TNF-α↓, *JNK↓, *Bcl-2↑, *BAX↑,

3299-

SIL,

Silymarin Effect on Mitophagy Pathway in the Human Colon Cancer HT-29 Cells

-

in-vitro,

Colon,

HT29

0 (control), 25, 50, and 100 μ, g/ml of Silymarin for 48

tumCV↓, MMP↓, ROS↑, selectivity↑,

3298-

SIL,

Silibinin, a natural flavonoid, induces autophagy via ROS-dependent mitochondrial dysfunction and loss of ATP involving BNIP3 in human MCF7 breast cancer cells

-

in-vitro,

BC,

MCF-7

LC3II↑, Beclin-1↑, Bcl-2↓, ROS↑, MMP↓, ATP↓, eff↓, BNIP3?, TumAuto↑, eff↑,

3297-

SIL,

Rad,

Studies on radiation sensitization efficacy by silymarin in colon carcinoma cells

-

in-vitro,

CRC,

HCT15

-

in-vitro,

CRC,

RKO

TumCP↓, RadioS↑, TumCCA↑, DNAdam↓, MMP↓, ROS↓, *radioP↑,

3296-

SIL,

Silibinin induces oral cancer cell apoptosis and reactive oxygen species generation by activating the JNK/c-Jun pathway

-

in-vitro,

Oral,

Ca9-22

0, 50, 100, 200 μM silibinin for 48 h

-

in-vivo,

Oral,

YD10B

TumCP↓, TumCCA↑, ROS↑, SOD1↓, SOD2↓, *JNK↑, toxicity?, TumCMig↓, TumCI↓, N-cadherin↓, Vim↓, E-cadherin↑, EMT↓, P53↑, cl‑Casp3↑, cl‑PARP↑, BAX↑, Bcl-2↓, SOD↓,

3295-

SIL,

Hepatoprotective effect of silymarin

-

Review,

NA,

NA

*hepatoP↑, *ROS↓, *GSH↑, *BioAv↝, ERK↓, NF-kB↓, STAT3↓, COX2↓, Inflam↓, IronCh↑, lipid-P↓, ALAT↓, AST↓, TNF-α↓, *α-SMA↓, *SOD↑,

3294-

SIL,

Silymarin: a review on paving the way towards promising pharmacological agent

-

Review,

Nor,

NA

-

Review,

Arthritis,

NA

*hepatoP↑, *Inflam↓, *chemoP↑, *glucose↓, *antiOx↑, *ROS↓, *ACC↓, *FASN↓, *radioP↑, *NF-kB↓, *TGF-β↓, *AST↓, *α-SMA↝, *eff↑, *neuroP↑, eff↑, ROS↓,

3293-

SIL,

Silymarin (milk thistle extract) as a therapeutic agent in gastrointestinal cancer

-

Review,

Var,

NA

hepatoP↑, TumMeta↓, Inflam↓, chemoP↑, radioP↑, Half-Life↝, *GSTs↑, p‑JNK↑, BAX↑, p‑p38↑, cl‑PARP↑, Bcl-2↓, p‑ERK↓, TumVol↓, eff↑, TumCCA↑, STAT3↓, Mcl-1↓, survivin↓, Bcl-xL↓, Casp3↑, Casp9↑, eff↑, CXCR4↓, Dose↝,

3292-

SIL,

Fe,

Anti-tumor activity of silymarin nanoliposomes in combination with iron: In vitro and in vivo study

-

in-vitro,

BC,

4T1

-

in-vivo,

BC,

4T1

mice

*antiOx↑, ROS↑, OS↑, Weight↑, TumVol↓, eff↑, Fenton↑,

3291-

SIL,

Antioxidant effects and mechanism of silymarin in oxidative stress induced cardiovascular diseases

-

Review,

Nor,

NA

*antiOx↑, *ROS↓, *cardioP↑, *BioAv↓, *Half-Life↝, *other↑, IronCh↑,

3324-

SIL,

Silymarin prevents NLRP3 inflammasome activation and protects against intracerebral hemorrhage

*ROS↓, *TAC↑, *NF-kB↓, *IL2↓, *NRF2↑, *HO-1↑, *neuroP↑, *Inflam↓, *NLRP3↓,

3290-

SIL,

A review of therapeutic potentials of milk thistle (Silybum marianum L.) and its main constituent, silymarin, on cancer, and their related patents

-

Analysis,

Var,

NA

hepatoP↑, chemoP↑, *lipid-P↓, *antiOx↑, tumCV↓, TumCMig↓, Apoptosis↑, ROS↑, GSH↓, Bcl-2↓, survivin↓, cycD1↓, NOTCH1↓, BAX↑, NF-kB↓, COX2↓, LOX1↓, iNOS↓, TNF-α↓, IL1↓, Inflam↓, *toxicity↓, CXCR4↓, EGFR↓, ERK↓, MMP↓, Cyt‑c↑, TumCCA↑, RB1↑, P53↑, P21↑, p27↑, cycE↓, CDK4↓, p‑pRB↓, Hif1a↓, cMyc↓, IL1β↓, IFN-γ↓, PCNA↓, PSA↓, CYP1A1↓,

3289-

SIL,

Silymarin: a promising modulator of apoptosis and survival signaling in cancer

-

Review,

Var,

NA

*BioAv↝, *BioAv↓, Fas↑, FasL↑, FADD↑, pro‑Casp8↑, Apoptosis↑, DR5↑, Bcl-2↑, BAX↑, Casp3↑, PI3K↓, Foxm1↓, p‑mTOR↓, p‑P70S6K↓, Hif1a↓, Akt↑, angioG↓, STAT3↓, NF-kB↓, lipid-P↓, eff↑, CDK1↓, survivin↓, CycB↓, Mcl-1↓, Casp9↑, AP-1↓, BioAv↑,

3333-

SIL,

Silymarin attenuated nonalcoholic fatty liver disease through the regulation of endoplasmic reticulum stress proteins GRP78 and XBP-1 in mice

-

in-vivo,

NA,

NA

mice

*GRP78/BiP↓, *XBP-1↓,

3332-

SIL,

Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2

-

in-vitro,

Lung,

A549

*antiOx↑, *hepatoP↑, MMP2↓, uPA↓, TIMP2↑,

3331-

SIL,

The clinical anti-inflammatory effects and underlying mechanisms of silymarin

-

Review,

NA,

NA

*Inflam↓, *NF-kB↓, *NLRP3↓, *COX2↓, *iNOS↓, *neuroP↑, *p‑ERK↓, *p38↓, *MAPK↓, *EGFR↓, *ROS↓, *lipid-P?, *5LO↓,

3330-

SIL,

Mechanistic Insights into the Pharmacological Significance of Silymarin

-

Review,

Var,

NA

*neuroP↑, *hepatoP↑, *cardioP↑, *antiOx↓, *NLRP3↓, *NAD↑, ROS↓, NLRP3↓, TumCMig↓, *COX2↓, *iNOS↓, *MPO↓, *AChE↓, *LDH↓, *Telomerase↓, *Fas↓,

3329-

SIL,

Silymarin regulates the HIF-1 and iNOS expression in the brain and Gills of the hypoxic-reoxygenated rainbow trout (Oncorhynchus mykis)

-

in-vivo,

Nor,

NA

rainbow trout

*NO↓, *MDA↓, *TAC↑, *Hif1a↓, *iNOS↓,

3328-

SIL,

Modulatory effect of silymarin on inflammatory mediators in experimentally induced benign prostatic hyperplasia: emphasis on PTEN, HIF-1α, and NF-κB

-

in-vivo,

BPH,

NA

injected testosterone (3 mg/kg/day, subcutaneously (s.c.)) for 2 weeks.

Rats

*NF-kB↓, *Hif1a↓, *PTEN↑, *Weight↓, *NO↓, *IL6↓, *IL8↓, *COX2↓, *iNOS↓,

3327-

SIL,

Effects of silymarin on HIF‑1α and MDR1 expression in HepG‑2 cells under hypoxia

-

in-vitro,

Liver,

HepG2

SM at 0, 10, 20, and 40 mg/L for 8 h

MDR1↓, Hif1a↓, P-gp↓,

3326-

SIL,

Silymarin suppresses proliferation of human hepatocellular carcinoma cells under hypoxia through downregulation of the HIF-1α/VEGF pathway

-

in-vitro,

Liver,

HepG2

58.46

-

in-vitro,

Liver,

Hep3B

75.13 umol/L

*hepatoP↑, chemoP↑, ChemoSen↑, TumCP↓, TumCMig↓, TumCI↓, Hif1a↓, VEGF↓, angioG↓,

3325-

SIL,

Modulatory effect of silymarin on pulmonary vascular dysfunction through HIF-1α-iNOS following rat lung ischemia-reperfusion injury

-

in-vivo,

Nor,

NA

Rats

*Inflam↓, *ROS↓, *Casp3↑, *Casp9↑, *Hif1a↓, *iNOS↓, *SOD↑, *MDA↓,

3312-

SIL,

Silymarin Alleviates Oxidative Stress and Inflammation Induced by UV and Air Pollution in Human Epidermis and Activates β-Endorphin Release through Cannabinoid Receptor Type 2

-

Human,

Nor,

NA

skin

*antiOx↑, *Inflam↓, *ROS↓, *IL1α↓, *AhR↑, *NRF2↑, *IL8↓,

3323-

SIL,

Anticancer therapeutic potential of silibinin: current trends, scope and relevance

-

Review,

Var,

NA

Inflam↓, angioG↓, antiOx↑, TumMeta↓, TumCP↓, TumCCA↑, TumCD↑, α-SMA↓, p‑Akt↓, p‑STAT3↓, COX2↓, IL6↓, MMP2↓, HIF-1↓, Snail↓, Slug↓, Zeb1↓, NF-kB↓, p‑EGFR↓, JAK2↓, PI3K↓, PD-L1↓, VEGF↓, CDK4↓, CDK2↓, cycD1↓, E2Fs↓,

3322-

SIL,

Therapeutic intervention of silymarin on the migration of non-small cell lung cancer cells is associated with the axis of multiple molecular targets including class 1 HDACs, ZEB1 expression, and restoration of miR-203 and E-cadherin expression

-

in-vitro,

Lung,

A549

0, 5, 10 and 20 µg/mL) for 24 h

-

in-vitro,

Lung,

H1299

-

in-vitro,

Lung,

H460

HDAC↓, HDAC1↓, HDAC2↓, HDAC3↓, HDAC8↓, HATs↑, Zeb1↓, E-cadherin↑, TumCMig↓,

3321-

SIL,

Silymarin (Milk thistle)

-

Review,

AD,

NA

*neuroP↝, *Dose↝, *Half-Life?, *BioAv↝, *cognitive↑, *Aβ↓, *Inflam↓, *OS↑, *memory↑,

3320-

SIL,

Neuroprotective Potential of Silymarin against CNS Disorders: Insight into the Pathways and Molecular Mechanisms of Action

-

Review,

AD,

NA

*hepatoP↑, *neuroP↑, *ROS↓, *β-Amyloid↓, *Inflam↓, *Aβ↓, *NF-kB↓, *TNF-α↓, *TNF-β↓, *iNOS↓, *NO↓, *COX2↓,

3319-

SIL,

Silymarin and neurodegenerative diseases: Therapeutic potential and basic molecular mechanisms

-

Review,

AD,

NA

-

Review,

Park,

NA

-

Review,

Stroke,

NA

*neuroP↑, *ROS↓, *Inflam↓, *Apoptosis↓, *BBB?, *tau↓, *NF-kB↓, *IL1β↓, *TNF-α↓, *IL4↓, *MAPK↓, *memory↑, *cognitive↑, *Aβ↓, *ROS↓, *lipid-P↓, *GSH↑, *MDA↓, *SOD↑, *Catalase↑, *AChE↓, *BChE↓, *p‑ERK↓, *p‑JNK↓, *p‑p38↓, *GutMicro↑, *COX2↓, *iNOS↓, *TLR4↓, *neuroP↑, *Strength↑, *AMPK↑, *MMP↑, *necrosis↓, *NRF2↑, *HO-1↑,

3318-

SIL,

Pharmaceutical prospects of Silymarin for the treatment of neurological patients: an updated insight

-

Review,

AD,

NA

-

Review,

Park,

NA

*hepatoP↑, *neuroP↑, *TLR4↓, *TNF-α↓, *IL1β↓, *NF-kB↓, *memory↑, *cognitive↑, *NRF2↑, *HO-1↑, *ROS↓, *Akt↑, *mTOR↑, *SOD↑, *Catalase↑, *GSH↑, *IL10↑, *IL6↑, *NO↓, *MDA↓, *AChE↓, *MAPK↓,

3317-

SIL,

Unlocking the Neuroprotective Potential of Silymarin: A Promising Ally in Safeguarding the Brain from Alzheimer's Disease and Other Neurological Disorders

-

Review,

NA,

NA

*neuroP↑,

3316-

SIL,

Chemo,

Silymarin Nanoparticles Counteract Cognitive Impairment Induced by Doxorubicin and Cyclophosphamide in Rats; Insights into Mitochondrial Dysfunction and Nrf2/HO-1 Axis

Inflam↓, antiOx↓, neuroP↑, cognitive↑, NRF2↑, HO-1↑, memory↑, AChE↓, Casp3↓,

3314-

SIL,

Silymarin: Unveiling its pharmacological spectrum and therapeutic potential in liver diseases—A comprehensive narrative review

-

Review,

NA,

NA

*antiOx↑, *hepatoP↑, *Half-Life↑, *ROS↓, *GSH↑, *hepatoP↑, *lipid-P↓, *TNF-α↓, *IFN-γ↓, *IL2↓, *IL4↓, *NF-kB↓, *iNOS↓, *OATPs↓, *OCT4↓, *Inflam↓, *PGE2↓, MMPs↓, VEGF↓, angioG↓, STAT3↓, *ALAT↓, *AST↓, Dose↝,

3313-

SIL,

Silymarin attenuates post-weaning bisphenol A-induced renal injury by suppressing ferroptosis and amyloidosis through Kim-1/Nrf2/HO-1 signaling modulation in male Wistar rats

-

in-vivo,

NA,

NA

50-100 mg/kg/day

Twenty-four male Wistar rats

*NRF2↑, *HO-1↑, *creat↓, *BUN↓, *RenoP↑, *MDA↓, *TNF-α↓, *IL1β↓, *Cyt‑c↓, *Casp3↓, *GSTs↓, *GSH↑, *GPx4↑, *SOD↑, *GSR↓, *Ferroptosis↓,

2217-

SK,

Shikonin Inhibits Endoplasmic Reticulum Stress-Induced Apoptosis to Attenuate Renal Ischemia/Reperfusion Injury by Activating the Sirt1/Nrf2/HO-1 Pathway

-

in-vivo,

Nor,

NA

mice

-

in-vitro,

Nor,

HK-2

*ER Stress↓, *SIRT1↑, *NRF2↑, *HO-1↑, *eff↓, *RenoP↑, *GRP78/BiP↓, *CHOP↓, *Casp12↓, *BAX↓, *cl‑Casp3↓,

2364-

SK,

Pyruvate Kinase M2 Mediates Glycolysis Contributes to Psoriasis by Promoting Keratinocyte Proliferation

-

in-vivo,

PSA,

NA

For 2-DG or Shikonin treatment, mice were intraperitoneally injected with 2-DG (500 mg/kg in saline, daily for 5 days) or Shikonin (25 mg/kg in saline/1% DMSO. daily for 5 days).

mice

eff↑, lactateProd↓, PKM2↓,

2363-

SK,

Inhibition of PKM2 by shikonin impedes TGF-β1 expression by repressing histone lactylation to alleviate renal fibrosis

-

in-vivo,

CKD,

NA

mice

PKM2↓, lactateProd↓, TGF-β↓,

2362-

SK,

RIP1 and RIP3 contribute to shikonin-induced glycolysis suppression in glioma cells via increase of intracellular hydrogen peroxide

-

in-vitro,

GBM,

U87MG

-

in-vivo,

GBM,

NA

Rat C6 tumor xenograft in nude mice

-

in-vitro,

GBM,

U251

RIP1↑, RIP3↑, Glycolysis↓, G6PD↓, HK2↓, PKM2↓, H2O2↑, GSH↓, ROS↑,

2361-

SK,

Natural shikonin and acetyl-shikonin improve intestinal microbial and protein composition to alleviate colitis-associated colorectal cancer

-

in-vivo,

CRC,

NA

mice

GutMicro↑, Dose↝, IL1β↓, IL6↓, TNF-α↓, PKM2↓,

2360-

SK,

Shikonin inhibits growth, invasion and glycolysis of nasopharyngeal carcinoma cells through inactivating the phosphatidylinositol 3 kinase/AKT signal pathway

-

in-vitro,

NPC,

HONE1

4 or 8 umol/L

-

in-vitro,

NPC,

SUNE-1

TumCP↓, Apoptosis↑, TumCMig↓, TumCI↓, GlucoseCon↓, lactateProd↓, ATP↓, PKM2↓, PI3K↓, Akt↓, MMP3↓, MMP9↓, TIMP1↑,

2359-

SK,

Regulating lactate-related immunometabolism and EMT reversal for colorectal cancer liver metastases using shikonin targeted delivery

-

in-vivo,

Liver,

NA

mice

TumCG↓, PKM2↓, EMT↓, TGF-β↓, Glycolysis↓, lactateProd↓, ATP↓,

2358-

SK,

SIRT1 improves lactate homeostasis in the brain to alleviate parkinsonism via deacetylation and inhibition of PKM2

-

in-vivo,

Park,

NA

mice

*eff↑, *PKM2↓, *motorD↑, *lactateProd↓,

2357-

SK,

GTPBP4 promotes hepatocellular carcinoma progression and metastasis via the PKM2 dependent glucose metabolism

-

Study,

HCC,

NA

182 patients with HCC undergoing curative hepatectomy

-

in-vivo,

NA,

NA

mouse

AntiTum↑, GTPBP4↓, PKM2↓, lactateProd↓, GlucoseCon↓, Glycolysis↓, E-cadherin↑, TumCG↓,

2356-

SK,

ESM1 enhances fatty acid synthesis and vascular mimicry in ovarian cancer by utilizing the PKM2-dependent warburg effect within the hypoxic tumor microenvironment

-

in-vitro,

Ovarian,

CaOV3

-

in-vitro,

Ovarian,

OV90

-

in-vivo,

NA,

NA

(1 mg/kg) by intraperitoneal injection once every 3 days

mice

PKM2↓, Glycolysis↓, FASN↓, lactateProd↓, Warburg↓, TumCG↓, VM↓,

2355-

SK,

Pharmacological properties and derivatives of shikonin-A review in recent years

-

Review,

Var,

NA

AntiCan↑, TumCP↓, TumCMig↓, Apoptosis↑, TumAuto↑, Necroptosis↑, ROS↑, TrxR1↓, PKM2↓, RIP1↓, RIP3↓, Src↓, FAK↓, PI3K↓, Akt↓, mTOR↓, GRP58↓, MMPs↓, ATF2↓, cl‑PARP↑, Casp3↑, p‑p38↑, p‑JNK↑, p‑ERK↓,

2354-

SK,

PKM2-dependent glycolysis promotes NLRP3 and AIM2 inflammasome activation

-

in-vivo,

Sepsis,

NA

mice

PKM2↓, *PKM2↓, *IL1β↓, *IL18↓, *HMGB1↓, *Casp1↓, *NLRP3↓, *AIM2↓, *p‑eIF2α↓, *Sepsis↓,

2225-

SK,

Shikonin protects skin cells against oxidative stress and cellular dysfunction induced by fine particulate matter

-

in-vitro,

Nor,

HaCaT

*antiOx↑, *ROS↓, *GSH↑, *GCLC↑, *GSS↑, *Akt↑, *NRF2↑,

2232-

SK,

Shikonin Induces Autophagy and Apoptosis in Esophageal Cancer EC9706 Cells by Regulating the AMPK/mTOR/ULK Axis

-

in-vitro,

ESCC,

EC9706

2.26 ± 0.12 µM

tumCV↓, TumCMig↓, TumCI↓, TumAuto↑, Apoptosis↑, Bcl-2↓, BAX↑, cl‑Casp3↑, cl‑Casp8↑, cl‑PARP↑, AMPK↑, mTOR↑, TumVol↓, OS↑, LC3I↑,

2233-

SK,

Clinical trial on the effects of shikonin mixture on later stage lung cancer

-

Trial,

Lung,

NA

19 cases of later-stage lung cancer

TumVol↓, Remission↑, OS↑, QoL↑, Weight↑, *toxicity∅,

2234-

SK,

Shikonin Suppresses Cell Tumorigenesis in Gastric Cancer Associated with the Inhibition of c-Myc and Yap-1

-

in-vitro,

GC,

NA

TumCP↓, TumCI↓, TumCMig↓, cMyc↓, YAP/TEAD↓,

2231-

SK,

Shikonin Exerts Cytotoxic Effects in Human Colon Cancers by Inducing Apoptotic Cell Death via the Endoplasmic Reticulum and Mitochondria-Mediated Pathways

-

in-vitro,

CRC,

SNU-407

3 µM after 48 h

Apoptosis↑, ER Stress↑, PERK↑, eIF2α↑, CHOP↑, mt-Ca+2↑, MMP↓, Bcl-2↓, Casp3↑, Casp9↑, ERK↑, JNK↑, p38↓,

2230-

SK,

Shikonin induces ROS-based mitochondria-mediated apoptosis in colon cancer

-

in-vitro,

CRC,

HCT116

-

in-vivo,

NA,

NA

TumCG↓, Bcl-2↓, ROS↑, Bcl-xL↓, MMP↓, Casp↑, selectivity↑, cycD1↓, TumCCA↑, eff↓,

2229-

SK,

Shikonin induces apoptosis and prosurvival autophagy in human melanoma A375 cells via ROS-mediated ER stress and p38 pathways

-

in-vitro,

Melanoma,

A375

Apoptosis↑, TumAuto↑, TumCP↓, TumCCA↑, P21↑, cycD1↓, ER Stress↑, p‑eIF2α↑, CHOP↑, cl‑Casp3↑, p38↑, LC3B-II↑, Beclin-1↑, ROS↑, eff↓,

2228-

SK,

Shikonin induced Apoptosis Mediated by Endoplasmic Reticulum Stress in Colorectal Cancer Cells

-

in-vitro,

CRC,

HCT116

0.25, 0.5, 1, 1.5, 2, 2.5 and 3 μM

-

in-vitro,

CRC,

HCT15

-

in-vivo,

NA,

NA

intraperitoneal injection (3 mg/kg, 3 times per week

mouse

Apoptosis↑, Bcl-2↓, Casp3↑, Casp9↑, cl‑PARP↑, GRP78/BiP↑, PERK↑, eIF2α↑, ATF4↑, CHOP↑, JNK↑, eff↓, ER Stress↑, ROS↑, TumCG↓,

2227-

SK,

Shikonin induces mitochondria-mediated apoptosis and enhances chemotherapeutic sensitivity of gastric cancer through reactive oxygen species

-

in-vitro,

GC,

BGC-823

13.35uM

-

in-vitro,

GC,

SGC-7901

9.63uM

-

in-vitro,

Nor,

GES-1

>20 μM

selectivity↑, TumCP↓, TumCD↑, ROS↑, MMP↓, Casp↑, Cyt‑c↑, Endon↑, AIF↑, eff↓, ChemoSen↑, TumCCA↑, GSH/GSSG↓, lipid-P↑,

2226-

SK,

Shikonin, a Chinese plant-derived naphthoquinone, induces apoptosis in hepatocellular carcinoma cells through reactive oxygen species: A potential new treatment for hepatocellular carcinoma

-

in-vitro,

HCC,

HUH7

-

in-vitro,

HCC,

Bel-7402

selectivity↑, ROS↑, eff↓, Akt↓, RIP1↓, NF-kB↓,

2224-

SK,

Shikonin induces apoptosis and autophagy via downregulation of pyrroline-5-carboxylate reductase1 in hepatocellular carcinoma cells

-

in-vitro,

HCC,

SMMC-7721 cell

-

in-vitro,

HCC,

HUH7

-

in-vitro,

HCC,

HepG2

PYCR1↓, PI3K↓, Akt↓, mTOR↓, eff↑,

2223-

SK,

Non-metabolic enzyme function of PKM2 in hepatocellular carcinoma: A review

-

in-vitro,

Var,

NA

PKM2↓,

2222-

SK,

The anti-tumor effect of shikonin on osteosarcoma by inducing RIP1 and RIP3 dependent necroptosis

-

in-vitro,

OS,

U2OS

-

in-vitro,

OS,

143B

-

in-vivo,

NA,

NA

mice

Necroptosis↑, RIP1↑, RIP3↑, OS↑, P53↑,

2221-

SK,

Shikonin Induces Apoptosis, Necrosis, and Premature Senescence of Human A549 Lung Cancer Cells through Upregulation of p53 Expression

-

in-vitro,

Lung,

A549

0.5, 1.0, 2.5, 5.0, or 10.0 μg/mL)

3.52ug/mL

Apoptosis↑, TumCP↓, tumCV↓, Necroptosis↑, P53↑, ROS↑, NF-kB↓,

2220-

SK,

Shikonin Alleviates Gentamicin-Induced Renal Injury in Rats by Targeting Renal Endocytosis, SIRT1/Nrf2/HO-1, TLR-4/NF-κB/MAPK, and PI3K/Akt Cascades

-

in-vivo,

Nor,

NA

Nine-week-old Wistar rats were administered 6.25, 12.5, and 25 mg/kg/day shikonin orally, one hour after the i.p. injection of 100 mg/kg/day gentamicin for seven days

*RenoP↑, *ROS↓, *SIRT1↓, *NRF2↑, *HO-1↑, *GSH↑, *TAC↑, *SOD↑, *MDA↓, *NO↓, *iNOS↓, *NHE3↑, *PI3K↑,

2219-

SK,

Shikonin induces apoptosis of HaCaT cells via the mitochondrial, Erk and Akt pathways

-

in-vitro,

Nor,

HaCaT

(0–4 µM) for 24 and 48 h

6.34uM@24h

*MMP↓, *ROS↑, *Casp3↑, *TumCG↓,

2218-

SK,

Shikonin Alleviates Endothelial Cell Injury Induced by ox-LDL via AMPK/Nrf2/HO-1 Signaling Pathway

-

in-vitro,

Nor,

HUVECs

*Dose↝, *Apoptosis↓, *Casp3↓, *Bcl-2↑, *Inflam↓, *VCAM-1↓, *ICAM-1↓, *E-sel↓, *ROS↓, *SOD↑, *AMPK↑, *NRF2↑, *HO-1↑, *TNF-α↓, *IL1β↓, *IL6↓,

2216-

SK,

Shikonin upregulates the expression of drug-metabolizing enzymes and drug transporters in primary rat hepatocytes

-

in-vivo,

Nor,

NA

0-2 μM

Sprague-Dawley rats

*NRF2↑, *AhR↑, *CYP1A1↑, *CYP1A2↑, *CYP2C6↑, *CYP2D1↑, *CYP3A2↑, *NQO1↑,

2417-

SK,

Shikonin inhibits the Warburg effect, cell proliferation, invasion and migration by downregulating PFKFB2 expression in lung cancer

-

in-vitro,

Lung,

A549

-

in-vitro,

Lung,

H446

TumCP↓, TumCMig↓, TumCI↓, GlucoseCon↓, lactateProd↓, PFKFB2↓, Warburg↓, GLUT1∅, LDHA∅, PKM2∅, GLUT3∅, PDH∅,

2370-

SK,

The role of pyruvate kinase M2 in anticancer therapeutic treatments

-

Review,

Var,

NA

Glycolysis↓, PKM2↓, EGFR↓, PI3K↓, p‑Akt↓, Hif1a↓,

2415-

SK,

Shikonin induces programmed death of fibroblast synovial cells in rheumatoid arthritis by inhibiting energy pathways

-

in-vivo,

Arthritis,

NA

paw swelling in rat arthritic tissues

Apoptosis?, TumAuto↑, ROS↑, ATP↓, Glycolysis↓, PI3K↓, Akt↓, mTOR↓, *Apoptosis↓, *Inflam↓, *TNF-α↓, *IL6↓, *IL8↓, *IL10↓, *IL17↓, *hepatoP↑, *RenoP↑, PKM2↓, GLUT1↓, HK2↓,

2416-

SK,

Shikonin induces cell death by inhibiting glycolysis in human testicular cancer I-10 and seminoma TCAM-2 cells

-

in-vitro,

Testi,

TCAM-2

MMP↓, ROS↑, lactateProd↓, Bcl-2↓, cl‑Casp3↓, PKM2↓, GLUT1↓, HK2↓, LC3B↑,

2418-

SK,

Experimental Study of Hepatocellular Carcinoma Treatment by Shikonin Through Regulating PKM2

-

in-vitro,

HCC,

SMMC-7721 cell

-

in-vitro,

HCC,

HUH7

-

in-vitro,

HCC,

HepG2

tumCV↓, GlucoseCon↓, lactateProd↓, ChemoSen↑, PKM2↓, Glycolysis↓,

2419-

SK,

Regulation of glycolysis and the Warburg effect in wound healing

-

in-vivo,

Nor,

NA

Glycolysis↓, GLUT1↓, GLUT3↓, HK2↓, HK1↓, PFK1↓, PFK2↓, PKM2↓, lactateProd↓, GlucoseCon↓,

2420-

SK,

Pyruvate kinase M2 regulates mitochondrial homeostasis in cisplatin-induced acute kidney injury

-

in-vivo,

AKI,

NA

PKM2↓, other↝,

2470-

SK,

PKM2/PDK1 dual-targeted shikonin derivatives restore the sensitivity of EGFR-mutated NSCLC cells to gefitinib by remodeling glucose metabolism

-

in-vitro,

Lung,

H1299

PKM2↓, PDK1↓, Glycolysis↓,

2469-

SK,

Shikonin induces the apoptosis and pyroptosis of EGFR-T790M-mutant drug-resistant non-small cell lung cancer cells via the degradation of cyclooxygenase-2

-

in-vitro,

Lung,

H1975

0-8uM

Apoptosis↑, Pyro↑, Casp↑, cl‑PARP↑, GSDME↑, ROS↑, COX2↓, PDK1↓, Akt↓, ERK↓, eff↓, eff↓, eff↑,

3050-

SK,

Systemic administration of Shikonin ameliorates cognitive impairment and neuron damage in NPSLE mice

-

in-vivo,

Nor,

NA

mice

*Inflam↓, *neuroP↑, *cognitive↑,

3040-

SK,

Pharmacological Properties of Shikonin – A Review of Literature since 2002

-

Review,

Var,

NA

-

Review,

IBD,

NA

-

Review,

Stroke,

NA

*Half-Life↝, *BioAv↓, *BioAv↑, *BioAv↑, *Inflam↓, *TNF-α↓, *other↑, *MPO↓, *COX2↓, *NF-kB↑, *STAT3↑, *antiOx↑, *ROS↓, *neuroP↑, *SOD↑, *Catalase↑, *GPx↑, *Bcl-2↑, *BAX↓, cardioP↑, AntiCan↑, NF-kB↓, ROS↑, PKM2↓, TumCCA↑, Necroptosis↑, Apoptosis↑, DNAdam↑, MMP↓, Cyt‑c↑, LDH↝,

3041-

SK,

Promising Nanomedicines of Shikonin for Cancer Therapy

-

Review,

Var,

NA

Glycolysis↓, TAMS↝, BioAv↓, Half-Life↝, P21↑, ERK↓, ROS↑, GSH↓, MMP↓, TrxR↓, MMP13↓, MMP2↓, MMP9↓, SIRT2↑, Hif1a↓, PKM2↓, TumCP↓, TumMeta↓, TumCI↓,

3042-

SK,

The protective effects of Shikonin on lipopolysaccharide/D -galactosamine-induced acute liver injury via inhibiting MAPK and NF-kB and activating Nrf2/HO-1 signaling pathways

-

in-vivo,

Nor,

NA

mice

*TNF-α↓, *IL1β↓, *IL6↓, *IFN-γ↓, *ALAT↓, *AST↓, *MPO↓, *ROS↓, *JNK↓, *ERK↓, *p38↓, *NF-kB↓, *p‑IKKα↓, *SOD↑, *GSH↑, *HO-1↑, *NRF2↑, *hepatoP↑,

3043-

SK,

Shikonin Induces Apoptosis by Inhibiting Phosphorylation of IGF-1 Receptor in Myeloma Cells.

-

in-vitro,

Melanoma,

RPMI-8226

IGF-1↓, Apoptosis↑, TumCCA↑, MMP↓, Casp3↑, P53↑, BAX↑, Mcl-1↓, EGFR↓, Src↑, KDR/FLK-1↓, p‑IGF-1↓, PI3K↓, Akt↓,

3044-

SK,

Shikonin Inhibits Non-Small-Cell Lung Cancer H1299 Cell Growth through Survivin Signaling Pathway

-

in-vitro,

Lung,

H1299

-

in-vitro,

Lung,

H460

TumCP↓, survivin↓, TumCCA↓, CDK2↓, CDK4↓, XIAP↓, Casp3↑, Casp9↑, cycD1↓, cycE↓,

3045-

SK,

Cutting off the fuel supply to calcium pumps in pancreatic cancer cells: role of pyruvate kinase-M2 (PKM2)

-

in-vitro,

PC,

MIA PaCa-2

ECAR↓, Glycolysis↓, ATP↓, PKM2↓, TumCMig↓, Ca+2↑, GlucoseCon↓, lactateProd↓, MMP↓, ROS↑,

3046-

SK,

Shikonin attenuates lung cancer cell adhesion to extracellular matrix and metastasis by inhibiting integrin β1 expression and the ERK1/2 signaling pathway

-

in-vitro,

Lung,

A549

TumCP↓, TumCI↓, TumCMig↓, p‑ERK↓, ITGB1↓,

3047-

SK,

Shikonin suppresses colon cancer cell growth and exerts synergistic effects by regulating ADAM17 and the IL-6/STAT3 signaling pathway

-

in-vitro,

CRC,

HCT116

-

in-vitro,

CRC,

SW48

TumCG↓, p‑STAT3↓, ADAM17↓, Apoptosis↑, Casp3↑, cl‑PARP↑, cycD1↓, cycE↓, TumCCA↑, JAK1?, p‑JAK1↓, p‑JAK2↓, p‑eIF2α↑, eff↓, ROS↑, IL6↓,

3048-

SK,

Shikonin inhibits triple-negative breast cancer-cell metastasis by reversing the epithelial-to-mesenchymal transition via glycogen synthase kinase 3β-regulated suppression of β-catenin signaling

-

in-vitro,

BC,

MDA-MB-231

-

in-vitro,

BC,

4T1

-

in-vitro,

Nor,

MCF12A

-

in-vivo,

NA,

NA

tumCV↓, selectivity↑, EMT↓, TumCMig↓, TumCI↓, E-cadherin↑, N-cadherin↓, Vim↓, Snail↓, β-catenin/ZEB1↓, GSK‐3β↑,

3049-

SK,

Shikonin Attenuates Chronic Cerebral Hypoperfusion-Induced Cognitive Impairment by Inhibiting Apoptosis via PTEN/Akt/CREB/BDNF Signaling

-

in-vivo,

Nor,

NA

Fifty-two rats

-

NA,

Stroke,

NA

*neuroP↑, *p‑PTEN↓, *p‑Akt↑, *Bcl-2↑, *BAX↓, *cognitive↑,

3051-

SK,

Resveratrol mediates its anti-cancer effects by Nrf2 signaling pathway activation

-

Review,

Var,

NA

Nrf1↑, Apoptosis↑, TumCP↓, eff⇅, chemoP↑, eff↑, VCAM-1↓, Hif1a↓,

1280-

SK,

Shikonin Induces Apoptotic Cell Death via Regulation of p53 and Nrf2 in AGS Human Stomach Carcinoma Cells

-

in-vitro,

GC,

AGS

35–250 nM

ROS↑, Casp3↑, P53↑, NRF2↓,

1281-

SK,

Enhancement of NK cells proliferation and function by Shikonin

-

in-vivo,

Colon,

Caco-2

mice

Perforin↑, GranB↑, p‑ERK↑, p‑Akt↑, NK cell↑, eff↝,

1284-

SK,

Shikonin induces ferroptosis in multiple myeloma via GOT1-mediated ferritinophagy

-

in-vitro,

Melanoma,

RPMI-8226

-

in-vitro,

Melanoma,

U266

Ferroptosis↑, LDH↓, ROS↑, Iron↑, lipid-P↑, ATP↓, HMGB1↓, GPx4↓, MDA↑, SOD↓, GSH↓,

1312-

SK,

Shikonin induces apoptosis through reactive oxygen species/extracellular signal-regulated kinase pathway in osteosarcoma cells

-

in-vitro,

OS,

143B

0-8uM

2.01microM

ROS↑, p‑ERK↑, Bcl-2↓, cl‑PARP↑, Apoptosis↑, TumCCA↑, Bcl-2↑, proCasp3↓,

1346-

SK,

An Oxidative Stress Mechanism of Shikonin in Human Glioma Cells

-

in-vitro,

GBM,

U87MG

2, 8, 50 and 100 μM

-

in-vitro,

GBM,

Hs683

NRF2↓, ROS↑, Apoptosis↑, Cyt‑c↑, GSH↓, MMP↓, P53↑, HO-1⇅,

1345-

SK,

The Critical Role of Redox Homeostasis in Shikonin-Induced HL-60 Cell Differentiation via Unique Modulation of the Nrf2/ARE Pathway

-

in-vitro,

AML,

HL-60

100 ng/mL

CD14↑, CD11b↑, ROS↑, GSH↓, GSH/GSSG↓, GPx↑, Catalase↓, Diff↑,

1344-

SK,

Novel multiple apoptotic mechanism of shikonin in human glioma cells

-

in-vitro,

GBM,

U87MG

-

in-vitro,

GBM,

Hs683

-

in-vitro,

GBM,

M059K

ROS↑, GSH↓, MMP↓, P53↑, cl‑PARP↑, Catalase↓, SOD1↑, Bcl-2↓, BAX↑, eff↓,

1343-

SK,

Simple ROS-responsive micelles loaded Shikonin for efficient ovarian cancer targeting therapy by disrupting intracellular redox homeostasis

-

in-vitro,

Ovarian,

A2780S

-

in-vivo,

NA,

A2780S

mice

*BioAv↓, ROS↑, GSH↓, TumCG↓,

1342-

SK,

RIP1 and RIP3 contribute to shikonin-induced DNA double-strand breaks in glioma cells via increase of intracellular reactive oxygen species

-

in-vitro,

GBM,

NA

-

in-vivo,

NA,

NA

mice

RIP1↑, RIP3↑, DNAdam↑, ROS↑, GSH↓,

2011-

SK,

Shikonin Attenuates Acetaminophen-Induced Hepatotoxicity by Upregulation of Nrf2 through Akt/GSK3β Signaling

-

in-vitro,

Nor,

HL7702

L-02

-

in-vivo,

Nor,

NA

mice

*NRF2↑, *hepatoP↑, *ALAT↓, *AST↓, *MPO↓, *ROS↓, *GSH↑,

2010-

SK,

Shikonin inhibits gefitinib-resistant non-small cell lung cancer by inhibiting TrxR and activating the EGFR proteasomal degradation pathway

-

in-vitro,

Lung,

H1975

2.6uM

-

in-vitro,

Lung,

H1650

3.9uM

-

in-vitro,

Nor,

CCD19

12.2uM

Normal cells, shows selectivity

EGFR↓, selectivity↑, Casp↑, PARP↑, Apoptosis↑, ROS↑, eff↓, selectivity↑,

2009-

SK,

Necroptosis inhibits autophagy by regulating the formation of RIP3/p62/Keap1 complex in shikonin-induced ROS dependent cell death of human bladder cancer

-

in-vitro,

Bladder,

NA

TumCG↓, selectivity↑, *toxicity∅, Necroptosis↑, ROS↑, p62↑, Keap1↑, *NRF2↑, eff↑,

2008-

SK,

Cisplatin,

Enhancement of cisplatin-induced colon cancer cells apoptosis by shikonin, a natural inducer of ROS in vitro and in vivo

-

in-vitro,

CRC,

HCT116

-

in-vivo,

NA,

NA

mice

ChemoSen↑, selectivity↑, i-ROS↑, DNAdam↑, MMP↓, TumCCA↑, eff↓, *toxicity↓,

2007-

SK,

Shikonin Directly Targets Mitochondria and Causes Mitochondrial Dysfunction in Cancer Cells

-

in-vitro,

lymphoma,

U937

<10uM

-

in-vitro,

BC,

MCF-7

-

in-vitro,

BC,

SkBr3

-

in-vitro,

CRC,

HCT116

-

in-vitro,

OS,

U2OS

-

NA,

Nor,

RPE-1

RPE-1-GFP-EB3 cells were treated with 25 μM shikonin

tumCV↓, selectivity↑, Dose↝, other↑, MMP↓, ROS↑, DNAdam↑, Ca+2↑, Casp9↑, Cyt‑c↑, *toxicity↓,

2191-

SK,

Shikonin Suppresses Skin Carcinogenesis via Inhibiting Cell Proliferation

-

in-vitro,

Melanoma,

NA

PKM2↓, ATF4↓, CDK4↓, COX2↓, MAPK↓,

2192-

SK,

Shikonin Inhibits Tumor Growth of ESCC by suppressing PKM2 mediated Aerobic Glycolysis and STAT3 Phosphorylation

-

in-vitro,

ESCC,

KYSE-510

-

in-vitro,

ESCC,

Eca109

19.9 µM

-

in-vivo,

NA,

NA

TumCP↓, Glycolysis↓, GlucoseCon↓, lactateProd↓, PKM2↓, p‑PKM2↓, p‑STAT3↓, GLUT1↓, HK2↓, TumW↓,

2190-

SK,

Shikonin exerts antitumor activity by causing mitochondrial dysfunction in hepatocellular carcinoma through PKM2-AMPK-PGC1α signaling pathway

-

in-vitro,

HCC,

HCCLM3

TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, MMP↓, ROS↑, OCR↓, ATP↓, PKM2↓,

2189-

SK,

PKM2 inhibitor shikonin suppresses TPA-induced mitochondrial malfunction and proliferation of skin epidermal JB6 cells

-

in-vitro,

Melanoma,

NA

PKM2↓, chemoP↑, eff↝, lactateProd↓, ROS↑, *ROS?, *PKM2↓,

2188-

SK,

Molecular mechanism of shikonin inhibiting tumor growth and potential application in cancer treatment

-

Review,

Var,

NA

ROS↑, EGFR↓, PI3K↓, Akt↓, angioG↓, Apoptosis↑, Necroptosis↑, GSH↓, Ca+2↓, MMP↓, ERK↓, p38↑, proCasp3↑, eff↓, VEGF↓, FOXO3↑, EGR1↑, SIRT1↑, RIP1↑, RIP3↑, BioAv↓, NF-kB↓, Half-Life↓,

2187-

SK,

VitK3,

Shikonin, vitamin K3 and vitamin K5 inhibit multiple glycolytic enzymes in MCF-7 cells

-

in-vitro,

BC,

MCF-7

Glycolysis↓, PKM2↓,

2186-

SK,

Shikonin differentially regulates glucose metabolism via PKM2 and HIF1α to overcome apoptosis in a refractory HCC cell line

-

in-vitro,

HCC,

HepG2

-

in-vitro,

HCC,

HCCLM3

Glycolysis↓, PKM2↓, Apoptosis↑, ROS↑, OXPHOS⇅, eff↓,

2185-

SK,

Shikonin Inhibits Tumor Growth in Mice by Suppressing Pyruvate Kinase M2-mediated Aerobic Glycolysis

-

in-vitro,

Lung,

LLC1

10 μM

-

in-vitro,

Melanoma,

B16-BL6

-

in-vivo,

NA,

NA

mouse

Glycolysis↓, GlucoseCon↓, lactateProd↓, PKM2↓, selectivity↑, Warburg↓, TumVol↓, TumW↓,

2184-

SK,

Cisplatin,

PKM2 Inhibitor Shikonin Overcomes the Cisplatin Resistance in Bladder Cancer by Inducing Necroptosis

-

in-vitro,

CRC,

T24

PKM2↓, ChemoSen↑, Necroptosis↑,

2183-

SK,

Shikonin Inhibites Migration and Invasion of Thyroid Cancer Cells by Downregulating DNMT1

-

in-vitro,

Thyroid,

TPC-1

0.744 μg/mL

TumCMig↓, TumCI↓, PTEN↑, DNMT1↓,

2182-

SK,

Cisplatin,

Shikonin inhibited glycolysis and sensitized cisplatin treatment in non-small cell lung cancer cells via the exosomal pyruvate kinase M2 pathway

-

in-vitro,

Lung,

A549

2 µM, 4 µM, 6 µM, and 8 µM

5.739 µM

-

in-vitro,

Lung,

PC9

6.302 µM

-

in-vivo,

NA,

NA

mice

tumCV↓, TumCP↓, TumCI↓, TumCMig↓, Apoptosis↑, PKM2↓, Glycolysis↓, GlucoseCon↓, lactateProd↓, ChemoSen↑, TumVol↓, TumW↓, GLUT1↓,

2181-

SK,

Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2

-

in-vitro,

BC,

MCF-7

0-20uM for 1 h

0.3 mM,

-

in-vitro,

Lung,

A549

-

in-vitro,

Cerv,

HeLa

Glycolysis↓, lactateProd↓, GlucoseCon↓, PKM2↓, LDH∅,

2201-

SK,

Shikonin promotes ferroptosis in HaCaT cells through Nrf2 and alleviates imiquimod-induced psoriasis in mice

-

in-vitro,

PSA,

HaCaT

-

in-vivo,

NA,

NA

mice

*eff↑, *IL6↓, *IL17↓, *TNF-α↓, *lipid-P↑, *NRF2↓, *HO-1↝, *NCOA4↝, *GPx4↓, *Ferroptosis↓, *Inflam↓, *ROS↓, *Iron↓,

2214-

SK,

Shikonin Attenuates Cochlear Spiral Ganglion Neuron Degeneration by Activating Nrf2-ARE Signaling Pathway

-

in-vitro,

Nor,

NA

0-10uM

*NRF2↑, *HO-1↑, *NQO1↑, *antiOx↑, *neuroP↑, *ROS↓, *MDA↓, *SOD↑, GSH↑,

2213-

SK,

Shikonin attenuates cerebral ischemia/reperfusion injury via inhibiting NOD2/RIP2/NF-κB-mediated microglia polarization and neuroinflammation

-

in-vivo,

Stroke,

NA

MCAO/R rats

*neuroP↑, *Inflam↓, *iNOS↓, *TNF-α↓, *IL1β↓, *IL6↓, *ARG↑, *TGF-β↑, *IL10↑, *NF-kB↓, *eff↓,

2212-

SK,

Shikonin Exerts an Antileukemia Effect against FLT3-ITD Mutated Acute Myeloid Leukemia Cells via Targeting FLT3 and Its Downstream Pathways

-

in-vitro,

AML,

NA

FLT3↓, NF-kB↓, miR-155↓, Diff↑, TumCG↓,

2211-

SK,

Shikonin mitigates ovariectomy-induced bone loss and RANKL-induced osteoclastogenesis via TRAF6-mediated signaling pathways

-

in-vivo,

ostP,

NA

mice, RANKL-induced

*BMD↑, *p‑NF-kB↓, *p‑p50↓, *p‑p65↓, *p‑ERK↓, *p‑cJun↓, *p‑p38↓,

2210-

SK,

Shikonin inhibits the cell viability, adhesion, invasion and migration of the human gastric cancer cell line MGC-803 via the Toll-like receptor 2/nuclear factor-kappa B pathway

-

in-vitro,

BC,

MGC803

1.854 μm

TumCA↓, TumCI↓, TumCMig↓, MMP2↓, MMP7↓, TLR2↓, p65↓, NF-kB↓, eff↑, ROS↑,

2209-

SK,

Shikonin inhibits tumor invasion via down-regulation of NF-κB-mediated MMP-9 expression in human ACC-M cells

-

in-vitro,

adrenal,

ACC-M

(0, 2.5, 5, 10 μM) for 24 h

MMP9↓, NF-kB↓, IKKα↓,

2203-

SK,

Shikonin suppresses small cell lung cancer growth via inducing ATF3-mediated ferroptosis to promote ROS accumulation

-

in-vitro,

Lung,

NA

TumCP↓, Apoptosis↓, TumCMig↓, TumCI↓, Ferroptosis↑, ERK↓, GPx4↓, 4-HNE↑, ROS↑, GSH↓, ATF3↑, HDAC1↓, ac‑Histones↑,

2202-

SK,

Enhancing Tumor Therapy of Fe(III)-Shikonin Supramolecular Nanomedicine via Triple Ferroptosis Amplification

-

in-vitro,

Var,

NA

Iron↑, Ferroptosis↑, pH↝, H2O2↑, ROS↑, Fenton↑, GSH↓, GPx4↓, lipid-P↑,

2215-

SK,

doxoR,

Shikonin alleviates doxorubicin-induced cardiotoxicity via Mst1/Nrf2 pathway in mice

-

in-vivo,

Nor,

NA

mice

*cardioP↑, *ROS↓, *Inflam↓, *Mst1↓, *NRF2↑, *eff↓, *antiOx↑, *SOD↑, *GSH↑, *TNF-α↓, BAX↓, Bcl-2↑,

2200-

SK,

Shikonin inhibits the growth of anaplastic thyroid carcinoma cells by promoting ferroptosis and inhibiting glycolysis

-

in-vitro,

Thyroid,

CAL-62

1, 3 and 5 μM SKN for 24 h

-

in-vitro,

Thyroid,

8505C

NF-kB↓, GPx4↓, TrxR1↓, PKM2↓, GLUT1↓, Glycolysis↓, Ferroptosis↑, GlucoseCon↓, lactateProd↓, ROS↑,

2199-

SK,

Induction of Ferroptosis by Shikonin in Gastric Cancer via the DLEU1/mTOR/GPX4 Axis

-

in-vitro,

GC,

NA

ROS↑, lipid-P↑, Iron↑, MDA↑, GPx4↓, Ferritin↓, DLEU1↓, mTOR↓, Ferroptosis↑,

2198-

SK,

Shikonin suppresses proliferation of osteosarcoma cells by inducing ferroptosis through promoting Nrf2 ubiquitination and inhibiting the xCT/GPX4 regulatory axis

-

in-vitro,

OS,

MG63

0.75 uM, 1.5 uM and 3 uM

1.432 uM

-

in-vitro,

OS,

143B

1.638 uM

TumCP↓, TumCCA↑, Ferroptosis↑, Iron↑, ROS↑, lipid-P↑, MDA↑, mtDam↑, NRF2↓, xCT↓, GPx4↓, GSH/GSSG↓, Keap1↑,

2197-

SK,

Shikonin derivatives for cancer prevention and therapy

-

Review,

Var,

NA

ROS↑, Ca+2↑, BAX↑, Bcl-2↓, MMP9↓, NF-kB↓, PKM2↓, Hif1a↓, NRF2↓, P53↑, DNMT1↓, MDR1↓, COX2↓, VEGF↓, EMT↓, MMP7↓, MMP13↓, uPA↓, RIP1↑, RIP3↑, Casp3↑, Casp7↑, Casp9↑, P21↓, DFF45↓, TRAIL↑, PTEN↑, mTOR↓, AR↓, FAK↓, Src↓, Myc↓, RadioS↑,

2196-

SK,

Research progress in mechanism of anticancer action of shikonin targeting reactive oxygen species

-

Review,

Var,

NA

*ALAT↓, *AST↓, *Inflam?, *EMT↑, ROS?, TrxR1↓, PERK↑, eIF2α↑, ATF4↑, CHOP↑, IRE1↑, JNK↑, eff↝, DR5↑, Glycolysis↓, PKM2↓, ChemoSen↑, GPx4↓, HO-1↑,

2195-

SK,

Shikonin induces ferroptosis in osteosarcomas through the mitochondrial ROS-regulated HIF-1α/HO-1 axis

-

in-vitro,

OS,

NA

TumCP↓, Ferroptosis↓, Hif1a↑, HO-1↑, Iron↑, ROS↑, GSH/GSSG↓, GPx4↓,

2194-

SK,

Efficacy of Shikonin against Esophageal Cancer Cells and its possible mechanisms in vitro and in vivo

-

in-vitro,

ESCC,

Eca109

-

in-vitro,

ESCC,

EC9706

-

in-vivo,

NA,

NA

(20μg/dose/day)

mice

tumCV↓, TumCCA↑, Apoptosis↑, EGFR↓, PI3K↓, Hif1a↓, PKM2↓, cycD1↓, AntiTum↑,

2193-

SK,

Shikonin Suppresses Lymphangiogenesis via NF-κB/HIF-1α Axis Inhibition

-

in-vitro,

Nor,

HMVEC-dLy

*NF-kB↓, *Hif1a↓, other↓,

1050-

SK,

Shikonin improves the effectiveness of PD-1 blockade in colorectal cancer by enhancing immunogenicity via Hsp70 upregulation

-

in-vitro,

Colon,

CT26

HSP70/HSPA5↑, ROS↑, PKM2↓,

977-

SK,

A novel antiestrogen agent Shikonin inhibits estrogen-dependent gene transcription in human breast cancer cells

-

in-vitro,

BC,

T47D

SK (1-5uM) for 24 h

-

in-vitro,

BC,

MDA-MB-231

-

in-vitro,

BC,

MCF-7

-

in-vitro,

Nor,

HMEC

TumCG↓, ERα↓, selectivity↑, *toxicity↓,

1073-

SK,

Chemo,

Natural Compound Shikonin Is a Novel PAK1 Inhibitor and Enhances Efficacy of Chemotherapy against Pancreatic Cancer Cells

-

in-vitro,

PC,

PANC1

7.252 ± 0.054 μM

-

in-vitro,

PC,

Bxpc-3

PAK1↓, TumCP↓, Apoptosis↑, ChemoSen↑, ROS↑,

965-

SK,

Shikonin suppresses proliferation and induces cell cycle arrest through the inhibition of hypoxia-inducible factor-1α signaling

-

in-vitro,

CRC,

HCT116

(0.3 to 30 uM)

shikonin did not adversely affect cell viability up to a concentration of 10 uM

-

in-vitro,

CRC,

SW-620

Hif1a↓, ROS↓, mTOR↓, p70S6↓, 4E-BP1↓, eIF2α↓, TumCCA↑, TumCP↓, Half-Life↝,

1049-

SK,

Shikonin inhibits immune checkpoint PD-L1 expression on macrophage in sepsis by modulating PKM2

-

in-vivo,

NA,

NA

sepsis mice

TNF-α↓, IL6↓, IFN-γ↓, IL1β↓, PD-L1↓, p‑PKM2↓,

1068-

SM,

Danshen Improves Survival of Patients With Breast Cancer and Dihydroisotanshinone I Induces Ferroptosis and Apoptosis of Breast Cancer Cells

-

in-vitro,

BC,

MCF-7

5-10uM

-

in-vitro,

BC,

MDA-MB-231

-

in-vivo,

BC,

NA

30 mg/kg, intraperitoneal injection

mouse

-

Human,

BC,

NA

average clinical dose of danshen is 3 g per day for clinical Chinese medicine

TumCG↓, Ferroptosis↑, GPx4↓, TumVol↓, OS↑, GSH/GSSG↓,

1191-

SM,

Salvia miltiorrhiza extract inhibits TPA‑induced MMP‑9 expression and invasion through the MAPK/AP‑1 signaling pathw

-

in-vitro,

BC,

MCF-7

Inflam↓, MMP9↓, TumCI↓, AP-1↓, lipidLev↓,

1133-

SM,

Salvianolic Acid A, a Component of Salvia miltiorrhiza, Attenuates Endothelial-Mesenchymal Transition of HPAECs Induced by Hypoxia

-

in-vitro,

Nor,

HPAECs

*ROS↓, *p‑Smad1↑, *p‑SMAD5↑, *SMAD2↓, *SMAD3↓, *p‑ERK↓, *p‑Cofilin↓,

1195-

SM,

Salvia miltiorrhiza polysaccharide activates T Lymphocytes of cancer patients through activation of TLRs mediated -MAPK and -NF-κB signaling pathways

-

in-vitro,

Lung,

A549

-

in-vitro,

Liver,

HepG2

-

in-vitro,

CRC,

HCT116

T-Cell↑, TumCP∅, IL4↑, IL6↑, IFN-γ↑, TLR4↑, TLR1↑, TLR2↑, p‑JNK↑, p‑ERK↑, IKKα↑,

1194-

SM,

Salvia miltiorrhiza protects against diabetic nephropathy through metabolome regulation and wnt/β-catenin and TGF-β signaling inhibition

-

in-vivo,

Diabetic,

NA

intraperitoneal injection of 30 mg/kg STZ each day for three days

rats

β-catenin/ZEB1↓, TGF-β↓,

1192-

SM,

Abietane diterpenes from Salvia miltiorrhiza inhibit the activation of hypoxia-inducible factor-1

-

in-vitro,

GC,

AGS

0.34, 3.36, 1.58, and 2.05 microM on AGS cells

-

in-vitro,

Liver,

HepG3

0.28, 3.18, 1.36, and 2.29 microM on Hep3B cells

Hif1a↓, VEGF↓,

1193-

SM,

Cryptotanshinone from the Salvia miltiorrhiza Bunge Attenuates Ethanol-Induced Liver Injury by Activation of AMPK/SIRT1 and Nrf2 Signaling Pathways

-

in-vivo,

Alcohol,

NA

mice

-

in-vitro,

Liver,

HepG2

*p‑AMPK↑, *SIRT1↑, *NRF2↑, *CYP2E1↓, *lipoGen↓, *ROS↓, *Inflam↓,

1291-

SM,

Tanshinone IIA inhibits human breast cancer cells through increased Bax to Bcl-xL ratios

-

in-vitro,

BC,

MDA-MB-231

TumCP↓, TumCCA↑, BAX↑, Bcl-2↓,

2205-

SNP,

Potential protective efficacy of biogenic silver nanoparticles synthesised from earthworm extract in a septic mice model

-

in-vivo,

Nor,

NA

mice, septic

*Dose↝, *eff↑, *RenoP↑, *antiOx↑, *MDA↓, *NO↓, *hepatoP↑, *toxicity↝, *GSH↑, *SOD↑, *GSTs↑, *Catalase↑,

2208-

SNP,

Sepsis diagnosis and treatment using nanomaterials

-

Review,

NA,

NA

Bacteria↓,

2207-

SNP,

TQ,

Protective effects of Nigella sativa L. seeds aqueous extract-based silver nanoparticles on sepsis-induced damages in rats

-

in-vivo,

Nor,

NA

Rats

*eff↑, *RenoP↑, *hepatoP↑, *MDA↓, *SOD↑, *GSH↑, *TNF-α↓, *IL1β↓,

2206-

SNP,

RES,

ENHANCED EFFICACY OF RESVERATROL-LOADED SILVER NANOPARTICLE IN ATTENUATING SEPSIS-INDUCED ACUTE LIVER INJURY: MODULATION OF INFLAMMATION, OXIDATIVE STRESS, AND SIRT1 ACTIVATION

-

in-vivo,

Nor,

NA

Rats

*hepatoP↑, *Inflam↓, *NF-kB↓, *VEGF↓, *SIRT1↑, *ROS↓, *Dose↝, *Catalase↑, *MDA↓, *MPO↓, *NO↓, *ALAT↓, *AST↓, *antiOx↑,

1406-

SNP,

The antioxidant effects of silver, gold, and zinc oxide nanoparticles on male mice in in vivo condition

-

in-vivo,

Nor,

NA

AgNPs at 500, 250, and 125 ppm 15 days

mice

*ROS↓, *GPx↑, *Catalase↑, *ROS↑,

1903-

SNP,

Novel Silver Complexes Based on Phosphanes and Ester Derivatives of Bis(pyrazol-1-yl)acetate Ligands Targeting TrxR: New Promising Chemotherapeutic Tools Relevant to SCLC Managemen

-

in-vitro,

Lung,

U1285

2uM, 24hr

TrxR↓, eff↝, ROS↑,

1906-

SNP,

GoldNP,

Cu,

Current Progresses in Metal-based Anticancer Complexes as Mammalian TrxR Inhibitors

-

Review,

Var,

NA

TrxR↓, eff↓, eff↓,

1905-

SNP,

Evaluation of the effect of silver and silver nanoparticles on the function of selenoproteins using an in-vitro model of the fish intestine: The cell line RTgutGC

-

in-vivo,

Nor,

NA

fish

*TrxR↓, *ROS∅, GPx↑,

1902-

SNP,

Modulation of the mechanism of action of antibacterial silver N-heterocyclic carbene complexes by variation of the halide ligand

-

in-vitro,

NA,

NA

0.03–0.12 μM

bacterial

TrxR↓, GSR↓, GSH↓,

1907-

SNP,

GoldNP,

Cu,

In vitro antitumour activity of water soluble Cu(I), Ag(I) and Au(I) complexes supported by hydrophilic alkyl phosphine ligands

-

in-vitro,

Lung,

A549

-

in-vitro,

BC,

MCF-7

-

in-vitro,

Melanoma,

A375

-

in-vitro,

Colon,

HCT15

-

in-vitro,

Cerv,

HeLa

TrxR↓, eff↓, eff↓, other∅,

1908-

SNP,

Exposure to Silver Nanoparticles Inhibits Selenoprotein Synthesis and the Activity of Thioredoxin Reductase

-

in-vitro,

Lung,

A549

TrxR↓, TrxR1↓, ROS↑, ER Stress↑, TumCP↓, selenoP↓,

1909-

SNP,

The Antibacterial Drug Candidate SBC3 is a Potent Inhibitor of Bacterial Thioredoxin Reductase

-

in-vivo,

Nor,

NA

Bacteria

TrxR↓,

1594-

SNP,

Citrate,

Silver Citrate Nanoparticles Inhibit PMA-Induced TNFα Expression via Deactivation of NF-κB Activity in Human Cancer Cell-Lines, MCF-7

-

in-vitro,

BC,

MCF-7

TNF-α↓, NF-kB↓, antiOx↑, TumCP↓,

2539-

SNP,

SDT,

Combined effect of silver nanoparticles and therapeutical ultrasound on ovarian carcinoma cells A2780

-

in-vitro,

Melanoma,

A2780S

tumCV↓, sonoP↑, BioEnh↑,

2538-

SNP,

SDT,

Z,

Dual-functional silver nanoparticle-enhanced ZnO nanorods for improved reactive oxygen species generation and cancer treatment

-

Study,

Var,

NA

-

vitro+vivo,

NA,

NA

mice

ROS↑, eff↑, eff↑, TumCP↓, toxicity↓,

2834-

SNP,

Gluc,

Electrochemical oxidation of glucose on silver nanoparticle-modified composite electrodes

-

Study,

NA,

NA

Dose?,

2835-

SNP,

Gluc,

Carbohydrate functionalization of silver nanoparticles modulates cytotoxicity and cellular uptake

-

in-vitro,

Liver,

HepG2

Dose↝, eff↑, ROS↑, eff↝, eff↑, eff↝, eff↑, eff↝,

2836-

SNP,

Gluc,

Glucose capped silver nanoparticles induce cell cycle arrest in HeLa cells

-

in-vitro,

Cerv,

HeLa

eff↝, TumCCA↑, eff↑, eff↑, ROS↑, GSH↓, SOD↓, lipid-P↑, LDH↑,

2837-

SNP,

Trojan-Horse Mechanism in the Cellular Uptake of Silver Nanoparticles Verified by Direct Intra- and Extracellular Silver Speciation Analysis

-

in-vitro,

NA,

NA

eff↑,

2288-

SNP,

Silver Nanoparticle-Mediated Cellular Responses in Various Cell Lines: An in Vitro Model

-

Review,

Var,

NA

*ROS↑, Akt↓, ERK↓, DNAdam↑, Ca+2↑, ROS↑, MMP↓, Cyt‑c↑, TumCCA↑, DNAdam↑, Apoptosis↑, P53↑, p‑ERK↑, ER Stress↑, cl‑ATF6↑, GRP78/BiP↑, CHOP↑, UPR↑,

2287-

SNP,

Silver nanoparticles induce endothelial cytotoxicity through ROS-mediated mitochondria-lysosome damage and autophagy perturbation: The protective role of N-acetylcysteine

-

in-vitro,

Nor,

HUVECs

*TumCP↓, *ROS↑, *eff↓, *MDA↑, *GSH↓, *MMP↓, *ATP↓, *LC3II↑, *p62↑, *Bcl-2↓, *BAX↑, *Casp3↑,

2286-

SNP,

Short-term changes in intracellular ROS localisation after the silver nanoparticles exposure depending on particle size

-

in-vitro,

Nor,

3T3

, we used AgNPs-70 and AgNPs-1 as well as AgNO3 as a source of Ag+

*eff↑, *mt-ROS↑, *eff↑,

887-

SNP,

Antibacterial potential of silver nanoparticles against isolated urinary tract infectious bacterial pathogens

-

in-vitro,

UTI,

NA

Bacteria↓,

888-

SNP,

Antibacterial Effects of Silver Nanoparticles on the Bacterial Strains Isolated from Catheterized Urinary Tract Infection Cases

-

in-vivo,

UTI,

NA

Bacteria↓,

335-

SNP,

PDT,

Biogenic Silver Nanoparticles for Targeted Cancer Therapy and Enhancing Photodynamic Therapy

-

Review,

NA,

NA

ROS↑, GSH↓, GPx↑, Catalase↓, SOD↓, p38↑, BAX↑, Bcl-2↓,

333-

SNP,

HPT,

Enhancement effect of cytotoxicity response of silver nanoparticles combined with thermotherapy on C6 rat glioma cells

-

in-vivo,

GBM,

NA

rat

OS↑,

336-

SNP,

PDT,

Photodynamic ability of silver nanoparticles in inducing cytotoxic effects in breast and lung cancer cell lines

-

in-vitro,

BC,

MCF-7

Apoptosis↑,

337-

SNP,

immuno,

Silver nanoparticle induced immunogenic cell death can improve immunotherapy

-

Review,

NA,

NA

PD-L1↓,

338-

SNP,

Biogenic silver nanoparticles: In vitro and in vivo antitumor activity in bladder cancer

-

vitro+vivo,

Bladder,

5637

mice

TumCD↑, Apoptosis↑, TumCMig↓, TumCP↓,

339-

SNP,

Cancer cell specific cytotoxic potential of the silver nanoparticles synthesized using the endophytic fungus, Penicillium citrinum CGJ-C2

-

in-vitro,

BC,

MCF-7

-

in-vitro,

Melanoma,

A431

-

in-vitro,

HCC,

HepG2

TumCD↑,

340-

SNP,

Screening bioactivities of Caesalpinia pulcherrima L. swartz and cytotoxicity of extract synthesized silver nanoparticles on HCT116 cell line

-

in-vitro,

CRC,

HCT116

18ug

TumCD↑,

341-

SNP,

Bioprospecting a native silver-resistant Bacillus safensis strain for green synthesis and subsequent antibacterial and anticancer activities of silver nanoparticles

-

in-vitro,

Liver,

HepG2

TumCD↑, ROS↑,

342-

SNP,

Silver nanoparticles; a new hope in cancer therapy?

-

Review,

NA,

NA

ROS↑, DNAdam↑, Apoptosis↑, mtDam↑,

343-

SNP,

Silver nanoparticles of different sizes induce a mixed type of programmed cell death in human pancreatic ductal adenocarcinoma

-

in-vitro,

PC,

PANC1

3.19 or 1.67 ug/mL

BAX↑, Bcl-2↓, P53↑, TumAuto↑,

344-

SNP,

Cytotoxicity and ROS production of manufactured silver nanoparticles of different sizes in hepatoma and leukemia cells

-

in-vitro,

Liver,

HepG2

ROS↑, GSH↓,

345-

SNP,

Antitumor activity of silver nanoparticles in Dalton’s lymphoma ascites tumor model

-

vitro+vivo,

lymphoma,

NA

mice

OS↑, ascitic↓,

346-

SNP,

RSQ,

Investigating Silver Nanoparticles and Resiquimod as a Local Melanoma Treatment

-

in-vivo,

Melanoma,

SK-MEL-28

AgNP (2 mg/kg) and RSQ (25 mg/kg) administration routes used were peri- and intratumora

mice

-

in-vivo,

Melanoma,

WM35

ROS↑, Ca+2↝, Casp3↑, Casp8↑, Casp9↑, CD4+↑, CD8+↑, tumCV↓, eff↓, *toxicity↓,

347-

SNP,

The Role of Silver Nanoparticles in the Diagnosis and Treatment of Cancer: Are There Any Perspectives for the Future?

-

Review,

NA,

NA

ROS↑, Apoptosis↑, ER Stress↑,

348-

SNP,

Induction of p53 mediated mitochondrial apoptosis and cell cycle arrest in human breast cancer cells by plant mediated synthesis of silver nanoparticles from Bergenia ligulata (Whole plant)

-

in-vitro,

BC,

MCF-7

Apoptosis↑, ROS↑, MMP↓, P53↑, BAX↑, cl‑Casp3↑,

349-

SNP,

Insight into the molecular mechanism, cytotoxic, and anticancer activities of phyto-reduced silver nanoparticles in MCF-7 breast cancer cell lines

-

in-vitro,

BC,

MCF-7

Apoptosis↑, ROS↑, CellMemb↑,

350-

SNP,

Cytotoxic and Apoptotic Effects of Green Synthesized Silver Nanoparticles via Reactive Oxygen Species-Mediated Mitochondrial Pathway in Human Breast Cancer Cells

-

in-vitro,

BC,

MCF-7

40ug/mL

ROS↑, MMP↓, P53↑, BAX↑, Casp3↑, Casp9↑, Bcl-2↓,

351-

SNP,

Study of antitumor activity in breast cell lines using silver nanoparticles produced by yeast

-

in-vitro,

BC,

MCF-7

5ug/mL

-

in-vitro,

BC,

T47D

Casp9↑, Casp3↑, Casp7↑, Bcl-2↓,

352-

SNP,

Synthesis of silver nanoparticles (Ag NPs) for anticancer activities (MCF 7 breast and A549 lung cell lines) of the crude extract of Syzygium aromaticum

-

in-vitro,

BC,

MCF-7

TumCD↑,

353-

SNP,

The mechanism of cell death induced by silver nanoparticles is distinct from silver cations

-

in-vitro,

BC,

SUM159

TNBC

lipid-P↑, H2O2↑, ROS↑, Apoptosis↑,

354-

SNP,

Silver nanoparticles induce SH-SY5Y cell apoptosis via endoplasmic reticulum- and mitochondrial pathways that lengthen endoplasmic reticulum-mitochondria contact sites and alter inositol-3-phosphate receptor function

-

in-vitro,

neuroblastoma,

SH-SY5Y

Ca2+ overload and disrupted homeostasis in the mitochondria triggered apoptotic cell death.

TumCD↑, ER Stress↑, GRP78/BiP↑, p‑PERK↑, CHOP↑, Ca+2↑, XBP-1↑, p‑IRE1↑,

355-

SNP,

Cytotoxicity and Genotoxicity of Biogenic Silver Nanoparticles in A549 and BEAS-2B Cell Lines

-

in-vitro,

Lung,

A549

20–28 μg/ml

-

in-vitro,

NA,

BEAS-2B

12–35 μg/ml

normal cells

ROS↑, DNAdam↑, Apoptosis↑,

356-

SNP,

MF,

Anticancer and antibacterial potentials induced post short-term exposure to electromagnetic field and silver nanoparticles and related pathological and genetic alterations: in vitro study

-

in-vitro,

BC,

MCF-7

10 µM/ml + 1mT,2hr

likely 50-60Hz and 1mT

-

in-vitro,

Bladder,

HTB-22

4uM/ml

calculated IC50 value of AgNPs was 4.15 ± 0.20 μM/ml

Apoptosis↑, P53↑, iNOS↑, NF-kB↑, Bcl-2↓, ROS↑, SOD↑, TumCCA↑, eff↑, Catalase↑, other↑,

322-

SNP,

Cisplatin,

Heterogeneous Responses of Ovarian Cancer Cells to Silver Nanoparticles as a Single Agent and in Combination with Cisplatin

-

in-vitro,

Ovarian,

A2780S

25nm AgNPs capped with polyvinylpyrrolidone (PVP

15ug/mL

IC50: 7.9ug/mL : 3.1uM for combination treatment

-

in-vitro,

Ovarian,

SKOV3

-

in-vitro,

Ovarian,

OVCAR-3

745ug/mL

less sensitive to AgNPs

ROS↑, DNAdam↑, GSH/GSSG↓,

305-

SNP,

Activity and pharmacology of homemade silver nanoparticles in refractory metastatic head and neck squamous cell cancer

-

Case Report,

HNSCC,

NA

9-15ppm/120mL/d

home made (fresh) 7nm

OS↑,

306-

SNP,

Cancer Therapy by Silver Nanoparticles: Fiction or Reality?

-

Analysis,

NA,

NA

EPR↝, ROS↑, IL1↑, IL8↑, ER Stress↑, NA↑,

309-

SNP,

Interference of silver, gold, and iron oxide nanoparticles on epidermal growth factor signal transduction in epithelial cells

-

in-vitro,

NA,

A431

10nm

ROS↑, Akt↓, p‑ERK↓,

312-

SNP,

wortm,

Inhibition of autophagy enhances the anticancer activity of silver nanoparticles

-

vitro+vivo,

NA,

HeLa

10 μg/mL(10ppm)

39.25 μg/mL

APA↑, p62↓, PIK3CA↑, TumVol↓,

316-

SNP,

Endoplasmic reticulum stress: major player in size-dependent inhibition of P-glycoprotein by silver nanoparticles in multidrug-resistant breast cancer cells

-

in-vitro,

BC,

MCF-7

75nm

GRP78/BiP↑, ER Stress↑, ROS↑, mtDam↑,

317-

SNP,

Autophagic effects and mechanisms of silver nanoparticles in renal cells under low dose exposure

-

in-vitro,

Kidney,

HEK293

TumAuto↑, p62↑,

318-

SNP,

Silver nanoparticles regulate autophagy through lysosome injury and cell hypoxia in prostate cancer cells

-

in-vitro,

Pca,

PC3

lysoM↓, lysosome↓, AMPKα↑, TumAuto↑, mTOR↑,

319-

SNP,

Endoplasmic reticulum stress signaling is involved in silver nanoparticles-induced apoptosis

Apoptosis↑, Ca+2↑, ER Stress↑, PERK↑, IRE1↑, cl‑ATF6↑,

320-

SNP,

Silver nanoparticles induce endoplasmatic reticulum stress response in zebrafish

-

vitro+vivo,

NA,

HUH7

also zebrafish liver cells

ROS↑, ER Stress↑, TNF-α↑,

321-

SNP,

I-131 doping of silver nanoparticles platform for tumor theranosis guided drug delivery

-

in-vivo,

NA,

NA

mice

other↑,

334-

SNP,

Silver-Based Nanoparticles Induce Apoptosis in Human Colon Cancer Cells Mediated Through P53

-

in-vitro,

Colon,

HCT116

Bax:Bcl2↑, P53↑, P21↑, Casp3↑, Casp8↑, Casp9↑, Akt↓, NF-kB↓, DNAdam↑,

324-

SNP,

CPT,

Silver Nanoparticles Potentiates Cytotoxicity and Apoptotic Potential of Camptothecin in Human Cervical Cancer Cells

-

in-vitro,

Cerv,

HeLa

ROS↑, Casp3↑, Casp9↑, Casp6↑, GSH↓, SOD↓, GPx↓, MMP↓, P53↑, P21↑, Cyt‑c↑, BID↑, BAX↑, Bcl-2↓, Bcl-xL↓, Akt↓, Raf↓, ERK↓, MAP2K1/MEK1↓, JNK↑, p38↑,

325-

SNP,

Silver nanoparticles modulate ABC transporter activity and enhance chemotherapy in multidrug resistant cancer

Apoptosis↑, ABC↓,

326-

SNP,

TSA,

Modulating chromatin structure and DNA accessibility by deacetylase inhibition enhances the anti-cancer activity of silver nanoparticles

-

in-vitro,

Cerv,

HeLa

Apoptosis↑, ChrMod↝, eff↑,

327-

SNP,

MS-275,

Combination Effect of Silver Nanoparticles and Histone Deacetylases Inhibitor in Human Alveolar Basal Epithelial Cells

-

in-vitro,

Lung,

A549

1uM,1uM

Apoptosis↑, ROS↑, LDH↓, TNF-α↑, mtDam↑, TumAuto↑, Casp3↑, Casp9↑, DNAdam↑,

328-

SNP,

Rad,

Silver nanoparticles outperform gold nanoparticles in radiosensitizing U251 cells in vitro and in an intracranial mouse model of glioma

-

vitro+vivo,

GBM,

U251

75.9 μg/mL

Apoptosis↑, TumAuto↑,

329-

SNP,

Rad,

Enhancement of radiotherapy efficacy by silver nanoparticles in hypoxic glioma cells

-

in-vitro,

GBM,

U251

Apoptosis↑, TumAuto↑,

330-

SNP,

Rad,

Reactive oxygen species acts as executor in radiation enhancement and autophagy inducing by AgNPs

-

in-vitro,

GBM,

U251

TumAuto↑, ROS↑,

331-

SNP,

Rad,

Silver nanoparticles: a novel radiation sensitizer for glioma?

-

vitro+vivo,

GBM,

NA

rats

OS↑,

332-

SNP,

Rad,

Enhancement of Radiosensitization by Silver Nanoparticles Functionalized with Polyethylene Glycol and Aptamer As1411 for Glioma Irradiation Therapy

-

in-vivo,

GBM,

NA

mice

OS↑,

386-

SNP,

Tam,

Synergistic anticancer effects and reduced genotoxicity of silver nanoparticles and tamoxifen in breast cancer cells

-

in-vitro,

BC,

MCF-7

35uM(AgNP)+20uM(Tam)

-

in-vitro,

BC,

MDA-MB-231

P53↑, BAX↑, Bcl-2↓, Casp3↑, DNAdam↑, TumCCA↑,

396-

SNP,

Systemic Evaluation of Mechanism of Cytotoxicity in Human Colon Cancer HCT-116 Cells of Silver Nanoparticles Synthesized Using Marine Algae Ulva lactuca Extract

-

in-vitro,

Colon,

HCT116

P53↑, BAX↑, P21↑, Bcl-2↓,

380-

SNP,

QC,

CA,

Chit,

Quercetin- and caffeic acid-functionalized chitosan-capped colloidal silver nanoparticles: one-pot synthesis, characterization, and anticancer and antibacterial activities

-

in-vitro,

MG,

U118MG

TumCG↓,

381-

SNP,

Silver Nanoparticles Exert Apoptotic Activity in Bladder Cancer 5637 Cells Through Alteration of Bax/Bcl-2 Genes Expression

-

in-vitro,

Bladder,

5637

51.12 µg/mL

more toxic with smaller NPs (this was 30nm)

ROS↑, BAX↑, Bcl-2↓, Casp3↑, Casp7↑, Apoptosis↑,

382-

SNP,

Investigation the apoptotic effect of silver nanoparticles (Ag-NPs) on MDA-MB 231 breast cancer epithelial cells via signaling pathways

-

in-vitro,

BC,

MDA-MB-231

Apoptosis↑, BAX↑, Bcl-2↓, P53↑, PTEN↑, hTERT↓, p‑ERK↓, cycD1↓,

383-

SNP,

In vitro and in vivo evaluation of anti-tumorigenesis potential of nano silver for gastric cancer cells

-

in-vitro,

GC,

MKN45

22.4 µg/mL

Ki-67↓, TumCP↓, CD34↓, BAX↑,

384-

SNP,

Dual functions of silver nanoparticles in F9 teratocarcinoma stem cells, a suitable model for evaluating cytotoxicity- and differentiation-mediated cancer therapy

-

in-vitro,

Testi,

F9

LDH↓, ROS↑, mtDam↑, DNAdam↑, P53↑, P21↑, BAX↑, Casp3↑, Bcl-2↓, Casp9↑, Nanog↓, OCT4↓,

403-

SNP,

RF,

Synergetic effects of silver and gold nanoparticles in the presence of radiofrequency radiation on human kidney cells

-

in-vitro,

NA,

HNK

40 μM

normal kidney cells

Apoptosis↝,

402-

SNP,

MF,

Anticancer and antibacterial potentials induced post short-term exposure to electromagnetic field and silver nanoparticles and related pathological and genetic alterations: in vitro study

-

in-vitro,

BC,

MCF-7

10 µM/ml+EMF(1mT)

4.15 μM/ml for AgNPs

P53↑, iNOS↑, NF-kB↑, Bcl-2↓, miR-125b↓, ROS↑, SOD↑,

400-

SNP,

MF,

Polyvinyl Alcohol Capped Silver Nanostructures for Fortified Apoptotic Potential Against Human Laryngeal Carcinoma Cells Hep-2 Using Extremely-Low Frequency Electromagnetic Field

-

in-vitro,

Laryn,

HEp2

50mT/30mins

3.29 0.4 mol/mL

6x improvement when LEMF added (50mT/15mins)

TumCP↓, Casp3↑, P53↑, Beclin-1↑, TumAuto↑, GSR↑, ROS↑, MDA↑, ROS↑, SIRT1↑, Ca+2↑, Endon↑, DNAdam↑, Apoptosis↑, NF-kB↓,

399-

SNP,

SIL,

Cytotoxic potentials of silibinin assisted silver nanoparticles on human colorectal HT-29 cancer cells

-

in-vitro,

CRC,

HT-29

8 ng/mL

P53↑,

398-

SNP,

Silver nanoparticles induced testicular damage targeting NQO1 and APE1 dysregulation, apoptosis via Bax/Bcl-2 pathway, fibrosis via TGF-β/α-SMA upregulation in rats

-

in-vivo,

Testi,

NA

rats

Bcl-2↓, Casp3↑, GSH↓, MDA↑, NO↑, H2O2↑, SOD↓,

397-

SNP,

GEM,

Silver nanoparticles enhance the apoptotic potential of gemcitabine in human ovarian cancer cells: combination therapy for effective cancer treatment

-

in-vitro,

Ovarian,

A2780S

50 nM GEM, 50 nM AgNPs

6nm

P53↑, P21↑, BAX↑, Bak↑, Cyt‑c↑, Casp3↑, Casp9↑, Bcl-2↓, ROS↑, MMP↓,

358-

SNP,

Preparation of triangular silver nanoparticles and their biological effects in the treatment of ovarian cancer

-

vitro+vivo,

Ovarian,

SKOV3

mice

TumCCA↑, ROS↑, Casp3↑, TumCG↓, cycD1↓,

395-

SNP,

The apoptotic and genomic studies on A549 cell line induced by silver nitrate

-

in-vitro,

Lung,

A549

13.5uM@72hr

BAX↑, MMP↓, NA↑,

394-

SNP,

Anticancer activity of Moringa oleifera mediated silver nanoparticles on human cervical carcinoma cells by apoptosis induction

-

in-vitro,

Cerv,

HeLa

ROS↑,

393-

SNP,

Green synthesized plant-based silver nanoparticles: therapeutic prospective for anticancer and antiviral activity

-

in-vitro,

NA,

HCT116

mtDam↑, ROS↑, TumCCA↑, Casp3↑, BAX↑, Bcl-2↓, P53↑,

392-

SNP,

Biogenic silver nanoparticles synthesized from Piper longum fruit extract inhibit HIF-1α/VEGF mediated angiogenesis in prostate cancer cells

VEGF↓, HIF-1↓,

391-

SNP,

Silver nanoparticles inhibit VEGF-and IL-1β-induced vascular permeability via Src dependent pathway in porcine retinal endothelial cells

VEGF↓, IL1↓,

390-

SNP,

Anti-cancerous effect of albumin coated silver nanoparticles on MDA-MB 231 human breast cancer cell line

-

in-vitro,

BC,

MDA-MB-231

5 μM

IC50 is 30x higher for normal white blood cells

-

in-vivo,

BC,

NA

mice

ROS↑, TumVol↓,

389-

SNP,

Citrate,

Silver Citrate Nanoparticles Inhibit PMA-Induced TNFα Expression via Deactivation of NF-κB Activity in Human Cancer Cell-Lines, MCF-7

-

in-vitro,

BC,

MCF-7

TNF-α↓, NF-kB↓,

388-

SNP,

Apoptotic efficacy of multifaceted biosynthesized silver nanoparticles on human adenocarcinoma cells

-

in-vitro,

BC,

MCF-7

5 and 10 µg/mL

ROS↑, Casp3↑, BAX↑, P53↑,

387-

SNP,

Silver nanoparticles induce mitochondria-dependent apoptosis and late non-canonical autophagy in HT-29 colon cancer cells

-

in-vitro,

Colon,

HT-29

33.45 μg/mL

Cyt‑c↑, P53↑, BAX↑, Casp3↑, Casp9↑, Casp12↑, Beclin-1↑, CHOP↑, LC3s↑, XBP-1↑,

385-

SNP,

Probiotic-derived silver nanoparticles target mTOR/MMP-9/BCL-2/dependent AMPK activation for hepatic cancer treatment

-

in-vitro,

Hepat,

HepG2

4.217 µg/ml

-

in-vitro,

Hepat,

WI38

154.1 µg/ml

healthy cells

TNF-α↑, IL33↑, mTOR↓, MMP9↓, Bcl-2↓, ROS↑, Apoptosis↑,

378-

SNP,

Antitumor efficacy of silver nanoparticles reduced with β-D-glucose as neoadjuvant therapy to prevent tumor relapse in a mouse model of breast cancer

-

ex-vivo,

BC,

4T1

8.1 μg/mL

TumVol↓, TumMeta↓, Ki-67↓,

357-

SNP,

Hypoxia-mediated autophagic flux inhibits silver nanoparticle-triggered apoptosis in human lung cancer cells

-

in-vitro,

Lung,

A549

-

in-vitro,

Lung,

L132

mtDam↑, ROS↑, Hif1a↑, LC3s↑, p62↑, eff↓,

359-

SNP,

Anti-cancer & anti-metastasis properties of bioorganic-capped silver nanoparticles fabricated from Juniperus chinensis extract against lung cancer cells

-

in-vitro,

Lung,

A549

9.87ug/ml

-

in-vitro,

Nor,

HEK293

111.3ug/ml

normal cells

Casp3↑, Casp9↑, P53↑, ROS↑, MMP2↓, MMP9↓, TumCCA↑, *toxicity↓, TumCMig↓, TumCI↓,

360-

SNP,

Moringa,

Cytotoxic and Genotoxic Evaluation of Biosynthesized Silver Nanoparticles Using Moringa oleifera on MCF-7 and HUVEC Cell Lines

-

in-vitro,

BC,

MCF-7

5ug/mL

-

in-vitro,

BC,

HUVECs

not significantly affected

DNAdam↑,

361-

SNP,

Annona muricata assisted biogenic synthesis of silver nanoparticles regulates cell cycle arrest in NSCLC cell lines

-

in-vitro,

Lung,

A549

80 ± 6.3 nm as average size

6 µg/ml

Apoptosis↑, Casp↑, TumCCA↑,

362-

SNP,

Comparative and Mechanistic Study on the Anticancer Activity of Quinacrine-Based Silver and Gold Hybrid Nanoparticles in Head and Neck Cancer

-

vitro+vivo,

SCC,

SCC9

0.5ug/mL

DNAdam↑, TumVol↓,

363-

SNP,

Silver nanoparticles induce oxidative cell damage in human liver cells through inhibition of reduced glutathione and induction of mitochondria-involved apoptosis

ROS↑, lipid-P↑, Apoptosis↑, BAX↑, Bcl-2↓, MMP↓, Cyt‑c↑, Casp3↑, Casp9↑, JNK↑,

364-

SNP,

Differential Action of Silver Nanoparticles on ABCB1 (MDR1) and ABCC1 (MRP1) Activity in Mammalian Cell Lines

-

in-vitro,

Lung,

A549

202ug/cm3

most resistant

-

in-vitro,

Hepat,

HepG2

15.8ug/cm3

Decreased mRNA expression of most ABC transporters (not ABCB1)

-

in-vitro,

CRC,

SW-620

39.4ug/cm3

Increased mRNA expression of most ABC transporters (not ABCB1)

TumCD↑,

365-

SNP,

Silver nanoparticles affect glucose metabolism in hepatoma cells through production of reactive oxygen species

-

in-vitro,

Hepat,

HepG2

0.5–7.5 µg/mL 5 nm

ROS↑, GlucoseCon↓, TumCD↑, NRF2↓,

366-

SNP,

Silver nanoparticles inhibit the function of hypoxia-inducible factor-1 and target genes: insight into the cytotoxicity and antiangiogenesis

-

in-vitro,

BC,

MCF-7

15.5ug/mL

HIF-1↓, Hif1a↓, VEGF↓, GLUT1↓,

367-

SNP,

Presence of an Immune System Increases Anti-Tumor Effect of Ag Nanoparticle Treated Mice

-

in-vivo,

NA,

NA

mice

ROS↑, mtDam↑, TumCG↓,

368-

SNP,

In vitro evaluation of silver nanoparticles on human tumoral and normal cells

-

in-vitro,

Var,

NA

6.72-13.45 µg/ml

mtDam↑, LDH↓,

369-

SNP,

Silver nanoparticles induce oxidative cell damage in human liver cells through inhibition of reduced glutathione and induction of mitochondria-involved apoptosis

-

in-vitro,

Liver,

NA

ROS↑, GSH↓, DNAdam↑, lipid-P↝, Apoptosis↑, BAX↑, Bcl-2↓, MMP↓, Casp9↑, Casp3↑, JNK↑,

370-

SNP,

Differential genotoxicity mechanisms of silver nanoparticles and silver ions

-

in-vitro,

lymphoma,

TK6

1.00-1.75 µg/ml

ROS↑,

371-

SNP,

Cytotoxicity and genotoxicity of silver nanoparticles in the human lung cancer cell line, A549

-

in-vitro,

Lung,

A549

ROS↑, mtDam↑,

372-

SNP,

Investigating oxidative stress and inflammatory responses elicited by silver nanoparticles using high-throughput reporter genes in HepG2 cells: effect of size, surface coating, and intracellular uptake

-

in-vitro,

Hepat,

HepG2

NRF2↑, GSH↓,

373-

SNP,

Cytotoxic Potential and Molecular Pathway Analysis of Silver Nanoparticles in Human Colon Cancer Cells HCT116

-

in-vitro,

Colon,

HCT116

LDH↓, ROS↑, MDA↑, ATP↓, GSH↓, MMP↓,

374-

SNP,

Silver nanoparticles selectively treat triple‐negative breast cancer cells without affecting non‐malignant breast epithelial cells in vitro and in vivo

-

in-vitro,

BC,

MCF-7

-

in-vitro,

BC,

MDA-MB-231

-

in-vivo,

NA,

NA

6, 9, or 12 mg total silver/kg

mice

ER Stress↑, DNAdam↑, ROS↑, Apoptosis↑, GSH/GSSG↓, NADPH/NADP+↓, TumCG↓, UPR↑,

375-

SNP,

ALA,

Alpha-Lipoic Acid Prevents Side Effects of Therapeutic Nanosilver without Compromising Cytotoxicity in Experimental Pancreatic Cancer

-

in-vitro,

PC,

Bxpc-3

we used α-lipoic acid concentrations of 0.5 and 1 mM

-

in-vitro,

PC,

PANC1

-

in-vitro,

PC,

MIA PaCa-2

-

in-vivo,

NA,

NA

dropping 200 µL or 400 µL of a 14 ppm AgNP solution, 200 µL or 400 µL of a 0.5 mM α-lipoic acid solution, or both solutions together on the chorioallantoic membrane (CAM)

chick embryos

mtDam↑, ROS↑, *toxicity↓, Dose∅, selectivity↑,

376-

SNP,

Antitumor activity of colloidal silver on MCF-7 human breast cancer cells

-

in-vitro,

BC,

MCF-7

3.5 ng/mL

Apoptosis↑, LDH↓, SOD↑, DNAdam↑,

377-

SNP,

Anticancer Action of Silver Nanoparticles in SKBR3 Breast Cancer Cells through Promotion of Oxidative Stress and Apoptosis

-

in-vitro,

BC,

SkBr3

ROS↑, Apoptosis↑, Bax:Bcl2↑, VEGF↑, Akt↓, PI3K↓, TAC↓, TOS↑, OSI↑, MDA↑, Casp3↑, Casp7↑,

379-

SNP,

Effects of green-synthesized silver nanoparticles on lung cancer cells in vitro and grown as xenograft tumors in vivo

-

in-vivo,

Lung,

H1299

10ug/g of body wgt

scid mouse

NF-kB↓, Bcl-2↓, Casp3↑, survivin↑, TumCG↓,

1512-

Squ,

Combination therapy in combating cancer

-

Review,

NA,

NA

ChemoSideEff↓, *ROS↓, *GSH↑, eff↑, chemoP↑,

107-

SS,

Saikosaponin B1 and Saikosaponin D inhibit tumor growth in medulloblastoma allograft mice via inhibiting the Hedgehog signaling pathway

-

vitro+vivo,

MB,

NA

241.8 nM

SSB1

HH↓, Smo↓, Gli↓, Gli1↓, PTCH1↓,

1575-

statins,

Citrate,

Inhibition of Lung Cancer Growth: ATP Citrate Lyase Knockdown and Statin Treatment Leads to Dual Blockade of Mitogen-Activated Protein Kinase (MAPK) and Phosphatidylinositol-3-Kinase (PI3K)/AKT Pathways

-

in-vitro,

NSCLC,

A549

Generation of ACL knockdown cell lines

eff↑, HMG-CoA↓, eff↑, AntiTum↑, EGFR↓, eff↑, ROS↑, EMT↓, E-cadherin↑, MUC1↑, p‑ACLY↓, p‑Akt↓, eff↑,

1626-

STF,

dietFMD,

When less may be more: calorie restriction and response to cancer therapy

-

Review,

Var,

NA

CRM↑, ChemoSen↑, RadioS↑, eff↑, eff↑, IGF-1↓, TumCG↓, AMPK↑, eff↑, ChemoSen↑, RadioS↑, ROS↑, DNAdam↑, eff↑, HO-1↓,

112-

SuD,

Inhibition of Gli/hedgehog signaling in prostate cancer cells by “cancer bush” Sutherlandia frutescens extract

-

in-vitro,

Pca,

PC3

167 ug/mL

-

in-vitro,

Pca,

LNCaP

HH↓, Gli1↓, PTCH1↓,

1137-

Tau,

Taurine Attenuates Epithelial-Mesenchymal Transition-Related Genes in Human Prostate Cancer Cells

-

in-vitro,

Pca,

NA

N-cadherin↓, Twist↓, Zeb1↓, Snail↓, Vim↓, E-cadherin↑,

1051-

Tau,

immuno,

Taurine enhances the antitumor efficacy of PD-1 antibody by boosting CD8+ T cell function

-

in-vivo,

Lung,

NA

mouse

TumCG↓,

1202-

Tb,

The influence of theobromine on angiogenic activity and proangiogenic cytokines production of human ovarian cancer cells

-

in-vitro,

Ovarian,

NA

angioG↓, VEGF↓,

2373-

TMZ,

The role of pyruvate kinase M2 in anticancer therapeutic treatments

-

Review,

Var,

NA

PKM2↓, DNAdam↑,

139-

Tomatine,

CUR,

Combination of α-Tomatine and Curcumin Inhibits Growth and Induces Apoptosis in Human Prostate Cancer Cells

-

in-vitro,

Pca,

PC3

NF-kB↓, Bcl-2↓, p‑Akt↓, p‑ERK↓,

113-

TQ,

Selective Targeting of the Hedgehog Signaling Pathway by PBM Nanoparticles in Docetaxel-Resistant Prostate Cancer

-

vitro+vivo,

Pca,

C4-2B

139 uM

C4-2B-R

HH↓, Shh↓, Gli1↓,

1138-

TQ,

Thymoquinone inhibits epithelial-mesenchymal transition in prostate cancer cells by negatively regulating the TGF-β/Smad2/3 signaling pathway

-

in-vitro,

Pca,

DU145

-

in-vitro,

Pca,

PC3

TumMeta↓, EMT↓, E-cadherin↑, Vim↓, Slug↓, TGF-β↓, SMAD2↓, SMAD3↓,

1019-

TQ,

Thymoquinone suppresses migration of LoVo human colon cancer cells by reducing prostaglandin E2 induced COX-2 activation

-

vitro+vivo,

CRC,

LoVo

20 μmol/L

also mice

TumCP↓, p‑PI3K↓, p‑Akt↓, p‑GSK‐3β↓, β-catenin/ZEB1↓, COX2↓, PGE2↓, EP2↓, EP4↓,

962-

TQ,

Thymoquinone affects hypoxia-inducible factor-1α expression in pancreatic cancer cells via HSP90 and PI3K/AKT/mTOR pathways

-

in-vitro,

PC,

PANC1

0, 5, 10, 15, 20, 25, 30, and 35 µM

11uM

experiments were constructed in hypoxic conditions (O2 content was 1%)

-

in-vitro,

Nor,

hTERT-HPNE

no effect

normal pancreatic duct epithelial (hTERT-HPNE) cells

-

in-vitro,

PC,

AsPC-1

11uM

-

in-vitro,

PC,

Bxpc-3

26uM

TumCMig↓, TumCI↓, Apoptosis↑, Hif1a↓, PI3k/Akt/mTOR↓, TumCCA↑, *toxicity↓, *TumCI∅, *TumCMig∅,

1052-

TQ,

Thymoquinone Anticancer Effects Through the Upregulation of NRF2 and the Downregulation of PD-L1 in MDA-MB-231 Triple-Negative Breast Cancer Cells

-

in-vitro,

BC,

MDA-MB-231

TQ (0-50 µM)24hr

NRF2↑, PD-L1↓, Apoptosis↑,

1932-

TQ,

Recent Findings on Thymoquinone and Its Applications as a Nanocarrier for the Treatment of Cancer and Rheumatoid Arthritis

-

Review,

Var,

NA

ROS↑,

1937-

TQ,

Migration and Proliferation Effects of Thymoquinone-Loaded Nanostructured Lipid Carrier (TQ-NLC) and Thymoquinone (TQ) on In Vitro Wound Healing Models

-

NA,

Nor,

3T3

3-12uM

*ROS↓, *antiOx↓, *BioAv↓, *BioAv↑, *NO↑, *SOD↑, *GPx↑, *Catalase↑,

1936-

TQ,

Thymoquinone induces apoptosis and increase ROS in ovarian cancer cell line

-

in-vitro,

Ovarian,

CaOV3

6ug/mL

-

in-vitro,

Nor,

WRL68

selectivity↑, TumCP↓, MMP↓, Bcl-2↓, BAX↑, ROS↑,

1935-

TQ,

Potential anticancer properties and mechanisms of thymoquinone in osteosarcoma and bone metastasis

-

Review,

OS,

NA

Apoptosis↑, TumCCA↑, angioG↓, TumMeta↓, ROS↑, P53↑, Twist↓, E-cadherin↑, N-cadherin↓, NF-kB↓, IL8↓, XIAP↓, Bcl-2↓, STAT3↓, MAPK↓, PI3K↓, Akt↓, ERK↓, MMP2↓, MMP9↓, *ROS↓, HO-1↑, selectivity↑, TumCG↓,

1934-

TQ,

Studies on molecular mechanisms of growth inhibitory effects of thymoquinone against prostate cancer cells: role of reactive oxygen species

-

in-vitro,

Pca,

PC3

25-150um/L

80uM

-

in-vitro,

Pca,

C4-2B

50uM

ROS↑, GSH↓, eff↓,

1933-

TQ,

Thymoquinone: potential cure for inflammatory disorders and cancer

-

Review,

Var,

NA

antiOx↑, Inflam↓, AntiCan↑, TumCCA↑, ROS↑, angioG↓, Apoptosis↑, Casp↑, eff↑, eff↝,

1308-

TQ,

Thymoquinone induces apoptosis via targeting the Bax/BAD and Bcl-2 pathway in breast cancer cells

-

in-vitro,

BC,

MCF-7

tumCV↓, TumCP↓, BAX↑, P53⇅, Apoptosis↑,

1309-

TQ,

QC,

Thymoquinone and quercetin induce enhanced apoptosis in non-small cell lung cancer in combination through the Bax/Bcl2 cascade

-

in-vitro,

Lung,

NA

IC50 values of Tq and Qu alone in A549 cells were found to be 45.78 and 35.69 µM

Bcl-2↓, BAX↑, Apoptosis↑,

2129-

TQ,

doxoR,

Thymoquinone up-regulates PTEN expression and induces apoptosis in doxorubicin-resistant human breast cancer cells

-

in-vitro,

BC,

MCF-7

25, 50 or 100 µM TQ

ChemoSen↑, PTEN↑, p‑Akt↓, TumCCA↑, P53↑, P21↑, Apoptosis↑, MMP↓, Casp↑, cl‑PARP↑, Bax:Bcl2↑, eff↓, DNAdam↓, p‑γH2AX↑, ROS↑,

2126-

TQ,

Biological and therapeutic activities of thymoquinone: Focus on the Nrf2 signaling pathway

-

Review,

Nor,

NA

*antiOx↑, *Bacteria↓, *RenoP↑, *hepatoP↑, *neuroP↑, *Inflam↓, *Keap1↓, *NRF2↑, *other↝,

2130-

TQ,

Thymoquinone Attenuates Brain Injury via an Anti-oxidative Pathway in a Status Epilepticus Rat Model

-

in-vivo,

Nor,

NA

rat

*eff↑, *memory↑, *NRF2↑, *HO-1↑, *SOD↑, *ROS↓,

2131-

TQ,

Therapeutic impact of thymoquninone to alleviate ischemic brain injury via Nrf2/HO-1 pathway

-

in-vitro,

Stroke,

NA

-

in-vivo,

Nor,

NA

schemic brain damage in C57BL/6 J mice

*eff↑, *OS↑, *Inflam↓, *ROS↓, *NRF2↑, *HO-1↑,

2132-

TQ,

Thymoquinone treatment modulates the Nrf2/HO-1 signaling pathway and abrogates the inflammatory response in an animal model of lung fibrosis

-

in-vivo,

Nor,

NA

10 and 20 mg/kg p.o.) for 28 days

Lung fibrosis was induced in rats

*Weight∅, *antiOx↑, *lipid-P↓, *MMP7↓, *Casp3↓, *BAX↓, *TGF-β↓, *Diff↑, *NRF2↓, *HO-1↓, *NF-kB↓, *IκB↑,

2133-

TQ,

CUR,

Cisplatin,

Thymoquinone and curcumin combination protects cisplatin-induced kidney injury, nephrotoxicity by attenuating NFκB, KIM-1 and ameliorating Nrf2/HO-1 signalling

-

in-vitro,

Nor,

HEK293

-

in-vivo,

NA,

NA

Sprague–Dawley rats. 50 mg/kg BW Tq + 100 mg/kg BW Cur, with or without cisplatin-treatment were administered for 5 days

*creat↓, *TNF-α↓, *IL6↓, *MRP↓, *GFR↑, *mt-ATPase↑, *p‑Akt↑, *NRF2↑, *HO-1↑, *Casp3↓, *NF-kB↓, *RenoP↑,

2134-

TQ,

Modulation of Nrf2/HO1 Pathway by Thymoquinone to Exert Protection Against Diazinon-induced Myocardial Infarction in Rats

-

in-vivo,

Nor,

NA

20 mg/kg p.o.

Male Sprague–Dawley rats

*ALAT↓, *AST↓, *MDA↓, *ROS↓, *GSSG↓, *GSH↑, *VitE↑, *VitC↑, *NRF2↑, *HO-1↑, *NQO1↑, *SOD↑, *cardioP↑, *GSH/GSSG↑, *GPx↑,

2135-

TQ,

Thymoquinone induces heme oxygenase-1 expression in HaCaT cells via Nrf2/ARE activation: Akt and AMPKα as upstream targets

-

in-vitro,

Nor,

HaCaT

TQ (1, 5, 10, 20 lM) for 6 h

skin cells

*HO-1↑, *NRF2↑, *e-ERK↑, *e-Akt↑, *AMPKα↑, *ROS↑, *eff↓, *tumCV∅,

2136-

TQ,

Nigella sativa and thymoquinone suppress cyclooxygenase-2 and oxidative stress in pancreatic tissue of streptozotocin-induced diabetic rats

-

in-vivo,

Nor,

NA

streptozotocin (STZ)-induced diabetic rats

*COX2↓, *lipid-P↓, *SOD↑, *ROS↓, *Inflam↓, *NF-kB↓,

2137-

TQ,

Gastroprotective activity of Nigella sativa L oil and its constituent, thymoquinone against acute alcohol-induced gastric mucosal injury in rats

-

in-vivo,

Nor,

NA

Male Wistar albino rats

*GSH↑, *SOD↑, *GSTA1↑,

2138-

TQ,

Thymoquinone has a synergistic effect with PHD inhibitors to ameliorate ischemic brain damage in mice

-

in-vivo,

Nor,

NA

TQ (5 mg/kg

Male C57 mice were used to establish an ischemic stroke model by using endothelin-1

*Hif1a↑, *VEGF↑, *TrkB↑, *PI3K↑, *angioG↑, *neuroG↑, *motorD↑,

2139-

TQ,

Thymoquinone regulates microglial M1/M2 polarization after cerebral ischemia-reperfusion injury via the TLR4 signaling pathway

-

in-vivo,

Nor,

NA

acute ischemic stroke using a mouse middle cerebral artery ischemia-reperfusion (I/R) model.

*TLR4↓, *NF-kB↓, *Inflam↓, *Hif1a↑, *motorD↑,

2115-

TQ,

Protective effects of Nigella sativa on gamma radiation-induced jejunal mucosal damage in rats

-

in-vivo,

Nor,

NA

Thirty 12–14-week-old Male Wistar albino rats

*radioP↑, *MDA↓, *GSH↑,

2114-

TQ,

Anti-Aging Effect of Nigella Sativa Fixed Oil on D-Galactose-Induced Aging in Mice

-

in-vivo,

Nor,

NA

0.1, 0.2 and 0.5 mL/kg

male mice for 42 days

*ALAT↓, *AST↓, *lipid-P↓, *GSH↑, *Bax:Bcl2↓, *proCasp3↓, *cl‑Casp3↓, *antiOx↑,

2128-

TQ,

Thymoquinone inhibits phorbol ester-induced activation of NF-κB and expression of COX-2, and induces expression of cytoprotective enzymes in mouse skin in vivo

-

in-vivo,

NA,

NA

female HR-1 hairless mouse skin

*COX2↓, *NF-kB↓, *p‑Akt↓, *p‑cJun↓, *p‑p38↓, *HO-1↑, *NADPH↑, *GSTA1↑, *antiOx↑, *Inflam↓, *NQO1↑, *GCLC↑, *GSTA1↑,

2127-

TQ,

Therapeutic Potential of Thymoquinone in Glioblastoma Treatment: Targeting Major Gliomagenesis Signaling Pathways

-

Review,

GBM,

NA

chemoP↑, ChemoSen↑, BioAv↑, PTEN↑, PI3K↓, Akt↓, TumCCA↓, NF-kB↓, p‑Akt↓, p65↓, XIAP↓, Bcl-2↓, COX2↓, VEGF↓, mTOR↓, RAS↓, Raf↓, MEK↓, ERK↓, MMP2↓, MMP9↓, TumCMig↓, TumCI↓, Casp↑, cl‑PARP↑, ROS⇅, ROS↑, MMP↓, eff↑, Telomerase↓, DNAdam↑, Apoptosis↑, STAT3↓, RadioS↑,

2113-

TQ,

Potential role of Nigella sativa (NS) in abating oxidative stress-induced toxicity in rats: a possible protection mechanism

-

in-vivo,

Nor,

NA

rats

*antiOx↑, *RenoP↑, *hepatoP↑, *SOD↑, *GSH↑, *ROS↓, *lipid-P↓, ALAT↓, creat↓,

2125-

TQ,

Thymoquinone Selectively Kills Hypoxic Renal Cancer Cells by Suppressing HIF-1α-Mediated Glycolysis

-

in-vitro,

RCC,

RCC4

-

in-vitro,

RCC,

Caki-1

Hif1a↓, eff↝, uPAR↓, VEGF↓, CAIX↓, PDK1↓, GLUT1↓, LDHA↓, Glycolysis↓, e-lactateProd↓, i-ATP↓,

2124-

TQ,

Thymoquinone: an emerging natural drug with a wide range of medical applications

-

Review,

Var,

NA

hepatoP↑, Bax:Bcl2↑, cycD1↓, P21↑, TRAIL↑, P53↑, TumCCA↑, hepatoP↑, *ALAT↓, *AST↓, *MDA↓, *GSSG↓, *SOD↓, *COX2↓, *lipid-P↓, PPARγ↑, p38↑, ROS↑, ChemoSen↑, selectivity↑, selectivity↑,

2123-

TQ,

Thymoquinone suppresses growth and induces apoptosis via generation of reactive oxygen species in primary effusion lymphoma

-

in-vitro,

lymphoma,

PEL

10, 25, 50 uM @ 24h

Akt↓, ROS↑, BAX↓, MMP↓, Cyt‑c↑, eff↑, Casp9↑, Casp3↑, cl‑PARP↑, DR5↑,

2122-

TQ,

Review on Molecular and Therapeutic Potential of Thymoquinone in Cancer

-

Review,

Var,

NA

ChemoSen↓, *ROS↓, *GSH↑, RenoP↑, hepatoP↑, COX2↓, NF-kB↓, chemoP↑, neuroP↑, TumCCA↑, P21↑, p27↑, ROS↑, DNAdam↑, MUC4↓,

2121-

TQ,

Thymoquinone Inhibits Tumor Growth and Induces Apoptosis in a Breast Cancer Xenograft Mouse Model: The Role of p38 MAPK and ROS

-

in-vitro,

BC,

MCF-7

-

in-vitro,

BC,

MDA-MB-231

p‑p38↑, ROS↑, TumCP↓, eff↑, XIAP↓, survivin↓, Bcl-xL↓, Bcl-2↓, Ki-67↓, *Catalase↑, *SOD↑, *GSH↑, hepatoP↑, p‑MAPK↑, JNK↓, eff↓,

2120-

TQ,

Thymoquinone induces apoptosis of human epidermoid carcinoma A431 cells through ROS-mediated suppression of STAT3

-

in-vitro,

Melanoma,

A431

ROS↑, Apoptosis↑, P53↑, BAX↑, MDM2↓, Bcl-2↓, Bcl-xL↓, Casp9↑, Casp7↑, Casp3↑, STAT3↓, cycD1↓, survivin↓, eff↓,

2119-

TQ,

Dual properties of Nigella Sativa: anti-oxidant and pro-oxidant

-

Review,

Var,

NA

*ROS↓, ROS↑, chemoP↑, RenoP↑, hepatoP↑, NLRP3↓, neuroP↑, NF-kB↓, P21↑, HDAC↓, Apoptosis↑, TumCP↓, GSH↓, GADD45A↑, GSK‐3β↑,

2118-

TQ,

Rad,

In vivo radioprotective effects of Nigella sativa L oil and reduced glutathione against irradiation-induced oxidative injury and number of peripheral blood lymphocytes in rats

-

in-vivo,

Nor,

NA

rats

*ROS↓, RenoP↑, hepatoP↑,

2117-

TQ,

Effects of Nigella sativa L. on Lipid Peroxidation and Reduced Glutathione Levels in Erythrocytes of Broiler Chickens

-

in-vivo,

Nor,

NA

Broiler chickens

*GSH↑, *ROS↓,

2116-

TQ,

Cisplatin,

Oral administration of Nigella sativa oil ameliorates the effect of cisplatin on membrane enzymes, carbohydrate metabolism and oxidative damage in rat liver

-

in-vivo,

Nor,

NA

rats

*hepatoP↑, *antiOx↑, *ROS↓, ALAT↓, AST↓,

2092-

TQ,

Dissecting the Potential Roles of Nigella sativa and Its Constituent Thymoquinone on the Prevention and on the Progression of Alzheimer's Disease

-

Review,

AD,

NA

*iNOS↓, *ROS↓, *GSH↑, *neuroP↑, *MMPs↓, *MMP↑, *TXNIP↓, *Prx↑, *memory↑, *MDA↓, *SOD↑, *Catalase↑, *BioAv↑,

2103-

TQ,

Anti-inflammatory effects of the Nigella sativa seed extract, thymoquinone, in pancreatic cancer cells

-

in-vitro,

PC,

Hs766t

25–75 µM

-

in-vitro,

PC,

MIA PaCa-2

MCP1↓, TNF-α↓, IL1β↓, COX2↓, NF-kB↓, HDAC↓, P21↑,

2102-

TQ,

A review on therapeutic potential of Nigella sativa: A miracle herb

-

Review,

Var,

NA

angioG↓, NF-kB↓, PPARγ↓, Bcl-2↓, Bcl-xL↓, MUC4↓, cJun↑, p38↑, P21↑, HDAC↓, radioP↑, hepatoP↑,

2101-

TQ,

HDAC inhibition by Nigella sativa L. sprouts extract in hepatocellular carcinoma: an approach to study anti-cancer potential

-

Study,

HCC,

NA

HDAC↓, eff↑, eff↑, AntiCan↑,

2100-

TQ,

Dual properties of Nigella Sative: Anti-oxidant and Pro-oxidant

-

Review,

NA,

NA

ROS⇅, *antiOx↑, *SOD↑, *MPO↑, *neuroP↑, *chemoP↑, *radioP↑, NF-kB↓, IAP1↓, IAP2↓, XIAP↓, Bcl-xL↓, survivin↓, COX2↓, MMP9↓, VEGF↓, ROS↑, P21↑, HDAC↓, GSH↓, GADD45A↑, AIF↑, STAT3↓,

2099-

TQ,

Cisplatin,

Thymoquinone and cisplatin as a therapeutic combination in lung cancer: In vitro and in vivo

-

in-vitro,

Lung,

H460

-

in-vitro,

Lung,

H146

-

in-vivo,

NA,

NA

mice

ChemoSen↑, TumCP↓, tumCV↓, Apoptosis↑, NF-kB↓,

2098-

TQ,

Anticancer activity of Nigella sativa (black seed) and its relationship with the thermal processing and quinone composition of the seed

-

in-vitro,

Colon,

MC38

-

in-vitro,

lymphoma,

L428

NF-kB↓, eff↑, eff↓,

2097-

TQ,

Crude extract of Nigella sativa inhibits proliferation and induces apoptosis in human cervical carcinoma HeLa cells

-

in-vitro,

Cerv,

HeLa

IC50 values for 25, 50, 75 and 100 ug/ml were observed after 72, 48, 24 and 24 h

Cyt‑c↑, Bax:Bcl2↑, Casp3↑, Casp9↑, Casp8↑, cl‑PARP↑, cMyc↓, hTERT↓, cycD1↓, CDK4↓, P53↑, P21↑, TumCP↓, Apoptosis↓, selectivity↑,

2096-

TQ,

Effect of total hydroalcholic extract of Nigella sativa and its n-hexane and ethyl acetate fractions on ACHN and GP-293 cell lines

-

in-vitro,

Nor,

GP-293

-

in-vitro,

Kidney,

ACHN

selectivity↑, eff↝,

2095-

TQ,

Review on the Potential Therapeutic Roles of Nigella sativa in the Treatment of Patients with Cancer: Involvement of Apoptosis

-

Review,

Var,

NA

TumCCA↑, Apoptosis↑, ROS↑, Cyt‑c↑, Bax:Bcl2↑, Casp3↑, Casp9↑, cl‑PARP↑, P53↑, P21↑, cMyc↓, hTERT↓, cycD1↓, CDK4↓, NF-kB↓, IAP1↓, IAP2↓, XIAP↓, Bcl-xL↓, survivin↓, COX2↓, MMP9↓, VEGF↓, eff↑,

2105-

TQ,

Thymoquinone Promotes Pancreatic Cancer Cell Death and Reduction of Tumor Size through Combined Inhibition of Histone Deacetylation and Induction of Histone Acetylation

-

in-vitro,

PC,

AsPC-1

10–50 μM

-

in-vitro,

PC,

MIA PaCa-2

-

in-vitro,

PC,

Hs766t

-

in-vivo,

NA,

NA

mice

tumCV↓, TumCP↓, TumCCA↑, Apoptosis↑, P53↑, Bcl-2↓, P21↑, ac‑H4↑, HDAC↓, HDAC1↓, HDAC2↓, HDAC3↓, TumVol↓,

2094-

TQ,

Cytotoxicity of Nigella sativa Extracts Against Cancer Cells: A Review of In Vitro and In Vivo Studies

-

Review,

Var,

NA

ROS↑, angioG↓, TumMeta↓, VEGF↓, MMPs↓, P53↑, BAX↑, Casp↑, Bcl-2↓, survivin↓, *ROS↓, ChemoSen↑, chemoP↑, MDR1↓, BioAv↓, BioAv↑,

2106-

TQ,

Cancer: Thymoquinone antioxidant/pro-oxidant effect as potential anticancer remedy

-

Review,

Var,

NA

Apoptosis↑, TumCCA↑, ROS↑, *Catalase↑, *SOD↑, *GR↑, *GSTA1↓, *GPx↑, *H2O2↓, *ROS↓, *lipid-P↓, *HO-1↑, p‑Akt↓, AMPKα↑, NK cell↑, selectivity↑, Dose↝, eff↑, GSH↓, eff↓, P53↑, p‑STAT3↓, PI3K↑, MAPK↑, GSK‐3β↑, ChemoSen↑, RadioS↑, BioAv↓, NRF2↑,

2107-

TQ,

Cytotoxicity of Nigella sativa seed oil and extract against human lung cancer cell line

-

in-vitro,

Lung,

A549

tumCV↑,

2108-

TQ,

Anti-cancer properties and mechanisms of action of thymoquinone, the major active ingredient of Nigella sativa

-

Review,

Var,

NA

HDAC↓, TumCCA↑, cycD1↓, p16↑, P53↑, Bax:Bcl2↑, Bcl-xL↓, NF-kB↓, IAP1↓, IAP2↓, XIAP↓, survivin↓, COX2↓, cMyc↓, ROS↑, Casp3↑, cl‑PARP↑, Cyt‑c↑, STAT3↓,

2093-

TQ,

Regulation of NF-κB Expression by Thymoquinone; A Role in Regulating Pro-Inflammatory Cytokines and Programmed Cell Death in Hepatic Cancer Cells

-

in-vitro,

Liver,

HepG2

TQ (125–1000 ug/mL).

-

in-vitro,

Nor,

NA

TumCD↑, selectivity↑, Casp3↑, DLC1↑, NF-kB↑, LDH↑, *toxicity↓,

2104-

TQ,

The Potential Role of Nigella sativa Seed Oil as Epigenetic Therapy of Cancer

-

in-vitro,

BC,

MCF-7

-

in-vitro,

Cerv,

HeLa

TumCP↓, Apoptosis↑, UHRF1↓, DNMT1↓, HDAC1↓, eff↝,

2091-

TQ,

Determination of anti-cancer effects of Nigella sativa seed oil on MCF7 breast and AGS gastric cancer cells

-

in-vitro,

BC,

MCF-7

-

in-vitro,

GC,

AGS

Dose↝, Casp3↑, Bcl-2↓, MMP2↓, MMP9↓, HSP70/HSPA5↓,

2090-

TQ,

Thymoquinone as a Potential Adjuvant Therapy for Cancer Treatment: Evidence from Preclinical Studies

-

Review,

Var,

NA

AntiCan↑, ChemoSen↑, RadioS↑, chemoP↑, radioP↑,

2089-

TQ,

Modulation of Hydrogen Peroxide-Induced Oxidative Stress in Human Neuronal Cells by Thymoquinone-Rich Fraction and Thymoquinone via Transcriptomic Regulation of Antioxidant and Apoptotic Signaling Genes

-

in-vitro,

Nor,

SH-SY5Y

*neuroP↑, *ROS↓, *SOD1↑, *Catalase↑,

2088-

TQ,

Nigella sativa L. and Its Bioactive Constituents as Hepatoprotectant: A Review

-

Review,

Nor,

NA

*hepatoP↑, *lipid-P↓, *Thiols↑, *ROS↓, *Catalase↑, *SOD↑, *GSTs↑, *NF-kB↓, *COX2↓, *LOX1↓,

2087-

TQ,

Nigella sativa thymoquinone-rich fraction greatly improves plasma antioxidant capacity and expression of antioxidant genes in hypercholesterolemic rats

-

in-vivo,

Nor,

NA

rats

*LDL↓, *SOD1↑, *Catalase↑, *GPx↑, *antiOx↑,

2086-

TQ,

Cardioprotective effects of Nigella sativa oil on cyclosporine A-induced cardiotoxicity in rats

-

in-vivo,

Nor,

NA

N. sativa oil (21 days, 2 ml/kg, orally)

24 male Wistar albino young healthy rats (8-12 weeks) weighing 150-200 g

*SOD↑, *Catalase↑, *GSH↑, *cardioP↑, *lipid-P↓,

2085-

TQ,

Anticancer Activities of Nigella Sativa (Black Cumin)

-

Review,

Var,

NA

MMP↓, Casp3↑, Casp8↑, Casp9↓, cl‑PARP↑, Cyt‑c↑, Bax:Bcl2↑, NF-kB↓, IAP1↓, IAP2↓, XIAP↓, Bcl-xL↓, survivin↓, cJun↑, p38↑, Akt↑, chemoP↑, radioP↑,

2084-

TQ,

Thymoquinone, as an anticancer molecule: from basic research to clinical investigation

-

Review,

Var,

NA

*ROS↓, *chemoP↑, ROS↑, ROS⇅, MUC4↓, selectivity↑, AR↓, cycD1↓, Bcl-2↓, Bcl-xL↓, survivin↓, Mcl-1↓, VEGF↓, cl‑PARP↑, ROS↑, HSP70/HSPA5↑, P53↑, miR-34a↑, Rac1↓, TumCCA↑, NOTCH↓, NF-kB↓, IκB↓, p‑p65↓, IAP1↓, IAP2↑, XIAP↓, TNF-α↓, COX2↓, Inflam↓, α-tubulin↓, Twist↓, EMT↓, mTOR↓, PI3K↓, Akt↓, BioAv↓, ChemoSen↑, BioAv↑, PTEN↑, chemoP↑, RadioS↑, *Half-Life↝, *BioAv↝,

2083-

TQ,

Thymoquinone inhibits proliferation in gastric cancer via the STAT3 pathway in vivo and in vitro

-

in-vitro,

GC,

HGC27

-

in-vitro,

GC,

BGC-823

-

in-vitro,

GC,

SGC-7901

-

in-vivo,

NA,

NA

mouse

p‑STAT3↓, JAK2↓, c-Src↓, Bcl-2↓, cycD1↓, survivin↓, VEGF↓, Casp3?, Casp7?, Casp9?, *toxicity∅, TumVol↓,

2109-

TQ,

Thymoquinone Induces Mitochondria-Mediated Apoptosis in Acute Lymphoblastic Leukaemia in Vitro

-

in-vitro,

ALL,

CEM

1.5 µg/mL

Apoptosis↓, Bcl-2↓, BAX↑, ROS↑, HSP70/HSPA5↑, Casp3↑, Casp8↑,

2110-

TQ,

Nigella sativa seed oil suppresses cell proliferation and induces ROS dependent mitochondrial apoptosis through p53 pathway in hepatocellular carcinoma cells

-

in-vitro,

HCC,

HepG2

50–250 μg/ml) of NSO

44.6 μg/ml

-

in-vitro,

BC,

MCF-7

46.2 μg/ml

-

in-vitro,

Lung,

A549

245 μg/ml

-

in-vitro,

Nor,

HEK293

1136 μg/ml

indicates selectivity

P53↑, lipid-P↑, GSH↓, ROS↑, MMP↓, BAX↑, Casp3↑, Casp9↑, Bcl-2↓, tumCV↓, selectivity↑,

2111-

TQ,

MTX,

Effect of Nigella sativa (black seeds) against methotrexate-induced nephrotoxicity in mice

-

in-vivo,

Nor,

NA

mice

*RenoP↑, *GSH↑,

2112-

TQ,

Crude flavonoid extract of the medicinal herb Nigella sativa inhibits proliferation and induces apoptosis in breastcancer cells

-

in-vitro,

BC,

MCF-7

45 mg/ml@72hr

Apoptosis↑, DNAdam↑, ROS↑, GSH↓, MMP↓, Casp3↑, Casp7↑, Casp9↑, Bax:Bcl2↑, P53↑, P21↑, cycD1↓, GSSG↑, GSH/GSSG↓,

1928-

TQ,

Thymoquinone Crosstalks with DR5 to Sensitize TRAIL Resistance and Stimulate ROS-Mediated Cancer Apoptosis

-

in-vitro,

BC,

MCF-7

-

in-vitro,

BC,

MDA-MB-231

TumCP↓, DR4↑, DR5↑, Casp8↑, FADD↑, Bcl-2↓, ROS↑, NO↑, MDA↑,

1929-

TQ,

Thymoquinone Suppresses the Proliferation, Migration and Invasiveness through Regulating ROS, Autophagic Flux and miR-877-5p in Human Bladder Carcinoma Cells

-

in-vitro,

Bladder,

5637

0-50uM

75 µM

-

in-vitro,

Bladder,

T24

60 µM

tumCV↓, TumCP↓, TumCI↓, Casp↑, ROS↑, PD-L1↓, EMT↓, MMP↓, eff↓,

1930-

TQ,

Therapeutic implications and clinical manifestations of thymoquinone

-

Review,

Var,

NA

AntiCan↑, antiOx↑, Inflam↓, TumCP↓, TumCCA↑, Apoptosis↑, ROS↑, TumMeta↓, TumCI↓,

1931-

TQ,

doxoR,

Thymoquinone enhances the anticancer activity of doxorubicin against adult T-cell leukemia in vitro and in vivo through ROS-dependent mechanisms

-

in-vivo,

AML,

NA

Dox 50-750 nM, TQ 5-40uM

mice

eff↑, tumCV↓, TumCCA↑, ROS↑, MMP↓, eff↑, TumVol↓, eff↑, Ki-67↓,

2353-

TQ,

The effects of thymoquinone on pancreatic cancer: Evidence from preclinical studies

-

Review,

PC,

NA

BioAv↝, BioAv↑, MUC4↓, PKM2↓, eff↑, TumVol↓, HDAC↓, NF-kB↓, Bcl-2↓, Bcl-xL↓, survivin↓, XIAP↓, COX2↓, PGE1↓,

3420-

TQ,

Thymoquinone alleviates the accumulation of ROS and pyroptosis and promotes perforator skin flap survival through SIRT1/NF-κB pathway

-

in-vitro,

Nor,

HUVECs

-

in-vitro,

NA,

NA

rat

*NF-kB↓, *NLRP3↓, *angioG↑, *MMP9↑, *VEGF↑, *OS↑, *Pyro?, *ROS↓, *Apoptosis↓, *SIRT1↑, *SOD1↑, *HO-1↑, *eNOS↑, *ASC?, *Casp1↓, *IL1β↓, *IL18↓,

3431-

TQ,

PI3K-AKT Pathway Modulation by Thymoquinone Limits Tumor Growth and Glycolytic Metabolism in Colorectal Cancer

-

in-vitro,

CRC,

HCT116

21.71 µM

-

in-vitro,

CRC,

SW48

20.53 µM

Glycolysis↓, Warburg↓, HK2↓, ATP↓, NADPH↓, PI3K↓, Akt↓, TumCP↓, E-cadherin↑, N-cadherin↓, Hif1a↓, PKM2↓, GlucoseCon↓, lactateProd↓, EMT↓,

3421-

TQ,

Insights into the molecular interactions of thymoquinone with histone deacetylase: evaluation of the therapeutic intervention potential against breast cancer

-

Analysis,

Nor,

NA

-

in-vivo,

Nor,

NA

-

in-vitro,

BC,

MCF-7

-

in-vitro,

Nor,

HaCaT

HDAC↓, P21↑, Maspin↑, BAX↑, B2M↓, TumCCA↑, selectivity↑, *toxicity↓, TumCMig↓, TumCP↓,

3422-

TQ,

Thymoquinone, as a Novel Therapeutic Candidate of Cancers

-

Review,

Var,

NA

selectivity↑, P53↑, PTEN↑, NF-kB↓, PPARγ↓, cMyc↓, Casp↑, *BioAv↓, BioAv↝, eff↑, survivin↓, Bcl-xL↓, Bcl-2↓, Akt↓, BAX↑, cl‑PARP↑, CXCR4↓, MMP9↓, VEGFR2↓, Ki-67↓, COX2↓, JAK2↓, cSrc↓, Apoptosis↑, p‑STAT3↓, cycD1↓, Casp3↑, Casp7↑, Casp9↑, N-cadherin↓, Vim↓, Twist↓, E-cadherin↑, ChemoSen↑, eff↑, EMT↓, ROS↑, DNMT1↓, eff↑, EZH2↓, hepatoP↑, Zeb1↓, RadioS↑, HDAC↓, HDAC1↓, HDAC2↓, HDAC3↓, *NAD↑, *SIRT1↑, SIRT1↓, *Inflam↓, *CRP↓, *TNF-α↓, *IL6↓, *IL1β↓, *eff↑, *MDA↓, *NO↓, *GSH↑, *SOD↑, *Catalase↑, *GPx↑, PI3K↓, mTOR↓,

3424-

TQ,

Thymoquinone Is a Multitarget Single Epidrug That Inhibits the UHRF1 Protein Complex

-

Review,

Var,

NA

DNMT1↓, HDAC1↓, TumCCA↑, ROS↑, Apoptosis↑, angioG↓, TumMeta↓, selectivity↑, BioAv↓, BioAv↓, HDAC1↓, HDAC4↓, UHRF1↓, selectivity↑, G9a↓,

3425-

TQ,

Advances in research on the relationship between thymoquinone and pancreatic cancer

Apoptosis↑, TumCP↓, TumCI↓, TumMeta↓, ChemoSen↑, angioG↓, Inflam↓, NF-kB↓, PI3K↓, Akt↓, TGF-β↓, Jun↓, p38↑, MAPK↑, MMP9↓, PKM2↓, ROS↑, JNK↑, MUC4↓, TGF-β↑, Dose↝, FAK↓, NOTCH↓, PTEN↑, mTOR↓, Warburg↓, XIAP↓, COX2↓, Casp9↑, Ki-67↓, CD34↓, VEGF↓, MCP1↓, survivin↓, Cyt‑c↑, Casp3↑, H4↑, HDAC↓,

3426-

TQ,

Thymoquinone-Induced Reactivation of Tumor Suppressor Genes in Cancer Cells Involves Epigenetic Mechanisms

-

in-vitro,

BC,

MDA-MB-468

-

in-vitro,

ALL,

JK

24 h with 20 µM of TQ

UHRF1↓, DNMT1↓, DNMT3A↓, DNMTs↓, HDAC1↓, HDAC4↓, HDAC↓, DLC1↑, PPARγ↑, FOXO↑, TET2↑, CYP1B1↑, G9a↓,

3427-

TQ,

Chemopreventive and Anticancer Effects of Thymoquinone: Cellular and Molecular Targets

ROS⇅, Fas↑, DR5↑, TRAIL↑, Casp3↑, Casp8↑, Casp9↑, P53↑, mTOR↓, Bcl-2↓, BID↓, CXCR4↓, JNK↑, p38↑, MAPK↑, LC3II↑, ATG7↑, Beclin-1↑, AMPK↑, PPARγ↑, eIF2α↓, P70S6K↓, VEGF↓, ERK↓, NF-kB↓, XIAP↓, survivin↓, p65↓, DLC1↑, FOXO↑, TET2↑, CYP1B1↑, UHRF1↓, DNMT1↓, HDAC1↓, IL2↑, IL1↓, IL6↓, IL10↓, IL12↓, TNF-α↓, iNOS↓, COX2↓, 5LO↓, AP-1↓, PI3K↓, Akt↓, cMET↓, VEGFR2↓, CXCL1↓, ITGA5↓, Wnt↓, β-catenin/ZEB1↓, GSK‐3β↓, Myc↓, cycD1↓, N-cadherin↓, Snail↓, Slug↓, Vim↓, Twist↓, Zeb1↓, MMP2↓, MMP7↓, MMP9↓, JAK2↓, STAT3↓, NOTCH↓, cycA1↓, CDK2↓, CDK4↓, CDK6↓, CDC2↓, CDC25↓, Mcl-1↓, E2Fs↓, p16↑, p27↑, P21↑, ChemoSen↑,

3402-

TQ,

Enhanced Apoptosis in Pancreatic Cancer Cells through Thymoquinone-rich Nigella sativa L. Methanol Extract: Targeting NRF2/HO-1 and TNF-α Pathways

-

in-vitro,

PC,

PANC1

-

in-vitro,

PC,

MIA PaCa-2

tumCV↓, NRF2↑, HO-1↑, TNF-α↓,

3401-

TQ,

Molecular mechanisms and signaling pathways of black cumin (Nigella sativa) and its active constituent, thymoquinone: a review

-

Review,

Var,

NA

TumCP↓, *antiOx↑, *ROS↓, NRF2↑, NF-kB↓, TumCCA↑, *GABA↑, P53↑, P21↑, AMPK↑, neuroP↑, cardioP↑, hepatoP↑,

3400-

TQ,

Chemo,

Thymoquinone Ameliorates Carfilzomib-Induced Renal Impairment by Modulating Oxidative Stress Markers, Inflammatory/Apoptotic Mediators, and Augmenting Nrf2 in Rats

-

in-vitro,

Nor,

NA

10 and 20 mg/kg b.w.)

TQ against CFZ-induced renal toxicity in rats

*GSH↑, *SOD↑, *lipid-P↓, *IL1β↑, *IL6↓, *TNF-α↓, *Casp3↓, *Catalase↑, *NRF2↑, *RenoP↑,

3399-

TQ,

Anticancer Effects of Thymoquinone through the Antioxidant Activity, Upregulation of Nrf2, and Downregulation of PD-L1 in Triple-Negative Breast Cancer Cells

-

in-vitro,

BC,

MDA-MB-231

-

NA,

BC,

MDA-MB-468

ROS↓, H2O2↓, Catalase↑, SOD↑, GSH↑, NQO1↑, GCLM↑, NRF2↑, PD-L1↓, GSSG↑, GPx1⇅, GPx4↓,

3398-

TQ,

5-FU,

Impact of thymoquinone on the Nrf2/HO-1 and MAPK/NF-κB axis in mitigating 5-fluorouracil-induced acute kidney injury in vivo

-

in-vivo,

Nor,

NA

50-100mg/kg bw

Male albino Wistar rats

*RenoP↑, *TAC↑, *ROS↓, *lipid-P↓, *p38↓, *MAPK↓, *NF-kB↓, *NRF2↑, *HO-1↑, *MDA↓, *GPx↑, *GSR↑, *Catalase↑, *BUN↓, *LDH↓, *IL1β↓,

3397-

TQ,

Thymoquinone: A Promising Therapeutic Agent for the Treatment of Colorectal Cancer

-

Review,

CRC,

NA

6-112uM (table 1)

ChemoSen↑, *Half-Life↝, *BioAv↝, *antiOx↑, *Inflam↓, *hepatoP↑, TumCP↓, TumCCA↑, Apoptosis↑, angioG↑, selectivity↑, JNK↑, p38↑, p‑NF-kB↑, ERK↓, PI3K↓, PTEN↑, Akt↓, mTOR↓, EMT↓, Twist↓, E-cadherin↓, ROS⇅, *Catalase↑, *SOD↑, *GSTA1↑, *GPx↑, *PGE2↓, *IL1β↓, *COX2↓, *MMP13↓, MMPs↓, TumMeta↓, VEGF↓, STAT3↓, BAX↑, Bcl-2↑, Casp9↑, Casp7↑, Casp3↑, cl‑PARP↑, survivin↓, cMyc↓, cycD1↓, p27↑, P21↑, GSK‐3β↓, β-catenin/ZEB1↓, chemoP↑,

3429-

TQ,

Thymoquinone exerts potent growth-suppressive activity on leukemia through DNA hypermethylation reversal in leukemia cells

-

in-vitro,

ALL,

NA

-

in-vivo,

NA,

NA

mouse

DNMT1↓, Sp1/3/4↓, NF-kB↓, Apoptosis↑, Casp↑, Bcl-xL↓, COX2↓, iNOS↓, 5LO↓, TNF-α↓, cycD1↓, BioAv↝, TumCG↓,

3430-

TQ,

Targeting microRNAs with thymoquinone: a new approach for cancer therapy

-

Review,

Var,

NA

miR-29b↑, Sp1/3/4↓, TumCG↓, Rac1↓, angioG↓, TumMeta↓,

3410-

TQ,

Anti-inflammatory effects of thymoquinone and its protective effects against several diseases

-

Review,

Arthritis,

NA

*Inflam↓, *antiOx↑, *COX2↓, *NRF2↑, *HO-1↑, *IL1β↓, *IL6↓, *TNF-α↓, *IFN-γ↓, *PGE2↓, *cardioP↑, *Catalase↑, *SOD↑, *Thiols↑, *neuroP↑, *IL12↓, *MCP1↓, *CXCc↓, *ROS↓,

3432-

TQ,

Thymoquinone: Review of Its Potential in the Treatment of Neurological Diseases

-

Review,

AD,

NA

-

Review,

Park,

NA

*memory↑, *cognitive↑, *ROS↓, *Inflam↓, *antiOx↑, *TLR1↓, *AChE↓, *MMP↑, *neuroP↑, *lipid-P↓, *SOD↑, *GSH↑, *Ach↑,

3403-

TQ,

A multiple endpoint approach reveals potential in vitro anticancer properties of thymoquinone in human renal carcinoma cells

-

in-vitro,

RCC,

786-O

TQ (1-100 μM) for 24 and 48 h

8.4 uM for 48 h

tumCV↓, ROS↑, TumCCA↑, eff↓, TumCI↓,

3404-

TQ,

The Neuroprotective Effects of Thymoquinone: A Review

-

Review,

Var,

NA

-

Review,

AD,

NA

-

Review,

Park,

NA

-

Review,

Stroke,

NA

*Inflam↓, AntiCan↑, *TNF-α↓, *IL6↓, *IL1β↓, *NF-kB↓, *iNOS↓, *NRF2↑, *neuroP↑, *MMP↑, *ROS↓, *MDA↓, *GSH↑, *Catalase↑, *SOD↑, *IL12↓, *MCP1↓, *IP-10/CXCL-10↓, *PGE2↓,

3405-

TQ,

doxoR,

Protective effect of thymoquinone against doxorubicin-induced cardiotoxicity and the underlying mechanism

-

vitro+vivo,

NA,

NA

mice

*cardioP↑, *NRF2↑, *HO-1↑, *ROS↓, *NQO1↑, *COX2↓, *NOX4↓, *GPx4↑, *FTH1↑, *p‑mTOR↓, *TGF-β↓,

3406-

TQ,

Se,

A study to determine the effect of nano-selenium and thymoquinone on the Nrf2 gene expression in Alzheimer’s disease

-

in-vivo,

AD,

NA

nano-selenium (5 mg/kg); thymoquinone (2 mg/kg);

50 albino male rats

*NRF2↑, *GSH↑, *MDA↓, *TNF-α↓,

3407-

TQ,

Thymoquinone and its pharmacological perspective: A review

-

Review,

NA,

NA

*antiOx↑, *ROS↓, *GSTs↑, *GSR↑, *GSH↑, *RenoP↑, *IL1β↓, *TNF-α↓, *MMP13↓, *COX2↓, *PGE2↓, *radioP↑, Twist↓, EMT↓, NF-kB↓, p‑PI3K↓, p‑Akt↓, p‑GSK‐3β↓, DNMT1↓, HDAC↓,

3408-

TQ,

Thymoquinone: A small molecule from nature with high therapeutic potential

-

Review,

AD,

NA

-

Review,

Park,

NA

*neuroP↑, *hepatoP↑, *cardioP↑, *Inflam↓, *antiOx↑, ChemoSen↑, eff↑, eff↑, TumCP↓, TumCCA↑, angioG↓, cycA1↓, cycD1↓, cycE↓, CDK2↓,

3409-

TQ,

Thymoquinone therapy remediates elevated brain tissue inflammatory mediators induced by chronic administration of food preservatives

-

in-vivo,

Nor,

NA

50 mg/kg

Forty adult male rats

*MDA↓, *TGF-β↓, *CRP↓, *NF-kB↓, *TNF-α↓, *IL1β↓, *Casp3↓, *GSH↑, *NRF2↑, *IL10↑, *neuroP↑, *ROS↓, *Apoptosis↓, *Inflam↓,

3419-

TQ,

Thymoquinone, a Novel Multi-Strike Inhibitor of Pro-Tumorigenic Breast Cancer (BC) Markers: CALR, NLRP3 Pathway and sPD-L1 in PBMCs of HR+ and TNBC Patients

-

in-vitro,

BC,

NA

PBMCs isolated from HR+ BC patients were treated with increasing concentrations of TQ (20, 50, and 100 µM) for 24, 48, and 72 h.

peripheral blood mononuclear cells (PBMCs)

*NLRP3↓, *IL1β↓, *Casp1?,

3411-

TQ,

Anticancer and Anti-Metastatic Role of Thymoquinone: Regulation of Oncogenic Signaling Cascades by Thymoquinone

-

Review,

Var,

NA

p‑STAT3↓, cycD1↓, JAK2↓, β-catenin/ZEB1↓, cMyc↓, MMP7↓, MET↓, p‑Akt↓, p‑mTOR↓, CXCR4↓, Bcl-2↓, BAX↑, ROS↑, Cyt‑c↑, Twist↓, Zeb1↓, E-cadherin↑, p‑p38↑, p‑MAPK↑, ERK↑, eff↑, ERK↓, TumCP↓, TumCMig↓, TumCI↓,

3412-

TQ,

Thymoquinone induces oxidative stress-mediated apoptosis through downregulation of Jak2/STAT3 signaling pathway in human melanoma cells

-

in-vitro,

Melanoma,

SK-MEL-28

-

in-vivo,

NA,

NA

SK-MEL-28 tumor xenografts

Apoptosis↑, JAK2↓, STAT3↓, cycD1↓, survivin↓, ROS↑, eff↓,

3413-

TQ,

Thymoquinone induces apoptosis in human colon cancer HCT116 cells through inactivation of STAT3 by blocking JAK2- and Src‑mediated phosphorylation of EGF receptor tyrosine kinase

-

in-vitro,

CRC,

HCT116

tumCV↓, Apoptosis↓, BAX↑, Bcl-2↓, Casp9↑, Casp7↑, Casp3↑, cl‑PARP↑, STAT3↓, survivin↓, cMyc↓, cycD1↓, p27↑, P21↑, EGFR↓, ROS↑,

3414-

TQ,

Thymoquinone induces apoptosis through inhibition of JAK2/STAT3 signaling via production of ROS in human renal cancer Caki cells

-

in-vitro,

RCC,

Caki-1

tumCV↓, Apoptosis↑, P53↑, BAX↑, Cyt‑c↑, cl‑Casp9↑, cl‑Casp3↑, cl‑PARP↑, Bcl-2↓, Bcl-xL↓, p‑STAT3↓, p‑JAK2↓, STAT3↓, survivin↓, cycD1↓, ROS↑, eff↓,

3415-

TQ,

The anti-neoplastic impact of thymoquinone from Nigella sativa on small cell lung cancer: In vitro and in vivo investigations

-

in-vitro,

Lung,

H446

1-100uM

tumCV↓, TumCCA↑, ROS↓, CycB↑, CycD3↑, cycA1↓, cycE↓, cDC2↓, antiOx↑, PARP↓, NRF2↓, ARE/EpRE↑, eff↑,

3416-

TQ,

Thymoquinone induces apoptosis in bladder cancer cell via endoplasmic reticulum stress-dependent mitochondrial pathway

-

in-vitro,

Bladder,

T24

TQ (20–100 μM) for 24 h

-

in-vitro,

Bladder,

253J

-

in-vitro,

Nor,

SV-HUC-1

TumCP↓, Apoptosis↑, ER Stress↑, cl‑Casp3↑, cl‑Casp8↑, cl‑Casp7↑, cl‑PARP↑, Cyt‑c↑, PERK↑, IRE1↑, ATF6↑, p‑eIF2α↑, ATF4↑, GRP78/BiP↑, CHOP↑,

3417-

TQ,

Antiproliferative Effects of Thymoquinone in MCF-7 Breast and HepG2 Liver Cancer Cells: Possible Role of Ceramide and ER Stress

-

in-vitro,

BC,

MCF-7

-

in-vitro,

Liver,

HepG2

TumCP↓, NF-kB↓, cl‑Casp3↑, GRP78/BiP↑, ER Stress↑, Apoptosis↑,

3418-

TQ,

Thymoquinone suppresses metastasis of melanoma cells by inhibition of NLRP3 inflammasome

-

in-vitro,

Melanoma,

A375

-

in-vivo,

NA,

NA

B16F10) melanoma cell line

TumMeta↓, TumCMig↓, NLRP3↓, Casp1↓, IL1β↓, IL18↓, ROS↓, NF-kB↓,

3553-

TQ,

Study Effectiveness and Stability Formulation Nanoemulsion of Black Cumin Seed (Nigella sativa L.) Essential Oil: A Review

-

Review,

Nor,

NA

*AntiCan↑, *Inflam↓, *antiOx↑, *AntiAge↑, *hepatoP↑, *cardioP↑, *neuroP↑, *eff↑,

3558-

TQ,

Behavioral and histological study on the neuroprotective effect of thymoquinone on the cerebellum in AlCl3-induced neurotoxicity in rats through modulation of oxidative stress, apoptosis, and autophagy

-

in-vivo,

AD,

NA

Rats

*MDA↓, *NO↓, *GSH↑, *neuroP↑, *cognitive↑,

3554-

TQ,

Neuroprotective efficacy of thymoquinone against amyloid beta-induced neurotoxicity in human induced pluripotent stem cell-derived cholinergic neurons

-

in-vitro,

AD,

NA

*GSH↑, *ROS↓, *neuroP↑, *Casp3↓, *Casp7↓, *antiOx↓, *H2O2↓,

3555-

TQ,

Thymoquinone administration ameliorates Alzheimer's disease-like phenotype by promoting cell survival in the hippocampus of amyloid beta1-42 infused rat model

-

in-vivo,

AD,

NA

adult female rats.

*memory↑, *BAX↓, *Aβ↓, *p‑tau↓, *AChE↓, *p‑Akt↓, *Ach↑, *Inflam↓,

3556-

TQ,

Thymoquinone alleviates the experimentally induced Alzheimer’s disease inflammation by modulation of TLRs signaling

-

in-vivo,

AD,

NA

10, 20, and 40 mg/kg/day for 14 days

Ninety six Sprague-Dawley male albino rats

*Inflam↓, *memory↑, *cognitive↑, *Aβ↑, *TNF-α↓, *IL1β↓, *TLR2↓, *NF-kB↓, *IRF3↓, TLR4↓, MyD88↓, TRIF↓,

3572-

TQ,

Enhanced oral bioavailability and hepatoprotective activity of thymoquinone in the form of phospholipidic nano-constructs

-

in-vivo,

Nor,

NA

TQ, phospholipid nanoconstructs (PNCs)

*BioAv↑, *hepatoP↑, *ALAT↓, *ALP↓, *AST↓,

3571-

TQ,

The Role of Thymoquinone in Inflammatory Response in Chronic Diseases

-

Review,

Var,

NA

-

Review,

Stroke,

NA

*BioAv↓, *BioAv↑, *Inflam↓, *antiOx↑, *ROS↓, *GSH↑, *GSTs↑, *MPO↓, *NF-kB↓, *COX2↓, *IL1β↓, *TNF-α↓, *IFN-γ↓, *IL6↓, *cardioP↑, *lipid-P↓, *TAC↑, *RenoP↑, Apoptosis↑, TumCCA↑, TumCP↓, TumCMig↓, angioG↓, TNF-α↓, NF-kB↓, ROS↑, EMT↓, *Aβ↓, *p‑tau↓, *BACE↓, *TLR2↓, *TLR4↓, *MyD88↓, *IRF3↓, *eff↑, eff↑, DNAdam↑, *iNOS↓,

3570-

TQ,

Thymoquinone alleviates the experimentally induced Alzheimer's disease inflammation by modulation of TLRs signaling

-

in-vivo,

AD,

NA

rat model of AD induced by a combination of aluminum chloride (AlCl3

*Inflam↓, *Aβ↓, *TNF-α↓, *IL1β↓, *TLR2↓, *IRF3↓, *TLR4↓, *memory↑, *NF-kB↓, *MyD88↓, *TRIF↓, *BBB↑, *cognitive↑,

3565-

TQ,

Thymoquinone as a potential therapeutic for Alzheimer’s disease in transgenic Drosophila melanogaster model

*cognitive↑, *ROS↓, *SOD↑, *AChE↝, *Aβ↓,

3564-

TQ,

The Potential Neuroprotective Effect of Thymoquinone on Scopolamine-Induced In Vivo Alzheimer's Disease-like Condition: Mechanistic Insights

-

in-vivo,

AD,

NA

Thirty mice

*Inflam↓, *AntiCan↑, *antiOx↑, *neuroP↑, *cognitive↑, *Aβ↓, *PPARγ↑, *NF-kB↓, *p‑tau↓, *MMP↑, *memory↑, *NF-kB↓, *ROS↓,

3563-

TQ,

Thymoquinone (TQ) demonstrates its neuroprotective effect via an anti-inflammatory action on the Aβ(1–42)-infused rat model of Alzheimer's disease

-

in-vivo,

AD,

NA

A rat model of AD was established in 6 month-old rats

*memory↑, *IFN-γ↑, *neuroP↑, *Inflam↓, *cognitive↑,

3557-

TQ,

Thymoquinone protects against lipopolysaccharides-induced neurodegeneration and Alzheimer-like model in mice.

-

in-vivo,

AD,

NA

thirty-five Swiss mice

*Inflam↓, *antiOx↑, *cognitive↑, *TNF-α↓, *IL1β↓, *AChE↓, *IL10↑, *ChAT↑, *Aβ↓,

3561-

TQ,

Studi In Silico Potensi Piperine, Piperlongumine, dan Thymoquinone Sebagai Obat Alzheimer

-

NA,

AD,

NA

*AChE↓, *BBB↑,

3560-

TQ,

Protective effects of thymoquinone on D-galactose and aluminum chloride induced neurotoxicity in rats: biochemical, histological and behavioral changes

-

in-vivo,

AD,

NA

orally TQ (20 mg/kg/dose) dissolved in corn oil daily for 14 consecutive days

Forty Sprague Dawley male albino rats

*cognitive↑, *SOD↑, *TAC↑, *AChE↓, *MDA↓, *NO↓, *TNF-α↓, *Bcl-2↑, *Ach↑, *neuroP↑,

3559-

TQ,

Molecular signaling pathway targeted therapeutic potential of thymoquinone in Alzheimer’s disease

-

Review,

AD,

NA

-

Review,

Var,

NA

*antiOx↑, *Inflam↑, *AChE↓, AntiCan↑, *cardioP↑, *RenoP↑, *neuroP↑, *hepatoP↑, TumCG↓, Apoptosis↑, PI3K↓, Akt↑, TumCCA↑, angioG↓, *NF-kB↓, *TLR2↓, *TLR4↓, *MyD88↓, *TRIF↓, *IRF3↓, *IL1β↓, *IL6↓, *IL12↓, *NRF2↑, *COX2↓, *VEGF↓, *MMP9↓, *cMyc↓, *cycD1↓, *TumCP↓, *TumCI↓, *MDA↓, *TGF-β↓, *CRP↓, *Casp3↓, *GSH↑, *IL10↑, *iNOS↑, *lipid-P↓, *SOD↑, *H2O2↓, *ROS↓, *LDH↓, *Catalase↑, *GPx↑, *AChE↓, *cognitive↑, *MAPK↑, *JNK↑, *BAX↓, *memory↑, *Aβ↓, *MMP↑,

2454-

Trip,

Natural product triptolide induces GSDME-mediated pyroptosis in head and neck cancer through suppressing mitochondrial hexokinase-ΙΙ

-

in-vitro,

HNSCC,

HaCaT

-

in-vivo,

NA,

NA

xenograft tumors in nude mice

GSDME-N↑, Pyro↑, cMyc↓, HK2↓, BAD↑, BAX↑, Casp3↑, NRF2↓, xCT↓, ROS↑, eff↑, Glycolysis↓, GlucoseCon↓, lactateProd↓, ATP↓, xCT↓, eff↑,

2413-

TTT,

Tumor treating fields (TTFields) impairs aberrant glycolysis in glioblastoma as evaluated by [18F]DASA-23, a non-invasive probe of pyruvate kinase M2 (PKM2) expression

-

in-vitro,

GBM,

U87MG

We used [18F]DASA-23, a novel radiotracer that measures PKM2 expression and which has been shown to be safe in humans,

PKM2↓, Glycolysis↓, OXPHOS↑,

2412-

TTT,

A review of tumor treating fields (TTFields): advancements in clinical applications and mechanistic insights

-

Review,

GBM,

NA

TumCG↓, eff↝, OS↑,

2411-

UA,

Ursolic acid in health and disease

-

Review,

Var,

NA

Inflam↓, antiOx↑, NF-kB↓, Bcl-xL↓, Bcl-2↓, cycD1↓, Ki-67↓, CD31↓, STAT3↓, EGFR↓, P53↑, P21↓, HK2↓, PKM2↓, ATP↓, lactateProd↓, p‑ERK↓, MMP↓, NO↑, ATM↑, Casp3↑, AMPK↑, JNK↑, FAO↑, FASN↓, *GSH↑, *SOD↑, *Catalase↑, *GPx↑, *GSTs↑, neuroP↑,

2350-

UA,

Ursolic acid-mediated changes in glycolytic pathway promote cytotoxic autophagy and apoptosis in phenotypically different breast cancer cells

-

in-vitro,

BC,

MCF-7

20uM

-

in-vitro,

BC,

MDA-MB-231

Akt↓, Glycolysis↓, HK2↓, PKM2↓, ATP↓, lactateProd↓, AMPK↑, TumAuto↑, Apoptosis↑, ERK↓, MMP↓, NO↑, ROS↑, DNAdam↑,

1020-

UA,

Root Bark of Morus alba L. and Its Bioactive Ingredient, Ursolic Acid, Suppress the Proliferation of Multiple Myeloma Cells by Inhibiting Wnt/β-Catenin Pathway

-

in-vitro,

Melanoma,

RPMI-8226

β-catenin/ZEB1↓, TCF↓, cMyc↓, cycD1↓, TumCP↓, TumCCA↑, Apoptosis↑, cl‑Casp3↑, cl‑PARP↑, Casp7↑,

1058-

UA,

Ursolic acid, an antagonist for transforming growth factor (TGF)-beta1

-

in-vivo,

NA,

NA

6.9+/-0.8 microM.

mouse

TGF-β↓,

119-

UA,

CUR,

RES,

Combinatorial treatment with natural compounds in prostate cancer inhibits prostate tumor growth and leads to key modulations of cancer cell metabolism

-

in-vitro,

Pca,

DU145

-

in-vitro,

Pca,

PC3

ROS⇅, p‑STAT3↓, Src↓, AMPK↑,

1139-

UA,

Ursolic acid inhibits epithelial-mesenchymal transition by suppressing the expression of astrocyte-elevated gene-1 in human nonsmall cell lung cancer A549 cells

-

in-vitro,

Lung,

A549

TumMeta↓, AEG1↓, E-cadherin↑, N-cadherin↓, Vim↓, EMT↓,

942-

UA,

Ursolic Acid Inhibits Breast Cancer Metastasis by Suppressing Glycolytic Metabolism via Activating SP1/Caveolin-1 Signaling

-

vitro+vivo,

BC,

MCF-7

25~50 mg/kg/d) by intraperitoneal injection

Zebrafish and Mouse

-

in-vitro,

BC,

MDA-MB-231

Cav1↑, Glycolysis↓, cMyc↓, LDHA↓, Nrf1↓, PGC-1α↓, Sp1/3/4↑, TumCG↓,

1310-

UA,

Ursolic acid triggers apoptosis and Bcl-2 downregulation in MCF-7 breast cancer cells

-

in-vitro,

BC,

MCF-7

53 microM

GR↝, AP-1↝, cl‑PARP↑, Bcl-2↓, NA↑,

1888-

VitB1/Thiamine,

DCA,

High Dose Vitamin B1 Reduces Proliferation in Cancer Cell Lines Analogous to Dichloroacetate

-

in-vitro,

PC,

SK-N-BE

-

NA,

PC,

PANC1

p‑PDH↓, GlucoseCon↓, lactateProd↓, MMP↓, Casp3↑, eff↑, PDKs↓, selectivity↑, TumCG↓, Dose∅, MMP↓, ROS∅, toxicity↑, antiOx↑,

1836-

VitC,

VitK3,

Chemo,

Vitamins C and K3: A Powerful Redox System for Sensitizing Leukemia Lymphocytes to Everolimus and Barasertib

-

in-vitro,

AML,

NA

tumCV↓, selectivity↑, Apoptosis↑, eff↑, ChemoSen↑,

1819-

VitC,

VitK3,

The association of vitamins C and K3 kills cancer cells mainly by autoschizis, a novel form of cell death. Basis for their potential use as coadjuvants in anticancer therapy

-

Review,

Var,

NA

Dose?, TumCD↑, selectivity↑, H2O2↑, ROS↑, DNAdam↑,

3116-

VitC,

Vitamin C Inhibits NF-kB Activation by TNF Via the Activation of p38 Mitogen-Activated Protein Kinase

-

in-vitro,

Nor,

ECV304

-

in-vitro,

Nor,

HUVECs

*NF-kB↓, *p38↑, *MAPK↑,

3117-

VitC,

Vitamin C induces Tet-dependent DNA demethylation and a blastocyst-like state in ES cells

-

in-vitro,

Nor,

mESC

TET1↑, eff↝,

3118-

VitC,

Vitamin C boosts DNA demethylation in TET2 germline mutation carriers

-

Trial,

Nor,

NA

clinical trial of 1 year, we investigated the effects of oral 1 g/day vitamin C supplementation

TET2↑,

3119-

VitC,

Ascorbic acid–induced TET activation mitigates adverse hydroxymethylcytosine loss in renal cell carcinoma

-

in-vitro,

RCC,

NA

TET2↑, TumCG↓, tumCV↓,

3120-

VitC,

Upregulation of TET activity with ascorbic acid induces epigenetic modulation of lymphoma cells

-

in-vitro,

lymphoma,

NA

TET2↑, Smad1↑, ChemoSen↑, other↝,

3121-

VitC,

immuno,

Ascorbic acid induced TET2 enzyme activation enhances cancer immunotherapy efficacy in renal cell carcinoma

-

in-vivo,

RCC,

A498

xenograft model

-

in-vitro,

RCC,

786-O

TET2↑, eff↑, eff↑,

3122-

VitC,

Ascorbic Acid Promotes Plasma Cell Differentiation through Enhancing TET2/3-Mediated DNA Demethylation

TET2↑, TET3↑,

3123-

VitC,

Ascorbic Acid Enhances Tet-Mediated 5-Methylcytosine Oxidation and Promotes DNA Demethylation in Mammals

-

in-vitro,

Nor,

mESC

*TET2↑, other↝,

3124-

VitC,

Ascorbic acid improves parthenogenetic embryo development through TET proteins in mice

-

in-vivo,

Nor,

NA

mice

TET2↑, TET1↑, TET3↑,

3125-

VitC,

Vitamin C inhibits NLRP3 inflammasome activation and delays the development of age-related hearing loss in male C57BL/6 mice

-

in-vivo,

Nor,

NA

mice

*Hear↑, *Inflam↓, *NLRP3↓,

3126-

VitC,

Safety of High-Dose Vitamin C in Non-Intensive Care Hospitalized Patients with COVID-19: An Open-Label Clinical Study

-

Study,

NA,

NA

*NLRP3↓, *ROS↓, *antiOx↑,

3104-

VitC,

Pro- and Antioxidant Effects of Vitamin C in Cancer in correspondence to Its Dietary and Pharmacological Concentrations

*antiOx↑, *ROS↓, *DNAdam↓, ROS↑, TET1↑, CSCs↓, HIF-1↓, BioAv↑, selectivity↑,

3127-

VitC,

Vitamin C inhibits the activation of the NLRP3 inflammasome by scavenging mitochondrial ROS

-

in-vitro,

Nor,

NA

Mouse bone marrow-derived macrophages (BMDMs

-

in-vivo,

Nor,

NA

*NLRP3↓, *AIM2↓, *mt-ROS↓, *IL1β↓,

3115-

VitC,

The NF-κB Transcriptional Network Is a High-Dose Vitamin C-Targetable Vulnerability in Breast Cancer

-

in-vitro,

BC,

NA

NF-kB↓, Hif1a↓, P53↑,

3114-

VitC,

Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression

-

in-vitro,

AML,

NA

TET2↑, eff↑, ROS↑, Fenton↑, Hif1a↓,

3113-

VitC,

Vitamin C enhances NF-κB-driven epigenomic reprogramming and boosts the immunogenic properties of dendritic cells

-

in-vitro,

Nor,

NA

Dendritic cells

TET2↑, NF-kB↑,

3112-

VitC,

Antioxidative and Anti-Inflammatory Activity of Ascorbic Acid

-

Review,

Nor,

NA

*ROS↓, *antiOx↑, *SOD↑, *Catalase↑, *GPx↑, *NRF2↑, *AP-1↑, *Inflam↓, *CRP↓, IFN-γ↓,

3111-

VitC,

https://pmc.ncbi.nlm.nih.gov/articles/PMC4492638/

-

Trial,

Nor,

NA

Inflam↓, CRP↓, IL6↓,

3110-

VitC,

Vitamin C Attenuates Oxidative Stress, Inflammation, and Apoptosis Induced by Acute Hypoxia through the Nrf2/Keap1 Signaling Pathway in Gibel Carp (Carassius gibelio)

-

in-vivo,

Nor,

NA

Gibel Carp

*IL2↑, *IL6↑, *IL12↑, *NRF2↑, *Catalase↑, *SOD↑, *GPx↑, *GRP78/BiP↓, *ER Stress↓,

3109-

VitC,

Vitamin C Inhibited Pulmonary Metastasis through Activating Nrf2/HO-1 Pathway

-

in-vitro,

Lung,

H1299

TumMeta↓, NRF2↑, HO-1↑, cl‑Casp3↑, cl‑Casp9↑, DNAdam↑, Apoptosis↑, other↑, selectivity↑,

3108-

VitC,

QC,

The role of quercetin and vitamin C in Nrf2-dependent oxidative stress production in breast cancer cells

-

in-vitro,

BC,

MDA-MB-231

-

in-vitro,

Lung,

A549

NRF2↓, HO-1↓, ROS↑, NRF2⇅,

3107-

VitC,

Repurposing Vitamin C for Cancer Treatment: Focus on Targeting the Tumor Microenvironment

-

Review,

Var,

NA

Risk↓, *ROS↓, ROS↑, VEGF↓, COX2↓, ER Stress↑, IRE1↑, JNK↑, CHOP↑, Hif1a↓, eff↑, Glycolysis↓, MMPs↓, TumMeta↓, YAP/TEAD↓, eff↑, TET1↑,

3106-

VitC,

Protective effect of vitamin C on oxidative stress: a randomized controlled trial

-

Trial,

Nor,

NA

244 Japanese subjects with atrophic gastritis

*ROS↓,

3105-

VitC,

ROS-lowering doses of vitamins C and A accelerate malignant melanoma metastasis

-

Review,

Var,

NA

TumMeta↑,

3153-

VitC,

Vitamin C Status and Cognitive Function: A Systematic Review

-

Review,

AD,

NA

cognitive↑, eff↑,

3140-

VitC,

Vitamin-C-dependent downregulation of the citrate metabolism pathway potentiates pancreatic ductal adenocarcinoma growth arrest

-

in-vitro,

PC,

MIA PaCa-2

-

in-vitro,

Nor,

HEK293

citrate↓, FASN↓, ACLY↓, LDH↓, Glycolysis↓, Warburg↓, PDK1↓, GLUT1↓, LDHA↓, ECAR↓, PDH↑, eff↑,

3151-

VitC,

Role of Vitamin C in the Function of the Vascular Endothelium

-

Review,

Nor,

NA

angioG↓,

3150-

VitC,

Vitamin C: A Review on its Role in the Management of Metabolic Syndrome

-

Review,

Obesity,

NA

*glucose↓, *BG↓, *antiOx↑, *ROS↓,

3149-

VitC,

Hepatoprotective benefits of vitamin C against perfluorooctane sulfonate-induced liver damage in mice through suppressing inflammatory reaction and ER stress

-

in-vivo,

Nor,

NA

mice

*hepatoP↑, *ALAT↓, *AST↓, *TNF-α↓, *IL6↓, *ER Stress↓, *ATF6↓, *eIF2α↓, *GRP78/BiP↓, *XBP-1↓, *Inflam↓,

3148-

VitC,

Antioxidants in brain tumors: current therapeutic significance and future prospects

-

Review,

Var,

NA

*antiOx↑, *ROS↓, chemoP↑, ChemoSen↑, TET2↑, eff↑, OS↑, QoL↑, eff↑,

3147-

VitC,

Vitamin C modulates the metabolic and cytokine profiles, alleviates hepatic endoplasmic reticulum stress, and increases the life span of Gulo−/− mice

-

in-vivo,

Nor,

NA

mice

*OS↑, *ER Stress↓, *GRP78/BiP↓,

3146-

VitC,

Vitamin C protects against hypoxia, inflammation, and ER stress in primary human preadipocytes and adipocytes

-

in-vivo,

Nor,

NA

*Obesity↓, *ER Stress↓, *Inflam↓, Hif1a↓, VEGF↓, GLUT1↓, GRP78/BiP↓,

3145-

VitC,

Vitamin C inhibits the growth of colorectal cancer cell HCT116 and reverses the glucose‐induced oncogenic effect by downregulating the Warburg effect

-

in-vitro,

CRC,

HCT116

Warburg↓, TumCG↓, Glycolysis↓, GlucoseCon↓, ATP↓, lactateProd↓, selectivity↑, GLUT1↓, PKM2↓, LDHA↓, mTOR↓,

3144-

VitC,

Some characteristics of Rabbit muscle phosphofructokinase-1 inhibition by ascorbate

-

in-vitro,

Nor,

NA

Rabbit muscle

PFK1↓, LDH↓,

3143-

VitC,

ATO,

Vitamin C enhances the sensitivity of osteosarcoma to arsenic trioxide via inhibiting aerobic glycolysis

-

in-vitro,

OS,

NA

TumCP↓, TumCMig↓, TumCI↓, eff↑, Glycolysis↓, lactateProd↓, ATP↓, PGK1↓, PGM1↓, LDHA↓,

3142-

VitC,

Vitamin C promotes apoptosis in breast cancer cells by increasing TRAIL expression

-

in-vitro,

BC,

MDA-MB-231

-

in-vitro,

BC,

MCF-7

-

in-vitro,

Nor,

MCF12A

TET2↑, Apoptosis↑, TRAIL↑, BAX↑, Casp↑, Cyt‑c↑, HK2↓, PDK1↓, BNIP3↓,

3141-

VitC,

High-dose Vitamin C inhibits PD-L1 expression by activating AMPK in colorectal cancer

-

in-vitro,

CRC,

HCT116

Glycolysis↓, eff↑, PD-L1↓, AMPK↑, HK2↓, NF-kB↓, Warburg↓, tumCV↓, GLUT1↓, PKM2↓, LDHA↓, CD4+↑, CD8+↑,

3128-

VitC,

Vitamin C Mitigates Oxidative Stress and Tumor Necrosis Factor-Alpha in Severe Community-Acquired Pneumonia and LPS-Induced Macrophages

-

in-vitro,

Nor,

NA

*ROS↓, *DNAdam↓, *TNF-α↓, *IL6↓, *p38↓,

3139-

VitC,

Vitamin C and sodium bicarbonate enhance the antioxidant ability of H9C2 cells and induce HSPs to relieve heat stress

-

in-vitro,

Nor,

H9c2

*Apoptosis∅, *LDH∅, *MDA∅, *SOD↓, eff↝,

3138-

VitC,

The Hypoxia-inducible Factor Renders Cancer Cells More Sensitive to Vitamin C-induced Toxicity

-

in-vitro,

RCC,

RCC4

-

in-vitro,

CRC,

HCT116

-

in-vitro,

BC,

MDA-MB-435

-

in-vitro,

Ovarian,

SKOV3

-

in-vitro,

Colon,

SW48

-

in-vitro,

GBM,

U251

eff↑, Warburg↓, BioAv↑, ROS↑, DNAdam↑, ATP↓, eff↑, necrosis↑, PARP↑,

3137-

VitC,

Vitamin C inhibits the growth of colorectal cancer cell HCT116 and reverses the glucose-induced oncogenic effect by downregulating the Warburg effect

-

in-vitro,

CRC,

HCT116

Warburg↓, TumCG↓,

3136-

VitC,

Vitamin C uncouples the Warburg metabolic switch in KRAS mutant colon cancer

-

in-vitro,

Colon,

SW48

-

in-vitro,

Colon,

LoVo

ERK↓, p‑PKM2↓, GLUT1↓, Warburg↓, TumCD↑, eff↑, ROS↓, cMyc↓,

3135-

VitC,

The interplay between vitamin C and thyroid

-

Review,

Thyroid,

NA

AntiCan↑, ChemoSen↑, radioP↑, MAPK↓, ERK↓, PI3K↓, Akt↓, QoL↑, OS↑,

3134-

VitC,

Vitamin C promotes human endothelial cell growth via the ERK-signaling pathway

-

in-vitro,

Nor,

HUVECs

*ERK↑,

3133-

VitC,

Vitamin C supplementation had no side effect in non-cancer, but had anticancer properties in ovarian cancer cells

-

in-vitro,

Ovarian,

NA

*SVCT-2↑, *GLUT1↓, SVCT-2↓, GLUT1↑, TumCP↓, CDK2↓, PARP↓, selectivity↑,

3132-

VitC,

Vitamin C affects G0/G1 cell cycle and autophagy by downregulating of cyclin D1 in gastric carcinoma cells

-

in-vitro,

GC,

MKN45

TumCCA↑, cycD1↓,

3131-

VitC,

Antioxidant Vitamin C attenuates experimental abdominal aortic aneurysm development in an elastase-induced rat model

-

in-vivo,

Nor,

NA

rat

*MMP2↓, *MMP9↓, *TNF-α↓, *IL1β↓, *TIMP2↑, *TIMP1↓, *antiOx↑, *Inflam↓,

3130-

VitC,

Effect of high-dose vitamin C on MMP2 expression and invasive ability in human pancreatic cancer cell line PANC-1

-

in-vitro,

PC,

PANC1

MMP2↓, TumCI↓,

3129-

VitC,

Therapeutic treatment with vitamin C reduces focal cerebral ischemia-induced brain infarction in rats by attenuating disruptions of blood brain barrier and cerebral neuronal apoptosis

-

in-vivo,

Stroke,

NA

*BBB↑, *MMP9↓, *MMPs↓, *MMP2↓, *CLDN1↝, *ZO-1↝, eff↑,

2592-

VitC,

Ascorbic acid restores sensitivity to imatinib via suppression of Nrf2-dependent gene expression in the imatinib-resistant cell line

-

in-vitro,

CLL,

NA

NRF2↓, GSH↓,

3101-

VitC,

Vitamin C stimulates or attenuates reactive oxygen and nitrogen species (ROS, RNS) production depending on cell state: Quantitative amperometric measurements of oxidative bursts at PLB-985 and RAW 264.7 cells at the single cell level

-

in-vitro,

Nor,

RAW264.7

-

in-vitro,

AML,

PLB-985

*antiOx↑, *ROS↓, *RNS↓, ROS↑,

3102-

VitC,

Two Faces of Vitamin C—Antioxidative and Pro-Oxidative Agent

-

Review,

Var,

NA

-

Review,

Stroke,

NA

*radioP↑, *Dose↝, ROS↑, *neuroP↑, other↓, *ROS↓, *MMP↑,

3103-

VitC,

Effect of Vitamin C on Reactive Oxygen Species Formation in Erythrocytes of Sickle Cell Anemia Patients

-

Human,

Nor,

NA

*ROS↓,

2485-

VitC,

TACE,

High-Dose Vitamin C Promotes Regression of Multiple Pulmonary Metastases Originating from Hepatocellular Carcinoma

-

Case Report,

HCC,

NA

ROS↑, Dose↝, Dose↝, TumCG↓, Remission↑,

636-

VitC,

Acute Effects of Vitamin C Exposure On Colonic Crypts: Direct Modulation of pH Regulation

-

in-vivo,

NA,

NA

10 mM

rats

pH↓, SVCT-2∅,

635-

VitC,

VitK3,

The combination of ascorbate and menadione causes cancer cell death by oxidative stress and replicative stress

-

in-vitro,

NA,

NA

RNR↓, GSH↓, Trx1↓, GPx↓, lipid-P↑, AIF↑, ROS↑,

634-

VitC,

Intravenous ascorbic acid to prevent and treat cancer-associated sepsis?

-

Analysis,

NA,

NA

other↓, iNOS↓, eNOS↑,

633-

VitC,

Diverse antitumor effects of ascorbic acid on cancer cells and the tumor microenvironment

-

Analysis,

NA,

NA

Fenton↑, ROS↑, EMT↓, DNAdam↑, PARP↑, NAD↓, ATP↓, Apoptosis↑,

632-

VitC,

High-Dose Vitamin C: Preclinical Evidence for Tailoring Treatment in Cancer Patients

-

Review,

NA,

NA

SVCT-2∅, ROS↑, Hif1a↓, PARP∅, TET2↑,

631-

VitC,

Vitamin C preferentially kills cancer stem cells in hepatocellular carcinoma via SVCT-2

-

vitro+vivo,

Liver,

NA

1mM

SVCT-2∅, ROS↑, DNAdam↑, ATP↓, TumCCA↑, Apoptosis↑, OS↑, CD133↓, EpCAM↓, OV6↓, γH2AX↑,

114-

VitC,

QC,

Chemoprevention of prostate cancer cells by vitamin C plus quercetin: role of Nrf2 in inducing oxidative stress

-

in-vitro,

Pca,

PC3

0.1-1000 uM

-

in-vitro,

NA,

DU145

GPx↓, GSR↓, NQO1↓, NRF2↓, ROS↑,

1067-

VitC,

Vitamin C activates pyruvate dehydrogenase (PDH) targeting the mitochondrial tricarboxylic acid (TCA) cycle in hypoxic KRAS mutant colon cancer

-

in-vivo,

CRC,

NA

pharmacological doses of vitamin C

mice

PDK1↓, Hif1a↓, GLUT1↓, ATP↓, MMP↓,

614-

VitC,

Vitamin C Pharmacokinetics: Implications for Oral and Intravenous Use

other↑,

612-

VitC,

VitK3,

Effects of sodium ascorbate (vitamin C) and 2-methyl-1,4-naphthoquinone (vitamin K3) treatment on human tumor cell growth in vitro. I. Synergism of combined vitamin C and K3 action

H2O2↑,

615-

VitC,

High Dose IV Vitamin C and Metastatic Breast Cancer: A Case Report

-

Case Report,

NA,

NA

OS↑, Remission↑,

616-

VitC,

Suppression of alkaline phosphatase in prostate cancer patients by high dose intravenous Vitamin C Treatment: Three cases

-

Case Report,

NA,

NA

PSA↓, ALP↓,

617-

VitC,

Chemo,

The Use of Vitamin C with Chemotherapy in Cancer Treatment: An Annotated Bibliography

-

Review,

NA,

NA

TumCG↓, ChemoSideEff↓,

618-

VitC,

Low levels of catalase enzyme make cancer cells vulnerable to high-dose ascorbate

Catalase↓,

619-

VitC,

Natural resistance to ascorbic acid induced oxidative stress is mainly mediated by catalase activity in human cancer cells and catalase-silencing sensitizes to oxidative stress

Catalase↝,

620-

VitC,

Case Study: High-Dose Intravenous Vitamin C in the Treatment of a Patient with Adenocarcinoma of the Kidney

-

Case Report,

NA,

NA

OS↑,

621-

VitC,

Sixteen-Year History with High Dose Intravenous Vitamin C Treatment for Various Types of Cancer and Other Diseases

ChemoSideEff∅,

622-

VitC,

Treatment of Pancreatic Cancer with Pharmacological Ascorbate

-

vitro+vivo,

PC,

NA

H2O2↑,

623-

VitC,

The Involvement of Ascorbic Acid in Cancer Treatment

-

Review,

NA,

NA

ROS↑, GLUT1↓, ATP↓,

624-

VitC,

Ascorbic Acid in Colon Cancer: From the Basic to the Clinical Applications

-

Review,

NA,

NA

OS↑,

625-

VitC,

The Effect of Vitamin C (Ascorbic Acid) in the Treatment of Patients with Cancer: A Systematic Review

OS↑, Pain↓, NA↓,

626-

VitC,

Systematic Review of Intravenous Ascorbate in Cancer Clinical Trials

-

Review,

NA,

NA

OS↑, H2O2↑,

627-

VitC,

High-Dose Vitamin C for Cancer Therapy

-

Review,

NA,

NA

ROS↑, PARP↑, GAPDH↓, DNAdam↑, ATP↓,

628-

VitC,

Mg,

Enhanced Anticancer Effect of Adding Magnesium to Vitamin C Therapy: Inhibition of Hormetic Response by SVCT-2 Activation

-

in-vivo,

Colon,

CT26

mouse

-

in-vitro,

NA,

MCF-7

1–10 mM(Mg)

(MgSO4 and MgCl2) no cytotoxicity at any of the tested concentrations.

-

in-vitro,

NA,

SkBr3

AntiCan↑, SVCT-2↝, TumCD↑, ROS↑, P21↑, proCasp3↑, TumVol↓, DNAdam↑, NAD↓,

629-

VitC,

Cu,

Fe,

The antioxidant ascorbic acid mobilizes nuclear copper leading to a prooxidant breakage of cellular DNA: implications for chemotherapeutic action against cancer

-

in-vitro,

NA,

NA

ROS↑, DNAdam↑, NAD↓,

630-

VitC,

Metabolomic alterations in human cancer cells by vitamin C-induced oxidative stress

-

in-vitro,

BC,

MCF-7

2.4 mM

-

in-vitro,

BC,

HT-29

TCA↑, ATP↓, NAD↓, H2O2↑, GSH/GSSG↓,

593-

VitC,

MF,

Protective Effect of Ascorbic Acid on Molecular Behavior Changes of Hemoglobin Induced by Magnetic Field Induced by Magnetic Field

RPM↓,

588-

VitC,

MF,

Preparation of magnetic nanoparticle integrated nanostructured lipid carriers for controlled delivery of ascorbyl palmitate

other↑,

596-

VitC,

High-Dose Vitamin C in Advanced-Stage Cancer Patients

-

Review,

NA,

NA

ChemoSideEff↓, ROS↑, H2O2↑, Fenton↑, Hif1a↝, Dose↑, BioAv↓, Dose↝, Half-Life↝, IL1β↓, IL2↓, IL8↓, TNF-α↓,

597-

VitC,

STF,

GlucDep,

The Result of Vitamin C Treatment of Patients with Cancer: Conditions Influencing the Effectiveness

other↝, H2O2↑, ROS↑,

598-

VitC,

Ascorbic Acid in Cancer Treatment: Let the Phoenix Fly

-

Review,

NA,

NA

1g/kg over 90–120 minutes two to three times weekly is well tolerated

H2O2↑, ROS↑, TET1↑, DNAdam↑, G6PD∅,

599-

VitC,

Generation of Hydrogen Peroxide in Cancer Cells: Advancing Therapeutic Approaches for Cancer Treatment

-

Review,

NA,

NA

H2O2↑, DNAdam↑, ROS↑, Fenton↑, Apoptosis↑, necrosis↑,

600-

VitC,

VitK3,

Serum markers variation consistent with autoschizis induced by ascorbic acid-menadione in patients with prostate cancer

-

in-vitro,

NA,

NA

autoS↑, TumCD↑,

580-

VitC,

MF,

Extremely low frequency magnetic field induces oxidative stress in mouse cerebellum

-

in-vivo,

Nor,

NA

60 Hz ELF-MF at 2.3 mT intensity for 3 hours

mouse cerebellum

*other↓, *MDA↓, *GPx∅, *SOD↑, *GSH∅,

579-

VitC,

MF,

Effect of Magnetic Field on Ascorbic Acid Oxidase Activity, I

-

in-vitro,

NA,

NA

other↝,

605-

VitC,

Therapeutic Use of Vitamin C in Cancer: Physiological Considerations

-

Review,

NA,

NA

ROS↑, ChemoSideEff↓,

606-

VitC,

Understanding the Therapeutic Potential of Ascorbic Acid in the Battle to Overcome Cancer

-

Review,

NA,

NA

ROS↑, H2O2↑, Fenton↑,

607-

VitC,

Intravenously administered vitamin C as cancer therapy: three cases

-

Case Report,

NA,

NA

14 000 μmol/L

necrosis↑, OS↑,

608-

VitC,

The Levels of Ascorbic Acid in Blood and Mononuclear Blood Cells After Oral Liposome-Encapsulated and Oral Non-Encapsulated Vitamin C Supplementation, Taken Without and with IV Hydrocortisone

other↑, other↑,

609-

VitC,

ALA,

VitK3,

Se,

Vitamin C and Cancer: Is There A Use For Oral Vitamin C?

OS↑,

610-

VitC,

Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver hydrogen peroxide to tissues

-

in-vitro,

lymphoma,

JPL119

0.5 mM

-

in-vitro,

BC,

MCF-7

2.5mM

-

in-vitro,

BC,

MDA-MB-231

7 mM

-

in-vitro,

BC,

HS587T

20 mM

-

in-vitro,

Nor,

NA

>25 mM not known

not harm to normal cell **** insensitive to 20 mM ascorbate

Apoptosis↑, necrosis↑, H2O2↑, *toxicity↓,

611-

VitC,

Characterization of a new malignant human T-cell line (PFI-285) sensitive to ascorbic acid

-

in-vitro,

NA,

NA

50 mumol/l

TumCD↑,

613-

VitC,

High-dose Vitamin C (Ascorbic Acid) Therapy in the Treatment of Patients with Advanced Cancer

-

Review,

NA,

NA

typ<5mM

H2O2↑,

300-

VitC,

ALA,

Combination of High-Dose Parenteral Ascorbate (Vitamin C) and Alpha-Lipoic Acid Failed to Enhance Tumor-Inhibitory Effect But Increased Toxicity in Preclinical Cancer Models

-

in-vitro,

BC,

MDA-MB-231

Asc (0-20 mM), ALA (0-1 mM)

-

in-vitro,

Colon,

HCT116

-

in-vitro,

Ovarian,

PANC1

-

in-vitro,

Pca,

PC3

TumCG∅,

1215-

VitC,

immuno,

Metabolomics reveals ascorbic acid inhibits ferroptosis in hepatocytes and boosts the effectiveness of anti-PD1 immunotherapy in hepatocellular carcinoma

-

ex-vivo,

HCC,

NA

-

in-vivo,

HCC,

NA

mice

other↓, *GPx4↑, *GSH↑, GPx4↓, GSH↓, selectivity↑,

1216-

VitC,

Ascorbic acid induces ferroptosis via STAT3/GPX4 signaling in oropharyngeal cancer

-

in-vitro,

Laryn,

FaDu

-

in-vitro,

SCC,

SCC-154

Iron↝, ROS↑, tumCV↓, Ki-67↓, TumCCA↑, Ferroptosis↑, GSH↓, ROS↑, MDA↑, STAT3↓, GPx4↓, p‑STAT3↓,

1217-

VitC,

High-dose vitamin C suppresses the invasion and metastasis of breast cancer cells via inhibiting epithelial-mesenchymal transition

-

in-vitro,

BC,

Bcap37

low-dose, 0.01 mM; medium-dose, 0.1 mM; high-dose, 2 mM

-

in-vitro,

BC,

MDA-MB-231

-

in-vivo,

NA,

NA

mice

TumCMig↓, E-cadherin↑, Vim↓, EMT↓,

1218-

VitC,

ASA,

Ascorbic acid enhances the inhibitory effect of aspirin on neuronal cyclooxygenase-2-mediated prostaglandin E2 production

-

in-vitro,

GBM,

SK-N-SH

PGE2↓, COX2↓,

1219-

VitC,

Ascorbic acid and ascorbate-2-phosphate decrease HIF activity and malignant properties of human melanoma cells

-

in-vitro,

Melanoma,

NA

Hif1a↓,

1220-

VitC,

VitB1/Thiamine,

The Effect of Thiamine, Ascorbic Acid, and the Combination of Them on the Levels of Matrix Metalloproteinase-9 (MMP-9) and Tissue Inhibitor of Matrix Metalloproteinase-1 (TIMP-1) in Sepsis Patients

-

Trial,

Sepsis,

NA

MMP9:TIMP1↑, Sepsis↓,

1223-

VitD3,

Vitamin D3 Treatment Influences PGE2 and TGFβ in Normal and Increased Breast Cancer Risk Women

-

Trial,

NA,

NA

We reported that vitamin D3 increased transforming growth factor (TGF)β2 and decreased prostaglandin (PG)E2 in the breast of normal-risk women, suggesting a protective effect.

*TGF-β↑, *PGE2↓,

115-

VitD3,

Vitamin D3 triggers antitumor activity through targeting hedgehog signaling in human renal cell carcinoma Vitamin D3 Inhibits Hedgehog Signaling and Proliferation in Murine Basal Cell Carcinomas

-

in-vivo,

RCC,

NA

-

in-vivo,

BCC,

NA

HH↓, GLI2↓, Shh↓, Gli1↓,

1313-

VitD3,

MEL,

The effects of melatonin and vitamin D3 on the gene expression of BCl-2 and BAX in MCF-7 breast cancer cell line

-

in-vitro,

BC,

MCF-7

optimum dose of melatonin (5 nM) and vitamin D3 (0.5 nM

BAX↑, Bcl-2↓, Bax:Bcl2↑, eff↑,

1738-

VitD3,

VITAL study: an incomplete picture?

-

Trial,

Var,

NA

AntiCan↑, *BioAv↓, Dose↑,

1739-

VitD3,

Effect of Vitamin D3 Supplements on Development of Advanced Cancer

-

Trial,

Var,

NA

AntiCan↑, Dose↝, Risk↓, TumCP↓, Inflam↓, eff∅,

1741-

VitD3,

Vitamin D Deficiency: Effects on Oxidative Stress, Epigenetics, Gene Regulation, and Aging

-

Review,

Var,

NA

*Inflam↓, *antiOx↑, *eff↑, *ROS↓, *NRF2↑, *GPx↑, *Dose↝, Dose↑,

1740-

VitD3,

Vitamin D and Cancer: An Historical Overview of the Epidemiology and Mechanisms

-

Review,

Var,

NA

Risk↓, eff↑, eff↑, Risk↓, Risk↓, ChemoSen↑, RadioS↑, Cyt‑c↑, Casp3↑, Casp9↑, hTERT↓, eff↑, E-cadherin↑, CLDN2↑, ZO-1↑, Snail↓, Zeb1↓, Vim↓, VEGF↓, NK cell↑, Risk↓, eff↑,

2171-

VitD3,

Vitamin D and the Immune System

-

Analysis,

Nor,

NA

eff↑, Dose↝, eff↝, eff↑, eff↑,

2369-

VitD3,

Long Non-coding RNA MEG3 Activated by Vitamin D Suppresses Glycolysis in Colorectal Cancer via Promoting c-Myc Degradation

-

in-vitro,

CRC,

DLD1

-

in-vitro,

CRC,

RKO

MEG3↑, Glycolysis↓, lactateProd↓, LDHA↓, PKM2↓, HK2↓,

2368-

VitD3,

Vitamin D3 supplementation shapes the composition of gut microbiota and improves some obesity parameters induced by high-fat diet in mice

-

in-vivo,

Obesity,

NA

Male C57BL/6 J mice

*Weight↓, *TNF-α↓, *IL1β↓, LPS↓, *ZO-1↑, *GutMicro↑,

2367-

VitD3,

Vitamin D activates FBP1 to block the Warburg effect and modulate blast metabolism in acute myeloid leukemia

-

in-vivo,

AML,

NA

mouse models

FBP1↑, Warburg↓, Glycolysis↓, lactateProd↓,

2366-

VitD3,

Vitamin D3 decreases glycolysis and invasiveness, and increases cellular stiffness in breast cancer cells

-

in-vitro,

BC,

MCF-7

Glycolysis↓, tumCV↓, Apoptosis↑, mTOR↓, AMPK↑, EMT↓, E-cadherin↑, F-actin↑, Vim↓,

2365-

VitD3,

Vitamin D Affects the Warburg Effect and Stemness Maintenance of Non- Small-Cell Lung Cancer Cells by Regulating the PI3K/AKT/mTOR Signaling Pathway

-

in-vitro,

Lung,

A549

-

in-vitro,

Lung,

H1975

-

in-vivo,

NA,

NA

Glycolysis↓, Warburg↓, GLUT1↓, LDHA↓, HK2↓, PKM2↓, OCT4↓, SOX2↓, Nanog↓, PI3K↓, Akt↓, mTOR↓,

2282-

VitK2,

Vitamin K prevents oxidative cell death by inhibiting activation of 12-lipoxygenase in developing oligodendrocytes

-

in-vitro,

Nor,

NA

Primary pre-OL cultures were prepared from the forebrains of 1–2-day-old Sprague-Dawley rat pups

*ROS↓, *12LOX↓,

2285-

VitK2,

New insights into vitamin K biology with relevance to cancer

-

Review,

Var,

NA

Risk↓, AntiCan↑, eff↑, MMP↓, ROS↑, Cyt‑c↑, eff↓, SXR↑,

2284-

VitK2,

Menadione-induced DNA damage in a human tumor cell line

-

in-vitro,

BC,

MCF-7

DNAdam↑, ROS↑,

2283-

VitK2,

Vitamin K Contribution to DNA Damage—Advantage or Disadvantage? A Human Health Response

-

Review,

Var,

NA

*ER Stress↓, *toxicity↓, *toxicity↑, ROS↑, PI3K↑, Akt↑, Hif1a↑, GlucoseCon↑, lactateProd↑, ChemoSen↑, eff↑, eff↑,

2274-

VitK2,

Vitamin K2 Modulates Mitochondrial Dysfunction Induced by 6-Hydroxydopamine in SH-SY5Y Cells via Mitochondrial Quality-Control Loop

-

in-vitro,

Nor,

SH-SY5Y

(0–40 µM) for 6 h

SH-SY5Y cells are similar to neurones and are a widely used neurodegenerative diseases model

*Bcl-2↓, *BAX↑, *MMP↑, *ROS↓, *p62↓, *LC3A↑, *Dose↝, *Apoptosis↓, *PINK1↑, *PARK2↑,

2281-

VitK2,

The biological responses of vitamin K2: A comprehensive review

-

Review,

Var,

NA

*ROS↓, *12LOX↓, *NF-kB↓, *BMD↑, *hepatoP↑, cycD1↓, PKCδ↓, STAT3↓, ERK↑, MAPK↓, ROS↑, PI3K↝, Akt↝, Hif1a↝, *neuroP↑,

2280-

VitK2,

Vitamin K2 induces non-apoptotic cell death along with autophagosome formation in breast cancer cell lines

-

in-vitro,

BC,

MDA-MB-231

-

in-vitro,

BC,

MDA-MB-468

-

in-vitro,

AML,

HL-60

HL-60 leukemia cells were used as a control for VK2-induced apoptosis.

ROS↑, p62↓, eff↓,

2279-

VitK2,

Vitamin K2 Induces Mitochondria-Related Apoptosis in Human Bladder Cancer Cells via ROS and JNK/p38 MAPK Signal Pathways

-

in-vitro,

Bladder,

T24

0-100uM

-

in-vitro,

Bladder,

J82

-

in-vitro,

Nor,

HEK293

-

in-vitro,

Nor,

L02

-

in-vivo,

NA,

NA

mice

MMP↓, Cyt‑c↑, Casp3↑, p‑JNK↑, p‑p38↑, ROS↑, eff↓, tumCV↓, selectivity↑, *toxicity↓, TumVol↓,

2278-

VitK2,

VitK3,

VitC,

Vitamin K: Redox-modulation, prevention of mitochondrial dysfunction and anticancer effect

-

Review,

Var,

NA

ChemoSen↑, ROS↑, eff↑,

2277-

VitK2,

Vitamin K2 suppresses rotenone-induced microglial activation in vitro

-

in-vitro,

Nor,

BV2

MK-4 (0.5–20 μmol/L

-

NA,

AD,

NA

-

NA,

Park,

NA

*p38↓, *ROS↓, *Casp1↓, *MMP↑, *NF-kB↓, *IL1β↓, *iNOS↓, *COX2↓, *TNF-α↓,

2276-

VitK2,

Vitamin K2 (MK-7) Intercepts Keap-1/Nrf-2/HO-1 Pathway and Hinders Inflammatory/Apoptotic Signaling and Liver Aging in Naturally Aging Rat

-

in-vivo,

Nor,

NA

rat

*Albumin↑, *AST↓, *ALAT↓, *Keap1↓, *NRF2↑, *HO-1↑, *COX2↓, *iNOS↓, *TNF-α↓, *TIMP1↓, *TGF-β↓, *ROS↓, *DNAdam↓, *Inflam↓,

2275-

VitK2,

Delivery of the reduced form of vitamin K2(20) to NIH/3T3 cells partially protects against rotenone induced cell death

-

in-vitro,

Nor,

NIH-3T3

0-3 µM

MK-4, vitamin K2(20)), a safe drug for osteoporosis

*MMP↓, *ROS↓, *HO-1↓,

1213-

VitK2,

Vitamin K2 Inhibits Hepatocellular Carcinoma Cell Proliferation by Binding to 17β-Hydroxysteroid Dehydrogenase 4

-

in-vitro,

HCC,

HepG2

HSD17B4↓, Akt↓, MEK↓, ERK↓, STAT3↓, TumCP↓,

1214-

VitK2,

Vitamin K2 promotes PI3K/AKT/HIF-1α-mediated glycolysis that leads to AMPK-dependent autophagic cell death in bladder cancer cells

-

in-vitro,

Bladder,

T24

50 μM

-

in-vitro,

Bladder,

J82

Glycolysis↑, GlucoseCon↑, lactateProd↑, TCA↓, PI3K↑, Akt↑, AMPK↑, mTORC1↓, TumAuto↑, GLUT1↑, HK2↑, LDHA↑, ACC↓, PDH↓, eff↓, cMyc↓, Hif1a↑, p‑Akt↑, eff↓, eff↓, eff↓, eff↓, ROS↑,

1212-

VitK2,

Vitamin K2 stimulates osteoblastogenesis and suppresses osteoclastogenesis by suppressing NF-κB activation

-

in-vitro,

ostP,

NA

NF-kB↓,

1211-

VitK2,

Mechanisms of PKC-Mediated Enhancement of HIF-1α Activity and its Inhibition by Vitamin K2 in Hepatocellular Carcinoma Cells

-

in-vitro,

HCC,

HUH7

Hif1a↓, PKCδ↓,

1816-

VitK2,

Role of Vitamin K in Selected Malignant Neoplasms in Women

-

Review,

Var,

NA

TumCP↓, TumMeta↓, TumAuto↑, Apoptosis↑, Apoptosis↑, Casp3↑, Casp7↑, ROS↑, AR↓, EMT↓, Wnt↓, MMP↓, Cyt‑c↑, NF-kB↓, cycD1↓, TumCCA↓,

1840-

VitK2,

The mechanisms of vitamin K2-induced apoptosis of myeloma cells

-

in-vitro,

Melanoma,

NA

TumCG↓, Apoptosis↑, Casp3↑, ROS↑, p‑MAPK↑,

1833-

VitK2,

Divergent effects of vitamins K1 and K2 on triple negative breast cancer cells

-

in-vitro,

BC,

HS587T

-

in-vitro,

BC,

MDA-MB-231

-

in-vitro,

BC,

SUM159

TumCP↓, other↑,

1830-

VitK2,

Vitamin K Intake and Risk of Lung Cancer: The Japan Collaborative Cohort Study

-

Study,

Lung,

NA

Risk↓, NF-kB↓, PKCδ↓,

1829-

VitK2,

Vitamin K: New insights related to senescence and cancer metastasis

-

Review,

Var,

NA

TumCP↓, TumCG↓, ChemoSen↑, ROS↑,

1825-

VitK2,

Vitamin K intake and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial

-

Analysis,

Pca,

NA

Risk∅,

1824-

VitK2,

Vitamin K and its analogs: Potential avenues for prostate cancer management

-

Review,

Pca,

NA

AntiCan↑, toxicity∅, Risk↓, Apoptosis↑, ROS↑, TumCCA↑, eff↑, DNAdam↑, MMP↓, Cyt‑c↑, pro‑Casp3↑, FasL↑, Fas↑, TumAuto↑, ChemoSen↑, RadioS↑,

1822-

VitK2,

Vitamin K: A novel cancer chemosensitizer

-

Review,

Var,

NA

ChemoSen↑, Apoptosis↑, TumCCA↑, P-gp↓,

1817-

VitK2,

Research progress on the anticancer effects of vitamin K2

-

Review,

Var,

NA

TumCCA↑, Apoptosis↑, TumAuto↑, TumCI↓, TumCG↓, ChemoSen↓, ChemoSideEff↓, toxicity∅, eff↑, cycD1↓, CDK4↓, eff↑, IKKα↓, NF-kB↓, other↑, p27↑, cMyc↓, i-ROS↑, Bcl-2↓, BAX↑, p38↑, MMP↓, Casp9↑, p‑ERK↓, RAS↓, MAPK↓, p‑P53↑, Casp8↑, Casp3↑, cJun↑, MMPs↓, eff↑, eff↑,

1823-

VitK2,

VitK3,

Vitamins K2, K3 and K5 exert antitumor effects on established colorectal cancer in mice by inducing apoptotic death of tumor cells

-

in-vitro,

CRC,

NA

-

in-vivo,

NA,

NA

mice

TumCP↓, TumCCA↑, Casp3↑,

1818-

VitK2,

New insights on vitamin K biology with relevance to cancer

-

Review,

Var,

NA

TumCG↓, ChemoSen↑, toxicity∅, OS↑, BMD↑, eff↑, MMP↓, ROS↑, eff↓, ERK↑, JNK↑, p38↑, Cyt‑c↑, Casp↑, ATP↓, lactateProd↑, AMPK↑, Rho↓, TumCG↓, BioAv↑, cardioP↑, Risk↓,

1832-

VitK3,

VitC,

Vitamin K3 and vitamin C alone or in combination induced apoptosis in leukemia cells by a similar oxidative stress signalling mechanism

-

in-vitro,

AML,

K562

ROS↑, H2O2↑, NF-kB↑, P53↑, cJun↑, Casp3↑, MMP↓, DNAdam↑, Dose?,

1815-

VitK3,

VitK2,

Vitamin K

-

Review,

Nor,

NA

*Dose↝, BMD↑,

1839-

VitK3,

Vitamin K3 derivative inhibits androgen receptor signaling in targeting aggressive prostate cancer cells

-

in-vitro,

Pca,

NA

TumCP↓, Apoptosis↑, TumCCA↑, ROS↑, eff↓, AR↓, Trx↓, Bcl-2↓,

1838-

VitK3,

PDT,

Photodynamic Effects of Vitamin K3 on Cervical Carcinoma Cells Activating Mitochondrial Apoptosis Pathways

-

in-vitro,

Cerv,

NA

eff↑, ROS↑, tumCV↓, TumCG↓, Apoptosis↑, cl‑Casp3↑, cl‑Casp9↑, Bcl-xL↑, Cyt‑c↑, Bcl-2↓,

1837-

VitK3,

VitC,

Alpha-Tocopheryl Succinate Inhibits Autophagic Survival of Prostate Cancer Cells Induced by Vitamin K3 and Ascorbate to Trigger Cell Death

-

in-vivo,

Pca,

NA

mice

eff↑, ROS↑, TumAuto↑,

1835-

VitK3,

VitC,

Potential therapeutic application of the association of vitamins C and K3 in cancer treatment

-

Review,

Var,

NA

ROS↑, TumCD↑, TumCG↓, OS↑,

1834-

VitK3,

PDT,

Effects of Vitamin K3 Combined with UVB on the Proliferation and Apoptosis of Cutaneous Squamous Cell Carcinoma A431 Cells

-

in-vitro,

Melanoma,

A431

eff↑, TumCG↓, TumCP↓, ROS↑, MMP↓,

1831-

VitK3,

VitK2,

The anticancer effects of vitamin K

-

Review,

Var,

NA

AntiCan↑, Dose∅,

1820-

VitK3,

Vitamin K3 (menadione) suppresses epithelial-mesenchymal-transition and Wnt signaling pathway in human colorectal cancer cells

-

in-vitro,

CRC,

SW480

-

in-vitro,

CRC,

SW-620

selectivity↑, TumCI↓, TumCMig↓, EMT↓, E-cadherin↑, ZO-1↑, N-cadherin↓, Vim↓, Zeb1↓, MMP2↓, MMP9↓, TOPflash↓, β-catenin/ZEB1↓, p300↓, cycD1↓, TumCCA↑,

1821-

VitK3,

Menadione (Vitamin K3) induces apoptosis of human oral cancer cells and reduces their metastatic potential by modulating the expression of epithelial to mesenchymal transition markers and inhibiting migration

-

in-vitro,

Oral,

NA

-

in-vitro,

Nor,

HEK293

-

in-vitro,

Nor,

HaCaT

selectivity↑, TumCD↓, BAX↑, P53↑, Bcl-2↓, p65↓, E-cadherin↑, EMT↓, Vim↓, Fibronectin↓, TumCG↓, TumCMig↓,

1828-

VitK3,

VitC,

Pankiller effect of prolonged exposure to menadione on glioma cells: potentiation by vitamin C

-

in-vivo,

GBM,

NA

rats

eff↑, ROS↑, Dose∅,

1827-

VitK3,

A biophysical approach to menadione membrane interactions: relevance for menadione-induced mitochondria dysfunction and related deleterious/therapeutic effects

-

Analysis,

Var,

NA

ROS↑, ChemoSen↑,

1826-

VitK3,

PRX1 knockdown potentiates vitamin K3 toxicity in cancer cells: a potential new therapeutic perspective for an old drug

-

in-vitro,

Cerv,

HeLa

-

in-vitro,

Lung,

A549

eff↑, ROS↑,

2428-

VitK3,

Vitamin K3 and K5 are inhibitors of tumor pyruvate kinase M2

-

Study,

Var,

NA

PKM2↓, ChemoSen↑,

2372-

VitK3,

The role of pyruvate kinase M2 in anticancer therapeutic treatments

-

Review,

Var,

NA

PKM2↓, eff↑, AntiCan↑,

1755-

WBV,

Reduction of breast cancer extravasation via vibration activated osteocyte regulation

Dose∅, TumMeta↑, eff∅, Piezo1↑, COX2↑, RANKL↓, TumCG∅, tumCV∅, TumCI↓,

1756-

WBV,

Low-frequency mechanical vibration induces apoptosis of A431 epidermoid carcinoma cells

-

in-vitro,

MB,

A431

Apoptosis↑, GlucoseCon↝, other↓,

1757-

WBV,

The Impact of Vibration Therapy Interventions on Skin Condition and Skin Temperature Changes in Young Women with Lipodystrophy: A Pilot Study

-

Human,

Nor,

NA

Dose∅, other↑,

1758-

WBV,

Whole-body vibration in breast cancer survivors: a pilot study exploring its effects on muscle activity and subjectively perceived exertion

-

Human,

BC,

NA

eff↑,

1759-

WBV,

Prostate cancer and occupational exposure to whole-body vibration in a national population-based cohort study

-

Study,

Pca,

NA

Risk↓,

1760-

WBV,

Molecular jackhammers eradicate cancer cells by vibronic-driven action

-

in-vitro,

Melanoma,

NA

TumCD↑,

1761-

WBV,

Low Intensity Vibration Mitigates Tumor Progression and Protect Bone Quantity and Quality in a Murine Model of Myeloma

-

in-vivo,

Melanoma,

NA

mice

Dose∅, BMD↑, TumCI↓,

1753-

WBV,

Ex,

Physical Exercise with or without Whole-Body Vibration in Breast Cancer Patients Suffering from Aromatase Inhibitor—Induced Musculoskeletal Symptoms: A Pilot Randomized Clinical Study

-

Trial,

BC,

NA

Pain↓, Strength↑, QoL↑, Dose∅,

1752-

WBV,

Chemo,

Feasibility of whole body vibration during intensive chemotherapy in patients with hematological malignancies – a randomized controlled pilot study

-

Trial,

Var,

NA

*BP∅, eff↑, Dose∅, other↑, *toxicity∅, eff↑,

1751-

WBV,

Yoda1 Enhanced Low-Magnitude High-Frequency Vibration on Osteocytes in Regulation of MDA-MB-231 Breast Cancer Cell Migration

-

in-vitro,

BC,

MDA-MB-231

-

in-vitro,

AML,

RAW264.7

BMD↑, YAP/TEAD↑, TumCG↓, Strength↑, TumCI↓, Fas↑, Ca+2↑,

1754-

WBV,

Vibration Therapy for Cancer-Related Bone Diseases

-

Review,

Var,

NA

*BMD↑, *toxicity∅, other↓, Dose↝, Dose↑, eff↑, eff↑, eff↑,

1750-

WBV,

Whole body vibration exercise in the management of cancer therapy-related morbidities: A systematic review

-

Review,

Var,

NA

Wmax↑, UrinaryC↑, other↓, other↓, Dose?,

2427-

Wog,

Anti-cancer natural products isolated from chinese medicinal herbs

-

Review,

Var,

NA

NO↓, PGE2↓, COX2↓, Ca+2↑, mtDam↑, *toxicity↓, eff↑, eff↓,

2301-

Wog,

Flavonoids Targeting HIF-1: Implications on Cancer Metabolism

-

Review,

Var,

NA

HK2↓, PDK1↓, LDHA↓, Hif1a↓, PI3K↓, Akt↓, Glycolysis↓, P53↑, GLUT1↓,

2621-

Wog,

Natural compounds targeting glycolysis as promising therapeutics for gastric cancer: A review

-

Review,

Var,

NA

15 μg/ml

Hif1a↓, MCT4↓, LDH↓, lactateProd↓, ECAR↓, TumCP↓, Glycolysis↓,

2397-

Wor,

Phytochemicals targeting glycolysis in colorectal cancer therapy: effects and mechanisms of action

-

Review,

Var,

NA

lactateProd↓, GlucoseCon↓, GLUT3↓, HK2↓, PKM2↓, LDHA↓,

1913-

Xyl,

Partial Substitution of Glucose with Xylitol Prolongs Survival and Suppresses Cell Proliferation and Glycolysis of Mice Bearing Orthotopic Xenograft of Oral Cancer

-

in-vivo,

Oral,

NA

mice

TumVol↓, OS↑, PFK↓, toxicity↓, Dose∅, Ki-67↓,

1221-

Z,

Unexpected zinc dependency of ferroptosis: what is in a name?

-

Analysis,

Nor,

NA

*Ferroptosis↑, *ROS↑, *lipid-P↑,

1222-

Z,

Zinc regulates primary ovarian tumor growth and metastasis through the epithelial to mesenchymal transition

-

in-vitro,

Ovarian,

NA

EMT↑, TumCMig↑, TumCI↑, ERK↑, Akt↑,

961-

Z,

Zinc Downregulates HIF-1α and Inhibits Its Activity in Tumor Cells In Vitro and In Vivo

-

in-vitro,

RCC,

RCC4

-

vitro+vivo,

GBM,

U373MG

-

in-vitro,

Nor,

HUVECs

Hif1a↓, HIF-1↓, VEGF↓, TumCI↓,

604-

ZO,

Plant-Mediated Zinc Oxide Nanoparticles: Advances in the New Millennium towards Understanding Their Therapeutic Role in Biomedical Applications

-

Review,

NA,

NA

ROS↑, Apoptosis↑, DNAdam↑,

2414-

β‐Ele,

Beta‐elemene inhibits breast cancer metastasis through blocking pyruvate kinase M2 dimerization and nuclear translocation

-

in-vitro,

BC,

MDA-MB-231

-

in-vitro,

BC,

MCF-7

-

in-vivo,

NA,

NA

mice

TumCMig↓, TumCI↓, TumMeta↓, Glycolysis↓, GlucoseCon↓, lactateProd↓, PKM2↓, EGFR↓, GLUT1↓, LDHA↓, ECAR↓, OCR↓,

2425-

γ-Toc,

Anticancer Effects of γ-Tocotrienol Are Associated with a Suppression in Aerobic Glycolysis

-

in-vitro,

NA,

MCF-7

6–8 µM

-

in-vivo,

NA,

NA

mouse

TumCG↓, GlucoseCon↓, ATP↓, lactateProd↓, Glycolysis↓, HK2↓, PFK↓, PKM2↓, LDHA↓, Akt↓, p‑mTOR↓, cMyc↓,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 3574

Results for Effect on Cancer/Diseased Cells:
12LOX?,1,   12LOX↓,7,   14-3-3 proteins↓,1,   4-HNE↑,1,   4E-BP1↓,2,   p‑4E-BP1↓,4,   5HT↓,3,   5LO↓,9,   67LR↓,1,   6PGD↓,2,   ABC↓,1,   ABCG2↓,2,   Ac-histone H3↑,1,   ACAA1↓,1,   ACC↓,7,   ACC↑,4,   ACC-α↓,1,   p‑ACC-α↑,1,   ACC1↓,2,   AChE↓,1,   ACLY↓,19,   p‑ACLY↓,1,   ACOX1↑,1,   ACSL1↓,1,   ACSL4↑,2,   ACSL4∅,1,   ACSL5↑,2,   ACSS2↓,2,   ACTA2↓,1,   ADAM17↓,2,   adiP↑,1,   ADP:ATP↓,2,   ADP:ATP↑,3,   AEG1↓,2,   AFP↓,4,   AGRN↓,1,   AhR↓,1,   AIF↑,22,   AIF↝,1,   AKR1C2↓,1,   Akt↓,239,   Akt↑,16,   Akt↝,2,   Akt∅,1,   p‑Akt↓,118,   p‑Akt↑,4,   p‑Akt↝,1,   AKT1↓,7,   Akt2↓,2,   ALAT↓,11,   ALAT↑,1,   ALAT↝,1,   ALAT∅,1,   Albumin↑,1,   ALC↓,1,   ALDH↓,4,   ALDH1A1↓,9,   ALDOA↓,3,   ALDOAiso2↓,1,   Alix/AIP‑1↓,2,   ALP↓,5,   ALP↑,1,   ALP↝,1,   AMACR↝,1,   AminoA↓,1,   AMP↓,2,   AMP↑,1,   AMPK↓,3,   AMPK↑,77,   AMPK↝,2,   p‑AMPK↑,13,   AMPKα↓,2,   AMPKα↑,6,   angioG↓,148,   angioG↑,5,   angioS↑,1,   annexin II↓,1,   AntiAg↓,2,   AntiAg↑,12,   AntiAg↝,1,   AntiAg∅,1,   AntiAge↑,1,   AntiCan↓,3,   AntiCan↑,87,   AntiCan?,1,   AntiCan∅,2,   antiOx↓,12,   antiOx↑,54,   antiOx⇅,1,   AntiTum↓,1,   AntiTum↑,39,   ANXA7↑,2,   AP-1↓,22,   AP-1↑,2,   AP-1↝,3,   APA↑,1,   APAF1↑,8,   APC↑,1,   Apoptosis?,4,   Apoptosis↓,16,   Apoptosis↑,627,   Apoptosis↝,3,   m-Apoptosis↑,1,   mt-Apoptosis↑,4,   APP↓,1,   Appetite↑,3,   AQPs↓,2,   AR↓,45,   AR↝,1,   AR-FL↓,1,   AR-V7?,1,   AR-V7↑,1,   ARE/EpRE↑,2,   ASC↓,2,   ASC↑,2,   ascitic↓,4,   ASK1↑,4,   aSmase↑,1,   aSmase↝,1,   AST↓,7,   AST↑,1,   AST↝,1,   AST∅,1,   ATF2↓,2,   ATF3↓,1,   ATF3↑,5,   ATF4↓,2,   ATF4↑,32,   ATF4↝,1,   p‑ATF4↝,1,   ATF6↑,9,   cl‑ATF6↑,3,   c-ATF6↑,1,   ATFs↑,4,   ATG3↓,1,   ATG3↑,4,   ATG5↑,10,   ATG5↝,1,   ATG7↑,7,   ATM↓,2,   ATM↑,7,   ATM↝,1,   p‑ATM↑,3,   ATP↓,84,   ATP↑,6,   ATP⇅,1,   ATP↝,2,   ATP∅,2,   i-ATP↓,2,   i-ATP↑,1,   mt-ATP↓,1,   ATP:AMP↓,1,   ATPase↓,3,   ATR↑,2,   p‑ATR↑,1,   autolysosome↑,1,   autoS↑,1,   AVOs↑,1,   AXIN1↓,1,   AXIN1↑,1,   Axin2↓,1,   AXL↓,4,   Aβ↓,1,   B2M↓,1,   BACH1↑,1,   Bacteria↓,4,   Bacteria↑,1,   BAD↓,5,   BAD↑,15,   BAD↝,1,   p‑BAD↓,3,   Bak↑,21,   BAX↓,11,   BAX↑,300,   BAX⇅,1,   BAX↝,2,   BAX∅,1,   Bax:Bcl2↑,70,   BBB↓,1,   BBB↑,11,   BCAP↓,1,   Bcl-2↓,339,   Bcl-2↑,8,   Bcl-2↝,1,   Bcl-2∅,2,   cl‑Bcl-2↓,1,   cl‑Bcl-2↑,1,   Bcl-xL↓,81,   Bcl-xL↑,1,   Bcl-xL↝,2,   Bcl-xL∅,1,   BCR↓,1,   BCR-ABL↓,1,   Beclin-1↓,5,   Beclin-1↑,35,   Beclin-1↝,1,   Bfl-1↓,1,   BG↓,13,   BID↓,2,   BID↑,15,   cl‑BID↑,2,   BIM↓,1,   BIM↑,16,   BioAv↓,62,   BioAv↑,82,   BioAv↝,23,   BioAv∅,1,   BioEnh?,1,   BioEnh↑,18,   BMD↑,6,   BMI1↓,4,   BMP2↓,1,   BMP2↑,1,   BMPs↑,4,   BNIP3?,2,   BNIP3↓,1,   BNIP3↑,7,   BNIP3↝,1,   BNP↓,1,   BOK↑,2,   BowelM↑,2,   BP↓,3,   BRAF↑,1,   BRAF↝,1,   BRCA1↓,1,   BRCA1↑,5,   BRCA2↑,1,   breath↑,2,   Brk/PTK6↓,1,   BTG3↑,1,   CA↓,2,   Ca+2?,1,   Ca+2↓,15,   Ca+2↑,91,   Ca+2↝,7,   i-Ca+2?,1,   i-Ca+2↓,2,   i-Ca+2↑,4,   mt-Ca+2↑,1,   CA125↓,3,   cachexia↓,3,   CAFs/TAFs↓,4,   CAFs/TAFs↝,1,   CAIX↓,4,   CAIX↑,1,   cal2↓,1,   cal2↑,3,   Calcium↑,1,   CaMKII ↓,2,   cAMP⇅,1,   carcinogenesis↓,1,   cardioP↑,23,   CardioT↓,3,   Cartilage↑,1,   Casp↓,1,   Casp↑,64,   Casp↝,1,   Casp∅,1,   Casp1↓,6,   Casp1↑,1,   cl‑Casp1↓,1,   cl‑Casp1↑,1,   proCasp1↓,1,   Casp10↑,3,   Casp10∅,1,   Casp12?,1,   Casp12↑,11,   cl‑Casp12↑,1,   cl‑Casp12↝,1,   pro‑Casp12↓,1,   Casp2↑,5,   Casp3?,4,   Casp3↓,9,   Casp3↑,386,   Casp3↝,3,   Casp3∅,2,   cl‑Casp3↓,3,   cl‑Casp3↑,71,   cl‑Casp3∅,1,   proCasp3↓,5,   proCasp3↑,2,   pro‑Casp3↑,1,   pro‑Casp3↝,1,   Casp6↑,1,   Casp7?,1,   Casp7↓,1,   Casp7↑,50,   cl‑Casp7↑,2,   Casp8↓,1,   Casp8↑,88,   Casp8↝,1,   Casp8∅,4,   cl‑Casp8↑,17,   proCasp8↓,1,   pro‑Casp8↑,1,   Casp9?,2,   Casp9↓,2,   Casp9↑,199,   Casp9↝,1,   Casp9∅,1,   cl‑Casp9↓,1,   cl‑Casp9↑,25,   proCasp9↓,3,   proCasp9↑,1,   Catalase↓,21,   Catalase↑,22,   Catalase↝,1,   Catalase∅,1,   Cav1↓,2,   Cav1↑,2,   CBP↓,2,   CBP↑,1,   CC(CDKs/cyclins)↓,1,   CCDC150↓,1,   CCL20↑,1,   CCR7↓,1,   CD11b↑,1,   CD133↓,18,   CD14↓,1,   CD14↑,1,   CD24↓,7,   CD25+↓,4,   CD31↓,8,   CD31↑,1,   CD34↓,3,   CD38↑,1,   CD4+↓,7,   CD4+↑,11,   CD44↓,19,   CD44↑,1,   CD8+↓,1,   CD8+↑,20,   CDC16↓,1,   CDC2↓,8,   CDC2↑,1,   cDC2↓,9,   p‑cDC2↑,1,   CDC25↓,22,   p‑CDC25↑,1,   Cdc42↓,3,   Cdc42↑,1,   CDC7↓,1,   CDH1↑,3,   CDK1↓,28,   CDK1↑,4,   p‑CDK1↓,2,   p‑CDK1↑,1,   CDK1/2/5/9↓,1,   CDK1/2/5/9∅,1,   CDK2↓,62,   CDK2↑,4,   CDK4↓,74,   CDK4↑,4,   CDK4↝,1,   CDK4∅,1,   CDK4/6↓,5,   CDK6↓,28,   CDK6↑,6,   CDK6∅,1,   CDK8↓,3,   CDKN1C↑,1,   CDX2↓,1,   CEA↓,2,   CEBPA↑,1,   CEBPB?,1,   CEBPB↓,1,   CellMemb↓,1,   CellMemb↑,8,   cellSen↑,1,   Ceru↓,1,   cFLIP↓,15,   cFos↓,10,   cFos↑,2,   ChemChap↑,1,   chemoP↓,2,   chemoP↑,87,   chemoR↓,2,   ChemoSen↓,9,   ChemoSen↑,282,   ChemoSen⇅,1,   ChemoSen∅,2,   ChemoSideEff↓,35,   ChemoSideEff∅,2,   CHK1↓,5,   CHK1↑,3,   p‑CHK1↓,1,   p‑CHK1↑,3,   Chk2↓,2,   Chk2↑,7,   p‑Chk2↓,1,   p‑Chk2↑,2,   Chl∅,1,   cholinesterase↓,1,   CHOP↓,3,   CHOP↑,81,   p‑CHOP↝,1,   cl‑CHOP↑,1,   ChrMod↝,1,   CIP2A↓,1,   circ-PRKCA↓,1,   citrate↓,2,   i-citrate↑,1,   cJun↓,10,   cJun↑,6,   p‑cJun↑,2,   CK2↓,15,   CLDN1↓,5,   CLDN2↓,2,   CLDN2↑,1,   CLP↑,1,   cMET↓,11,   p‑cMET↓,1,   p‑cMET↑,1,   cMYB↓,3,   cMyc↓,89,   cMyc↑,1,   p‑cMyc↑,1,   cognitive?,1,   cognitive↑,12,   COL1↓,3,   COL1A1↓,4,   COL2A1↓,1,   COL3A1↓,2,   COL4↓,2,   COL9A3↓,1,   COMP↓,1,   compI↓,1,   compIII↓,1,   compIII↑,1,   COMT↓,4,   COMT↑,1,   Copper↑,1,   CoQ10↑,1,   COX1↓,6,   COX2↓,162,   COX2↑,4,   COX2↝,3,   COX2∅,1,   CPT1A↓,4,   CPT1A↑,1,   CR3↝,1,   creat↓,1,   CREB↓,1,   p‑CREB↓,1,   CREB2↓,1,   CREBBP↓,1,   CRM↑,2,   CRP↓,9,   i-CRT↓,1,   CSCs↓,53,   CSCsMark↓,1,   CSR1↝,1,   cSrc↓,4,   CT-I↓,1,   CTC↓,2,   CTGF↓,1,   CTR1↑,1,   CUL4B↑,1,   Cupro↑,2,   CXCc↓,3,   CXCc↑,1,   CXCL1↓,2,   CXCL12↓,5,   CXCL9↓,1,   CXCR2↑,1,   CXCR4↓,29,   CXCR4↝,1,   Cyc↓,12,   Cyc↝,1,   cycA1↓,17,   cycA1↑,5,   CycB↓,39,   CycB↑,7,   cycD1↓,184,   cycD1↑,4,   cycD1↝,2,   cycD1∅,1,   CycD3↓,2,   CycD3↑,1,   cycE↓,40,   cycE↑,4,   cycE1↓,5,   cycF↓,2,   CYFRA21-1↓,1,   CYP11A1↓,2,   CYP17A1↓,1,   CYP19?,1,   CYP19↓,5,   CYP1A1↓,6,   CYP1A1↑,2,   CYP1A2↓,2,   CYP1B1↑,2,   CYP2C9↓,1,   CYP3A4↓,2,   Cyt‑c↓,1,   Cyt‑c↑,203,   Cyt‑c↝,5,   Cyt‑c?,1,   DCells↑,4,   decorin↑,1,   DFF45↓,2,   DFF45↑,3,   DGAT1↓,1,   DHCR24↑,1,   DHT↓,1,   DHT↑,1,   Diablo↑,15,   Diablo↝,1,   Diff↓,3,   Diff↑,8,   DJ-1↓,1,   DLC1↑,5,   DLEU1↓,1,   DNA-PK↑,4,   DNA-PK↝,1,   DNAdam↓,8,   DNAdam↑,150,   mt-DNAdam↑,1,   DNAdamC↑,1,   DNArepair↓,3,   DNArepair↑,2,   DNMT1↓,32,   DNMT1↑,2,   DNMT1↝,1,   DNMT3A↓,14,   DNMT3A↑,1,   DNMTs↓,33,   Dose?,24,   Dose↓,13,   Dose↑,28,   Dose⇅,1,   Dose↝,111,   Dose∅,82,   DR4↑,9,   DR4∅,2,   DR5↓,1,   DR5↑,54,   DR5∅,1,   E-cadherin↓,20,   E-cadherin↑,123,   E-cadherin↝,1,   E2Fs↓,8,   E6↓,8,   E7↓,7,   ECAR↓,25,   ECAR↝,1,   ECAR∅,1,   ECM/TCF↓,4,   EF-1α↓,1,   EFEMP↓,1,   eff?,2,   eff↓,222,   eff↑,611,   eff⇅,2,   eff↝,73,   eff∅,8,   EGF↓,7,   EGF↑,1,   EGFR↓,88,   EGFR↑,1,   EGFR↝,1,   p‑EGFR↓,7,   EGR1↑,1,   EGR4↓,1,   eIF2α↓,4,   eIF2α↑,17,   p‑eIF2α↓,2,   p‑eIF2α↑,21,   p‑eIF2α↝,1,   EIF4E↓,1,   Elvol3↓,1,   EM↑,3,   EMMPRIN↓,1,   EMT?,1,   EMT↓,190,   EMT↑,5,   Endoglin↓,1,   Endoglin↑,1,   Endon↑,4,   ENO1↓,3,   p‑ENO1↓,1,   ENO2↓,1,   eNOS↓,4,   eNOS↑,2,   ENOX2↓,5,   ENOX2↑,1,   EP2↓,2,   EP300↓,1,   EP300↑,1,   EP4↓,1,   EP4↑,1,   EpCAM↓,4,   EphB4↓,1,   EphB4↝,1,   EPR↓,1,   EPR↑,3,   EPR↝,1,   ER Stress↓,8,   ER Stress↑,144,   ER Stress↝,2,   ER-α36↓,7,   ER(estro)↓,5,   ER(estro)↑,1,   ERCC1↓,1,   ERK↓,104,   ERK↑,25,   ERK↝,2,   ERK∅,1,   p‑ERK↓,51,   p‑ERK↑,16,   p‑ERK⇅,2,   p‑ERK↝,1,   e-ERK↑,1,   ERK5↑,1,   ERS↑,1,   ERα↓,7,   ERα↑,1,   ERβ↑,2,   EZH2↓,17,   F-actin↓,4,   F-actin↑,1,   FABP4↓,1,   FABP4↑,1,   FADD↑,8,   FADD∅,1,   FAK↓,30,   FAK↑,1,   p‑FAK↓,7,   p‑FAK↑,1,   m-FAM72A↓,1,   FAO↓,2,   FAO↑,1,   Fap1↓,1,   Fas↓,2,   Fas↑,29,   Fas↝,1,   fascin↓,1,   FasL↓,1,   FasL↑,12,   FASN↓,30,   FASN↑,3,   i-FASN↓,1,   FBI-1↓,2,   FBP1↑,1,   FBPase↑,3,   FBXW7↝,1,   FDG↓,2,   Fenton↑,23,   Ferritin↓,6,   Ferritin↑,1,   Ferroptosis↓,2,   Ferroptosis↑,57,   FGF↓,5,   FGF↑,1,   FGF21↑,1,   FGFR1↓,4,   FGFR2↓,2,   Fibronectin↓,12,   Fibronectin↑,1,   Fibrosis↓,1,   FKBP5↓,1,   FLRT2↑,1,   FLT3↓,2,   FLT4↝,1,   FOSB↑,2,   FOSL1↑,1,   FOXD3↑,2,   Foxm1↓,8,   FOXO↓,2,   FOXO↑,5,   FOXO1↓,2,   FOXO1↑,1,   FOXO3↓,3,   FOXO3↑,10,   p‑FOXO3↓,2,   FOXO4↓,1,   FOXO4↑,1,   FOXP3↓,5,   FoxP3+↓,4,   frataxin↑,1,   FTH1↓,6,   FTH1↑,1,   FTL↑,2,   Furin↓,4,   G6PD↓,4,   G6PD∅,1,   G9a↓,4,   GABA↑,1,   GADD34↑,3,   GADD45A↑,5,   Galectin-9↓,1,   GAPDH↓,6,   GCLC↑,2,   GCLM↓,1,   GCLM↑,2,   GDF15↓,1,   GDH↓,1,   GFR↑,1,   GIT1↓,1,   GIT1↑,1,   Gli↓,4,   Gli1↓,51,   Gli1↝,1,   GLI2↓,11,   GLI2↝,1,   GLO-I↓,5,   GLS↓,3,   GLS↑,1,   glucoNG↓,3,   glucoNG↑,2,   glucose↓,3,   glucose↑,1,   GlucoseCon↓,89,   GlucoseCon↑,5,   GlucoseCon↝,1,   GlucoseCon∅,1,   glut↓,3,   GLUT1↓,74,   GLUT1↑,4,   GLUT1∅,1,   GLUT2↓,4,   GLUT3↓,7,   GLUT3↑,2,   GLUT3∅,1,   GLUT4↓,6,   GlutaM↓,1,   GlutMet↓,3,   GlutMet↑,1,   glyC↓,1,   Glycolysis↓,196,   Glycolysis↑,2,   Glycolysis↝,1,   Glycolysis∅,1,   GM-CSF↓,3,   GNLY↓,1,   GnT-V↝,1,   GP1BB↓,1,   GPI↓,1,   GPx↓,15,   GPx↑,18,   GPx1↓,3,   GPx1↑,1,   GPx1⇅,1,   GPx1∅,1,   GPx4↓,41,   GPx4↑,2,   GPx4∅,1,   GR↑,1,   GR↝,1,   GranA↓,1,   GranB↓,1,   GranB↑,1,   GREM1↓,1,   GRP58↓,2,   GRP78/BiP↓,6,   GRP78/BiP↑,58,   GRP78/BiP↝,1,   GRP94↑,6,   p‑GS3Kβ↓,1,   GSDMC↑,1,   GSDMD↑,3,   GSDME↑,1,   GSDME-N↑,2,   GSH?,1,   GSH↓,141,   GSH↑,18,   GSH∅,2,   mt-GSH↓,1,   GSH/GSSG↓,17,   GSK‐3β↓,20,   GSK‐3β↑,9,   GSK‐3β↝,1,   p‑GSK‐3β↓,9,   p‑GSK‐3β↑,1,   GSR↓,6,   GSR↑,4,   GSS↑,1,   GSSG↑,5,   GSTA1↓,1,   GSTA1↑,2,   GSTP1/GSTπ↓,5,   GSTP1/GSTπ↝,1,   GSTs↓,7,   GSTs↑,4,   GSTs↝,1,   GSTZ1∅,1,   GTPBP4↓,1,   GutMicro↓,1,   GutMicro↑,24,   GutMicro↝,3,   H19↓,1,   H19↑,1,   H2O2?,1,   H2O2↓,2,   H2O2↑,45,   e-H2O2↓,1,   i-H2O2↓,1,   i-H2O2∅,1,   mt-H2O2↑,2,   H3↓,4,   H3↑,4,   p‑H3↓,1,   p‑H3↑,1,   ac‑H3↓,1,   ac‑H3↑,12,   H3K18↓,1,   H3K27ac∅,1,   H4↓,1,   H4↑,3,   ac‑H4↓,2,   ac‑H4↑,9,   ac‑H4∅,1,   Half-Life?,1,   Half-Life↓,11,   Half-Life↑,1,   Half-Life↝,25,   Half-Life∅,7,   HATs↓,11,   HATs↑,6,   HCAR1↓,2,   HDAC↓,116,   HDAC↑,1,   HDAC∅,1,   HDAC1↓,24,   HDAC10↓,1,   HDAC10↑,1,   HDAC11↓,2,   HDAC2↓,15,   HDAC3↓,12,   HDAC4↓,6,   HDAC4↝,1,   HDAC6↓,3,   HDAC8↓,11,   HDL↓,1,   HEC1↝,1,   HemoG↓,1,   heparanase↝,1,   hepatoP↓,1,   hepatoP↑,23,   hepatoP↝,1,   HER2/EBBR2↓,22,   p‑HER2/EBBR2↓,1,   HEY1↓,2,   HGF/c-Met↓,4,   HH↓,49,   HIF-1↓,15,   HIF-1↑,1,   Hif1a↓,210,   Hif1a↑,9,   Hif1a↝,5,   HIF2a↓,1,   Hippo↓,1,   Hippo↑,1,   ac‑Histones↑,1,   HK1↓,5,   HK2↓,110,   HK2↑,1,   HK2∅,1,   HLA↑,2,   HMG-CoA↓,1,   HMGB1↓,4,   i-HMGB1↓,1,   HMTs↓,3,   HMTs↑,1,   HNE↑,1,   hnRNPA1↓,2,   HO-1↓,29,   HO-1↑,49,   HO-1⇅,1,   HO-2↓,1,   HO-2↑,1,   homoC↓,4,   homoC↝,1,   HR↓,2,   HRI↓,1,   Hsc70↝,1,   p‑Hsc70↑,1,   HSD17B4↓,1,   HSD3B↓,1,   HSF1↓,3,   HSP27↓,9,   HSP27↑,3,   HSP27↝,1,   HSP70/HSPA5↓,18,   HSP70/HSPA5↑,16,   HSP70/HSPA5⇅,1,   HSP70/HSPA5↝,1,   HSP70/HSPA5∅,1,   e-HSP70/HSPA5↓,1,   HSP72↓,1,   HSP72↑,1,   HSP90↓,25,   HSP90↝,1,   HSP90∅,1,   ac‑HSP90↑,1,   HSPs↓,3,   HSPs↑,1,   HSPs∅,1,   hTERT↓,25,   hyperG↓,1,   Hypoxia↓,1,   IAP1↓,15,   IAP1↑,1,   IAP2↓,10,   IAP2↑,1,   cl‑IAP2↑,1,   ICAD↓,2,   ICAD↑,1,   ICAM-1↓,7,   ICD↑,3,   Id1↓,2,   IDH1↑,2,   IDH2↓,1,   IDO1↓,2,   IFN-γ↓,12,   IFN-γ↑,10,   IGF-1↓,35,   IGF-1↑,1,   IGF-1↝,1,   p‑IGF-1↓,1,   IGF-1R↓,18,   IGF-1R↑,1,   IGF-1R↝,1,   p‑IGF-1R↓,1,   IGF-2↓,2,   IGF-2↑,1,   IGFBP1↑,3,   IGFBP3↓,1,   IGFBP3↑,9,   IGFBP7↑,1,   IGFR↓,2,   p‑IGFR↓,1,   Igs↓,1,   Igs↑,2,   Ikaros↑,1,   IKKα↓,19,   IKKα↑,9,   p‑IKKα↓,4,   IL1↓,16,   IL1↑,5,   IL10↓,18,   IL10↑,8,   IL12↓,5,   IL12↑,3,   IL17↓,2,   IL18↓,5,   IL1α↓,2,   IL1β↓,41,   IL1β↑,2,   IL2↓,5,   IL2↑,8,   IL22↓,1,   IL23↓,1,   IL28↓,1,   IL33↑,1,   IL4↓,5,   IL4↑,4,   IL5↓,1,   IL6↓,86,   IL6↑,3,   IL6↝,1,   IL8↓,19,   IL8↑,5,   IL9↓,1,   IM↓,1,   IMPDH1↝,1,   IMPDH2↝,1,   importin α/β↓,1,   INF-γ↓,1,   INF-γ↑,1,   Inflam↓,77,   Inflam↑,3,   iNOS↓,27,   iNOS↑,3,   Insulin↓,6,   IP-10/CXCL-10↓,1,   IR↓,2,   IRAK4↓,1,   IRE1↓,1,   IRE1↑,13,   IRE1∅,1,   p‑IRE1↓,1,   p‑IRE1↑,1,   IRF3↓,1,   Iron↓,1,   Iron↑,25,   Iron↝,2,   Iron∅,1,   i-Iron↓,1,   i-Iron↑,2,   IronCh↑,7,   IRP1↑,1,   ITGA1∅,1,   ITGA11↓,1,   ITGA5↓,3,   ITGA5↑,3,   ITGA5∅,1,   ITGB1↓,9,   ITGB1↑,4,   ITGB1∅,1,   ITGB3↓,2,   ITGB3∅,1,   ITGB4↓,3,   ITGB4∅,1,   ITGB6↓,1,   IκB↓,4,   IκB↑,2,   p‑IκB↓,3,   p‑IκB↑,2,   JAK↓,12,   p‑JAK↓,2,   JAK1?,1,   JAK1↓,7,   p‑JAK1↓,2,   JAK2↓,22,   p‑JAK2↓,6,   JAK3↓,1,   p‑JAK3↓,1,   JNK↓,15,   JNK↑,60,   JNK↝,2,   p‑JNK↓,10,   p‑JNK↑,13,   Jun↓,3,   p‑Jun↑,1,   JWA↑,1,   K17↓,1,   KCNQ1OT1↓,1,   KDR/FLK-1↓,3,   Keap1↓,5,   Keap1↑,3,   Keap1↝,2,   ox-Keap1↓,1,   rd-Keap1↑,1,   KeyT↑,1,   Ki-67↓,55,   Ki-67↑,2,   KIF2C↓,1,   KISS1↑,1,   KLF2↓,1,   KLF4↓,1,   KLF5↓,1,   KRAS↓,2,   L-sel↑,1,   lact/pyru↓,1,   lactateProd↓,103,   lactateProd↑,4,   lactateProd∅,1,   e-lactateProd↓,1,   LAMA5↓,1,   LAMA5↑,3,   LAMB3↑,1,   LAMP1?,1,   LAMP2↓,1,   LAMP2↑,2,   LAMs↓,2,   LAR↓,1,   LAT↓,1,   LAT↑,1,   LC3‑Ⅱ/LC3‑Ⅰ↓,2,   LC3‑Ⅱ/LC3‑Ⅰ↑,9,   LC3A↑,1,   LC3B↓,1,   LC3B↑,8,   LC3B-II↑,8,   LC3I↓,1,   LC3I↑,2,   LC3II↓,2,   LC3II↑,29,   LC3s↑,6,   LC3s↝,1,   LDH?,1,   LDH↓,35,   LDH↑,8,   LDH↝,1,   LDH∅,1,   e-LDH↑,1,   i-LDH↓,1,   LDHA↓,65,   LDHA↑,1,   LDHA∅,2,   LDHB↓,1,   LDL↓,5,   LEF1↓,6,   Let-7↑,9,   LGR5↓,2,   LIF↑,1,   lipid-P?,1,   lipid-P↓,18,   lipid-P↑,42,   lipid-P↝,1,   lipidDe↓,1,   lipidLev↓,1,   lipidLev↑,1,   lipoGen↓,5,   LOX1↓,5,   LPS↓,1,   LRP6↓,2,   p‑LRP6↓,1,   lysoM↓,1,   lysoMP↓,2,   lysoMP↑,2,   LysoPr↑,1,   lysosome↓,2,   M1↓,1,   pol-M1↑,1,   M2 MC↓,3,   M2 MC↑,1,   pol-M2 MC↓,1,   Macrophages↓,1,   Macrophages↑,1,   MAD↓,1,   MALAT1↓,8,   MAOA↓,1,   MAP2K1/MEK1↓,1,   MAPK↓,53,   MAPK↑,41,   MAPK↝,3,   p‑MAPK↓,1,   p‑MAPK↑,5,   MARK4↓,3,   Maspin↑,2,   Matr↓,1,   MATs↓,1,   Mcl-1↓,52,   Mcl-1↑,2,   Mcl-1↝,1,   MCP1↓,12,   MCT1↓,4,   MCT4↓,3,   MCU↓,1,   MDA↓,8,   MDA↑,37,   MDM2↓,17,   MDM2↑,1,   p‑MDM2↓,1,   MDMX↓,1,   MDR1↓,15,   MDSCs↓,3,   MeCP2↓,1,   MEG3↑,2,   MEK↓,11,   p‑MEK↓,5,   memory↑,7,   MET↓,5,   MET↑,1,   p‑MET↓,1,   Mets↑,1,   MGMT↓,3,   MGO↑,1,   Mich↑,1,   MIP-1β↓,1,   MIP2↓,2,   miR-125b↓,1,   miR-126↓,1,   miR-126↑,1,   miR-127-5p↑,2,   miR-129-5p↑,1,   miR-130a↓,2,   miR-133a-3p↝,1,   miR-139-5p↑,1,   miR-141↑,1,   miR-142-3p↑,1,   miR-143↑,1,   miR-145↑,3,   miR-148a↓,1,   miR-155↓,5,   miR-155↑,1,   miR-19b↓,2,   miR-200b↑,3,   miR-200c↓,1,   miR-200c↑,4,   miR-203↓,1,   miR-203↑,1,   miR-205↑,2,   miR-21↓,13,   miR-21↑,2,   miR-21↝,1,   miR-210↓,1,   miR-210↑,2,   miR-215-5p↑,1,   miR-218↑,1,   miR-22↑,1,   miR-25-5p↓,1,   miR-27a-3p↓,4,   miR-29b↓,1,   miR-29b↑,2,   miR-301a-3p↓,1,   miR-30a-5p↑,2,   miR-320a↓,1,   miR-330-5p↑,2,   miR-340↑,1,   miR-34a↑,9,   miR-384↑,1,   miR-409-3p↑,1,   miR-486↑,1,   miR-497↑,1,   miR-548ah-5p↑,1,   miR-7641↓,1,   mitResp↓,13,   mitResp↑,5,   MKI67↑,1,   MKK4↓,1,   MKP1↓,2,   MKP2↓,2,   MKP5↑,1,   MLKL↑,4,   p‑MLKL↓,1,   MMP?,2,   MMP↓,306,   MMP↑,6,   MMP↝,2,   MMP∅,3,   MMP-10↓,4,   MMP1↓,9,   MMP1↑,1,   MMP1:TIMP1↑,1,   MMP11↓,1,   MMP13↓,7,   MMP17↓,1,   MMP2↓,157,   MMP2↑,2,   MMP2⇅,1,   MMP2↝,2,   MMP2∅,1,   proMMP2↓,1,   MMP3↓,7,   MMP3↑,1,   MMP7↓,18,   MMP7∅,1,   MMP9↓,194,   MMP9↑,3,   MMP9⇅,1,   MMP9↝,1,   MMP9∅,1,   pro‑MMP9↓,1,   MMP9:TIMP1↓,1,   MMP9:TIMP1↑,1,   MMPs↓,49,   MMPs↝,1,   MOB1↓,1,   Mortalin↓,1,   mPGES-1↓,1,   MPO↓,6,   MPT↑,4,   MRGPRF↓,1,   MRP↓,1,   MRP1↓,2,   MSCmark↓,2,   MSH2↑,1,   mtDam↑,50,   mTOR↓,150,   mTOR↑,12,   mTOR⇅,1,   mTOR↝,2,   mTOR∅,1,   p‑mTOR↓,32,   p‑mTOR↑,2,   mTORC1↓,9,   p‑mTORC1↓,1,   mTORC2↓,3,   mTORC2↑,1,   MUC1↓,2,   MUC1↑,1,   MUC1-C↓,1,   MUC4↓,8,   Myc↓,9,   MyD88↓,2,   N-cadherin?,1,   N-cadherin↓,72,   N-cadherin↑,2,   N-cadherin↝,1,   n-MYC↓,3,   NA?,1,   NA↓,9,   NA↑,8,   NAD↓,6,   NAD↑,3,   NAD↝,1,   NADH↓,2,   NADH↑,1,   NADH:NAD↓,1,   NADHdeh?,1,   NADHdeh↓,2,   NADPH↓,12,   NADPH↑,7,   NADPH↝,1,   NADPH/NADP+↓,2,   NAF1↓,3,   NAIP↓,2,   Nanog↓,23,   NBR2↑,1,   NCAM↓,1,   NCAM↑,1,   NCOA4↑,3,   NCOA4↝,1,   NDRG1↑,1,   Necroptosis↑,14,   necrosis↑,15,   NEDD9↓,4,   Nestin↓,7,   Neurog1↑,1,   neuroP↓,1,   neuroP↑,36,   NeuroT↓,1,   Neut↓,1,   NF-kB↓,322,   NF-kB↑,19,   NF-kB⇅,1,   NF-kB↝,2,   p‑NF-kB↓,5,   p‑NF-kB↑,2,   NF2↑,1,   NFAT↑,2,   NFE2L2↑,1,   NH3↓,2,   NHE1↓,5,   NHE1↝,1,   NICD↓,1,   NK cell↑,10,   NKD2↑,2,   NKG2D↑,2,   NKX3.1↓,2,   NKX3.1↑,1,   NLRP3↓,17,   NLRP3↑,2,   NM23↝,1,   NNMT↓,1,   NO↓,14,   NO↑,15,   NO↝,1,   NOS2↓,1,   NOS2↝,1,   NOTCH↓,19,   NOTCH↑,1,   NOTCH⇅,1,   NOTCH1↓,20,   NOTCH1↑,3,   NOTCH1↝,1,   NOTCH2↓,2,   NOTCH2↑,1,   NOTCH3↓,4,   NOX↓,3,   NOX↑,1,   NOX4↓,2,   NOX4↑,1,   NOXA↑,6,   NPC1L1↓,1,   NQO1?,1,   NQO1↓,4,   NQO1↑,11,   NQO2↑,1,   NRAS↓,1,   Nrf1↓,1,   Nrf1↑,1,   NRF2↓,51,   NRF2↑,81,   NRF2⇅,4,   NRF2↝,1,   NRF2∅,2,   p‑NRF2↓,1,   p‑NRF2↑,1,   NSE↓,1,   nucleolin↑,1,   OAA↑,1,   OATPs↓,1,   OCR↓,18,   OCR↑,12,   OCT4↓,20,   oncosis↑,2,   OS?,1,   OS↓,5,   OS↑,117,   OS∅,2,   OSI↑,2,   other?,5,   other↓,42,   other↑,49,   other⇅,1,   other↝,37,   other∅,10,   OV6↓,1,   OXPHOS↓,16,   OXPHOS↑,15,   OXPHOS⇅,1,   OXPHOS↝,2,   mt-OXPHOS↓,1,   mt-OXPHOS↑,2,   P-gp↓,25,   P-gp↑,1,   p16↑,10,   p19↑,3,   P21?,2,   P21↓,9,   P21↑,160,   P21↝,1,   p27↓,2,   p27↑,54,   P2X7↓,1,   p300↓,4,   p38↓,18,   p38↑,56,   p‑p38↓,8,   p‑p38↑,18,   p42↓,1,   p42↑,1,   p‑p42↓,1,   p‑p42↑,1,   p‑p44↓,1,   p‑p44↑,1,   P450↓,10,   P450↝,1,   p50↓,7,   P53?,3,   P53↓,10,   P53↑,198,   P53⇅,1,   P53↝,4,   P53∅,2,   p‑P53↑,11,   ac‑P53↑,1,   p53 Wildtype∅,1,   p62↓,24,   p62↑,18,   p65↓,23,   p65↑,1,   p‑p65↓,4,   p‑p65↑,1,   ac‑p65↑,1,   p66Shc↓,1,   p66Shc↑,1,   p70S6↓,7,   p‑p70S6↓,4,   p‑p70S6↑,1,   P70S6K↓,7,   P70S6K↑,1,   p‑P70S6K↓,5,   p‑P70S6K↑,1,   p73↑,1,   p85S6K↓,1,   P90RSK↓,2,   p‑P90RSK↑,1,   Pain↓,7,   PAK↓,2,   PAK1↓,3,   PAO↑,1,   Paraptosis↑,6,   PARK2↑,2,   PARP↓,11,   PARP↑,36,   PARP↝,1,   PARP∅,1,   p‑PARP↑,4,   cl‑PARP↓,4,   cl‑PARP↑,141,   cl‑PARP∅,2,   proPARP↓,1,   PARP1↓,1,   PARP1↑,3,   PARP1↝,1,   cl‑PARP1↑,4,   PARP16↓,1,   p‑pax↓,1,   PCAF↓,1,   PCBP1↓,1,   PCK1↓,2,   p‑PCK1↓,1,   PCLAF↓,1,   PCNA↓,40,   PCNA↝,1,   PD-1↓,6,   PD-1↑,1,   PD-1↝,3,   PD-L1↓,42,   PD-L1↑,5,   PD-L2↓,1,   PDCD4↑,1,   PDGF↓,13,   p‑PDGF↓,1,   PDGFR-BB↓,2,   PDGFR-BB↑,1,   p‑PDGFR-BB↓,1,   PDGFRA↓,2,   PDH↓,6,   PDH↑,11,   PDH↝,1,   PDH∅,1,   p‑PDH↓,2,   p‑PDH↑,1,   PDHA1↓,1,   PDHB↓,1,   PDI↑,2,   PDK1?,2,   PDK1↓,35,   p‑PDK1↓,4,   PDK3↓,1,   PDK3↑,1,   PDKs↓,14,   p‑PDKs↓,1,   PDT+↓,1,   Perforin↓,1,   Perforin↑,1,   PERK↓,2,   PERK↑,24,   p‑PERK↓,2,   p‑PERK↑,6,   p‑PERK↝,1,   PFK↓,19,   PFK1↓,14,   PFK2?,1,   PFK2↓,4,   PFKFB2↓,1,   PFKP?,1,   PFKP↓,4,   PGAM1↓,1,   PGC-1α↓,1,   PGC-1α↑,4,   PGC1A↑,1,   PGD2↓,1,   PGE1↓,1,   PGE2↓,38,   PGK1↓,4,   PGM1↓,2,   PGM1∅,1,   pH↓,3,   pH↑,6,   pH↝,3,   i-pH↓,2,   i-pH↑,1,   PHDs↓,1,   PHDs↑,1,   PI3K↓,147,   PI3K↑,10,   PI3K↝,3,   p‑PI3K↓,16,   p‑PI3K↑,1,   PI3K/Akt↓,24,   PI3K/Akt↑,1,   PI3K/Akt⇅,1,   PI3K/Akt↝,1,   PI3k/Akt/mTOR↓,10,   PI3k/Akt/mTOR↝,1,   p‑PI3k/Akt/mTOR↓,1,   PI3K/mTOR/ETS2↓,1,   PIAS-3↑,1,   Piezo1↑,1,   PIK3CA↓,1,   PIK3CA↑,1,   p‑PIK3R1↓,1,   PINK1↑,1,   PIP3↑,1,   PIR↓,1,   Pirin↓,1,   PKA↓,6,   PKCδ↓,14,   PKCδ↑,1,   p‑PKCδ↓,1,   PKL↓,1,   PKM1↑,1,   PKM2↓,139,   PKM2↑,1,   PKM2∅,2,   p‑PKM2↓,4,   PKM2:PKM1↓,2,   PLC↝,1,   PleEff↓,1,   circ‑PLEKHM3↑,1,   PLIN1↓,1,   POLD1↓,1,   polyA↓,1,   PPARα↓,2,   PPARα↑,2,   PPARα↝,1,   cl‑PPARα↓,1,   PPARγ↓,4,   PPARγ↑,13,   PPP↓,5,   PPP2R1A↑,1,   PR↑,1,   PRAS40↓,1,   pRB↓,2,   pRB↑,2,   p‑pRB↓,5,   PRC2↓,1,   PRKCG↑,1,   proApCas↑,1,   proline↓,1,   Prot↓,1,   Prot↝,1,   Proteasome↓,2,   Prx↓,6,   Prx3↑,1,   Prx4↓,1,   Prx4↑,1,   Prx6↑,3,   PrxI↓,1,   PrxI∅,1,   PrxII↓,1,   PrxII↑,1,   PrxII∅,1,   pS2/TFF1↑,1,   PSA↓,31,   PSA↝,1,   PSA∅,1,   PSMB5↓,2,   PTCH1↓,16,   PTCH2↓,1,   PTEN↓,4,   PTEN↑,58,   PTEN↝,2,   p‑PTEN↓,1,   PTP1B↓,1,   PTPN6↑,2,   PUMA↑,8,   PUMA⇅,1,   PUMA↝,1,   PYCR1↓,2,   Pyro↑,8,   Pyruv↓,5,   QoL↑,17,   QoL∅,2,   R5P↝,1,   Rac1↓,5,   RAD51↓,3,   RAD51↑,1,   radioP↑,30,   RadioS↓,1,   RadioS↑,116,   RadioS∅,1,   Raf↓,13,   e-Raf↓,1,   c-Raf↓,1,   RAGE↓,2,   RANKL↓,2,   RANTES?,1,   RANTES↓,2,   RARα↓,1,   RARβ↑,2,   RARγ↑,1,   RAS↓,19,   RAS↑,2,   RB1↓,1,   RB1↑,5,   p‑RB1↓,11,   RBM3↑,1,   RECK↑,1,   REL↑,1,   Remission↓,1,   Remission↑,17,   RenoP↑,18,   RET↓,2,   RHBDD1↓,1,   Rho↓,12,   Rho↑,1,   RIP1↓,3,   RIP1↑,5,   p‑RIP1↑,1,   RIP3↓,1,   RIP3↑,7,   p‑RIP3↑,2,   Risk↓,67,   Risk↑,5,   Risk↝,2,   Risk∅,5,   RNR↓,1,   RNS↓,2,   ROCK1↓,9,   ROCK1↑,2,   ROMO1↑,1,   ROS?,6,   ROS↓,87,   ROS↑,939,   ROS⇅,31,   ROS↝,6,   ROS∅,7,   i-ROS?,1,   i-ROS↓,1,   i-ROS↑,5,   mt-ROS↓,2,   mt-ROS↑,25,   RPM↓,1,   RPM↑,7,   RPS6KA1↓,1,   RPSA↓,1,   p‑RSK↓,1,   p‑RSK↑,1,   RTK-RAS↓,1,   p‑S6↓,4,   S6K↓,1,   p‑S6K↓,4,   SA↓,1,   SAM-e↑,1,   SAM-e↝,2,   SAT1↑,1,   SCD1↓,1,   SCF↓,3,   SD↑,1,   SDC1↑,1,   SDH↓,4,   SDH↑,1,   Securin↓,1,   selectivity?,2,   selectivity↓,2,   selectivity↑,251,   selectivity∅,1,   selenoP↓,2,   selm↑,1,   selm↝,1,   Sepsis↓,3,   serineP↓,2,   SESN2↑,2,   Set9↑,1,   SETBP1↓,1,   sFasL↑,1,   SFRP5↑,1,   SHARP↑,2,   Sharpin↓,1,   Shc↓,1,   Shh↓,23,   SHP1↓,1,   SHP1↑,1,   SIRT1↓,16,   SIRT1↑,26,   SIRT2↓,1,   SIRT2↑,1,   SIRT3↓,1,   SIRT3↑,11,   SIRT6↓,1,   SIRT6↑,2,   SK↓,1,   SLC12A5↓,3,   SLC25A1↓,1,   Sleep↑,2,   Slug↓,33,   Smad1↑,3,   SMAD2↓,9,   p‑SMAD2↓,14,   SMAD3↓,16,   p‑SMAD3↓,11,   SMAD4↓,3,   SMAD4↑,1,   p‑SMAD4↓,1,   SMCT1↑,1,   SMCT1∅,1,   SMG1↑,1,   Smo↓,21,   Snail?,1,   Snail↓,70,   Snail↑,6,   SNCG↓,1,   SOCS-3↑,1,   SOCS1↑,3,   SOD↓,32,   SOD↑,30,   SOD∅,1,   SOD1↓,4,   SOD1↑,6,   SOD2↓,8,   SOD2↑,6,   ac‑SOD2↓,1,   sonoP↑,5,   sonoS↑,1,   SOX2↓,18,   SOX4↓,2,   SOX4↑,1,   SOX9?,1,   SOX9↓,3,   SOX9↑,2,   Sp1/3/4↓,43,   Sp1/3/4↑,3,   SPARC↓,1,   SPARC↑,1,   SPP1↝,1,   Src↓,7,   Src↑,1,   p‑Src↓,1,   c-Src↓,1,   SRD5A1↑,1,   SREBF2↓,2,   SREBP1?,1,   SREBP1↓,6,   SREBP2↓,1,   SSAT↑,1,   SSBP1↑,1,   STAC2↓,1,   StAR↓,1,   STAT↓,9,   p‑STAT↓,1,   STAT1↓,4,   p‑STAT1↓,2,   p‑STAT2↓,1,   STAT3↓,143,   STAT3↑,5,   STAT3⇅,1,   p‑STAT3↓,41,   p‑STAT3↑,2,   mt-STAT3↓,1,   STAT4↓,2,   STAT5↓,5,   p‑STAT5↓,2,   STAT6↓,2,   p‑STAT6↓,1,   STEAP3↑,1,   Strength↑,7,   Strength∅,1,   Sufu↓,1,   Sufu↑,1,   survivin↓,104,   survivin↑,1,   survivin↝,1,   SUZ12↓,1,   SVCT-2↓,1,   SVCT-2↝,1,   SVCT-2∅,3,   SXR↑,1,   Symptoms↓,1,   Symptoms∅,1,   T-cadherin↑,1,   T-Cell↓,1,   T-Cell↑,15,   T-Cell↝,1,   T-SOD↓,1,   TAC?,1,   TAC↓,2,   talin↓,1,   TAMS↝,1,   TAp63α↑,3,   tau↓,1,   p‑tau↓,1,   TAZ↓,4,   p‑TAZ↑,1,   TBARS↑,2,   TBX15↑,1,   TCA?,1,   TCA↓,5,   TCA↑,3,   TCF↓,9,   TCF↑,1,   TCF-4↓,3,   Telomerase↓,21,   testos↓,1,   TET1↓,1,   TET1↑,17,   TET2↓,1,   TET2↑,14,   TET3↑,4,   Tf↓,2,   Tf↑,3,   TFAP2A↓,1,   TFEB↑,1,   TfR1/CD71↓,4,   TfR1/CD71↑,3,   TGF-β↓,56,   TGF-β↑,4,   TGF-β1↓,1,   TGFβR1↑,1,   Th1 response↓,1,   Th1 response↑,3,   Th17↓,1,   Th2↑,2,   THBS2↓,1,   Thiols↓,3,   i-Thiols↓,1,   TILs↑,2,   TIM-3↓,1,   TIM-3↑,1,   TIMP1↓,5,   TIMP1↑,12,   TIMP2↓,2,   TIMP2↑,15,   TIMP3↑,3,   TKT↓,1,   TKT↝,1,   TLR1↑,1,   TLR2↓,1,   TLR2↑,1,   TLR4↓,13,   TLR4↑,1,   TNF-α↓,79,   TNF-α↑,12,   TNF-α↝,2,   TNF-α∅,1,   TNF-β↓,1,   TNFR 1↑,3,   TOP1?,1,   TOP1↓,17,   TOP1↑,2,   TOP1∅,1,   TOP2↓,11,   TOP2↑,4,   TOPflash↓,1,   TOPflash↑,1,   TOS↓,1,   TOS↑,3,   toxicity?,1,   toxicity↓,24,   toxicity↑,3,   toxicity↝,7,   toxicity∅,15,   TP53↓,3,   TP53↑,7,   TPI↓,1,   TPM4↓,1,   TRAIL↓,1,   TRAIL↑,15,   TRAILR↑,5,   Treg lymp↓,7,   TregCell↓,1,   TRIB3↑,1,   TRIF↓,2,   Trop2↓,1,   TRPM7↓,1,   TRPV1↑,4,   Trx↓,12,   Trx↑,1,   Trx1↓,7,   Trx1↑,1,   Trx2↓,2,   TrxR↓,36,   TrxR1?,1,   TrxR1↓,12,   TrxR2↓,1,   TS↓,3,   TSC1↑,2,   TSC2↑,5,   p‑TSC2↑,1,   TSP-1↑,7,   TumAuto↓,5,   TumAuto↑,111,   TumAuto↝,1,   TumCA↓,2,   TumCCA?,4,   TumCCA↓,8,   TumCCA↑,429,   TumCD↓,2,   TumCD↑,63,   TumCD∅,2,   TumCG?,1,   TumCG↓,322,   TumCG↑,8,   TumCG∅,2,   TumCI?,1,   TumCI↓,197,   TumCI↑,2,   TumCM/A↑,1,   TumCMig↓,224,   TumCMig↑,4,   TumCP↓,384,   TumCP↑,7,   TumCP⇅,1,   TumCP∅,3,   tumCV?,1,   tumCV↓,178,   tumCV↑,4,   tumCV∅,3,   TumMeta↓,99,   TumMeta↑,6,   TumVol↓,97,   TumVol↑,1,   TumW↓,36,   TUNEL↑,1,   Twist↓,39,   Twist↑,2,   TXA2↓,1,   TXA2↑,1,   TXNIP↓,1,   TXNIP↑,3,   Tyro3↓,2,   tyrosinase↓,1,   UBE2C↓,1,   UCP1↓,1,   UHRF1↓,5,   uPA↓,36,   uPA↝,1,   uPAR↓,4,   UPR↓,1,   UPR↑,30,   mt-UPR↑,1,   UrinaryC↑,1,   USF1↑,1,   VCAM-1↓,4,   VDR↑,1,   VEGF↓,223,   VEGF↑,4,   VEGF↝,2,   VEGFR2↓,24,   VGCC↑,1,   VHL↓,1,   Vim?,1,   Vim↓,102,   Vim↑,6,   VitC↓,1,   VitD↑,2,   VitE↓,1,   VM↓,1,   Warburg↓,46,   Weight↓,3,   Weight↑,8,   Weight∅,12,   Wmax↑,1,   Wnt?,1,   Wnt↓,55,   Wnt↑,1,   Wnt/(β-catenin)↓,23,   Wnt/(β-catenin)↑,1,   XBP-1↓,1,   XBP-1↑,9,   xCT↓,10,   xCT∅,1,   XIAP↓,52,   XIAP↝,1,   XIST↓,1,   YAP/TEAD↓,7,   YAP/TEAD↑,2,   p‑YAP/TEAD↝,1,   YMcells↓,1,   YMcells↑,1,   ZBTB10↑,2,   Zeb1↓,33,   Zeb1↑,4,   ZEB2↓,2,   ZEB2↑,2,   ZFX↓,2,   ZO-1↓,1,   ZO-1↑,9,   α-SMA↓,9,   α-SMA↑,2,   α-tubulin↓,4,   α-tubulin↑,2,   ac‑α-tubulin↑,2,   β-catenin/ZEB1↓,107,   β-catenin/ZEB1↑,2,   β-catenin/ZEB1↝,2,   p‑β-catenin/ZEB1↓,2,   p‑β-catenin/ZEB1↑,1,   β-oxidation↓,3,   β-TRCP↑,2,   γH2AX↓,1,   γH2AX↑,19,   p‑γH2AX↑,5,  
Total Targets: 2040

Results for Effect on Normal Cells:
12LOX↓,8,   12LOX↑,1,   5HT↓,1,   5HT↑,4,   5LO↓,5,   ACC↓,3,   ACC↑,2,   p‑ACC↑,1,   Acetyl-CoA↑,3,   Ach↑,11,   AChE↓,23,   AChE↝,1,   ACLY↓,1,   ACLY∅,1,   ACSL4↓,1,   ACSL4∅,1,   ACTA2↓,1,   adiP↑,4,   ADP:ATP↓,1,   AhR↑,3,   AIF↓,1,   AIM2↓,2,   Akt?,1,   Akt↓,10,   Akt↑,17,   p‑Akt↓,4,   p‑Akt↑,4,   e-Akt↑,1,   ALAT↓,32,   ALAT∅,1,   Albumin↑,1,   ALDH↑,1,   ALDOA↑,1,   ALP↓,7,   ALP↑,2,   ALP∅,1,   AMP↓,1,   AMPK↓,2,   AMPK↑,26,   AMPK⇅,1,   p‑AMPK↑,4,   AMPKα↑,1,   angioG↓,7,   angioG↑,12,   angioG↝,1,   AntiAg↑,17,   AntiAg∅,1,   AntiAge↑,8,   AntiCan↓,1,   AntiCan↑,11,   antiOx?,3,   antiOx↓,14,   antiOx↑,202,   mt-antiOx↑,1,   AntiTum↑,1,   AP-1↓,9,   AP-1↑,1,   APAF1↓,1,   Apoptosis↓,44,   Apoptosis↑,1,   Apoptosis∅,2,   ARG↑,2,   ARNT↑,1,   ASC?,1,   ASC↓,2,   ascitic↓,1,   ASK1↓,1,   AST↓,35,   AST∅,1,   ATF4↓,3,   ATF4↑,1,   ATF6↓,4,   ATM↑,1,   ATP↓,3,   ATP↑,16,   ATP↝,1,   ATP∅,1,   mt-ATPase↑,1,   Aβ↓,42,   Aβ↑,1,   BACE↓,1,   Bacteria↓,2,   BAD↓,1,   BAX↓,21,   BAX↑,3,   Bax:Bcl2↓,4,   Bax:Bcl2↑,2,   BBB?,3,   BBB↓,2,   BBB↑,36,   BChE↓,2,   Bcl-2↓,2,   Bcl-2↑,14,   Bcl-2∅,1,   Bcl-xL↑,1,   Beclin-1↓,1,   Beclin-1↑,3,   BG↓,8,   BioAv?,3,   BioAv↓,71,   BioAv↑,82,   BioAv↝,40,   BioAv∅,1,   BioEnh↑,19,   BioEnh↝,1,   BMAL1↑,1,   BMD↑,14,   BMP2↑,2,   BMPs↓,1,   BMPs↑,1,   BP↓,7,   BP↝,1,   BP∅,1,   BUN↓,5,   Ca+2?,2,   Ca+2↓,16,   Ca+2↑,10,   Ca+2↝,5,   Ca+2∅,1,   p‑Ca+2↓,1,   i-Ca+2↓,2,   mt-Ca+2↓,1,   cachexia↑,1,   cal2↓,1,   Calcium↑,2,   CaMKII ↓,1,   cAMP↑,3,   cardioP?,1,   cardioP↓,1,   cardioP↑,73,   cardioP⇅,1,   CardioT↓,4,   Cartilage↑,1,   Casp↓,1,   Casp1?,1,   Casp1↓,8,   cl‑Casp1↓,1,   proCasp1↓,1,   Casp12↓,5,   Casp3?,1,   Casp3↓,27,   Casp3↑,5,   Casp3∅,2,   cl‑Casp3↓,6,   cl‑Casp3↑,1,   proCasp3↓,1,   Casp6↓,1,   Casp7↓,1,   Casp8↑,1,   cl‑Casp8↑,2,   Casp9↓,7,   Casp9↑,2,   Casp9∅,1,   cl‑Casp9↓,1,   cl‑Casp9↑,1,   Catalase↓,5,   Catalase↑,100,   Catalase↝,2,   CD25+↓,1,   CD34↑,1,   CD4+↑,1,   CD69↓,1,   CDK2↓,1,   CEA↓,1,   CEBPA↓,1,   cellD↓,1,   cFos↓,1,   ChAT↑,9,   ChemChap↓,1,   ChemChap↑,2,   chemoP↑,16,   ChemoSen↑,1,   ChemoSideEff↓,1,   Choline↑,1,   CHOP↓,11,   cJun↓,1,   p‑cJun↓,4,   CK2↑,1,   CLDN1↝,1,   CLDN5↑,1,   cMyc↓,2,   cMyc↑,1,   p‑cMyc↑,1,   p‑Cofilin↓,1,   cognitive↓,1,   cognitive↑,75,   cognitive∅,1,   COL1↓,2,   COL1↑,1,   COL1∅,1,   COL1A1↓,1,   COL2A1↑,2,   COL3A1↓,2,   Copper↓,2,   cortisol↑,1,   COX1↓,2,   COX2↓,72,   COX2↑,1,   COX2∅,1,   cPLA2↓,1,   creat↓,9,   CRM↑,1,   CRP↓,6,   CTLA-4↓,1,   CXCc↓,2,   CXCc↑,1,   CXCL1↓,1,   CXCL12↑,1,   CXCR2↑,1,   cycA1↓,1,   cycD1↓,2,   cycE↑,1,   CYP1A1↑,1,   CYP1A2↑,1,   CYP2C6↑,1,   CYP2D1↑,1,   CYP2E1↓,1,   CYP3A2↑,1,   Cyt‑c↓,9,   Cyt‑c↑,3,   Cyt‑c∅,4,   cytoP↑,2,   DHT↑,1,   Diff↓,1,   Diff↑,10,   DNAdam↓,14,   DNAdam↑,1,   DNAdam∅,1,   DNArepair↑,1,   DNMT1↓,2,   DNMT3A↓,1,   DNMTs↓,2,   Dose?,2,   Dose↓,1,   Dose↑,6,   Dose⇅,1,   Dose↝,37,   Dose∅,10,   DR4↓,1,   E-cadherin↓,1,   E-cadherin↑,5,   E-sel↓,4,   E2Fs↑,2,   ECAR↓,5,   ECAR↑,1,   ECAR∅,1,   eff↓,18,   eff↑,81,   eff↝,6,   EGF↑,1,   EGFR↓,1,   EGR4↑,1,   eIF2α↓,2,   p‑eIF2α↓,2,   EMT↓,4,   EMT↑,2,   eNOS↓,2,   eNOS↑,3,   p‑eNOS↑,1,   ER Stress↓,33,   ER Stress↑,1,   ERK↓,9,   ERK↑,11,   p‑ERK↓,10,   p‑ERK↑,3,   e-ERK↑,1,   F-actin↓,1,   F-actin↑,1,   FABP4↓,2,   FAK↑,2,   FAO↓,1,   FAO↑,5,   Fas↓,2,   Fas↑,2,   FASN↓,7,   Fenton↓,2,   Ferritin↑,1,   Ferroptosis↓,9,   Ferroptosis↑,2,   FGF↑,6,   FGF21↑,2,   Fibronectin↓,2,   FOXO↑,1,   FOXO1↑,2,   FOXO1↝,1,   FOXO3?,1,   FOXO3↑,1,   FTH1↑,1,   G6PD↑,2,   GABA↑,1,   GADD45A↑,1,   GAPDH↑,1,   GCLC↑,3,   GCLM↑,1,   GDH↓,1,   GFR↑,1,   Gli1↑,1,   glucoNG↓,3,   glucose↓,9,   glucose↑,1,   GlucoseCon↓,4,   GlucoseCon↑,16,   GLUT1↓,2,   GLUT1↑,3,   GLUT3↑,3,   GLUT4↓,1,   GLUT4↑,7,   GlutMet↑,1,   Glycolysis↓,6,   Glycolysis↑,10,   Glycolysis↝,3,   GM-CSF↑,1,   GPI↑,1,   GPx↓,3,   GPx↑,66,   GPx↝,1,   GPx∅,1,   GPx1↑,4,   GPx4↓,1,   GPx4↑,9,   GPx4∅,1,   GR↓,1,   GR↑,3,   GR↝,1,   GRP58↓,1,   GRP78/BiP↓,20,   GSDMD?,1,   GSDMD↓,1,   GSH↓,11,   GSH↑,141,   GSH∅,2,   GSH/GSSG↓,1,   GSH/GSSG↑,2,   GSK‐3β↓,6,   GSK‐3β↑,1,   p‑GSK‐3β↑,1,   GSR↓,3,   GSR↑,12,   GSS↑,2,   GSSG↓,5,   GSSG∅,1,   GSTA1↓,2,   GSTA1↑,8,   GSTs↓,2,   GSTs↑,19,   GutMicro↓,1,   GutMicro↑,16,   H2O2↓,10,   H2O2↑,2,   H2O2∅,1,   H2S↑,3,   Half-Life?,2,   Half-Life↓,13,   Half-Life↑,11,   Half-Life↝,17,   Half-Life∅,6,   HATs↓,1,   HbA1c↓,1,   HDAC↓,12,   HDAC↑,2,   HDAC1↓,1,   HDAC3↓,2,   HDL↑,1,   HDL∅,1,   Hear↑,1,   heparanase↑,1,   hepatoP↓,1,   hepatoP↑,80,   HEY1↑,1,   HGF/c-Met↑,1,   HIF-1↓,1,   Hif1a↓,15,   Hif1a↑,10,   Hif1a∅,2,   HIF2a↑,1,   ac‑Histones↑,1,   HK1↑,1,   HK2↓,7,   HK2↑,6,   HMGB1↓,5,   HMGCR↓,1,   HO-1↓,4,   HO-1↑,96,   HO-1⇅,1,   HO-1↝,1,   HO-1∅,1,   HO-2↓,1,   hs-CRP↓,2,   HSF1↑,2,   HSP27↓,1,   HSP70/HSPA5↑,10,   HSP70/HSPA5↝,1,   HSP90↑,1,   HSPs↑,2,   hyperG↓,1,   IAP1↓,1,   ICAM-1↓,14,   IFN-γ↓,11,   IFN-γ↑,5,   IGF-1↓,6,   IGF-1↑,3,   IGF-1R↓,1,   IGFBP3↑,1,   IGFR↓,1,   IKKα↓,4,   IKKα↑,1,   p‑IKKα↓,3,   IL1↓,6,   IL1↑,1,   IL10↓,8,   IL10↑,23,   IL12↓,5,   IL12↑,1,   IL17↓,8,   IL17↑,2,   IL18↓,6,   IL1α↓,1,   IL1β↓,81,   IL1β↑,3,   IL2↓,9,   IL2↑,5,   IL22↓,2,   IL4↓,6,   IL4↑,2,   IL5↓,1,   IL6↓,78,   IL6↑,8,   IL8↓,21,   Imm↑,1,   Inf↓,1,   INF-γ↓,2,   Inflam?,3,   Inflam↓,237,   Inflam↑,4,   iNOS↓,50,   iNOS↑,4,   Insulin↓,4,   Insulin↑,3,   IP-10/CXCL-10↓,1,   IP-10/CXCL-10↑,1,   IRE1↓,5,   IRF3↓,4,   Iron↓,6,   IronCh↓,1,   IronCh↑,25,   ITGA5↓,1,   ITGB1↓,1,   ITGB1↑,1,   IκB↑,2,   p‑IκB↓,1,   JAK↓,2,   p‑JAK1↓,1,   JAK2↓,2,   JAK2↑,2,   p‑JAK2↓,2,   JNK↓,12,   JNK↑,2,   p‑JNK↓,9,   p‑JNK↑,3,   Jun↑,1,   Keap1↓,12,   Keap1↑,1,   ox-Keap1↑,1,   KeyT↑,1,   Ki-67↓,2,   KLF4↑,1,   lactateProd↓,5,   LAMs↑,1,   LC3‑Ⅱ/LC3‑Ⅰ↑,1,   LC3A↑,1,   LC3II↑,2,   LDH↓,16,   LDH↑,1,   LDH∅,1,   LDHA↓,4,   LDHA↑,5,   LDHB↑,1,   LDL↓,8,   LIF↑,1,   lipid-P?,1,   lipid-P↓,64,   lipid-P↑,2,   mt-lipid-P↓,1,   lipidDe↓,1,   lipidLev↓,2,   lipoGen↓,2,   LOX1↓,2,   M1↓,1,   Macrophages↓,1,   Mag↑,2,   MAOA↓,1,   MAPK↓,21,   MAPK↑,8,   p‑MAPK↓,1,   MATs↓,1,   MCP1↓,11,   MCP1↑,1,   MCU↓,1,   MDA↓,90,   MDA↑,2,   MDA∅,1,   p‑MEK↓,1,   memory↑,59,   memory∅,1,   Mets↝,1,   MIP‑1α↓,2,   miR-155↓,1,   miR-22↑,1,   miR-29b↑,1,   miR-34b-5p↓,1,   mitResp↓,3,   mitResp↑,5,   p‑MKK4↑,1,   MLKL↓,1,   MMP↓,8,   MMP↑,36,   MMP↝,1,   MMP∅,3,   MMP1↓,3,   MMP13↓,3,   MMP2↓,14,   MMP2↑,4,   MMP3↓,3,   MMP3↑,1,   MMP7↓,1,   MMP9↓,15,   MMP9↑,4,   MMPs↓,4,   MMPs↑,2,   motorD↓,1,   motorD↑,19,   mPGES-1↓,1,   MPO↓,14,   MPO↑,2,   MPT↑,1,   MRP↓,1,   MSCs↑,1,   Mst1↓,1,   mtDam↓,9,   mtDam↑,1,   mTOR↓,7,   mTOR↑,5,   p‑mTOR↓,2,   p‑mTOR↑,1,   MyD88↓,4,   N-cadherin↓,1,   n-MYC↑,1,   NA↓,1,   NAD↑,3,   NAD↝,1,   NADH:NAD↑,1,   NADPH↓,8,   NADPH↑,8,   NADPH∅,1,   NADPH/NADP+↑,1,   NCOA4↝,1,   necrosis↓,2,   Netrins↑,1,   neuroG↑,2,   neuroP↓,1,   neuroP↑,157,   neuroP↝,1,   Neut↓,1,   Neut↑,1,   NF-kB↓,123,   NF-kB↑,7,   p‑NF-kB↓,6,   NFAM1↑,1,   NFAT↑,2,   NH3↓,1,   NH3↑,1,   NHE3↑,1,   NLRP3↓,31,   NO↓,48,   NO↑,6,   NOS2↓,3,   NOTCH↑,1,   NOX↓,1,   NOX4↓,8,   NPY↑,1,   NQO1↑,23,   Nrf1?,1,   Nrf1↑,2,   NRF2↓,7,   NRF2↑,161,   NRF2⇅,1,   NRF2∅,2,   p‑NRF2↑,2,   NSE↑,1,   OATPs↓,1,   Obesity↓,2,   OCN↑,1,   OCN∅,1,   OCR↓,3,   OCR↑,2,   OCT4↓,1,   OPN↑,1,   OS↓,1,   OS↑,16,   OSM↑,1,   other?,3,   other↓,10,   other↑,23,   other↝,13,   OXPHOS↓,3,   OXPHOS↑,5,   P-gp↓,1,   p16↓,1,   P21↓,3,   P21↑,3,   p300↓,1,   p38↓,11,   p38↑,6,   p‑p38↓,7,   P450↓,1,   P450↑,2,   p‑p50↓,1,   P53↓,4,   P53↑,2,   P53↝,1,   p62↓,3,   p62↑,2,   p65↓,4,   p‑p65↓,2,   P70S6K↓,2,   p‑P70S6K↓,1,   p‑P70S6K↑,1,   Pain↓,7,   PAR-2↓,1,   PARK2↑,1,   PARP↓,1,   PARP∅,1,   p‑PARP↓,1,   cl‑PARP↑,2,   cl‑PARP1↓,1,   PCNA↓,1,   PDGF↑,1,   PDGFR-BB↓,1,   PDGFR-BB↑,1,   PDH↑,1,   PDI↓,1,   PDK1↓,1,   p‑PDK1↓,1,   PDKs↓,2,   PERK↓,5,   p‑PERK↓,1,   PFK↓,1,   PFK↑,1,   PFK1↓,1,   PFK2↓,1,   PFKFB2↓,1,   PFKL↑,3,   PFKM↑,2,   PFKP↓,1,   PFKP↑,1,   PGC-1α↓,1,   PGC-1α↑,12,   PGC1A↑,2,   PGE2↓,28,   PGE2↑,1,   PGM1?,1,   pH↑,1,   pH↝,1,   PI3K↓,7,   PI3K↑,13,   PINK1↑,1,   PKA↑,2,   PKCδ?,1,   PKCδ↓,3,   PKCδ↑,4,   PKM1↑,1,   PKM2↓,18,   PKM2↑,7,   PONs↓,1,   PPARα↑,5,   PPARγ↓,2,   PPARγ↑,7,   p‑PPARγ↓,1,   PPP↓,2,   Prx↓,1,   Prx↑,5,   Prx4∅,1,   PrxII↑,1,   PTEN↓,2,   PTEN↑,4,   p‑PTEN↓,1,   Pyro?,1,   Pyro↓,1,   QoL↑,2,   RAAS↓,1,   Rac1↑,1,   p‑Rac1↓,1,   RAD51↓,1,   radioP↑,19,   Raf↓,1,   RAGE↓,1,   RANTES↓,1,   RAS↓,1,   REL↑,1,   RenoP↓,1,   RenoP↑,41,   Rho↓,7,   RIP1↓,1,   Risk↓,2,   Risk↑,1,   Risk↝,1,   RNS↓,3,   ROCK1↓,6,   ROMO1↑,1,   ROS?,4,   ROS↓,378,   ROS↑,30,   ROS⇅,5,   ROS∅,21,   mt-ROS↓,4,   mt-ROS↑,2,   RUNX2↑,1,   RUNX2∅,1,   SAM-e↓,1,   SAM-e↑,1,   SCD1↓,1,   selectivity↑,5,   Sema3A/PlexinA1↑,1,   Sepsis↓,13,   serineP↓,1,   SHBG↓,1,   Shh↑,1,   SIRT1↓,2,   SIRT1↑,29,   SIRT2↑,3,   SIRT3↑,6,   SIRT6↑,1,   Smad1↑,1,   p‑Smad1↑,1,   SMAD2↓,1,   SMAD3↓,2,   SMAD4↑,1,   SMAD5↑,1,   p‑SMAD5↑,1,   Smad7↑,2,   Snail↓,1,   SOD?,1,   SOD↓,8,   SOD↑,138,   SOD↝,2,   SOD1↑,9,   SOD2↓,1,   SOD2↑,10,   SOX9↑,2,   Sp1/3/4↓,6,   Sp1/3/4↑,1,   Src↓,1,   SREBF2↓,1,   SREBP1↓,6,   SREBP2↓,1,   SREBP2↑,1,   STAC2↑,1,   STAT↓,2,   STAT1↓,1,   p‑STAT1↓,1,   STAT3?,1,   STAT3↓,8,   STAT3↑,2,   p‑STAT3↓,3,   STAT4↓,1,   Strength↑,3,   SVCT-2↑,1,   TAC↑,14,   TAC∅,1,   tau↓,5,   p‑tau↓,6,   p‑tau↑,1,   TBARS↓,3,   TCA↑,1,   TCF-4↓,1,   Telomerase↓,1,   testos↑,1,   TET2↑,1,   TfR1/CD71↓,1,   TGF-β↓,13,   TGF-β↑,7,   TGF-β1↓,2,   TGF-β1↑,2,   Th1 response↓,2,   Th17↓,1,   Th2↑,2,   Thiols↑,3,   TIMP1↓,3,   TIMP1↑,2,   TIMP2↑,2,   TLR1↓,1,   TLR2↓,7,   TLR4↓,14,   TLR4↑,1,   TLR4∅,1,   TNF-α↓,110,   TNF-α↑,7,   TNF-β↓,1,   TOP2↑,1,   TOS↓,2,   toxicity?,2,   toxicity↓,94,   toxicity↑,9,   toxicity↝,9,   toxicity∅,57,   Treg lymp↓,1,   TREM-1↓,1,   TRIF↓,2,   TrkB↑,1,   TRPV1↑,1,   Trx↓,2,   Trx↑,5,   Trx1↑,2,   TrxR↓,1,   TrxR↑,1,   TrxR1↑,2,   TumCCA↑,3,   TumCG↓,1,   TumCG↑,1,   TumCG∅,1,   TumCI↓,1,   TumCI∅,1,   TumCMig↓,1,   TumCMig↑,1,   TumCMig∅,1,   TumCP↓,4,   tumCV↓,1,   tumCV↑,1,   tumCV∅,1,   TXNIP↓,4,   TXNIP↑,2,   UCP1↓,1,   uPA↓,1,   UPR↓,4,   UPR↑,1,   uricA↓,2,   VCAM-1↓,13,   VEGF↓,13,   VEGF↑,16,   VEGFR2↑,1,   p‑VEGFR2↓,1,   VGCC↑,1,   Vim↓,7,   VitC↑,8,   VitD↑,5,   VitE↑,7,   Warburg↓,1,   Weight↓,7,   Weight↑,1,   Weight∅,2,   Wnt↓,1,   Wnt↑,3,   XBP-1↓,3,   YAP/TEAD↑,1,   Zeb1↓,1,   ZO-1↓,1,   ZO-1↑,4,   ZO-1↝,1,   α-SMA↓,14,   α-SMA↑,1,   α-SMA↝,1,   α-tubulin↓,2,   β-Amyloid↓,4,   β-catenin/ZEB1↓,3,   β-catenin/ZEB1↑,5,   β-Endo↑,1,   p‑γH2AX↓,1,  
Total Targets: 867

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rpid,rpid2

 

Home Page